assay_tissue,bao_format,assay_strain,relationship_type,assay_subcellular_fraction,description,src_id,assay_cell_type,assay_tax_id,assay_type,assay_organism,tissue_id,confidence_score,curated_by,chembl_id,src_assay_id,assay_id,assay_test_type,variant_id,tid,doc_id,cell_id,assay_category
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,1,,,B,,,8,Autocuration,CHEMBL615117,,1,,,12052,11087,,
,BAO_0000219,,U,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,1,,,F,,,0,Autocuration,CHEMBL615118,,2,,,22226,684,,
,BAO_0000019,,U,,,1,,,B,,,0,Autocuration,CHEMBL615119,,3,,,22226,15453,,
,BAO_0000249,,H,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,1,,9913.0,B,Bos taurus,,4,Autocuration,CHEMBL615120,,4,,,104729,17841,,
,BAO_0000219,,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,143B,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615121,,5,,,80001,17430,163.0,
,BAO_0000219,,N,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),1,143B,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615122,,6,,,80001,17430,163.0,
,BAO_0000219,,N,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,1,143B,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615123,,7,,,80001,13799,163.0,
,BAO_0000219,,N,,In vitro cell cytotoxicity was determined against 143B cell line,1,143B,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615124,,8,,,80001,17774,163.0,
,BAO_0000219,,N,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,1,143B,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615125,,9,,,80001,3801,163.0,
,BAO_0000219,,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,143B,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615126,,10,,,80001,17430,163.0,
,BAO_0000219,,N,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,1,143B,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615127,,11,,,80001,17430,163.0,
,BAO_0000219,,N,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,1,143B,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615128,,12,,,80001,17774,163.0,
,BAO_0000218,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,1280.0,F,Staphylococcus aureus,,1,Intermediate,CHEMBL857900,,13,,,50185,11324,,
,BAO_0000218,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,1280.0,F,Staphylococcus aureus,,1,Intermediate,CHEMBL615129,,14,,,50185,11324,,
,BAO_0000218,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,1280.0,F,Staphylococcus aureus,,1,Intermediate,CHEMBL615130,,15,,,50185,11324,,
,BAO_0000218,,N,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",1,,1280.0,F,Staphylococcus aureus,,1,Intermediate,CHEMBL615131,,16,,,50185,11324,,
,BAO_0000357,,D,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,1,,10116.0,A,Rattus norvegicus,,9,Expert,CHEMBL884521,,17,,,100122,11347,,
,BAO_0000357,,H,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),1,,,B,,,8,Autocuration,CHEMBL615132,,18,,,12054,16474,,
,BAO_0000019,,H,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,1,,,B,,,8,Autocuration,CHEMBL615133,,19,,,12054,10091,,
,BAO_0000357,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,,B,,,8,Autocuration,CHEMBL615134,,20,,,12054,16474,,
,BAO_0000357,,H,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),1,,,B,,,8,Autocuration,CHEMBL615135,,21,,,12054,16474,,
,BAO_0000357,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),1,,,B,,,8,Autocuration,CHEMBL615136,,22,,,12054,16474,,
,BAO_0000357,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,,B,,,8,Autocuration,CHEMBL615137,,23,,,12054,16474,,
,BAO_0000357,,H,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,1,,,B,,,8,Autocuration,CHEMBL615138,,24,,,12054,16474,,
,BAO_0000219,,U,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",1,,,B,,,0,Autocuration,CHEMBL836324,,25,,,22226,14352,,
,BAO_0000357,,H,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL615139,,26,,,12054,5646,,
,BAO_0000357,,H,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL615140,,27,,,12054,5646,,
,BAO_0000219,,H,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,1,,,B,,,8,Autocuration,CHEMBL615141,,28,,,12426,10997,,
,BAO_0000357,,H,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,1,,3847.0,B,soya bean,,8,Autocuration,CHEMBL615142,,29,,,12054,6309,,
,BAO_0000357,,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL615143,,30,,,12054,167,,
,BAO_0000357,,H,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL615144,,31,,,12054,167,,
,BAO_0000357,,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL872867,,32,,,12054,11087,,
,BAO_0000357,,H,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL615145,,33,,,12054,11087,,
,BAO_0000357,,H,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL615146,,34,,,12054,13622,,
,BAO_0000357,,H,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL615147,,35,,,12054,13622,,
,BAO_0000019,,U,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL615148,,36,,,22226,11347,,
,BAO_0000019,,U,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,1,,562.0,B,Escherichia coli,,0,Autocuration,CHEMBL615149,,37,,,22226,5926,,
,BAO_0000019,,U,,Dissociation constant with dimeric 16S rRNA RNA construct B,1,,,B,,,0,Autocuration,CHEMBL615150,,38,,,22226,4567,,
,BAO_0000225,,M,,Dissociation constant towards 16S rRNA construct A,1,,,B,,,3,Intermediate,CHEMBL615151,,39,,,22222,3782,,
,BAO_0000225,,M,,Dissociation constant towards 16S rRNA construct B,1,,,B,,,3,Intermediate,CHEMBL615152,,40,,,22222,3782,,
,BAO_0000225,,M,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,1,,562.0,B,Escherichia coli,,3,Expert,CHEMBL615153,,41,,,100263,4466,,
,BAO_0000225,,M,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,1,,562.0,B,Escherichia coli,,3,Expert,CHEMBL615154,,42,,,100263,6592,,
,BAO_0000019,,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,B,,,8,Autocuration,CHEMBL615155,,43,,,13053,898,,
,BAO_0000019,,H,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,B,,,8,Autocuration,CHEMBL615156,,44,,,13053,898,,
,BAO_0000019,,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,,9606.0,B,Homo sapiens,,8,Autocuration,CHEMBL615157,,45,,,20001,13163,,
,BAO_0000019,,H,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,1,,9606.0,B,Homo sapiens,,8,Autocuration,CHEMBL615158,,46,,,20001,13163,,
,BAO_0000019,,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615159,,47,,,12971,10691,,
,BAO_0000019,,D,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615172,,48,,,12971,10691,,
,BAO_0000019,,D,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615173,,49,,,12971,10691,,
,BAO_0000019,,D,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615174,,50,,,12971,10691,,
,BAO_0000019,,H,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),1,,,B,,,8,Autocuration,CHEMBL884518,,51,,,13053,898,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),1,,,B,,,8,Autocuration,CHEMBL615175,,52,,,11512,912,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,1,,,B,,,8,Autocuration,CHEMBL615176,,53,,,11512,912,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,1,,,B,,,8,Autocuration,CHEMBL615177,,54,,,11512,912,,
,BAO_0000249,,D,Membranes,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615178,,55,,,104740,15103,,
,BAO_0000219,,N,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615179,,56,,,80002,5116,506.0,
,BAO_0000219,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,1,Oocytes,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL615180,,57,,,104835,14578,,
,BAO_0000219,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,1,Oocytes,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL615181,,58,,,104821,14578,,
,BAO_0000219,,D,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,1,Oocytes,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL615182,,59,,,104848,14578,,
,BAO_0000219,,N,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,1,1A9,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615183,,60,,,80002,4787,506.0,
,BAO_0000219,,N,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615184,,61,,,80002,4787,506.0,
,BAO_0000219,,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615185,,62,,,80002,3547,506.0,
,BAO_0000219,,N,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615186,,63,,,80002,3547,506.0,
,BAO_0000219,,N,,Effective dose of compound against replication of 1A9 cell line was evaluated,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615187,,64,,,80002,6726,506.0,
,BAO_0000219,,N,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,1,1A9,9606.0,F,Homo sapiens,,1,Expert,CHEMBL885343,,65,,,80002,3455,506.0,
,BAO_0000219,,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615188,,66,,,80002,5726,506.0,
,BAO_0000219,,N,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615189,,67,,,80002,5726,506.0,
,BAO_0000219,,N,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615190,,68,,,80002,5726,506.0,
,BAO_0000219,,N,,Inhibitory activity against Taxol resistant 1A9 cell lines,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615191,,69,,,80002,3395,506.0,
,BAO_0000219,,N,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,1,1A9,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615192,,70,,,80002,3415,506.0,
,BAO_0000219,,N,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,1,1A9,9606.0,F,Homo sapiens,,1,Expert,CHEMBL827083,,71,,,80002,3415,506.0,
,BAO_0000219,,N,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,1,1A9,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615193,,72,,,80002,17099,506.0,
,BAO_0000219,,N,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615194,,73,,,80002,17099,506.0,
,BAO_0000219,,N,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615195,,74,,,80002,17099,506.0,
,BAO_0000219,,N,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,1,1A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615196,,75,,,80002,17099,506.0,
,BAO_0000219,,N,,Inhibitory concentration against Jurkat cells,1,Jurkat,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615197,,76,,,81072,17721,503.0,
,BAO_0000019,,U,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL615198,,77,,,22226,1229,,
,BAO_0000357,,D,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,1,,10116.0,A,Rattus norvegicus,,9,Expert,CHEMBL615199,,78,,,100121,11347,,
,BAO_0000357,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,,B,,,8,Expert,CHEMBL615200,,79,,,11231,17117,,
,BAO_0000357,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",1,,,B,,,8,Expert,CHEMBL615201,,80,,,11231,17117,,
,BAO_0000357,,H,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",1,,,B,,,8,Expert,CHEMBL615202,,81,,,11231,17117,,
,BAO_0000251,,H,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",1,,5476.0,B,Candida albicans,,8,Autocuration,CHEMBL615203,,82,,,11231,11375,,
,BAO_0000251,,H,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",1,,5476.0,B,Candida albicans,,8,Autocuration,CHEMBL615204,,83,,,11231,11375,,
,BAO_0000251,,H,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",1,,4932.0,B,Saccharomyces cerevisiae,,8,Autocuration,CHEMBL615205,,84,,,11231,11375,,
,BAO_0000251,,H,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",1,,4932.0,B,Saccharomyces cerevisiae,,8,Autocuration,CHEMBL615206,,85,,,11231,11375,,
Liver,BAO_0000251,,H,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",1,,9823.0,B,Sus scrofa,2107.0,8,Autocuration,CHEMBL615207,,86,,,12083,11375,,
,BAO_0000019,,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",1,,10116.0,B,Rattus norvegicus,,8,Autocuration,CHEMBL827084,,87,,,11231,791,,
,BAO_0000019,,H,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",1,,10116.0,B,Rattus norvegicus,,8,Autocuration,CHEMBL615208,,88,,,11231,791,,
,BAO_0000019,,H,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",1,,10116.0,B,Rattus norvegicus,,8,Autocuration,CHEMBL615209,,89,,,11231,791,,
Liver,BAO_0000251,,D,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615210,,90,,,12083,11375,,
Liver,BAO_0000251,,D,Microsomes,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615211,,91,,,12083,11375,,
Liver,BAO_0000251,,D,Microsomes,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615212,,92,,,12083,153,,
,BAO_0000357,,H,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),1,,,B,,,8,Expert,CHEMBL615213,,93,,,11377,8269,,
,BAO_0000357,,H,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,1,,,B,,,8,Expert,CHEMBL615273,,94,,,11377,8269,,
,BAO_0000219,,N,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615274,,95,,,81020,17653,726.0,
,BAO_0000219,,N,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615275,,96,,,81020,14277,726.0,
,BAO_0000219,,N,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615276,,97,,,81020,1717,726.0,
,BAO_0000219,,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615277,,98,,,81020,14091,726.0,
,BAO_0000219,,N,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615326,,99,,,81020,14091,726.0,
,BAO_0000218,,N,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,1,,10407.0,F,Hepatitis B virus,,1,Expert,CHEMBL883130,,100,,,50606,17653,,
,BAO_0000219,,N,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884519,,101,,,81020,13105,726.0,
,BAO_0000219,,N,,Concentration required to inhibit 50% of 2.2.15 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615327,,102,,,81020,1717,726.0,
,BAO_0000219,,N,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,1,HepG2,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL615328,,103,,,81020,13105,726.0,
,BAO_0000218,,N,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615329,,104,,,50587,13600,,
,BAO_0000218,,N,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615330,,105,,,50587,13467,,
,BAO_0000218,,N,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",1,2.2.15,10407.0,F,Hepatitis B virus,,1,Expert,CHEMBL615331,,106,,,50606,17477,,
,BAO_0000218,,N,,In vitro anti-HBV activity in 2.2.15 cells,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615332,,107,,,50587,1593,,
,BAO_0000218,,N,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615333,,108,,,50587,1593,,
,BAO_0000218,,N,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615334,,109,,,50587,15089,,
,BAO_0000218,,N,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615335,,110,,,50587,15089,,
,BAO_0000218,,N,,Cytotoxicity in 2.2.15 cells,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615336,,111,,,50587,1593,,
,BAO_0000218,,N,,Cytotoxicity in 2.2.15 cells; Not determined,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615337,,112,,,50587,1593,,
,BAO_0000218,,N,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615338,,113,,,50587,13600,,
,BAO_0000218,,N,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615339,,114,,,50587,13467,,
,BAO_0000218,,N,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,1,2.2.15,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615340,,115,,,50587,13467,,
,BAO_0000219,,N,,Antiviral activity against HBV was determined in 2.215 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615341,,116,,,81020,14764,726.0,
,BAO_0000251,,U,Microsomes,Inhibition of 20-HETE synthesis in human renal microsomes,1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615342,,117,,,22226,6531,,
,BAO_0000019,,U,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,1,,,B,,,0,Autocuration,CHEMBL615343,,118,,,22226,17322,,
,BAO_0000219,,N,,Inhibitory concentration against 2008 (ovarian) cells,1,2008,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615344,,119,,,80612,17072,388.0,
,BAO_0000219,,N,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,1,2008,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615345,,120,,,80612,16936,388.0,
,BAO_0000219,,N,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),1,2008,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615346,,121,,,80612,16936,388.0,
,BAO_0000219,,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,1,2008,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615347,,122,,,80612,17146,388.0,
,BAO_0000219,,N,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,1,2008,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615348,,123,,,80612,17146,388.0,
,BAO_0000219,,N,,In vitro inhibition of 2008/R ovarian cancer cell line,1,2008/R,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL827085,,124,,,80613,10797,561.0,
,BAO_0000219,,N,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,1,2008/R,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615349,,125,,,80613,10797,561.0,
,BAO_0000219,,N,,In vitro inhibition of 2008/S ovarian cancer cell line,1,2008/S,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615350,,126,,,80614,10797,389.0,
,BAO_0000219,,N,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,1,2008/S,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615351,,127,,,80614,10797,389.0,
,BAO_0000220,,S,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,1,,9606.0,B,Homo sapiens,,2,Expert,CHEMBL615352,,128,,,100256,4823,,
,BAO_0000220,,S,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,1,,9606.0,B,Homo sapiens,,2,Intermediate,CHEMBL615353,,129,,,100256,12912,,
,BAO_0000220,,S,,Inhibition of chymotrypsin-like activity of 20S proteasome,1,,,B,,,2,Expert,CHEMBL615354,,130,,,100256,2957,,
,BAO_0000220,,S,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,1,,,B,,,2,Expert,CHEMBL615355,,131,,,100256,2957,,
,BAO_0000220,,S,,Inhibitory activity against 20S proteosome,1,,,B,,,2,Intermediate,CHEMBL615356,,132,,,100256,3260,,
,BAO_0000019,,U,,Compound was tested for inhibitory activity against tryptase,1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615357,,133,,,22226,3451,,
,BAO_0000219,,N,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615358,,134,,,81020,13885,726.0,
,BAO_0000219,,N,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,1,HepG2,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL827086,,135,,,81020,13885,726.0,
,BAO_0000019,,U,,Compound was tested for the inhibition of Alpha-glucosidase,1,,,B,,,0,Autocuration,CHEMBL615359,,136,,,22226,3676,,
,BAO_0000357,,H,,Inhibitory concentration against human neutrophil elastase (HNE),1,,,B,,,8,Autocuration,CHEMBL615360,,137,,,235,6043,,
Heart,BAO_0000218,,U,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,1,,10116.0,F,Rattus norvegicus,948.0,0,Autocuration,CHEMBL615361,,138,,,22226,11140,,
,BAO_0000019,,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,F,,,8,Autocuration,CHEMBL615362,,139,,,19640,10543,,
,BAO_0000019,,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,F,,,8,Expert,CHEMBL615363,,140,,,19640,10543,,
,BAO_0000357,,H,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,B,,,8,Autocuration,CHEMBL615364,,141,,,19640,10543,,
,BAO_0000019,,H,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,1,,,F,,,8,Expert,CHEMBL615365,,142,,,19640,10543,,
,BAO_0000219,,N,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,1,P338,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615366,,143,,,80360,11365,524.0,
,BAO_0000219,,N,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,1,P338,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615367,,144,,,80360,11365,524.0,
,BAO_0000219,,N,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,1,PBL,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615368,,145,,,80384,11803,554.0,
,BAO_0000019,,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,1,,9940.0,F,Ovis aries,,0,Autocuration,CHEMBL615369,,146,,,22226,11803,,
,BAO_0000019,,U,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,1,,9940.0,F,Ovis aries,,0,Autocuration,CHEMBL615370,,147,,,22226,11803,,
,BAO_0000357,,H,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),1,,,B,,,8,Autocuration,CHEMBL615673,,148,,,191,12278,,
,BAO_0000019,,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615674,,149,,,22226,8249,,
,BAO_0000019,,U,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615675,,150,,,22226,8249,,
,BAO_0000219,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,1,CCRF-CEM,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615676,,151,,,22226,8249,635.0,
,BAO_0000219,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,1,CCRF-CEM,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615677,,152,,,22226,8249,635.0,
,BAO_0000219,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,1,CCRF-CEM,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615678,,153,,,22226,8249,635.0,
,BAO_0000219,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,1,CCRF-CEM,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615679,,154,,,22226,8249,635.0,
,BAO_0000019,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615680,,155,,,22226,8249,,
,BAO_0000019,,U,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615681,,156,,,22226,8249,,
,BAO_0000249,,H,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,1,,,B,,,6,Autocuration,CHEMBL857972,,157,,,104290,16992,,
,BAO_0000218,,N,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,1,,1314.0,F,Streptococcus pyogenes,,1,Intermediate,CHEMBL857899,,158,,,50264,10543,,
,BAO_0000218,,N,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),1,,10335.0,F,Human herpesvirus 3,,1,Intermediate,CHEMBL615371,,159,,,50527,17833,,
,BAO_0000218,,N,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,1,HEL,10335.0,F,vericilla zoster virus,,1,Expert,CHEMBL615372,,160,,,50527,17290,468.0,
,BAO_0000218,,N,,Antiviral activity against 07/1 strain of VZV; ND: No data,1,,10335.0,F,vericilla zoster virus,,1,Intermediate,CHEMBL615373,,161,,,50527,17290,,
,BAO_0000218,,N,,Antiviral activity against 07/1 strain of VZV; ND=No data,1,,10335.0,F,vericilla zoster virus,,1,Intermediate,CHEMBL615374,,162,,,50527,17290,,
,BAO_0000218,,N,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",1,,561.0,F,escherichia cloac,,1,Intermediate,CHEMBL615375,,163,,,50145,10932,,
,BAO_0000019,,U,,Ratio of Ki at A2 to Ki at A1 receptors,1,,,B,,,0,Autocuration,CHEMBL615376,,164,,,22226,9707,,
,BAO_0000249,,H,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",1,,5476.0,B,Candida albicans,,8,Expert,CHEMBL615377,,165,,,11143,2346,,
,BAO_0000357,,H,,"Inhibition of 1,3-beta-glucan synthase",1,,284593.0,B,Candida glabrata CBS 138,,8,Expert,CHEMBL615378,,166,,,18077,2205,,
,BAO_0000219,,N,,Inhibition of growth of 1-87 human tumor cell line,1,1-87 tumor cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615379,,167,,,80609,11900,832.0,
,BAO_0000219,,D,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615380,,168,,,12166,14864,,
,BAO_0000357,,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO),1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615381,,169,,,100171,16474,,
,BAO_0000357,,D,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615382,,170,,,100171,16474,,
,BAO_0000357,,D,,% inhibition against soybean 1-lipoxygenase (SLO),1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615383,,171,,,100171,16474,,
,BAO_0000357,,D,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615384,,172,,,100171,16474,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615385,,173,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615386,,174,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615387,,175,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615388,,176,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615214,,177,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL827087,,178,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615215,,179,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615216,,180,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615217,,181,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615218,,182,,,100171,3094,,
,BAO_0000357,,D,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,1,,3847.0,B,Glycine max,,9,Autocuration,CHEMBL615219,,183,,,100171,3094,,
,BAO_0000019,,U,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,1,,10090.0,B,Mus musculus,,0,Autocuration,CHEMBL615220,,184,,,22226,10413,,
,BAO_0000219,,N,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),1,C3H 10T1/2,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615221,,185,,,80049,16929,294.0,
,BAO_0000019,,U,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL615222,,186,,,22226,1229,,
,BAO_0000357,,H,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,,B,,,8,Autocuration,CHEMBL615223,,187,,,11489,16587,,
,BAO_0000357,,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),1,,,B,,,8,Autocuration,CHEMBL615224,,188,,,11862,16587,,
,BAO_0000357,,H,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,1,,,B,,,8,Autocuration,CHEMBL615225,,189,,,11862,16587,,
,BAO_0000357,,H,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,1,,,B,,,8,Autocuration,CHEMBL615226,,190,,,11489,16587,,
,BAO_0000357,,H,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,1,,,B,,,8,Autocuration,CHEMBL615227,,191,,,11862,16587,,
,BAO_0000019,,D,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,1,,9913.0,F,Bos taurus,,9,Expert,CHEMBL615228,,192,,,12347,8058,,
,BAO_0000357,,D,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615229,,193,,,100120,9065,,
Adrenal gland,BAO_0000357,,D,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,1,,10116.0,B,Rattus norvegicus,2369.0,9,Expert,CHEMBL615230,,194,,,100120,8865,,
,BAO_0000357,,D,,Inhibition of rat adrenal 11-beta-hydroxylase,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615231,,195,,,100120,9066,,
,BAO_0000357,,D,,Inhibition of rat adrenal 11-beta-hydroxylase,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL884520,,196,,,100120,8394,,
,BAO_0000357,,D,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615232,,197,,,100120,8394,,
,BAO_0000019,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,1,,,B,,,8,Autocuration,CHEMBL615233,,198,,,10328,6431,,
,BAO_0000357,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,,B,,,8,Autocuration,CHEMBL827088,,199,,,11490,6431,,
,BAO_0000357,,H,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,1,,,B,,,8,Autocuration,CHEMBL615234,,200,,,11490,6431,,
,BAO_0000019,,H,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,1,,,F,,,8,Autocuration,CHEMBL615235,,201,,,11134,9295,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,B,,,8,Autocuration,CHEMBL615236,,202,,,12052,10193,,
,BAO_0000019,,H,,Compound was tested in vitro for inhibition of 12-LO human platelet,1,,,B,,,8,Autocuration,CHEMBL615237,,203,,,11134,13622,,
,BAO_0000019,,H,,Inhibitory concentration against human platelet 12-lipoxygenase,1,,,F,,,8,Autocuration,CHEMBL615238,,204,,,11134,12079,,
,BAO_0000019,,H,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,1,,,B,,,8,Autocuration,CHEMBL615239,,205,,,11134,13622,,
,BAO_0000019,,D,,Inhibitory concentration against human platelet 12-lipoxygenase,1,,9606.0,F,Homo sapiens,,9,Autocuration,CHEMBL615240,,206,,,11134,12079,,
,BAO_0000019,,H,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,1,,,B,,,8,Expert,CHEMBL615241,,207,,,11835,13500,,
,BAO_0000357,,H,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,1,,,B,,,8,Expert,CHEMBL615242,,208,,,11601,13723,,
,BAO_0000019,,H,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),1,,,B,,,8,Autocuration,CHEMBL615243,,209,,,11134,16474,,
,BAO_0000019,,H,,Inhibitory activity against human platelet 12-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL615244,,210,,,11134,1630,,
,BAO_0000019,,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,1,,,B,,,8,Autocuration,CHEMBL615245,,211,,,11134,167,,
,BAO_0000019,,H,,% inhibition against human platelet 12-lipoxygenase (12-HLO),1,,,B,,,8,Autocuration,CHEMBL615246,,212,,,11134,16474,,
,BAO_0000019,,H,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,1,,,B,,,8,Autocuration,CHEMBL615247,,213,,,11134,167,,
,BAO_0000019,,H,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,1,,,B,,,8,Autocuration,CHEMBL615248,,214,,,11134,16474,,
,BAO_0000357,,H,,Inhibitory activity towards porcine 12-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL615249,,215,,,11601,10091,,
,BAO_0000357,,H,,Tested for inhibition against porcine 12-LO,1,,,B,,,8,Autocuration,CHEMBL615250,,216,,,11601,11966,,
,BAO_0000019,,H,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,1,,,B,,,8,Autocuration,CHEMBL615251,,217,,,12052,951,,
,BAO_0000019,,H,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,1,,,B,,,8,Autocuration,CHEMBL615252,,218,,,12052,10997,,
,BAO_0000019,,H,,In vitro inhibition of rat platelet 12-lipoxygenase,1,,,B,,,8,Expert,CHEMBL828340,,219,,,12052,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,B,,,8,Autocuration,CHEMBL615253,,220,,,12052,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,1,,,B,,,8,Autocuration,CHEMBL615254,,221,,,12052,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,1,,,B,,,8,Autocuration,CHEMBL615255,,222,,,12052,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,1,,,B,,,8,Autocuration,CHEMBL615256,,223,,,12052,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL615257,,224,,,12052,10193,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,1,,,B,,,8,Autocuration,CHEMBL615258,,225,,,12052,11087,,
,BAO_0000219,,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,1,41M,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615259,,226,,,80007,15569,621.0,
,BAO_0000219,,N,,In vitro antitumor activity against 41M cell line.,1,41M,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615260,,227,,,80007,12989,621.0,
,BAO_0000219,,N,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,1,41M,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615261,,228,,,80007,16745,621.0,
,BAO_0000219,,N,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,1,41M,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615262,,229,,,80007,15569,621.0,
,BAO_0000219,,N,,In vitro antitumor activity against 41McisR cell line.,1,41M,9606.0,F,Homo sapiens,,1,Expert,CHEMBL615263,,230,,,80007,12989,621.0,
,BAO_0000219,,N,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,1,41M,9606.0,F,Homo sapiens,,1,Expert,CHEMBL838393,,231,,,80007,12989,621.0,
,BAO_0000219,,N,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,1,41M,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615264,,232,,,80007,16745,621.0,
,BAO_0000357,,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615265,,233,,,84,6210,,
,BAO_0000357,,D,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615266,,234,,,68,6210,,
,BAO_0000357,,H,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),1,,,B,,,8,Expert,CHEMBL615267,,235,,,68,6226,,
,BAO_0000357,,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,,B,,,8,Expert,CHEMBL615268,,236,,,10201,17855,,
,BAO_0000357,,H,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,1,,,B,,,8,Expert,CHEMBL615269,,237,,,10201,17855,,
,BAO_0000357,,H,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,1,,,B,,,8,Expert,CHEMBL615270,,238,,,10201,17855,,
,BAO_0000357,,H,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,,B,,,8,Autocuration,CHEMBL615271,,239,,,12220,10413,,
,BAO_0000357,,H,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615272,,240,,,11303,10413,,
,BAO_0000357,,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615103,,241,,,11303,10413,,
,BAO_0000357,,H,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615104,,242,,,11303,10413,,
,BAO_0000357,,H,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",1,,,B,,,8,Autocuration,CHEMBL615105,,243,,,12220,10413,,
,BAO_0000357,,H,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",1,,,B,,,8,Autocuration,CHEMBL872866,,244,,,12220,10413,,
,BAO_0000357,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615106,,245,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615107,,246,,,11303,7587,,
,BAO_0000357,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615108,,247,,,11303,7587,,
,BAO_0000357,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615109,,248,,,11303,7587,,
,BAO_0000357,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615110,,249,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL840105,,250,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615111,,251,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615112,,252,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615113,,253,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615114,,254,,,11303,7587,,
,BAO_0000357,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615115,,255,,,11303,7587,,
,BAO_0000019,,H,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL615116,,256,,,11303,7587,,
,BAO_0000357,,H,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",1,,,B,,,8,Autocuration,CHEMBL615698,,257,,,11303,7323,,
,BAO_0000019,,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",1,,9823.0,B,Sus scrofa,,0,Autocuration,CHEMBL615699,,258,,,22226,7587,,
,BAO_0000019,,U,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",1,,9823.0,B,Sus scrofa,,0,Autocuration,CHEMBL615700,,259,,,22226,7587,,
,BAO_0000357,,H,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,1,,4932.0,B,Saccharomyces cerevisiae,,8,Expert,CHEMBL615701,,260,,,100249,13750,,
,BAO_0000019,,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615702,,261,,,22226,7662,,
,BAO_0000019,,U,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615703,,262,,,22226,7662,,
,BAO_0000019,,U,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615704,,263,,,22226,7662,,
,BAO_0000019,,H,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,,F,,,6,Autocuration,CHEMBL615705,,264,,,104698,12211,,
,BAO_0000019,,H,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",1,,,F,,,6,Autocuration,CHEMBL615706,,265,,,104698,12211,,
Ileum,BAO_0000221,,D,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL615707,,266,,,20033,12211,,
,BAO_0000019,,H,,Stimulatory activity of intragastric pressure was tested in the rat,1,,,F,,,8,Expert,CHEMBL615708,,267,,,10623,12211,,
,BAO_0000357,,H,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,1,,,B,,,8,Autocuration,CHEMBL615709,,268,,,121,15453,,
,BAO_0000218,,U,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615710,,269,,,22226,11884,,
,BAO_0000019,,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,,F,,,8,Autocuration,CHEMBL615711,,270,,,12688,7185,,
,BAO_0000357,,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615712,,271,,,121,6876,,
,BAO_0000357,,D,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL836325,,272,,,121,6876,,
,BAO_0000019,,H,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,1,,,F,,,8,Autocuration,CHEMBL615713,,273,,,12198,11863,,
,BAO_0000357,,H,,Inhibition constant of high-affinity 5-HT uptake,1,,,B,,,8,Autocuration,CHEMBL615714,,274,,,12198,11863,,
,BAO_0000019,,H,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,1,,,F,,,8,Autocuration,CHEMBL615715,,275,,,12198,11863,,
,BAO_0000019,,H,,Maximum rate was determined for high affinity transport of 5-HT,1,,,F,,,8,Autocuration,CHEMBL615716,,276,,,12198,11863,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-HT uptake,1,,,F,,,4,Autocuration,CHEMBL615717,,277,,,104714,4639,,
,BAO_0000019,,H,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,1,,,B,,,8,Expert,CHEMBL881818,,278,,,10577,15796,,
,BAO_0000357,,H,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL884540,,279,,,105,15796,,
,BAO_0000224,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615718,,280,,,104744,12801,,
,BAO_0000224,,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,1,,,B,,,4,Autocuration,CHEMBL615719,,281,,,104744,12801,,
,BAO_0000249,,H,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,1,,,B,,,4,Autocuration,CHEMBL615720,,282,,,104744,12120,,
,BAO_0000249,,H,Membranes,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,1,,,B,,,4,Autocuration,CHEMBL615721,,283,,,104744,12120,,
,BAO_0000019,,H,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL615722,,284,,,104744,11963,,
,BAO_0000019,,H,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,1,,,F,,,8,Autocuration,CHEMBL615723,,285,,,51,11701,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615724,,286,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615725,,287,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615726,,288,,,51,9995,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),1,,,F,,,8,Autocuration,CHEMBL615727,,289,In vivo,,10576,16394,,
,BAO_0000019,,D,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL615728,,290,,,105570,11574,,
,BAO_0000219,,H,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL857971,,291,,,279,15779,449.0,
,BAO_0000357,,H,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL615729,,292,,,107,15363,,
,BAO_0000019,,D,,Efficacy against 5-hydroxytryptamine 2A receptor,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615730,,293,,,12687,15363,,
,BAO_0000019,,H,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,1,,,F,,,8,Expert,CHEMBL615731,,294,,,12687,15329,,
,BAO_0000019,,H,,Relative potency towards 5-HT2A receptor of rat tail artery,1,,,F,,,8,Expert,CHEMBL615732,,295,,,12687,15329,,
,BAO_0000019,,H,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,,F,,,8,Expert,CHEMBL615733,,296,,,12687,15329,,
,BAO_0000019,,H,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,1,,,F,,,8,Expert,CHEMBL615734,,297,,,12687,15329,,
,BAO_0000019,,H,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,1,,,F,,,8,Autocuration,CHEMBL615735,,298,,,12687,15329,,
,BAO_0000019,,H,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,1,,,F,,,8,Expert,CHEMBL615736,,299,,,12687,15329,,
Ileum,BAO_0000221,,D,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL615737,,300,,,20033,273,,
Ileum,BAO_0000221,,D,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL615738,,301,,,20033,273,,
Ileum,BAO_0000221,,D,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL615739,,302,,,20033,273,,
,BAO_0000357,,H,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,1,,,B,,,8,Autocuration,CHEMBL615278,,303,,,10623,12092,,
,BAO_0000019,,D,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615279,,304,,,10623,1317,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Expert,CHEMBL615280,,305,,,168,12409,,
,BAO_0000019,,U,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,1,,9031.0,B,Gallus gallus,,0,Autocuration,CHEMBL615281,,306,,,22226,11126,,
,BAO_0000019,,U,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615282,,307,,,22226,11126,,
,BAO_0000019,,U,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615283,,308,,,22226,11126,,
,BAO_0000219,,N,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,1,HL-60,9606.0,B,Homo sapiens,,1,Autocuration,CHEMBL615284,,309,,,80156,11126,649.0,
,BAO_0000019,,U,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615285,,310,,,22226,11126,,
,BAO_0000019,,U,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615286,,311,,,22226,11126,,
,BAO_0000219,,D,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,1,Oocytes,9606.0,B,Homo sapiens,,7,Autocuration,CHEMBL615287,,312,,,104703,17807,,
,BAO_0000220,,S,,Chymotryptic inhibitory activity against 26S proteasome,1,,,F,,,2,Intermediate,CHEMBL615288,,313,,,100256,16575,,
,BAO_0000220,,S,,Inhibitory activity against 26S proteasome degradation of IkB,1,,,B,,,2,Intermediate,CHEMBL615289,,314,,,100256,15407,,
,BAO_0000219,,N,,In vitro inhibition of 2780/DOX ovarian cancer cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615290,,315,,,81034,10797,478.0,
,BAO_0000219,,N,,In vitro inhibition of 2780/S ovarian cancer cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884522,,316,,,81034,10797,478.0,
,BAO_0000019,,U,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615291,,317,,,22226,3469,,
,BAO_0000225,,M,,Association constant for binding to AATT 28-mer AATT hairpin,1,,,B,,,3,Intermediate,CHEMBL615292,,318,,,22222,16037,,
,BAO_0000225,,M,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,1,,,B,,,3,Intermediate,CHEMBL615293,,319,,,22222,16037,,
,BAO_0000225,,M,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,,B,,,3,Intermediate,CHEMBL615294,,320,,,22222,16037,,
,BAO_0000225,,M,,Reaction Rate Parameter for 28-mer AATT hairpin,1,,,B,,,3,Intermediate,CHEMBL615295,,321,,,22222,16037,,
,BAO_0000019,,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL825021,,322,,,22226,16524,,
,BAO_0000019,,U,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615296,,323,,,22226,16524,,
,BAO_0000019,,U,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL615297,,324,,,22226,16524,,
,BAO_0000019,,U,,Cytotoxicity against cell line 2SC/20 determined by MTT test,1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL615298,,325,,,22226,16758,,
,BAO_0000019,,U,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL615299,,326,,,22226,16758,,
,BAO_0000019,,U,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL615300,,327,,,22226,16758,,
,BAO_0000357,,H,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,1,,,B,,,8,Autocuration,CHEMBL615301,,328,,,241,14360,,
,BAO_0000357,,D,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615302,,329,,,241,14360,,
,BAO_0000019,,U,,Selectivity ratio of ID50 in liver and heart,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615303,,330,,,22226,9964,,
,BAO_0000019,,H,,"Selectivity, ratio of relative ID50 in liver and heart",1,,,B,,,8,Autocuration,CHEMBL615304,,331,,,12132,9964,,
,BAO_0000019,,H,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,1,,,B,,,8,Autocuration,CHEMBL615305,,332,,,12132,9964,,
,BAO_0000218,,H,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615306,,333,,,12132,9964,,
,BAO_0000218,,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615307,,334,,,12132,9964,,
,BAO_0000218,,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615308,,335,In vivo,,12132,9964,,
,BAO_0000218,,H,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,F,,,8,Autocuration,CHEMBL615309,,336,In vivo,,12132,9964,,
,BAO_0000019,,U,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",1,,,B,,,0,Autocuration,CHEMBL615310,,337,,,22226,9964,,
,BAO_0000019,,H,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,1,,,B,,,8,Autocuration,CHEMBL615311,,338,,,12132,9964,,
,BAO_0000019,,U,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615312,,339,,,22226,9964,,
,BAO_0000019,,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,,B,,,8,Autocuration,CHEMBL615313,,340,,,12132,9964,,
,BAO_0000019,,H,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,1,,,F,,,8,Autocuration,CHEMBL615314,,341,,,12132,9964,,
,BAO_0000019,,H,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615315,,342,,,12132,9964,,
,BAO_0000218,,U,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615316,,343,,,22226,9964,,
,BAO_0000218,,H,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,1,,,B,,,8,Autocuration,CHEMBL615317,,344,In vivo,,12132,9964,,
,BAO_0000218,,H,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615318,,345,,,12132,9964,,
,BAO_0000218,,U,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615319,,346,,,22226,9964,,
,BAO_0000019,,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,,B,,,8,Autocuration,CHEMBL615320,,347,,,12132,9964,,
,BAO_0000019,,H,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",1,,,F,,,8,Autocuration,CHEMBL615321,,348,,,12132,9964,,
,BAO_0000019,,U,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615322,,349,,,22226,3796,,
,BAO_0000357,,H,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615323,,350,,,19690,4251,,
,BAO_0000357,,H,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615407,,351,,,19690,4251,,
,BAO_0000357,,H,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL857267,,352,,,19690,4251,,
,BAO_0000357,,H,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,1,,562.0,B,Escherichia coli,,8,Autocuration,CHEMBL615408,,353,,,19690,4251,,
,BAO_0000357,,H,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,1,,,B,,,8,Autocuration,CHEMBL615409,,354,,,19690,166,,
,BAO_0000357,,H,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,1,,,B,,,8,Autocuration,CHEMBL615410,,355,,,19690,17861,,
,BAO_0000357,,H,,Inhibition constant against 3-dehydroquinate synthase,1,,,B,,,8,Autocuration,CHEMBL615411,,356,,,19690,166,,
,BAO_0000357,,H,,Association rate constant against 3-dehydroquinate synthase,1,,,B,,,8,Autocuration,CHEMBL615412,,357,,,19690,166,,
,BAO_0000357,,H,,Rate constant against 3-dehydroquinate synthase,1,,,B,,,8,Autocuration,CHEMBL615413,,358,,,19690,166,,
,BAO_0000019,,U,,Inhibitory activity against fuc-TVII,1,,,B,,,0,Autocuration,CHEMBL615414,,359,,,22226,3548,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615415,,360,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615416,,361,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615417,,362,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615418,,363,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615419,,364,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615420,,365,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615421,,366,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615422,,367,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615423,,368,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL872868,,369,,,12236,9877,,
Liver,BAO_0000251,,D,Microsomes,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,1,,10116.0,B,Rattus norvegicus,2107.0,9,Autocuration,CHEMBL615424,,370,,,12236,9877,,
,BAO_0000224,,H,,Inhibitory activity against 3-phosphoglycerate kinase.,1,,,B,,,4,Autocuration,CHEMBL825022,,371,,,104832,3003,,
,BAO_0000224,,H,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,1,,,B,,,4,Autocuration,CHEMBL615425,,372,,,104832,3003,,
,BAO_0000224,,H,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",1,,,B,,,4,Autocuration,CHEMBL615426,,373,,,104832,3003,,
,BAO_0000357,,D,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615427,,374,,,10612,17185,,
,BAO_0000219,,N,,Cytotoxicity on 3677 melanoma cells,1,3677 melanoma cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615428,,375,,,80616,6072,844.0,
,BAO_0000219,,N,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,1,3677 melanoma cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615429,,376,,,80616,6072,844.0,
,BAO_0000219,,N,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,1,MC-38,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615430,,377,,,80617,5018,700.0,
,BAO_0000019,,U,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,1,,9606.0,F,Homo sapiens,,0,Intermediate,CHEMBL615431,,378,,,22226,2852,,
,BAO_0000218,,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,1,B16,,F,,,0,Autocuration,CHEMBL615432,,379,,,22226,8663,798.0,
,BAO_0000218,,U,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,1,B16,,F,,,0,Autocuration,CHEMBL615433,,380,,,22226,8663,798.0,
,BAO_0000019,,D,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,1,,12131.0,F,Human rhinovirus 14,,9,Expert,CHEMBL615434,,381,,,12464,3245,,
,BAO_0000218,,N,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,1,,169066.0,F,Human rhinovirus sp.,,1,Intermediate,CHEMBL615435,,382,,,50085,3245,,
,BAO_0000218,,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,1,,169066.0,F,human rhinovirus type 14,,1,Intermediate,CHEMBL615436,,383,,,50679,3877,,
,BAO_0000218,,N,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,1,,169066.0,F,human rhinovirus type 14,,1,Intermediate,CHEMBL615437,,384,,,50679,3877,,
,BAO_0000019,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,12131.0,F,Human rhinovirus 14,,9,Expert,CHEMBL615438,,385,,,12464,5861,,
,BAO_0000019,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,12131.0,F,Human rhinovirus 14,,9,Expert,CHEMBL615439,,386,,,12464,5861,,
,BAO_0000019,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,1,,12131.0,F,Human rhinovirus 14,,9,Expert,CHEMBL615440,,387,,,12464,5861,,
,BAO_0000019,,D,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,1,,12131.0,F,Human rhinovirus 14,,9,Expert,CHEMBL615441,,388,,,12464,5861,,
,BAO_0000218,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,1,,12059.0,F,Enterovirus,,1,Intermediate,CHEMBL615641,,389,,,50665,13748,,
,BAO_0000218,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,1,,12059.0,F,Enterovirus,,1,Intermediate,CHEMBL872065,,390,,,50665,13748,,
,BAO_0000218,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,1,,12059.0,F,Enterovirus,,1,Intermediate,CHEMBL825023,,391,,,50665,13748,,
,BAO_0000218,,N,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,1,,12059.0,F,Enterovirus,,1,Intermediate,CHEMBL615642,,392,,,50665,13748,,
,BAO_0000357,,H,,Inhibition of human rhinovirus 3C protease,1,,147712.0,B,Human rhinovirus B,,8,Expert,CHEMBL615643,,393,,,12464,13748,,
,BAO_0000019,,U,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,1,,9606.0,B,Homo sapiens,,0,Autocuration,CHEMBL615644,,394,,,22226,17699,,
,BAO_0000218,,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615645,,395,,,80619,7145,833.0,
,BAO_0000218,,N,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615646,,396,,,80619,7145,833.0,
,BAO_0000218,,N,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615647,,397,,,80619,7145,833.0,
,BAO_0000218,,N,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615648,,398,,,80619,7145,833.0,
,BAO_0000218,,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615649,,399,,,80619,7145,833.0,
,BAO_0000218,,N,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,1,3EM 37,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615650,,400,,,80619,7145,833.0,
,BAO_0000218,,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615651,,401,,,80620,5325,847.0,
,BAO_0000218,,N,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615652,,402,,,80620,5325,847.0,
,BAO_0000218,,N,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,1,3LL cell line,10090.0,F,Mus musculus,,1,Expert,CHEMBL615653,,403,,,80620,5325,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615654,,404,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615655,,405,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL825024,,406,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615656,,407,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615657,,408,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615658,,409,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615659,,410,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615660,,411,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615661,,412,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615662,,413,,,80620,16169,847.0,
,BAO_0000219,,N,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615663,,414,,,80620,16169,847.0,
,BAO_0000219,,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615664,,415,,,80620,16169,847.0,
,BAO_0000219,,N,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615665,,416,,,80620,16169,847.0,
,BAO_0000219,,N,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615666,,417,,,80620,16169,847.0,
,BAO_0000219,,N,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615667,,418,,,80620,16169,847.0,
,BAO_0000219,,N,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615668,,419,,,80620,16169,847.0,
,BAO_0000219,,N,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615669,,420,,,80620,16169,847.0,
,BAO_0000219,,N,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615670,,421,,,80620,16169,847.0,
,BAO_0000219,,N,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL836739,,422,,,80620,16169,847.0,
,BAO_0000219,,N,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615671,,423,,,80620,16169,847.0,
,BAO_0000219,,N,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615672,,424,,,80620,16169,847.0,
,BAO_0000219,,N,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615791,,425,,,80620,16169,847.0,
,BAO_0000219,,N,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615792,,426,,,80620,16169,847.0,
,BAO_0000219,,N,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615793,,427,,,80620,16169,847.0,
,BAO_0000219,,N,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615794,,428,,,80620,16169,847.0,
,BAO_0000219,,N,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,1,3LL cell line,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615795,,429,,,80620,16169,847.0,
,BAO_0000219,,N,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,1,3LLD122,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL615590,,430,,,80621,15547,971.0,
,BAO_0000218,,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,1,,,F,,,0,Autocuration,CHEMBL615591,,431,,,22226,8663,,
,BAO_0000218,,U,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,1,,,F,,,0,Autocuration,CHEMBL615592,,432,,,22226,8663,,
,BAO_0000218,,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,1,,,F,,,0,Autocuration,CHEMBL615593,,433,,,22226,8663,,
,BAO_0000218,,U,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,1,,,F,,,0,Autocuration,CHEMBL615594,,434,,,22226,8663,,
,BAO_0000219,,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615595,,435,,,80951,4504,723.0,
,BAO_0000219,,N,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615596,,436,,,80951,4504,723.0,
,BAO_0000219,,H,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,1,NIH3T3,,F,,,8,Expert,CHEMBL615597,,437,,,11169,12695,723.0,
,BAO_0000219,,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615598,,438,,,80951,12695,723.0,
,BAO_0000219,,N,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615599,,439,,,80951,12695,723.0,
,BAO_0000219,,N,,Effective dose against murine 3T3 fibroblasts cells,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615600,,440,,,80951,17642,723.0,
,BAO_0000219,,N,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615601,,441,,,80951,17642,723.0,
,BAO_0000219,,N,,Cytotoxic effect on 3T3 cells,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615602,,442,,,80951,12340,723.0,
,BAO_0000219,,N,,Cytotoxic effect on 3T3 cells,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615603,,443,,,80951,12340,723.0,
,BAO_0000219,,N,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615604,,444,,,80951,12716,723.0,
,BAO_0000219,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615605,,445,,,80951,6277,723.0,
,BAO_0000219,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615606,,446,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL884526,,447,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615607,,448,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615608,,449,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615609,,450,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615682,,451,,,80951,6277,723.0,
,BAO_0000219,,N,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615683,,452,,,80951,6277,723.0,
,BAO_0000218,,N,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615684,,453,,,80951,17780,723.0,
,BAO_0000219,,D,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,1,,10090.0,F,Mus musculus,,7,Autocuration,CHEMBL615685,,454,,,104860,12751,,
,BAO_0000219,,N,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615686,,455,,,80951,12380,723.0,
,BAO_0000219,,N,,Inhibitory activity against 3T3 cell line,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615687,,456,,,80951,14892,723.0,
,BAO_0000219,,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL884523,,457,,,80951,12695,723.0,
,BAO_0000019,,H,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,1,,,F,,,8,Expert,CHEMBL615688,,458,,,11169,12695,,
,BAO_0000219,,N,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615689,,459,,,80951,12695,723.0,
,BAO_0000219,,N,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615690,,460,,,80951,12695,723.0,
,BAO_0000019,,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,1,,,F,,,8,Expert,CHEMBL615691,,461,,,11169,12695,,
,BAO_0000019,,H,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,1,,,F,,,8,Expert,CHEMBL615692,,462,,,11169,12695,,
,BAO_0000219,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615693,,463,,,80951,6277,723.0,
,BAO_0000219,,N,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615324,,464,,,80951,6277,723.0,
,BAO_0000219,,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,1,NIH3T3,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615325,,465,,,9,4959,723.0,
,BAO_0000219,,D,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),1,NIH3T3,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615490,,466,,,9,4959,723.0,
,BAO_0000219,,D,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,1,NIH3T3,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615491,,467,,,188,4959,723.0,
,BAO_0000219,,D,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),1,NIH3T3,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615492,,468,,,188,4959,723.0,
,BAO_0000219,,N,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615493,,469,,,80951,12082,723.0,
,BAO_0000219,,N,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615494,,470,,,80951,12082,723.0,
,BAO_0000219,,N,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615495,,471,,,80951,12082,723.0,
,BAO_0000219,,N,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615496,,472,,,80951,12082,723.0,
,BAO_0000219,,N,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615497,,473,,,80951,2643,723.0,
,BAO_0000219,,N,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615498,,474,,,80951,11926,723.0,
,BAO_0000219,,N,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,1,NIH3T3,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL615499,,475,,,80951,15204,723.0,
,BAO_0000219,,N,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL835522,,476,,,80951,15992,723.0,
,BAO_0000219,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615500,,477,,,80951,16279,723.0,
,BAO_0000219,,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615501,,478,,,80951,16279,723.0,
,BAO_0000219,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615502,,479,,,80951,16279,723.0,
,BAO_0000219,,N,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615503,,480,,,80951,16279,723.0,
,BAO_0000219,,N,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615504,,481,,,80951,16279,723.0,
,BAO_0000219,,N,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615505,,482,,,80951,16279,723.0,
,BAO_0000219,,N,,Inhibition of swiss 3T3 mouse fibroblast proliferation,1,NIH3T3,10090.0,F,Mus musculus,,1,Expert,CHEMBL615506,,483,,,80951,12831,723.0,
,BAO_0000219,,N,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,1,NIH3T3,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615507,,484,,,80951,13497,723.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615508,,485,,,80006,13715,620.0,
,BAO_0000219,,N,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615509,,486,,,80006,13618,620.0,
,BAO_0000219,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615510,,487,,,80006,11902,620.0,
,BAO_0000219,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615511,,488,,,80006,11902,620.0,
,BAO_0000219,,N,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615512,,489,,,80006,11902,620.0,
,BAO_0000218,,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615513,,490,,,80006,14840,620.0,
,BAO_0000218,,N,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615514,,491,,,80006,14840,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615515,,492,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615516,,493,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615517,,494,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615518,,495,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615519,,496,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615520,,497,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615521,,498,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615522,,499,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615523,,500,,,80006,13715,620.0,
,BAO_0000218,,N,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,3T3-L1,,F,,,1,Expert,CHEMBL615524,,501,,,80006,13715,620.0,
,BAO_0000218,,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,3T3-L1,,F,,,1,Expert,CHEMBL615525,,502,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615526,,503,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615527,,504,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615528,,505,,,80006,13715,620.0,
,BAO_0000218,,N,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,3T3-L1,,F,,,1,Expert,CHEMBL615529,,506,,,80006,13715,620.0,
,BAO_0000218,,N,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,3T3-L1,,F,,,1,Expert,CHEMBL615530,,507,,,80006,13715,620.0,
,BAO_0000218,,N,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,3T3-L1,,F,,,1,Expert,CHEMBL615531,,508,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615532,,509,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615533,,510,,,80006,13715,620.0,
,BAO_0000219,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615534,,511,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615535,,512,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615536,,513,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615537,,514,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL615538,,515,,,80006,13715,620.0,
,BAO_0000218,,N,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,1,3T3-L1,,F,,,1,Intermediate,CHEMBL836166,,516,,,80006,13715,620.0,
,BAO_0000219,,H,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,1,3T3-L1,,F,,,8,Expert,CHEMBL615539,,517,,,11214,6411,620.0,
,BAO_0000219,,N,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615540,,518,,,80006,6411,620.0,
,BAO_0000219,,H,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,1,3T3-L1,,F,,,8,Expert,CHEMBL615541,,519,,,11214,6411,620.0,
,BAO_0000219,,N,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615542,,520,,,80006,3966,620.0,
,BAO_0000219,,N,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,1,3T3-L1,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL615543,,521,,,80006,3966,620.0,
,BAO_0000219,,N,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615544,,522,,,80006,15556,620.0,
,BAO_0000219,,N,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615545,,523,,,80006,5845,620.0,
,BAO_0000219,,N,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615546,,524,,,80006,14422,620.0,
,BAO_0000219,,N,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615547,,525,,,80006,5845,620.0,
,BAO_0000219,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615548,,526,,,80006,14508,620.0,
,BAO_0000219,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615549,,527,,,80006,14508,620.0,
,BAO_0000219,,N,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,1,3T3-L1,10090.0,F,Mus musculus,,1,Expert,CHEMBL615550,,528,,,80006,14508,620.0,
,BAO_0000219,,N,,Inhibitory activity against rat fibroblast (3Y1) cell line,1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL615551,,529,,,80622,6349,1118.0,
,BAO_0000219,,N,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL615552,,530,,,80622,15899,1118.0,
,BAO_0000219,,N,,Cytotoxicity in 3Y1 cells.,1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL615553,,531,,,80622,15899,1118.0,
,BAO_0000219,,N,,Cytostatic effect in 3Y1 cells.,1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL615554,,532,,,80622,15899,1118.0,
,BAO_0000219,,N,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL615555,,533,,,80622,15899,1118.0,
,BAO_0000219,,N,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,1,3Y1 cell line,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL615556,,534,,,80622,17038,1118.0,
,BAO_0000019,,U,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,1,,,B,,,0,Autocuration,CHEMBL615557,,535,,,22226,12421,,
,BAO_0000019,,U,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,,B,,,0,Autocuration,CHEMBL615558,,536,,,22226,12947,,
,BAO_0000019,,U,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,1,,,B,,,0,Autocuration,CHEMBL872066,,537,,,22226,12947,,
,BAO_0000019,,D,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,1,,9823.0,B,Sus scrofa,,9,Expert,CHEMBL615559,,538,,,11607,4896,,
,BAO_0000019,,H,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,1,,,B,,,8,Autocuration,CHEMBL615560,,539,,,11607,6148,,
,BAO_0000019,,H,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,1,,,B,,,8,Autocuration,CHEMBL615561,,540,,,11607,16432,,
,BAO_0000019,,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,1,,,B,,,8,Expert,CHEMBL857062,,541,,,11607,4978,,
,BAO_0000019,,H,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),1,,,B,,,8,Expert,CHEMBL615562,,542,,,11607,4978,,
,BAO_0000019,,H,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,1,,,B,,,8,Autocuration,CHEMBL615563,,543,,,11607,3723,,
,BAO_0000357,,H,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),1,,,B,,,8,Autocuration,CHEMBL615564,,544,,,11607,3518,,
,BAO_0000019,,H,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,1,,,B,,,8,Autocuration,CHEMBL615565,,545,,,11607,4164,,
,BAO_0000019,,H,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,1,,,B,,,8,Autocuration,CHEMBL615566,,546,,,11607,3518,,
,BAO_0000019,,D,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,1,,9823.0,B,Sus scrofa,,9,Expert,CHEMBL615567,,547,,,11607,4164,,
,BAO_0000019,,H,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,1,,,B,,,8,Autocuration,CHEMBL615568,,548,,,11607,3518,,
,BAO_0000357,,H,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),1,,,B,,,8,Autocuration,CHEMBL615569,,549,,,11607,3518,,
,BAO_0000019,,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,1,,,B,,,8,Autocuration,CHEMBL615570,,550,,,11607,4978,,
,BAO_0000019,,H,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),1,,,B,,,8,Autocuration,CHEMBL615571,,551,,,11607,4978,,
,BAO_0000224,,H,,Binding affinity against melatonin (MT1) receptor (pC1),1,,,B,,,4,Autocuration,CHEMBL615572,,552,,,104733,6455,,
,BAO_0000019,,U,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,1,,,B,,,0,Autocuration,CHEMBL615573,,553,,,22226,2222,,
,BAO_0000019,,U,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,1,,,B,,,0,Autocuration,CHEMBL615574,,554,,,22226,13020,,
,BAO_0000019,,U,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,1,,,B,,,0,Autocuration,CHEMBL615575,,555,,,22226,13021,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,1,,,B,,,8,Autocuration,CHEMBL615576,,556,,,10619,14532,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615577,,557,,,10619,14118,,
Hippocampus,BAO_0000221,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,1,,,B,,10000000.0,8,Autocuration,CHEMBL615578,,558,,,51,11884,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615579,,559,,,51,13969,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL615580,,560,,,51,13392,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,1,,,B,,,8,Expert,CHEMBL615581,,561,,,51,14430,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615582,,562,,,51,12248,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615583,,563,,,51,12249,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615584,,564,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL833691,,565,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615585,,566,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615586,,567,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL884524,,568,,,51,9995,,
Hippocampus,BAO_0000221,,H,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615587,,569,,,51,12249,,
Hippocampus,BAO_0000221,,H,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,,,B,,10000000.0,8,Autocuration,CHEMBL615588,,570,,,51,11799,,
,BAO_0000249,,D,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615589,,571,,,10576,14331,,
Hippocampus,BAO_0000221,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,1,,9913.0,B,Bos taurus,10000000.0,8,Expert,CHEMBL615442,,572,,,51,11884,,
Hippocampus,BAO_0000221,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL615443,,573,,,51,14331,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615444,,574,,,51,11701,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,1,,,B,,10000000.0,8,Expert,CHEMBL615445,,575,,,51,11701,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615446,,576,,,51,12248,,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL615447,,577,,,51,12248,449.0,
Hippocampus,BAO_0000221,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615448,,578,,,51,12248,,
Hippocampus,BAO_0000221,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615449,,579,,,51,12249,,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL615450,,580,,,51,12248,449.0,
Hippocampus,BAO_0000221,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",1,,,B,,10000000.0,8,Expert,CHEMBL615451,,581,,,51,11799,,
,BAO_0000357,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,,B,,,8,Autocuration,CHEMBL615452,,582,,,51,634,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615453,,583,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615454,,584,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615455,,585,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615456,,586,,,51,9995,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615457,,587,,,51,9995,,
Hippocampus,BAO_0000218,,H,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,1,,,B,,10000000.0,8,Expert,CHEMBL615458,,588,,,51,12210,,
Hippocampus,BAO_0000221,,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615459,,589,,,51,13311,,
,BAO_0000219,,D,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615460,,590,,,51,2331,449.0,
,BAO_0000019,,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL615461,,591,,,51,1375,,
,BAO_0000019,,H,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL615462,,592,,,51,1375,,
Hippocampus,BAO_0000221,,H,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,1,,10141.0,F,Cavia porcellus,10000000.0,8,Autocuration,CHEMBL615463,,593,,,51,11574,,
Ileum,BAO_0000221,,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615464,,594,,,51,12867,,
Ileum,BAO_0000221,,H,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615465,,595,,,51,12867,,
Ileum,BAO_0000221,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615466,,596,,,51,12867,,
Ileum,BAO_0000221,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615467,,597,,,51,12867,,
Ileum,BAO_0000221,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615468,,598,,,51,12867,,
Ileum,BAO_0000221,,H,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,1,,10141.0,B,Cavia porcellus,2116.0,8,Autocuration,CHEMBL615469,,599,,,51,12867,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL615470,,600,,,51,11574,,
,BAO_0000357,,H,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL615471,,601,,,51,13114,,
,BAO_0000357,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL615472,,602,,,51,13181,,
Hippocampus,BAO_0000221,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,,10141.0,B,Cavia porcellus,10000000.0,8,Autocuration,CHEMBL883242,,603,,,106,10639,,
Hippocampus,BAO_0000221,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,1,,10141.0,F,Cavia porcellus,10000000.0,8,Autocuration,CHEMBL615473,,604,,,106,10639,,
,BAO_0000218,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,CHO,10029.0,B,Cricetulus griseus,,8,Autocuration,CHEMBL615474,,605,,,11863,11883,449.0,
,BAO_0000357,,H,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615475,,606,,,51,17785,,
,BAO_0000219,,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,1,HeLa,,F,,,8,Autocuration,CHEMBL615476,,607,,,51,1558,308.0,
,BAO_0000219,,H,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,1,HeLa,,F,,,8,Autocuration,CHEMBL615477,,608,,,51,1558,308.0,
,BAO_0000019,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL615478,,609,,,51,15740,,
,BAO_0000219,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL615160,,610,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,1,CHO,,F,,,8,Expert,CHEMBL615161,,611,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615162,,612,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615163,,613,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL615164,,614,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL615165,,615,,,51,17624,449.0,
,BAO_0000219,,H,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,1,CHO,,B,,,8,Autocuration,CHEMBL615166,,616,,,51,17624,449.0,
,BAO_0000219,,H,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,1,,,F,,,8,Autocuration,CHEMBL615167,,617,,,51,14256,,
,BAO_0000219,,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615168,,618,,,51,3445,308.0,
,BAO_0000219,,D,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615169,,619,,,51,3445,308.0,
,BAO_0000219,,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615170,,620,,,51,17200,449.0,
,BAO_0000219,,D,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615171,,621,,,51,17200,449.0,
,BAO_0000019,,H,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL615694,,622,,,51,15180,,
,BAO_0000019,,H,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL615695,,623,,,51,15180,,
,BAO_0000019,,H,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL615696,,624,,,51,16026,,
,BAO_0000219,,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL615697,,625,,,51,2759,449.0,
,BAO_0000219,,D,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL859410,,626,,,51,2759,449.0,
,BAO_0000219,,H,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,CHO,,F,,,8,Autocuration,CHEMBL615841,,627,,,51,2759,449.0,
,BAO_0000219,,D,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615842,,628,,,51,2759,449.0,
,BAO_0000219,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL835003,,629,,,51,2759,449.0,
,BAO_0000219,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),1,CHO,,F,,,8,Autocuration,CHEMBL615843,,630,,,51,2759,449.0,
,BAO_0000219,,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615979,,631,,,51,2759,449.0,
,BAO_0000219,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),1,CHO,,F,,,8,Autocuration,CHEMBL615980,,632,,,51,2759,449.0,
,BAO_0000219,,D,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615981,,633,,,51,2759,449.0,
,BAO_0000019,,D,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615982,,634,,,51,3445,,
,BAO_0000019,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615983,,635,,,51,5272,,
,BAO_0000019,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615984,,636,,,51,5272,,
,BAO_0000019,,D,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615985,,637,,,51,5272,,
,BAO_0000219,,H,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,CHO,,F,,,8,Autocuration,CHEMBL615986,,638,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,CHO,,F,,,8,Autocuration,CHEMBL615987,,639,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615988,,640,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,1,CHO,,F,,,8,Expert,CHEMBL615989,,641,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615990,,642,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615991,,643,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,CHO,,F,,,8,Autocuration,CHEMBL615992,,644,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615993,,645,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,CHO,,F,,,8,Expert,CHEMBL615994,,646,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615995,,647,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,1,CHO,,F,,,8,Autocuration,CHEMBL615996,,648,,,51,17624,449.0,
,BAO_0000219,,H,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,1,CHO,,F,,,8,Autocuration,CHEMBL615997,,649,,,51,17624,449.0,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,F,,,8,Autocuration,CHEMBL615998,,650,,,51,6563,,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,F,,,8,Autocuration,CHEMBL615999,,651,,,51,6563,,
,BAO_0000019,,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,,F,,,8,Autocuration,CHEMBL616000,,652,,,51,6563,,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,HEK293,,F,,,8,Autocuration,CHEMBL616001,,653,,,51,17296,722.0,
,BAO_0000019,,D,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616002,,654,,,51,6876,,
,BAO_0000019,,H,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",1,,,F,,,8,Expert,CHEMBL616003,,655,,,51,6876,,
,BAO_0000019,,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616004,,656,,,51,5272,,
,BAO_0000019,,D,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616005,,657,,,51,5272,,
,BAO_0000019,,H,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,F,,,8,Autocuration,CHEMBL616006,,658,,,51,5548,,
,BAO_0000019,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",1,,,F,,,8,Expert,CHEMBL616007,,659,,,51,5548,,
,BAO_0000019,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,F,,,8,Autocuration,CHEMBL616008,,660,,,51,5548,,
,BAO_0000019,,H,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",1,,,F,,,8,Autocuration,CHEMBL616009,,661,,,51,5548,,
,BAO_0000019,,H,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",1,,,F,,,8,Expert,CHEMBL616010,,662,,,51,5929,,
,BAO_0000019,,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616011,,663,,,51,5929,,
,BAO_0000019,,D,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL615740,,664,,,51,5929,,
,BAO_0000019,,H,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL615741,,665,,,51,16245,,
,BAO_0000019,,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,,F,,,8,Expert,CHEMBL615742,,666,,,51,5640,,
,BAO_0000019,,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",1,,,F,,,8,Autocuration,CHEMBL615743,,667,,,51,5640,,
,BAO_0000219,,H,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,1,CHO,,F,,,8,Autocuration,CHEMBL615744,,668,,,51,14509,449.0,
,BAO_0000219,,H,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,1,CHO,,F,,,8,Expert,CHEMBL615745,,669,,,51,14509,449.0,
,BAO_0000357,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL615746,,670,,,51,15331,,
,BAO_0000357,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL615747,,671,,,51,15331,,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,F,,,8,Autocuration,CHEMBL615748,,672,,,51,6563,,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",1,,,F,,,8,Autocuration,CHEMBL615749,,673,,,51,6563,,
,BAO_0000019,,H,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,1,,,F,,,8,Autocuration,CHEMBL615750,,674,,,51,6563,,
,BAO_0000019,,D,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616259,,675,,,51,6563,,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,F,,,8,Autocuration,CHEMBL616260,,676,,,51,6563,,
,BAO_0000019,,D,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616261,,677,,,51,5272,,
,BAO_0000019,,D,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616262,,678,,,51,5272,,
,BAO_0000019,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616263,,679,,,51,5272,,
,BAO_0000019,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616264,,680,,,51,5272,,
,BAO_0000019,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616265,,681,,,51,5272,,
,BAO_0000019,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616266,,682,,,51,5272,,
,BAO_0000019,,D,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616267,,683,,,51,5272,,
,BAO_0000019,,D,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616268,,684,,,51,5272,,
,BAO_0000357,,D,,Inhibition of human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616269,,685,,,51,16146,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL884528,,686,,,51,17624,449.0,
,BAO_0000219,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,1,HEK293,,B,,,9,Expert,CHEMBL616270,,687,,,105,13706,722.0,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616271,,688,,,51,15250,449.0,
,BAO_0000219,,H,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL616272,,689,,,51,17624,449.0,
,BAO_0000357,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,1,,,B,,,8,Expert,CHEMBL616273,,690,,,51,6861,,
,BAO_0000357,,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616274,,691,,,51,17200,,
,BAO_0000219,,H,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616275,,692,,,51,17624,449.0,
,BAO_0000219,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616276,,693,,,51,17624,449.0,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616277,,694,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616278,,695,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616279,,696,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616280,,697,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616281,,698,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616282,,699,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616283,,700,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616284,,701,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616285,,702,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616286,,703,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616287,,704,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616288,,705,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL616289,,706,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615610,,707,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615611,,708,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615612,,709,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615613,,710,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615614,,711,In vivo,,22226,12058,,
,BAO_0000218,,U,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL615615,,712,In vivo,,22226,12058,,
,BAO_0000019,,H,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,1,,,B,,,4,Autocuration,CHEMBL615616,,713,,,105093,11440,,
Hypothalamus,BAO_0000249,,H,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,1,,,B,,1898.0,8,Autocuration,CHEMBL615617,,714,,,11923,6238,,
,BAO_0000019,,H,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,1,,,B,,,8,Autocuration,CHEMBL615618,,715,,,10577,10046,,
,BAO_0000019,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,1,,,B,,,8,Autocuration,CHEMBL615619,,716,,,10577,10046,,
,BAO_0000019,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,,B,,,8,Expert,CHEMBL615620,,717,,,10577,10046,,
,BAO_0000357,,H,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",1,,,B,,,8,Autocuration,CHEMBL615621,,718,,,55,167,,
,BAO_0000357,,H,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",1,,,B,,,8,Autocuration,CHEMBL615622,,719,,,55,167,,
,BAO_0000019,,H,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),1,,,F,,,8,Autocuration,CHEMBL615623,,720,,,12166,11520,,
,BAO_0000019,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,F,,,8,Autocuration,CHEMBL615624,,721,,,12166,11520,,
,BAO_0000019,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,F,,,8,Autocuration,CHEMBL615625,,722,,,12166,11520,,
,BAO_0000019,,H,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,1,,,F,,,8,Autocuration,CHEMBL767045,,723,,,12166,11520,,
,BAO_0000019,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL615626,,724,,,55,135,,
,BAO_0000019,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL615627,,725,,,55,135,,
,BAO_0000019,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL615628,,726,,,55,11311,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL615629,,727,,,55,10193,,
,BAO_0000357,,D,,Inhibitory concentration against 5-lipoxygenase from human whole blood,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615630,,728,,,55,12281,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL615631,,729,,,55,11311,,
,BAO_0000218,,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,,F,,,8,Autocuration,CHEMBL615632,,730,,,17087,12576,,
,BAO_0000357,,H,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,1,,,B,,,8,Autocuration,CHEMBL615633,,731,,,17087,12281,,
,BAO_0000218,,H,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,1,,,F,,,8,Autocuration,CHEMBL615634,,732,,,17087,12576,,
,BAO_0000019,,H,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL615635,,733,,,55,11089,,
,BAO_0000357,,H,,In vitro inhibition of rat 5-Lipoxygenase,1,,,B,,,8,Expert,CHEMBL615636,,734,,,12166,11006,,
,BAO_0000357,,D,,Inhibitory activity against 5-Lipoxygenase,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615637,,735,,,12166,11481,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,1,RBL-1,,B,,,8,Expert,CHEMBL615638,,736,,,12166,10864,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,RBL-1,,B,,,8,Autocuration,CHEMBL615639,,737,,,12166,3595,702.0,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,1,RBL-1,,B,,,8,Autocuration,CHEMBL615640,,738,,,12166,11311,702.0,
,BAO_0000019,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,1,,,B,,,8,Autocuration,CHEMBL615796,,739,,,12166,11311,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL615845,,740,,,12166,11311,,
,BAO_0000357,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,,B,,,8,Autocuration,CHEMBL615846,,741,,,12166,11006,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL615847,,742,,,12166,3595,702.0,
,BAO_0000357,,H,,The compound was tested for inhibition of isolated 5-Lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL615848,,743,,,12166,11311,,
,BAO_0000019,,U,,Ratio of IC50 against 5-LO and COX,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615849,,744,,,22226,11481,,
,BAO_0000357,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,1,,,B,,,8,Autocuration,CHEMBL615850,,745,,,12166,11006,,
,BAO_0000357,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,1,,,B,,,8,Autocuration,CHEMBL615851,,746,,,12166,11006,,
,BAO_0000219,,H,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,1,,,B,,,8,Autocuration,CHEMBL615852,,747,,,12166,11311,,
,BAO_0000019,,H,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,1,,,F,,,8,Autocuration,CHEMBL615853,,748,,,12166,11006,,
Prostate gland,BAO_0000357,,H,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,1,,,B,,2367.0,8,Autocuration,CHEMBL884527,,749,,,120,4288,,
,BAO_0000019,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,1,,8932.0,B,Columba livia,,0,Autocuration,CHEMBL872871,,750,,,22226,7587,,
,BAO_0000019,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,1,,8932.0,B,Columba livia,,0,Autocuration,CHEMBL615854,,751,,,22226,7587,,
,BAO_0000019,,U,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,1,,8932.0,B,Columba livia,,0,Autocuration,CHEMBL767046,,752,,,22226,7587,,
,BAO_0000357,,H,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,1,,,B,,,8,Autocuration,CHEMBL615855,,753,,,10732,11249,,
,BAO_0000019,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615856,,754,,,12198,8003,,
,BAO_0000019,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615857,,755,,,12198,8003,,
,BAO_0000019,,D,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615858,,756,,,12198,8003,,
Hippocampus,BAO_0000221,,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615859,,757,,,10576,12416,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,1,,,B,,,8,Autocuration,CHEMBL615860,,758,,,51,16293,,
,BAO_0000019,,U,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,0,Autocuration,CHEMBL615861,,759,,,22226,13047,,
,BAO_0000019,,U,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,0,Autocuration,CHEMBL615862,,760,,,22226,13047,,
,BAO_0000019,,U,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,0,Autocuration,CHEMBL615863,,761,,,22226,13047,,
,BAO_0000019,,U,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,0,Autocuration,CHEMBL615864,,762,,,22226,13047,,
Hippocampus,BAO_0000221,,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,,B,,10000000.0,4,Autocuration,CHEMBL615865,,763,,,104744,10085,,
Hippocampus,BAO_0000221,,H,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,,B,,10000000.0,4,Autocuration,CHEMBL615866,,764,,,104744,10085,,
Hippocampus,BAO_0000221,,H,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,1,,,B,,10000000.0,4,Autocuration,CHEMBL615867,,765,,,104744,10085,,
,BAO_0000249,,H,Membranes,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,1,,,B,,,4,Autocuration,CHEMBL615868,,766,,,104744,9841,,
,BAO_0000249,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615869,,767,,,104744,8822,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615870,,768,,,104744,9806,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615871,,769,,,104744,9806,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,1,,,B,,,4,Autocuration,CHEMBL615872,,770,,,104744,8868,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,1,,,B,,10000000.0,4,Autocuration,CHEMBL833492,,771,,,104744,9036,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,1,,,B,,10000000.0,4,Autocuration,CHEMBL615873,,772,,,104744,11374,,
,BAO_0000224,,H,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,1,,,B,,,4,Autocuration,CHEMBL615479,,773,,,104744,10881,,
,BAO_0000019,,H,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,1,,,B,,,4,Autocuration,CHEMBL615480,,774,,,104744,8822,,
,BAO_0000249,,D,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615481,,775,,,104744,9806,,
,BAO_0000019,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL872869,,776,,,104744,15463,,
,BAO_0000019,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL615482,,777,,,104744,15463,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,,B,,955.0,4,Autocuration,CHEMBL615483,,778,,,104744,14542,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,,B,,955.0,4,Autocuration,CHEMBL615484,,779,,,104744,14542,,
,BAO_0000019,,H,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,1,,,B,,,4,Autocuration,CHEMBL615485,,780,,,104744,8569,,
,BAO_0000224,,D,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615486,,781,,,104744,10062,,
,BAO_0000224,,H,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,1,,,B,,,4,Autocuration,CHEMBL615487,,782,,,104744,4771,,
,BAO_0000224,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,B,,,4,Autocuration,CHEMBL615488,,783,,,104744,10062,,
,BAO_0000224,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,B,,,4,Autocuration,CHEMBL615489,,784,,,104744,10062,,
,BAO_0000224,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,1,,,B,,,4,Autocuration,CHEMBL615389,,785,,,104744,10062,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,,B,,,4,Autocuration,CHEMBL615390,,786,,,104744,15463,,
,BAO_0000019,,H,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,1,,,B,,,4,Autocuration,CHEMBL615391,,787,,,104744,15463,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL615392,,788,,,104744,9098,,
,BAO_0000019,,U,,Affinity for 5-hydroxytryptamine 1 receptor,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615393,,789,,,22226,3070,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,1,,,B,,955.0,4,Autocuration,CHEMBL615394,,790,,,104744,14542,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,1,,,B,,955.0,4,Autocuration,CHEMBL615395,,791,,,104744,14542,,
,BAO_0000224,,H,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,1,,,B,,,4,Autocuration,CHEMBL615396,,792,,,104744,6398,,
Brain,BAO_0000221,,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,1,,,B,,955.0,4,Autocuration,CHEMBL615397,,793,,,104744,1344,,
,BAO_0000019,,H,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL615398,,794,,,104744,11963,,
,BAO_0000019,,U,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615399,,795,,,22226,8908,,
,BAO_0000019,,H,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,1,,,B,,,4,Autocuration,CHEMBL615400,,796,,,104744,9098,,
,BAO_0000019,,D,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL615401,,797,,,104744,8841,,
,BAO_0000019,,U,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL615402,,798,,,22226,8814,,
,BAO_0000019,,H,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,1,,,B,,,4,Autocuration,CHEMBL615403,,799,,,104744,11752,,
Brain,BAO_0000221,,H,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,1,,,B,,955.0,4,Autocuration,CHEMBL615404,,800,,,104744,11642,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL615781,,801,,,104744,11642,,
Brain,BAO_0000220,,H,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,1,,,B,,955.0,4,Autocuration,CHEMBL615782,,802,,,104744,9231,,
Brain,BAO_0000221,,H,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,1,,,B,,955.0,4,Autocuration,CHEMBL615783,,803,,,104744,11351,,
,BAO_0000019,,U,,Compound was tested for binding affinity against 5-HT1 receptor,1,,,B,,,0,Autocuration,CHEMBL873481,,804,,,22226,4639,,
,BAO_0000019,,U,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,1,,,B,,,0,Autocuration,CHEMBL615784,,805,,,22226,1205,,
,BAO_0000357,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,,B,,,8,Expert,CHEMBL615785,,806,,,10576,10025,,
,BAO_0000249,,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL615786,,807,,,10576,13241,,
,BAO_0000218,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,,F,,,8,Autocuration,CHEMBL615787,,808,In vivo,,10576,16245,,
,BAO_0000218,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,,F,,,8,Autocuration,CHEMBL615788,,809,In vivo,,10576,16245,,
,BAO_0000019,,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL767044,,810,,,10576,12438,,
,BAO_0000218,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,1,,,F,,,8,Autocuration,CHEMBL615789,,811,In vivo,,10576,16245,,
,BAO_0000218,,H,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,1,,,F,,,8,Autocuration,CHEMBL615790,,812,In vivo,,10576,16245,,
,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,1,,,F,,,8,Autocuration,CHEMBL615813,,813,,,10576,15740,,
,BAO_0000219,,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,1,,,F,,,8,Autocuration,CHEMBL615814,,814,,,10576,15535,,
,BAO_0000219,,H,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,1,,,F,,,8,Expert,CHEMBL615815,,815,,,51,15535,,
,BAO_0000219,,H,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,1,,,F,,,8,Autocuration,CHEMBL615816,,816,,,10576,15535,,
,BAO_0000249,,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,1,,,B,,,8,Expert,CHEMBL615817,,817,,,10576,9888,,
Hippocampus,BAO_0000221,,H,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,1,,,B,,10000000.0,8,Autocuration,CHEMBL615818,,818,,,10576,10085,,
Hippocampus,BAO_0000221,,H,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,1,,,B,,10000000.0,8,Autocuration,CHEMBL615819,,819,,,10576,10085,,
,BAO_0000249,,H,Membranes,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,1,,,B,,,8,Expert,CHEMBL615820,,820,,,10576,17331,,
Hippocampus,BAO_0000221,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615821,,821,,,10576,10845,,
Hippocampus,BAO_0000221,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615822,,822,,,10576,10845,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL615823,,823,,,10576,10845,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615824,,824,,,10576,10845,,
Hippocampus,BAO_0000221,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615825,,825,,,10576,10845,,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615826,,826,,,10576,13730,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615827,,827,,,10576,13508,,
Hippocampus,BAO_0000249,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL615828,,828,,,10576,13508,,
Hippocampus,BAO_0000221,,H,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615829,,829,,,10576,12073,,
Hippocampus,BAO_0000221,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL615830,,830,,,10576,4671,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,1,,,B,,10000000.0,8,Expert,CHEMBL615831,,831,,,10576,13631,,
,BAO_0000357,,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615832,,832,,,10576,12438,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615833,,833,,,10576,10483,,
Hippocampus,BAO_0000221,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL615834,,834,,,10576,10483,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,1,,,B,,,8,Intermediate,CHEMBL615835,,835,,,10576,12352,,
Hippocampus,BAO_0000249,,H,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,1,,,B,,10000000.0,8,Autocuration,CHEMBL615836,,836,,,10576,14732,,
,BAO_0000019,,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615837,,837,,,10576,11049,,
,BAO_0000019,,D,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615838,,838,,,10576,11049,,
,BAO_0000249,,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",1,,,B,,,8,Expert,CHEMBL615839,,839,,,10576,13657,,
,BAO_0000019,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL884525,,840,,,10576,11473,,
,BAO_0000249,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,,B,,,8,Autocuration,CHEMBL615840,,841,,,10576,2014,,
Hippocampus,BAO_0000221,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL615405,,842,,,10576,3086,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,B,,,8,Expert,CHEMBL615406,,843,,,10576,15854,,
Hippocampus,BAO_0000221,,H,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,,,B,,10000000.0,8,Expert,CHEMBL615900,,844,,,10576,10922,,
Hippocampus,BAO_0000221,,H,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,1,,,B,,10000000.0,8,Expert,CHEMBL615901,,845,,,10576,13346,,
,BAO_0000357,,H,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,1,,,B,,,8,Expert,CHEMBL615902,,846,,,10576,15311,,
Hippocampus,BAO_0000221,,H,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,1,,,B,,10000000.0,8,Autocuration,CHEMBL615903,,847,,,10576,10922,,
,BAO_0000357,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,1,,,B,,,8,Autocuration,CHEMBL615904,,848,,,10576,10025,,
,BAO_0000357,,H,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,1,,,B,,,8,Expert,CHEMBL615905,,849,,,10576,10025,,
,BAO_0000019,,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,B,,,8,Autocuration,CHEMBL615906,,850,,,10576,9742,,
,BAO_0000019,,H,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,F,,,8,Autocuration,CHEMBL615907,,851,,,10576,9742,,
,BAO_0000019,,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,B,,,8,Expert,CHEMBL615908,,852,,,10576,12304,,
Hippocampus,BAO_0000221,,H,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615909,,853,,,10576,15789,,
,BAO_0000019,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",1,,,B,,,8,Autocuration,CHEMBL615910,,854,,,10576,9912,,
,BAO_0000019,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",1,,,B,,,8,Autocuration,CHEMBL615911,,855,,,10576,9912,,
,BAO_0000019,,H,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",1,,,B,,,8,Autocuration,CHEMBL615912,,856,,,10576,9912,,
,BAO_0000019,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615913,,857,,,10576,16693,,
,BAO_0000357,,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,B,,,8,Expert,CHEMBL615914,,858,,,10576,13276,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,,,B,,10000000.0,8,Autocuration,CHEMBL615915,,859,,,10576,12678,,
,BAO_0000357,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,1,,,B,,,8,Autocuration,CHEMBL615916,,860,,,10576,11825,,
,BAO_0000357,,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,1,,,B,,,8,Expert,CHEMBL615917,,861,,,10576,12443,,
,BAO_0000357,,H,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL615918,,862,,,10576,13830,,
Hippocampus,BAO_0000249,,H,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,1,,,B,,10000000.0,8,Expert,CHEMBL615919,,863,,,10576,14286,,
Hippocampus,BAO_0000221,,D,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615920,,864,,,10576,14356,,
,BAO_0000357,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615921,,865,,,10576,15306,,
,BAO_0000357,,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),1,,,B,,,8,Expert,CHEMBL615922,,866,,,10576,15306,,
,BAO_0000249,,D,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL881290,,867,,,10576,16616,,
Hippocampus,BAO_0000221,,H,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",1,,,B,,10000000.0,8,Autocuration,CHEMBL615923,,868,,,10576,3651,,
Hippocampus,BAO_0000221,,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,F,,10000000.0,8,Autocuration,CHEMBL615924,,869,,,10576,14331,,
Hippocampus,BAO_0000221,,H,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,F,,10000000.0,8,Autocuration,CHEMBL615925,,870,,,10576,14331,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615926,,871,,,10576,14178,,
,BAO_0000019,,D,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615927,,872,,,10576,10639,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL615928,,873,,,10576,12306,,
,BAO_0000357,,D,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615929,,874,,,10576,1348,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615930,,875,,,10576,13605,,
,BAO_0000219,,H,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL615931,,876,,,51,17624,449.0,
,BAO_0000219,,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL615932,,877,,,51,17624,449.0,
,BAO_0000219,,H,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL615933,,878,,,51,17624,449.0,
,BAO_0000357,,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615934,,879,,,51,15267,,
,BAO_0000357,,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,1,,,B,,,8,Autocuration,CHEMBL615935,,880,,,51,16532,,
,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",1,,,F,,,8,Autocuration,CHEMBL615936,,881,,,51,6563,,
,BAO_0000219,,H,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,1,CHO,,B,,,8,Autocuration,CHEMBL615937,,882,,,51,4751,449.0,
,BAO_0000357,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615938,,883,,,51,15463,,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL615797,,884,,,51,3805,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615798,,885,,,51,5640,,
,BAO_0000357,,H,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,1,,,B,,,8,Autocuration,CHEMBL872870,,886,,,51,6563,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL615799,,887,,,51,5548,,
,BAO_0000357,,H,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615800,,888,,,51,6347,,
,BAO_0000219,,H,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,HEK293,,F,,,8,Autocuration,CHEMBL615801,,889,,,51,17296,722.0,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,1,,,B,,,8,Autocuration,CHEMBL615802,,890,,,51,13047,,
,BAO_0000357,,H,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,1,,,B,,,8,Autocuration,CHEMBL615803,,891,,,51,15740,,
,BAO_0000019,,H,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",1,,,F,,,8,Expert,CHEMBL835002,,892,,,51,5640,,
,BAO_0000019,,H,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",1,,,F,,,8,Autocuration,CHEMBL615804,,893,,,51,5640,,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,1,HeLa,,B,,,8,Expert,CHEMBL615805,,894,,,51,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,1,CHO,,B,,,8,Autocuration,CHEMBL615806,,895,,,51,4751,449.0,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615807,,896,,,51,6491,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,1,,,B,,,8,Autocuration,CHEMBL615808,,897,,,51,4707,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615809,,898,,,51,13910,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,1,HeLa,,B,,,8,Autocuration,CHEMBL615810,,899,,,51,16190,308.0,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615811,,900,,,51,16633,,
,BAO_0000219,,H,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL615812,,901,,,51,11898,449.0,
,BAO_0000219,,H,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL615751,,902,,,51,11898,449.0,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615752,,903,,,51,14331,,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,1,CHO,,B,,,8,Expert,CHEMBL615753,,904,,,51,17624,449.0,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,1,CHO,,B,,,8,Autocuration,CHEMBL615754,,905,,,51,17624,449.0,
,BAO_0000357,,H,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615755,,906,,,51,3307,,
,BAO_0000219,,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615756,,907,,,51,6563,449.0,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615757,,908,,,51,14165,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL615758,,909,,,51,5732,,
,BAO_0000357,,H,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,,B,,,8,Expert,CHEMBL615759,,910,,,51,13366,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615760,,911,,,51,17626,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,1,HeLa,,B,,,8,Expert,CHEMBL615761,,912,,,51,6588,308.0,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL872104,,913,,,51,16209,,
,BAO_0000357,,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615762,,914,,,51,15463,,
,BAO_0000357,,H,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615763,,915,,,51,15463,,
,BAO_0000357,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL615764,,916,,,51,14770,,
,BAO_0000219,,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),1,Cell line,,B,,,8,Autocuration,CHEMBL615765,,917,,,51,16245,1167.0,
,BAO_0000019,,H,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),1,,,B,,,8,Autocuration,CHEMBL615766,,918,,,51,16245,,
,BAO_0000357,,H,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615767,,919,,,51,5548,,
,BAO_0000357,,H,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615768,,920,,,51,5548,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615769,,921,,,51,5548,,
,BAO_0000357,,H,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,1,,,B,,,8,Expert,CHEMBL615770,,922,,,51,6876,,
,BAO_0000357,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615771,,923,,,51,2598,,
,BAO_0000357,,H,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,1,,,B,,,8,Expert,CHEMBL615772,,924,,,51,17785,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL615773,,925,,,51,6013,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615774,,926,,,51,5929,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615775,,927,,,51,16633,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL615776,,928,,,51,1558,,
,BAO_0000357,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL615777,,929,,,51,16026,,
,BAO_0000219,,H,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL615778,,930,,,51,12469,,
,BAO_0000357,,D,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615779,,931,,,51,15874,,
,BAO_0000357,,H,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL615780,,932,,,51,15874,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616298,,933,,,51,3935,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616299,,934,,,51,15818,,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616300,,935,,,51,13706,485.0,
,BAO_0000219,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,1,CHO-K1,,F,,,8,Expert,CHEMBL616301,,936,,,51,13729,485.0,
,BAO_0000019,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616302,,937,,,51,15413,,
,BAO_0000019,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),1,,,B,,,8,Autocuration,CHEMBL616117,,938,,,51,15413,,
,BAO_0000019,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),1,,,B,,,8,Autocuration,CHEMBL616118,,939,,,51,15413,,
,BAO_0000019,,H,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,1,,,B,,,8,Autocuration,CHEMBL616119,,940,,,51,15413,,
,BAO_0000219,,D,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616120,,941,,,51,3445,308.0,
,BAO_0000357,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616121,,942,,,51,15740,,
,BAO_0000357,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,1,,,B,,,8,Autocuration,CHEMBL616122,,943,,,51,15740,,
,BAO_0000357,,H,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616123,,944,,,51,17626,,
,BAO_0000357,,D,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616124,,945,,,51,4234,,
,BAO_0000357,,H,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,1,,,B,,,8,Expert,CHEMBL616125,,946,,,51,5640,,
,BAO_0000357,,H,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,,8,Expert,CHEMBL616126,,947,,,51,5272,,
,BAO_0000219,,H,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616127,,948,,,51,4622,449.0,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616128,,949,,,51,17085,,
,BAO_0000357,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,1,,,B,,,8,Autocuration,CHEMBL616129,,950,,,51,3025,,
,BAO_0000357,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616130,,951,,,51,15315,,
,BAO_0000357,,H,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,1,,,B,,,8,Autocuration,CHEMBL616131,,952,,,51,15267,,
,BAO_0000219,,H,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,1,HeLa,,B,,,8,Autocuration,CHEMBL616132,,953,,,51,17158,308.0,
,BAO_0000219,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616133,,954,,,51,14214,308.0,
,BAO_0000357,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616134,,955,,,51,17133,,
,BAO_0000357,,H,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,1,,,B,,,8,Autocuration,CHEMBL616135,,956,,,51,16532,,
,BAO_0000357,,D,,Affinity for 5-hydroxytryptamine 1A receptor subtype,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616136,,957,,,51,2391,,
,BAO_0000019,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,1,,,B,,,8,Autocuration,CHEMBL616137,,958,,,51,14447,,
,BAO_0000019,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,1,,,B,,,8,Autocuration,CHEMBL872105,,959,,,51,14447,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,1,,,B,,,8,Autocuration,CHEMBL616138,,960,,,51,15086,,
,BAO_0000357,,D,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616139,,961,,,51,13051,,
,BAO_0000019,,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",1,,,F,,,8,Autocuration,CHEMBL616140,,962,,,51,16026,,
,BAO_0000019,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,1,,,B,,,8,Expert,CHEMBL616141,,963,,,51,17085,,
,BAO_0000357,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616142,,964,,,51,17133,,
,BAO_0000357,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,1,,,B,,,8,Autocuration,CHEMBL616143,,965,,,51,17133,,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616144,,966,,,51,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616145,,967,,,51,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616012,,968,,,51,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616013,,969,,,51,17211,308.0,
,BAO_0000019,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,F,,,8,Autocuration,CHEMBL616014,,970,,,51,16394,,
,BAO_0000019,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,F,,,8,Autocuration,CHEMBL616015,,971,,,51,16394,,
,BAO_0000019,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",1,,,F,,,8,Autocuration,CHEMBL616016,,972,,,51,16394,,
,BAO_0000218,,H,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,1,,,F,,,8,Autocuration,CHEMBL616017,,973,In vivo,,51,16394,,
,BAO_0000019,,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,1,,,B,,,8,Autocuration,CHEMBL616018,,974,,,51,16394,,
,BAO_0000019,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,1,,,F,,,8,Autocuration,CHEMBL616019,,975,,,51,15740,,
,BAO_0000019,,H,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,1,,,F,,,8,Autocuration,CHEMBL616020,,976,,,51,15740,,
,BAO_0000357,,H,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL858018,,977,,,51,15740,,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,HEK293,,F,,,8,Autocuration,CHEMBL616021,,978,,,51,17296,722.0,
,BAO_0000019,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",1,,,F,,,8,Expert,CHEMBL616022,,979,,,51,5640,,
,BAO_0000019,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",1,,,F,,,8,Autocuration,CHEMBL616023,,980,,,51,5640,,
,BAO_0000019,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",1,,,F,,,8,Autocuration,CHEMBL616024,,981,,,51,5640,,
,BAO_0000019,,H,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",1,,,F,,,8,Autocuration,CHEMBL616025,,982,,,51,5640,,
,BAO_0000219,,H,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,1,CHO,,F,,,8,Autocuration,CHEMBL616026,,983,,,51,2759,449.0,
,BAO_0000019,,H,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",1,,,F,,,8,Autocuration,CHEMBL616027,,984,,,51,16394,,
,BAO_0000019,,D,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616028,,985,,,51,16394,,
,BAO_0000019,,D,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616029,,986,,,51,3445,,
,BAO_0000219,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,1,CHO,,B,,,8,Expert,CHEMBL616030,,987,,,51,4316,449.0,
,BAO_0000019,,H,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,1,,,B,,,8,Expert,CHEMBL616031,,988,,,51,4316,,
,BAO_0000019,,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616032,,989,,,51,15180,,
,BAO_0000019,,D,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616033,,990,,,51,15180,,
,BAO_0000019,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,F,,,8,Autocuration,CHEMBL616034,,991,,,51,15042,,
,BAO_0000019,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,F,,,8,Autocuration,CHEMBL616035,,992,,,51,15042,,
,BAO_0000019,,H,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL616036,,993,,,51,15042,,
,BAO_0000019,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,F,,,8,Autocuration,CHEMBL616037,,994,,,51,15042,,
,BAO_0000019,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,F,,,8,Autocuration,CHEMBL616038,,995,,,51,15042,,
,BAO_0000019,,H,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,1,,,F,,,8,Autocuration,CHEMBL616039,,996,,,51,15042,,
,BAO_0000019,,H,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL616040,,997,,,51,15042,,
,BAO_0000219,,D,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,HeLa,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616041,,998,,,51,15180,308.0,
,BAO_0000219,,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,HeLa,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616042,,999,,,51,15180,308.0,
,BAO_0000219,,D,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,1,HeLa,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616043,,1000,,,51,15180,308.0,
,BAO_0000019,,H,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL616044,,1001,,,51,16245,,
,BAO_0000019,,H,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL616045,,1002,,,51,16026,,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,1,HEK293,,F,,,8,Autocuration,CHEMBL616046,,1003,,,51,17296,722.0,
,BAO_0000219,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,CHO,,F,,,8,Autocuration,CHEMBL616047,,1004,,,51,2759,449.0,
,BAO_0000219,,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,CHO,,F,,,8,Autocuration,CHEMBL616048,,1005,,,51,2759,449.0,
,BAO_0000219,,D,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616049,,1006,,,51,2759,449.0,
,BAO_0000219,,H,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),1,CHO,,F,,,8,Autocuration,CHEMBL616050,,1007,,,51,2759,449.0,
,BAO_0000219,,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,1,,,F,,,8,Expert,CHEMBL616051,,1008,,,51,15419,,
,BAO_0000219,,H,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,1,,,F,,,8,Autocuration,CHEMBL616212,,1009,,,51,15419,,
,BAO_0000019,,H,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL616213,,1010,,,51,16026,,
,BAO_0000219,,H,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,1,,,B,,,8,Expert,CHEMBL616214,,1011,In vitro,,51,1414,,
,BAO_0000219,,H,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,1,,,B,,,8,Expert,CHEMBL616215,,1012,In vitro,,51,1414,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL616216,,1013,,,51,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616217,,1014,,,51,12861,,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616218,,1015,,,51,5104,,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616219,,1016,,,51,5105,,
,BAO_0000357,,H,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616220,,1017,,,51,16312,,
,BAO_0000357,,D,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL833493,,1018,,,51,15180,,
,BAO_0000357,,H,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616221,,1019,,,51,5033,,
,BAO_0000219,,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616222,,1020,,,51,16909,449.0,
,BAO_0000019,,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL616223,,1021,,,51,2590,,
,BAO_0000019,,H,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,1,,,F,,,8,Autocuration,CHEMBL616224,,1022,,,51,2590,,
,BAO_0000019,,H,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,1,,,B,,,8,Expert,CHEMBL616225,,1023,,,51,16394,,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616226,,1024,,,51,4540,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,1,HEK293,,B,,,8,Autocuration,CHEMBL616227,,1025,,,51,17296,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616228,,1026,,,51,17296,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,HEK293,,B,,,8,Autocuration,CHEMBL616229,,1027,,,51,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,1,HEK293,,B,,,8,Autocuration,CHEMBL616230,,1028,,,51,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,1,HEK293,,B,,,8,Autocuration,CHEMBL616231,,1029,,,51,15779,722.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616232,,1030,,,51,6166,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,1,HEK293,,B,,,8,Autocuration,CHEMBL616233,,1031,,,51,15779,722.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL857973,,1032,,,51,4199,722.0,
,BAO_0000219,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,1,,,B,,,8,Autocuration,CHEMBL616234,,1033,,,51,15316,,
,BAO_0000357,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616235,,1034,,,51,14875,,
,BAO_0000219,,H,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,HeLa,,B,,,8,Expert,CHEMBL616236,,1035,,,51,14727,308.0,
,BAO_0000019,,H,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,1,,,B,,,8,Expert,CHEMBL616237,,1036,,,51,14727,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,1,HEK293,,B,,,8,Autocuration,CHEMBL616238,,1037,,,51,15146,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616239,,1038,,,51,5213,722.0,
,BAO_0000219,,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,1,,,B,,,8,Autocuration,CHEMBL616240,,1039,,,51,16429,,
,BAO_0000219,,D,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616241,,1040,,,51,15042,308.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,1,HEK293,,B,,,8,Autocuration,CHEMBL616242,,1041,,,51,14818,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL616243,,1042,,,51,4829,722.0,
,BAO_0000357,,D,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,1,,,B,,,9,Expert,CHEMBL616244,,1043,,,51,17200,,
,BAO_0000357,,D,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,1,,9606.0,B,Homo sapiens,,9,Autocuration,CHEMBL616245,,1044,,,51,13051,,
,BAO_0000357,,H,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,,B,,,8,Autocuration,CHEMBL616246,,1045,,,106,5486,,
,BAO_0000357,,H,,Binding affinity against 5-HT1D receptor,1,,,B,,,8,Autocuration,CHEMBL616247,,1046,,,105,5254,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616248,,1047,,,105,5254,,
,BAO_0000357,,H,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL616249,,1048,,,107,15331,,
,BAO_0000357,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,,9606.0,B,Homo sapiens,,8,Autocuration,CHEMBL616250,,1049,,,10576,13506,,
,BAO_0000357,,H,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616251,,1050,,,51,15267,,
,BAO_0000218,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,1,,,F,,,8,Autocuration,CHEMBL616252,,1051,In vivo,,11863,16616,,
,BAO_0000218,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,1,,,F,,,8,Autocuration,CHEMBL616253,,1052,In vivo,,11863,16616,,
,BAO_0000218,,H,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,1,,,F,,,8,Autocuration,CHEMBL616254,,1053,In vivo,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL616255,,1054,,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL832872,,1055,,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL616256,,1056,,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL616257,,1057,,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL616258,,1058,,,11863,16616,,
,BAO_0000218,,D,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL616384,,1059,,,11863,16616,,
Hippocampus,BAO_0000221,,H,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616385,,1060,,,11863,10297,,
,BAO_0000357,,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,1,,,B,,,8,Expert,CHEMBL616386,,1061,,,11863,13704,,
Hippocampus,BAO_0000221,,D,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,,10090.0,B,Mus musculus,10000000.0,9,Expert,CHEMBL616387,,1062,,,11863,10297,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL616388,,1063,,,11863,10297,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,1,,10090.0,B,Mus musculus,10000000.0,9,Expert,CHEMBL616389,,1064,,,11863,10297,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL616390,,1065,,,11863,10297,,
,BAO_0000357,,H,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616391,,1066,,,11863,217,,
Hippocampus,BAO_0000221,,D,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,1,,10090.0,B,Mus musculus,10000000.0,9,Expert,CHEMBL616392,,1067,,,11863,10297,,
,BAO_0000357,,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616393,,1068,,,51,4921,,
,BAO_0000357,,H,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616394,,1069,,,51,4921,,
,BAO_0000019,,H,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616395,,1070,,,51,4996,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity at 5- HT1A receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616396,,1071,,,51,12918,,
,BAO_0000019,,H,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL872907,,1072,,,51,5333,,
,BAO_0000019,,H,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616397,,1073,,,51,4437,,
,BAO_0000019,,H,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616398,,1074,,,51,1742,,
,BAO_0000357,,H,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616399,,1075,,,51,16688,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL857065,,1076,,,51,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616400,,1077,,,51,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616401,,1078,,,51,12861,,
,BAO_0000019,,H,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,1,,,B,,,8,Expert,CHEMBL616402,,1079,,,10624,12490,,
,BAO_0000019,,H,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616403,,1080,,,51,11828,,
Hippocampus,BAO_0000221,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,1,,9823.0,B,Sus scrofa,10000000.0,8,Autocuration,CHEMBL616404,,1081,,,51,11866,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616405,,1082,,,51,12827,,
,BAO_0000019,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616406,,1083,,,51,12918,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,1,,9823.0,F,Sus scrofa,,8,Expert,CHEMBL616407,,1084,,,51,12919,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616408,,1085,,,51,13047,,
,BAO_0000249,,D,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616409,,1086,,,10576,15796,,
Hippocampus,BAO_0000221,,D,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616410,,1087,,,10576,3651,,
,BAO_0000357,,H,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,1,,,B,,,8,Autocuration,CHEMBL616411,,1088,,,10576,188,,
,BAO_0000249,,D,Membranes,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL616412,,1089,,,10576,16616,,
Hippocampus,BAO_0000249,,D,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,,10116.0,F,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616413,,1090,,,10576,16616,,
Hippocampus,BAO_0000221,,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL616414,,1091,,,10576,12306,,
Hippocampus,BAO_0000221,,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616415,,1092,,,10576,17167,,
,BAO_0000019,,H,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,1,,,B,,,8,Autocuration,CHEMBL616416,,1093,,,10576,14776,,
,BAO_0000357,,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,1,,,B,,,8,Expert,CHEMBL616417,,1094,,,10576,12158,,
,BAO_0000357,,H,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL616418,,1095,,,10576,13481,,
,BAO_0000219,,H,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,B,,,8,Autocuration,CHEMBL616419,,1096,In vitro,,10576,13427,,
,BAO_0000357,,H,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616420,,1097,,,10576,10210,,
,BAO_0000249,,H,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,,B,,,8,Autocuration,CHEMBL616421,,1098,,,10576,10205,,
,BAO_0000249,,H,Membranes,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,1,,,B,,,8,Autocuration,CHEMBL616422,,1099,,,10576,10205,,
,BAO_0000249,,H,Membranes,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,1,,,B,,,8,Expert,CHEMBL616423,,1100,,,10576,10205,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616424,,1101,,,10576,12280,,
,BAO_0000357,,H,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616425,,1102,,,10576,17386,,
,BAO_0000357,,H,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,1,,,B,,,8,Expert,CHEMBL616426,,1103,,,10576,13654,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616427,,1104,,,10576,14423,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616428,,1105,,,10576,15412,,
Hippocampus,BAO_0000221,,H,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616290,,1106,,,10576,12073,,
,BAO_0000357,,D,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616052,,1107,,,10576,4101,,
,BAO_0000357,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616053,,1108,,,10576,10062,,
,BAO_0000249,,H,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616054,,1109,,,10576,6238,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616055,,1110,,,10576,16273,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,1,,,B,,,8,Autocuration,CHEMBL616056,,1111,,,10576,11139,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,,B,,,8,Expert,CHEMBL616057,,1112,,,10576,16796,,
Brain,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,,10116.0,B,Rattus norvegicus,955.0,9,Expert,CHEMBL616058,,1113,,,10576,9548,,
Brain,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,,,B,,955.0,8,Autocuration,CHEMBL616059,,1114,,,10576,10381,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616060,,1115,,,10576,13408,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616061,,1116,,,10576,13825,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL616062,,1117,,,10576,11147,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616063,,1118,,,10576,10552,,
Striatum,BAO_0000249,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,,,B,,2435.0,8,Autocuration,CHEMBL616064,,1119,,,10576,10552,,
,BAO_0000249,,D,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616065,,1120,,,10576,17136,,
,BAO_0000249,,D,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616066,,1121,,,10576,5778,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616067,,1122,,,10576,13481,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,1,,,B,,10000000.0,8,Autocuration,CHEMBL616068,,1123,,,10576,13481,,
Hippocampus,BAO_0000221,,H,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Intermediate,CHEMBL616069,,1124,,,10576,13630,,
,BAO_0000249,,H,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,B,,,8,Expert,CHEMBL616070,,1125,,,10576,16245,,
Hippocampus,BAO_0000221,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616071,,1126,,,10576,14509,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,,,B,,10000000.0,8,Expert,CHEMBL616072,,1127,,,10576,14509,,
Hippocampus,BAO_0000221,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL616073,,1128,,,10576,14509,,
Hippocampus,BAO_0000221,,H,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL616074,,1129,,,10576,14509,,
,BAO_0000019,,H,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,1,,,B,,,8,Expert,CHEMBL616075,,1130,,,10576,14256,,
,BAO_0000357,,H,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616076,,1131,,,10576,11139,,
,BAO_0000019,,D,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616077,,1132,,,10576,11047,,
,BAO_0000019,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616078,,1133,,,10576,11047,,
,BAO_0000019,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616079,,1134,,,10576,11047,,
,BAO_0000219,,D,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,CHO-K1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616080,,1135,,,10576,2395,485.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616081,,1136,,,10576,9699,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616082,,1137,,,10576,12028,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,1,,,B,,10000000.0,8,Autocuration,CHEMBL616083,,1138,,,10576,12028,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,B,,,8,Autocuration,CHEMBL616084,,1139,,,10576,5815,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,1,,,B,,,8,Expert,CHEMBL616085,,1140,,,10576,16616,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616086,,1141,,,10576,5815,,
Hippocampus,BAO_0000221,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",1,,,B,,10000000.0,8,Autocuration,CHEMBL616087,,1142,,,10576,2761,,
,BAO_0000357,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,1,,,B,,,8,Expert,CHEMBL616088,,1143,,,10576,13133,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,1,,,B,,,8,Autocuration,CHEMBL616089,,1144,,,10576,10444,,
,BAO_0000357,,D,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616090,,1145,,,10576,13278,,
,BAO_0000357,,H,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616091,,1146,,,10576,15874,,
Striatum,BAO_0000249,,H,Membranes,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",1,,,B,,2435.0,8,Autocuration,CHEMBL616092,,1147,,,10576,10552,,
,BAO_0000357,,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),1,,,B,,,8,Autocuration,CHEMBL616093,,1148,,,10576,11130,,
,BAO_0000218,,H,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),1,,,B,,,8,Autocuration,CHEMBL616094,,1149,In vivo,,10576,11130,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,1,,,B,,955.0,8,Autocuration,CHEMBL616095,,1150,,,10576,14542,,
,BAO_0000357,,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616096,,1151,,,10576,13670,,
,BAO_0000249,,H,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,1,,,B,,,8,Expert,CHEMBL616097,,1152,,,10576,9888,,
,BAO_0000249,,D,Membranes,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616098,,1153,,,10576,3678,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616099,,1154,,,10576,11332,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616100,,1155,,,10576,11332,,
,BAO_0000357,,H,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616101,,1156,,,10576,1185,,
,BAO_0000249,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,1,,,B,,,8,Expert,CHEMBL616102,,1157,,,10576,2014,,
,BAO_0000357,,H,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616103,,1158,,,10576,1185,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,1,,,B,,,8,Expert,CHEMBL616104,,1159,,,10576,14429,,
,BAO_0000019,,H,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",1,,,B,,,8,Expert,CHEMBL616105,,1160,,,10576,16288,,
,BAO_0000019,,D,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616106,,1161,,,10576,5432,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,1,,,B,,,8,Autocuration,CHEMBL616107,,1162,,,10576,14429,,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,1,,,B,,,8,Expert,CHEMBL616108,,1163,,,10576,13672,,
Hippocampus,BAO_0000221,,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL616109,,1164,,,10576,11296,,
,BAO_0000357,,H,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,1,,,B,,,8,Autocuration,CHEMBL616110,,1165,,,10576,11296,,
,BAO_0000219,,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,1,CHO,,B,,,8,Expert,CHEMBL616111,,1166,,,10576,14749,449.0,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL616112,,1167,,,10576,15086,,
Hippocampus,BAO_0000221,,H,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616113,,1168,,,10576,13462,,
,BAO_0000019,,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616114,,1169,,,10576,15363,,
,BAO_0000019,,H,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616115,,1170,,,10576,15363,,
,BAO_0000357,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616116,,1171,,,10576,10796,,
Brain,BAO_0000221,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,1,,,B,,955.0,8,Expert,CHEMBL615844,,1172,,,10576,12816,,
Hippocampus,BAO_0000221,,H,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,,B,,10000000.0,8,Expert,CHEMBL615939,,1173,,,10576,13542,,
,BAO_0000019,,H,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,1,,,B,,,8,Expert,CHEMBL615940,,1174,,,10576,13308,,
Hippocampus,BAO_0000221,,H,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,1,,,B,,10000000.0,8,Expert,CHEMBL615941,,1175,,,10576,13541,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,1,,,B,,10000000.0,8,Autocuration,CHEMBL615942,,1176,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL615943,,1177,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,1,,,B,,10000000.0,8,Autocuration,CHEMBL615944,,1178,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,1,,,B,,10000000.0,8,Autocuration,CHEMBL615945,,1179,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,1,,,B,,10000000.0,8,Autocuration,CHEMBL615946,,1180,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,1,,,B,,10000000.0,8,Autocuration,CHEMBL615947,,1181,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,1,,,B,,10000000.0,8,Autocuration,CHEMBL615948,,1182,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,1,,,B,,10000000.0,8,Autocuration,CHEMBL615949,,1183,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,1,,,B,,10000000.0,8,Autocuration,CHEMBL615950,,1184,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,1,,,B,,10000000.0,8,Autocuration,CHEMBL615951,,1185,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,1,,,B,,10000000.0,8,Autocuration,CHEMBL615952,,1186,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,1,,,B,,10000000.0,8,Autocuration,CHEMBL615953,,1187,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,1,,,B,,10000000.0,8,Autocuration,CHEMBL615954,,1188,,,10576,10058,,
Hippocampus,BAO_0000221,,D,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL615955,,1189,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,1,,,B,,10000000.0,8,Autocuration,CHEMBL615956,,1190,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,1,,,B,,10000000.0,8,Autocuration,CHEMBL615957,,1191,,,10576,10058,,
,BAO_0000019,,H,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,1,,,B,,,8,Expert,CHEMBL615958,,1192,,,10576,12879,,
,BAO_0000019,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,1,,,B,,,8,Expert,CHEMBL615959,,1193,,,10576,11964,,
,BAO_0000019,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),1,,,B,,,8,Autocuration,CHEMBL615960,,1194,,,10576,11964,,
,BAO_0000019,,H,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),1,,,B,,,8,Autocuration,CHEMBL615961,,1195,,,10576,11964,,
Brain,BAO_0000221,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,1,,,B,,955.0,8,Expert,CHEMBL615962,,1196,,,10576,9548,,
,BAO_0000019,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,1,,,B,,,8,Expert,CHEMBL615963,,1197,,,10576,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,1,,,B,,,8,Autocuration,CHEMBL615964,,1198,,,10576,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,1,,,B,,,8,Autocuration,CHEMBL615965,,1199,,,10576,9098,,
,BAO_0000219,,H,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL615966,,1200,,,10576,13248,449.0,
,BAO_0000249,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,1,,,B,,,8,Expert,CHEMBL615967,,1201,,,10576,3147,,
,BAO_0000019,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,,B,,,8,Expert,CHEMBL615968,,1202,,,10576,13949,,
,BAO_0000218,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),1,CHO,,B,,,8,Autocuration,CHEMBL615969,,1203,,,10576,11883,449.0,
,BAO_0000218,,H,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),1,,,B,,,8,Autocuration,CHEMBL615970,,1204,,,10576,11883,,
,BAO_0000357,,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615971,,1205,,,10576,11883,,
,BAO_0000249,,H,Membranes,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,B,,,8,Expert,CHEMBL615972,,1206,,,10576,15535,,
,BAO_0000249,,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,1,,,B,,,8,Autocuration,CHEMBL615973,,1207,,,10576,15535,,
,BAO_0000249,,H,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,1,,,B,,,8,Autocuration,CHEMBL615974,,1208,,,10576,15535,,
,BAO_0000219,,D,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL615975,,1209,,,51,16372,449.0,
,BAO_0000249,,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,1,,,B,,,8,Expert,CHEMBL615976,,1210,,,10576,14608,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL872106,,1211,,,10576,4795,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL615977,,1212,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,1,,,B,,,8,Autocuration,CHEMBL615978,,1213,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,1,,,B,,,8,Autocuration,CHEMBL616166,,1214,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,1,,,B,,,8,Autocuration,CHEMBL616167,,1215,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,1,,,B,,,8,Autocuration,CHEMBL616168,,1216,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,1,,,B,,,8,Autocuration,CHEMBL616169,,1217,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,1,,,B,,,8,Autocuration,CHEMBL616170,,1218,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,1,,,B,,,8,Autocuration,CHEMBL616171,,1219,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,1,,,B,,,8,Autocuration,CHEMBL616172,,1220,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,1,,,B,,,8,Autocuration,CHEMBL616173,,1221,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,1,,,B,,,8,Autocuration,CHEMBL616174,,1222,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,1,,,B,,,8,Autocuration,CHEMBL616175,,1223,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,1,,,B,,,8,Autocuration,CHEMBL616176,,1224,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,1,,,B,,,8,Autocuration,CHEMBL616177,,1225,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,1,,,B,,,8,Autocuration,CHEMBL616178,,1226,,,10576,13863,,
,BAO_0000019,,H,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,1,,,B,,,8,Autocuration,CHEMBL616179,,1227,,,10576,9742,,
,BAO_0000357,,H,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616180,,1228,,,10576,12073,,
,BAO_0000357,,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616181,,1229,,,10576,4101,,
,BAO_0000019,,H,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,1,,,B,,,8,Autocuration,CHEMBL616182,,1230,,,10576,15360,,
Hippocampus,BAO_0000221,,H,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,,B,,10000000.0,8,Autocuration,CHEMBL616183,,1231,,,10576,11576,,
,BAO_0000019,,H,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,1,,,B,,,8,Expert,CHEMBL615874,,1232,,,10576,5834,,
,BAO_0000219,,D,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,1,CHO-K1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615875,,1233,,,10576,2395,485.0,
,BAO_0000019,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,1,,,B,,,8,Autocuration,CHEMBL615876,,1234,,,10576,1375,,
,BAO_0000019,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,1,,,B,,,8,Autocuration,CHEMBL615877,,1235,,,10576,1375,,
,BAO_0000357,,H,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),1,,,B,,,8,Autocuration,CHEMBL615878,,1236,,,10576,3967,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,1,,,B,,,8,Expert,CHEMBL615879,,1237,,,10576,12884,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,1,,,B,,,8,Expert,CHEMBL615880,,1238,,,10576,2343,,
,BAO_0000019,,H,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,,,B,,,8,Autocuration,CHEMBL615881,,1239,,,10576,11511,,
,BAO_0000019,,D,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL615882,,1240,,,10576,11511,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,1,,,F,,,8,Autocuration,CHEMBL615883,,1241,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),1,,,F,,,8,Autocuration,CHEMBL615884,,1242,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),1,,,F,,,8,Autocuration,CHEMBL615885,,1243,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),1,,,F,,,8,Autocuration,CHEMBL615886,,1244,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),1,,,F,,,8,Autocuration,CHEMBL615887,,1245,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),1,,,F,,,8,Autocuration,CHEMBL615888,,1246,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),1,,,F,,,8,Autocuration,CHEMBL615889,,1247,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),1,,,F,,,8,Autocuration,CHEMBL615890,,1248,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),1,,,F,,,8,Autocuration,CHEMBL615891,,1249,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),1,,,F,,,8,Autocuration,CHEMBL615892,,1250,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),1,,,F,,,8,Autocuration,CHEMBL615893,,1251,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),1,,,F,,,8,Autocuration,CHEMBL615894,,1252,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),1,,,F,,,8,Autocuration,CHEMBL615895,,1253,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),1,,,F,,,8,Autocuration,CHEMBL615896,,1254,In vivo,,10576,16394,,
,BAO_0000218,,H,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,1,,,F,,,8,Autocuration,CHEMBL615897,,1255,In vivo,,10576,16394,,
,BAO_0000249,,D,Membranes,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL615898,,1256,,,10576,16616,,
,BAO_0000019,,H,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,1,,,B,,,8,Autocuration,CHEMBL615899,,1257,,,10576,16796,,
,BAO_0000019,,H,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,1,,,B,,,8,Autocuration,CHEMBL616291,,1258,,,10576,16796,,
,BAO_0000357,,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,1,,,B,,,8,Autocuration,CHEMBL616292,,1259,,,10576,15629,,
,BAO_0000249,,H,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",1,,,F,,,8,Autocuration,CHEMBL616293,,1260,,,10576,13241,,
Hippocampus,BAO_0000221,,H,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL616294,,1261,,,10576,12073,,
Hippocampus,BAO_0000249,,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,1,,,B,,10000000.0,8,Autocuration,CHEMBL616295,,1262,,,10576,14286,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,1,,,B,,955.0,8,Autocuration,CHEMBL616296,,1263,,,10576,14542,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616297,,1264,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616605,,1265,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616606,,1266,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,,F,,,8,Autocuration,CHEMBL616607,,1267,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,1,,,F,,,8,Expert,CHEMBL616608,,1268,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616609,,1269,,,10576,13630,,
,BAO_0000019,,D,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL616610,,1270,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616611,,1271,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,1,,,F,,,8,Expert,CHEMBL616612,,1272,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616613,,1273,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,1,,,F,,,8,Expert,CHEMBL616614,,1274,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616615,,1275,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,,F,,,8,Expert,CHEMBL616616,,1276,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616617,,1277,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616618,,1278,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616619,,1279,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,1,,,F,,,8,Expert,CHEMBL616620,,1280,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,,F,,,8,Expert,CHEMBL616621,,1281,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,1,,,F,,,8,Autocuration,CHEMBL616622,,1282,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,1,,,F,,,8,Expert,CHEMBL616146,,1283,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL832873,,1284,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,1,,,F,,,8,Autocuration,CHEMBL616147,,1285,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL872872,,1286,,,10576,13630,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,1,,,F,,,8,Autocuration,CHEMBL616148,,1287,,,10576,13630,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,1,,,B,,10000000.0,8,Autocuration,CHEMBL616149,,1288,,,10576,9783,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,1,,,B,,10000000.0,8,Expert,CHEMBL616150,,1289,,,10576,9783,,
,BAO_0000249,,D,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616151,,1290,,,10576,14331,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,1,,,B,,10000000.0,8,Expert,CHEMBL872873,,1291,,,10576,15260,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,1,,,B,,10000000.0,8,Autocuration,CHEMBL616670,,1292,,,10576,15260,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,1,,,B,,10000000.0,8,Autocuration,CHEMBL616671,,1293,,,10576,15260,,
,BAO_0000249,,D,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL884861,,1294,,,10576,16616,,
,BAO_0000357,,H,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616672,,1295,,,10576,15629,,
,BAO_0000019,,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,,B,,,8,Autocuration,CHEMBL616673,,1296,,,10576,15086,,
,BAO_0000019,,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,1,,,F,,,8,Expert,CHEMBL616674,,1297,,,10576,5717,,
,BAO_0000357,,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616675,,1298,,,10576,12652,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,1,,,B,,10000000.0,8,Autocuration,CHEMBL616676,,1299,,,10576,14608,,
Hippocampus,BAO_0000221,,H,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL616677,,1300,,,10576,12306,,
Hippocampus,BAO_0000221,,H,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL616678,,1301,,,10576,12306,,
,BAO_0000357,,D,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616679,,1302,,,10576,15247,,
Hippocampus,BAO_0000221,,H,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL616680,,1303,,,10576,17529,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616681,,1304,,,10576,14826,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616682,,1305,,,10576,14826,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,1,,,B,,10000000.0,8,Autocuration,CHEMBL616683,,1306,,,10576,13241,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,1,,,B,,10000000.0,8,Autocuration,CHEMBL616684,,1307,,,10576,14093,,
Hippocampus,BAO_0000221,,H,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,1,,,B,,10000000.0,8,Autocuration,CHEMBL616685,,1308,,,10576,14093,,
Brain,BAO_0000221,,H,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,1,,,B,,955.0,8,Autocuration,CHEMBL616686,,1309,,,10576,14442,,
,BAO_0000357,,H,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,,B,,,8,Autocuration,CHEMBL616687,,1310,,,10576,9919,,
,BAO_0000357,,H,,Affinity for 5-hydroxytryptamine 1A receptor site,1,,,B,,,8,Autocuration,CHEMBL616688,,1311,,,10576,9919,,
Hippocampus,BAO_0000221,,H,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616689,,1312,,,10576,11440,,
,BAO_0000357,,H,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616690,,1313,,,10576,11257,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL616691,,1314,,,10576,10330,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616692,,1315,,,10576,17331,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,1,,,B,,,8,Expert,CHEMBL616693,,1316,,,10576,16567,,
,BAO_0000019,,D,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616694,,1317,,,10576,12058,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,1,,,B,,10000000.0,8,Autocuration,CHEMBL616695,,1318,,,10576,9699,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,1,,,B,,,8,Autocuration,CHEMBL616696,,1319,,,10576,9547,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,1,,,B,,,8,Autocuration,CHEMBL616697,,1320,,,10576,10330,,
,BAO_0000357,,H,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616698,,1321,,,10576,14331,,
,BAO_0000019,,D,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616949,,1322,,,10576,14060,,
Hippocampus,BAO_0000221,,H,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL616950,,1323,,,10576,14744,,
,BAO_0000357,,H,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,1,,,B,,,8,Autocuration,CHEMBL832875,,1324,,,10576,13506,,
Brain,BAO_0000221,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,,B,,955.0,8,Expert,CHEMBL616951,,1325,,,10576,10862,,
Brain,BAO_0000221,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,,B,,955.0,8,Expert,CHEMBL616952,,1326,,,10576,10862,,
,BAO_0000357,,H,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,1,,,B,,,8,Expert,CHEMBL616953,,1327,,,10576,10062,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,1,,,B,,,8,Autocuration,CHEMBL616954,,1328,,,10576,12073,,
,BAO_0000357,,H,,GTPgammaS radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL616955,,1329,,,106,14875,,
,BAO_0000357,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,,B,,,8,Autocuration,CHEMBL616956,,1330,,,106,2391,,
,BAO_0000019,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,1,,,F,,,8,Autocuration,CHEMBL616957,,1331,,,106,2391,,
,BAO_0000019,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,1,,,F,,,8,Autocuration,CHEMBL616958,,1332,,,106,2391,,
,BAO_0000357,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616959,,1333,,,106,2391,,
,BAO_0000357,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,1,,,B,,,8,Autocuration,CHEMBL616960,,1334,,,106,2391,,
,BAO_0000019,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,1,,,F,,,8,Autocuration,CHEMBL616961,,1335,,,106,2391,,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,1,HeLa,,B,,,8,Expert,CHEMBL616962,,1336,,,106,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,1,HeLa,,B,,,8,Autocuration,CHEMBL616963,,1337,,,106,17211,308.0,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616524,,1338,,,106,6491,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616525,,1339,,,106,16190,449.0,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,1,,,B,,,8,Autocuration,CHEMBL872908,,1340,,,106,14165,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,1,,,B,,,8,Autocuration,CHEMBL616526,,1341,,,106,14165,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616527,,1342,,,106,4234,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,,B,,,8,Expert,CHEMBL616528,,1343,,,106,6328,,
,BAO_0000357,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616529,,1344,,,106,14770,,
,BAO_0000357,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616530,,1345,,,106,2598,,
,BAO_0000357,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Expert,CHEMBL616531,,1346,,,106,6897,,
,BAO_0000357,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616532,,1347,,,106,6897,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616533,,1348,,,106,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Expert,CHEMBL616534,,1349,,,106,5843,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,1,,,B,,,8,Expert,CHEMBL616535,,1350,,,106,14454,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,1,,,B,,,8,Autocuration,CHEMBL616536,,1351,,,106,16209,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616537,,1352,,,106,3935,,
,BAO_0000219,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,1,CHO-K1,,F,,,8,Expert,CHEMBL616538,,1353,,,106,13729,485.0,
,BAO_0000019,,H,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,1,,,F,,,8,Expert,CHEMBL616539,,1354,,,106,14251,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Expert,CHEMBL616540,,1355,,,106,17085,,
,BAO_0000357,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,,B,,,8,Autocuration,CHEMBL616429,,1356,,,106,3025,,
,BAO_0000357,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Expert,CHEMBL616430,,1357,,,106,15315,,
,BAO_0000219,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616431,,1358,,,106,14214,,
,BAO_0000357,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616432,,1359,,,106,3804,,
,BAO_0000357,,D,,Affinity for 5-hydroxytryptamine 1B receptor subtype,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616433,,1360,,,106,2391,,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616434,,1361,,,106,4175,,
,BAO_0000219,,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,1,CHO,,B,,,8,Autocuration,CHEMBL616435,,1362,,,106,17296,449.0,
,BAO_0000019,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,1,,,B,,,8,Expert,CHEMBL616436,,1363,,,106,17085,,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616437,,1364,,,106,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616438,,1365,,,106,17211,308.0,
,BAO_0000219,,H,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,1,HeLa,,B,,,8,Autocuration,CHEMBL616439,,1366,,,106,17211,308.0,
,BAO_0000357,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616440,,1367,,,106,15926,,
,BAO_0000219,,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616441,,1368,,,106,16312,485.0,
,BAO_0000357,,H,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,1,,,B,,,8,Expert,CHEMBL616442,,1369,,,106,5843,,
,BAO_0000357,,H,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616443,,1370,,,106,5843,,
,BAO_0000219,,H,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,1,CHO-K1,,B,,,8,Expert,CHEMBL616444,,1371,,,106,16312,485.0,
,BAO_0000357,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616445,,1372,,,106,15926,,
,BAO_0000357,,D,,Binding activity against human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616446,,1373,,,106,15926,,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616447,,1374,,,106,4540,449.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616448,,1375,,,106,6166,,
,BAO_0000219,,H,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616449,,1376,,,106,17296,449.0,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616450,,1377,,,106,17296,449.0,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL857974,,1378,,,106,17296,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616451,,1379,,,106,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616452,,1380,,,106,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,CHO,,B,,,8,Autocuration,CHEMBL616453,,1381,,,106,15779,449.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616454,,1382,,,106,4199,449.0,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616455,,1383,,,106,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL616456,,1384,,,106,15146,449.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616457,,1385,,,106,5213,,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL616458,,1386,,,106,14818,449.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL616459,,1387,,,106,4829,449.0,
,BAO_0000019,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,1,,,F,,,8,Expert,CHEMBL616460,,1388,,,106,14454,,
,BAO_0000019,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,1,,,F,,,8,Expert,CHEMBL616461,,1389,,,106,14454,,
,BAO_0000219,,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,CHO,,F,,,8,Autocuration,CHEMBL616462,,1390,,,106,14875,449.0,
,BAO_0000219,,H,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",1,CHO,,F,,,8,Autocuration,CHEMBL616463,,1391,,,106,14875,449.0,
,BAO_0000019,,H,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",1,,,F,,,8,Autocuration,CHEMBL616464,,1392,,,105,15250,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,1,CHO,,B,,,8,Autocuration,CHEMBL616465,,1393,,,105,15250,449.0,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL832874,,1394,,,17105,15086,,
,BAO_0000019,,H,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,1,,9986.0,F,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616184,,1395,,,106,3025,,
,BAO_0000019,,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616185,,1396,,,106,14998,,
,BAO_0000019,,H,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",1,,9986.0,B,Oryctolagus cuniculus,,8,Intermediate,CHEMBL616186,,1397,,,106,14998,,
,BAO_0000019,,H,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616187,,1398,,,106,14998,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,1,,,B,,,8,Expert,CHEMBL616188,,1399,,,10577,13969,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 1B receptor,1,,,B,,,9,Intermediate,CHEMBL873475,,1400,,,10577,13392,,
Striatum,BAO_0000019,,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,1,,10116.0,B,Rattus norvegicus,2435.0,9,Expert,CHEMBL616189,,1401,,,10577,3651,,
,BAO_0000357,,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,,B,,,8,Expert,CHEMBL616190,,1402,,,10577,10025,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,1,,,B,,,8,Autocuration,CHEMBL616191,,1403,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,1,,,B,,,8,Autocuration,CHEMBL616192,,1404,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,1,,,B,,,8,Autocuration,CHEMBL616193,,1405,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,1,,,B,,,8,Autocuration,CHEMBL616194,,1406,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,1,,,B,,,8,Autocuration,CHEMBL616195,,1407,,,10576,13863,,
,BAO_0000357,,H,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,1,,,B,,,8,Autocuration,CHEMBL616196,,1408,,,10576,13863,,
Hippocampus,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616197,,1409,,,10576,4622,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Intermediate,CHEMBL616198,,1410,,,10576,14911,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,1,,,B,,10000000.0,8,Autocuration,CHEMBL616199,,1411,,,10576,12678,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,1,,,B,,10000000.0,8,Expert,CHEMBL616200,,1412,,,10576,12678,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL616201,,1413,,,10576,14235,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,,,B,,10000000.0,8,Expert,CHEMBL616202,,1414,,,10576,14949,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,1,,,B,,10000000.0,8,Expert,CHEMBL616203,,1415,,,10576,14949,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,1,,,B,,10000000.0,8,Expert,CHEMBL616204,,1416,,,10576,14949,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,1,,,B,,10000000.0,8,Expert,CHEMBL616205,,1417,,,10576,14949,,
Hippocampus,BAO_0000221,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,1,,,B,,10000000.0,8,Expert,CHEMBL616206,,1418,,,10576,14949,,
,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,1,,,B,,,8,Expert,CHEMBL616207,,1419,,,10576,16118,,
,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,1,,,B,,,8,Autocuration,CHEMBL616208,,1420,,,10576,3268,,
,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,1,,,B,,,8,Autocuration,CHEMBL616209,,1421,,,10576,3268,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,1,,,B,,,8,Expert,CHEMBL616210,,1422,,,10576,16117,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,1,,,B,,10000000.0,8,Expert,CHEMBL616211,,1423,,,10576,9783,,
Hippocampus,BAO_0000221,,H,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,1,,,B,,10000000.0,8,Autocuration,CHEMBL616504,,1424,,,10576,9783,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616505,,1425,,,10576,14356,,
,BAO_0000019,,H,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,1,,,F,,,8,Autocuration,CHEMBL616506,,1426,,,10576,15740,,
Hippocampus,BAO_0000221,,H,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,1,,,B,,10000000.0,8,Autocuration,CHEMBL872107,,1427,,,10576,12306,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616507,,1428,,,10576,13348,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616303,,1429,,,10576,10394,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,1,,,B,,10000000.0,8,Autocuration,CHEMBL616304,,1430,,,10576,15260,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,,B,,10000000.0,8,Expert,CHEMBL616305,,1431,,,10576,10046,,
Hippocampus,BAO_0000221,,H,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,1,,,F,,10000000.0,8,Intermediate,CHEMBL616306,,1432,,,10576,15260,,
,BAO_0000357,,H,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616307,,1433,,,10576,12851,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL881829,,1434,,,10576,2148,,
,BAO_0000357,,H,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,1,,,B,,,8,Expert,CHEMBL616308,,1435,,,10576,13134,,
,BAO_0000019,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,1,,,B,,,8,Autocuration,CHEMBL616309,,1436,,,10576,12462,,
,BAO_0000019,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,1,,,B,,,8,Expert,CHEMBL616310,,1437,,,10576,12462,,
,BAO_0000219,,H,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616311,,1438,,,10576,12462,449.0,
,BAO_0000357,,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL616312,,1439,,,10576,11933,,
,BAO_0000357,,H,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,1,,,B,,,8,Autocuration,CHEMBL616313,,1440,,,10576,11933,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616314,,1441,,,10576,403,,
Hippocampus,BAO_0000221,,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616315,,1442,,,10576,15538,,
Hippocampus,BAO_0000221,,H,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,1,,,B,,10000000.0,8,Autocuration,CHEMBL616567,,1443,,,10576,15538,,
Hippocampus,BAO_0000221,,H,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL616568,,1444,,,10576,15538,,
,BAO_0000019,,H,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,1,,,B,,,8,Intermediate,CHEMBL616569,,1445,,,10576,12464,,
,BAO_0000357,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,1,,,B,,,8,Expert,CHEMBL616570,,1446,,,10576,1455,,
,BAO_0000357,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,1,,,B,,,8,Autocuration,CHEMBL616571,,1447,,,10576,12652,,
Hippocampus,BAO_0000221,,H,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,1,,,B,,10000000.0,8,Autocuration,CHEMBL616572,,1448,,,10576,12639,,
,BAO_0000249,,H,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,1,,,B,,,8,Expert,CHEMBL616573,,1449,,,10576,13949,,
,BAO_0000357,,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616574,,1450,,,10576,12463,,
Hippocampus,BAO_0000221,,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,1,,,B,,10000000.0,8,Expert,CHEMBL616575,,1451,,,10576,14829,,
Hippocampus,BAO_0000221,,H,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,1,,,B,,10000000.0,8,Autocuration,CHEMBL872108,,1452,,,10576,14829,,
,BAO_0000357,,H,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616576,,1453,,,10576,12092,,
,BAO_0000249,,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,1,,,B,,,8,Autocuration,CHEMBL616577,,1454,,,10576,403,,
,BAO_0000249,,H,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,1,,,B,,,8,Autocuration,CHEMBL616578,,1455,,,10576,403,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,1,,,B,,,8,Expert,CHEMBL616579,,1456,,,10576,3967,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616580,,1457,,,10576,12771,,
,BAO_0000019,,H,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,1,,,B,,,8,Autocuration,CHEMBL616581,,1458,,,10576,15086,,
Hippocampus,BAO_0000221,,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616582,,1459,,,10576,14909,,
Hippocampus,BAO_0000221,,H,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL616583,,1460,,,10576,14949,,
Hippocampus,BAO_0000221,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616584,,1461,,,10576,2309,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616585,,1462,,,10576,4170,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616586,,1463,,,10576,11642,,
Hippocampus,BAO_0000221,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616587,,1464,,,10576,11642,,
Hippocampus,BAO_0000221,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616588,,1465,,,10576,12953,,
Hippocampus,BAO_0000221,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616589,,1466,,,10576,12953,,
Hippocampus,BAO_0000221,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,1,,,B,,10000000.0,8,Expert,CHEMBL616590,,1467,,,10576,12953,,
,BAO_0000219,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",1,CHO,,B,,,8,Expert,CHEMBL616591,,1468,,,10576,12903,449.0,
,BAO_0000357,,H,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616592,,1469,,,10576,12536,,
,BAO_0000357,,H,,The inhibition activity of 5-HT1A at 1 uM,1,,,B,,,8,Autocuration,CHEMBL616593,,1470,,,10576,10058,,
,BAO_0000219,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",1,CHO-K1,,B,,,8,Expert,CHEMBL616594,,1471,,,10576,12902,485.0,
,BAO_0000249,,H,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,1,,,B,,,8,Expert,CHEMBL616595,,1472,,,10576,14057,,
,BAO_0000357,,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,1,,,B,,,8,Autocuration,CHEMBL616596,,1473,,,10576,11296,,
Hippocampus,BAO_0000221,,H,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616597,,1474,,,10576,11296,,
Hippocampus,BAO_0000221,,H,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,1,,,B,,10000000.0,8,Expert,CHEMBL616598,,1475,,,10576,11296,,
,BAO_0000249,,D,Membranes,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL616599,,1476,,,10576,16616,,
Hippocampus,BAO_0000249,,D,Membranes,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",1,,10116.0,F,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616600,,1477,,,10576,16616,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,1,,,B,,,8,Autocuration,CHEMBL616601,,1478,,,10576,16567,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,1,,,B,,,8,Autocuration,CHEMBL616602,,1479,,,10576,16567,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,1,,,B,,,8,Autocuration,CHEMBL616603,,1480,,,10576,16567,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,1,,,B,,,8,Autocuration,CHEMBL616604,,1481,,,10576,16567,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,1,,,B,,,8,Autocuration,CHEMBL616316,,1482,,,10576,17136,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,1,,,B,,,8,Autocuration,CHEMBL616317,,1483,,,10576,17136,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616318,,1484,,,10576,16616,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,1,,,B,,10000000.0,8,Autocuration,CHEMBL616319,,1485,,,10576,17331,,
Hippocampus,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,1,,,B,,10000000.0,8,Autocuration,CHEMBL616320,,1486,,,10576,17331,,
Hippocampus,BAO_0000221,,D,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616321,,1487,,,10576,17167,,
,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,,F,,,8,Autocuration,CHEMBL616322,,1488,,,10576,15740,,
,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,1,,,F,,,8,Autocuration,CHEMBL616323,,1489,,,10576,15740,,
,BAO_0000357,,H,,Ratio of binding affinity to 5-HT 1A and D2 receptor,1,,,B,,,8,Autocuration,CHEMBL616324,,1490,,,10576,4671,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,,,B,,10000000.0,8,Autocuration,CHEMBL616325,,1491,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,1,,,B,,10000000.0,8,Autocuration,CHEMBL616326,,1492,,,10576,10058,,
Hippocampus,BAO_0000221,,H,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,1,,,B,,10000000.0,8,Autocuration,CHEMBL616327,,1493,,,10576,10058,,
,BAO_0000357,,H,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616328,,1494,,,10576,12073,,
,BAO_0000249,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,,B,,,8,Autocuration,CHEMBL858110,,1495,,,10576,2759,,
,BAO_0000249,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),1,,,F,,,8,Autocuration,CHEMBL616329,,1496,,,10576,2759,,
,BAO_0000249,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,,B,,,8,Autocuration,CHEMBL616330,,1497,,,10576,2759,,
,BAO_0000249,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),1,,,F,,,8,Autocuration,CHEMBL616331,,1498,,,10576,2759,,
,BAO_0000249,,H,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,,F,,,8,Autocuration,CHEMBL616332,,1499,,,10576,2759,,
Brain,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,,B,,955.0,8,Autocuration,CHEMBL857063,,1500,,,10576,9737,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616333,,1501,,,10576,9737,,
,BAO_0000019,,H,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,1,,,F,,,8,Expert,CHEMBL616334,,1502,,,10576,5717,,
Hippocampus,BAO_0000221,,H,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616335,,1503,,,10576,12253,,
,BAO_0000019,,H,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,1,,,B,,,8,Autocuration,CHEMBL616336,,1504,,,10576,14025,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,1,,,B,,,8,Expert,CHEMBL616337,,1505,,,10576,10425,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,1,,,B,,,8,Autocuration,CHEMBL616338,,1506,,,10576,14998,,
Hippocampus,BAO_0000221,,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,1,,,B,,10000000.0,8,Autocuration,CHEMBL616339,,1507,,,10576,13694,,
Hippocampus,BAO_0000221,,H,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,1,,,B,,10000000.0,8,Autocuration,CHEMBL616340,,1508,,,10576,13694,,
,BAO_0000357,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616341,,1509,,,10576,4342,,
,BAO_0000357,,D,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616342,,1510,,,10576,12936,,
,BAO_0000019,,D,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616343,,1511,,,10576,13144,,
,BAO_0000019,,H,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,1,,,B,,,8,Expert,CHEMBL616344,,1512,,,10576,13343,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,B,,,8,Expert,CHEMBL616345,,1513,,,10576,12132,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,1,,,B,,,8,Expert,CHEMBL616346,,1514,,,10576,15419,,
Hippocampus,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616347,,1515,,,10576,1479,,
,BAO_0000019,,H,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,1,,,B,,,8,Expert,CHEMBL616348,,1516,,,10576,14287,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616349,,1517,,,10576,13116,,
,BAO_0000249,,D,Membranes,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616152,,1518,,,10576,2759,,
,BAO_0000249,,H,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,1,,,B,,,8,Autocuration,CHEMBL616153,,1519,,,10576,2759,,
,BAO_0000019,,H,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",1,,,B,,,8,Expert,CHEMBL616154,,1520,,,10576,14748,,
,BAO_0000019,,H,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,1,,,B,,,8,Autocuration,CHEMBL616155,,1521,,,10576,12304,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616156,,1522,,,10576,12409,,
Hippocampus,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL616157,,1523,,,10576,12409,,
Hippocampus,BAO_0000221,,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,1,,,B,,10000000.0,8,Autocuration,CHEMBL616158,,1524,,,10576,13267,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616159,,1525,,,10576,15194,,
,BAO_0000357,,H,,pKi value against rat 5-hydroxytryptamine 1A receptor.,1,,,B,,,8,Expert,CHEMBL616160,,1526,,,10576,14256,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,1,,,B,,,8,Autocuration,CHEMBL616161,,1527,,,10576,16567,,
,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,1,,,F,,,8,Autocuration,CHEMBL616162,,1528,,,10576,15740,,
,BAO_0000357,,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616163,,1529,,,12687,13278,,
,BAO_0000249,,H,Membranes,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,1,,,B,,,8,Expert,CHEMBL616164,,1530,,,10626,1970,,
Brain,BAO_0000221,,H,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,1,,,B,,955.0,8,Autocuration,CHEMBL616165,,1531,,,10576,10034,,
,BAO_0000019,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,1,,10116.0,B,Rattus norvegicus,,8,Autocuration,CHEMBL616355,,1532,,,51,13348,,
,BAO_0000019,,H,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,1,,,F,,,8,Autocuration,CHEMBL616356,,1533,,,10576,13630,,
Brain,BAO_0000221,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,1,,,B,,955.0,8,Autocuration,CHEMBL616357,,1534,,,10576,10862,,
,BAO_0000019,,H,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",1,,,B,,,8,Autocuration,CHEMBL616358,,1535,,,10576,12058,,
,BAO_0000357,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616359,,1536,,,51,4639,,
,BAO_0000357,,H,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,1,,,B,,,8,Expert,CHEMBL616360,,1537,,,51,15453,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL616361,,1538,,,51,4820,,
,BAO_0000357,,H,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616362,,1539,,,51,1089,,
,BAO_0000249,,H,Brain membranes,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,1,,,B,,,8,Autocuration,CHEMBL616363,,1540,,,51,386,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL616364,,1541,,,51,6011,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616365,,1542,,,51,5014,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Expert,CHEMBL616366,,1543,,,51,4402,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Expert,CHEMBL872906,,1544,,,51,17066,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL616367,,1545,,,51,17515,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616368,,1546,,,51,2474,,
,BAO_0000357,,H,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616369,,1547,,,51,4775,,
,BAO_0000357,,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616370,,1548,,,51,14294,,
,BAO_0000357,,D,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616371,,1549,,,51,14294,,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616372,,1550,,,51,12249,449.0,
,BAO_0000219,,H,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,1,,,B,,,8,Expert,CHEMBL616373,,1551,,,51,11376,,
,BAO_0000218,,H,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616374,,1552,In vivo,,51,2474,,
Hippocampus,BAO_0000221,,H,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL616375,,1553,,,51,13311,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616376,,1554,,,51,4373,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,1,,,B,,,8,Expert,CHEMBL857064,,1555,,,51,1633,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616377,,1556,,,51,11866,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616378,,1557,,,51,4373,,
,BAO_0000357,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616379,,1558,,,51,4687,,
,BAO_0000357,,H,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616380,,1559,,,11863,16946,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,1,,,B,,,8,Autocuration,CHEMBL616381,,1560,,,11863,13291,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616382,,1561,,,11863,14159,,
,BAO_0000357,,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616383,,1562,,,11863,10812,,
,BAO_0000219,,D,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,1,CHO,10090.0,B,Mus musculus,,9,Expert,CHEMBL616350,,1563,,,11863,3032,449.0,
,BAO_0000357,,H,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616351,,1564,,,11863,16655,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,1,,,B,,,8,Autocuration,CHEMBL616352,,1565,,,11863,14532,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616353,,1566,,,11863,13944,,
,BAO_0000357,,H,,Binding affinity against serotonergic 5-HT1a receptor,1,,,B,,,8,Autocuration,CHEMBL616354,,1567,,,11863,13033,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616508,,1568,,,11863,10321,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 1A receptor,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL616559,,1569,,,11863,2968,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616560,,1570,,,11863,13964,,
,BAO_0000357,,H,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",1,,,B,,,8,Autocuration,CHEMBL616561,,1571,,,11863,15527,,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616562,,1572,,,11863,12248,449.0,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616563,,1573,,,11863,12249,449.0,
,BAO_0000357,,H,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616564,,1574,,,11863,15120,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616565,,1575,,,11863,13313,,
,BAO_0000218,,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616566,,1576,,,11863,2613,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL616989,,1577,,,11863,16700,,
,BAO_0000357,,H,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL857975,,1578,,,11863,2201,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL616990,,1579,,,11863,1274,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL616991,,1580,,,11863,1317,,
,BAO_0000357,,H,,Tested against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616992,,1581,,,11863,12146,,
,BAO_0000357,,H,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL616993,,1582,,,11863,14059,,
,BAO_0000019,,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL616994,,1583,,,106,14025,,
,BAO_0000019,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616995,,1584,,,106,14025,,
,BAO_0000219,,D,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,HEK293,9593.0,B,Gorilla gorilla,,9,Intermediate,CHEMBL616996,,1585,,,105571,14447,722.0,
,BAO_0000218,,H,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL616997,,1586,In vivo,,106,3025,,
,BAO_0000218,,H,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL616998,,1587,In vivo,,106,3025,,
,BAO_0000019,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL616999,,1588,,,106,15329,,
,BAO_0000019,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL617000,,1589,,,106,15329,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL617001,,1590,,,106,15847,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL858111,,1591,,,106,15847,,
,BAO_0000019,,H,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,1,,,F,,,8,Autocuration,CHEMBL617002,,1592,,,106,14165,,
,BAO_0000019,,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),1,,,F,,,8,Autocuration,CHEMBL617003,,1593,,,106,14214,,
,BAO_0000019,,H,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),1,,,F,,,8,Autocuration,CHEMBL617004,,1594,,,106,14214,,
,BAO_0000019,,D,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617005,,1595,,,106,14214,,
,BAO_0000219,,D,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,1,CHO-K1,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616623,,1596,,,106,13729,485.0,
,BAO_0000219,,H,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,1,CHO,,F,,,8,Autocuration,CHEMBL616624,,1597,,,106,3025,449.0,
,BAO_0000357,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL883243,,1598,,,106,2391,,
,BAO_0000019,,H,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,1,,,F,,,8,Autocuration,CHEMBL616625,,1599,,,106,2391,,
,BAO_0000219,,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",1,CHO,,F,,,8,Expert,CHEMBL616626,,1600,,,106,14956,449.0,
,BAO_0000219,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,1,CHO,,F,,,8,Autocuration,CHEMBL616627,,1601,,,106,2598,449.0,
,BAO_0000219,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,1,CHO,,F,,,8,Autocuration,CHEMBL616628,,1602,,,106,2598,449.0,
,BAO_0000219,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,1,CHO,,F,,,8,Autocuration,CHEMBL616629,,1603,,,106,2598,449.0,
,BAO_0000219,,H,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,1,CHO,,F,,,8,Autocuration,CHEMBL616630,,1604,,,106,2598,449.0,
,BAO_0000019,,H,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",1,,,F,,,8,Expert,CHEMBL616631,,1605,,,106,14956,,
,BAO_0000019,,H,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",1,,,F,,,8,Autocuration,CHEMBL616632,,1606,,,106,14956,,
,BAO_0000357,,D,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616633,,1607,,,106,14214,,
,BAO_0000219,,H,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,1,CHO,,B,,,8,Expert,CHEMBL616634,,1608,,,106,3463,449.0,
,BAO_0000357,,H,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL616635,,1609,,,106,15331,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 1B receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL885358,,1610,,,106,16146,,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616636,,1611,,,106,14159,449.0,
,BAO_0000219,,H,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,1,CHO,,B,,,8,Expert,CHEMBL616637,,1612,,,106,14158,449.0,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616638,,1613,,,106,14159,,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616639,,1614,,,106,15250,449.0,
,BAO_0000219,,H,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,CHO,,B,,,8,Expert,CHEMBL616640,,1615,,,106,15250,449.0,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616641,,1616,,,106,15331,449.0,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,1,CHO,,B,,,8,Expert,CHEMBL616642,,1617,,,106,15332,449.0,
,BAO_0000219,,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616643,,1618,,,106,14956,449.0,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL616644,,1619,,,106,3805,,
,BAO_0000357,,H,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,1,,,B,,,8,Autocuration,CHEMBL616645,,1620,,,106,14875,,
,BAO_0000019,,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,9986.0,F,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616646,,1621,,,105,14454,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,9986.0,F,Oryctolagus cuniculus,,8,Expert,CHEMBL616647,,1622,,,105,14454,,
,BAO_0000357,,H,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),1,,,B,,,8,Autocuration,CHEMBL616509,,1623,,,105,16288,,
,BAO_0000357,,H,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),1,,,B,,,8,Autocuration,CHEMBL616510,,1624,,,105,16288,,
,BAO_0000357,,H,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616511,,1625,,,105,16312,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL616512,,1626,,,105,1348,,
,BAO_0000357,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616513,,1627,,,105,5834,,
Striatum,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,,9913.0,B,Bos taurus,2435.0,8,Autocuration,CHEMBL616514,,1628,,,105,13366,,
,BAO_0000357,,H,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL616515,,1629,,,105,1414,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616516,,1630,,,105,14998,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616517,,1631,,,105,11473,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616518,,1632,,,105,11473,,
,BAO_0000357,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616519,,1633,,,105,10639,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616520,,1634,,,105,10639,,
,BAO_0000357,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616521,,1635,,,105,1375,,
,BAO_0000357,,H,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616522,,1636,,,105,1375,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL884531,,1637,,,105,16532,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616523,,1638,,,105,11147,,
Striatum,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,1,,9913.0,B,Bos taurus,2435.0,8,Autocuration,CHEMBL616731,,1639,,,105,13366,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616732,,1640,,,105,10444,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616733,,1641,,,105,16532,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616734,,1642,,,105,16532,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616735,,1643,,,105,12827,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616736,,1644,,,105,12827,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,9913.0,F,Bos taurus,,8,Expert,CHEMBL616737,,1645,,,105,12919,,
,BAO_0000019,,H,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616738,,1646,,,105,14025,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,9913.0,F,Bos taurus,,8,Expert,CHEMBL616739,,1647,,,105,12919,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,9913.0,F,Bos taurus,,8,Expert,CHEMBL616740,,1648,,,105,12919,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,1,,9913.0,F,Bos taurus,,8,Expert,CHEMBL616741,,1649,,,105,12919,,
,BAO_0000219,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,1,HEK293,9593.0,B,Gorilla gorilla,,8,Autocuration,CHEMBL616742,,1650,,,105,14447,722.0,
,BAO_0000019,,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616743,,1651,,,105570,1375,,
,BAO_0000019,,D,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616744,,1652,,,105570,1375,,
,BAO_0000019,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616745,,1653,,,105570,12409,,
,BAO_0000019,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616746,,1654,,,105570,12409,,
,BAO_0000019,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616747,,1655,,,105570,12409,,
,BAO_0000019,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616748,,1656,,,105570,12409,,
,BAO_0000019,,D,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616648,,1657,,,105570,12409,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616649,,1658,,,105570,11574,,
,BAO_0000357,,D,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616650,,1659,,,105570,1558,,
,BAO_0000218,,D,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616651,,1660,,,105570,12409,,
,BAO_0000218,,D,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616652,,1661,,,105570,12409,,
,BAO_0000218,,D,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616653,,1662,,,105570,12409,,
,BAO_0000218,,D,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL616654,,1663,,,105570,12409,,
,BAO_0000019,,D,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616655,,1664,,,105570,12253,,
,BAO_0000357,,D,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616656,,1665,,,105570,12936,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL616657,,1666,,,105,13181,,
Striatum,BAO_0000357,,D,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL616658,,1667,,,105570,12409,,
,BAO_0000357,,D,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL616659,,1668,,,105570,10639,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616660,,1669,,,51,5254,,
,BAO_0000357,,H,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,1,,,B,,,8,Autocuration,CHEMBL616661,,1670,,,106,13051,,
,BAO_0000019,,H,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Expert,CHEMBL616662,,1671,,,105,3463,,
,BAO_0000019,,H,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL616663,,1672,,,105,15315,,
,BAO_0000019,,H,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL616664,,1673,,,105,6011,,
,BAO_0000219,,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL881820,,1674,,,105,14159,449.0,
,BAO_0000219,,H,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",1,CHO,,F,,,8,Autocuration,CHEMBL616665,,1675,,,105,14159,449.0,
,BAO_0000219,,H,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,CHO,,B,,,8,Expert,CHEMBL616666,,1676,,,105,15250,449.0,
,BAO_0000219,,H,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,1,CHO,,B,,,8,Autocuration,CHEMBL616667,,1677,,,105,15250,449.0,
,BAO_0000219,,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,CHO,,F,,,8,Expert,CHEMBL616668,,1678,,,105,15331,449.0,
,BAO_0000219,,D,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616669,,1679,,,105,15332,449.0,
,BAO_0000219,,H,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",1,CHO,,F,,,8,Expert,CHEMBL617040,,1680,,,105,15332,449.0,
,BAO_0000219,,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",1,CHO,,F,,,8,Autocuration,CHEMBL617041,,1681,,,105,3294,449.0,
,BAO_0000219,,H,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",1,CHO,,F,,,8,Expert,CHEMBL617042,,1682,,,105,14158,449.0,
,BAO_0000219,,H,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",1,CHO,,F,,,8,Expert,CHEMBL617043,,1683,,,105,14956,449.0,
,BAO_0000019,,H,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL617044,,1684,,,105,12469,,
,BAO_0000219,,H,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,1,CHO,,F,,,8,Expert,CHEMBL617045,,1685,,,105,3463,449.0,
,BAO_0000219,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617046,,1686,,,105,15250,449.0,
,BAO_0000219,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617047,,1687,,,105,15250,449.0,
,BAO_0000019,,H,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",1,,,F,,,8,Expert,CHEMBL617048,,1688,,,105,14956,,
,BAO_0000019,,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",1,,,F,,,8,Autocuration,CHEMBL616897,,1689,,,105,14159,,
,BAO_0000019,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL616898,,1690,,,105,14159,,
,BAO_0000219,,D,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL858201,,1691,,,105,14499,449.0,
,BAO_0000019,,H,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL616899,,1692,,,105,15315,,
,BAO_0000219,,H,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),1,,,B,,,8,Autocuration,CHEMBL616900,,1693,In vitro,,105,3294,,
,BAO_0000219,,H,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,1,CHO,,B,,,8,Expert,CHEMBL616901,,1694,,,105,3463,449.0,
,BAO_0000357,,H,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL616902,,1695,,,105,15331,,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616903,,1696,,,105,14159,449.0,
,BAO_0000219,,H,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,1,CHO,,B,,,8,Expert,CHEMBL616904,,1697,,,105,14158,449.0,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616905,,1698,,,105,14159,,
,BAO_0000219,,H,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,1,CHO,,B,,,8,Expert,CHEMBL616906,,1699,,,105,15250,449.0,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616907,,1700,,,105,15250,449.0,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616908,,1701,,,105,15331,449.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616909,,1702,,,105,15332,449.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616910,,1703,,,105,14499,449.0,
,BAO_0000219,,H,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616911,,1704,,,105,15332,449.0,
,BAO_0000219,,H,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL616912,,1705,,,105,14956,449.0,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL616913,,1706,,,105,3805,,
,BAO_0000219,,D,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616914,,1707,,,105,6011,449.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616915,,1708,,,105,16190,449.0,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616916,,1709,,,105,14165,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616917,,1710,,,105,4234,,
,BAO_0000357,,H,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",1,,,B,,,8,Autocuration,CHEMBL616918,,1711,,,105,15527,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,1,,,B,,,8,Expert,CHEMBL616919,,1712,,,105,6328,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616920,,1713,,,105,16209,,
,BAO_0000357,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL872914,,1714,,,105,14770,,
,BAO_0000357,,H,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616921,,1715,,,105,2598,,
,BAO_0000357,,H,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Expert,CHEMBL616922,,1716,,,105,6897,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616923,,1717,,,105,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Expert,CHEMBL616924,,1718,,,105,5843,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,1,,,B,,,8,Expert,CHEMBL875909,,1719,,,105,14454,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,1,,,B,,,8,Autocuration,CHEMBL616925,,1720,,,105,14454,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,1,,,B,,,8,Autocuration,CHEMBL616926,,1721,,,105,14454,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616927,,1722,,,105,15818,,
,BAO_0000219,,H,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,1,CHO-K1,,F,,,8,Expert,CHEMBL616928,,1723,,,105,13729,485.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616929,,1724,In vitro,,105,6011,,
,BAO_0000357,,D,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616930,,1725,,,105,4234,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Expert,CHEMBL616931,,1726,,,105,17085,,
,BAO_0000357,,H,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,,B,,,8,Autocuration,CHEMBL616932,,1727,,,105,3025,,
,BAO_0000357,,H,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Expert,CHEMBL616933,,1728,,,105,15315,,
,BAO_0000219,,D,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616934,,1729,,,105,14214,,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616935,,1730,,,105,3804,,
,BAO_0000357,,H,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL616936,,1731,,,105,16700,,
,BAO_0000357,,D,,Affinity for 5-hydroxytryptamine 1D receptor subtype,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616937,,1732,,,105,2391,,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616938,,1733,,,105,4175,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616939,,1734,,,105,17085,,
,BAO_0000019,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,1,,,B,,,8,Expert,CHEMBL616940,,1735,,,105,17085,,
,BAO_0000357,,D,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616941,,1736,,,105,15926,,
,BAO_0000219,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616942,,1737,,,105,16312,485.0,
,BAO_0000219,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616943,,1738,,,105,16312,485.0,
,BAO_0000219,,H,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,1,CHO,,B,,,4,Autocuration,CHEMBL616944,,1739,,,104802,14956,449.0,
,BAO_0000019,,H,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",1,,,F,,,8,Autocuration,CHEMBL616945,,1740,,,105,3294,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL616946,,1741,,,105,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616947,,1742,,,105,12861,,
,BAO_0000219,,H,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,1,CHO-K1,,B,,,8,Expert,CHEMBL616948,,1743,,,105,16312,485.0,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616851,,1744,,,105,5104,,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616852,,1745,,,105,5105,,
,BAO_0000357,,H,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616853,,1746,,,105,14499,,
,BAO_0000357,,D,,Binding activity against human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616854,,1747,,,105,15926,,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616855,,1748,,,105,4540,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL616856,,1749,,,105,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL616857,,1750,,,105,15779,449.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616858,,1751,,,105,6166,,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL616859,,1752,,,105,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,1,CHO,,B,,,8,Autocuration,CHEMBL616860,,1753,,,105,15779,449.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616861,,1754,,,105,17451,722.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616541,,1755,,,105,17451,722.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,1,HEK293,,B,,,8,Autocuration,CHEMBL616542,,1756,,,105,17451,722.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616543,,1757,,,105,4199,449.0,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616544,,1758,,,105,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL616545,,1759,,,105,15146,449.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616546,,1760,,,105,5213,,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL616547,,1761,,,105,14818,449.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL616548,,1762,,,105,4829,449.0,
,BAO_0000019,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,1,,,F,,,8,Expert,CHEMBL616549,,1763,,,105,14454,,
,BAO_0000019,,H,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,1,,,F,,,8,Expert,CHEMBL616550,,1764,,,105,14454,,
,BAO_0000357,,H,,Binding affinity against 5-HT2C receptor,1,,,B,,,8,Autocuration,CHEMBL857066,,1765,,,108,5254,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616551,,1766,,,108,5254,,
,BAO_0000357,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,,B,,,8,Autocuration,CHEMBL616552,,1767,,,10577,10639,,
,BAO_0000019,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,1,,,F,,,8,Autocuration,CHEMBL832876,,1768,,,10577,10639,,
,BAO_0000019,,H,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",1,,,B,,,8,Expert,CHEMBL616553,,1769,,,10577,12352,,
,BAO_0000357,,H,,Binding affinity towards 5-HT1B was determined,1,,,B,,,8,Autocuration,CHEMBL616554,,1770,,,10577,9098,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,1,,,B,,,8,Expert,CHEMBL616555,,1771,,,10577,14430,,
,BAO_0000019,,H,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",1,,,B,,,8,Expert,CHEMBL616556,,1772,,,10577,13657,,
,BAO_0000019,,H,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",1,,,B,,,8,Autocuration,CHEMBL616557,,1773,,,10577,13657,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,B,,,8,Expert,CHEMBL616558,,1774,,,10577,15854,,
,BAO_0000019,,D,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616749,,1775,,,10577,10639,,
,BAO_0000357,,H,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,1,,,B,,,8,Autocuration,CHEMBL616750,,1776,,,10577,10025,,
,BAO_0000357,,H,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",1,,,B,,,8,Autocuration,CHEMBL616751,,1777,,,10577,10025,,
,BAO_0000249,,H,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,,B,,,8,Autocuration,CHEMBL616752,,1778,,,10577,14286,,
Striatum,BAO_0000019,,H,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,1,,,B,,2435.0,8,Autocuration,CHEMBL616753,,1779,,,10577,3651,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616754,,1780,,,10577,14178,,
,BAO_0000019,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL616755,,1781,,,10577,10639,,
Striatum,BAO_0000019,,H,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,1,,,B,,2435.0,8,Autocuration,CHEMBL616756,,1782,,,10577,13605,,
Striatum,BAO_0000019,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,1,,,B,,2435.0,8,Autocuration,CHEMBL616757,,1783,,,10577,5834,,
Striatum,BAO_0000357,,H,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,1,,,B,,2435.0,8,Autocuration,CHEMBL616758,,1784,,,10577,10922,,
,BAO_0000249,,H,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,1,,,B,,,8,Autocuration,CHEMBL616759,,1785,,,10577,14286,,
,BAO_0000357,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,1,,,B,,,8,Autocuration,CHEMBL616760,,1786,,,10577,11825,,
Striatum,BAO_0000019,,H,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,1,,,B,,2435.0,8,Autocuration,CHEMBL616761,,1787,,,10577,14826,,
Striatum,BAO_0000019,,H,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,1,,,B,,2435.0,8,Autocuration,CHEMBL616762,,1788,,,10577,9699,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,1,,,B,,,8,Autocuration,CHEMBL616763,,1789,,,10577,14423,,
,BAO_0000357,,H,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,1,,,B,,,8,Expert,CHEMBL872909,,1790,,,10577,10062,,
,BAO_0000357,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616764,,1791,,,10577,10062,,
,BAO_0000357,,D,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616765,,1792,,,10577,12280,,
Striatum,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,1,,,B,,2435.0,8,Autocuration,CHEMBL616766,,1793,,,10577,15412,,
Striatum,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,1,,,B,,2435.0,8,Autocuration,CHEMBL616767,,1794,,,10577,15412,,
,BAO_0000357,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616768,,1795,,,10577,10062,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616769,,1796,,,10577,11147,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,1,,,B,,,8,Autocuration,CHEMBL616770,,1797,,,10577,9547,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,1,,,B,,,8,Autocuration,CHEMBL616771,,1798,,,10577,10444,,
Striatum,BAO_0000019,,H,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,1,,,B,,2435.0,8,Autocuration,CHEMBL616772,,1799,,,10577,12469,,
,BAO_0000019,,H,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,1,,,B,,,8,Expert,CHEMBL616773,,1800,,,10577,9098,,
,BAO_0000019,,H,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,1,,,B,,,8,Autocuration,CHEMBL616774,,1801,,,10577,9098,,
,BAO_0000357,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616775,,1802,,,10577,9699,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616776,,1803,,,10577,10394,,
,BAO_0000357,,H,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616777,,1804,,,10577,12092,,
,BAO_0000357,,H,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL616778,,1805,,,10577,16700,,
,BAO_0000249,,D,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616779,,1806,,,10577,403,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 1B receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616780,,1807,,,10577,12771,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,1,,,B,,,8,Autocuration,CHEMBL616781,,1808,,,10577,11642,,
,BAO_0000357,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616782,,1809,,,10577,12953,,
,BAO_0000357,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616783,,1810,,,10577,12953,,
Striatum,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,1,,,B,,2435.0,8,Expert,CHEMBL616784,,1811,,,10577,12953,,
,BAO_0000357,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL616785,,1812,,,10577,12953,,
Brain,BAO_0000249,,H,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,,B,,955.0,8,Autocuration,CHEMBL857067,,1813,,,10577,9737,,
,BAO_0000019,,H,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616786,,1814,,,10577,9737,,
Brain,BAO_0000249,,H,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,,B,,955.0,8,Autocuration,CHEMBL616787,,1815,,,10577,9737,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,1,,,B,,,8,Autocuration,CHEMBL616788,,1816,,,10577,12827,,
,BAO_0000357,,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616789,,1817,,,10577,5033,,
,BAO_0000019,,D,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616790,,1818,,,10577,9786,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Expert,CHEMBL616791,,1819,,,10577,13116,,
,BAO_0000019,,H,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,1,,,B,,,8,Autocuration,CHEMBL616792,,1820,,,10577,16429,,
,BAO_0000249,,D,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616793,,1821,,,10577,12409,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616794,,1822,,,10577,15194,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616795,,1823,,,10577,15194,,
,BAO_0000019,,H,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL616796,,1824,,,104686,5486,,
,BAO_0000357,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616797,,1825,,,106,4639,,
,BAO_0000249,,H,Brain membranes,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,1,,,B,,,8,Autocuration,CHEMBL616798,,1826,,,106,386,,
,BAO_0000357,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,1,,,B,,,8,Autocuration,CHEMBL616799,,1827,,,106,2474,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL616800,,1828,,,106,6011,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616801,,1829,,,106,5014,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL616802,,1830,,,106,17515,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616803,,1831,,,106,4373,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,1,,,B,,,8,Expert,CHEMBL857068,,1832,,,106,1633,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,1,,,B,,,8,Autocuration,CHEMBL616804,,1833,,,106,1633,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616805,,1834,,,106,4373,,
,BAO_0000357,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616806,,1835,,,106,4687,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor,1,,,B,,,8,Autocuration,CHEMBL616807,,1836,,,106,11574,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616808,,1837,,,106,10321,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL616809,,1838,,,106,15527,,
,BAO_0000357,,H,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,1,,,B,,,8,Autocuration,CHEMBL616810,,1839,,,106,17200,,
,BAO_0000224,,H,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,1,,,B,,,4,Autocuration,CHEMBL616811,,1840,,,104802,14423,,
,BAO_0000357,,H,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL616812,,1841,,,108,5834,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616813,,1842,,,108,11473,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616814,,1843,,,108,11473,,
,BAO_0000357,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616815,,1844,,,108,10639,,
,BAO_0000357,,H,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616816,,1845,,,108,10639,,
,BAO_0000357,,H,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616817,,1846,,,108,14331,,
,BAO_0000357,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616818,,1847,,,108,10796,,
,BAO_0000357,,H,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616819,,1848,,,108,9098,,
,BAO_0000357,,H,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616820,,1849,,,108,14331,,
,BAO_0000019,,H,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL616821,,1850,,,108,11828,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL616822,,1851,,,108,11866,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616823,,1852,,,108,13047,,
,BAO_0000357,,D,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616824,,1853,,,12689,188,,
,BAO_0000357,,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616825,,1854,,,12689,11825,,
,BAO_0000357,,D,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616826,,1855,,,12689,11825,,
,BAO_0000019,,D,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616827,,1856,,,12689,11624,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616828,,1857,,,12689,11139,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616829,,1858,,,12689,11147,,
,BAO_0000019,,D,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616830,,1859,,,12689,10444,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616831,,1860,,,12689,11624,,
,BAO_0000019,,D,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616832,,1861,,,12689,11662,,
,BAO_0000019,,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616833,,1862,,,12689,11662,,
,BAO_0000019,,D,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL616834,,1863,,,12689,11662,,
,BAO_0000019,,D,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL829595,,1864,,,12689,11662,,
,BAO_0000357,,D,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616835,,1865,,,12689,9098,,
,BAO_0000249,,D,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL872910,,1866,,,12689,10394,,
,BAO_0000357,,H,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,1,,,B,,,8,Expert,CHEMBL616836,,1867,,,12689,11933,,
,BAO_0000357,,D,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616837,,1868,,,12689,12092,,
,BAO_0000019,,D,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616466,,1869,,,12689,12253,,
,BAO_0000219,,D,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,1,HEK293,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL616467,,1870,,,12689,12253,722.0,
,BAO_0000357,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,,B,,,8,Autocuration,CHEMBL616468,,1871,,,108,1558,,
,BAO_0000357,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL616469,,1872,,,108,2474,,
,BAO_0000357,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL616470,,1873,,,108,2474,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,,B,,,8,Autocuration,CHEMBL616471,,1874,,,12689,11574,,
,BAO_0000357,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,1,,,B,,,8,Autocuration,CHEMBL616472,,1875,,,12689,1558,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1C receptor,1,,,B,,,8,Autocuration,CHEMBL616473,,1876,,,12689,13944,,
,BAO_0000357,,H,,Binding affinity against serotonergic 5-HT1c receptor,1,,,B,,,8,Autocuration,CHEMBL616474,,1877,,,12689,13033,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL616475,,1878,,,12689,10321,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616476,,1879,,,12689,11866,,
,BAO_0000019,,H,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616477,,1880,,,105,14454,,
,BAO_0000224,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616478,,1881,,,104686,11574,,
,BAO_0000224,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616479,,1882,,,104686,11574,,
,BAO_0000019,,H,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,1,,,B,,,4,Autocuration,CHEMBL616480,,1883,,,104686,13631,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL616481,,1884,,,104686,9630,,
,BAO_0000249,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL616482,,1885,,,104686,8822,,
Brain,BAO_0000221,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,1,,10116.0,B,Rattus norvegicus,955.0,5,Autocuration,CHEMBL884713,,1886,,,104686,9064,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,1,,,B,,,4,Autocuration,CHEMBL616483,,1887,,,104686,8868,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,1,,,B,,,4,Autocuration,CHEMBL616484,,1888,,,104686,9064,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,1,,,B,,,4,Autocuration,CHEMBL616485,,1889,,,104686,9806,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL616486,,1890,,,104686,9098,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,1,,,B,,,4,Autocuration,CHEMBL616487,,1891,,,104686,8868,,
,BAO_0000224,,H,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,,B,,,4,Autocuration,CHEMBL616488,,1892,,,104686,12765,,
,BAO_0000019,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616489,,1893,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616490,,1894,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,1,,,B,,,4,Autocuration,CHEMBL616491,,1895,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,1,,,B,,,4,Autocuration,CHEMBL616492,,1896,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616493,,1897,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,1,,,B,,,4,Autocuration,CHEMBL616494,,1898,,,104686,11473,,
,BAO_0000019,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL616495,,1899,,,104686,11473,,
,BAO_0000019,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,1,,,B,,,4,Autocuration,CHEMBL616496,,1900,,,104686,3086,,
,BAO_0000019,,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616497,,1901,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616498,,1902,,,104686,11049,,
,BAO_0000019,,H,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,1,,,B,,,4,Autocuration,CHEMBL616499,,1903,,,104686,10639,,
,BAO_0000019,,H,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,1,,,B,,,4,Autocuration,CHEMBL616500,,1904,,,104686,10922,,
Brain,BAO_0000221,,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,,10116.0,B,Rattus norvegicus,955.0,5,Autocuration,CHEMBL616501,,1905,,,104686,9064,,
Brain,BAO_0000221,,H,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,1,,,B,,955.0,4,Autocuration,CHEMBL616502,,1906,,,104686,10748,,
,BAO_0000249,,H,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,,B,,,4,Autocuration,CHEMBL884529,,1907,,,104686,11614,,
,BAO_0000249,,H,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,,B,,,4,Autocuration,CHEMBL616503,,1908,,,104686,11615,,
,BAO_0000224,,H,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL616964,,1909,,,104686,11615,,
,BAO_0000249,,H,Membranes,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,1,,,B,,,4,Autocuration,CHEMBL616965,,1910,,,104686,11614,,
,BAO_0000224,,H,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,1,,,B,,,4,Autocuration,CHEMBL616966,,1911,,,104686,11702,,
,BAO_0000224,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,B,,,4,Autocuration,CHEMBL616967,,1912,,,104686,11702,,
,BAO_0000224,,D,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL616968,,1913,,,104686,11702,,
,BAO_0000224,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,B,,,4,Autocuration,CHEMBL616969,,1914,,,104686,11702,,
,BAO_0000019,,H,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,1,,,B,,,4,Autocuration,CHEMBL884530,,1915,,,104686,13346,,
,BAO_0000224,,H,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL616970,,1916,,,104686,10025,,
,BAO_0000224,,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,,B,,,4,Autocuration,CHEMBL616971,,1917,,,104686,10025,,
,BAO_0000224,,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,,B,,,4,Autocuration,CHEMBL616972,,1918,,,104686,10025,,
,BAO_0000224,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,1,,,B,,,4,Autocuration,CHEMBL616973,,1919,,,104686,9036,,
,BAO_0000224,,H,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,1,,,B,,,4,Autocuration,CHEMBL616974,,1920,,,104686,9036,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,1,,,B,,,4,Autocuration,CHEMBL616975,,1921,,,104686,9161,,
,BAO_0000019,,H,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL616976,,1922,,,104686,12304,,
,BAO_0000224,,H,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL616977,,1923,,,104686,13276,,
,BAO_0000224,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,,B,,,4,Autocuration,CHEMBL616978,,1924,,,104686,11825,,
,BAO_0000224,,H,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,1,,,B,,,4,Autocuration,CHEMBL616979,,1925,,,104686,12443,,
,BAO_0000224,,H,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL616980,,1926,,,104686,13830,,
,BAO_0000249,,H,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,1,,,B,,,4,Autocuration,CHEMBL616981,,1927,,,104686,9592,,
,BAO_0000249,,H,Membranes,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,1,,,B,,,4,Autocuration,CHEMBL616982,,1928,,,104686,9592,,
,BAO_0000224,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,1,,,B,,,4,Autocuration,CHEMBL616983,,1929,,,104686,10881,,
,BAO_0000019,,H,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,1,,,B,,,4,Autocuration,CHEMBL616984,,1930,,,104686,13605,,
,BAO_0000224,,D,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL616985,,1931,,,104686,11624,,
,BAO_0000224,,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,,B,,,4,Autocuration,CHEMBL616986,,1932,,,104686,4101,,
,BAO_0000224,,H,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,1,,,B,,,4,Autocuration,CHEMBL616987,,1933,,,104686,4101,,
,BAO_0000019,,H,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,1,,,B,,,4,Autocuration,CHEMBL616988,,1934,,,104686,15360,,
,BAO_0000019,,H,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,1,,,B,,,4,Autocuration,CHEMBL617243,,1935,,,104686,11576,,
,BAO_0000019,,H,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,1,,,B,,,4,Autocuration,CHEMBL617244,,1936,,,104686,5834,,
,BAO_0000219,,D,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,CHO-K1,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617245,,1937,,,104686,2395,485.0,
,BAO_0000249,,H,Membranes,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,1,,,B,,,4,Autocuration,CHEMBL617246,,1938,,,104686,11965,,
,BAO_0000224,,H,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),1,,,B,,,4,Autocuration,CHEMBL617546,,1939,,,104686,3967,,
,BAO_0000249,,H,Brain membranes,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),1,,,B,,,4,Autocuration,CHEMBL617547,,1940,,,104686,11130,,
,BAO_0000219,,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,B,,,4,Autocuration,CHEMBL617548,,1941,In vitro,,104686,13427,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617549,,1942,,,104686,9443,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,,B,,,4,Autocuration,CHEMBL617550,,1943,,,104686,9443,,
,BAO_0000224,,H,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,1,,,B,,,4,Autocuration,CHEMBL617551,,1944,,,104686,11825,,
,BAO_0000249,,H,Membranes,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,1,,,B,,,4,Autocuration,CHEMBL617552,,1945,,,104686,12120,,
,BAO_0000249,,H,Membranes,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,1,,,B,,,4,Autocuration,CHEMBL617553,,1946,,,104686,12120,,
Thoracic aorta,BAO_0000019,,H,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,1,,,F,,1515.0,4,Autocuration,CHEMBL617554,,1947,,,104686,11963,,
,BAO_0000019,,H,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617555,,1948,,,104686,9069,,
,BAO_0000224,,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,,B,,,4,Autocuration,CHEMBL617556,,1949,,,104686,8868,,
,BAO_0000357,,H,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,1,,,B,,,8,Autocuration,CHEMBL617557,,1950,,,10624,17200,,
,BAO_0000357,,H,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,1,,,B,,,8,Autocuration,CHEMBL617558,,1951,,,10624,17200,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,1,,,B,,,8,Expert,CHEMBL617559,,1952,,,17106,13969,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 1D receptor,1,,,B,,,9,Expert,CHEMBL617560,,1953,,,17106,13392,,
,BAO_0000249,,H,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,B,,,8,Autocuration,CHEMBL617561,,1954,,,17106,1742,,
,BAO_0000249,,H,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,B,,,8,Autocuration,CHEMBL617562,,1955,,,17106,1742,,
Striatum,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,1,,,B,,2435.0,8,Autocuration,CHEMBL617563,,1956,,,17106,14331,,
,BAO_0000019,,H,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL617564,,1957,,,17106,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,1,,,B,,,8,Expert,CHEMBL617565,,1958,,,17106,12861,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL856076,,1959,,,17106,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617566,,1960,,,17106,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,B,,,8,Expert,CHEMBL875911,,1961,,,17106,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,,B,,,8,Autocuration,CHEMBL617567,,1962,,,17106,12861,,
,BAO_0000249,,H,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,1,,,B,,,8,Autocuration,CHEMBL617568,,1963,,,17106,675,,
,BAO_0000019,,H,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,1,,,B,,,8,Expert,CHEMBL617569,,1964,,,17106,12490,,
,BAO_0000249,,H,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,1,,,B,,,8,Expert,CHEMBL617570,,1965,,,17106,11828,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,1,,,B,,,8,Autocuration,CHEMBL617571,,1966,,,17106,11866,,
,BAO_0000357,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617572,,1967,,,105,773,,
,BAO_0000357,,H,,The compound was tested for intrinsic activity against 5-HT1D receptor,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL617573,,1968,,,105,13047,,
,BAO_0000019,,H,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL617574,,1969,,,105,13047,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-HT1D receptor,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL617575,,1970,,,105,13047,,
,BAO_0000357,,H,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,1,,,B,,,8,Autocuration,CHEMBL617576,,1971,,,10578,188,,
,BAO_0000019,,H,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,1,,,F,,,8,Autocuration,CHEMBL617577,,1972,,,10578,10639,,
,BAO_0000019,,H,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,1,,,F,,,8,Autocuration,CHEMBL617578,,1973,,,10578,12438,,
,BAO_0000357,,H,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL617579,,1974,,,10578,12438,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,1,,,B,,,8,Expert,CHEMBL617580,,1975,,,10578,15854,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL617581,,1976,,,10578,10394,,
,BAO_0000357,,H,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617582,,1977,,,10578,12092,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,1,,,B,,,8,Expert,CHEMBL617583,,1978,,,10578,3389,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL617584,,1979,,,105,6011,,
,BAO_0000357,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL617585,,1980,,,105,4639,,
,BAO_0000357,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL875912,,1981,,,105,2474,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL617586,,1982,,,105,5014,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617587,,1983,,,105,17515,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617588,,1984,,,105,11866,,
,BAO_0000357,,H,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL857980,,1985,,,105,4687,,
,BAO_0000357,,H,,Tested against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL617589,,1986,,,105,12146,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617590,,1987,,,105,10321,,
,BAO_0000219,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617591,,1988,,,105,13267,722.0,
,BAO_0000357,,D,,Binding affinity against 5-Hydroxytryptamine 1D receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617592,,1989,,,105,1274,,
,BAO_0000357,,H,,,1,,,B,,,8,Autocuration,CHEMBL617593,,1990,,,105,15250,,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL617594,,1991,,,106,13706,485.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL617595,,1992,,,105,13706,485.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,1,HEK293,,B,,,8,Autocuration,CHEMBL617596,,1993,,,105,13706,722.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,HEK293,,B,,,8,Autocuration,CHEMBL617597,,1994,,,105,13706,722.0,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,,B,,,8,Autocuration,CHEMBL617598,,1995,,,105,13047,,
,BAO_0000357,,H,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,1,,,B,,,8,Autocuration,CHEMBL872916,,1996,,,105,13366,,
,BAO_0000357,,H,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,1,,,B,,,8,Expert,CHEMBL617599,,1997,,,105,13366,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,1,,,B,,,8,Autocuration,CHEMBL617091,,1998,,,105,1558,,
,BAO_0000219,,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",1,CHO-K1,,B,,,8,Expert,CHEMBL617092,,1999,,,105,12902,485.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL617093,,2000,,,105,13706,485.0,
,BAO_0000019,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,1,,,F,,,8,Autocuration,CHEMBL617094,,2001,,,105,13706,,
,BAO_0000019,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,F,,,8,Autocuration,CHEMBL617095,,2002,,,105,13706,,
,BAO_0000019,,H,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,F,,,8,Autocuration,CHEMBL617096,,2003,,,105,14251,,
,BAO_0000019,,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,F,,,8,Autocuration,CHEMBL617097,,2004,,,105,14251,,
,BAO_0000019,,H,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,1,,,F,,,8,Autocuration,CHEMBL617098,,2005,,,105,14251,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617301,,2006,,,105,13313,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617302,,2007,,,105,13313,,
,BAO_0000357,,H,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Autocuration,CHEMBL617303,,2008,,,105,13366,,
,BAO_0000357,,H,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Expert,CHEMBL617304,,2009,,,105,13051,,
,BAO_0000219,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",1,CHO,,B,,,8,Expert,CHEMBL617305,,2010,,,105,12903,449.0,
,BAO_0000219,,D,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,1,,9606.0,B,Homo sapiens,,9,Autocuration,CHEMBL617306,,2011,,,105,12469,,
,BAO_0000357,,H,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,1,,,B,,,8,Autocuration,CHEMBL617307,,2012,,,17106,5619,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL617308,,2013,,,105,13047,,
,BAO_0000357,,H,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Autocuration,CHEMBL617309,,2014,,,105,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Autocuration,CHEMBL617310,,2015,,,105,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Autocuration,CHEMBL617311,,2016,,,105,16633,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617312,,2017,,,105,16633,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Autocuration,CHEMBL617313,,2018,,,105,3269,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,1,,,B,,,8,Expert,CHEMBL617314,,2019,,,105,12409,,
,BAO_0000019,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,F,,,8,Autocuration,CHEMBL617315,,2020,,,106,13706,,
,BAO_0000219,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,1,HEK293,,B,,,8,Autocuration,CHEMBL617316,,2021,,,106,13706,722.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,1,HEK293,,B,,,8,Autocuration,CHEMBL617317,,2022,,,106,13706,722.0,
,BAO_0000219,,H,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL617318,,2023,,,106,12903,449.0,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,1,,,B,,,8,Autocuration,CHEMBL617319,,2024,,,106,13047,,
,BAO_0000357,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,B,,,9,Expert,CHEMBL617320,,2025,,,106,13366,,
,BAO_0000357,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,B,,,9,Expert,CHEMBL617321,,2026,,,106,13366,,
,BAO_0000357,,D,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,1,,,B,,,9,Expert,CHEMBL617322,,2027,,,106,13366,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616862,,2028,,,106,13366,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616863,,2029,,,106,13366,,
,BAO_0000219,,H,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL616864,,2030,,,106,12469,449.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616865,,2031,,,106,13706,485.0,
,BAO_0000219,,H,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616866,,2032,,,106,13706,485.0,
,BAO_0000019,,H,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,1,,,F,,,8,Autocuration,CHEMBL616867,,2033,,,106,13706,,
,BAO_0000219,,H,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",1,CHO-K1,,B,,,8,Expert,CHEMBL616868,,2034,,,106,12902,485.0,
,BAO_0000357,,H,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,1,,,B,,,8,Expert,CHEMBL616869,,2035,,,105,13051,,
,BAO_0000219,,H,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",1,CHO,,B,,,8,Expert,CHEMBL616870,,2036,,,106,12903,449.0,
,BAO_0000219,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,1,CHO-K1,,F,,,8,Autocuration,CHEMBL616871,,2037,,,105,1558,485.0,
,BAO_0000219,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,1,CHO-K1,,F,,,8,Autocuration,CHEMBL616872,,2038,,,105,1558,485.0,
,BAO_0000219,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,1,CHO-K1,,F,,,8,Autocuration,CHEMBL616873,,2039,,,105,1558,485.0,
,BAO_0000219,,H,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,1,CHO-K1,,F,,,8,Autocuration,CHEMBL616838,,2040,,,105,1558,485.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,1,,,B,,,8,Autocuration,CHEMBL616839,,2041,,,105,1558,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL616840,,2042,,,106,13047,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616841,,2043,,,105,13313,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616842,,2044,,,105,13313,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,1,,,B,,,8,Expert,CHEMBL857976,,2045,,,105,12409,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616843,,2046,,,10618,15250,449.0,
,BAO_0000357,,D,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616844,,2047,,,10618,1348,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,1,,,B,,,8,Autocuration,CHEMBL616845,,2048,,,10618,1348,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616846,,2049,,,10618,4234,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616847,,2050,,,10618,16209,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,1,,,B,,,8,Autocuration,CHEMBL616848,,2051,,,10618,10444,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL616849,,2052,,,10618,3935,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL872911,,2053,,,10618,15818,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL616850,,2054,,,10618,17085,,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616699,,2055,,,10618,12936,449.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616700,,2056,,,10618,6166,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL616701,,2057,,,10618,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL616702,,2058,,,10618,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,1,CHO,,B,,,8,Autocuration,CHEMBL616703,,2059,,,10618,15779,449.0,
,BAO_0000357,,H,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,1,,,B,,,8,Autocuration,CHEMBL616704,,2060,,,10618,13181,,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616705,,2061,,,10618,4199,449.0,
,BAO_0000357,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL616706,,2062,,,10618,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL616707,,2063,,,10618,15146,449.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL616708,,2064,,,10618,5213,,
,BAO_0000357,,H,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL616709,,2065,,,10618,12146,,
,BAO_0000219,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616710,,2066,,,10618,13267,449.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL616711,,2067,,,10618,14818,449.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL616712,,2068,,,10618,4829,449.0,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616713,,2069,,,10618,4373,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616714,,2070,,,10618,4373,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL616715,,2071,,,10618,14159,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 1E receptor,1,,,B,,,8,Autocuration,CHEMBL616716,,2072,,,10618,16633,,
,BAO_0000019,,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",1,,,F,,,8,Autocuration,CHEMBL616717,,2073,,,279,17085,,
,BAO_0000019,,H,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",1,,,F,,,8,Expert,CHEMBL616718,,2074,,,279,17085,,
,BAO_0000019,,H,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,1,,,F,,,8,Autocuration,CHEMBL875905,,2075,,,279,16209,,
,BAO_0000019,,H,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,1,,,F,,,8,Autocuration,CHEMBL616719,,2076,,,279,16209,,
,BAO_0000019,,H,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",1,,,F,,,8,Expert,CHEMBL616720,,2077,,,279,17085,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL616721,,2078,,,279,14159,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL616722,,2079,,,279,15250,449.0,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL616723,,2080,,,279,3805,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL616724,,2081,,,279,16190,449.0,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,1,,,B,,,8,Autocuration,CHEMBL616725,,2082,,,279,16190,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL616726,,2083,,,279,16209,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,1,,,B,,,8,Autocuration,CHEMBL616727,,2084,,,279,16209,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,1,,,B,,,8,Autocuration,CHEMBL616728,,2085,,,279,16209,,
,BAO_0000357,,H,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL616729,,2086,,,279,6866,,
,BAO_0000019,,H,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Expert,CHEMBL616730,,2087,,,279,17085,,
,BAO_0000357,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL617125,,2088,,,279,16312,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,1,,,B,,,8,Autocuration,CHEMBL857977,,2089,,,279,6166,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,1,CHO,,B,,,8,Autocuration,CHEMBL617126,,2090,,,279,15779,449.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL617127,,2091,,,279,4199,449.0,
,BAO_0000357,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL617128,,2092,,,279,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL617129,,2093,,,279,15146,449.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,1,,,B,,,8,Autocuration,CHEMBL617130,,2094,,,279,5213,,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL617131,,2095,,,279,14818,449.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL617132,,2096,,,279,4829,449.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",1,CHO,,B,,,8,Autocuration,CHEMBL617133,,2097,,,279,4829,449.0,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617134,,2098,,,279,4373,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617135,,2099,,,279,4373,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,1,,,B,,,8,Autocuration,CHEMBL617136,,2100,,,279,5014,,
,BAO_0000019,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",1,,,B,,,4,Autocuration,CHEMBL617137,,2101,,,104686,11662,,
,BAO_0000019,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,,B,,,4,Autocuration,CHEMBL617138,,2102,,,104686,11662,,
,BAO_0000019,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,B,,,4,Autocuration,CHEMBL617139,,2103,,,104686,11662,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617140,,2104,,,12687,14093,,
,BAO_0000218,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",1,,,F,,,4,Autocuration,CHEMBL617141,,2105,In vivo,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL858112,,2106,,,104686,11200,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,1,,,B,,,8,Intermediate,CHEMBL617142,,2107,,,17005,12352,,
,BAO_0000019,,U,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",1,,9913.0,B,Bos taurus,,0,Autocuration,CHEMBL617143,,2108,,,22226,13657,,
,BAO_0000019,,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,1,,9913.0,B,Bos taurus,,0,Autocuration,CHEMBL617144,,2109,,,22226,14331,,
,BAO_0000019,,U,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,1,,9913.0,B,Bos taurus,,0,Autocuration,CHEMBL617145,,2110,,,22226,14331,,
,BAO_0000019,,U,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,1,,,B,,,0,Autocuration,CHEMBL617146,,2111,,,22226,14331,,
,BAO_0000019,,H,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL617147,,2112,,,104784,12685,,
,BAO_0000019,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL617148,,2113,,,104784,14389,,
,BAO_0000019,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL617149,,2114,,,104784,14386,,
,BAO_0000224,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL617150,,2115,,,104784,5732,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL617151,,2116,,,104784,16293,,
,BAO_0000224,,H,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617201,,2117,,,104784,2078,,
,BAO_0000357,,H,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,1,,,B,,,8,Autocuration,CHEMBL617202,,2118,,,10209,5486,,
,BAO_0000218,,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,,B,,,4,Autocuration,CHEMBL617203,,2119,In vivo,,104826,11820,,
,BAO_0000019,,H,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL617204,,2120,,,104826,10297,,
,BAO_0000224,,H,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,1,,,B,,,4,Autocuration,CHEMBL617205,,2121,,,104826,13704,,
,BAO_0000019,,D,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,1,,10090.0,B,Mus musculus,,5,Autocuration,CHEMBL617206,,2122,,,104826,10297,,
,BAO_0000218,,H,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,1,,,B,,,4,Autocuration,CHEMBL617207,,2123,In vivo,,104826,11820,,
,BAO_0000019,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,1,,10090.0,B,Mus musculus,,5,Autocuration,CHEMBL617208,,2124,,,104826,10297,,
,BAO_0000224,,H,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617209,,2125,,,104826,11555,,
,BAO_0000224,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,1,,,B,,,4,Autocuration,CHEMBL617210,,2126,,,104826,11555,,
,BAO_0000224,,H,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,1,,,B,,,4,Autocuration,CHEMBL617211,,2127,,,104826,11555,,
,BAO_0000019,,D,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,1,,10090.0,B,Mus musculus,,5,Autocuration,CHEMBL617212,,2128,,,104826,10297,,
,BAO_0000224,,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,1,,9823.0,B,Sus scrofa,,4,Autocuration,CHEMBL617213,,2129,,,104784,16688,,
,BAO_0000224,,H,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,1,,9823.0,B,Sus scrofa,,4,Autocuration,CHEMBL617214,,2130,,,104784,16688,,
,BAO_0000221,,U,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,,B,,,0,Autocuration,CHEMBL617215,,2131,,,22226,5333,,
,BAO_0000221,,U,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,1,,,B,,,0,Autocuration,CHEMBL617216,,2132,,,22226,4437,,
,BAO_0000357,,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617217,,2133,,,17005,5033,,
,BAO_0000019,,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617218,,2134,,,104686,15267,,
,BAO_0000019,,H,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL872913,,2135,,,104686,15267,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,1,,,B,,,4,Autocuration,CHEMBL617219,,2136,,,104826,11820,,
,BAO_0000224,,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL873482,,2137,,,104686,9069,,
,BAO_0000019,,D,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617220,,2138,,,104686,9162,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,1,,,B,,,4,Autocuration,CHEMBL617221,,2139,,,104686,9162,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,1,,,B,,,4,Autocuration,CHEMBL617222,,2140,,,104686,9162,,
,BAO_0000019,,H,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,1,,,F,,,4,Autocuration,CHEMBL875906,,2141,,,104686,10428,,
,BAO_0000019,,H,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,1,,,B,,,4,Autocuration,CHEMBL617223,,2142,,,104686,9628,,
,BAO_0000224,,H,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617224,,2143,,,104686,12704,,
,BAO_0000224,,D,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617225,,2144,,,104686,15453,,
,BAO_0000224,,H,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,1,,,B,,,4,Autocuration,CHEMBL617226,,2145,,,104686,188,,
,BAO_0000224,,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,1,,,B,,,4,Autocuration,CHEMBL617227,,2146,,,104686,10349,,
,BAO_0000224,,H,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,1,,,B,,,4,Autocuration,CHEMBL617228,,2147,,,104686,10349,,
,BAO_0000224,,H,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,1,,,B,,,4,Autocuration,CHEMBL617229,,2148,,,104686,8868,,
,BAO_0000224,,H,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,1,,,B,,,4,Autocuration,CHEMBL617230,,2149,,,104686,10025,,
,BAO_0000224,,H,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",1,,,B,,,4,Autocuration,CHEMBL617231,,2150,,,104686,10025,,
,BAO_0000224,,H,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,1,,,B,,,4,Autocuration,CHEMBL617232,,2151,,,104686,11702,,
,BAO_0000224,,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617233,,2152,,,104686,11702,,
,BAO_0000224,,H,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,1,,,B,,,4,Autocuration,CHEMBL617234,,2153,,,104686,11702,,
,BAO_0000019,,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats,1,,,F,,,4,Autocuration,CHEMBL617235,,2154,,,104686,11702,,
,BAO_0000019,,H,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,1,,,F,,,4,Autocuration,CHEMBL617236,,2155,,,104686,11702,,
Hippocampus,BAO_0000221,,H,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,1,,,B,,10000000.0,4,Autocuration,CHEMBL617237,,2156,,,104686,10085,,
Hippocampus,BAO_0000221,,H,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,1,,,B,,10000000.0,4,Autocuration,CHEMBL617238,,2157,,,104686,10085,,
Brain,BAO_0000221,,D,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,1,,10116.0,B,Rattus norvegicus,955.0,5,Autocuration,CHEMBL617239,,2158,,,104686,9630,,
,BAO_0000019,,H,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,1,,,B,,,4,Autocuration,CHEMBL617240,,2159,,,104686,11070,,
,BAO_0000249,,H,Membranes,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,,B,,,4,Autocuration,CHEMBL617241,,2160,,,104686,9841,,
,BAO_0000249,,H,Membranes,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,1,,,B,,,4,Autocuration,CHEMBL875907,,2161,,,104686,9841,,
,BAO_0000019,,H,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,1,,,B,,,4,Autocuration,CHEMBL617242,,2162,,,104686,13291,,
,BAO_0000019,,H,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,1,,,F,,,4,Autocuration,CHEMBL617152,,2163,,,104686,10590,,
Brain,BAO_0000221,,D,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,1,,10116.0,B,Rattus norvegicus,955.0,5,Autocuration,CHEMBL617153,,2164,,,104686,9064,,
,BAO_0000249,,D,Membranes,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617154,,2165,,,104686,12268,,
Brain,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,1,,,B,,955.0,4,Autocuration,CHEMBL617155,,2166,,,104686,13508,,
,BAO_0000019,,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,,F,,,4,Autocuration,CHEMBL617156,,2167,,,104686,11279,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL617157,,2168,,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL617158,,2169,,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,,F,,,4,Autocuration,CHEMBL617159,,2170,,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,1,,,F,,,4,Autocuration,CHEMBL617160,,2171,,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL858113,,2172,,,104686,11200,,
Brain,BAO_0000220,,H,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,1,,,B,,955.0,4,Autocuration,CHEMBL617247,,2173,,,104686,9231,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617248,,2174,,,104686,9737,,
Brain,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,1,,,B,,955.0,4,Autocuration,CHEMBL617249,,2175,,,104686,9737,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617250,,2176,,,104686,9737,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617251,,2177,,,104686,9737,,
,BAO_0000019,,D,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617252,,2178,,,104686,11828,,
,BAO_0000019,,H,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617006,,2179,,,104686,12253,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617007,,2180,,,104686,12253,,
,BAO_0000019,,H,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",1,,,F,,,4,Autocuration,CHEMBL617008,,2181,,,104686,11279,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,1,,,B,,,4,Autocuration,CHEMBL617009,,2182,,,104686,11866,,
,BAO_0000224,,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617010,,2183,,,104686,14424,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL857978,,2184,,,104686,15180,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617011,,2185,,,104686,15180,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617012,,2186,,,104686,9786,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,1,,,B,,,4,Autocuration,CHEMBL617013,,2187,,,104686,12132,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,1,,,B,,,4,Autocuration,CHEMBL617014,,2188,,,104686,5486,,
,BAO_0000019,,H,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617015,,2189,,,104686,15316,,
,BAO_0000019,,H,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,1,,,B,,,4,Autocuration,CHEMBL617016,,2190,,,104686,16429,,
,BAO_0000224,,H,,pKi value for 5-hydroxytryptamine 2 receptor binding site,1,,,B,,,4,Autocuration,CHEMBL617017,,2191,,,104686,14617,,
Brain,BAO_0000221,,H,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,1,,,B,,955.0,4,Autocuration,CHEMBL617018,,2192,,,104686,11351,,
,BAO_0000019,,H,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,1,,,F,,,4,Autocuration,CHEMBL617019,,2193,,,104686,11279,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617020,,2194,,,105075,9523,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617021,,2195,,,105075,9523,,
,BAO_0000019,,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617022,,2196,,,105075,9523,,
,BAO_0000019,,H,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617023,,2197,,,105075,9523,,
,BAO_0000019,,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617024,,2198,,,105075,9523,,
,BAO_0000019,,H,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617025,,2199,,,105075,9523,,
,BAO_0000224,,H,,Hill coefficient of compound was determined,1,,,B,,,4,Autocuration,CHEMBL617026,,2200,,,105075,9523,,
,BAO_0000019,,U,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,1,,,B,,,0,Autocuration,CHEMBL617027,,2201,,,22226,4771,,
,BAO_0000019,,D,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617028,,2202,,,104686,5033,,
,BAO_0000019,,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,1,,,B,,,8,Expert,CHEMBL617029,,2203,,,12687,10845,,
,BAO_0000019,,H,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,1,,,B,,,8,Expert,CHEMBL875908,,2204,,,12687,10845,,
,BAO_0000357,,H,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),1,,,B,,,8,Autocuration,CHEMBL617030,,2205,,,12687,16288,,
,BAO_0000019,,H,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),1,,,B,,,8,Autocuration,CHEMBL617031,,2206,,,12687,16288,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,1,,,B,,,8,Autocuration,CHEMBL617032,,2207,,,12687,16190,,
,BAO_0000224,,D,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617033,,2208,,,104686,12463,,
,BAO_0000224,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",1,,,B,,,4,Autocuration,CHEMBL617034,,2209,,,104686,9699,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617035,,2210,,,104686,9699,,
,BAO_0000019,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,B,,,4,Autocuration,CHEMBL617036,,2211,,,104686,11662,,
,BAO_0000224,,H,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617037,,2212,,,104784,1205,,
,BAO_0000219,,U,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,1,,,B,,,0,Autocuration,CHEMBL617038,,2213,,,22226,11376,,
,BAO_0000219,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",1,,,B,,,4,Autocuration,CHEMBL617039,,2214,,,104784,11376,,
,BAO_0000224,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617161,,2215,,,104784,4639,,
,BAO_0000224,,H,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617162,,2216,,,104784,2222,,
,BAO_0000224,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617163,,2217,,,104784,1558,,
,BAO_0000224,,H,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617164,,2218,,,104784,1089,,
,BAO_0000249,,H,Brain membranes,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,1,,,B,,,4,Autocuration,CHEMBL617165,,2219,,,104784,386,,
,BAO_0000224,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617166,,2220,,,104784,2474,,
,BAO_0000224,,H,,Binding affinity towards 5-HT2 receptor,1,,,B,,,4,Autocuration,CHEMBL617167,,2221,,,104784,17066,,
,BAO_0000224,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL872912,,2222,,,104784,959,,
,BAO_0000224,,H,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,1,,,B,,,4,Autocuration,CHEMBL617168,,2223,,,104784,6398,,
,BAO_0000224,,H,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,1,,,B,,,4,Autocuration,CHEMBL617169,,2224,,,104686,11889,,
,BAO_0000224,,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617170,,2225,,,104784,4221,,
,BAO_0000224,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617171,,2226,,,104784,11026,,
,BAO_0000224,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL617172,,2227,,,104784,11866,,
,BAO_0000224,,H,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617173,,2228,,,104784,4221,,
,BAO_0000019,,U,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,1,,,B,,,0,Autocuration,CHEMBL617174,,2229,,,22226,13950,,
,BAO_0000224,,H,,5-hydroxytryptamine 2 receptor binding affinity,1,,,B,,,4,Autocuration,CHEMBL617175,,2230,,,104784,1263,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,1,,,B,,,8,Autocuration,CHEMBL617176,,2231,,,17005,13291,,
,BAO_0000357,,H,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617177,,2232,,,17005,10812,,
,BAO_0000224,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,,B,,,4,Autocuration,CHEMBL617178,,2233,,,104784,13020,,
,BAO_0000224,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,1,,,B,,,4,Autocuration,CHEMBL617179,,2234,,,104784,13021,,
,BAO_0000224,,H,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,1,,,B,,,4,Autocuration,CHEMBL617180,,2235,,,104784,13020,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,1,,,B,,,8,Autocuration,CHEMBL617181,,2236,,,17005,14532,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,,B,,,8,Autocuration,CHEMBL617182,,2237,,,17005,13944,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor,1,,,B,,,8,Autocuration,CHEMBL617183,,2238,,,17005,14331,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617184,,2239,,,17005,14118,,
,BAO_0000357,,H,,Binding affinity against serotonergic 5-HT2 receptor,1,,,B,,,8,Autocuration,CHEMBL617185,,2240,,,17005,13033,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617186,,2241,,,17005,10321,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity at 5- HT2 receptor,1,,,B,,,8,Autocuration,CHEMBL617187,,2242,,,17005,12918,,
,BAO_0000357,,H,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,1,,,B,,,8,Autocuration,CHEMBL617188,,2243,,,17005,15120,,
,BAO_0000218,,H,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,1,,,B,,,8,Autocuration,CHEMBL617189,,2244,,,17005,2613,,
,BAO_0000224,,D,,Inhibitory activity against cloned human 5-HT2 receptor,1,,9606.0,B,Homo sapiens,,5,Autocuration,CHEMBL617190,,2245,,,104784,13378,,
,BAO_0000219,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",1,CHO,9606.0,B,Homo sapiens,,5,Autocuration,CHEMBL617191,,2246,,,104784,2331,449.0,
,BAO_0000219,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",1,CHO,9606.0,B,Homo sapiens,,5,Autocuration,CHEMBL617192,,2247,,,104784,2331,449.0,
,BAO_0000219,,D,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",1,CHO,9606.0,B,Homo sapiens,,5,Autocuration,CHEMBL617193,,2248,,,104784,2331,449.0,
,BAO_0000219,,D,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",1,CHO,9606.0,B,Homo sapiens,,5,Autocuration,CHEMBL617194,,2249,,,104784,2331,449.0,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617195,,2250,,,104784,4170,,
,BAO_0000224,,H,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,1,,,B,,,4,Autocuration,CHEMBL881830,,2251,,,104784,15453,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,8,Autocuration,CHEMBL617196,,2252,,,17005,1479,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,1,,,B,,,4,Autocuration,CHEMBL617197,,2253,,,104686,11139,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL617198,,2254,,,17005,13969,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL873476,,2255,,,17005,13392,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,1,,,B,,,8,Expert,CHEMBL617199,,2256,,,17005,14430,,
,BAO_0000357,,H,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL617200,,2257,,,107,13181,,
,BAO_0000357,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,B,,,8,Autocuration,CHEMBL617484,,2258,,,51,17200,,
,BAO_0000357,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,B,,,8,Autocuration,CHEMBL617485,,2259,,,107,17200,,
,BAO_0000357,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,B,,,8,Autocuration,CHEMBL617486,,2260,,,51,17200,,
,BAO_0000357,,H,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL858022,,2261,,,107,13463,,
,BAO_0000219,,H,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL617049,,2262,,,107,6347,449.0,
,BAO_0000219,,D,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617050,,2263,,,107,6857,449.0,
,BAO_0000219,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,,F,,,8,Autocuration,CHEMBL617051,,2264,,,107,4176,,
,BAO_0000219,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,1,,,F,,,8,Autocuration,CHEMBL617052,,2265,,,107,4176,,
,BAO_0000219,,H,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,1,,,F,,,8,Autocuration,CHEMBL617053,,2266,,,107,4176,,
,BAO_0000219,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",1,CHO,,B,,,8,Autocuration,CHEMBL617054,,2267,,,107,6347,449.0,
,BAO_0000219,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",1,CHO,,B,,,8,Autocuration,CHEMBL617055,,2268,,,107,6347,449.0,
,BAO_0000357,,H,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,1,,,B,,,8,Autocuration,CHEMBL882924,,2269,,,107,15331,,
,BAO_0000357,,D,,Inhibition of human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617056,,2270,,,107,16146,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL617057,,2271,,,107,15250,449.0,
,BAO_0000219,,H,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,1,,,B,,,8,Expert,CHEMBL617058,,2272,,,107,13631,,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL617059,,2273,,,107,3805,,
,BAO_0000219,,H,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,1,CHO,,B,,,8,Autocuration,CHEMBL617060,,2274,,,107,4011,449.0,
,BAO_0000219,,H,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,1,CHO,,B,,,8,Expert,CHEMBL617061,,2275,,,107,4012,449.0,
,BAO_0000219,,H,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,1,L929,,B,,,8,Expert,CHEMBL617062,,2276,,,107,6366,307.0,
,BAO_0000219,,H,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL617063,,2277,,,107,15949,449.0,
,BAO_0000019,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,1,,,F,,,8,Autocuration,CHEMBL617064,,2278,,,107,14093,,
,BAO_0000019,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,F,,,8,Autocuration,CHEMBL617065,,2279,,,107,13481,,
,BAO_0000219,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL617066,,2280,,,107,6347,449.0,
,BAO_0000219,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,1,CHO,,B,,,8,Autocuration,CHEMBL617067,,2281,,,107,6347,449.0,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,1,,,F,,,8,Autocuration,CHEMBL617068,,2282,,,107,14093,,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,1,,,F,,,8,Autocuration,CHEMBL617069,,2283,,,107,14093,,
,BAO_0000019,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,F,,,8,Autocuration,CHEMBL617070,,2284,,,107,13481,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617071,,2285,,,107,14442,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL872915,,2286,,,107,14442,,
,BAO_0000357,,H,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL617072,,2287,,,107,14755,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,1,,,B,,,8,Autocuration,CHEMBL617073,,2288,,,107,16441,,
,BAO_0000357,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,1,,,B,,,8,Autocuration,CHEMBL617074,,2289,,,107,14744,,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL617075,,2290,,,107,16659,449.0,
,BAO_0000357,,H,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617076,,2291,,,107,3307,,
,BAO_0000019,,D,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617077,,2292,,,107,6857,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,1,,,B,,,8,Expert,CHEMBL617078,,2293,,,107,5635,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617079,,2294,,,107,4234,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617080,,2295,,,107,15527,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL617081,,2296,,,107,6588,449.0,
,BAO_0000219,,H,,Binding affinity towards human 5-HT2A receptor in BEK cells,1,,,B,,,8,Expert,CHEMBL617082,,2297,,,107,13631,,
,BAO_0000357,,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617083,,2298,,,107,17723,,
,BAO_0000357,,H,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617084,,2299,,,107,14770,,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617085,,2300,,,107,16293,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617086,,2301,,,107,16209,,
,BAO_0000219,,H,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,1,,,B,,,8,Autocuration,CHEMBL617087,,2302,,,107,12469,,
,BAO_0000357,,H,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617088,,2303,,,107,15363,,
,BAO_0000357,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617089,,2304,,,107,15363,,
,BAO_0000019,,H,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",1,,,B,,,8,Expert,CHEMBL617090,,2305,,,107,16441,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617513,,2306,,,107,8,,
,BAO_0000219,,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617514,,2307,,,107,4176,722.0,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617515,,2308,,,107,17085,,
,BAO_0000357,,H,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,,B,,,8,Autocuration,CHEMBL617516,,2309,,,107,17200,,
,BAO_0000357,,D,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617517,,2310,,,107,17200,,
,BAO_0000219,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617518,,2311,,,107,4013,449.0,
,BAO_0000357,,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617519,,2312,,,107,5088,,
,BAO_0000357,,D,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617520,,2313,,,107,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,1,,,B,,,8,Autocuration,CHEMBL617521,,2314,,,107,5088,,
,BAO_0000357,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617522,,2315,,,107,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617523,,2316,,,107,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,B,,,8,Autocuration,CHEMBL617524,,2317,,,107,5088,,
,BAO_0000019,,H,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,1,,,B,,,4,Autocuration,CHEMBL617525,,2318,,,104686,9786,,
,BAO_0000019,,D,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617526,,2319,,,104686,9205,,
,BAO_0000224,,H,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,1,,,B,,,4,Autocuration,CHEMBL617527,,2320,,,104686,11257,,
,BAO_0000019,,H,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,,B,,,4,Autocuration,CHEMBL617528,,2321,,,104686,9362,,
,BAO_0000019,,H,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,1,,,B,,,4,Autocuration,CHEMBL617529,,2322,,,104686,9362,,
,BAO_0000224,,H,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,1,,,B,,,4,Autocuration,CHEMBL617530,,2323,,,104686,10590,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,,B,,,4,Autocuration,CHEMBL617531,,2324,,,104686,10468,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,1,,,B,,,4,Autocuration,CHEMBL617532,,2325,,,104686,13050,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617533,,2326,,,104686,11624,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,1,,,B,,,4,Autocuration,CHEMBL617534,,2327,,,104686,10468,,
,BAO_0000224,,H,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617535,,2328,,,104686,10330,,
,BAO_0000224,,H,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,1,,,B,,,4,Autocuration,CHEMBL617536,,2329,,,104686,10062,,
,BAO_0000224,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617537,,2330,,,104686,11642,,
,BAO_0000224,,H,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617538,,2331,,,104686,10062,,
,BAO_0000219,,H,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,1,,,B,,,4,Autocuration,CHEMBL617539,,2332,In vitro,,104686,13427,,
,BAO_0000224,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617540,,2333,,,104686,12280,,
,BAO_0000224,,D,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617541,,2334,,,104686,4101,,
,BAO_0000224,,H,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617542,,2335,,,104686,10062,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,1,,,B,,,4,Autocuration,CHEMBL617543,,2336,,,104686,11147,,
,BAO_0000219,,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,CHO-K1,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617544,,2337,,,104686,2395,485.0,
,BAO_0000219,,D,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,1,CHO-K1,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617545,,2338,,,104686,2395,485.0,
,BAO_0000019,,D,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617413,,2339,,,104686,9098,,
,BAO_0000019,,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,1,,,B,,,4,Autocuration,CHEMBL617414,,2340,,,104686,9098,,
,BAO_0000019,,D,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617415,,2341,,,104686,9098,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617416,,2342,,,104686,9443,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,1,,,B,,,4,Autocuration,CHEMBL617417,,2343,,,104686,9443,,
,BAO_0000019,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",1,,,B,,,4,Autocuration,CHEMBL617418,,2344,,,104686,9699,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,1,,,B,,,4,Autocuration,CHEMBL617419,,2345,,,104686,9699,,
,BAO_0000224,,H,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL617420,,2346,,,104686,9098,,
,BAO_0000224,,D,,Affinity for 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617421,,2347,,,104686,3070,,
,BAO_0000224,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,1,,,B,,,4,Autocuration,CHEMBL617422,,2348,,,104686,9547,,
,BAO_0000019,,H,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,1,,,B,,,4,Autocuration,CHEMBL617423,,2349,,,104686,10444,,
,BAO_0000019,,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,1,,,B,,,4,Autocuration,CHEMBL617424,,2350,,,104686,14617,,
,BAO_0000019,,H,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,1,,,B,,,4,Autocuration,CHEMBL617425,,2351,,,104686,14617,,
,BAO_0000224,,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),1,,,B,,,4,Autocuration,CHEMBL617426,,2352,,,104686,11130,,
,BAO_0000218,,H,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),1,,,B,,,4,Autocuration,CHEMBL617427,,2353,In vivo,,104686,11130,,
Brain,BAO_0000221,,H,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,1,,,B,,955.0,4,Autocuration,CHEMBL617428,,2354,,,104686,14542,,
,BAO_0000224,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,1,,,B,,,4,Autocuration,CHEMBL617429,,2355,,,104686,2797,,
,BAO_0000019,,H,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,,B,,,4,Autocuration,CHEMBL617430,,2356,,,104686,11332,,
,BAO_0000019,,H,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,1,,,B,,,4,Autocuration,CHEMBL617431,,2357,,,104686,11332,,
Frontal cortex,BAO_0000019,,H,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,1,,,B,,1870.0,4,Autocuration,CHEMBL617432,,2358,,,104686,10752,,
,BAO_0000224,,H,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617433,,2359,,,104686,1185,,
,BAO_0000224,,H,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617434,,2360,,,104686,1185,,
,BAO_0000224,,D,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617435,,2361,,,104686,11624,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,1,,,B,,,4,Autocuration,CHEMBL617436,,2362,,,104686,1344,,
Striatum,BAO_0000019,,D,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,1,,10116.0,B,Rattus norvegicus,2435.0,5,Autocuration,CHEMBL617437,,2363,,,104686,15453,,
,BAO_0000019,,H,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",1,,,B,,,4,Autocuration,CHEMBL617438,,2364,,,104686,11662,,
,BAO_0000019,,H,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",1,,,B,,,4,Autocuration,CHEMBL617439,,2365,,,104686,11662,,
,BAO_0000224,,H,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617440,,2366,,,104686,10796,,
,BAO_0000224,,H,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617441,,2367,,,104686,9069,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL872918,,2368,,,104686,8814,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617442,,2369,,,104686,8908,,
,BAO_0000019,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,,B,,,4,Autocuration,CHEMBL617443,,2370,,,104686,9098,,
,BAO_0000019,,H,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,1,,,B,,,4,Autocuration,CHEMBL617444,,2371,,,104686,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,1,,,B,,,4,Autocuration,CHEMBL617445,,2372,,,104686,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,1,,,B,,,4,Autocuration,CHEMBL617446,,2373,,,104686,9098,,
,BAO_0000249,,H,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,1,,,B,,,4,Autocuration,CHEMBL617447,,2374,,,104686,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,1,,,B,,,4,Autocuration,CHEMBL617448,,2375,,,104686,9098,,
,BAO_0000019,,H,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,1,,,B,,,4,Autocuration,CHEMBL617449,,2376,,,104686,9098,,
,BAO_0000019,,H,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,1,,,B,,,4,Autocuration,CHEMBL617450,,2377,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,1,,,B,,,4,Autocuration,CHEMBL617451,,2378,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,1,,,B,,,4,Autocuration,CHEMBL617452,,2379,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,1,,,B,,,4,Autocuration,CHEMBL617453,,2380,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,1,,,B,,,4,Autocuration,CHEMBL617660,,2381,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,1,,,B,,,4,Autocuration,CHEMBL617661,,2382,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,1,,,B,,,4,Autocuration,CHEMBL617662,,2383,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,1,,,B,,,4,Autocuration,CHEMBL872919,,2384,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,1,,,B,,,4,Autocuration,CHEMBL617663,,2385,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,1,,,B,,,4,Autocuration,CHEMBL617664,,2386,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,1,,,B,,,4,Autocuration,CHEMBL617665,,2387,,,104686,9161,,
,BAO_0000019,,H,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,1,,,B,,,4,Autocuration,CHEMBL617666,,2388,,,104686,9161,,
,BAO_0000019,,H,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,1,,,B,,,4,Autocuration,CHEMBL617667,,2389,,,104686,12094,,
,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,1,,,B,,,4,Autocuration,CHEMBL617668,,2390,,,104686,12018,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,1,,,B,,,4,Autocuration,CHEMBL617669,,2391,,,104686,10394,,
,BAO_0000224,,H,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617670,,2392,,,104686,15260,,
,BAO_0000224,,D,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617671,,2393,,,104686,11624,,
,BAO_0000224,,H,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617672,,2394,,,104686,13654,,
,BAO_0000019,,H,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,1,,,B,,,4,Autocuration,CHEMBL617673,,2395,,,104686,9541,,
,BAO_0000224,,H,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,1,,,B,,,4,Autocuration,CHEMBL617674,,2396,,,104686,11933,,
,BAO_0000019,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,1,,,B,,,4,Autocuration,CHEMBL617675,,2397,,,104686,15538,,
,BAO_0000019,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,1,,,B,,,4,Autocuration,CHEMBL617676,,2398,,,104686,15538,,
,BAO_0000019,,H,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,1,,,B,,,4,Autocuration,CHEMBL617677,,2399,,,104686,15538,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,1,,,B,,,5,Autocuration,CHEMBL617678,,2400,,,104686,8841,,
,BAO_0000224,,H,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,1,,,B,,,4,Autocuration,CHEMBL617679,,2401,,,104686,1455,,
,BAO_0000224,,H,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,1,,,B,,,4,Autocuration,CHEMBL617680,,2402,,,104686,1455,,
,BAO_0000019,,H,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,1,,,B,,,4,Autocuration,CHEMBL617681,,2403,,,104686,11752,,
Brain,BAO_0000221,,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,1,,,B,,955.0,4,Autocuration,CHEMBL617682,,2404,,,104686,11642,,
,BAO_0000224,,H,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,1,,,B,,,4,Autocuration,CHEMBL617683,,2405,,,104686,12092,,
,BAO_0000224,,H,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,1,,,B,,,4,Autocuration,CHEMBL617684,,2406,,,104686,3967,,
,BAO_0000224,,D,,Binding affinity towards 5-hydroxytryptamine 2 receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL617685,,2407,,,104686,12771,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,1,,,B,,,4,Autocuration,CHEMBL617686,,2408,,,104686,11642,,
,BAO_0000224,,H,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,1,,,B,,,4,Autocuration,CHEMBL617687,,2409,,,104686,11628,,
,BAO_0000224,,H,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,1,,,B,,,4,Autocuration,CHEMBL617688,,2410,,,104686,13654,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL617689,,2411,,,104686,11200,,
,BAO_0000019,,H,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,1,,,F,,,4,Autocuration,CHEMBL617690,,2412,,,104686,11200,,
,BAO_0000218,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,,F,,,4,Autocuration,CHEMBL617691,,2413,In vivo,,104686,11200,,
,BAO_0000218,,H,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,,F,,,4,Autocuration,CHEMBL617692,,2414,In vivo,,104686,11200,,
,BAO_0000218,,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",1,,,F,,,4,Autocuration,CHEMBL617693,,2415,In vivo,,104686,11200,,
,BAO_0000218,,H,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",1,,,F,,,4,Autocuration,CHEMBL617694,,2416,In vivo,,104686,11200,,
Brain,BAO_0000221,,H,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,1,,,B,,955.0,8,Expert,CHEMBL857985,,2417,,,12687,15436,,
,BAO_0000019,,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617695,,2418,,,12687,15436,,
,BAO_0000019,,H,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,1,,,B,,,8,Autocuration,CHEMBL617696,,2419,,,12687,14025,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617697,,2420,,,12687,4342,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617257,,2421,,,12687,13735,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617258,,2422,,,12687,5816,,
,BAO_0000019,,H,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,1,,,B,,,8,Expert,CHEMBL617259,,2423,,,12687,14287,,
,BAO_0000357,,H,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,1,,,B,,,8,Autocuration,CHEMBL617260,,2424,,,12687,15738,,
,BAO_0000357,,D,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617261,,2425,,,12687,15738,,
,BAO_0000019,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617262,,2426,,,12687,15026,,
,BAO_0000019,,H,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,,B,,,8,Expert,CHEMBL617263,,2427,,,12687,16647,,
,BAO_0000019,,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,1,,,B,,,8,Autocuration,CHEMBL617264,,2428,,,12687,16647,,
,BAO_0000019,,D,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617265,,2429,,,12687,13345,,
,BAO_0000249,,H,Membranes,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617266,,2430,,,12687,1543,,
,BAO_0000019,,H,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,1,,,B,,,8,Autocuration,CHEMBL617267,,2431,,,12687,12444,,
,BAO_0000019,,H,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,1,,,B,,,8,Expert,CHEMBL617268,,2432,,,12687,16404,,
,BAO_0000219,,H,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL617269,,2433,,,12687,16404,449.0,
,BAO_0000357,,H,,Kinetic inhibition constant evaluated by measuring serotonergic activity,1,,,B,,,8,Expert,CHEMBL617323,,2434,,,12687,15577,,
,BAO_0000357,,H,,Serotonergic activity of the compound.,1,,,B,,,8,Autocuration,CHEMBL617324,,2435,,,12687,15577,,
,BAO_0000249,,H,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,1,,,B,,,8,Autocuration,CHEMBL617325,,2436,,,12687,2495,,
,BAO_0000019,,D,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617326,,2437,,,12687,15042,,
,BAO_0000249,,H,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,1,,,B,,,8,Expert,CHEMBL617327,,2438,,,12687,15026,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617328,,2439,,,12687,12919,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617329,,2440,,,12687,12919,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617330,,2441,,,12687,12919,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617331,,2442,,,12687,15194,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617332,,2443,,,12687,15194,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617333,,2444,,,107,4820,,
,BAO_0000357,,H,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,1,,,B,,,8,Autocuration,CHEMBL617334,,2445,,,107,6736,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,1,,,B,,,8,Autocuration,CHEMBL617335,,2446,,,107,5163,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,1,,,B,,,8,Autocuration,CHEMBL617336,,2447,,,107,5163,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL617337,,2448,,,107,6011,,
,BAO_0000357,,D,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617338,,2449,,,107,14294,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617339,,2450,,,107,5014,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617340,,2451,,,107,17066,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617341,,2452,,,107,17515,,
,BAO_0000357,,H,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617342,,2453,,,107,6736,,
,BAO_0000357,,H,,Affinity for 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617343,,2454,,,107,5163,,
,BAO_0000219,,H,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,1,NIH3T3,,B,,,8,Expert,CHEMBL617344,,2455,,,107,16911,723.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,1,,,B,,,8,Expert,CHEMBL617345,,2456,,,107,6841,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,1,,,B,,,8,Expert,CHEMBL617346,,2457,,,107,6119,,
,BAO_0000357,,H,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617347,,2458,,,107,3962,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617348,,2459,,,107,4373,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617349,,2460,,,107,4373,,
,BAO_0000019,,H,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,1,,,F,,,8,Autocuration,CHEMBL617350,,2461,,,107,3962,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,1,,,B,,,8,Expert,CHEMBL872339,,2462,,,107,1633,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617351,,2463,,,107,4373,,
,BAO_0000357,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617352,,2464,,,107,6576,,
,BAO_0000357,,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617353,,2465,,,107,4687,,
,BAO_0000357,,H,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617354,,2466,,,107,16946,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617355,,2467,,,107,14159,,
,BAO_0000219,,H,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,1,CHO,10090.0,B,Mus musculus,,8,Expert,CHEMBL617356,,2468,,,107,3032,449.0,
,BAO_0000357,,H,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617357,,2469,,,107,16655,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617358,,2470,,,107,13964,,
,BAO_0000357,,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617359,,2471,,,107,16989,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617360,,2472,,,107,16117,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL875913,,2473,,,107,16700,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617361,,2474,,,107,3269,,
,BAO_0000357,,D,,Binding affinity against 5-Hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617362,,2475,,,107,1274,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL617363,,2476,,,107,1317,,
,BAO_0000357,,H,,Tested against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617364,,2477,,,107,12146,,
,BAO_0000224,,H,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,,B,,,4,Autocuration,CHEMBL617365,,2478,,,105075,12652,,
,BAO_0000224,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,1,,,B,,,4,Autocuration,CHEMBL617366,,2479,,,105075,12652,,
,BAO_0000224,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,1,,,B,,,4,Autocuration,CHEMBL617367,,2480,,,105075,12652,,
,BAO_0000224,,H,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,1,,,B,,,4,Autocuration,CHEMBL617368,,2481,,,105075,12652,,
,BAO_0000357,,H,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),1,,,B,,,8,Autocuration,CHEMBL617369,,2482,,,107,16647,,
,BAO_0000219,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617370,,2483,,,227,15851,722.0,
,BAO_0000219,,D,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617371,,2484,,,227,6857,449.0,
,BAO_0000357,,H,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL617372,,2485,,,227,3805,,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617373,,2486,,,227,6491,,
,BAO_0000019,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,1,,,F,,,8,Autocuration,CHEMBL617374,,2487,,,227,14093,,
,BAO_0000019,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,1,,,F,,,8,Autocuration,CHEMBL617375,,2488,,,227,13481,,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,1,,,F,,,8,Autocuration,CHEMBL617376,,2489,,,227,14093,,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,1,,,F,,,8,Autocuration,CHEMBL617377,,2490,,,227,14093,,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,1,,,F,,,8,Autocuration,CHEMBL617378,,2491,,,227,14093,,
,BAO_0000019,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,,F,,,8,Autocuration,CHEMBL617379,,2492,,,227,13481,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,1,,,B,,,8,Autocuration,CHEMBL617380,,2493,,,227,14442,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,1,,,B,,,8,Autocuration,CHEMBL617381,,2494,,,227,14442,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,1,,,B,,,8,Autocuration,CHEMBL617382,,2495,,,227,14442,,
,BAO_0000357,,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617383,,2496,,,107,12369,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,1,,,B,,,8,Expert,CHEMBL617384,,2497,,,107,12369,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,1,,,B,,,8,Expert,CHEMBL617385,,2498,,,107,12369,,
,BAO_0000019,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,1,,,B,,,8,Autocuration,CHEMBL617386,,2499,,,107,14447,,
,BAO_0000019,,H,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,1,,,B,,,8,Autocuration,CHEMBL617387,,2500,,,107,14447,,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617388,,2501,,,107,17451,723.0,
,BAO_0000219,,H,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,CHO,,F,,,8,Autocuration,CHEMBL617389,,2502,,,107,6857,449.0,
,BAO_0000219,,D,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617390,,2503,,,107,6857,449.0,
,BAO_0000224,,H,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,1,,,B,,,4,Autocuration,CHEMBL617391,,2504,,,104817,5635,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL617392,,2505,,,107,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617393,,2506,,,107,12861,,
,BAO_0000219,,H,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,L929,,B,,,8,Autocuration,CHEMBL617394,,2507,,,107,5105,307.0,
,BAO_0000219,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,1,L929,,B,,,8,Expert,CHEMBL617395,,2508,,,107,5104,307.0,
,BAO_0000219,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,1,L929,,B,,,8,Expert,CHEMBL617396,,2509,,,107,5105,307.0,
,BAO_0000219,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,1,L929,,B,,,8,Autocuration,CHEMBL617397,,2510,,,107,5105,307.0,
,BAO_0000357,,H,,Binding affinity against 5-HT2A receptor,1,,,B,,,8,Autocuration,CHEMBL617398,,2511,,,107,5254,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617399,,2512,,,107,5254,,
,BAO_0000219,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617400,,2513,,,107,13267,722.0,
,BAO_0000219,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617401,,2514,,,107,13267,722.0,
,BAO_0000219,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617402,,2515,,,107,14157,722.0,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617403,,2516,,,107,12936,722.0,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,1,,,B,,,8,Expert,CHEMBL617404,,2517,,,107,14068,,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL857981,,2518,,,107,12936,722.0,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617405,,2519,,,107,12936,722.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617253,,2520,,,107,4540,722.0,
,BAO_0000357,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,1,,,B,,,8,Expert,CHEMBL617254,,2521,,,107,6166,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617255,,2522,,,107,17296,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617256,,2523,,,107,17296,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616874,,2524,,,107,17296,722.0,
,BAO_0000219,,D,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616875,,2525,,,107,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,1,HEK293,,B,,,8,Expert,CHEMBL616876,,2526,,,107,14391,722.0,
,BAO_0000219,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",1,HEK293,,B,,,8,Expert,CHEMBL616877,,2527,,,107,15851,722.0,
,BAO_0000219,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616878,,2528,,,107,15851,722.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,1,HEK293,,B,,,8,Expert,CHEMBL616879,,2529,,,107,3832,722.0,
,BAO_0000219,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,1,HEK293,,B,,,8,Expert,CHEMBL616880,,2530,,,107,3833,722.0,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616881,,2531,,,107,12936,722.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,NIH3T3,,B,,,8,Autocuration,CHEMBL616882,,2532,,,107,17451,723.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,NIH3T3,,B,,,8,Autocuration,CHEMBL616883,,2533,,,107,17451,723.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,NIH3T3,,B,,,8,Autocuration,CHEMBL616884,,2534,,,107,17451,723.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616885,,2535,,,107,4199,722.0,
,BAO_0000219,,H,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,1,CHO-K1,,B,,,8,Autocuration,CHEMBL616886,,2536,,,107,1883,485.0,
,BAO_0000219,,H,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,1,CHO-K1,,B,,,8,Expert,CHEMBL616887,,2537,,,107,1883,485.0,
,BAO_0000357,,D,,Binding affinity for human 5-hydroxytryptamine 2A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616888,,2538,,,107,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,1,HEK293,,B,,,8,Autocuration,CHEMBL616889,,2539,,,107,15146,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL616890,,2540,,,107,5213,722.0,
,BAO_0000219,,D,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL616891,,2541,,,107,16404,449.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,1,HEK293,,B,,,8,Autocuration,CHEMBL616892,,2542,,,107,14818,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL616893,,2543,,,107,4829,722.0,
,BAO_0000219,,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,1,NIH3T3,,F,,,8,Autocuration,CHEMBL616894,,2544,,,10620,12652,723.0,
,BAO_0000219,,H,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,1,NIH3T3,,B,,,8,Expert,CHEMBL616895,,2545,,,107,4682,723.0,
,BAO_0000019,,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,1,,,F,,,8,Autocuration,CHEMBL616896,,2546,,,10620,12652,,
,BAO_0000357,,H,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617099,,2547,,,10621,4921,,
,BAO_0000357,,H,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,1,,,B,,,8,Autocuration,CHEMBL617100,,2548,,,10621,4921,,
,BAO_0000357,,H,,Binding affinity against rabbit aorta 5-HT2A receptor,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL884532,,2549,,,107,16312,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL617101,,2550,,,107,14998,,
,BAO_0000357,,H,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL617102,,2551,,,107,14025,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL617103,,2552,,,107,13047,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-HT2A receptor,1,,9986.0,B,Oryctolagus cuniculus,,8,Expert,CHEMBL617104,,2553,,,107,13047,,
,BAO_0000219,,H,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL857979,,2554,,,10576,1883,485.0,
,BAO_0000019,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,1,,,B,,,8,Autocuration,CHEMBL857502,,2555,,,12687,13463,,
,BAO_0000019,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,,B,,,8,Autocuration,CHEMBL617105,,2556,,,12687,13463,,
Stomach,BAO_0000019,,H,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,1,,,B,,945.0,8,Autocuration,CHEMBL858021,,2557,,,12687,13463,,
Stomach,BAO_0000019,,D,,Binding affinity for 5-HT 2A in rat stomach fundus,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL875910,,2558,,,12687,13463,,
,BAO_0000019,,H,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,1,,,B,,,8,Autocuration,CHEMBL617106,,2559,,,12687,13463,,
,BAO_0000219,,H,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,1,NIH3T3,,B,,,8,Expert,CHEMBL617107,,2560,,,12687,16326,723.0,
,BAO_0000019,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,1,,,F,,,8,Autocuration,CHEMBL617108,,2561,,,12687,14093,,
,BAO_0000019,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,1,,,F,,,8,Autocuration,CHEMBL617109,,2562,,,12687,14093,,
,BAO_0000357,,H,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617110,,2563,,,12687,15740,,
,BAO_0000357,,H,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,1,,,B,,,8,Autocuration,CHEMBL617111,,2564,,,12687,16633,,
,BAO_0000019,,D,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617112,,2565,,,12687,17200,,
,BAO_0000357,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617113,,2566,,,12687,17133,,
,BAO_0000357,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617114,,2567,,,12687,17133,,
,BAO_0000357,,H,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617115,,2568,,,12687,17133,,
,BAO_0000219,,H,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,,F,,,8,Autocuration,CHEMBL617116,,2569,,,12687,17200,,
,BAO_0000019,,H,,Efficacy at 5-hydroxytryptamine 2A receptor,1,,,F,,,8,Autocuration,CHEMBL617117,,2570,,,12687,15363,,
,BAO_0000357,,H,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,,,B,,,8,Autocuration,CHEMBL617118,,2571,,,12687,17200,,
,BAO_0000357,,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617119,,2572,,,12687,17200,,
,BAO_0000357,,D,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617120,,2573,,,12687,17200,,
,BAO_0000219,,D,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617121,,2574,,,12687,17200,,
,BAO_0000219,,H,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,1,,,F,,,8,Autocuration,CHEMBL617122,,2575,,,12687,17200,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617123,,2576,,,12687,17211,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,1,,,B,,,8,Expert,CHEMBL617124,,2577,,,12687,17331,,
,BAO_0000249,,H,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,1,,,B,,,8,Expert,CHEMBL617600,,2578,,,12687,13565,,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL617601,,2579,,,12687,13730,,
,BAO_0000019,,H,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,1,,,B,,,8,Expert,CHEMBL882923,,2580,,,12687,12416,,
,BAO_0000357,,H,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617602,,2581,,,12687,15295,,
,BAO_0000019,,H,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,1,,,B,,,8,Autocuration,CHEMBL617603,,2582,,,12687,1742,,
,BAO_0000357,,H,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617604,,2583,,,12687,15295,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL617605,,2584,,,12687,14970,,
,BAO_0000019,,H,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL617606,,2585,,,12687,16693,,
,BAO_0000019,,D,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617607,,2586,,,12687,14776,,
,BAO_0000249,,H,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Autocuration,CHEMBL617455,,2587,,,12687,14286,,
,BAO_0000019,,D,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617456,,2588,,,12687,17200,,
,BAO_0000357,,H,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),1,,,B,,,8,Expert,CHEMBL617457,,2589,,,12687,15306,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617458,,2590,,,12687,14178,,
,BAO_0000019,,D,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617459,,2591,,,12687,14229,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,1,,,B,,,8,Expert,CHEMBL617460,,2592,,,12687,12884,,
,BAO_0000357,,H,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",1,,,B,,,8,Expert,CHEMBL617461,,2593,,,12687,13149,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617462,,2594,,,12687,15295,,
,BAO_0000357,,H,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,1,,,B,,,8,Autocuration,CHEMBL617463,,2595,,,12687,15740,,
,BAO_0000019,,H,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",1,,,B,,,8,Autocuration,CHEMBL617464,,2596,,,12687,15185,,
,BAO_0000019,,H,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",1,,,B,,,8,Autocuration,CHEMBL617465,,2597,,,12687,15185,,
,BAO_0000019,,H,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,1,,,B,,,8,Expert,CHEMBL617466,,2598,,,12687,17529,,
,BAO_0000019,,H,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,,B,,,8,Autocuration,CHEMBL617467,,2599,,,12687,14826,,
,BAO_0000019,,H,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,1,,,B,,,8,Expert,CHEMBL617468,,2600,,,12687,17211,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,1,,,B,,,8,Autocuration,CHEMBL617469,,2601,,,12687,14826,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617470,,2602,,,12687,14093,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,1,,,B,,,8,Autocuration,CHEMBL617471,,2603,,,12687,14093,,
,BAO_0000219,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,1,NIH3T3,,B,,,8,Expert,CHEMBL617472,,2604,,,12687,13246,723.0,
,BAO_0000357,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,1,,,B,,,8,Expert,CHEMBL617473,,2605,,,12687,13246,,
,BAO_0000019,,D,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617474,,2606,,,12687,15436,,
,BAO_0000019,,D,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617475,,2607,,,12687,15436,,
Brain,BAO_0000221,,H,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,1,,,B,,955.0,8,Autocuration,CHEMBL617476,,2608,,,12687,14442,,
,BAO_0000357,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617477,,2609,,,12687,12457,,
,BAO_0000219,,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,1,NIH3T3,,B,,,8,Expert,CHEMBL617478,,2610,,,12687,12457,723.0,
,BAO_0000221,,H,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",1,,,F,,,8,Autocuration,CHEMBL617479,,2611,,,12687,14755,,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617480,,2612,,,12687,4707,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Expert,CHEMBL617481,,2613,,,12687,13297,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,1,,,B,,,8,Expert,CHEMBL617482,,2614,,,12687,17331,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617483,,2615,,,12687,4664,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL621528,,2616,,,12687,16633,,
,BAO_0000219,,D,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,1,NIH3T3,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL621529,,2617,,,12687,4664,723.0,
,BAO_0000357,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,B,,,8,Expert,CHEMBL621530,,2618,,,12687,16133,,
,BAO_0000357,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL621531,,2619,,,12687,16133,,
,BAO_0000019,,D,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL621532,,2620,,,12687,14060,,
,BAO_0000357,,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,B,,,8,Expert,CHEMBL621533,,2621,,,12687,16326,,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL621534,,2622,,,12687,16659,449.0,
,BAO_0000019,,H,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,1,,,B,,,8,Autocuration,CHEMBL621535,,2623,,,12687,14776,,
,BAO_0000357,,H,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL621536,,2624,,,12687,13481,,
,BAO_0000357,,H,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL621537,,2625,,,12687,17386,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL621538,,2626,,,12687,6611,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL621539,,2627,,,12687,14423,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,1,,,B,,,8,Autocuration,CHEMBL621540,,2628,,,12687,15412,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,1,,,B,,,8,Autocuration,CHEMBL621541,,2629,,,12687,15412,,
,BAO_0000019,,H,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL621542,,2630,,,12687,6238,,
,BAO_0000357,,H,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,1,,,B,,,8,Expert,CHEMBL621543,,2631,,,12687,6648,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL621544,,2632,,,12687,5667,,
,BAO_0000357,,D,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL621545,,2633,,,12687,6611,,
,BAO_0000357,,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL621546,,2634,,,12687,13481,,
,BAO_0000357,,H,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,1,,,B,,,8,Autocuration,CHEMBL621547,,2635,,,12687,13481,,
,BAO_0000219,,H,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,1,NIH3T3,,B,,,8,Expert,CHEMBL618692,,2636,,,12687,15558,723.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL618693,,2637,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL872922,,2638,,,12687,16633,,
,BAO_0000357,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL618694,,2639,,,12687,6013,,
,BAO_0000357,,D,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618695,,2640,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,1,,,B,,,8,Autocuration,CHEMBL618696,,2641,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,1,,,B,,,8,Expert,CHEMBL618697,,2642,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,1,,,B,,,8,Autocuration,CHEMBL618892,,2643,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL618893,,2644,,,12687,6013,,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL618894,,2645,,,12687,16293,,
,BAO_0000219,,H,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,1,NIH3T3,,B,,,8,Expert,CHEMBL618895,,2646,,,12687,17175,723.0,
,BAO_0000357,,D,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618896,,2647,,,12687,13278,,
Caudate-putamen,BAO_0000019,,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,1,,,B,,5383.0,8,Autocuration,CHEMBL618897,,2648,,,12687,3682,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,1,,,B,,,8,Autocuration,CHEMBL618898,,2649,,,12687,2014,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,1,,,B,,,8,Autocuration,CHEMBL618899,,2650,,,12687,2014,,
,BAO_0000357,,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,1,,,B,,,8,Autocuration,CHEMBL618900,,2651,,,12687,4932,,
,BAO_0000019,,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,1,,,B,,,8,Autocuration,CHEMBL618901,,2652,,,12687,4932,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL618902,,2653,,,12687,3935,,
Hippocampus,BAO_0000221,,D,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,10000000.0,9,Expert,CHEMBL618903,,2654,,,12687,5432,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL618904,,2655,,,12687,15818,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,1,,,B,,,8,Autocuration,CHEMBL618905,,2656,,,12687,13672,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,1,,,B,,,8,Autocuration,CHEMBL618906,,2657,,,12687,13672,,
,BAO_0000219,,H,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,1,NIH3T3,,B,,,8,Expert,CHEMBL618907,,2658,,,12687,14749,723.0,
,BAO_0000019,,H,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,1,,,B,,,8,Autocuration,CHEMBL618908,,2659,,,12687,13462,,
,BAO_0000357,,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617909,,2660,,,12687,15740,,
,BAO_0000019,,H,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,1,,,B,,,8,Expert,CHEMBL617910,,2661,,,12687,16647,,
Brain,BAO_0000221,,H,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,1,,,B,,955.0,8,Autocuration,CHEMBL617911,,2662,,,12687,13345,,
,BAO_0000249,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Autocuration,CHEMBL872923,,2663,,,12687,16740,,
,BAO_0000249,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Autocuration,CHEMBL617912,,2664,,,12687,16740,,
,BAO_0000019,,D,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617913,,2665,,,12687,15535,,
,BAO_0000249,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Expert,CHEMBL617914,,2666,,,12687,16740,,
,BAO_0000249,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Autocuration,CHEMBL617915,,2667,,,12687,16740,,
,BAO_0000249,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,1,,,B,,,8,Autocuration,CHEMBL617916,,2668,,,12687,16740,,
,BAO_0000019,,D,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617917,,2669,,,12687,4795,,
,BAO_0000019,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,1,,,B,,,8,Expert,CHEMBL617918,,2670,,,12687,8,,
,BAO_0000019,,H,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,1,,,B,,,8,Autocuration,CHEMBL617919,,2671,,,12687,8,,
,BAO_0000019,,D,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617920,,2672,,,12687,17200,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617921,,2673,,,12687,2148,,
,BAO_0000224,,D,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",1,,10116.0,B,Rattus norvegicus,,5,Expert,CHEMBL617922,,2674,,,105102,13345,,
,BAO_0000357,,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,1,,,B,,,8,Autocuration,CHEMBL617923,,2675,,,12687,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,1,,,B,,,8,Autocuration,CHEMBL617924,,2676,,,12687,5088,,
,BAO_0000357,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617925,,2677,,,12687,17133,,
,BAO_0000357,,D,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617926,,2678,,,12687,17133,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,1,,,B,,,8,Autocuration,CHEMBL617927,,2679,,,12687,16532,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,1,,,B,,,8,Autocuration,CHEMBL617928,,2680,,,12687,15086,,
,BAO_0000019,,D,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617929,,2681,,,12687,2309,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,1,,,B,,,8,Expert,CHEMBL617930,,2682,,,12687,12953,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617931,,2683,,,12687,12953,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617932,,2684,,,12687,12953,,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,1,CHO,,B,,,8,Autocuration,CHEMBL617933,,2685,,,12687,16659,449.0,
,BAO_0000019,,H,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,,B,,,8,Autocuration,CHEMBL617934,,2686,,,12687,16740,,
,BAO_0000019,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,1,,,B,,,8,Autocuration,CHEMBL617935,,2687,,,12687,16740,,
,BAO_0000357,,H,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,1,,,B,,,8,Autocuration,CHEMBL617936,,2688,,,12687,17133,,
,BAO_0000019,,H,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,1,,,B,,,8,Autocuration,CHEMBL617937,,2689,,,12687,17211,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,1,,,B,,,8,Autocuration,CHEMBL617938,,2690,,,12687,17331,,
,BAO_0000218,,H,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,1,,,B,,,8,Autocuration,CHEMBL617939,,2691,,,12687,16633,,
,BAO_0000218,,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,1,,,B,,,8,Autocuration,CHEMBL617940,,2692,,,12687,16633,,
,BAO_0000218,,H,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,1,,,B,,,8,Autocuration,CHEMBL617941,,2693,,,12687,16633,,
,BAO_0000357,,H,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,1,,,B,,,8,Expert,CHEMBL617942,,2694,,,12687,15026,,
,BAO_0000357,,H,,Ratio of pKi of 5-HT2A to that of D2 receptor,1,,,B,,,8,Expert,CHEMBL617943,,2695,,,12687,15026,,
,BAO_0000224,,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,,B,,,4,Expert,CHEMBL617944,,2696,,,105093,16404,,
,BAO_0000224,,H,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,1,,,B,,,4,Expert,CHEMBL617945,,2697,,,105093,16404,,
,BAO_0000224,,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,1,,,B,,,4,Expert,CHEMBL617946,,2698,,,105075,16404,,
,BAO_0000357,,H,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,1,,,B,,,8,Autocuration,CHEMBL617947,,2699,,,12687,16404,,
,BAO_0000357,,H,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,1,,,B,,,8,Expert,CHEMBL617948,,2700,,,12687,16326,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,1,,,F,,,8,Autocuration,CHEMBL858116,,2701,,,12687,15847,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,1,,,F,,,8,Autocuration,CHEMBL617949,,2702,,,12687,15847,,
,BAO_0000019,,H,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,1,,,F,,,8,Autocuration,CHEMBL617950,,2703,,,12687,15329,,
Thoracic aorta,BAO_0000019,,H,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,1,,,F,,1515.0,8,Expert,CHEMBL617951,,2704,,,12687,16404,,
Thoracic aorta,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,1,,,F,,1515.0,8,Expert,CHEMBL617952,,2705,,,12687,16404,,
Thoracic aorta,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,1,,,F,,1515.0,8,Autocuration,CHEMBL617953,,2706,,,12687,16404,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL617954,,2707,,,12687,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,B,,,8,Expert,CHEMBL617955,,2708,,,12687,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,,B,,,8,Autocuration,CHEMBL857071,,2709,,,12687,12861,,
,BAO_0000019,,H,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,1,,,B,,,8,Expert,CHEMBL617270,,2710,,,12687,12490,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,1,N1E-115,,B,,,8,Autocuration,CHEMBL617271,,2711,,,12687,12827,339.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,1,N1E-115,,B,,,8,Autocuration,CHEMBL617272,,2712,,,12687,12827,339.0,
,BAO_0000019,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,1,,,B,,,8,Autocuration,CHEMBL617273,,2713,,,12687,12918,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL617274,,2714,,,12687,12919,,
,BAO_0000357,,H,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617275,,2715,,,108,17723,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617276,,2716,,,108,6013,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617277,,2717,,,108,16293,,
,BAO_0000019,,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617278,,2718,,,108,3857,,
,BAO_0000019,,H,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,1,,,B,,,8,Expert,CHEMBL617279,,2719,,,108,3857,,
,BAO_0000019,,H,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617280,,2720,,,108,3857,,
,BAO_0000357,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617281,,2721,,,108,15363,,
,BAO_0000357,,H,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617282,,2722,,,108,15363,,
,BAO_0000019,,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,1,,,B,,,8,Expert,CHEMBL617283,,2723,,,108,16441,,
,BAO_0000019,,H,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,1,,,B,,,8,Expert,CHEMBL617284,,2724,,,108,16441,,
,BAO_0000219,,H,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617285,,2725,,,108,4176,722.0,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617286,,2726,,,108,17085,,
,BAO_0000357,,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617287,,2727,,,108,17200,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,1,,,B,,,8,Expert,CHEMBL617288,,2728,,,108,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,1,,,B,,,8,Autocuration,CHEMBL617289,,2729,,,108,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL872917,,2730,,,108,5088,,
,BAO_0000357,,H,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617290,,2731,,,108,5088,,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL617291,,2732,,,108,16659,449.0,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,1,CHO,,B,,,8,Autocuration,CHEMBL617292,,2733,,,108,16659,449.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617293,,2734,,,108,17451,723.0,
,BAO_0000219,,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617294,,2735,,,108,6857,449.0,
,BAO_0000019,,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,,B,,,8,Expert,CHEMBL617295,,2736,,,108,3857,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL617296,,2737,,,108,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617297,,2738,,,108,12861,,
,BAO_0000219,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,1,CHO,,B,,,8,Expert,CHEMBL617298,,2739,,,108,5104,449.0,
,BAO_0000219,,H,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,1,CHO,,B,,,8,Expert,CHEMBL617299,,2740,,,108,5105,449.0,
,BAO_0000219,,H,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,1,CHO,,B,,,8,Autocuration,CHEMBL617300,,2741,,,108,5105,449.0,
,BAO_0000357,,H,,Binding affinity against 5-HT2C receptor,1,,,B,,,8,Autocuration,CHEMBL617454,,2742,,,108,5254,,
,BAO_0000219,,H,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617505,,2743,,,108,13267,722.0,
,BAO_0000219,,D,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617506,,2744,,,108,14157,722.0,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617507,,2745,,,108,12936,722.0,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,1,,,B,,,8,Expert,CHEMBL617508,,2746,,,108,14068,,
,BAO_0000219,,D,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL857982,,2747,,,108,12936,722.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617509,,2748,,,108,4540,722.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617510,,2749,,,108,4540,722.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617511,,2750,,,108,6166,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617512,,2751,,,108,17296,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617749,,2752,,,108,17296,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL617750,,2753,,,108,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL617751,,2754,,,108,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,1,HEK293,,B,,,8,Expert,CHEMBL617752,,2755,,,108,14391,722.0,
,BAO_0000219,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL617753,,2756,,,108,15779,722.0,
,BAO_0000219,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",1,HEK293,,B,,,8,Expert,CHEMBL617754,,2757,,,108,15851,722.0,
,BAO_0000219,,D,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617755,,2758,,,108,15851,722.0,
,BAO_0000219,,H,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",1,HEK293,,B,,,8,Autocuration,CHEMBL617756,,2759,,,108,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,1,HEK293,,B,,,8,Expert,CHEMBL617757,,2760,,,108,3832,722.0,
,BAO_0000219,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,1,HEK293,,B,,,8,Expert,CHEMBL617758,,2761,,,108,3833,722.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617759,,2762,,,108,17451,723.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617760,,2763,,,108,4199,722.0,
,BAO_0000219,,H,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,1,CHO-K1,,B,,,8,Expert,CHEMBL617761,,2764,,,108,1883,485.0,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617762,,2765,,,108,4321,,
,BAO_0000357,,H,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617763,,2766,,,108,14875,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,1,HEK293,,B,,,8,Autocuration,CHEMBL857983,,2767,,,108,15146,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617764,,2768,,,108,5213,722.0,
,BAO_0000219,,H,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,1,HeLa,,B,,,8,Autocuration,CHEMBL617765,,2769,,,108,16404,308.0,
,BAO_0000019,,H,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,1,,,F,,,8,Autocuration,CHEMBL617766,,2770,,,108,13267,,
Hippocampus,BAO_0000221,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,1,,,F,,10000000.0,8,Autocuration,CHEMBL617767,,2771,,,108,13267,,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,1,HEK293,,B,,,8,Autocuration,CHEMBL617768,,2772,,,108,14818,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL617769,,2773,,,108,4829,722.0,
,BAO_0000357,,H,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL858023,,2774,,,11864,13463,,
Stomach,BAO_0000019,,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,1,,,B,,945.0,8,Autocuration,CHEMBL617770,,2775,,,11864,13463,,
Stomach,BAO_0000019,,H,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,1,,,B,,945.0,8,Autocuration,CHEMBL617771,,2776,,,11864,13463,,
,BAO_0000219,,H,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,1,A9,,F,,,8,Autocuration,CHEMBL617772,,2777,,,11864,12652,625.0,
,BAO_0000219,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617773,,2778,,,11864,4682,723.0,
,BAO_0000219,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617850,,2779,,,11864,4682,723.0,
,BAO_0000219,,H,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,1,NIH3T3,,B,,,8,Autocuration,CHEMBL617851,,2780,,,11864,4682,723.0,
,BAO_0000019,,H,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,1,,,F,,,8,Autocuration,CHEMBL617852,,2781,,,11864,12652,,
Stomach,BAO_0000019,,H,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,1,,10090.0,B,Mus musculus,945.0,8,Autocuration,CHEMBL858024,,2782,,,12689,13463,,
Stomach,BAO_0000019,,D,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617853,,2783,,,12689,13463,,
,BAO_0000357,,H,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,1,,,B,,,8,Expert,CHEMBL617854,,2784,,,108,13969,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,9823.0,B,Sus scrofa,,8,Expert,CHEMBL873477,,2785,,,108,13392,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617855,,2786,,,108,13392,,
,BAO_0000019,,H,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,1,,,B,,,8,Expert,CHEMBL617856,,2787,,,108,14430,,
,BAO_0000019,,H,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,1,,,B,,,8,Autocuration,CHEMBL617857,,2788,,,108,1742,,
,BAO_0000249,,H,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,1,,,B,,,8,Autocuration,CHEMBL617858,,2789,,,108,14286,,
,BAO_0000357,,H,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617859,,2790,,,108,5619,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617860,,2791,,,108,15086,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,,B,,,8,Autocuration,CHEMBL617861,,2792,,,108,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,B,,,8,Expert,CHEMBL617862,,2793,,,108,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,1,,,B,,,8,Autocuration,CHEMBL617863,,2794,,,108,12861,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,1,,,B,,,8,Autocuration,CHEMBL617864,,2795,,,108,12827,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,1,,,B,,,8,Autocuration,CHEMBL617649,,2796,,,108,12827,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,,9823.0,F,Sus scrofa,,8,Expert,CHEMBL617650,,2797,,,108,12919,,
,BAO_0000019,,H,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,1,,9823.0,F,Sus scrofa,,8,Expert,CHEMBL617651,,2798,,,108,12919,,
,BAO_0000357,,H,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617652,,2799,,,108,16429,,
,BAO_0000019,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL857072,,2800,,,108,773,,
,BAO_0000357,,H,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617653,,2801,,,108,5033,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617654,,2802,,,12687,12861,,
,BAO_0000019,,H,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,1,,,F,,,8,Autocuration,CHEMBL617655,,2803,,,12689,14093,,
,BAO_0000357,,H,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,1,,,B,,,8,Expert,CHEMBL617656,,2804,,,12689,14970,,
,BAO_0000357,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL617657,,2805,,,12689,14970,,
,BAO_0000357,,H,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,1,,,B,,,8,Autocuration,CHEMBL617658,,2806,,,12689,14970,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617659,,2807,,,12689,14178,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617838,,2808,,,12689,14178,,
,BAO_0000249,,D,Brain membranes,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617839,,2809,,,12689,14229,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,1,,,B,,,8,Autocuration,CHEMBL617840,,2810,,,12689,16532,,
,BAO_0000019,,H,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,1,,,B,,,8,Autocuration,CHEMBL617841,,2811,,,12689,14826,,
,BAO_0000019,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,1,,,B,,,8,Autocuration,CHEMBL875915,,2812,,,12689,17211,,
,BAO_0000219,,H,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,1,,,B,,,8,Expert,CHEMBL617842,,2813,In vitro,,12689,17211,,
,BAO_0000219,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,1,NIH3T3,,B,,,8,Expert,CHEMBL617843,,2814,,,12689,13246,723.0,
,BAO_0000357,,H,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,1,,,B,,,8,Expert,CHEMBL617844,,2815,,,12689,13246,,
,BAO_0000357,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617845,,2816,,,12689,12457,,
,BAO_0000219,,H,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,1,NIH3T3,,B,,,8,Expert,CHEMBL617846,,2817,,,12689,12457,723.0,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617847,,2818,,,12689,4707,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617848,,2819,,,12689,13297,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617849,,2820,,,12689,16633,,
,BAO_0000357,,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,B,,,8,Expert,CHEMBL621507,,2821,,,12689,16133,,
,BAO_0000357,,H,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,1,,,B,,,8,Expert,CHEMBL621508,,2822,,,12689,16326,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL621509,,2823,,,12689,14423,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,1,,,B,,,8,Autocuration,CHEMBL621510,,2824,,,12689,15412,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,1,,,B,,,8,Autocuration,CHEMBL621511,,2825,,,12689,15412,,
,BAO_0000219,,H,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,1,A9,,B,,,8,Expert,CHEMBL621512,,2826,,,12689,15558,625.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL621513,,2827,,,12689,16633,,
,BAO_0000357,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,1,,,B,,,8,Expert,CHEMBL621514,,2828,,,12689,6013,,
,BAO_0000219,,H,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,1,,,B,,,8,Expert,CHEMBL621515,,2829,In vitro,,12689,17175,,
,BAO_0000219,,H,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,1,,,B,,,8,Autocuration,CHEMBL621516,,2830,,,12689,12469,,
Caudate-putamen,BAO_0000019,,H,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,1,,,B,,5383.0,8,Autocuration,CHEMBL621517,,2831,,,12689,3682,,
,BAO_0000357,,H,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,1,,,B,,,8,Autocuration,CHEMBL621518,,2832,,,12689,4932,,
,BAO_0000019,,H,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,1,,,B,,,8,Autocuration,CHEMBL621519,,2833,,,12689,4932,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621520,,2834,,,12689,3935,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621521,,2835,,,12689,15818,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621522,,2836,,,12689,15818,,
,BAO_0000219,,H,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,1,,,B,,,8,Expert,CHEMBL621523,,2837,,,12689,14749,,
,BAO_0000357,,H,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621524,,2838,,,12689,15740,,
,BAO_0000357,,D,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL621525,,2839,,,12689,17133,,
,BAO_0000357,,H,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,1,,,B,,,8,Autocuration,CHEMBL872921,,2840,,,12689,16532,,
,BAO_0000357,,H,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621526,,2841,,,12689,12369,,
,BAO_0000219,,H,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,1,,,B,,,8,Expert,CHEMBL621527,,2842,,,12689,12369,,
,BAO_0000019,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617865,,2843,,,12689,2309,,
,BAO_0000357,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617866,,2844,,,12689,12953,,
,BAO_0000019,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617867,,2845,,,12689,12953,,
,BAO_0000357,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL617487,,2846,,,12689,12953,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617488,,2847,,,12689,12953,,
,BAO_0000357,,H,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,1,,,B,,,8,Autocuration,CHEMBL617489,,2848,,,12689,17133,,
,BAO_0000019,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,1,,,B,,,8,Autocuration,CHEMBL617490,,2849,,,12689,17211,,
,BAO_0000019,,H,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,1,,,B,,,8,Autocuration,CHEMBL617491,,2850,,,12689,17211,,
,BAO_0000019,,H,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,1,,,B,,,8,Autocuration,CHEMBL617492,,2851,,,12689,14025,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,1,,,B,,,8,Autocuration,CHEMBL617493,,2852,,,12689,14998,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617494,,2853,,,12689,4342,,
,BAO_0000019,,D,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL617495,,2854,,,12689,13735,,
,BAO_0000357,,H,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617496,,2855,,,12689,13181,,
,BAO_0000219,,H,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,1,CHO-K1,,B,,,8,Autocuration,CHEMBL617497,,2856,,,12689,1883,485.0,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL617498,,2857,,,12689,15194,,
,BAO_0000357,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,1,,,B,,,8,Autocuration,CHEMBL617499,,2858,,,12689,15194,,
,BAO_0000019,,H,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,1,,,F,,,8,Autocuration,CHEMBL617500,,2859,,,12689,14579,,
,BAO_0000357,,H,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617501,,2860,,,108,4639,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL617502,,2861,,,108,4820,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,1,,,B,,,8,Autocuration,CHEMBL617503,,2862,,,227,14442,,
,BAO_0000357,,H,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL617504,,2863,,,227,14755,,
,BAO_0000357,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,1,,,B,,,8,Autocuration,CHEMBL617406,,2864,,,227,14744,,
,BAO_0000019,,D,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617407,,2865,,,227,6857,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL617408,,2866,,,227,16209,,
,BAO_0000357,,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617409,,2867,,,227,15363,,
,BAO_0000357,,H,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617410,,2868,,,227,15363,,
,BAO_0000357,,H,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617411,,2869,,,227,15363,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617412,,2870,,,227,17085,,
,BAO_0000357,,D,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617774,,2871,,,227,17200,,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617775,,2872,,,227,15851,722.0,
,BAO_0000219,,D,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617776,,2873,,,227,15851,722.0,
,BAO_0000219,,D,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617777,,2874,,,227,6857,449.0,
,BAO_0000219,,D,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617778,,2875,,,227,6857,449.0,
,BAO_0000219,,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL617779,,2876,,,227,15779,722.0,
,BAO_0000219,,H,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,1,HEK293,,B,,,8,Expert,CHEMBL617780,,2877,,,227,15851,722.0,
,BAO_0000219,,H,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",1,HEK293,,B,,,8,Autocuration,CHEMBL617781,,2878,,,227,15779,722.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617782,,2879,,,227,14157,722.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617783,,2880,,,227,4540,722.0,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617784,,2881,,,227,6166,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL617785,,2882,,,227,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,1,HEK293,,B,,,8,Expert,CHEMBL857984,,2883,,,227,14391,722.0,
,BAO_0000219,,H,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,1,HEK293,,B,,,8,Expert,CHEMBL617786,,2884,,,227,3832,722.0,
,BAO_0000219,,H,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,1,HEK293,,B,,,8,Expert,CHEMBL617787,,2885,,,227,3833,722.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617788,,2886,,,227,15851,722.0,
,BAO_0000219,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617789,,2887,,,227,15851,722.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617790,,2888,,,227,4199,722.0,
,BAO_0000219,,H,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,1,CHO-K1,,B,,,8,Expert,CHEMBL617791,,2889,,,227,1883,485.0,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Expert,CHEMBL617608,,2890,,,227,4321,,
,BAO_0000219,,H,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,1,HEK293,,B,,,8,Autocuration,CHEMBL617609,,2891,,,227,15146,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL617610,,2892,,,227,5213,722.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,1,HEK293,,B,,,8,Autocuration,CHEMBL617611,,2893,,,227,14818,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL617612,,2894,,,227,4829,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL617613,,2895,,,227,4829,722.0,
,BAO_0000019,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL617614,,2896,,,227,14025,,
Stomach,BAO_0000019,,H,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,1,,,B,,945.0,8,Expert,CHEMBL617615,,2897,,,12688,13463,,
Stomach,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,1,,,B,,945.0,8,Expert,CHEMBL858114,,2898,,,12688,7259,,
Stomach,BAO_0000357,,H,,Affinity against serotonergic receptor in the isolated rat stomach fundus,1,,,B,,945.0,8,Autocuration,CHEMBL617616,,2899,,,12688,7259,,
Stomach,BAO_0000019,,D,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,1,,10116.0,F,Rattus norvegicus,945.0,9,Expert,CHEMBL617617,,2900,,,12688,7185,,
,BAO_0000019,,D,,Antagonistic against 5-hydroxytryptamine 2B receptor,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL875914,,2901,,,12688,7185,,
Stomach,BAO_0000019,,H,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,1,,,F,,945.0,8,Autocuration,CHEMBL617618,,2902,,,12688,13267,,
Stomach,BAO_0000357,,D,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617619,,2903,,,12688,13735,,
,BAO_0000019,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,1,,,F,,,8,Autocuration,CHEMBL617620,,2904,,,12688,15738,,
,BAO_0000019,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,1,,,F,,,8,Autocuration,CHEMBL617621,,2905,,,12688,15738,,
,BAO_0000019,,H,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,1,,,F,,,8,Autocuration,CHEMBL617622,,2906,,,12688,15738,,
Stomach,BAO_0000357,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617623,,2907,,,12688,12936,,
Stomach,BAO_0000357,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617624,,2908,,,12688,12936,,
Stomach,BAO_0000357,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617625,,2909,,,12688,12936,,
Stomach,BAO_0000357,,D,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,1,,10116.0,B,Rattus norvegicus,945.0,9,Expert,CHEMBL617626,,2910,,,12688,12936,,
Stomach,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,,,F,,945.0,8,Autocuration,CHEMBL617627,,2911,,,12688,16404,,
Stomach,BAO_0000019,,H,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,,,F,,945.0,8,Expert,CHEMBL617628,,2912,,,12688,16404,,
Stomach,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,1,,,F,,945.0,8,Autocuration,CHEMBL617629,,2913,,,12688,16404,,
Stomach,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,1,,,F,,945.0,8,Autocuration,CHEMBL858115,,2914,,,12688,16404,,
Stomach,BAO_0000019,,D,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,1,,10116.0,F,Rattus norvegicus,945.0,9,Expert,CHEMBL617630,,2915,,,12688,16404,,
Thoracic aorta,BAO_0000019,,H,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,1,,,F,,1515.0,8,Autocuration,CHEMBL617631,,2916,,,12688,16404,,
,BAO_0000357,,H,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,,B,,,8,Autocuration,CHEMBL617632,,2917,,,12688,7483,,
,BAO_0000357,,H,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,1,,,B,,,8,Expert,CHEMBL617633,,2918,,,12688,7483,,
,BAO_0000357,,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,1,,,B,,,8,Autocuration,CHEMBL617634,,2919,,,12688,7483,,
,BAO_0000357,,H,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,1,,,B,,,8,Autocuration,CHEMBL617635,,2920,,,12688,7483,,
Stomach,BAO_0000019,,D,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,1,,10116.0,F,Rattus norvegicus,945.0,9,Autocuration,CHEMBL617637,,2922,,,12688,16404,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 1A receptor,1,,,B,,,8,Autocuration,CHEMBL617638,,2923,,,227,6347,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617639,,2924,,,227,4373,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,1,,,B,,,8,Autocuration,CHEMBL617640,,2925,,,227,4373,,
,BAO_0000357,,H,,Evaluated for the binding affinity to 5-HT 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617641,,2926,,,227,4687,,
,BAO_0000357,,H,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617642,,2927,,,227,16946,,
,BAO_0000357,,H,,Binding affinities against 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617643,,2928,,,227,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 2B receptor,1,,,B,,,8,Autocuration,CHEMBL617644,,2929,,,227,16633,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617645,,2930,,,227,16633,,
,BAO_0000357,,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,,,B,,,8,Expert,CHEMBL617646,,2931,,,108,15026,,
,BAO_0000357,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617647,,2932,,,108,15738,,
,BAO_0000357,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617648,,2933,,,108,15738,,
,BAO_0000357,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617875,,2934,,,108,15738,,
,BAO_0000357,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617876,,2935,,,108,15738,,
,BAO_0000357,,H,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL617877,,2936,,,108,16404,,
,BAO_0000357,,H,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL617878,,2937,,,108,15026,,
,BAO_0000357,,H,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617879,,2938,,,108,15738,,
,BAO_0000019,,H,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL617880,,2939,,,108,16312,,
Striatum,BAO_0000357,,D,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617881,,2940,,,20033,5486,,
,BAO_0000357,,H,,Binding affinity against 5-HT1A receptor,1,,,B,,,8,Autocuration,CHEMBL857073,,2941,,,51,5254,,
,BAO_0000219,,H,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,1,CHO,,F,,,8,Expert,CHEMBL617882,,2942,,,108,3857,449.0,
,BAO_0000219,,D,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL617883,,2943,,,108,6857,449.0,
,BAO_0000219,,H,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,1,,,F,,,8,Autocuration,CHEMBL617884,,2944,,,108,4176,,
,BAO_0000219,,H,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL617885,,2945,,,108,6347,449.0,
,BAO_0000219,,H,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",1,CHO,,B,,,8,Autocuration,CHEMBL617886,,2946,,,108,6347,449.0,
,BAO_0000357,,D,,Inhibition of human 5-hydroxytryptamine 2C receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617887,,2947,,,108,16146,,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL617888,,2948,,,108,3805,,
,BAO_0000019,,H,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,1,,,B,,,8,Autocuration,CHEMBL617889,,2949,,,108,3857,,
,BAO_0000357,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL617890,,2950,,,108,5635,,
,BAO_0000357,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,,B,,,8,Autocuration,CHEMBL617891,,2951,,,108,5635,,
,BAO_0000357,,H,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,1,,,B,,,8,Autocuration,CHEMBL617892,,2952,,,108,5635,,
,BAO_0000219,,H,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,1,CHO,,B,,,8,Expert,CHEMBL617893,,2953,,,108,4012,449.0,
,BAO_0000219,,H,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL617894,,2954,,,108,6366,449.0,
,BAO_0000219,,H,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL617895,,2955,,,108,15949,449.0,
,BAO_0000219,,H,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,1,CHO,,B,,,8,Autocuration,CHEMBL617896,,2956,,,108,17211,449.0,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL617897,,2957,,,108,6491,,
,BAO_0000019,,H,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,1,,,F,,,8,Autocuration,CHEMBL617898,,2958,,,108,14093,,
,BAO_0000019,,H,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,1,,,F,,,8,Autocuration,CHEMBL617899,,2959,,,108,13481,,
,BAO_0000219,,H,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,1,CHO,10116.0,B,Rattus norvegicus,,8,Expert,CHEMBL617900,,2960,,,108,6347,449.0,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,1,,,F,,,8,Autocuration,CHEMBL617901,,2961,,,108,14093,,
,BAO_0000019,,H,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,1,,,F,,,8,Autocuration,CHEMBL617902,,2962,,,108,14093,,
,BAO_0000019,,H,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,F,,,8,Autocuration,CHEMBL617903,,2963,,,108,13481,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL617904,,2964,,,108,14442,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL617905,,2965,,,108,14442,,
,BAO_0000357,,H,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,1,,,B,,,8,Autocuration,CHEMBL617906,,2966,,,108,14442,,
,BAO_0000357,,H,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL617907,,2967,,,108,14755,,
,BAO_0000357,,H,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,1,,,B,,,8,Autocuration,CHEMBL617908,,2968,,,108,14744,,
,BAO_0000219,,H,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL620617,,2969,,,108,16659,449.0,
,BAO_0000019,,D,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620618,,2970,,,108,6857,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,1,,,B,,,8,Expert,CHEMBL620619,,2971,,,108,5635,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620620,,2972,,,108,4234,,
,BAO_0000357,,H,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,1,,,B,,,8,Autocuration,CHEMBL620621,,2973,,,108,16209,,
,BAO_0000249,,D,Membranes,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL872920,,2974,,,104698,5778,,
,BAO_0000223,,H,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,1,,,B,,,6,Autocuration,CHEMBL620622,,2975,,,104698,5094,,
,BAO_0000019,,D,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL620623,,2976,,,104698,809,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,1,,,B,,,6,Autocuration,CHEMBL620624,,2977,,,104698,1578,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,1,,,B,,,6,Autocuration,CHEMBL620625,,2978,,,104698,809,,
,BAO_0000219,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,1,,,B,,,6,Autocuration,CHEMBL620626,,2979,,,104698,12469,,
,BAO_0000019,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,1,,,B,,,6,Autocuration,CHEMBL621307,,2980,,,104698,14290,,
,BAO_0000019,,H,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,1,,,B,,,6,Autocuration,CHEMBL621308,,2981,,,104698,14290,,
,BAO_0000223,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,1,,,B,,,6,Autocuration,CHEMBL621309,,2982,,,104698,10609,,
,BAO_0000223,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,1,,,B,,,6,Autocuration,CHEMBL621310,,2983,,,104698,10609,,
,BAO_0000223,,H,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,1,,,B,,,6,Autocuration,CHEMBL621311,,2984,,,104698,10609,,
,BAO_0000249,,H,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,,B,,,6,Autocuration,CHEMBL621502,,2985,,,104698,15253,,
,BAO_0000249,,H,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",1,,,B,,,6,Autocuration,CHEMBL621503,,2986,,,104698,15253,,
,BAO_0000249,,H,Membranes,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,1,,,B,,,6,Autocuration,CHEMBL621504,,2987,,,104698,11683,,
,BAO_0000223,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL621505,,2988,,,104698,12092,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,,B,,,6,Autocuration,CHEMBL621506,,2989,,,104698,1946,,
,BAO_0000223,,H,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,1,,,B,,,6,Autocuration,CHEMBL619781,,2990,,,104698,11623,,
,BAO_0000223,,H,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,1,,,B,,,6,Autocuration,CHEMBL619782,,2991,,,104698,11623,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,1,,,B,,,6,Autocuration,CHEMBL619783,,2992,,,104698,14788,,
,BAO_0000019,,D,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619784,,2993,,,104698,5432,,
,BAO_0000249,,H,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,B,,,6,Autocuration,CHEMBL619785,,2994,,,104698,14826,,
,BAO_0000223,,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL619786,,2995,,,104698,2222,,
,BAO_0000019,,H,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,1,,,B,,,6,Autocuration,CHEMBL619787,,2996,,,104698,11963,,
,BAO_0000019,,H,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,1,,,B,,,6,Autocuration,CHEMBL872925,,2997,,,104698,14145,,
,BAO_0000019,,H,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,1,,,B,,,6,Autocuration,CHEMBL619788,,2998,,,104698,17819,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,,B,,,6,Autocuration,CHEMBL619789,,2999,,,104698,10394,,
,BAO_0000249,,H,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,1,,,B,,,6,Autocuration,CHEMBL619790,,3000,,,104698,10394,,
,BAO_0000019,,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,,B,,,6,Autocuration,CHEMBL619791,,3001,,,104698,15034,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,1,,,B,,,6,Autocuration,CHEMBL619792,,3002,,,104698,691,,
,BAO_0000249,,H,Membranes,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,1,,,B,,,6,Autocuration,CHEMBL619793,,3003,,,104698,12092,,
,BAO_0000223,,D,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619794,,3004,,,104698,11752,,
Brain,BAO_0000221,,H,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,1,,,B,,955.0,6,Autocuration,CHEMBL619795,,3005,,,104698,11752,,
,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,1,,,B,,,6,Autocuration,CHEMBL619796,,3006,,,104698,301,,
,BAO_0000223,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,1,,,B,,,6,Autocuration,CHEMBL620448,,3007,,,104698,16532,,
,BAO_0000223,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,,B,,,6,Autocuration,CHEMBL620449,,3008,,,104698,16532,,
,BAO_0000223,,H,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,1,,,B,,,6,Autocuration,CHEMBL620450,,3009,,,104698,12092,,
,BAO_0000223,,H,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,1,,,B,,,6,Autocuration,CHEMBL620451,,3010,,,104698,11684,,
,BAO_0000223,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,1,,,B,,,6,Autocuration,CHEMBL620631,,3011,,,104698,11684,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,1,,,B,,,6,Autocuration,CHEMBL620632,,3012,,,104698,12953,,
,BAO_0000019,,H,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,1,,,B,,,6,Autocuration,CHEMBL620633,,3013,,,104698,12953,,
,BAO_0000223,,H,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,1,,,B,,,6,Autocuration,CHEMBL620634,,3014,,,104698,12953,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,1,,,B,,,6,Autocuration,CHEMBL620635,,3015,,,104698,12861,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620636,,3016,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620637,,3017,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620638,,3018,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620639,,3019,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620640,,3020,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620641,,3021,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620642,,3022,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620643,,3023,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620644,,3024,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620645,,3025,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620646,,3026,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620647,,3027,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620648,,3028,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620649,,3029,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620650,,3030,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620651,,3031,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL872875,,3032,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL620652,,3033,In vivo,,104698,11454,,
,BAO_0000019,,H,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,1,,,F,,,6,Autocuration,CHEMBL620653,,3034,,,104698,10609,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,1,,,B,,,6,Autocuration,CHEMBL857076,,3035,,,104698,12861,,
,BAO_0000019,,D,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL620654,,3036,,,104698,12861,,
,BAO_0000223,,H,,Binding activity radioligand.,1,,,B,,,6,Autocuration,CHEMBL620655,,3037,,,104698,12861,,
,BAO_0000249,,H,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,1,,,B,,,6,Autocuration,CHEMBL620656,,3038,,,104698,10728,,
,BAO_0000249,,H,Brain membranes,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,1,,,B,,,6,Autocuration,CHEMBL620657,,3039,,,104698,10728,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,1,,,B,,,8,Autocuration,CHEMBL620658,,3040,,,108,5163,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,1,,,B,,,8,Autocuration,CHEMBL620659,,3041,,,108,5163,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL620660,,3042,,,108,6011,,
,BAO_0000357,,H,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL620661,,3043,,,108,5014,,
,BAO_0000357,,H,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL620662,,3044,,,108,5635,,
,BAO_0000357,,H,,Affinity for 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL620663,,3045,,,108,5163,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,1,,,B,,,8,Autocuration,CHEMBL620664,,3046,,,108,6841,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,1,,,B,,,8,Expert,CHEMBL620665,,3047,,,108,6119,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620666,,3048,,,108,4373,,
,BAO_0000357,,H,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,1,,,B,,,8,Autocuration,CHEMBL620667,,3049,,,108,1633,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,1,,,B,,,8,Expert,CHEMBL620668,,3050,,,108,1633,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620669,,3051,,,108,4373,,
,BAO_0000357,,H,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL620670,,3052,,,108,6576,,
,BAO_0000357,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL620671,,3053,,,108,4687,,
,BAO_0000357,,H,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,1,,,B,,,8,Autocuration,CHEMBL620672,,3054,,,108,12146,,
,BAO_0000357,,H,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,1,,,B,,,8,Autocuration,CHEMBL620673,,3055,,,108,12146,,
,BAO_0000357,,H,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL620674,,3056,,,108,16946,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL620675,,3057,,,108,14159,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL620676,,3058,,,108,16700,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Autocuration,CHEMBL621382,,3059,,,108,3269,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 2C receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL621383,,3060,,,108,1274,,
,BAO_0000357,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,1,,,B,,,8,Autocuration,CHEMBL621384,,3061,,,108,1317,,
,BAO_0000357,,H,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL621385,,3062,,,144,5834,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,1,,9913.0,B,Bos taurus,,8,Autocuration,CHEMBL617989,,3063,,,144,11147,,
,BAO_0000019,,H,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,1,,10141.0,F,Cavia porcellus,,4,Expert,CHEMBL617990,,3064,,,104714,14145,,
Ileum,BAO_0000221,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL875085,,3065,,,104714,10561,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617991,,3066,,,104714,15847,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617992,,3067,,,104714,15847,,
Ileum,BAO_0000221,,H,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617993,,3068,,,104714,10561,,
Ileum,BAO_0000221,,H,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617994,,3069,,,104714,11454,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617995,,3070,,,104714,4639,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617996,,3071,,,104714,4639,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617997,,3072,,,104714,4639,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617998,,3073,,,104714,4639,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL617999,,3074,,,104714,4639,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618000,,3075,,,104714,4639,,
Ileum,BAO_0000221,,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617815,,3076,,,104714,15253,,
Ileum,BAO_0000221,,H,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617816,,3077,,,104714,15253,,
Ileum,BAO_0000221,,H,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617817,,3078,,,104714,11963,,
Ileum,BAO_0000221,,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617818,,3079,,,104714,1946,,
Ileum,BAO_0000221,,H,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617819,,3080,,,104714,1946,,
,BAO_0000223,,H,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL617820,,3081,,,104714,12045,,
Ileum,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617821,,3082,,,104714,1559,,
Ileum,BAO_0000221,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617822,,3083,,,104714,273,,
Ileum,BAO_0000221,,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617823,,3084,,,104714,273,,
Ileum,BAO_0000221,,H,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617824,,3085,,,104714,188,,
Ileum,BAO_0000221,,H,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617825,,3086,,,104714,12919,,
Ileum,BAO_0000221,,H,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617826,,3087,,,104714,12918,,
Ileum,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617827,,3088,,,104714,1559,,
Ileum,BAO_0000221,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,,10141.0,F,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617828,,3089,,,104714,273,,
Ileum,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617829,,3090,,,104714,1559,,
Ileum,BAO_0000221,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617830,,3091,,,104714,1559,,
Ileum,BAO_0000221,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617831,,3092,,,104714,1559,,
Ileum,BAO_0000221,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL617832,,3093,,,104714,14424,,
,BAO_0000019,,U,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,1,,10141.0,B,Cavia porcellus,,0,Autocuration,CHEMBL617833,,3094,,,22226,13181,,
,BAO_0000357,,H,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,1,,,B,,,8,Autocuration,CHEMBL617834,,3095,,,51,5486,,
,BAO_0000223,,D,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,1,,9606.0,B,Homo sapiens,,5,Expert,CHEMBL617835,,3096,,,104714,6491,,
,BAO_0000223,,H,,Binding affinity towards 5-HT3 receptor,1,,,B,,,4,Autocuration,CHEMBL617836,,3097,,,104714,6013,,
,BAO_0000223,,H,,Binding activity radioligand.,1,,,B,,,4,Autocuration,CHEMBL617837,,3098,,,104714,12861,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,1,,,B,,,4,Autocuration,CHEMBL620392,,3099,,,104714,12861,,
,BAO_0000223,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL620393,,3100,,,104714,5104,,
,BAO_0000223,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL620394,,3101,,,104714,5105,,
,BAO_0000223,,H,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,1,,,B,,,4,Autocuration,CHEMBL620395,,3102,,,104714,5104,,
,BAO_0000019,,U,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,1,,,B,,,0,Autocuration,CHEMBL620396,,3103,,,22226,3935,,
,BAO_0000219,,H,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,1,NG108-15,,B,,,4,Expert,CHEMBL620582,,3104,,,105030,13657,433.0,
,BAO_0000218,,H,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",1,,,B,,,4,Autocuration,CHEMBL620583,,3105,In vivo,,105030,10369,,
,BAO_0000019,,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,,B,,,4,Autocuration,CHEMBL620584,,3106,,,105030,10369,,
,BAO_0000224,,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,1,,,B,,,4,Autocuration,CHEMBL620585,,3107,,,105030,12918,,
,BAO_0000224,,H,,Compound was evaluated for the binding affinity at 5- HT3 receptor,1,,,B,,,4,Autocuration,CHEMBL620586,,3108,,,105030,12918,,
,BAO_0000019,,H,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),1,,,B,,,4,Autocuration,CHEMBL620587,,3109,,,105030,10369,,
,BAO_0000019,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,,B,,,4,Autocuration,CHEMBL620588,,3110,,,105030,773,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor agonism in mouse,1,,,F,,,4,Autocuration,CHEMBL620589,,3111,,,105030,12918,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,1,,,B,,,4,Autocuration,CHEMBL620590,,3112,,,105030,10561,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,,B,,,4,Autocuration,CHEMBL617956,,3113,,,105030,12827,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,1,,,B,,,4,Autocuration,CHEMBL617957,,3114,,,105030,12827,,
,BAO_0000224,,H,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,1,,,B,,,4,Autocuration,CHEMBL617958,,3115,,,105030,12918,,
,BAO_0000219,,H,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,,B,,,4,Autocuration,CHEMBL617959,,3116,,,105030,273,,
,BAO_0000219,,H,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,1,,,B,,,4,Autocuration,CHEMBL617960,,3117,,,105030,273,,
,BAO_0000224,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,,,B,,,4,Autocuration,CHEMBL617961,,3118,,,105030,10561,,
,BAO_0000219,,H,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,1,,,B,,,4,Autocuration,CHEMBL617962,,3119,In vitro,,105030,5033,,
,BAO_0000219,,H,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,1,N1E-115,,B,,,4,Autocuration,CHEMBL617963,,3120,,,105030,16429,339.0,
,BAO_0000019,,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,,B,,,8,Autocuration,CHEMBL617964,,3121,,,11765,10322,,
,BAO_0000219,,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,1,,,B,,,8,Autocuration,CHEMBL617965,,3122,,,11765,14331,,
,BAO_0000357,,D,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,1,,10090.0,B,Mus musculus,,9,Autocuration,CHEMBL617966,,3123,,,10630,13462,,
,BAO_0000019,,H,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,1,,,B,,,8,Autocuration,CHEMBL857074,,3124,,,17106,12861,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617967,,3125,,,144,15086,,
,BAO_0000357,,H,,Binding activity radioligand.,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL617968,,3126,,,144,12861,,
,BAO_0000223,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,1,,9986.0,B,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617969,,3127,,,104714,10561,,
,BAO_0000223,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,1,,9986.0,B,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617970,,3128,,,104714,10561,,
,BAO_0000223,,H,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,1,,9986.0,B,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617971,,3129,,,104714,10561,,
,BAO_0000019,,H,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,,9986.0,B,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617972,,3130,,,104714,10561,,
,BAO_0000019,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617973,,3131,,,104714,273,,
,BAO_0000019,,H,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617974,,3132,,,104714,273,,
Ileum,BAO_0000221,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),1,,9986.0,F,Oryctolagus cuniculus,2116.0,4,Autocuration,CHEMBL617975,,3133,,,104714,273,,
,BAO_0000019,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617976,,3134,,,104714,273,,
,BAO_0000019,,H,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617977,,3135,,,104714,273,,
,BAO_0000019,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617978,,3136,,,104714,273,,
,BAO_0000019,,H,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),1,,9986.0,F,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617979,,3137,,,104714,273,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,1,CHO,9986.0,B,Oryctolagus cuniculus,,4,Autocuration,CHEMBL617980,,3138,,,104714,13047,449.0,
,BAO_0000019,,D,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617981,,3139,,,104698,1650,,
,BAO_0000019,,H,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),1,,,B,,,8,Autocuration,CHEMBL617982,,3140,,,12020,16288,,
,BAO_0000357,,H,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),1,,,B,,,8,Autocuration,CHEMBL617983,,3141,,,12020,16288,,
,BAO_0000019,,D,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617984,,3142,,,104698,10254,,
,BAO_0000019,,H,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",1,,,B,,,6,Autocuration,CHEMBL617985,,3143,,,104698,14532,,
Heart,BAO_0000218,,H,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,,,F,,948.0,6,Autocuration,CHEMBL617986,,3144,In vivo,,104698,13392,,
Heart,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,,,F,,948.0,6,Autocuration,CHEMBL617987,,3145,,,104698,13392,,
Heart,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",1,,,F,,948.0,6,Autocuration,CHEMBL617988,,3146,,,104698,13392,,
Heart,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",1,,,F,,948.0,6,Autocuration,CHEMBL617792,,3147,,,104698,13392,,
Heart,BAO_0000019,,H,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",1,,,F,,948.0,6,Autocuration,CHEMBL617793,,3148,,,104698,13392,,
,BAO_0000019,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",1,,,F,,,6,Autocuration,CHEMBL617794,,3149,,,104698,13392,,
,BAO_0000019,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,,F,,,6,Autocuration,CHEMBL617795,,3150,,,104698,13392,,
,BAO_0000019,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",1,,,F,,,6,Autocuration,CHEMBL617796,,3151,,,104698,13392,,
,BAO_0000019,,H,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",1,,,F,,,6,Autocuration,CHEMBL617797,,3152,,,104698,13392,,
,BAO_0000218,,D,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617798,,3153,In vivo,,104698,1089,,
,BAO_0000218,,H,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),1,,,F,,,6,Autocuration,CHEMBL617799,,3154,In vivo,,104698,1089,,
,BAO_0000218,,D,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617800,,3155,In vivo,,104698,11454,,
,BAO_0000019,,D,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617801,,3156,,,104698,11454,,
,BAO_0000218,,D,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617802,,3157,In vivo,,104698,12205,,
,BAO_0000019,,D,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617803,,3158,,,104698,1089,,
,BAO_0000019,,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,,B,,,6,Autocuration,CHEMBL617804,,3159,,,104698,5094,,
,BAO_0000019,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617805,,3160,,,104698,2622,,
,BAO_0000223,,H,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL617806,,3161,,,104698,245,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,1,,,B,,,6,Autocuration,CHEMBL617807,,3162,,,104698,14788,,
,BAO_0000019,,H,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,1,,,B,,,6,Autocuration,CHEMBL617808,,3163,,,104698,14788,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,1,,,B,,,6,Autocuration,CHEMBL617809,,3164,,,104698,3020,,
,BAO_0000019,,H,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,1,,,B,,,6,Autocuration,CHEMBL617810,,3165,,,104698,1742,,
Brain,BAO_0000249,,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,1,,,B,,955.0,6,Autocuration,CHEMBL617811,,3166,,,104698,17394,,
Brain,BAO_0000221,,H,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,1,,,B,,955.0,6,Autocuration,CHEMBL617812,,3167,,,104698,17394,,
,BAO_0000249,,H,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,B,,,6,Autocuration,CHEMBL617813,,3168,,,104698,17394,,
,BAO_0000249,,H,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,1,,,B,,,6,Autocuration,CHEMBL617814,,3169,,,104698,14286,,
,BAO_0000019,,H,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,1,,,B,,,6,Autocuration,CHEMBL617698,,3170,,,104698,14178,,
,BAO_0000019,,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617699,,3171,,,104698,14178,,
,BAO_0000019,,D,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617700,,3172,,,104698,14178,,
,BAO_0000223,,D,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617701,,3173,,,104698,14178,,
,BAO_0000019,,H,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,1,,,B,,,6,Autocuration,CHEMBL617702,,3174,,,104698,15034,,
,BAO_0000249,,H,Membranes,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",1,,,B,,,6,Autocuration,CHEMBL617703,,3175,,,104698,1089,,
,BAO_0000019,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617704,,3176,,,104698,1089,,
,BAO_0000223,,H,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,1,,,B,,,6,Autocuration,CHEMBL617705,,3177,,,104698,16532,,
,BAO_0000223,,D,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL617706,,3178,,,104698,12801,,
,BAO_0000219,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),1,NG108-15,,B,,,6,Autocuration,CHEMBL617707,,3179,,,104698,15194,433.0,
,BAO_0000219,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,1,NG108-15,,B,,,6,Autocuration,CHEMBL617708,,3180,,,104698,15194,433.0,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,1,,,B,,,6,Autocuration,CHEMBL617709,,3181,,,104698,15194,,
,BAO_0000019,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,1,,,B,,,6,Autocuration,CHEMBL617710,,3182,,,104698,15194,,
,BAO_0000019,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,1,,,B,,,6,Autocuration,CHEMBL882925,,3183,,,104698,15194,,
,BAO_0000019,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,1,,,B,,,6,Autocuration,CHEMBL617711,,3184,,,104698,15194,,
,BAO_0000019,,H,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,1,,,F,,,6,Autocuration,CHEMBL617712,,3185,,,104698,10610,,
,BAO_0000019,,D,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617713,,3186,,,104698,10355,,
,BAO_0000019,,H,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",1,,,F,,,6,Autocuration,CHEMBL617714,,3187,,,104698,691,,
,BAO_0000218,,H,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,1,,,F,,,6,Autocuration,CHEMBL617715,,3188,,,104698,10611,,
,BAO_0000218,,H,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,1,,,F,,,6,Autocuration,CHEMBL617716,,3189,In vivo,,104698,12801,,
,BAO_0000218,,H,,Inhibition of 5-HT evoked reflex bradycardia in rat.,1,,,F,,,6,Autocuration,CHEMBL617717,,3190,,,104698,10609,,
,BAO_0000218,,H,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617718,,3191,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617719,,3192,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),1,,,F,,,6,Autocuration,CHEMBL617720,,3193,In vivo,,104698,11454,,
,BAO_0000218,,D,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,1,,10116.0,F,Rattus norvegicus,,7,Autocuration,CHEMBL617721,,3194,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617722,,3195,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,1,,,F,,,6,Autocuration,CHEMBL617723,,3196,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617724,,3197,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617725,,3198,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617726,,3199,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617727,,3200,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617728,,3201,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617729,,3202,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617730,,3203,In vivo,,104698,11454,,
,BAO_0000218,,H,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617731,,3204,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617732,,3205,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617733,,3206,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617734,,3207,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,1,,,F,,,6,Autocuration,CHEMBL872874,,3208,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,1,,,F,,,6,Autocuration,CHEMBL617735,,3209,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,1,,,F,,,6,Autocuration,CHEMBL617736,,3210,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,1,,,F,,,6,Autocuration,CHEMBL617737,,3211,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,1,,,F,,,6,Autocuration,CHEMBL617738,,3212,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617739,,3213,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617740,,3214,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617741,,3215,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617742,,3216,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617743,,3217,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617744,,3218,In vivo,,104698,11454,,
,BAO_0000218,,H,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,1,,,F,,,6,Autocuration,CHEMBL617745,,3219,In vivo,,104698,11454,,
,BAO_0000218,,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",1,,,F,,,6,Autocuration,CHEMBL617746,,3220,,,104698,670,,
,BAO_0000218,,H,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",1,,,F,,,6,Autocuration,CHEMBL617747,,3221,,,104698,670,,
,BAO_0000218,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,1,,,F,,,6,Autocuration,CHEMBL617748,,3222,In vivo,,104698,10321,,
,BAO_0000218,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,1,,,F,,,6,Autocuration,CHEMBL618909,,3223,In vivo,,104698,10321,,
,BAO_0000218,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,1,,,F,,,6,Autocuration,CHEMBL618910,,3224,In vivo,,104698,10321,,
,BAO_0000218,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,1,,,F,,,6,Autocuration,CHEMBL618911,,3225,In vivo,,104698,10321,,
,BAO_0000218,,H,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,1,,,F,,,6,Autocuration,CHEMBL618912,,3226,In vivo,,104698,10321,,
,BAO_0000218,,H,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),1,,,F,,,6,Autocuration,CHEMBL618913,,3227,In vivo,,104698,10322,,
,BAO_0000019,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,,F,,,6,Autocuration,CHEMBL618914,,3228,,,104698,15412,,
,BAO_0000019,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,1,,,F,,,6,Autocuration,CHEMBL618915,,3229,,,104698,15412,,
,BAO_0000223,,D,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL618916,,3230,,,104698,15412,,
,BAO_0000019,,H,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,1,,,F,,,6,Autocuration,CHEMBL618917,,3231,,,104698,15412,,
Hippocampus,BAO_0000221,,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,1,,,B,,10000000.0,7,Intermediate,CHEMBL618918,,3232,,,104698,15412,,
,BAO_0000019,,D,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL618919,,3233,,,104698,15412,,
,BAO_0000019,,D,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL618920,,3234,,,104698,17394,,
,BAO_0000223,,H,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL618921,,3235,,,104698,12457,,
,BAO_0000019,,H,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL618922,,3236,,,104698,12457,,
,BAO_0000019,,H,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,1,,,B,,,6,Autocuration,CHEMBL618923,,3237,,,104698,12205,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,1,,,B,,,6,Autocuration,CHEMBL618924,,3238,,,104698,14532,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,1,,,B,,,6,Autocuration,CHEMBL618925,,3239,,,104698,1122,,
,BAO_0000019,,H,,Binding affinity towards 5-HT3 receptor in rat was evaluated,1,,,B,,,6,Autocuration,CHEMBL618926,,3240,,,104698,5094,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL618927,,3241,,,20033,809,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL618928,,3242,,,20033,809,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL618929,,3243,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL618930,,3244,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL618931,,3245,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619594,,3246,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619595,,3247,,,20033,14290,,
Ileum,BAO_0000221,,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619596,,3248,,,20033,13961,,
Ileum,BAO_0000221,,D,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619755,,3249,,,20033,13961,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619756,,3250,,,20033,809,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619757,,3251,,,20033,809,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619758,,3252,,,20033,809,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619759,,3253,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619760,,3254,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619761,,3255,,,20033,14290,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619762,,3256,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619763,,3257,,,20033,14290,,
Ileum,BAO_0000221,,D,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL617868,,3258,,,20033,14290,,
,BAO_0000357,,D,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL617869,,3259,,,20033,15034,,
Striatum,BAO_0000249,,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL882926,,3260,,,20033,5094,,
Striatum,BAO_0000249,,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617870,,3261,,,20033,5094,,
Striatum,BAO_0000357,,D,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617871,,3262,,,20033,5399,,
Striatum,BAO_0000357,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617872,,3263,,,20033,17394,,
Striatum,BAO_0000357,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617873,,3264,,,20033,17394,,
Striatum,BAO_0000357,,D,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL617874,,3265,,,20033,17394,,
Ileum,BAO_0000221,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619067,,3266,,,20033,13961,,
Ileum,BAO_0000221,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619068,,3267,,,20033,13961,,
Ileum,BAO_0000221,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619069,,3268,,,20033,13961,,
,BAO_0000357,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619070,,3269,,,20033,16946,,
,BAO_0000357,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619071,,3270,,,20033,16946,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL619072,,3271,,,20033,15034,,
,BAO_0000019,,D,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL619073,,3272,,,20033,15034,,
,BAO_0000019,,D,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL619074,,3273,,,20033,12918,,
,BAO_0000357,,D,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619075,,3274,,,20033,16946,,
Striatum,BAO_0000357,,D,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL619076,,3275,,,20033,17394,,
Striatum,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL619077,,3276,,,20033,15034,,
Striatum,BAO_0000249,,D,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL619078,,3277,,,20033,5094,,
Striatum,BAO_0000249,,D,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL619079,,3278,,,20033,5094,,
Ileum,BAO_0000221,,D,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,1,,10141.0,B,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619080,,3279,,,20033,17358,,
,BAO_0000357,,D,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,1,,10141.0,B,Cavia porcellus,,9,Expert,CHEMBL619081,,3280,,,20033,12953,,
,BAO_0000357,,D,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619082,,3281,,,20033,12953,,
,BAO_0000357,,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619083,,3282,,,20033,12953,,
,BAO_0000357,,D,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619084,,3283,,,20033,12953,,
Ileum,BAO_0000221,,D,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL859397,,3284,,,20033,273,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619085,,3285,,,20033,12918,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619086,,3286,,,20033,12919,,
Ileum,BAO_0000221,,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619087,,3287,,,20033,273,,
Ileum,BAO_0000221,,D,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619088,,3288,,,20033,273,,
,BAO_0000357,,D,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619089,,3289,,,20033,13181,,
,BAO_0000357,,H,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL619090,,3290,,,168,13181,,
,BAO_0000019,,D,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL619091,,3291,,,20033,15034,,
,BAO_0000357,,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619092,,3292,,,20033,5033,,
,BAO_0000019,,D,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619093,,3293,,,20033,1980,,
,BAO_0000219,,H,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,1,HEK293,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL619094,,3294,,,168,13181,722.0,
,BAO_0000019,,D,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619095,,3295,,,20033,14287,,
,BAO_0000357,,D,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL857988,,3296,,,20033,1317,,
,BAO_0000357,,D,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619096,,3297,,,20033,15316,,
Striatum,BAO_0000357,,D,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,1,,10141.0,B,Cavia porcellus,2435.0,9,Intermediate,CHEMBL619097,,3298,,,20033,16429,,
Hippocampus,BAO_0000221,,D,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,1,,10141.0,B,Cavia porcellus,10000000.0,9,Intermediate,CHEMBL619098,,3299,,,20033,14818,,
,BAO_0000357,,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619751,,3300,,,20033,15194,,
,BAO_0000357,,D,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619752,,3301,,,20033,15194,,
Ileum,BAO_0000221,,D,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL875096,,3302,,,20033,13961,,
,BAO_0000357,,H,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,1,,,B,,,8,Autocuration,CHEMBL619004,,3303,,,108,5486,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL619005,,3304,,,168,16209,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL619006,,3305,,,168,17085,,
,BAO_0000219,,H,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,1,HeLa,,B,,,8,Autocuration,CHEMBL619007,,3306,,,168,4199,308.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL619008,,3307,,,168,15146,,
,BAO_0000357,,H,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL619009,,3308,,,168,5213,,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",1,HeLa,,B,,,8,Autocuration,CHEMBL619010,,3309,,,168,4829,308.0,
,BAO_0000357,,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,1,,,B,,,8,Autocuration,CHEMBL619011,,3310,,,10622,17358,,
,BAO_0000357,,H,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,1,,,B,,,8,Autocuration,CHEMBL619012,,3311,,,10622,17358,,
,BAO_0000219,,H,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,1,,,B,,,8,Autocuration,CHEMBL619013,,3312,,,10622,16946,,
,BAO_0000357,,H,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,1,,,B,,,8,Autocuration,CHEMBL619014,,3313,,,10622,17358,,
Cardiac atrium,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,1,,,F,,2081.0,8,Autocuration,CHEMBL857503,,3314,,,11249,268,,
Cardiac atrium,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,1,,,F,,2081.0,8,Autocuration,CHEMBL619015,,3315,,,11249,268,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL619016,,3316,,,11249,15086,,
Hippocampus,BAO_0000221,,H,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,1,,,B,,10000000.0,8,Autocuration,CHEMBL619017,,3317,,,11249,14875,,
Hippocampus,BAO_0000221,,H,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,1,,9823.0,B,Sus scrofa,10000000.0,8,Autocuration,CHEMBL619018,,3318,,,168,13267,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL619019,,3319,,,168,13047,,
,BAO_0000357,,D,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619020,,3320,,,10623,1650,,
,BAO_0000019,,H,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,,F,,,8,Autocuration,CHEMBL619021,,3321,,,10623,567,,
,BAO_0000357,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,1,,,B,,,8,Autocuration,CHEMBL619022,,3322,,,10623,17358,,
,BAO_0000357,,H,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,1,,,B,,,8,Autocuration,CHEMBL619023,,3323,,,10623,188,,
,BAO_0000019,,H,,lntrinsic activity relative to 5-HT receptor,1,,,F,,,8,Autocuration,CHEMBL619024,,3324,,,10623,670,,
,BAO_0000019,,H,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,1,,,F,,,8,Autocuration,CHEMBL619025,,3325,,,10623,204,,
,BAO_0000019,,H,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,1,,,F,,,8,Expert,CHEMBL619026,,3326,,,10623,1946,,
,BAO_0000019,,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,1,,,F,,,8,Autocuration,CHEMBL619027,,3327,,,10623,6398,,
,BAO_0000019,,H,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,1,,,F,,,8,Autocuration,CHEMBL619028,,3328,,,10623,6398,,
,BAO_0000019,,H,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,1,,,F,,,8,Autocuration,CHEMBL619029,,3329,,,10623,17358,,
,BAO_0000019,,H,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,1,,,F,,,8,Autocuration,CHEMBL619030,,3330,,,10623,6398,,
,BAO_0000357,,H,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,1,,,B,,,8,Expert,CHEMBL619031,,3331,,,10623,11752,,
,BAO_0000019,,H,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,1,,,F,,,8,Autocuration,CHEMBL619032,,3332,,,10623,809,,
,BAO_0000357,,D,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619033,,3333,,,10623,14178,,
,BAO_0000357,,H,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,1,,,B,,,8,Autocuration,CHEMBL619034,,3334,,,10623,567,,
,BAO_0000357,,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,1,,,B,,,8,Autocuration,CHEMBL619035,,3335,,,10623,1946,,
,BAO_0000357,,H,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,1,,,B,,,8,Autocuration,CHEMBL619036,,3336,,,10623,1946,,
,BAO_0000019,,D,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619037,,3337,,,10623,13961,,
Striatum,BAO_0000249,,H,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,1,,,B,,2435.0,8,Autocuration,CHEMBL619038,,3338,,,10623,6238,,
,BAO_0000249,,H,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,1,,,B,,,8,Autocuration,CHEMBL619039,,3339,,,10623,14290,,
,BAO_0000249,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,1,,,B,,,8,Expert,CHEMBL619040,,3340,,,10623,14290,,
Striatum,BAO_0000019,,D,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,,10116.0,B,Rattus norvegicus,2435.0,9,Expert,CHEMBL619041,,3341,,,10623,809,,
Striatum,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,1,,,B,,2435.0,8,Autocuration,CHEMBL619042,,3342,,,10623,1578,,
Striatum,BAO_0000249,,H,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,1,,,B,,2435.0,8,Expert,CHEMBL619043,,3343,,,10623,16709,,
Striatum,BAO_0000019,,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,1,,,B,,2435.0,8,Expert,CHEMBL619044,,3344,,,10623,1946,,
Striatum,BAO_0000249,,H,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,1,,,B,,2435.0,8,Expert,CHEMBL619045,,3345,,,10623,15253,,
Striatum,BAO_0000249,,H,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,,,B,,2435.0,8,Expert,CHEMBL619046,,3346,,,10623,4535,,
,BAO_0000249,,H,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,1,,,B,,,8,Expert,CHEMBL619047,,3347,,,10623,13961,,
Brain,BAO_0000221,,H,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,1,,,F,,955.0,8,Autocuration,CHEMBL619048,,3348,,,10623,17358,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,1,,,F,,,8,Autocuration,CHEMBL859398,,3349,,,10623,15847,,
,BAO_0000019,,H,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,1,,,F,,,8,Autocuration,CHEMBL619049,,3350,,,10623,15847,,
,BAO_0000019,,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,1,,,F,,,8,Autocuration,CHEMBL857886,,3351,,,10623,670,,
,BAO_0000019,,H,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,1,,,F,,,8,Autocuration,CHEMBL619050,,3352,,,10623,670,,
,BAO_0000019,,H,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,1,,,F,,,8,Autocuration,CHEMBL620591,,3353,,,10623,1317,,
,BAO_0000357,,D,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620592,,3354,,,10623,12936,,
Striatum,BAO_0000249,,H,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,1,,,B,,2435.0,8,Expert,CHEMBL620593,,3355,,,10623,4535,,
,BAO_0000019,,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL620594,,3356,,,10623,14424,,
,BAO_0000019,,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,1,,,F,,,8,Expert,CHEMBL875079,,3357,,,10623,14424,,
,BAO_0000019,,H,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,,F,,,8,Expert,CHEMBL620595,,3358,,,10623,14424,,
,BAO_0000019,,D,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL620596,,3359,,,10623,14424,,
,BAO_0000019,,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,1,,,F,,,8,Autocuration,CHEMBL620597,,3360,,,10623,14424,,
,BAO_0000019,,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,1,,,F,,,8,Expert,CHEMBL620598,,3361,,,10623,14424,,
,BAO_0000218,,H,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),1,,,F,,,8,Expert,CHEMBL620599,,3362,,,10623,14424,,
,BAO_0000019,,H,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,1,,,F,,,8,Autocuration,CHEMBL620600,,3363,,,10623,14424,,
,BAO_0000019,,H,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,1,,10116.0,F,Rattus norvegicus,,8,Autocuration,CHEMBL620601,,3364,,,168,1980,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,1,,,F,,,8,Autocuration,CHEMBL620602,,3365,,,168,4639,,
,BAO_0000357,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL620603,,3366,,,168,17358,,
,BAO_0000357,,H,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,1,,,B,,,8,Autocuration,CHEMBL620604,,3367,,,168,17358,,
,BAO_0000357,,H,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,1,,,B,,,8,Autocuration,CHEMBL620605,,3368,,,168,17358,,
,BAO_0000357,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL620606,,3369,,,168,1558,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,F,,,8,Autocuration,CHEMBL620607,,3370,,,168,17358,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-HT4 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620608,,3371,,,168,16117,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,F,,,8,Autocuration,CHEMBL620609,,3372,,,168,17358,,
,BAO_0000019,,H,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,1,,,F,,,8,Autocuration,CHEMBL620610,,3373,,,168,17358,,
,BAO_0000357,,H,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL620611,,3374,,,168,17358,,
,BAO_0000357,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,1,,,B,,,8,Autocuration,CHEMBL620612,,3375,,,168,17358,,
,BAO_0000357,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,1,,,B,,,8,Autocuration,CHEMBL620613,,3376,,,168,17358,,
,BAO_0000357,,H,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,1,,,B,,,8,Autocuration,CHEMBL620614,,3377,,,168,17358,,
,BAO_0000357,,H,,Binding affinity against 5-Hydroxytryptamine 4 receptor,1,,,B,,,8,Expert,CHEMBL620615,,3378,,,168,1274,,
,BAO_0000249,,H,Brain membranes,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,1,,,B,,,6,Autocuration,CHEMBL857075,,3379,,,104698,10728,,
,BAO_0000249,,H,Brain membranes,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,1,,,B,,,6,Autocuration,CHEMBL620616,,3380,,,104698,11695,,
,BAO_0000249,,H,Brain membranes,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,1,,,B,,,6,Autocuration,CHEMBL619411,,3381,,,104698,11695,,
,BAO_0000019,,H,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,1,,,B,,,6,Autocuration,CHEMBL619412,,3382,,,104698,12490,,
,BAO_0000019,,D,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619413,,3383,,,104698,11828,,
Hippocampus,BAO_0000221,,H,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,1,,,B,,10000000.0,6,Autocuration,CHEMBL619414,,3384,,,104698,12253,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,1,,,B,,,6,Autocuration,CHEMBL619415,,3385,,,104698,10561,,
,BAO_0000019,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,1,,,B,,,6,Autocuration,CHEMBL619416,,3386,,,104698,10561,,
,BAO_0000019,,H,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,1,,,F,,,6,Autocuration,CHEMBL619417,,3387,,,104698,14432,,
,BAO_0000223,,D,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619418,,3388,,,104698,12936,,
,BAO_0000223,,D,,Binding affinity against 5-Hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619419,,3389,,,104698,1274,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,1,,,B,,,6,Autocuration,CHEMBL619420,,3390,,,104698,1980,,
,BAO_0000249,,H,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,1,,,B,,,6,Autocuration,CHEMBL619421,,3391,,,104698,670,,
,BAO_0000019,,D,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619422,,3392,,,104698,968,,
,BAO_0000019,,H,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,1,,,B,,,6,Autocuration,CHEMBL619423,,3393,,,104698,14287,,
,BAO_0000019,,H,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,1,,,B,,,6,Autocuration,CHEMBL875080,,3394,,,104698,567,,
,BAO_0000019,,H,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,1,,,B,,,6,Autocuration,CHEMBL619424,,3395,,,104698,13267,,
,BAO_0000249,,H,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,1,,,B,,,6,Autocuration,CHEMBL619425,,3396,,,104698,14826,,
,BAO_0000223,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,1,,,B,,,6,Autocuration,CHEMBL619426,,3397,,,104698,15194,,
,BAO_0000223,,H,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,1,,,B,,,6,Autocuration,CHEMBL619427,,3398,,,104698,15194,,
,BAO_0000223,,D,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,1,,10116.0,B,Rattus norvegicus,,7,Autocuration,CHEMBL619645,,3399,,,104698,10394,,
,BAO_0000249,,D,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",1,,,B,,,9,Expert,CHEMBL619646,,3400,,,10576,13657,,
Brain,BAO_0000221,,H,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,1,,,F,,955.0,8,Autocuration,CHEMBL619647,,3401,,,12020,1879,,
,BAO_0000019,,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,1,,,F,,,8,Autocuration,CHEMBL619648,,3402,,,12020,1879,,
,BAO_0000019,,H,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,1,,,F,,,8,Autocuration,CHEMBL619165,,3403,,,12020,1879,,
,BAO_0000218,,H,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,1,,,F,,,8,Autocuration,CHEMBL620719,,3404,In vivo,,12020,204,,
,BAO_0000019,,H,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL872924,,3405,,,12020,1879,,
,BAO_0000357,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL620720,,3406,,,12020,1879,,
,BAO_0000019,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL620721,,3407,,,12020,1879,,
,BAO_0000019,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL620722,,3408,,,12020,1879,,
,BAO_0000019,,H,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",1,,,B,,,6,Autocuration,CHEMBL620723,,3409,,,104698,10641,,
,BAO_0000019,,H,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,1,,,B,,,8,Autocuration,CHEMBL620724,,3410,,,12020,773,,
,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,1,,,B,,,6,Autocuration,CHEMBL620725,,3411,,,104698,11952,,
,BAO_0000019,,D,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,1,,10116.0,F,Rattus norvegicus,,9,Autocuration,CHEMBL620726,,3412,,,12020,14145,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Expert,CHEMBL620727,,3413,,,144,17066,,
,BAO_0000223,,H,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,1,,,B,,,4,Autocuration,CHEMBL620728,,3414,,,104714,6398,,
,BAO_0000019,,U,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,,B,,,0,Autocuration,CHEMBL620729,,3415,,,22226,10321,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,1,,,F,,,4,Autocuration,CHEMBL858288,,3416,,,104714,511,,
,BAO_0000223,,H,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL620730,,3417,,,104714,4639,,
,BAO_0000223,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL620731,,3418,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL620732,,3419,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618042,,3420,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618043,,3421,,,104714,4639,,
,BAO_0000223,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL618044,,3422,,,104714,1558,,
,BAO_0000019,,H,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,1,,,F,,,4,Autocuration,CHEMBL618045,,3423,,,104714,268,,
,BAO_0000223,,H,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,1,,,B,,,4,Autocuration,CHEMBL618046,,3424,,,104714,2474,,
,BAO_0000019,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,1,,,F,,,4,Autocuration,CHEMBL618047,,3425,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,1,,,F,,,4,Autocuration,CHEMBL875084,,3426,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,1,,,F,,,4,Autocuration,CHEMBL618048,,3427,,,104714,5067,,
,BAO_0000223,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,1,,,B,,,4,Autocuration,CHEMBL618049,,3428,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,1,,,F,,,4,Autocuration,CHEMBL619764,,3429,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,1,,,F,,,4,Autocuration,CHEMBL619765,,3430,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,1,,,F,,,4,Autocuration,CHEMBL619766,,3431,,,104714,5067,,
,BAO_0000223,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,1,,,B,,,4,Autocuration,CHEMBL619767,,3432,,,104714,5067,,
,BAO_0000223,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,1,,,B,,,4,Autocuration,CHEMBL619768,,3433,,,104714,5067,,
,BAO_0000019,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,1,,,F,,,4,Autocuration,CHEMBL619769,,3434,,,104714,5067,,
,BAO_0000223,,H,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,1,,,B,,,4,Autocuration,CHEMBL619770,,3435,,,104714,5067,,
,BAO_0000223,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL619771,,3436,,,104714,5067,,
,BAO_0000219,,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,1,,,B,,,4,Autocuration,CHEMBL619772,,3437,,,104714,14331,,
,BAO_0000223,,H,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,1,,,B,,,4,Autocuration,CHEMBL619773,,3438,,,104714,5067,,
,BAO_0000219,,H,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,1,NG108-15,,B,,,4,Autocuration,CHEMBL619774,,3439,,,104714,6179,433.0,
,BAO_0000019,,H,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,1,,,B,,,4,Autocuration,CHEMBL875083,,3440,,,104714,4265,,
,BAO_0000219,,H,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,1,NG108-15,,B,,,4,Autocuration,CHEMBL620718,,3441,,,104714,4265,433.0,
,BAO_0000223,,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,,B,,,4,Autocuration,CHEMBL618127,,3442,,,104714,17358,,
,BAO_0000223,,H,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,1,,,B,,,4,Autocuration,CHEMBL618128,,3443,,,104714,17358,,
,BAO_0000219,,H,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,1,,,B,,,4,Autocuration,CHEMBL618129,,3444,In vitro,,104714,13628,,
,BAO_0000223,,H,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,,B,,,4,Autocuration,CHEMBL618130,,3445,,,104714,4612,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,1,,,F,,,4,Autocuration,CHEMBL618131,,3446,,,104714,17358,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618132,,3447,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618133,,3448,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618134,,3449,,,104714,4639,,
,BAO_0000019,,H,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618135,,3450,,,104714,4639,,
,BAO_0000223,,H,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,1,,,B,,,4,Autocuration,CHEMBL618136,,3451,,,104714,511,,
,BAO_0000223,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL618137,,3452,,,104714,1479,,
,BAO_0000223,,H,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,1,,,B,,,4,Autocuration,CHEMBL618138,,3453,,,104714,1317,,
,BAO_0000223,,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,1,,,B,,,4,Autocuration,CHEMBL618139,,3454,,,104714,12146,,
,BAO_0000223,,H,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,1,,,B,,,4,Autocuration,CHEMBL618140,,3455,,,104714,12146,,
,BAO_0000223,,H,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,1,,,B,,,4,Autocuration,CHEMBL618141,,3456,,,104714,13969,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 2C receptor,1,,,B,,,8,Expert,CHEMBL873478,,3457,,,108,13392,,
,BAO_0000223,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,6,Autocuration,CHEMBL618142,,3458,,,104698,13392,,
,BAO_0000357,,H,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL618143,,3459,,,144,14159,,
,BAO_0000357,,H,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL618144,,3460,,,144,1558,,
,BAO_0000357,,H,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL618145,,3461,,,144,16655,,
,BAO_0000223,,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,,B,,,4,Autocuration,CHEMBL618146,,3462,,,104714,13020,,
,BAO_0000223,,H,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,1,,,B,,,4,Autocuration,CHEMBL618147,,3463,,,104714,13021,,
,BAO_0000223,,H,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,1,,,B,,,4,Autocuration,CHEMBL618148,,3464,,,104714,13020,,
,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,1,,,B,,,8,Autocuration,CHEMBL618149,,3465,,,144,10321,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL872927,,3466,,,144,15818,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL618150,,3467,,,144,15818,,
,BAO_0000357,,H,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,1,,,B,,,8,Autocuration,CHEMBL618151,,3468,,,144,17358,,
,BAO_0000357,,H,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,1,,,B,,,8,Autocuration,CHEMBL875094,,3469,,,144,2222,,
,BAO_0000019,,H,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,1,,,B,,,8,Autocuration,CHEMBL618152,,3470,,,144,10322,,
,BAO_0000357,,H,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL618153,,3471,,,144,16117,,
,BAO_0000357,,H,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,1,,,B,,,8,Autocuration,CHEMBL618888,,3472,,,144,17200,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,1,,,F,,,8,Autocuration,CHEMBL618889,,3473,,,144,17358,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL618890,,3474,,,144,16700,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,1,,,B,,,8,Autocuration,CHEMBL618891,,3475,,,144,1980,,
,BAO_0000019,,H,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,1,,,B,,,8,Autocuration,CHEMBL619054,,3476,,,144,1980,,
,BAO_0000223,,H,,Binding affinity against the 5-hydroxytryptamine 3 receptor,1,,,B,,,4,Autocuration,CHEMBL619055,,3477,,,104714,12409,,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,,B,,,8,Autocuration,CHEMBL619056,,3478,,,144,4365,,
,BAO_0000019,,H,,Percent efficacy against 5-hydroxytryptamine 3A receptor,1,,,F,,,8,Autocuration,CHEMBL619057,,3479,,,144,4365,,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 3A receptor,1,,,B,,,8,Autocuration,CHEMBL619058,,3480,,,144,4365,,
,BAO_0000219,,D,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,1,Oocytes,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL619059,,3481,,,12020,6769,,
,BAO_0000219,,D,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,1,Oocytes,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL619060,,3482,,,12020,6769,,
,BAO_0000219,,D,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,1,Oocytes,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL875095,,3483,,,12020,6769,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619061,,3484,,,20033,809,,
Ileum,BAO_0000221,,D,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619062,,3485,,,20033,809,,
,BAO_0000019,,D,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,1,,10141.0,F,Cavia porcellus,,9,Intermediate,CHEMBL619063,,3486,,,20033,14290,,
Ileum,BAO_0000221,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,1,,10141.0,B,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619064,,3487,,,20033,17358,,
,BAO_0000357,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL619065,,3488,,,20033,17358,,
Ileum,BAO_0000221,,D,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,1,,10141.0,B,Cavia porcellus,2116.0,9,Intermediate,CHEMBL619066,,3489,,,20033,17358,,
Ileum,BAO_0000221,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,,,B,,2116.0,8,Autocuration,CHEMBL619775,,3490,,,10209,17386,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL619776,,3491,,,10209,3269,,
,BAO_0000224,,H,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL619777,,3492,,,104841,7721,,
,BAO_0000224,,H,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL619778,,3493,,,104841,7721,,
Ileum,BAO_0000221,,H,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,1,,10141.0,B,Cavia porcellus,2116.0,4,Autocuration,CHEMBL619779,,3494,,,104841,9117,,
,BAO_0000224,,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL619780,,3495,,,104841,7721,,
,BAO_0000224,,H,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",1,,10141.0,B,Cavia porcellus,,4,Autocuration,CHEMBL619166,,3496,,,104841,7721,,
,BAO_0000019,,H,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL619167,,3497,,,104841,15796,,
,BAO_0000019,,H,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL619168,,3498,,,104841,15796,,
Cardiac atrium,BAO_0000219,,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,1,,9606.0,B,Homo sapiens,2081.0,9,Expert,CHEMBL619169,,3499,,,168,15650,,
Cardiac atrium,BAO_0000219,,D,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,1,,9606.0,B,Homo sapiens,2081.0,9,Expert,CHEMBL619170,,3500,,,168,15650,,
,BAO_0000019,,D,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",1,,9606.0,F,Homo sapiens,,5,Autocuration,CHEMBL619171,,3501,,,104841,6866,,
Cardiac atrium,BAO_0000219,,D,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",1,,9606.0,F,Homo sapiens,2081.0,9,Expert,CHEMBL619172,,3502,,,168,15650,,
,BAO_0000019,,U,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,1,,10090.0,B,Mus musculus,,0,Autocuration,CHEMBL619173,,3503,,,22226,10063,,
,BAO_0000019,,U,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,1,,10090.0,B,Mus musculus,,0,Autocuration,CHEMBL619174,,3504,,,22226,12665,,
,BAO_0000019,,H,,5-hydroxytryptamine receptor binding affinity was determined in rats,1,,,B,,,4,Autocuration,CHEMBL619175,,3505,,,104705,7504,,
,BAO_0000224,,H,,Binding affinity at rat 5-hydroxytryptamine receptor.,1,,,B,,,4,Autocuration,CHEMBL619176,,3506,,,104705,7504,,
,BAO_0000019,,H,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,1,,,B,,,4,Autocuration,CHEMBL619177,,3507,,,104705,7038,,
,BAO_0000224,,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,1,,,B,,,4,Autocuration,CHEMBL619178,,3508,,,104705,7626,,
,BAO_0000224,,H,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,1,,,B,,,4,Autocuration,CHEMBL619179,,3509,,,104705,7626,,
Stomach,BAO_0000019,,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,1,,,F,,945.0,4,Autocuration,CHEMBL619180,,3510,,,104705,7185,,
Stomach,BAO_0000019,,H,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,1,,,F,,945.0,4,Autocuration,CHEMBL619181,,3511,,,104705,7185,,
,BAO_0000019,,H,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,1,,,F,,,4,Autocuration,CHEMBL619182,,3512,,,104705,7185,,
,BAO_0000224,,H,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,1,,,B,,,4,Autocuration,CHEMBL619183,,3513,,,104705,6960,,
,BAO_0000224,,H,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",1,,,B,,,4,Autocuration,CHEMBL619184,,3514,,,104705,6960,,
Hippocampus,BAO_0000221,,H,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,1,,,B,,10000000.0,8,Autocuration,CHEMBL619185,,3515,,,10576,12416,,
,BAO_0000357,,H,,Binding affinity for rat 5-hydroxytryptamine transporter.,1,,,B,,,8,Expert,CHEMBL619186,,3516,,,12198,15753,,
,BAO_0000019,,H,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,1,,,B,,,4,Autocuration,CHEMBL619187,,3517,,,104705,8062,,
,BAO_0000019,,D,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619188,,3518,,,104705,9036,,
,BAO_0000224,,D,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619189,,3519,,,104705,15067,,
Brain,BAO_0000019,,D,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,1,,10116.0,F,Rattus norvegicus,955.0,9,Expert,CHEMBL619190,,3520,,,12198,15753,,
Cerebellum,BAO_0000221,,D,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,1,,10116.0,F,Rattus norvegicus,2037.0,9,Expert,CHEMBL619191,,3521,,,12198,15753,,
,BAO_0000019,,D,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619192,,3522,,,104705,15295,,
,BAO_0000224,,D,,Percent binding affinity against 5-hydroxytryptamine receptor,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619193,,3523,,,104705,6347,,
,BAO_0000019,,U,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,1,,,B,,,0,Autocuration,CHEMBL619194,,3524,,,22226,6763,,
,BAO_0000224,,D,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619195,,3525,,,104705,12092,,
,BAO_0000224,,D,,Affinity against 5-hydroxytryptamine receptor was determined,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL619196,,3526,,,104705,1579,,
Stomach,BAO_0000019,,D,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,1,,10116.0,B,Rattus norvegicus,945.0,5,Autocuration,CHEMBL619197,,3527,,,104705,1579,,
,BAO_0000219,,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619198,,3528,In vitro,,121,5963,,
,BAO_0000219,,D,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL875081,,3529,In vitro,,121,5963,,
,BAO_0000357,,H,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,1,,,B,,,8,Autocuration,CHEMBL884712,,3530,,,18065,5030,,
,BAO_0000357,,H,,Inhibition of 5-hydroxytryptamine reuptake,1,,,B,,,8,Expert,CHEMBL884710,,3531,,,121,15796,,
,BAO_0000019,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",1,,,F,,,8,Autocuration,CHEMBL619199,,3532,,,18065,15413,,
,BAO_0000019,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",1,,,F,,,8,Autocuration,CHEMBL619200,,3533,,,18065,15413,,
,BAO_0000019,,H,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",1,,,F,,,8,Autocuration,CHEMBL619201,,3534,,,18065,15413,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine receptor uptake,1,,,F,,,8,Autocuration,CHEMBL619202,,3535,,,18065,12409,,
,BAO_0000219,,D,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,1,CHO,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619203,,3536,,,51,16909,449.0,
,BAO_0000019,,D,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL619204,,3537,,,51,16909,,
,BAO_0000249,,H,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,1,,9606.0,B,Homo sapiens,,8,Autocuration,CHEMBL619205,,3538,,,10576,15629,,
,BAO_0000357,,H,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,1,,,B,,,8,Autocuration,CHEMBL619206,,3539,,,10576,15629,,
,BAO_0000249,,H,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,1,,,B,,,8,Expert,CHEMBL619207,,3540,,,10576,15629,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL619208,,3541,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL619209,,3542,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL619210,,3543,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL619211,,3544,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL619212,,3545,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620681,,3546,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620682,,3547,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620683,,3548,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620684,,3549,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620685,,3550,,,10825,10034,,
Striatum,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,1,,,F,,2435.0,8,Autocuration,CHEMBL620686,,3551,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620687,,3552,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620688,,3553,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620689,,3554,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620690,,3555,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620691,,3556,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620692,,3557,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL620693,,3558,,,10825,10034,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Expert,CHEMBL620694,,3559,,,168,1274,,
,BAO_0000019,,H,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,1,,,F,,,8,Autocuration,CHEMBL857986,,3560,,,168,17358,,
,BAO_0000357,,H,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,1,,,B,,,8,Autocuration,CHEMBL620695,,3561,,,168,14532,,
,BAO_0000357,,H,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Expert,CHEMBL620696,,3562,,,168,16989,,
,BAO_0000357,,H,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,1,,,B,,,8,Autocuration,CHEMBL620697,,3563,,,168,17200,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor,1,,,B,,,8,Autocuration,CHEMBL620698,,3564,,,168,15779,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,,B,,,8,Autocuration,CHEMBL620699,,3565,,,168,15779,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,1,,,B,,,8,Autocuration,CHEMBL620700,,3566,,,168,15779,,
,BAO_0000219,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,1,COS-7,,B,,,8,Autocuration,CHEMBL620701,,3567,,,168,15650,643.0,
,BAO_0000219,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,1,COS-7,,B,,,8,Autocuration,CHEMBL875082,,3568,,,168,15650,643.0,
,BAO_0000219,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,1,COS-7,,B,,,8,Autocuration,CHEMBL620702,,3569,,,168,15650,643.0,
,BAO_0000219,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,1,COS-7,,B,,,8,Autocuration,CHEMBL620703,,3570,,,168,15650,643.0,
,BAO_0000219,,H,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,C6,,B,,,8,Autocuration,CHEMBL620704,,3571,,,168,17046,673.0,
,BAO_0000219,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,1,C6,,B,,,8,Expert,CHEMBL620705,,3572,,,168,17046,673.0,
,BAO_0000219,,H,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,1,C6,,B,,,8,Expert,CHEMBL620706,,3573,,,168,15650,673.0,
,BAO_0000219,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,1,C6,,B,,,8,Expert,CHEMBL620707,,3574,,,168,17046,673.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 5 receptor,1,,,B,,,8,Expert,CHEMBL620708,,3575,,,10624,17066,,
,BAO_0000357,,H,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,1,,,B,,,8,Autocuration,CHEMBL620709,,3576,,,105,17200,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 5A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620710,,3577,,,10624,16146,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL620711,,3578,,,10624,15250,449.0,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620712,,3579,,,10624,6491,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620713,,3580,,,10624,17066,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620714,,3581,,,10624,17066,,
,BAO_0000357,,D,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620715,,3582,,,10624,4234,,
,BAO_0000357,,H,,Binding affinity towards 5-HT5A receptor,1,,,B,,,8,Autocuration,CHEMBL620716,,3583,,,10624,6013,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,,B,,,8,Expert,CHEMBL620717,,3584,,,10624,17175,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,1,,,B,,,8,Autocuration,CHEMBL618072,,3585,,,10624,15818,,
,BAO_0000357,,H,,Binding affinity towards cloned human 5-HT5A receptor was determined,1,,,B,,,8,Autocuration,CHEMBL857987,,3586,,,10624,6166,,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL618073,,3587,,,10624,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,HEK293,,B,,,8,Autocuration,CHEMBL618074,,3588,,,10624,15779,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),1,HEK293,,B,,,8,Autocuration,CHEMBL618075,,3589,,,10624,5213,722.0,
,BAO_0000357,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL618076,,3590,,,10625,17066,,
,BAO_0000357,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL618077,,3591,,,10625,17066,,
,BAO_0000357,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL618078,,3592,,,10625,17066,,
,BAO_0000357,,D,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL881821,,3593,,,10625,17066,,
,BAO_0000357,,D,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL618079,,3594,,,10625,17066,,
,BAO_0000357,,H,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,1,,,B,,,8,Expert,CHEMBL618080,,3595,,,10625,17175,,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL618081,,3596,,,10576,16190,722.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,1,HEK293,,B,,,8,Autocuration,CHEMBL618082,,3597,,,10626,16190,722.0,
,BAO_0000357,,H,,Binding affinity towards 5-HT5a receptor,1,,,B,,,8,Expert,CHEMBL618083,,3598,,,10624,4820,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 5A receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618084,,3599,,,10624,17066,,
,BAO_0000357,,H,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,1,,,B,,,8,Expert,CHEMBL618085,,3600,,,10624,17066,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,1,,,B,,,8,Expert,CHEMBL618086,,3601,,,10624,17175,,
,BAO_0000357,,H,,Binding affinities against 5-hydroxytryptamine 5A receptor,1,,,B,,,8,Autocuration,CHEMBL875092,,3602,,,10624,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 5A receptor,1,,,B,,,8,Autocuration,CHEMBL618087,,3603,,,10624,16633,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL872926,,3604,,,10624,16700,,
,BAO_0000019,,H,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,1,,10141.0,F,Cavia porcellus,,4,Autocuration,CHEMBL618088,,3605,,,104714,4639,,
,BAO_0000223,,H,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,1,,,B,,,4,Autocuration,CHEMBL618089,,3606,,,104714,5486,,
,BAO_0000357,,D,,Inhibition of human 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618090,,3607,,,10627,16146,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618091,,3608,,,10627,17273,,
,BAO_0000357,,H,,Inhibition against human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL618092,,3609,,,10627,17687,,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618093,,3610,,,10627,6491,,
,BAO_0000219,,H,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,1,HeLa,,B,,,8,Expert,CHEMBL618094,,3611,,,10627,16190,308.0,
,BAO_0000357,,D,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618095,,3612,,,10627,17066,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL875093,,3613,,,10627,17066,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618096,,3614,,,10627,17066,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618118,,3615,,,10627,17066,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618119,,3616,,,10627,3555,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Expert,CHEMBL618120,,3617,,,10627,5808,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL618121,,3618,,,10627,6013,,
,BAO_0000219,,H,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",1,HEK293,,B,,,8,Expert,CHEMBL618122,,3619,,,10627,15818,722.0,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,1,,,B,,,8,Autocuration,CHEMBL618123,,3620,,,10627,16209,,
,BAO_0000219,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,1,HEK293,,B,,,8,Expert,CHEMBL618124,,3621,,,10627,3935,722.0,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL618125,,3622,,,10627,15818,,
,BAO_0000219,,D,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618126,,3623,,,10627,3805,722.0,
,BAO_0000019,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,1,,,B,,,8,Expert,CHEMBL618236,,3624,,,10627,16441,,
,BAO_0000019,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,,B,,,8,Expert,CHEMBL618237,,3625,,,10627,16441,,
,BAO_0000219,,H,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,1,COS-7,,B,,,8,Expert,CHEMBL618238,,3626,,,10627,6786,643.0,
,BAO_0000357,,D,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618239,,3627,,,10627,4234,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL618240,,3628,,,10627,17085,,
,BAO_0000357,,H,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,1,,,B,,,8,Autocuration,CHEMBL618241,,3629,,,10627,17200,,
,BAO_0000219,,H,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,1,HEK293,,B,,,8,Autocuration,CHEMBL859399,,3630,,,10627,17451,722.0,
,BAO_0000019,,H,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,1,,,F,,,8,Autocuration,CHEMBL618242,,3631,,,10627,3935,,
,BAO_0000357,,H,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL857991,,3632,,,10627,5033,,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Expert,CHEMBL619951,,3633,,,10627,4540,,
,BAO_0000219,,D,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619952,,3634,,,10627,4540,308.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,1,HeLa,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619953,,3635,,,10627,4540,308.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,1,HeLa,,B,,,8,Autocuration,CHEMBL619954,,3636,,,10627,17296,308.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,HeLa,,B,,,8,Autocuration,CHEMBL619955,,3637,,,10627,17296,308.0,
,BAO_0000219,,H,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,1,HeLa,,B,,,8,Autocuration,CHEMBL619956,,3638,,,10627,17296,308.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL619957,,3639,,,10627,15779,449.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL619958,,3640,,,10627,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,1,HEK293,,B,,,8,Autocuration,CHEMBL620627,,3641,,,10627,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,1,HEK293,,B,,,8,Autocuration,CHEMBL620628,,3642,,,10627,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,1,HeLa,,B,,,8,Autocuration,CHEMBL620629,,3643,,,10627,15779,308.0,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620630,,3644,,,10627,6166,,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,1,HeLa,,B,,,8,Autocuration,CHEMBL620782,,3645,,,10627,17451,308.0,
,BAO_0000357,,H,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620783,,3646,,,10627,15316,,
,BAO_0000357,,H,,Binding affinity against human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Expert,CHEMBL620784,,3647,,,10627,4199,,
,BAO_0000219,,H,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,1,HeLa,,B,,,8,Expert,CHEMBL620785,,3648,,,10627,15146,308.0,
,BAO_0000357,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),1,,,B,,,8,Autocuration,CHEMBL857992,,3649,,,10627,5213,,
,BAO_0000219,,H,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,1,,,B,,,8,Autocuration,CHEMBL620786,,3650,,,10627,16429,,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,1,HeLa,,B,,,8,Autocuration,CHEMBL620787,,3651,,,10627,14818,308.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",1,HeLa,,B,,,8,Autocuration,CHEMBL620788,,3652,,,10627,4829,308.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",1,HeLa,,B,,,8,Autocuration,CHEMBL620789,,3653,,,10627,4829,308.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",1,HeLa,,B,,,8,Autocuration,CHEMBL620790,,3654,,,10627,4829,308.0,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL620791,,3655,,,10628,15250,449.0,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL620792,,3656,,,10628,14423,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620793,,3657,,,10628,15086,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620794,,3658,,,10628,4342,,
,BAO_0000219,,D,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,1,HeLa,9606.0,B,Homo sapiens,,9,Autocuration,CHEMBL620795,,3659,,,10627,16190,308.0,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Expert,CHEMBL620796,,3660,,,10627,4820,,
,BAO_0000357,,H,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,1,,,B,,,8,Autocuration,CHEMBL620797,,3661,,,10627,4639,,
,BAO_0000019,,D,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL620798,,3662,,,10627,17066,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL620799,,3663,,,10627,6011,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Expert,CHEMBL620800,,3664,,,10627,17066,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL620801,,3665,,,10627,17515,,
,BAO_0000357,,H,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL875100,,3666,,,10627,5014,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620802,,3667,,,10627,4373,,
,BAO_0000019,,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,1,,,F,,,8,Expert,CHEMBL620803,,3668,,,10627,17066,,
,BAO_0000019,,H,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,1,,,F,,,8,Expert,CHEMBL620804,,3669,,,10627,17066,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620805,,3670,,,10627,4373,,
,BAO_0000357,,H,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620806,,3671,,,10627,4687,,
,BAO_0000357,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,1,,,B,,,8,Autocuration,CHEMBL620807,,3672,,,10627,16946,,
,BAO_0000357,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,1,,,B,,,8,Autocuration,CHEMBL620808,,3673,,,10627,16946,,
,BAO_0000357,,H,,Binding affinities against 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620809,,3674,,,10627,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620810,,3675,,,10627,16633,,
,BAO_0000357,,D,,Binding affinity towards 5-hydroxytryptamine 6 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620811,,3676,,,10627,17066,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL620812,,3677,,,10627,16700,,
,BAO_0000357,,H,,Affinity against 5-hydroxytryptamine 6 receptor,1,,,B,,,8,Autocuration,CHEMBL620813,,3678,,,10627,3269,,
,BAO_0000357,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],1,,,B,,,8,Autocuration,CHEMBL620814,,3679,,,10627,5486,,
,BAO_0000357,,D,,Inhibition of human 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620815,,3680,,,10209,16146,,
,BAO_0000219,,H,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,1,HEK293,,B,,,8,Autocuration,CHEMBL620816,,3681,,,10209,5014,722.0,
,BAO_0000357,,H,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL620817,,3682,,,10209,15463,,
,BAO_0000357,,H,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),1,,,B,,,8,Autocuration,CHEMBL620818,,3683,,,10209,3805,,
,BAO_0000219,,H,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,1,HEK293,,B,,,8,Expert,CHEMBL620819,,3684,,,10209,5014,722.0,
,BAO_0000357,,D,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620820,,3685,,,10209,6491,,
,BAO_0000219,,H,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL620821,,3686,,,10209,16190,449.0,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620822,,3687,,,10209,17066,,
,BAO_0000357,,D,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620823,,3688,,,10209,17066,,
,BAO_0000357,,D,,Binding affinity against 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620824,,3689,,,10209,3555,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,1,CHO,,B,,,8,Expert,CHEMBL620825,,3690,,,10209,6588,449.0,
,BAO_0000357,,H,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,1,,,B,,,8,Autocuration,CHEMBL872930,,3691,,,10209,15463,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL620826,,3692,,,10209,6013,,
,BAO_0000357,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL620827,,3693,,,10209,16209,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL620828,,3694,,,10209,3935,,
,BAO_0000357,,H,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL620829,,3695,,,10209,15818,,
,BAO_0000219,,H,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,1,HEK293,,B,,,8,Expert,CHEMBL620830,,3696,,,10209,5014,722.0,
,BAO_0000019,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,1,,,B,,,8,Expert,CHEMBL620831,,3697,,,10209,16441,,
,BAO_0000019,,H,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,1,,,B,,,8,Expert,CHEMBL620832,,3698,,,10209,16441,,
,BAO_0000357,,D,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL621548,,3699,,,10209,4234,,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL621549,,3700,,,10209,17085,,
,BAO_0000357,,H,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,1,,,B,,,8,Autocuration,CHEMBL621550,,3701,,,10209,17200,,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,1,CHO,,B,,,8,Autocuration,CHEMBL621551,,3702,,,10209,17451,449.0,
,BAO_0000019,,H,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,1,,,B,,,8,Autocuration,CHEMBL621552,,3703,,,10209,17085,,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL857077,,3704,,,10209,5104,,
,BAO_0000357,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,1,,,B,,,8,Autocuration,CHEMBL618158,,3705,,,10209,5104,,
,BAO_0000219,,D,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,COS-7,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618159,,3706,,,10209,5033,643.0,
,BAO_0000219,,H,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,1,COS-7,,B,,,8,Autocuration,CHEMBL875101,,3707,,,10209,5486,643.0,
,BAO_0000219,,D,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618160,,3708,,,10209,4540,722.0,
,BAO_0000357,,H,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,1,,,B,,,8,Expert,CHEMBL618161,,3709,,,10209,6166,,
,BAO_0000219,,H,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,1,HEK293,,B,,,8,Expert,CHEMBL618162,,3710,,,10209,17342,722.0,
,BAO_0000357,,H,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,1,,,B,,,8,Expert,CHEMBL618163,,3711,,,10209,17342,,
,BAO_0000357,,H,,Binding affinity against 5-hydroxytryptamine 7 human receptors,1,,,B,,,8,Autocuration,CHEMBL618164,,3712,,,10209,17296,,
,BAO_0000219,,H,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,1,,,B,,,8,Expert,CHEMBL618165,,3713,,,10209,16429,,
,BAO_0000219,,H,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL618166,,3714,,,10209,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL857989,,3715,,,10209,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL619888,,3716,,,10209,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL619889,,3717,,,10209,15779,722.0,
,BAO_0000219,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,1,HEK293,,B,,,8,Autocuration,CHEMBL619890,,3718,,,10209,15779,722.0,
,BAO_0000219,,H,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,1,CHO,,B,,,8,Autocuration,CHEMBL619891,,3719,,,10209,17451,449.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),1,HEK293,,B,,,8,Autocuration,CHEMBL619892,,3720,,,10209,4199,722.0,
,BAO_0000219,,D,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,1,HEK293,,B,,,9,Expert,CHEMBL619893,,3721,,,10209,4199,722.0,
,BAO_0000219,,H,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),1,HEK293,,B,,,8,Autocuration,CHEMBL619894,,3722,,,10209,4199,722.0,
,BAO_0000219,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,1,HEK293,,B,,,9,Intermediate,CHEMBL619895,,3723,,,10209,3680,722.0,
,BAO_0000357,,D,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,1,,,B,,,9,Intermediate,CHEMBL619896,,3724,,,10209,3680,,
,BAO_0000219,,H,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,1,COS-7,,B,,,8,Autocuration,CHEMBL619897,,3725,,,10209,15316,643.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,1,HEK293,,B,,,8,Autocuration,CHEMBL619898,,3726,,,10209,15146,722.0,
,BAO_0000219,,H,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,1,HEK293,,B,,,8,Expert,CHEMBL619899,,3727,,,10209,5213,722.0,
,BAO_0000219,,H,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),1,HEK293,,B,,,8,Autocuration,CHEMBL619900,,3728,,,10209,5213,722.0,
,BAO_0000219,,D,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,1,HEK293,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619901,,3729,,,10209,14818,722.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,1,HEK293,,B,,,8,Autocuration,CHEMBL620580,,3730,,,10209,14818,722.0,
,BAO_0000219,,H,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,1,HEK293,,B,,,8,Autocuration,CHEMBL620581,,3731,,,10209,14818,722.0,
,BAO_0000219,,H,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",1,HEK293,,B,,,8,Autocuration,CHEMBL620733,,3732,,,10209,4829,722.0,
,BAO_0000357,,D,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,1,,9606.0,B,Homo sapiens,,9,Autocuration,CHEMBL620734,,3733,,,10209,17200,,
,BAO_0000357,,D,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL620735,,3734,,,10022,17066,,
,BAO_0000019,,H,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL620736,,3735,,,10209,14025,,
,BAO_0000219,,H,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,1,CHO,,B,,,8,Autocuration,CHEMBL620737,,3736,,,11923,15250,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620738,,3737,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620739,,3738,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620740,,3739,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL620741,,3740,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL620742,,3741,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,1,CHO,,B,,,8,Autocuration,CHEMBL620743,,3742,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620744,,3743,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620745,,3744,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,1,CHO,,B,,,8,Autocuration,CHEMBL620746,,3745,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL620747,,3746,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL620748,,3747,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,1,CHO,,B,,,8,Autocuration,CHEMBL620749,,3748,,,11923,16372,449.0,
,BAO_0000357,,H,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL620750,,3749,,,11923,17066,,
,BAO_0000357,,D,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620751,,3750,,,11923,17066,,
,BAO_0000357,,H,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL620752,,3751,,,11923,17386,,
,BAO_0000019,,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL872929,,3752,,,11923,14423,,
,BAO_0000357,,D,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620753,,3753,,,11923,15874,,
,BAO_0000357,,D,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620754,,3754,,,11923,15874,,
,BAO_0000219,,D,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,1,CHO,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620755,,3755,,,11923,16372,449.0,
,BAO_0000357,,H,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL620756,,3756,,,11923,4622,,
,BAO_0000357,,H,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL620757,,3757,,,11923,15086,,
,BAO_0000219,,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",1,CHO,,B,,,8,Autocuration,CHEMBL620758,,3758,,,11923,16372,449.0,
,BAO_0000219,,H,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",1,CHO,,B,,,8,Autocuration,CHEMBL620759,,3759,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,1,CHO,,B,,,8,Autocuration,CHEMBL620760,,3760,,,11923,16372,449.0,
,BAO_0000219,,H,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,1,CHO,,B,,,8,Autocuration,CHEMBL620761,,3761,,,11923,16372,449.0,
Ileum,BAO_0000221,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,,,F,,2116.0,8,Autocuration,CHEMBL620762,,3762,,,11923,17386,,
Ileum,BAO_0000221,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,1,,,F,,2116.0,8,Autocuration,CHEMBL620763,,3763,,,11923,17386,,
Ileum,BAO_0000221,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,1,,,F,,2116.0,8,Autocuration,CHEMBL620764,,3764,,,11923,17386,,
,BAO_0000249,,D,Membranes,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL857990,,3765,,,11923,5831,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL620765,,3766,,,11923,4342,,
,BAO_0000357,,H,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,1,,,B,,,8,Expert,CHEMBL620766,,3767,,,11923,17319,,
Hypothalamus,BAO_0000019,,H,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,1,,,B,,1898.0,8,Expert,CHEMBL620767,,3768,,,11923,17342,,
,BAO_0000357,,H,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,1,,,B,,,8,Autocuration,CHEMBL620768,,3769,,,11923,17342,,
Hypothalamus,BAO_0000249,,H,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,1,,,B,,1898.0,8,Expert,CHEMBL619051,,3770,,,11923,3680,,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL619052,,3771,,,11923,3680,,
,BAO_0000219,,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,1,HEK293,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL619053,,3772,,,11923,17319,722.0,
,BAO_0000219,,D,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,1,HEK293,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL619703,,3773,,,11923,17319,722.0,
,BAO_0000219,,D,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,1,HEK293,10116.0,F,Rattus norvegicus,,9,Autocuration,CHEMBL619704,,3774,,,11923,17319,722.0,
,BAO_0000357,,H,,Binding affinity towards 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL619851,,3775,,,10209,4820,,
,BAO_0000357,,H,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,1,,,B,,,8,Autocuration,CHEMBL619852,,3776,,,10209,4639,,
,BAO_0000357,,H,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,1,,,B,,,8,Autocuration,CHEMBL619853,,3777,,,10209,6011,,
,BAO_0000357,,D,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL619854,,3778,,,10209,17066,,
,BAO_0000357,,H,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL619855,,3779,,,10209,17066,,
,BAO_0000357,,H,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,1,,,B,,,8,Autocuration,CHEMBL619856,,3780,,,10209,17515,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL619857,,3781,,,10209,4373,,
,BAO_0000019,,H,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,1,,,F,,,8,Expert,CHEMBL619858,,3782,,,10209,17066,,
,BAO_0000357,,H,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL619859,,3783,,,10209,4373,,
,BAO_0000357,,H,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,1,,,B,,,8,Autocuration,CHEMBL619860,,3784,,,10209,4373,,
,BAO_0000357,,H,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL619861,,3785,,,10209,4687,,
,BAO_0000357,,H,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL619862,,3786,,,10209,17342,,
,BAO_0000357,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,1,,,B,,,8,Autocuration,CHEMBL619863,,3787,,,10209,16946,,
,BAO_0000357,,H,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,1,,,B,,,8,Autocuration,CHEMBL619864,,3788,,,10209,16946,,
,BAO_0000357,,H,,Binding affinities against 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL872928,,3789,,,10209,16633,,
,BAO_0000357,,H,,Binding affinities towards 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Autocuration,CHEMBL619865,,3790,,,10209,16633,,
,BAO_0000357,,H,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,1,,,B,,,8,Expert,CHEMBL619866,,3791,,,10209,17066,,
,BAO_0000357,,H,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,1,,,B,,,8,Autocuration,CHEMBL619867,,3792,,,10209,16700,,
Ileum,BAO_0000221,,H,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,1,,,B,,2116.0,8,Autocuration,CHEMBL619868,,3793,,,10209,17386,,
,BAO_0000019,,H,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,1,,,F,,,8,Autocuration,CHEMBL619869,,3794,,,55,14080,,
,BAO_0000019,,D,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL619870,,3795,,,55,14080,,
,BAO_0000357,,H,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,1,,,B,,,8,Autocuration,CHEMBL619871,,3796,,,55,409,,
,BAO_0000357,,H,,In vitro inhibition of human recombinant lipoxygenase enzyme,1,,,B,,,8,Autocuration,CHEMBL619872,,3797,,,55,409,,
,BAO_0000357,,H,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,1,,,B,,,8,Autocuration,CHEMBL619873,,3798,,,55,409,,
Blood,BAO_0000357,,H,,Inhibition of 5-lipoxygenase in human whole blood.,1,,,B,,178.0,8,Expert,CHEMBL619874,,3799,,,55,11090,,
Blood,BAO_0000357,,H,,Inhibition of 5-lipoxygenase in human whole blood.,1,,,B,,178.0,8,Expert,CHEMBL619875,,3800,,,55,11090,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,1,,,B,,,8,Autocuration,CHEMBL619876,,3801,,,55,948,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),1,,,B,,,8,Autocuration,CHEMBL619877,,3802,,,55,948,,
,BAO_0000219,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,1,,,F,,,8,Expert,CHEMBL619878,,3803,,,55,13622,,
Blood,BAO_0000019,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,1,,,F,,178.0,8,Autocuration,CHEMBL619879,,3804,,,55,13622,,
,BAO_0000357,,H,,In vitro inhibition of 5-lipoxygenase from human polymorphs,1,,,B,,,8,Autocuration,CHEMBL619880,,3805,,,55,9637,,
,BAO_0000357,,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),1,,,B,,,8,Autocuration,CHEMBL619881,,3806,,,55,11320,,
,BAO_0000357,,H,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL619882,,3807,,,55,11320,,
,BAO_0000357,,H,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,1,,,B,,,8,Autocuration,CHEMBL619883,,3808,,,55,6838,,
Blood,BAO_0000357,,D,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),1,,9606.0,B,Homo sapiens,178.0,9,Expert,CHEMBL619884,,3809,,,55,17667,,
,BAO_0000357,,H,,In vitro potency against human 5-Lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL619885,,3810,,,55,12703,,
,BAO_0000019,,D,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL619886,,3811,,,55,14312,,
Blood,BAO_0000019,,H,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,1,,,F,,178.0,8,Autocuration,CHEMBL619887,,3812,,,55,14312,,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,,F,,,8,Autocuration,CHEMBL875097,,3813,,,55,5364,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,1,,,B,,,8,Autocuration,CHEMBL618001,,3814,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,1,,,B,,,8,Autocuration,CHEMBL618002,,3815,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,1,,,B,,,8,Autocuration,CHEMBL618003,,3816,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,1,,,B,,,8,Autocuration,CHEMBL618004,,3817,,,55,951,,
,BAO_0000219,,H,,Inhibition of human 5-lipoxygenase in human cells,1,,,B,,,8,Autocuration,CHEMBL618005,,3818,,,55,12365,,
,BAO_0000357,,H,,Inhibition of human neutrophil 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL618006,,3819,,,55,10603,,
,BAO_0000019,,H,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,1,,,B,,,8,Autocuration,CHEMBL875086,,3820,,,55,10501,,
Blood,BAO_0000357,,H,,Inhibition of 5-lipoxygenase from human whole blood,1,,,B,,178.0,8,Expert,CHEMBL618007,,3821,,,55,12281,,
,BAO_0000357,,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,,B,,,8,Autocuration,CHEMBL618008,,3822,,,55,2567,,
,BAO_0000219,,H,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,1,,,B,,,8,Autocuration,CHEMBL618009,,3823,,,55,2567,,
,BAO_0000357,,H,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL618010,,3824,,,55,10193,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,B,,,8,Autocuration,CHEMBL618011,,3825,,,55,10193,,
,BAO_0000357,,H,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL618012,,3826,,,55,13623,,
,BAO_0000357,,H,,Tested against 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL882927,,3827,,,55,12780,,
,BAO_0000357,,H,,Tested for activity against 5-Lipoxygenase (5-LO),1,,,B,,,8,Autocuration,CHEMBL618013,,3828,,,55,12780,,
,BAO_0000357,,H,,Tested for activity against 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL618014,,3829,,,55,12780,,
,BAO_0000357,,H,,Tested for inhibition of 5-HPETE production by human 5-LO,1,,,B,,,8,Autocuration,CHEMBL618015,,3830,,,55,11966,,
,BAO_0000019,,H,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,1,,,F,,,8,Autocuration,CHEMBL618016,,3831,,,55,5364,,
,BAO_0000357,,H,,Inhibition of Human 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL618017,,3832,,,55,13165,,
,BAO_0000019,,H,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,1,,,B,,,8,Autocuration,CHEMBL618018,,3833,,,55,5364,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL875087,,3834,,,55,11311,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL618019,,3835,,,55,11311,,
,BAO_0000019,,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,1,,,B,,,8,Autocuration,CHEMBL618020,,3836,,,55,14863,,
,BAO_0000019,,H,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,1,,,B,,,8,Autocuration,CHEMBL618021,,3837,,,55,14863,,
Blood,BAO_0000357,,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),1,,,B,,178.0,8,Autocuration,CHEMBL618022,,3838,,,55,11087,,
,BAO_0000357,,H,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,1,,,B,,,8,Autocuration,CHEMBL618023,,3839,,,55,455,,
,BAO_0000357,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,B,,,8,Autocuration,CHEMBL618024,,3840,,,55,13183,,
,BAO_0000019,,H,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,1,,,B,,,8,Expert,CHEMBL873950,,3841,,,55,10319,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,B,,,8,Autocuration,CHEMBL618025,,3842,,,55,10193,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,1,,,B,,,8,Autocuration,CHEMBL618026,,3843,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,1,,,B,,,8,Autocuration,CHEMBL618027,,3844,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,1,,,B,,,8,Autocuration,CHEMBL618028,,3845,,,55,951,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,1,,,B,,,8,Autocuration,CHEMBL618029,,3846,,,55,951,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,1,,,B,,,8,Expert,CHEMBL618030,,3847,,,55,9859,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,1,,,B,,,8,Expert,CHEMBL618031,,3848,,,55,9859,,
,BAO_0000357,,H,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,1,,,B,,,8,Autocuration,CHEMBL618032,,3849,,,55,9859,,
,BAO_0000357,,H,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,1,,,B,,,8,Autocuration,CHEMBL618033,,3850,,,55,2567,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,1,,,B,,,8,Autocuration,CHEMBL618034,,3851,,,55,10193,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,1,,,B,,,8,Autocuration,CHEMBL875088,,3852,,,55,10193,,
,BAO_0000019,,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,1,,,B,,,8,Autocuration,CHEMBL618035,,3853,,,55,949,,
,BAO_0000019,,H,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,1,,,B,,,8,Autocuration,CHEMBL618036,,3854,,,55,949,,
,BAO_0000357,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,1,,,B,,,8,Expert,CHEMBL618037,,3855,,,55,10603,,
,BAO_0000357,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,,B,,,8,Expert,CHEMBL618038,,3856,,,55,10603,,
,BAO_0000019,,H,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,1,,,F,,,8,Autocuration,CHEMBL618761,,3857,,,55,10603,,
,BAO_0000357,,H,,Inhibition of lipoxygenase at the concentration of 0.1 uM,1,,,B,,,8,Expert,CHEMBL618762,,3858,,,55,10603,,
,BAO_0000357,,H,,Inhibition of lipoxygenase at the concentration of 1 uM,1,,,B,,,8,Expert,CHEMBL618763,,3859,,,55,10603,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,1,,,B,,,8,Autocuration,CHEMBL618764,,3860,,,55,10193,,
,BAO_0000357,,D,,Inhibition of 5-Lipoxygenase (5-LOX),1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL618765,,3861,,,55,14580,,
,BAO_0000357,,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,,B,,,8,Expert,CHEMBL618766,,3862,,,17087,11090,,
,BAO_0000357,,H,,Inhibition of 5-lipoxygenase in mouse macrophages.,1,,,B,,,8,Expert,CHEMBL618767,,3863,,,17087,11090,,
,BAO_0000357,,H,,Inhibitory activity against lipoxygenase-2 in mice,1,,,B,,,8,Autocuration,CHEMBL619380,,3864,,,17087,6339,,
,BAO_0000357,,H,,Inhibitory activity against murine lipoxygenase-2.,1,,,B,,,8,Expert,CHEMBL619381,,3865,,,17087,6339,,
,BAO_0000357,,D,,Inhibition of 5-lipoxygenase from mouse macrophage,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL619382,,3866,,,17087,12281,,
,BAO_0000357,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,1,,,B,,,8,Autocuration,CHEMBL619383,,3867,,,17087,11311,,
,BAO_0000019,,H,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL619384,,3868,,,55,11089,,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,1,,9823.0,B,Sus scrofa,,8,Autocuration,CHEMBL619385,,3869,,,55,10091,,
,BAO_0000019,,H,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,1,,9986.0,B,Oryctolagus cuniculus,,8,Autocuration,CHEMBL882928,,3870,,,55,14352,,
,BAO_0000019,,D,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619386,,3871,,,12166,13329,,
,BAO_0000019,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",1,,,B,,,8,Autocuration,CHEMBL619387,,3872,,,12166,13329,,
,BAO_0000019,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,,B,,,8,Autocuration,CHEMBL619388,,3873,,,12166,13329,,
,BAO_0000019,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",1,,,B,,,8,Autocuration,CHEMBL619389,,3874,,,12166,13329,,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),1,,,B,,,8,Expert,CHEMBL619390,,3875,,,12166,13329,,
,BAO_0000019,,H,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",1,,,B,,,8,Expert,CHEMBL619391,,3876,,,12166,13329,,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,1,,,B,,,8,Autocuration,CHEMBL619392,,3877,,,12166,13329,,
,BAO_0000019,,H,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),1,,,B,,,8,Autocuration,CHEMBL619393,,3878,,,12166,11311,,
,BAO_0000019,,H,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,1,,,B,,,8,Autocuration,CHEMBL619394,,3879,,,12166,11311,,
,BAO_0000219,,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,RBL-1,,B,,,8,Autocuration,CHEMBL619395,,3880,,,12166,105,702.0,
,BAO_0000219,,H,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",1,RBL-1,,B,,,8,Autocuration,CHEMBL619396,,3881,,,12166,105,702.0,
,BAO_0000357,,H,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),1,,,B,,,8,Autocuration,CHEMBL619397,,3882,,,12166,9138,,
,BAO_0000357,,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",1,,,B,,,8,Autocuration,CHEMBL619398,,3883,,,12166,9138,,
,BAO_0000357,,H,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",1,,,B,,,8,Autocuration,CHEMBL619399,,3884,,,12166,9138,,
,BAO_0000357,,H,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,,B,,,8,Autocuration,CHEMBL619400,,3885,,,12166,14427,,
,BAO_0000019,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",1,,,B,,,8,Autocuration,CHEMBL619401,,3886,,,12166,13329,,
,BAO_0000019,,H,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",1,,,B,,,8,Autocuration,CHEMBL619402,,3887,,,12166,13329,,
,BAO_0000219,,D,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,1,RBL-2H3,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619403,,3888,,,12166,14427,663.0,
,BAO_0000357,,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,1,,,B,,,8,Autocuration,CHEMBL619404,,3889,,,12166,14427,,
,BAO_0000357,,H,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,1,,,B,,,8,Autocuration,CHEMBL619405,,3890,,,12166,14427,,
,BAO_0000219,,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,1,RBL-1,,B,,,8,Expert,CHEMBL619406,,3891,,,12166,10293,702.0,
,BAO_0000219,,D,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619407,,3892,,,12166,338,702.0,
,BAO_0000357,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),1,,,B,,,8,Autocuration,CHEMBL619408,,3893,,,12166,303,,
,BAO_0000219,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,1,RBL-1,,B,,,8,Autocuration,CHEMBL619409,,3894,,,12166,303,702.0,
,BAO_0000219,,H,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,1,RBL-1,,B,,,8,Expert,CHEMBL619410,,3895,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,RBL-1,,B,,,8,Autocuration,CHEMBL619753,,3896,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,1,RBL-1,,B,,,8,Autocuration,CHEMBL619754,,3897,,,12166,137,702.0,
,BAO_0000357,,H,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL619903,,3898,,,12166,11481,,
,BAO_0000357,,H,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",1,,,B,,,8,Expert,CHEMBL619904,,3899,,,12166,11481,,
,BAO_0000357,,H,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,1,,,B,,,8,Expert,CHEMBL619905,,3900,,,12166,9029,,
,BAO_0000019,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,1,,,B,,,8,Autocuration,CHEMBL619906,,3901,,,12166,1701,,
,BAO_0000019,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,1,,,B,,,8,Autocuration,CHEMBL619907,,3902,,,12166,1701,,
,BAO_0000019,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,1,,,B,,,8,Autocuration,CHEMBL619908,,3903,,,12166,1701,,
,BAO_0000019,,H,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,1,,,B,,,8,Autocuration,CHEMBL619909,,3904,,,12166,1701,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,1,RBL-1,,F,,,8,Expert,CHEMBL619910,,3905,,,12166,13358,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,1,RBL-1,,B,,,8,Expert,CHEMBL882929,,3906,,,12166,1175,702.0,
,BAO_0000219,,H,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,1,RBL-1,,B,,,8,Expert,CHEMBL619911,,3907,,,12166,8797,702.0,
,BAO_0000019,,H,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,1,,,B,,,8,Autocuration,CHEMBL619912,,3908,,,12166,8797,,
,BAO_0000357,,D,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619913,,3909,,,12166,577,,
,BAO_0000219,,H,,In vitro inhibitory activity against RBL-1 5-LO,1,RBL-1,,B,,,8,Expert,CHEMBL619914,,3910,,,12166,9295,702.0,
,BAO_0000219,,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),1,RBL-1,,B,,,8,Autocuration,CHEMBL619915,,3911,,,12166,9295,702.0,
,BAO_0000219,,H,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),1,RBL-1,,B,,,8,Autocuration,CHEMBL619916,,3912,,,12166,9295,702.0,
,BAO_0000218,,H,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,1,,,B,,,8,Autocuration,CHEMBL619917,,3913,,,12166,9295,,
,BAO_0000357,,H,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,1,,,B,,,8,Autocuration,CHEMBL619918,,3914,,,12166,9295,,
,BAO_0000218,,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,1,,,B,,,8,Autocuration,CHEMBL619919,,3915,,,12166,216,,
,BAO_0000219,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,1,RBL-1,,B,,,8,Autocuration,CHEMBL883710,,3916,,,12166,11090,702.0,
Blood,BAO_0000019,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,1,,,B,,178.0,8,Autocuration,CHEMBL619920,,3917,,,12166,11090,,
,BAO_0000357,,H,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL619921,,3918,,,12166,10091,,
,BAO_0000019,,H,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,1,,,F,,,8,Autocuration,CHEMBL619922,,3919,,,12166,10274,,
,BAO_0000219,,H,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,1,,,F,,,8,Autocuration,CHEMBL619923,,3920,,,12166,13622,,
,BAO_0000219,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,1,RBL-1,,B,,,8,Expert,CHEMBL619924,,3921,,,12166,12118,702.0,
,BAO_0000357,,H,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,1,,,B,,,8,Expert,CHEMBL619925,,3922,,,12166,12576,,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,1,RBL-1,,B,,,8,Expert,CHEMBL619926,,3923,,,12166,9546,702.0,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL619927,,3924,,,12166,9521,702.0,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,1,RBL-1,,B,,,8,Expert,CHEMBL619928,,3925,,,12166,10626,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase,1,RBL-1,,B,,,8,Autocuration,CHEMBL619929,,3926,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,1,RBL-1,,B,,,8,Autocuration,CHEMBL875089,,3927,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,1,RBL-1,,B,,,8,Autocuration,CHEMBL619930,,3928,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,1,RBL-1,,B,,,8,Autocuration,CHEMBL619931,,3929,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,1,RBL-1,,B,,,8,Autocuration,CHEMBL619932,,3930,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,1,RBL-1,,B,,,8,Autocuration,CHEMBL619933,,3931,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,1,RBL-1,,B,,,8,Autocuration,CHEMBL619934,,3932,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,1,RBL-1,,B,,,8,Autocuration,CHEMBL619935,,3933,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,1,RBL-1,,B,,,8,Autocuration,CHEMBL619936,,3934,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,1,RBL-1,,B,,,8,Autocuration,CHEMBL619937,,3935,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,1,RBL-1,,B,,,8,Autocuration,CHEMBL619938,,3936,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,1,RBL-1,,B,,,8,Autocuration,CHEMBL619939,,3937,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,1,RBL-1,,B,,,8,Autocuration,CHEMBL619940,,3938,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,1,RBL-1,,B,,,8,Autocuration,CHEMBL875090,,3939,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,1,RBL-1,,B,,,8,Autocuration,CHEMBL619941,,3940,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,1,RBL-1,,B,,,8,Autocuration,CHEMBL619942,,3941,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,1,RBL-1,,B,,,8,Autocuration,CHEMBL883711,,3942,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,1,RBL-1,,B,,,8,Autocuration,CHEMBL619943,,3943,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,1,RBL-1,,B,,,8,Autocuration,CHEMBL619944,,3944,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,1,RBL-1,,B,,,8,Autocuration,CHEMBL619945,,3945,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,1,RBL-1,,B,,,8,Autocuration,CHEMBL619946,,3946,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,1,RBL-1,,B,,,8,Autocuration,CHEMBL619947,,3947,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,1,RBL-1,,B,,,8,Autocuration,CHEMBL619948,,3948,,,12166,9225,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,1,RBL-1,,B,,,8,Autocuration,CHEMBL619949,,3949,,,12166,9225,702.0,
,BAO_0000019,,H,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,1,,,B,,,8,Expert,CHEMBL619950,,3950,,,12166,9401,,
,BAO_0000019,,H,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,1,,,B,,,8,Autocuration,CHEMBL618050,,3951,,,12166,10325,,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,1,RBL-2H3,,F,,,8,Expert,CHEMBL875091,,3952,,,12166,1556,663.0,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,1,RBL-2H3,,F,,,8,Expert,CHEMBL618051,,3953,,,12166,1556,663.0,
,BAO_0000219,,D,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618052,,3954,,,12166,961,702.0,
,BAO_0000019,,H,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,1,,,B,,,8,Autocuration,CHEMBL618053,,3955,,,12166,6838,,
,BAO_0000019,,H,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),1,,,B,,,8,Expert,CHEMBL618054,,3956,,,12166,10325,,
,BAO_0000219,,D,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618055,,3957,,,12166,9209,702.0,
,BAO_0000219,,H,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,1,RBL-1,,B,,,8,Expert,CHEMBL618056,,3958,,,12166,11520,702.0,
,BAO_0000357,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined,1,,,B,,,8,Autocuration,CHEMBL618057,,3959,,,12166,137,,
,BAO_0000219,,H,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL618058,,3960,,,12166,4717,702.0,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,1,RBL-1,,B,,,8,Expert,CHEMBL618059,,3961,,,12166,10636,702.0,
,BAO_0000019,,D,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL618060,,3962,,,12166,14312,,
,BAO_0000219,,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL618061,,3963,,,12166,1203,702.0,
,BAO_0000019,,H,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,1,,,B,,,8,Autocuration,CHEMBL618062,,3964,,,12166,1203,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,1,RBL-1,,B,,,8,Expert,CHEMBL618063,,3965,,,12166,13622,702.0,
,BAO_0000357,,H,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,1,,,B,,,8,Autocuration,CHEMBL618064,,3966,,,12166,9793,,
,BAO_0000219,,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618065,,3967,,,12166,1143,702.0,
,BAO_0000219,,D,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618066,,3968,,,12166,11854,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,RBL-1,,B,,,8,Autocuration,CHEMBL618067,,3969,,,12166,3595,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,RBL-1,,B,,,8,Autocuration,CHEMBL618068,,3970,,,12166,3595,702.0,
,BAO_0000219,,D,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618069,,3971,,,12166,10501,702.0,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,RBL-1,,B,,,8,Expert,CHEMBL618070,,3972,,,12166,12526,702.0,
Limbic system,BAO_0000019,,H,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL618071,,3973,,,10825,10034,,
Limbic system,BAO_0000019,,H,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,1,,,F,,349.0,8,Autocuration,CHEMBL619247,,3974,,,10825,10034,,
,BAO_0000019,,H,,Approximate dose levels for a half maximal reduction of 5-HTP levels,1,,,F,,,8,Autocuration,CHEMBL619248,,3975,,,10825,10034,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,,B,,10000000.0,8,Autocuration,CHEMBL619249,,3976,,,10576,10046,,
Hippocampus,BAO_0000221,,H,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,1,,,B,,10000000.0,8,Autocuration,CHEMBL619250,,3977,,,10576,10046,,
,BAO_0000019,,H,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,1,,,B,,,8,Autocuration,CHEMBL619251,,3978,,,10577,10046,,
Blood,BAO_0000019,,H,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619252,,3979,,,55,12079,,
Blood,BAO_0000019,,H,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,1,,,F,,178.0,8,Autocuration,CHEMBL619253,,3980,,,55,12079,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL619254,,3981,,,12166,11311,,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,1,,,B,,,8,Expert,CHEMBL619255,,3982,,,17140,12338,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,1,,,B,,,8,Expert,CHEMBL619256,,3983,,,17140,12143,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),1,,,B,,,8,Autocuration,CHEMBL875418,,3984,,,17140,12143,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,,B,,,8,Expert,CHEMBL619257,,3985,,,17140,12143,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,1,,,B,,,8,Autocuration,CHEMBL619258,,3986,,,17140,12143,,
,BAO_0000357,,H,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,1,,,B,,,8,Expert,CHEMBL619259,,3987,,,17140,12365,,
,BAO_0000357,,H,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,1,,,B,,,8,Expert,CHEMBL619260,,3988,,,17140,13500,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619261,,3989,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619263,,3990,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619264,,3991,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619265,,3992,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619266,,3993,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619902,,3994,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620058,,3995,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620059,,3996,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620060,,3997,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620061,,3998,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620062,,3999,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620063,,4000,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620064,,4001,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620065,,4002,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620066,,4003,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620067,,4004,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620068,,4005,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620069,,4006,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620070,,4007,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620071,,4008,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620072,,4009,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620036,,4010,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL857702,,4011,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620037,,4012,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620038,,4013,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620039,,4014,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620040,,4015,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620041,,4016,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620042,,4017,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620043,,4018,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620044,,4019,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620045,,4020,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620046,,4021,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620047,,4022,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620048,,4023,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL857703,,4024,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620049,,4025,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620050,,4026,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL620051,,4027,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619213,,4028,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619214,,4029,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619804,,4030,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619805,,4031,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619806,,4032,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619807,,4033,In vivo,,55,12832,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",1,,9615.0,F,Canis lupus familiaris,178.0,8,Autocuration,CHEMBL619808,,4034,In vivo,,55,12832,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL619809,,4035,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL619810,,4036,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL619811,,4037,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL620769,,4038,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL620770,,4039,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL620771,,4040,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL620772,,4041,,,55,3595,,
,BAO_0000218,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,1,,9615.0,B,Canis lupus familiaris,,8,Autocuration,CHEMBL620773,,4042,,,55,3595,,
,BAO_0000357,,H,,Ability to inhibit 5-lipoxygenase in guinea pig,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL620774,,4043,,,55,9203,,
,BAO_0000357,,H,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),1,,10141.0,B,Cavia porcellus,,8,Expert,CHEMBL620775,,4044,,,55,82,,
,BAO_0000357,,H,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL620776,,4045,,,55,11090,,
Blood,BAO_0000218,,H,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",1,,10141.0,B,Cavia porcellus,178.0,8,Autocuration,CHEMBL620777,,4046,,,55,12832,,
,BAO_0000357,,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL620778,,4047,,,55,1065,,
,BAO_0000357,,H,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL620779,,4048,,,55,1065,,
,BAO_0000019,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,1,,10141.0,B,Cavia porcellus,,8,Expert,CHEMBL621500,,4049,,,55,12832,,
,BAO_0000019,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,,10141.0,B,Cavia porcellus,,8,Expert,CHEMBL621501,,4050,,,55,12832,,
,BAO_0000019,,H,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618098,,4051,,,55,12832,,
,BAO_0000019,,H,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618099,,4052,,,55,10504,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618100,,4053,,,55,7788,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618101,,4054,,,55,10001,,
,BAO_0000357,,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618102,,4055,,,55,10193,,
,BAO_0000357,,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618103,,4056,,,55,13243,,
,BAO_0000357,,H,,Inhibitory activity uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618104,,4057,,,55,13243,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL883712,,4058,,,55,969,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase at 10 uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618105,,4059,,,55,10001,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618106,,4060,,,55,7788,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618107,,4061,,,55,10001,,
,BAO_0000357,,H,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618108,,4062,,,55,10193,,
,BAO_0000357,,H,,Inhibitory activity uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618109,,4063,,,55,13243,,
,BAO_0000357,,H,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618110,,4064,,,55,13243,,
,BAO_0000357,,H,,Inhibitory activity uM,1,,10141.0,B,Cavia porcellus,,8,Expert,CHEMBL618111,,4065,,,55,13243,,
,BAO_0000019,,H,,Inhibitory activity uM,1,,10141.0,F,Cavia porcellus,,8,Autocuration,CHEMBL618112,,4066,,,55,13243,,
,BAO_0000019,,H,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618113,,4067,,,55,10504,,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,1,,10141.0,B,Cavia porcellus,,8,Autocuration,CHEMBL618114,,4068,,,55,7788,,
Ileum,BAO_0000221,,H,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,1,,10141.0,F,Cavia porcellus,2116.0,8,Expert,CHEMBL620871,,4069,,,55,10546,,
,BAO_0000357,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,B,,,8,Autocuration,CHEMBL620872,,4070,,,55,13183,,
,BAO_0000357,,H,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),1,,,B,,,8,Autocuration,CHEMBL620873,,4071,,,55,13183,,
,BAO_0000357,,H,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),1,,,B,,,8,Autocuration,CHEMBL620874,,4072,,,55,2578,,
,BAO_0000357,,H,,In vitro inhibition of human 5-Lipoxygenase.,1,,,B,,,8,Expert,CHEMBL620875,,4073,,,55,12780,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620876,,4074,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620877,,4075,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL857854,,4076,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620878,,4077,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620879,,4078,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620880,,4079,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620881,,4080,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620882,,4081,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620883,,4082,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620884,,4083,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620885,,4084,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620886,,4085,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620887,,4086,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618039,,4087,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618040,,4088,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618041,,4089,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618216,,4090,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618217,,4091,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618218,,4092,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618219,,4093,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618220,,4094,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618221,,4095,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618222,,4096,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618223,,4097,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618224,,4098,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618225,,4099,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618226,,4100,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618227,,4101,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618228,,4102,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618229,,4103,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618230,,4104,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618231,,4105,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618232,,4106,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618233,,4107,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618234,,4108,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618235,,4109,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618115,,4110,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618116,,4111,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL618117,,4112,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619968,,4113,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619969,,4114,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619970,,4115,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619971,,4116,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619972,,4117,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619973,,4118,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619974,,4119,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619975,,4120,,,22226,7411,,
,BAO_0000251,,U,Microsomes,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,1,,10116.0,B,Rattus norvegicus,,0,Autocuration,CHEMBL619976,,4121,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619977,,4122,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619978,,4123,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619979,,4124,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619980,,4125,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619981,,4126,,,22226,7411,,
,BAO_0000219,,N,,In vitro inhibition of 7226/S myeloma cancer cell line,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619982,,4127,,,80433,10797,741.0,
,BAO_0000219,,N,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),1,BEL-7404 tumor cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619983,,4128,,,80698,6881,993.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620031,,4129,,,80640,3838,391.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620032,,4130,,,80640,3838,391.0,
,BAO_0000219,,N,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,1,V79,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL620033,,4131,,,81264,12981,505.0,
,BAO_0000219,,N,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,1,V79,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL620034,,4132,,,81264,12981,505.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL620035,,4133,,,80635,7653,1119.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618318,,4134,,,80635,7653,1119.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618319,,4135,,,80635,7653,1119.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618320,,4136,,,80635,7653,1119.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618321,,4137,,,80635,7653,1119.0,
,BAO_0000219,,N,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,1,7800C1 cell line,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL883118,,4138,,,80635,7653,1119.0,
,BAO_0000219,,N,,In vitro antitumor activity against renal 786-0 tumor cell lines,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883795,,4139,,,80640,17229,391.0,
,BAO_0000219,,N,,Cytotoxic activity against 786-0 Renal cancer cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618322,,4140,,,80640,12858,391.0,
,BAO_0000219,,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618323,,4141,,,80640,16325,391.0,
,BAO_0000219,,N,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618324,,4142,,,80640,16325,391.0,
,BAO_0000219,,N,,In vitro antitumor activity against human renal 786-0 cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618325,,4143,,,80640,5858,391.0,
,BAO_0000219,,N,,Inhibition of Renal cancer in 786-0 cancer cell lines,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875416,,4144,,,80640,16325,391.0,
,BAO_0000219,,N,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618326,,4145,,,80640,14696,391.0,
,BAO_0000219,,N,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618327,,4146,,,80640,3786,391.0,
,BAO_0000219,,N,,inhibition of the growth of renal cancer(786-0) cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619215,,4147,,,80640,14696,391.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619216,,4148,,,80640,14769,391.0,
,BAO_0000219,,N,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619217,,4149,,,80640,15354,391.0,
,BAO_0000219,,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619218,,4150,,,80640,14255,391.0,
,BAO_0000219,,N,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619219,,4151,,,80640,14255,391.0,
,BAO_0000219,,N,,The IC50 value was measured on 786-0 cell line in renal tumor type.,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619220,,4152,,,80640,14255,391.0,
,BAO_0000219,,N,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619221,,4153,,,80640,14696,391.0,
,BAO_0000219,,N,,Tested for cytotoxic activity against renal cancer 786-0 cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619222,,4154,,,80640,12016,391.0,
,BAO_0000219,,N,,Compound was tested for growth inhibitory activity against 786-0 cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL857454,,4155,,,80640,2597,391.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL619223,,4156,,,12166,12526,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,1,RBL-1,,B,,,8,Autocuration,CHEMBL619224,,4157,,,12166,12526,702.0,
,BAO_0000019,,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,,,B,,,8,Autocuration,CHEMBL619225,,4158,,,12166,14799,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),1,RBL-1,,B,,,8,Expert,CHEMBL619226,,4159,,,12166,3595,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),1,RBL-1,,B,,,8,Expert,CHEMBL619227,,4160,,,12166,3595,702.0,
,BAO_0000357,,H,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL619228,,4161,,,12166,12767,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,1,,,B,,,8,Autocuration,CHEMBL619229,,4162,,,12166,10997,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,1,RBL-1,,B,,,8,Autocuration,CHEMBL619230,,4163,,,12166,11388,702.0,
,BAO_0000357,,H,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,1,,,B,,,8,Autocuration,CHEMBL619231,,4164,,,12166,167,,
,BAO_0000357,,H,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",1,,,B,,,8,Autocuration,CHEMBL619232,,4165,,,12166,167,,
,BAO_0000357,,H,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,1,,,B,,,8,Expert,CHEMBL619233,,4166,,,12166,13744,,
,BAO_0000357,,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL619234,,4167,,,12166,1630,,
,BAO_0000357,,H,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),1,,,B,,,8,Autocuration,CHEMBL619235,,4168,,,12166,1630,,
,BAO_0000019,,D,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL619236,,4169,,,12166,969,,
,BAO_0000219,,H,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL619237,,4170,,,12166,13621,702.0,
,BAO_0000357,,H,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,1,,,B,,,8,Autocuration,CHEMBL619238,,4171,,,12166,10089,,
,BAO_0000357,,H,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,1,,,B,,,8,Expert,CHEMBL619239,,4172,,,12166,10193,,
,BAO_0000357,,H,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,1,,,B,,,8,Autocuration,CHEMBL619240,,4173,,,12166,11966,,
,BAO_0000019,,H,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,,B,,,8,Autocuration,CHEMBL875417,,4174,,,12166,12251,,
,BAO_0000219,,H,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),1,RBL-1,,B,,,8,Autocuration,CHEMBL619241,,4175,,,12166,211,702.0,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,1,,,F,,,8,Expert,CHEMBL619242,,4176,,,12166,12251,,
,BAO_0000219,,H,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL883796,,4177,,,12166,12495,702.0,
,BAO_0000357,,H,,Tested for its inhibitory activity against 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL619243,,4178,,,12166,414,,
,BAO_0000357,,H,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,1,,,B,,,8,Autocuration,CHEMBL619244,,4179,,,12166,414,,
,BAO_0000019,,H,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",1,,,B,,,8,Expert,CHEMBL619245,,4180,,,12166,10325,,
,BAO_0000019,,H,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,,B,,,8,Expert,CHEMBL619246,,4181,,,12166,11966,,
,BAO_0000219,,H,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,RBL-1,,B,,,8,Expert,CHEMBL619984,,4182,,,12166,165,702.0,
,BAO_0000219,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL619985,,4183,,,12166,165,702.0,
,BAO_0000219,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,RBL-1,,B,,,8,Autocuration,CHEMBL619986,,4184,,,12166,165,702.0,
,BAO_0000219,,H,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,1,RBL-1,,B,,,8,Expert,CHEMBL619987,,4185,,,12166,165,702.0,
,BAO_0000218,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,1,,,B,,,8,Autocuration,CHEMBL619988,,4186,,,12166,11311,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,1,RBL-1,,B,,,8,Autocuration,CHEMBL619989,,4187,,,12166,11311,702.0,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL619990,,4188,,,12166,11311,702.0,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL619991,,4189,,,12166,11311,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),1,,,B,,,8,Autocuration,CHEMBL619992,,4190,,,12166,11311,,
,BAO_0000218,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),1,,,B,,,8,Autocuration,CHEMBL619993,,4191,In vivo,,12166,11311,,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,1,RBL-2H3,,F,,,8,Autocuration,CHEMBL619994,,4192,,,12166,11311,663.0,
,BAO_0000219,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,1,RBL-2H3,,F,,,8,Autocuration,CHEMBL619995,,4193,,,12166,11311,663.0,
,BAO_0000019,,H,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],1,,,B,,,8,Autocuration,CHEMBL619996,,4194,,,12166,11311,,
,BAO_0000019,,H,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL619997,,4195,,,12166,11732,,
,BAO_0000019,,H,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,1,,,B,,,8,Expert,CHEMBL619998,,4196,,,12166,11732,,
,BAO_0000019,,H,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,1,,,B,,,8,Expert,CHEMBL619999,,4197,,,12166,11087,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,1,,,B,,,8,Autocuration,CHEMBL620000,,4198,,,12166,11087,,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL620001,,4199,,,12166,11087,702.0,
,BAO_0000357,,D,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620002,,4200,,,12166,11087,,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,1,RBL-1,,B,,,8,Autocuration,CHEMBL620003,,4201,,,12166,496,702.0,
,BAO_0000219,,H,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,1,RBL-1,,F,,,8,Expert,CHEMBL620004,,4202,,,12166,13986,702.0,
,BAO_0000357,,H,,Compound was evaluated for the inhibition of 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL874063,,4203,,,12166,11520,,
,BAO_0000219,,H,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620005,,4204,,,12166,10293,702.0,
,BAO_0000219,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,1,RBL-1,,B,,,8,Autocuration,CHEMBL620006,,4205,,,12166,303,702.0,
,BAO_0000219,,H,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,1,RBL-1,,B,,,8,Autocuration,CHEMBL620007,,4206,,,12166,303,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620008,,4207,,,12166,9247,702.0,
,BAO_0000219,,D,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620009,,4208,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,1,RBL-1,,B,,,8,Autocuration,CHEMBL620010,,4209,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620011,,4210,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620677,,4211,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620678,,4212,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620679,,4213,,,12166,9247,702.0,
,BAO_0000219,,H,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620680,,4214,,,12166,9247,702.0,
,BAO_0000357,,D,,Inhibitory activity against 5-lipoxygenase at 10 uM,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620838,,4215,,,12166,11481,,
,BAO_0000357,,H,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,1,,,B,,,8,Autocuration,CHEMBL620839,,4216,,,12166,105,,
,BAO_0000357,,H,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,1,,,B,,,8,Expert,CHEMBL620840,,4217,,,12166,9029,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,1,RBL-1,,B,,,8,Expert,CHEMBL620841,,4218,,,12166,1175,702.0,
,BAO_0000219,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620842,,4219,,,12166,12118,702.0,
,BAO_0000219,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,1,RBL-1,,B,,,8,Autocuration,CHEMBL620843,,4220,,,12166,12118,702.0,
,BAO_0000219,,H,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620844,,4221,,,12166,12118,702.0,
,BAO_0000219,,H,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620845,,4222,,,12166,9225,702.0,
,BAO_0000019,,H,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,1,,,B,,,8,Autocuration,CHEMBL620846,,4223,,,12166,9401,,
,BAO_0000357,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,,B,,,8,Autocuration,CHEMBL873951,,4224,,,12166,137,,
,BAO_0000357,,H,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,1,,,B,,,8,Autocuration,CHEMBL620847,,4225,,,12166,137,,
,BAO_0000219,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,RBL-1,,B,,,8,Autocuration,CHEMBL620848,,4226,,,12166,4717,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620849,,4227,,,12166,3595,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,1,RBL-1,,B,,,8,Autocuration,CHEMBL620850,,4228,,,12166,10501,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620851,,4229,,,12166,10501,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,1,RBL-1,,B,,,8,Autocuration,CHEMBL620852,,4230,,,12166,10501,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,RBL-1,,B,,,8,Autocuration,CHEMBL875098,,4231,,,12166,12526,702.0,
,BAO_0000219,,D,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL620853,,4232,,,12166,14799,702.0,
,BAO_0000019,,H,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,1,,,B,,,8,Autocuration,CHEMBL620854,,4233,,,12166,14799,,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620855,,4234,,,12166,3595,702.0,
,BAO_0000219,,H,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,1,RBL-1,,B,,,8,Expert,CHEMBL839884,,4235,,,12166,3595,702.0,
,BAO_0000219,,H,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,RBL-1,,B,,,8,Autocuration,CHEMBL620856,,4236,,,12166,12526,702.0,
,BAO_0000219,,H,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,1,RBL-1,,B,,,8,Autocuration,CHEMBL620857,,4237,,,12166,12526,702.0,
,BAO_0000019,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,,B,,,8,Autocuration,CHEMBL620858,,4238,,,12166,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,,B,,,8,Autocuration,CHEMBL620859,,4239,,,12166,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,1,,,B,,,8,Autocuration,CHEMBL620860,,4240,,,12166,10193,,
,BAO_0000019,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,1,,,B,,,8,Autocuration,CHEMBL620861,,4241,,,12166,10193,,
,BAO_0000357,,H,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),1,,,B,,,8,Expert,CHEMBL620862,,4242,,,12166,9138,,
,BAO_0000357,,H,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,1,,,B,,,8,Autocuration,CHEMBL620863,,4243,,,12166,9138,,
,BAO_0000019,,H,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,1,,,B,,,8,Autocuration,CHEMBL620864,,4244,,,12166,11966,,
,BAO_0000219,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620865,,4245,,,12166,165,702.0,
,BAO_0000219,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620866,,4246,,,12166,165,702.0,
,BAO_0000219,,H,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,1,RBL-2H3,,B,,,8,Autocuration,CHEMBL620867,,4247,,,12166,11311,663.0,
,BAO_0000219,,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,RBL-2H3,,B,,,8,Autocuration,CHEMBL620868,,4248,,,12166,11311,663.0,
,BAO_0000219,,H,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,1,RBL-2H3,,F,,,8,Autocuration,CHEMBL620869,,4249,,,12166,11311,663.0,
,BAO_0000019,,H,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,1,,,F,,,8,Autocuration,CHEMBL873952,,4250,,,12166,11311,,
,BAO_0000357,,H,,The compound was tested for inhibition of isolated 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL875099,,4251,,,12166,11311,,
,BAO_0000219,,H,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,1,RBL-2H3,,F,,,8,Autocuration,CHEMBL620870,,4252,,,12166,11311,663.0,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,1,,,B,,,8,Autocuration,CHEMBL618261,,4253,,,12166,11087,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,1,,,B,,,8,Autocuration,CHEMBL618262,,4254,,,12166,11087,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,1,,,B,,,8,Autocuration,CHEMBL619428,,4255,,,12166,11087,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,,B,,,8,Autocuration,CHEMBL619429,,4256,,,12166,11087,,
,BAO_0000019,,H,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,1,,,B,,,8,Autocuration,CHEMBL619430,,4257,,,12166,11087,,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620017,,4258,,,12166,496,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL620018,,4259,,,12166,496,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620019,,4260,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620020,,4261,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620021,,4262,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620022,,4263,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,1,RBL-1,,F,,,8,Autocuration,CHEMBL620023,,4264,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620024,,4265,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620025,,4266,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620026,,4267,,,12166,13986,702.0,
,BAO_0000219,,H,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,1,RBL-1,,F,,,8,Autocuration,CHEMBL620027,,4268,,,12166,13986,702.0,
,BAO_0000019,,D,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL620028,,4269,,,12166,13986,,
,BAO_0000357,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL620029,,4270,,,12166,10193,,
,BAO_0000357,,H,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,1,,,B,,,8,Autocuration,CHEMBL620030,,4271,,,12166,9295,,
,BAO_0000219,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,1,RBL-1,,B,,,8,Autocuration,CHEMBL875415,,4272,,,12166,4717,702.0,
,BAO_0000219,,H,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,1,RBL-1,,B,,,8,Autocuration,CHEMBL618256,,4273,,,12166,4717,702.0,
,BAO_0000219,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,1,RBL-1,,B,,,8,Autocuration,CHEMBL618257,,4274,,,12166,11854,702.0,
,BAO_0000219,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618258,,4275,,,12166,11854,702.0,
,BAO_0000219,,H,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618259,,4276,,,12166,11854,702.0,
,BAO_0000019,,H,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,1,,,B,,,8,Autocuration,CHEMBL618260,,4277,,,12166,10193,,
,BAO_0000219,,H,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618215,,4278,,,12166,9295,702.0,
,BAO_0000219,,H,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618390,,4279,,,12166,9295,702.0,
,BAO_0000219,,H,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618391,,4280,,,12166,9295,702.0,
,BAO_0000219,,H,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618392,,4281,,,12166,9295,702.0,
,BAO_0000219,,H,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,1,RBL-1,,B,,,8,Autocuration,CHEMBL618393,,4282,,,12166,165,702.0,
,BAO_0000219,,H,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,1,,,B,,,8,Autocuration,CHEMBL618394,,4283,,,12166,11311,,
,BAO_0000219,,H,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,RBL-1,9606.0,B,Homo sapiens,,8,Expert,CHEMBL618395,,4284,,,12166,10489,702.0,
,BAO_0000219,,D,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618396,,4285,,,12166,10489,702.0,
,BAO_0000219,,D,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),1,RBL-1,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL858253,,4286,,,12166,10489,702.0,
,BAO_0000019,,D,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,1,,10116.0,B,Rattus norvegicus,,9,Autocuration,CHEMBL618397,,4287,,,12166,14799,,
,BAO_0000357,,H,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),1,,3847.0,B,Glycine max,,8,Autocuration,CHEMBL618398,,4288,,,12054,9295,,
,BAO_0000019,,U,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",1,,,B,,,0,Autocuration,CHEMBL618399,,4289,,,22226,16811,,
,BAO_0000357,,H,,In vitro inhibition of 5-Lipoxygenase; Inactive.,1,,,B,,,8,Expert,CHEMBL618400,,4290,,,55,168,,
,BAO_0000357,,H,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,1,,,B,,,8,Autocuration,CHEMBL618401,,4291,,,55,6309,,
,BAO_0000357,,H,,Inhibitory concentration against 5-lipoxygenase; No inhibition,1,,,B,,,8,Autocuration,CHEMBL618402,,4292,,,55,6309,,
,BAO_0000219,,H,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,1,RBL-1,,B,,,8,Autocuration,CHEMBL876400,,4293,,,55,3092,702.0,
,BAO_0000357,,H,,Inhibitory activity against 5-lipoxygenase.,1,,,B,,,8,Expert,CHEMBL618403,,4294,,,55,168,,
,BAO_0000357,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,1,,,B,,,8,Autocuration,CHEMBL618404,,4295,,,55,168,,
,BAO_0000357,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,1,,,B,,,8,Autocuration,CHEMBL618405,,4296,,,55,168,,
,BAO_0000357,,H,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,1,,,B,,,8,Autocuration,CHEMBL618406,,4297,,,55,168,,
,BAO_0000019,,H,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,1,,,F,,,8,Expert,CHEMBL618407,,4298,,,55,12338,,
,BAO_0000357,,H,,Tested for the inhibitory activity against 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL618408,,4299,,,55,4501,,
,BAO_0000357,,H,,Compound was tested for its inhibitory activity against 5-lipoxygenase,1,,,B,,,8,Autocuration,CHEMBL618409,,4300,,,55,1132,,
,BAO_0000357,,H,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,1,,,B,,,8,Autocuration,CHEMBL618410,,4301,,,55,2117,,
,BAO_0000357,,H,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,1,,,B,,,8,Autocuration,CHEMBL618411,,4302,,,55,168,,
,BAO_0000357,,H,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,1,,,B,,,8,Autocuration,CHEMBL618412,,4303,,,55,168,,
,BAO_0000219,,H,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,1,RBL-1,,B,,,8,Autocuration,CHEMBL618413,,4304,,,12166,13575,702.0,
,BAO_0000357,,H,,,1,,,B,,,8,Autocuration,CHEMBL618414,,4305,,,12166,11089,,
,BAO_0000357,,H,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),1,,,B,,,8,Autocuration,CHEMBL618415,,4306,,,10102,216,,
,BAO_0000019,,H,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,1,,,B,,,8,Autocuration,CHEMBL618416,,4307,,,10102,13165,,
,BAO_0000357,,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,1,,,B,,,8,Autocuration,CHEMBL876401,,4308,,,10102,3278,,
,BAO_0000357,,H,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,1,,,B,,,8,Expert,CHEMBL618417,,4309,,,10102,3278,,
,BAO_0000357,,H,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,1,,,B,,,8,Autocuration,CHEMBL618418,,4310,,,10102,11966,,
,BAO_0000357,,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",1,,,B,,,8,Autocuration,CHEMBL618419,,4311,,,10102,175,,
,BAO_0000357,,H,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",1,,,B,,,8,Autocuration,CHEMBL618420,,4312,,,10102,175,,
,BAO_0000357,,H,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,1,,,B,,,8,Autocuration,CHEMBL618421,,4313,,,10102,13449,,
,BAO_0000019,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,1,,,B,,,8,Autocuration,CHEMBL618422,,4314,,,11238,12014,,
,BAO_0000019,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),1,,,B,,,8,Autocuration,CHEMBL618423,,4315,,,11238,12014,,
,BAO_0000019,,H,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),1,,,B,,,8,Autocuration,CHEMBL618424,,4316,,,11238,12014,,
,BAO_0000220,,S,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,1,,,B,,,2,Intermediate,CHEMBL618425,,4317,,,100284,99,,
,BAO_0000019,,U,,The dark toxicity against 543 human galactophore carcinoma cells,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL618426,,4318,,,22226,4349,,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,1,Panel (56 tumour cell lines),9606.0,F,Homo sapiens,,1,Expert,CHEMBL618427,,4319,,,80623,4071,390.0,
,BAO_0000219,,N,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,1,5637,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618428,,4320,,,80008,17589,345.0,
,BAO_0000219,,N,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,1,5637,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618429,,4321,,,80008,15002,345.0,
,BAO_0000219,,N,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",1,5637,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618430,,4322,,,80008,13958,345.0,
,BAO_0000219,,N,,Growth inhibition against human 5637 cell lines,1,5637,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618431,,4323,,,80008,17589,345.0,
,BAO_0000219,,N,,Antitumor activity against human bladder carcinoma 5637 cells.,1,5637,9606.0,F,Homo sapiens,,1,Expert,CHEMBL883799,,4324,,,80008,16748,345.0,
,BAO_0000219,,N,,Antitumor activity against human bladder carcinoma 5637 cells,1,5637,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618432,,4325,,,80008,16747,345.0,
,BAO_0000219,,N,,Antitumor activity against human bladder carcinoma 5637 cells,1,5637,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618433,,4326,,,80008,16747,345.0,
,BAO_0000357,,D,,In vitro inhibition of bovine trypsin(Trp).,1,,9913.0,B,Bos taurus,,9,Expert,CHEMBL618434,,4327,,,10443,15285,,
,BAO_0000219,,H,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,1,CV-1,9527.0,B,Cercopithecidae,,8,Expert,CHEMBL618435,,4328,,,240,3726,407.0,
,BAO_0000357,,H,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,1,,,B,,,8,Autocuration,CHEMBL876402,,4329,,,10577,5033,,
,BAO_0000019,,H,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,1,,,F,,,6,Autocuration,CHEMBL618436,,4330,,,104698,11756,,
,BAO_0000218,,U,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,1,,,F,,,0,Autocuration,CHEMBL618437,,4331,In vivo,,22226,11953,,
,BAO_0000357,,D,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,1,,10141.0,B,Cavia porcellus,,9,Intermediate,CHEMBL618438,,4332,,,20033,5033,,
,BAO_0000251,,H,Microsomes,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,,10116.0,A,Rattus norvegicus,,8,Expert,CHEMBL883800,,4333,,,17045,11347,,
,BAO_0000251,,H,Microsomes,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,1,,10116.0,A,Rattus norvegicus,,8,Expert,CHEMBL618439,,4334,,,17045,11347,,
,BAO_0000019,,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL618440,,4335,,,22226,1229,,
,BAO_0000019,,U,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL618441,,4336,,,22226,1229,,
,BAO_0000019,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,1,,5691.0,B,Trypanosoma brucei,,8,Expert,CHEMBL618442,,4337,,,11938,17588,,
,BAO_0000019,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,1,,5691.0,B,Trypanosoma brucei,,8,Autocuration,CHEMBL618443,,4338,,,11938,17588,,
,BAO_0000019,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,1,,9940.0,B,Ovis aries,,8,Expert,CHEMBL619158,,4339,,,11938,17588,,
,BAO_0000019,,H,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,1,,9940.0,B,Ovis aries,,8,Autocuration,CHEMBL620974,,4340,,,11938,17588,,
,BAO_0000357,,H,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,1,,,B,,,8,Autocuration,CHEMBL620975,,4341,,,11938,16485,,
,BAO_0000019,,U,,Average inhibitory concentration against 60 human cell lines was reported,1,,9606.0,F,Homo sapiens,,0,Intermediate,CHEMBL620976,,4342,,,22226,4337,,
,BAO_0000019,,U,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,1,,9606.0,F,Homo sapiens,,0,Expert,CHEMBL620977,,4343,,,22226,4112,,
,BAO_0000219,,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,1,Panel NCI-60 (60 carcinoma cell lines),9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620978,,4344,,,80315,16160,542.0,
,BAO_0000219,,N,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,1,Panel NCI-60 (60 carcinoma cell lines),9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620979,,4345,,,80315,16160,542.0,
,BAO_0000219,,N,,In vitro mean growth inhibitory activity against 60-cell panel,1,Panel NCI-60 (60 carcinoma cell lines),,F,,,1,Expert,CHEMBL620980,,4346,,,80315,17376,542.0,
,BAO_0000219,,N,,In vitro mean growth lethal concentration against 60-cell panel,1,Panel NCI-60 (60 carcinoma cell lines),,F,,,1,Expert,CHEMBL620981,,4347,,,80315,17376,542.0,
,BAO_0000219,,N,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,1,Panel NCI-60 (60 carcinoma cell lines),,F,,,1,Expert,CHEMBL620982,,4348,,,80315,17376,542.0,
,BAO_0000219,,N,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,1,Panel NCI-60 (60 carcinoma cell lines),,F,,,1,Expert,CHEMBL620983,,4349,,,80315,17376,542.0,
,BAO_0000019,,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,,F,,,4,Autocuration,CHEMBL620984,,4350,,,104775,3241,,
,BAO_0000019,,H,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,1,,,F,,,4,Autocuration,CHEMBL620985,,4351,,,104775,3241,,
,BAO_0000357,,H,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,1,,,B,,,8,Expert,CHEMBL620986,,4352,,,275,3725,,
,BAO_0000218,,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,1,,5833.0,F,Plasmodium falciparum,,1,Expert,CHEMBL620987,,4353,,,50425,10805,,
,BAO_0000218,,N,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,1,,5833.0,F,Plasmodium falciparum,,1,Expert,CHEMBL620988,,4354,,,50425,10805,,
,BAO_0000218,,N,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,1,,5833.0,F,Plasmodium falciparum,,1,Expert,CHEMBL620989,,4355,,,50425,10805,,
,BAO_0000218,,N,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,1,,5833.0,F,Plasmodium falciparum,,1,Expert,CHEMBL620990,,4356,,,50425,10805,,
,BAO_0000218,,N,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,1,,5833.0,F,Plasmodium falciparum,,1,Intermediate,CHEMBL620991,,4357,,,50425,10805,,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620992,,4358,,,80628,10144,850.0,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620993,,4359,,,80628,10144,850.0,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620994,,4360,,,80628,10144,850.0,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620995,,4361,,,80628,10144,850.0,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620996,,4362,,,80628,10144,850.0,
,BAO_0000218,,N,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL875581,,4363,,,80628,10144,850.0,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620997,,4364,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620998,,4365,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620999,,4366,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621000,,4367,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621001,,4368,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621002,,4369,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621003,,4370,In vivo,,22224,10685,,
,BAO_0000218,,U,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621004,,4371,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621005,,4372,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621006,,4373,In vivo,,22224,10685,,
,BAO_0000218,,U,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621007,,4374,In vivo,,22224,10685,,
,BAO_0000218,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621008,,4375,,,22224,10144,,
,BAO_0000218,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL621009,,4376,,,22224,10144,,
,BAO_0000218,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL857705,,4377,,,22224,10144,,
,BAO_0000218,,U,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL619828,,4378,,,22224,10144,,
,BAO_0000218,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL619829,,4379,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL619830,,4380,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL619831,,4381,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL619832,,4382,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL619833,,4383,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL619834,,4384,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL619835,,4385,,,22224,10685,,
,BAO_0000218,,U,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL619836,,4386,,,22224,10685,,
,BAO_0000218,,N,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619837,,4387,,,80628,8831,850.0,
,BAO_0000218,,U,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,1,,,F,,,0,Autocuration,CHEMBL619838,,4388,In vivo,,22224,11704,,
,BAO_0000218,,N,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619839,,4389,,,50594,11704,,
,BAO_0000218,,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619840,,4390,In vivo,,80628,10685,850.0,
,BAO_0000218,,N,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619841,,4391,In vivo,,80628,10685,850.0,
,BAO_0000218,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),1,6C3HED,10090.0,F,Mus musculus,,1,Expert,CHEMBL857704,,4392,,,80628,11368,850.0,
,BAO_0000218,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),1,6C3HED,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619842,,4393,,,80628,11368,850.0,
,BAO_0000218,,N,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),1,6C3HED,10090.0,F,Mus musculus,,1,Expert,CHEMBL619843,,4394,,,80628,11368,850.0,
,BAO_0000019,,U,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",1,,1280.0,B,Staphylococcus aureus,,0,Autocuration,CHEMBL619844,,4395,,,22226,17763,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL857855,,4396,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619845,,4397,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619846,,4398,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619847,,4399,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL619848,,4400,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620893,,4401,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620894,,4402,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620895,,4403,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620896,,4404,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620897,,4405,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620898,,4406,,,22226,7411,,
Liver,BAO_0000251,,U,Microsomes,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,1,,10116.0,B,Rattus norvegicus,2107.0,0,Autocuration,CHEMBL620899,,4407,,,22226,7411,,
Plasma,BAO_0000218,,U,,The apparent total plasma clearance in monkey,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620900,,4408,In vivo,,22224,347,,
,BAO_0000218,,U,,Compound was evaluated for Hepatic clearance in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620901,,4409,In vivo,,22224,3341,,
,BAO_0000218,,U,,Lower clearance in monkey (i.v.) at 0.5 mpk,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620902,,4410,In vivo,,22224,17853,,
,BAO_0000218,,U,,Plasma clearance in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620903,,4411,In vivo,,22224,4514,,
,BAO_0000218,,U,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620904,,4412,In vivo,,22224,6062,,
,BAO_0000218,,U,,Plasma clearance of compound was determined in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620905,,4413,In vivo,,22224,6821,,
,BAO_0000218,,U,,Plasma clearance was calculated in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620906,,4414,In vivo,,22224,6057,,
,BAO_0000218,,U,,Plasma clearance in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL875420,,4415,In vivo,,22224,5145,,
,BAO_0000218,,U,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620907,,4416,In vivo,,22224,6641,,
,BAO_0000218,,U,,Plasma clearance was evaluated in rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620908,,4417,In vivo,,22224,5472,,
,BAO_0000218,,U,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620909,,4418,In vivo,,22224,4257,,
,BAO_0000218,,U,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620910,,4419,In vivo,,22224,5546,,
,BAO_0000218,,U,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620911,,4420,In vivo,,22224,5334,,
,BAO_0000218,,U,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620912,,4421,In vivo,,22224,5334,,
,BAO_0000218,,U,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620913,,4422,In vivo,,22224,17509,,
,BAO_0000218,,U,,Cmax in monkey after administration of 1 mg/kg iv,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620914,,4423,In vivo,,22224,6535,,
,BAO_0000218,,U,,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620915,,4424,In vivo,,22224,5668,,
,BAO_0000218,,U,,Cmax in cynomolgus monkey by iv administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620916,,4425,In vivo,,22224,5922,,
,BAO_0000218,,U,,Cmax in cynomolgus monkey by po administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620917,,4426,In vivo,,22224,5922,,
,BAO_0000218,,U,,Cmax value evaluated in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620918,,4427,In vivo,,22224,6078,,
,BAO_0000218,,U,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620919,,4428,In vivo,,22224,2661,,
Plasma,BAO_0000218,,U,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620920,,4429,In vivo,,22224,3249,,
Plasma,BAO_0000218,,U,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620921,,4430,In vivo,,22224,3249,,
Plasma,BAO_0000218,,U,,Maximal plasma concentration in squirrel monkeys,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620922,,4431,In vivo,,22224,5553,,
,BAO_0000218,,U,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620923,,4432,In vivo,,22224,1916,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620924,,4433,In vivo,,22224,6227,,
,BAO_0000218,,U,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620925,,4434,In vivo,,22224,4809,,
,BAO_0000218,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620926,,4435,In vivo,,22224,5355,,
,BAO_0000218,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620927,,4436,In vivo,,22224,5355,,
,BAO_0000218,,U,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620928,,4437,In vivo,,22224,5355,,
,BAO_0000218,,U,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620929,,4438,In vivo,,22224,5355,,
Plasma,BAO_0000218,,U,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620930,,4439,In vivo,,22224,6221,,
,BAO_0000218,,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620931,,4440,,,22224,167,,
,BAO_0000218,,U,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620932,,4441,,,22224,167,,
,BAO_0000218,,U,,Absolute bioavailability was evaluated in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620933,,4442,In vivo,,22224,4257,,
,BAO_0000218,,U,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620934,,4443,In vivo,,22224,6221,,
,BAO_0000218,,U,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620935,,4444,In vivo,,22224,17667,,
,BAO_0000218,,U,,Bioavailability of compound was determined in rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620936,,4445,In vivo,,22224,17267,,
,BAO_0000218,,U,,Bioavailability determined after oral administration in marmoset,1,,38020.0,A,marmosets,,0,Autocuration,CHEMBL620937,,4446,In vivo,,22224,4256,,
,BAO_0000218,,U,,Oral bioavailability in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL620938,,4447,In vivo,,22224,4256,,
,BAO_0000218,,U,,Bioavailability in monkey (p.o.) at 2.0 mpk,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620939,,4448,In vivo,,22224,17853,,
,BAO_0000218,,U,,Bioavailability was evaluated after oral administration in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620940,,4449,In vivo,,22224,16365,,
,BAO_0000218,,U,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL620941,,4450,In vivo,,22224,1916,,
,BAO_0000218,,U,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620942,,4451,In vivo,,22224,5334,,
,BAO_0000218,,U,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620943,,4452,In vivo,,22224,5334,,
,BAO_0000218,,U,,Bioavailability of the compound was determined in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620944,,4453,In vivo,,22224,17592,,
,BAO_0000218,,U,,Bioavailability in squirrel monkey (dose 5 mg/kg),1,,9521.0,A,Saimiri sciureus,,0,Autocuration,CHEMBL620945,,4454,In vivo,,22224,1399,,
,BAO_0000218,,U,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620946,,4455,In vivo,,22224,4809,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620947,,4456,In vivo,,22224,3341,,
,BAO_0000218,,U,,Compound was tested for bioavailability in squirrel monkey,1,,9521.0,A,Saimiri sciureus,,0,Autocuration,CHEMBL620948,,4457,In vivo,,22224,64,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620949,,4458,In vivo,,22224,5005,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620950,,4459,In vivo,,22224,5005,,
,BAO_0000218,,U,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL620951,,4460,In vivo,,22224,5237,,
,BAO_0000218,,U,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL620952,,4461,In vivo,,22224,5237,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dose 5 mg/kg),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL875421,,4462,In vivo,,22224,5302,,
,BAO_0000218,,U,,Oral bioavailability of compound at 5 mg/kg in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620953,,4463,In vivo,,22224,17667,,
,BAO_0000218,,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873491,,4464,In vivo,,50588,6161,,
,BAO_0000218,,N,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620954,,4465,In vivo,,50588,6161,,
Plasma,BAO_0000218,,N,,Plasma half life determined,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620955,,4466,,,50588,3854,,
Plasma,BAO_0000218,,N,,Plasma half life in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618097,,4467,,,50588,993,,
Plasma,BAO_0000218,,N,,Plasma half-life in Beagle dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618268,,4468,,,50588,4514,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618269,,4469,In vivo,,50588,5334,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618270,,4470,In vivo,,50588,5334,,
,BAO_0000218,,N,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618271,,4471,In vivo,,50588,1466,,
,BAO_0000218,,N,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873493,,4472,In vivo,,50588,1466,,
,BAO_0000218,,N,,Tested for the half life period in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621031,,4473,,,50588,5313,,
,BAO_0000218,,N,,Tested for the half life period in dog at dosage of 10 mpk,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621032,,4474,In vivo,,50588,5313,,
,BAO_0000218,,N,,The compound was tested for half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621033,,4475,,,50588,3880,,
Plasma,BAO_0000218,,N,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621034,,4476,,,50588,3639,,
,BAO_0000218,,N,,The half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621035,,4477,,,50588,3880,,
Plasma,BAO_0000218,,N,,The plasma half-life in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621036,,4478,,,50588,3918,,
Plasma,BAO_0000218,,N,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621037,,4479,,,50588,16452,,
,BAO_0000218,,N,,Half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619812,,4480,,,50588,17796,,
,BAO_0000218,,N,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619813,,4481,In vivo,,50588,5983,,
,BAO_0000218,,N,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873335,,4482,In vivo,,50588,1466,,
,BAO_0000218,,N,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619814,,4483,In vivo,,50588,16456,,
,BAO_0000218,,N,,Cmax in ferrets after 30 mg/kg oral dose,1,,9669.0,A,Mustela putorius furo,,1,Expert,CHEMBL619815,,4484,In vivo,,50506,6113,,
,BAO_0000218,,N,,Emesis in ferrets at 30 mg/kg oral dose,1,,9669.0,F,Mustela putorius furo,,1,Expert,CHEMBL619816,,4485,In vivo,,50506,6113,,
,BAO_0000218,,U,,Bioavailability in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL619817,,4486,In vivo,,22224,17796,,
,BAO_0000218,,N,,Volume of distribution in cynomolgus,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL619818,,4487,In vivo,,100710,17796,,
Plasma,BAO_0000218,,U,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,1,,10141.0,A,Cavia porcellus,1969.0,0,Autocuration,CHEMBL619819,,4488,,,22224,5308,,
,BAO_0000218,,U,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619820,,4489,,,22224,4877,,
,BAO_0000218,,U,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL875419,,4490,,,22224,4876,,
Plasma,BAO_0000218,,U,,AUC in guinea pig after 3mg/kg oral dose,1,,10141.0,A,Cavia porcellus,1969.0,0,Autocuration,CHEMBL619821,,4491,In vivo,,22224,4878,,
,BAO_0000218,,U,,Bioavailability in guinea pig was tested,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619822,,4492,In vivo,,22224,5308,,
,BAO_0000218,,U,,Tested for oral bioavailability in guinea pig at 5 mg/kg,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619823,,4493,In vivo,,22224,4877,,
,BAO_0000218,,U,,Tested for the oral bioavailability of the compound,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619824,,4494,In vivo,,22224,4876,,
,BAO_0000218,,U,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619825,,4495,In vivo,,22224,4876,,
,BAO_0000218,,U,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL619826,,4496,In vivo,,22224,5308,,
Lung,BAO_0000218,,U,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,1,,10141.0,A,Cavia porcellus,2048.0,0,Autocuration,CHEMBL619827,,4497,In vivo,,22224,4877,,
,BAO_0000218,,U,,Cmax in guinea pig after 3mg/kg oral dose,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618167,,4498,In vivo,,22224,4878,,
Blood,BAO_0000019,,U,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,178.0,0,Autocuration,CHEMBL618168,,4499,,,22224,5689,,
Brain,BAO_0000019,,U,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,955.0,0,Autocuration,CHEMBL618169,,4500,,,22224,5689,,
,BAO_0000019,,U,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618170,,4501,,,22224,5689,,
Intestine,BAO_0000019,,U,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,160.0,0,Autocuration,CHEMBL618171,,4502,,,22224,5689,,
Kidney,BAO_0000019,,U,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,2113.0,0,Autocuration,CHEMBL618172,,4503,,,22224,5689,,
Liver,BAO_0000019,,U,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,2107.0,0,Autocuration,CHEMBL618173,,4504,,,22224,5689,,
,BAO_0000019,,U,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618174,,4505,,,22224,5689,,
Spleen,BAO_0000019,,U,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,1,,10141.0,A,Cavia porcellus,2106.0,0,Autocuration,CHEMBL875408,,4506,,,22224,5689,,
,BAO_0000218,,U,,Elimination T1/2 in Guinea pig (PO dose),1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL839827,,4507,In vivo,,22224,14465,,
,BAO_0000019,,U,,Partition coefficient was measured as -log (counts per min ),1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618175,,4508,,,22224,5689,,
,BAO_0000218,,U,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618176,,4509,In vivo,,22224,611,,
,BAO_0000218,,U,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618177,,4510,In vivo,,22224,611,,
,BAO_0000218,,U,,Elimination T1/2 in Guinea pig (PO dose),1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618178,,4511,In vivo,,22224,14465,,
,BAO_0000218,,U,,"Tested for the half life period of the compound, intravenously",1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618179,,4512,In vivo,,22224,4876,,
,BAO_0000019,,U,,Half-life was measured,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL873489,,4513,,,22224,5689,,
,BAO_0000019,,U,,The time required for onset of inotropy after addition of a single dose of delta F75,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618180,,4514,,,22224,7515,,
,BAO_0000218,,U,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618181,,4515,In vivo,,22224,17667,,
,BAO_0000218,,U,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL618182,,4516,In vivo,,22224,17667,,
,BAO_0000218,,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL618183,,4517,In vivo,,22224,4727,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618184,,4518,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618185,,4519,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618186,,4520,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618187,,4521,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618188,,4522,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875409,,4523,In vivo,,50594,10107,,
,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618189,,4524,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL618190,,4525,In vivo,,50594,3655,,
Blood,BAO_0000218,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL618191,,4526,In vivo,,50594,3655,,
Blood,BAO_0000218,,N,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL618192,,4527,In vivo,,50594,3655,,
Bone,BAO_0000218,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL618193,,4528,In vivo,,50594,3655,,
Bone,BAO_0000218,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL618194,,4529,In vivo,,50594,3655,,
Bone,BAO_0000218,,N,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL618195,,4530,In vivo,,50594,3655,,
Brain,BAO_0000218,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618196,,4531,In vivo,,50594,3655,,
Brain,BAO_0000218,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618197,,4532,In vivo,,50594,3655,,
Brain,BAO_0000218,,N,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618198,,4533,In vivo,,50594,3655,,
Heart,BAO_0000218,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL618199,,4534,In vivo,,50594,3655,,
Heart,BAO_0000218,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL618200,,4535,In vivo,,50594,3655,,
Heart,BAO_0000218,,N,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL618201,,4536,In vivo,,50594,3655,,
Intestine,BAO_0000218,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL618202,,4537,In vivo,,50594,3655,,
Intestine,BAO_0000218,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL618203,,4538,In vivo,,50594,3655,,
Intestine,BAO_0000218,,N,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL618204,,4539,In vivo,,50594,3655,,
Kidney,BAO_0000218,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618205,,4540,In vivo,,50594,3655,,
Kidney,BAO_0000218,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618206,,4541,In vivo,,50594,3655,,
Kidney,BAO_0000218,,N,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618207,,4542,In vivo,,50594,3655,,
Liver,BAO_0000218,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618208,,4543,In vivo,,50594,3655,,
Liver,BAO_0000218,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618932,,4544,In vivo,,50594,3655,,
Liver,BAO_0000218,,N,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618933,,4545,In vivo,,50594,3655,,
Lung,BAO_0000218,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL618934,,4546,In vivo,,50594,3655,,
Lung,BAO_0000218,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL618935,,4547,In vivo,,50594,3655,,
Lung,BAO_0000218,,N,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL618936,,4548,In vivo,,50594,3655,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618937,,4549,In vivo,,50594,3655,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618938,,4550,In vivo,,50594,3655,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL619104,,4551,In vivo,,50594,3655,,
Spleen,BAO_0000218,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL619105,,4552,In vivo,,50594,3655,,
Spleen,BAO_0000218,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL619106,,4553,In vivo,,50594,3655,,
Spleen,BAO_0000218,,N,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL619107,,4554,In vivo,,50594,3655,,
Stomach,BAO_0000218,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL875410,,4555,In vivo,,50594,3655,,
Stomach,BAO_0000218,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL619108,,4556,In vivo,,50594,3655,,
Stomach,BAO_0000218,,N,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL619109,,4557,In vivo,,50594,3655,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619110,,4558,In vivo,,50594,16597,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619111,,4559,In vivo,,50594,16597,,
,BAO_0000218,,N,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619112,,4560,In vivo,,50594,16597,,
,BAO_0000218,,N,,MRT value at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619113,,4561,In vivo,,50594,16597,,
,BAO_0000218,,N,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619114,,4562,In vivo,,50594,17764,,
,BAO_0000218,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619115,,4563,In vivo,,50594,17764,,
,BAO_0000219,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619116,,4564,,,81034,3830,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619117,,4565,,,81034,3829,478.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against A2780 cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619118,,4566,,,81034,2040,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619119,,4567,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619120,,4568,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619121,,4569,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619122,,4570,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619123,,4571,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619124,,4572,,,81034,15684,478.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619125,,4573,,,81034,2859,478.0,
,BAO_0000219,,N,,In vitro inhibitory activity against human tumor cell line A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875411,,4574,,,81034,5618,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619126,,4575,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619127,,4576,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619128,,4577,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619129,,4578,,,81034,15684,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619130,,4579,,,81034,2113,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619131,,4580,,,81034,2113,478.0,
,BAO_0000219,,N,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619132,,4581,,,81034,16745,478.0,
,BAO_0000218,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619133,,4582,,,81034,16597,478.0,
,BAO_0000219,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619134,,4583,,,81034,15684,478.0,
,BAO_0000219,,N,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619135,,4584,,,81034,15684,478.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619136,,4585,,,81034,2040,478.0,
,BAO_0000219,,N,,Relative resistance factor in A2780 cisplatin-resistant line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619137,,4586,,,81034,2040,478.0,
,BAO_0000219,,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883713,,4587,,,81034,16165,478.0,
,BAO_0000219,,N,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875412,,4588,,,81034,16165,478.0,
,BAO_0000218,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619138,,4589,,,81034,16597,478.0,
,BAO_0000218,,N,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619262,,4590,,,81034,16597,478.0,
,BAO_0000219,,N,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619139,,4591,,,81034,3992,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619140,,4592,,,81034,10553,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619141,,4593,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619142,,4594,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619143,,4595,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619144,,4596,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619145,,4597,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619146,,4598,,,81034,15608,478.0,
,BAO_0000219,,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619147,,4599,,,81034,15569,478.0,
,BAO_0000219,,N,,Antiproliferative effect of compound on A2780/DX cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619148,,4600,,,81034,17420,478.0,
,BAO_0000219,,N,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619149,,4601,,,81034,17420,478.0,
,BAO_0000219,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619150,,4602,,,81034,15099,478.0,
,BAO_0000219,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619151,,4603,,,81034,15099,478.0,
,BAO_0000219,,N,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883794,,4604,,,81034,17672,478.0,
,BAO_0000219,,N,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619152,,4605,,,81034,17672,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780ADR cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619153,,4606,,,81034,17270,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780CIS cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619154,,4607,,,81034,17270,478.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619155,,4608,,,81034,5574,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619156,,4609,,,81034,2113,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619157,,4610,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619797,,4611,,,81034,16913,478.0,
,BAO_0000218,,U,,Oral bioavailability of compound in rhesus macaques,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL619798,,4612,In vivo,,22224,17839,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL619799,,4613,In vivo,,22224,6821,,
,BAO_0000218,,U,,Oral bioavailability evaluated in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL619800,,4614,In vivo,,22224,6078,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL619801,,4615,In vivo,,22224,6535,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL619802,,4616,In vivo,,22224,4449,,
,BAO_0000218,,U,,Oral bioavailability was calculated in rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL619803,,4617,In vivo,,22224,6057,,
,BAO_0000218,,U,,Oral bioavailability in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL619965,,4618,In vivo,,22224,5922,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL619966,,4619,In vivo,,22224,5940,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL619967,,4620,In vivo,,22224,6265,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dose 1 mg/kg),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620073,,4621,In vivo,,22224,6265,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dose 5 mg/kg),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620074,,4622,In vivo,,22224,6265,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620075,,4623,In vivo,,22224,5940,,
,BAO_0000218,,U,,Oral bioavailability in monkey,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620076,,4624,In vivo,,22224,5940,,
,BAO_0000218,,U,,Oral bioavailability in rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620077,,4625,In vivo,,22224,4514,,
,BAO_0000218,,U,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620078,,4626,In vivo,,22224,5546,,
,BAO_0000218,,U,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,1,,9521.0,A,Saimiri sciureus,,0,Autocuration,CHEMBL620079,,4627,In vivo,,22224,5553,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620080,,4628,In vivo,,22224,6641,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620081,,4629,In vivo,,22224,5472,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620082,,4630,In vivo,,22224,5668,,
,BAO_0000218,,U,,Oral bioavailability in monkey at 10 mg/kg of the compound,1,,9443.0,A,monkey,,0,Autocuration,CHEMBL620083,,4631,In vivo,,22224,5711,,
,BAO_0000218,,U,,Bioavailability in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620084,,4632,In vivo,,22224,5145,,
,BAO_0000218,,U,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620085,,4633,,,22224,3443,,
,BAO_0000218,,U,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL874595,,4634,,,22224,3443,,
,BAO_0000218,,U,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL873352,,4635,In vivo,,22224,3249,,
,BAO_0000218,,U,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620086,,4636,In vivo,,22224,3249,,
,BAO_0000218,,U,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620087,,4637,In vivo,,22224,5355,,
,BAO_0000218,,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620088,,4638,In vivo,,22224,5355,,
,BAO_0000218,,U,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620089,,4639,In vivo,,22224,5355,,
,BAO_0000218,,U,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620090,,4640,In vivo,,22224,4809,,
,BAO_0000218,,U,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620091,,4641,In vivo,,22224,4809,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620092,,4642,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620093,,4643,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620094,,4644,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620095,,4645,,,22224,14294,,
,BAO_0000218,,U,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620096,,4646,In vivo,,22224,3443,,
,BAO_0000218,,U,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620097,,4647,In vivo,,22224,3443,,
,BAO_0000019,,U,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620098,,4648,,,22224,11271,,
,BAO_0000218,,U,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620099,,4649,,,22224,3443,,
,BAO_0000218,,U,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620100,,4650,,,22224,3443,,
,BAO_0000019,,U,,Elimination Half-life of compound was determined in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620101,,4651,,,22224,6821,,
,BAO_0000019,,U,,Half life of compound was determined in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620102,,4652,,,22224,17267,,
Plasma,BAO_0000366,,U,,Half life in monkey plasma,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620103,,4653,,,22224,5819,,
Plasma,BAO_0000366,,U,,Half life in monkey plasma; Not detected,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL620104,,4654,,,22224,5819,,
,BAO_0000218,,U,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL874596,,4655,In vivo,,22224,1916,,
,BAO_0000218,,U,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL873490,,4656,In vivo,,22224,17509,,
,BAO_0000019,,U,,Terminal half life of the compound.,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620105,,4657,,,22224,1399,,
,BAO_0000218,,U,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620780,,4658,In vivo,,22224,1916,,
,BAO_0000218,,U,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620781,,4659,In vivo,,22224,4809,,
,BAO_0000218,,U,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620956,,4660,,,22224,5546,,
Urine,BAO_0000218,,U,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,1088.0,0,Autocuration,CHEMBL620957,,4661,,,22224,3443,,
Urine,BAO_0000218,,U,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,1088.0,0,Autocuration,CHEMBL620958,,4662,,,22224,3443,,
,BAO_0000218,,U,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620959,,4663,In vivo,,22224,4257,,
,BAO_0000218,,U,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620960,,4664,In vivo,,22224,6221,,
,BAO_0000218,,U,,Volume of distribution was evaluated in rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL620961,,4665,In vivo,,22224,5472,,
,BAO_0000218,,U,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL620962,,4666,In vivo,,22224,4727,,
,BAO_0000218,,U,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL620963,,4667,In vivo,,22224,4727,,
,BAO_0000218,,U,,Bioavailability in hamster was determined,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL620964,,4668,In vivo,,22224,4727,,
,BAO_0000218,,U,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL620965,,4669,In vivo,,22224,4727,,
,BAO_0000218,,U,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,1,,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL620966,,4670,In vivo,,22224,4727,,
Blood,BAO_0000221,,U,,Half life of compound was determined in hamster blood,1,,10029.0,A,Cricetulus griseus,178.0,0,Autocuration,CHEMBL620967,,4671,,,22224,4727,,
,BAO_0000019,,U,,Michaelis-Menten constant of the compound.,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL620968,,4672,,,22224,1452,,
,BAO_0000019,,U,,Vmax value was measured at 0 uM concentration of silyl ether.,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL874597,,4673,,,22224,1452,,
,BAO_0000019,,U,,Vmax value was measured at 10 uM concentration of silyl ether.,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL620969,,4674,,,22224,1452,,
,BAO_0000019,,U,,Vmax value was measured at 5 uM concentration of silyl ether.,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL620970,,4675,,,22224,1452,,
,BAO_0000357,,D,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL620971,,4676,,,235,11706,,
,BAO_0000218,,U,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620972,,4677,,,22224,1916,,
,BAO_0000019,,U,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620973,,4678,,,22224,17791,,
,BAO_0000019,,U,,Active metabolite of ifosfamide determined in humans; A-Active,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618243,,4679,,,22224,7766,,
,BAO_0000019,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618244,,4680,,,22224,6567,,
,BAO_0000019,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618245,,4681,,,22224,6567,,
,BAO_0000019,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618246,,4682,,,22224,6567,,
,BAO_0000019,,U,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618247,,4683,,,22224,6567,,
,BAO_0000218,,U,,Compound was evaluated for oral bioavailability in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618248,,4684,,,22224,17791,,
Urine,BAO_0000019,,U,,Metabolite of ifosfamide determined in urine; NF-Not found,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618249,,4685,,,22224,7766,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618250,,4686,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL874598,,4687,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618251,,4688,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618252,,4689,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618253,,4690,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618254,,4691,,,22224,6852,,
,BAO_0000019,,U,,Percent of compound in healthy individuals (Group D),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618255,,4692,,,22224,6852,,
Liver,BAO_0000251,,U,Microsomes,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618983,,4693,,,22224,4397,,
,BAO_0000019,,U,,Binding towards human plasma protein at 10 uM,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618984,,4694,,,22224,17409,,
,BAO_0000019,,U,,Binding towards human plasma protein at 100 uM,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618985,,4695,,,22224,17409,,
,BAO_0000019,,U,,Human plasma protein binding activity was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618986,,4696,,,22224,17176,,
,BAO_0000019,,U,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618987,,4697,,,22224,15444,,
,BAO_0000019,,U,,Percent binding of compound towards human plasma protein was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618988,,4698,,,22224,17267,,
Liver,BAO_0000251,,U,Microsomes,Plasma clearance in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618989,,4699,In vitro,,22224,5944,,
Liver,BAO_0000251,,U,Microsomes,In vitro intrinsic clearance in human liver microsome,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618990,,4700,In vitro,,22224,5668,,
Liver,BAO_0000251,,U,Microsomes,In vitro intrinsic clearance in human liver microsome,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618991,,4701,In vitro,,22224,5669,,
,BAO_0000251,,U,Microsomes,In vitro microsome metabolism clearance in human was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL876725,,4702,In vitro,,22224,5041,,
,BAO_0000251,,U,Microsomes,In vitro microsome metabolism clearance in human was determined; High,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618992,,4703,In vitro,,22224,5041,,
,BAO_0000251,,U,Microsomes,In vitro microsome metabolism clearance in human was determined; ND denotes no data,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618993,,4704,In vitro,,22224,5041,,
Liver,BAO_0000251,,U,Microsomes,Pharmacokinetic property (clearance) in human liver microsome,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618994,,4705,In vitro,,22224,5676,,
Liver,BAO_0000251,,U,Microsomes,Plasma clearance in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618995,,4706,In vitro,,22224,5944,,
Liver,BAO_0000251,,U,Microsomes,In vitro clearance in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618996,,4707,In vitro,,22224,17538,,
Liver,BAO_0000251,,U,Microsomes,Intrinsic clearance in human liver microsomes was determined,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618997,,4708,In vitro,,22224,6331,,
Liver,BAO_0000251,,U,Microsomes,Intrinsic clearance in human liver microsomes was determined,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618998,,4709,In vitro,,22224,5948,,
,BAO_0000218,,U,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618999,,4710,In vivo,,22224,5965,,
,BAO_0000218,,U,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620223,,4711,In vivo,,22224,1916,,
,BAO_0000218,,U,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620224,,4712,,,22224,5965,,
,BAO_0000019,,U,,Stability in human plasma 2 hr after incubation expressed as percent concentration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620225,,4713,,,22224,1299,,
,BAO_0000019,,U,,Stability in human plasma 4 hr after incubation expressed as percent concentration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620226,,4714,,,22224,1299,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL620227,,4715,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL876726,,4716,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL620228,,4717,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL620229,,4718,,,22224,7766,,
,BAO_0000218,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620230,,4719,In vivo,,50594,17764,,
,BAO_0000218,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620231,,4720,In vivo,,50594,17764,,
,BAO_0000218,,N,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620232,,4721,In vivo,,50594,17764,,
,BAO_0000218,,N,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620233,,4722,In vivo,,50594,17764,,
,BAO_0000218,,N,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620234,,4723,,,50594,14294,,
,BAO_0000218,,N,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620235,,4724,,,50594,14294,,
,BAO_0000218,,N,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620236,,4725,,,50594,14294,,
Liver,BAO_0000218,,N,,In vitro metabolic potential in mouse liver microsomes,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL620237,,4726,,,50594,6251,,
,BAO_0000218,,N,,Ability of compound to bind to plasma protein was evaluated in HSA cells,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620238,,4727,,,50594,17582,,
Adrenal gland,BAO_0000218,,N,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),1,,10090.0,A,Mus musculus,2369.0,1,Intermediate,CHEMBL620239,,4728,,,50594,17811,,
Brain,BAO_0000218,,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL620240,,4729,,,50594,17811,,
Brain,BAO_0000218,,N,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL620241,,4730,,,50594,17811,,
,BAO_0000218,,N,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876727,,4731,,,50594,17811,,
Kidney,BAO_0000218,,N,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL620242,,4732,,,50594,17811,,
,BAO_0000218,,N,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620243,,4733,,,50594,17811,,
,BAO_0000218,,N,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620244,,4734,,,50594,5288,,
Serum,BAO_0000218,,N,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,1,,10090.0,A,Mus musculus,1977.0,1,Intermediate,CHEMBL620245,,4735,,,50594,2717,,
Serum,BAO_0000218,,N,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,1,,10090.0,A,Mus musculus,1977.0,1,Intermediate,CHEMBL620246,,4736,,,50594,2717,,
Serum,BAO_0000218,,N,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,1,,10090.0,A,Mus musculus,1977.0,1,Intermediate,CHEMBL620247,,4737,,,50594,2717,,
Plasma,BAO_0000218,,N,,Half life of compound was determined in plasma of mice at 24 mg/Kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL620248,,4738,In vivo,,50594,17753,,
Plasma,BAO_0000218,,N,,Half life of compound was determined in plasma of mice at 40 mg/Kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL873497,,4739,In vivo,,50594,17753,,
Plasma,BAO_0000218,,N,,Half life of compound was determined in plasma of mice at 5 mg/Kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL620249,,4740,In vivo,,50594,17753,,
,BAO_0000218,,N,,Half life after intraperitoneal administration in mice at 18 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620250,,4741,In vivo,,50594,17764,,
,BAO_0000218,,N,,Half life after intraperitoneal administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620251,,4742,In vivo,,50594,17764,,
,BAO_0000218,,N,,Half life after intraperitoneal administration in mice at 25 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620252,,4743,In vivo,,50594,17764,,
,BAO_0000218,,N,,Half life after intraperitoneal administration in mice at 26 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620253,,4744,In vivo,,50594,17764,,
,BAO_0000218,,N,,Half life after intravenous administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620254,,4745,In vivo,,50594,17764,,
,BAO_0000218,,N,,Half life after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620255,,4746,In vivo,,50594,17764,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620256,,4747,In vivo,,50594,16597,,
,BAO_0000218,,N,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876728,,4748,In vivo,,50594,2675,,
,BAO_0000218,,N,,Maximum time required to reach Cp max was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620257,,4749,In vivo,,50594,2675,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620258,,4750,In vivo,,50594,16597,,
,BAO_0000218,,N,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620259,,4751,In vivo,,50594,4890,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620260,,4752,In vivo,,50594,429,,
Blood,BAO_0000218,,N,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL620261,,4753,In vivo,,50594,17837,,
,BAO_0000218,,N,,Half life at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620262,,4754,In vivo,,50594,16597,,
,BAO_0000218,,N,,Half life at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620263,,4755,In vivo,,50594,16597,,
,BAO_0000218,,N,,Half life in ob/ob mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620264,,4756,,,50594,6619,,
,BAO_0000218,,N,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620265,,4757,In vivo,,50594,4066,,
,BAO_0000218,,N,,Half-life was measured in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620266,,4758,,,50594,4239,,
,BAO_0000218,,N,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620267,,4759,In vivo,,50594,5969,,
,BAO_0000218,,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619364,,4760,,,50594,8999,,
,BAO_0000218,,N,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619365,,4761,,,50594,8999,,
Brain,BAO_0000218,,N,,T2 in brain of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL619366,,4762,,,50594,17641,,
Kidney,BAO_0000218,,N,,T2 in kidney of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL619367,,4763,,,50594,17641,,
Liver,BAO_0000218,,N,,T2 in liver of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL619368,,4764,,,50594,17641,,
Lung,BAO_0000218,,N,,T2 in lungs of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL619369,,4765,,,50594,17641,,
Spleen,BAO_0000218,,N,,T2 in spleen of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL876729,,4766,,,50594,17641,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619370,,4767,In vivo,,50594,16597,,
,BAO_0000218,,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619371,,4768,In vivo,,50594,4890,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619372,,4769,In vivo,,50594,429,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620012,,4770,In vivo,,50594,429,,
,BAO_0000218,,N,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620013,,4771,In vivo,,50594,5969,,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620014,,4772,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620015,,4773,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621010,,4774,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621011,,4775,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621012,,4776,,,81034,16913,478.0,
,BAO_0000219,,N,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621013,,4777,,,81034,16913,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780TAX cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621014,,4778,,,81034,17270,478.0,
,BAO_0000219,,N,,In vitro inhibitory activity against human tumor cell line A2780cis,1,A2780cisR,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618154,,4779,,,80017,5618,481.0,
,BAO_0000219,,N,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618155,,4780,,,81034,17777,478.0,
,BAO_0000219,,N,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,1,A2780cisR,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618156,,4781,,,80017,16112,481.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,A2780cisR,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618157,,4782,,,80017,15748,481.0,
,BAO_0000219,,N,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618328,,4783,,,81034,6633,478.0,
,BAO_0000219,,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618329,,4784,,,81034,16930,478.0,
,BAO_0000219,,N,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618330,,4785,,,81034,17496,478.0,
,BAO_0000219,,N,,In vitro antitumor activity against A2780cisR cell line.,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618331,,4786,,,81034,12989,478.0,
,BAO_0000219,,N,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618332,,4787,,,81034,4840,478.0,
,BAO_0000219,,N,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618333,,4788,,,81034,12989,478.0,
,BAO_0000219,,N,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,1,A2780cisR,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618334,,4789,,,80017,16745,481.0,
,BAO_0000219,,N,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618335,,4790,,,81034,16597,478.0,
,BAO_0000019,,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL618336,,4791,,,11736,16547,,
,BAO_0000019,,H,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,,,F,,,8,Expert,CHEMBL618337,,4792,,,11736,16547,,
,BAO_0000019,,D,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),1,,10116.0,F,Rattus norvegicus,,9,Expert,CHEMBL618338,,4793,,,11736,16547,,
,BAO_0000219,,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,1,HEK293,9606.0,F,Homo sapiens,,9,Expert,CHEMBL618339,,4794,,,278,15856,722.0,
,BAO_0000219,,D,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,1,HEK293,9606.0,F,Homo sapiens,,9,Expert,CHEMBL618340,,4795,,,278,15856,722.0,
,BAO_0000019,,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,1,,10090.0,B,Mus musculus,,9,Expert,CHEMBL618341,,4796,,,11831,16547,,
,BAO_0000019,,H,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,,,F,,,8,Expert,CHEMBL618342,,4797,,,11831,16547,,
,BAO_0000019,,D,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),1,,10090.0,F,Mus musculus,,9,Expert,CHEMBL618343,,4798,,,11831,16547,,
,BAO_0000357,,H,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,1,,,B,,,8,Expert,CHEMBL621038,,4799,,,280,17402,,
,BAO_0000219,,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),1,T-cells,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL621039,,4800,,,22226,11746,574.0,
,BAO_0000219,,U,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,1,T-cells,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL621040,,4801,,,22226,11746,574.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621041,,4802,,,80018,5455,455.0,
,BAO_0000219,,N,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621042,,4803,,,80018,2068,455.0,
,BAO_0000219,,N,,In vitro antitumor activity against A375cell line extracted form melanoma,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621043,,4804,,,80018,2683,455.0,
,BAO_0000219,,N,,Inhibition of cell growth in (A375) melan cell line,1,A-375,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621044,,4805,,,80018,15313,455.0,
,BAO_0000219,,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621045,,4806,,,80018,13739,455.0,
,BAO_0000219,,N,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621046,,4807,,,80018,13739,455.0,
,BAO_0000219,,N,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621047,,4808,,,80018,14750,455.0,
,BAO_0000219,,N,,Antiproliferative activity measured against A427 human lung carcinoma,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621048,,4809,,,80019,14777,797.0,
,BAO_0000219,,N,,Antiproliferative activity measured against A427 human lung carcinoma,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883798,,4810,,,80019,14777,797.0,
,BAO_0000219,,N,,Cytotoxicity against lung carcinoma A427 tumor cell lines,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621049,,4811,,,80019,17672,797.0,
,BAO_0000219,,N,,Inhibition of large cell lung carcinoma (A427),1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621050,,4812,,,80019,14368,797.0,
,BAO_0000219,,N,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621051,,4813,,,80019,14368,797.0,
,BAO_0000219,,N,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621052,,4814,,,80019,13866,797.0,
,BAO_0000219,,N,,Inhibitory concentration in human lung carcinoma A427 cell line,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621053,,4815,,,80019,2545,797.0,
,BAO_0000219,,N,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621054,,4816,,,80019,2545,797.0,
,BAO_0000218,,U,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621055,,4817,In vivo,,22224,6062,,
,BAO_0000218,,U,,Tested for volume of distribution upon iv administration to african green monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876398,,4818,In vivo,,22224,4578,,
,BAO_0000218,,U,,Volume of distribution in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621056,,4819,In vivo,,22224,17592,,
,BAO_0000218,,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL621057,,4820,In vivo,,22224,5005,,
,BAO_0000218,,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL621058,,4821,In vivo,,22224,5005,,
,BAO_0000218,,U,,Pharmacokinetic property(Vdss) in cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621059,,4822,In vivo,,22224,5922,,
,BAO_0000218,,U,,The distribution volume after intravenous administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621060,,4823,In vivo,,22224,5355,,
,BAO_0000218,,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621061,,4824,In vivo,,22224,5355,,
,BAO_0000218,,U,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621062,,4825,In vivo,,22224,5355,,
,BAO_0000218,,U,,Volume displacement was calculated in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621063,,4826,In vivo,,22224,6057,,
,BAO_0000218,,U,,Volume of distribution in steady state was determined in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621064,,4827,In vivo,,22224,5145,,
,BAO_0000218,,U,,Volume of distribution of compound was determined in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621065,,4828,In vivo,,22224,6821,,
,BAO_0000218,,U,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621066,,4829,In vivo,,22224,5334,,
,BAO_0000218,,U,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621067,,4830,In vivo,,22224,5334,,
,BAO_0000218,,U,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621068,,4831,In vivo,,22224,6641,,
,BAO_0000218,,U,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876399,,4832,In vivo,,22224,2661,,
,BAO_0000218,,U,,Volume distribution in monkey after administration of 1 mg/kg iv,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621069,,4833,In vivo,,22224,6535,,
,BAO_0000218,,U,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621070,,4834,In vivo,,22224,4809,,
,BAO_0000218,,U,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621071,,4835,In vivo,,22224,6062,,
,BAO_0000218,,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621072,,4836,In vivo,,22224,3443,,
,BAO_0000218,,U,,Oral systemic bioavailability upon iv administration to african green monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618209,,4837,In vivo,,22224,4578,,
,BAO_0000218,,U,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618210,,4838,In vivo,,22224,4809,,
,BAO_0000019,,U,,Baboon plasma free fraction. ,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618211,,4839,,,22224,11271,,
,BAO_0000218,,U,,Area under the curve was calculated in rhesus monkey after iv administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618212,,4840,,,22224,6057,,
,BAO_0000019,,U,,Area under the curve was calculated in rhesus monkey after peroral administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618213,,4841,,,22224,6057,,
,BAO_0000019,,U,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618214,,4842,,,22224,17853,,
,BAO_0000218,,U,,Half life period in monkey after 5 mg/kg dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL873492,,4843,In vivo,,22224,5302,,
,BAO_0000218,,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618272,,4844,In vivo,,22224,4257,,
,BAO_0000218,,U,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618273,,4845,In vivo,,22224,4257,,
Plasma,BAO_0000218,,U,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL618274,,4846,In vivo,,22224,13501,,
,BAO_0000218,,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618275,,4847,In vivo,,22224,5394,,
,BAO_0000218,,U,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618276,,4848,In vivo,,22224,2661,,
,BAO_0000019,,U,,Compound was evaluated for terminal half life in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618277,,4849,,,22224,3341,,
,BAO_0000218,,U,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618278,,4850,In vivo,,22224,3045,,
Plasma,BAO_0000218,,U,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,9544.0,A,Macaca mulatta,1969.0,0,Autocuration,CHEMBL618279,,4851,In vivo,,22224,5005,,
,BAO_0000019,,U,,Half life of compound was determined in squirrel monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618280,,4852,,,22224,4847,,
,BAO_0000218,,U,,Half life after iv administration in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL618281,,4853,In vivo,,22224,4256,,
Plasma,BAO_0000218,,U,,Half life in monkey plasma after administration of 1 mg/kg iv,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL618282,,4854,In vivo,,22224,6535,,
,BAO_0000019,,U,,Half life was calculated in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618283,,4855,,,22224,6057,,
,BAO_0000019,,U,,Half life in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618284,,4856,,,22224,17592,,
,BAO_0000218,,U,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618285,,4857,In vivo,,22224,6641,,
,BAO_0000019,,U,,Half life was evaluated in rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618286,,4858,,,22224,5472,,
,BAO_0000218,,U,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618287,,4859,In vivo,,22224,6221,,
,BAO_0000218,,U,,Half life period was determine after peroral administration at 10 mpk in Rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618288,,4860,In vivo,,22224,5668,,
,BAO_0000218,,U,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876393,,4861,In vivo,,22224,4809,,
,BAO_0000218,,U,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618289,,4862,In vivo,,22224,5546,,
,BAO_0000218,,U,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618290,,4863,In vivo,,22224,5553,,
,BAO_0000019,,U,,Half-life was calculated in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618291,,4864,,,22224,6078,,
,BAO_0000019,,U,,Half-life in Squirrel monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618292,,4865,,,22224,5147,,
,BAO_0000019,,U,,Half-life in rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618293,,4866,,,22224,5145,,
,BAO_0000218,,U,,Half-life was measured in monkey after an iv dose of 1 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618294,,4867,In vivo,,22224,6062,,
,BAO_0000218,,U,,Half-life period after intravenous administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618295,,4868,In vivo,,22224,5355,,
,BAO_0000218,,U,,Half-life period after oral administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618296,,4869,In vivo,,22224,5355,,
,BAO_0000218,,U,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618297,,4870,In vivo,,22224,5355,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618298,,4871,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618299,,4872,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618300,,4873,,,22224,7766,,
Urine,BAO_0000019,,U,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618301,,4874,,,22224,7766,,
Urine,BAO_0000019,,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618302,,4875,,,22224,7766,,
Urine,BAO_0000019,,U,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL876394,,4876,,,22224,7766,,
Urine,BAO_0000019,,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618303,,4877,,,22224,7766,,
Urine,BAO_0000019,,U,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618304,,4878,,,22224,7766,,
,BAO_0000218,,U,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618305,,4879,In vivo,,22224,1916,,
,BAO_0000218,,U,,Oral bioavailability in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618306,,4880,In vivo,,22224,16643,,
,BAO_0000019,,U,,Compound was tested for human plasma protein binding,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618307,,4881,,,22224,17248,,
,BAO_0000019,,U,,Compound was tested for human plasma protein binding; Not determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618308,,4882,,,22224,17248,,
,BAO_0000019,,U,,Protein binding activity of compound in human plasma; % Free,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618309,,4883,,,22224,6241,,
,BAO_0000019,,U,,Unbound fraction (plasma),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618310,,4884,,,22224,17716,,
Plasma,BAO_0000366,,U,,Half life for the hydrolysis of compound in human blood serum,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL873353,,4885,,,22224,17605,,
Plasma,BAO_0000366,,U,,Half life period in human plasma using phosphate buffer (0.08 M),1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618311,,4886,,,22224,17625,,
Plasma,BAO_0000366,,U,,Half life period in human plasma using phosphate buffer (0.1 M),1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618312,,4887,,,22224,17625,,
Plasma,BAO_0000366,,U,,Half-life in human plasma was determined,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618313,,4888,,,22224,17747,,
,BAO_0000019,,U,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618314,,4889,,,22224,15613,,
,BAO_0000019,,U,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618315,,4890,,,22224,354,,
,BAO_0000019,,U,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618316,,4891,,,22224,3741,,
,BAO_0000019,,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618317,,4892,,,22224,3741,,
,BAO_0000019,,U,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620138,,4893,,,22224,3741,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL858280,,4894,,,22224,17599,,
,BAO_0000019,,U,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620139,,4895,,,22224,5486,,
,BAO_0000251,,U,Microsomes,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620140,,4896,,,22224,5600,,
,BAO_0000019,,U,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620141,,4897,,,22224,14294,,
,BAO_0000019,,U,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620142,,4898,,,22224,14294,,
,BAO_0000019,,U,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620143,,4899,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620144,,4900,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620145,,4901,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in human microsomes; Trace,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620146,,4902,,,22224,14294,,
Liver,BAO_0000251,,U,Microsomes,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL620147,,4903,,,22224,6260,,
,BAO_0000251,,U,Microsomes,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL620148,,4904,,,22224,6187,,
Liver,BAO_0000251,,U,Microsomes,In vitro metabolic potential in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL620149,,4905,,,22224,6251,,
,BAO_0000019,,U,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL876412,,4906,,,22224,3246,,
,BAO_0000019,,U,,Tested for human plasma protein binding of the compound; Not tested,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619352,,4907,,,22224,17313,,
,BAO_0000019,,U,,Compound was tested for percent protein binding (PB) in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619353,,4908,,,22224,6227,,
Plasma,BAO_0000019,,U,,Protein binding in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL619354,,4909,,,22224,5530,,
,BAO_0000019,,U,,Permeability coefficient (B to A) in Caco-2 cell,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619355,,4910,,,22224,6108,,
,BAO_0000019,,U,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619356,,4911,,,22224,6108,,
,BAO_0000019,,U,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619357,,4912,,,22224,2774,,
,BAO_0000019,,U,,In vitro rate of absorption observed as Caco-2 permeability in humans,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619358,,4913,,,22224,16643,,
,BAO_0000219,,U,,Cellular permeability of compound was determined in Caco-2 cells; High,1,Caco-2,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619359,,4914,,,22224,17582,495.0,
,BAO_0000219,,U,,Permeability in Caco-2 cells of compound,1,Caco-2,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619360,,4915,,,22224,6838,495.0,
,BAO_0000019,,U,,Permeability coefficient (A to B) in Caco-2 cell,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619361,,4916,,,22224,6108,,
,BAO_0000019,,U,,Permeability coefficient (B to A) in Caco-2 cell,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619362,,4917,,,22224,6108,,
,BAO_0000019,,U,,Permeability coefficient (Papp) (Caco-2 cell monolayer),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619363,,4918,,,22224,6108,,
,BAO_0000019,,U,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618942,,4919,,,22224,2146,,
,BAO_0000019,,U,,Compound was tested for protein binding in human plasma,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618943,,4920,,,22224,4514,,
,BAO_0000019,,U,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618944,,4921,,,22224,6108,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL618945,,4922,,,22224,7766,,
,BAO_0000218,,N,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618946,,4923,In vivo,,50594,5969,,
,BAO_0000218,,N,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876413,,4924,In vivo,,50594,3277,,
,BAO_0000218,,N,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618947,,4925,In vivo,,50594,3802,,
Plasma,BAO_0000218,,N,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL618948,,4926,In vivo,,50594,2862,,
Plasma,BAO_0000218,,N,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL618949,,4927,In vivo,,50594,6348,,
,BAO_0000218,,N,,Tmax after intraperitoneal administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL618950,,4928,In vivo,,50594,17764,,
,BAO_0000218,,N,,Tmax after oral administration at 30 mg/kg in ICR mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618951,,4929,In vivo,,50594,5781,,
,BAO_0000218,,N,,Tmax after peroral administration in mice at 2.4 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618952,,4930,In vivo,,50594,17764,,
,BAO_0000218,,N,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618953,,4931,In vivo,,50594,4066,,
Brain,BAO_0000218,,N,,Tmax in brain of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618954,,4932,In vivo,,50594,17641,,
Kidney,BAO_0000218,,N,,Tmax in kidney of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618955,,4933,In vivo,,50594,17641,,
Liver,BAO_0000218,,N,,Tmax in liver of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618956,,4934,In vivo,,50594,17641,,
Lung,BAO_0000218,,N,,Tmax in lungs of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL618957,,4935,In vivo,,50594,17641,,
,BAO_0000218,,N,,Tmax in mice at 18 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL618958,,4936,In vivo,,50594,17764,,
,BAO_0000218,,N,,Tmax in mice at 23 uM/kg i.v. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL618959,,4937,In vivo,,50594,17764,,
,BAO_0000218,,N,,Tmax in mice at 25 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL618960,,4938,In vivo,,50594,17764,,
,BAO_0000218,,N,,Tmax in mice at 26 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL876723,,4939,In vivo,,50594,17764,,
Spleen,BAO_0000218,,N,,Tmax in spleen of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618961,,4940,In vivo,,50594,17641,,
,BAO_0000218,,N,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618962,,4941,In vivo,,50594,16597,,
,BAO_0000218,,N,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618963,,4942,In vivo,,50594,16597,,
,BAO_0000218,,N,,Tmax value in IRC mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618964,,4943,,,50594,5951,,
,BAO_0000218,,N,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618965,,4944,In vivo,,50594,5506,,
,BAO_0000218,,N,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618966,,4945,In vivo,,50594,5506,,
Urine,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL618967,,4946,,,50594,429,,
Urine,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL618968,,4947,,,50594,429,,
Urine,BAO_0000218,,N,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL618969,,4948,,,50594,4066,,
,BAO_0000218,,N,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618970,,4949,,,50594,17734,,
,BAO_0000218,,N,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618971,,4950,,,50594,17734,,
,BAO_0000218,,N,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618972,,4951,In vivo,,50594,6062,,
,BAO_0000218,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618973,,4952,In vivo,,50594,5969,,
,BAO_0000218,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618974,,4953,In vivo,,50594,5969,,
,BAO_0000218,,N,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618975,,4954,In vivo,,50594,5969,,
,BAO_0000218,,N,,Vd in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618976,,4955,In vivo,,50594,5980,,
,BAO_0000218,,N,,Volume of distribution in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618977,,4956,In vivo,,50594,17592,,
,BAO_0000218,,N,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876724,,4957,In vivo,,50594,6348,,
,BAO_0000218,,N,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618978,,4958,In vivo,,50594,17753,,
,BAO_0000218,,N,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618979,,4959,In vivo,,50594,17753,,
,BAO_0000218,,N,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618980,,4960,In vivo,,50594,17753,,
,BAO_0000218,,N,,Pharmacokinetic property (vdss) was measured in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618981,,4961,In vivo,,50594,4239,,
,BAO_0000218,,N,,Value distribution upon iv administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618982,,4962,In vivo,,50594,2862,,
,BAO_0000218,,N,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620150,,4963,In vivo,,50594,17734,,
,BAO_0000218,,N,,Volume of distribution was evaluated in mice after intravenous administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620151,,4964,In vivo,,50594,2675,,
,BAO_0000218,,N,,Volume of distribution was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620152,,4965,In vivo,,50594,2675,,
,BAO_0000218,,N,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620153,,4966,In vivo,,50594,17837,,
,BAO_0000218,,N,,Steady state volume of distribution was determined in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876395,,4967,In vivo,,50594,5727,,
,BAO_0000218,,N,,Volume distribution (steady state) of compound was determined in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620154,,4968,In vivo,,50594,17852,,
,BAO_0000218,,N,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620155,,4969,In vivo,,50594,17764,,
,BAO_0000218,,N,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620156,,4970,In vivo,,50594,16597,,
,BAO_0000218,,N,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620157,,4971,In vivo,,50594,6062,,
Kidney,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in in kidney tissue,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL620158,,4972,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL620159,,4973,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL620160,,4974,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL620161,,4975,In vivo,,50594,16438,,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620162,,4976,,,80019,10708,797.0,
,BAO_0000219,,N,,Inhibition of A431 human squamous cell carcinoma cell proliferation,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620163,,4977,,,80852,16597,500.0,
,BAO_0000219,,N,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620833,,4978,,,80852,16062,500.0,
,BAO_0000219,,N,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL876396,,4979,,,80852,16062,500.0,
,BAO_0000219,,N,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620834,,4980,,,80852,16958,500.0,
,BAO_0000219,,N,,Inhibition of A431 human carcinoma cell proliferation,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620835,,4981,,,80852,6700,500.0,
,BAO_0000219,,N,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620836,,4982,,,80852,17226,500.0,
,BAO_0000219,,N,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620837,,4983,,,80852,6828,500.0,
,BAO_0000219,,N,,In vitro cytotoxicity against epidermoid carcinoma cell line,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621017,,4984,,,80852,12314,500.0,
,BAO_0000218,,D,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621018,,4985,,,9,13412,500.0,
,BAO_0000219,,N,,Antiproliferative activity of compound was measured on human tumor cell line A431.,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621019,,4986,,,80852,13299,500.0,
,BAO_0000219,,N,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621020,,4987,,,80852,17420,500.0,
,BAO_0000219,,N,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621021,,4988,,,80852,13678,500.0,
,BAO_0000219,,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,1,A-431,,F,,,8,Expert,CHEMBL621022,,4989,,,9,14171,500.0,
,BAO_0000219,,N,,Tested for antiproliferative activity against human A431 cells,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621023,,4990,,,80852,6333,500.0,
,BAO_0000219,,D,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621024,,4991,,,9,2356,500.0,
,BAO_0000219,,N,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621025,,4992,,,80852,15578,500.0,
,BAO_0000219,,N,,Inhibition of A431 cell proliferation,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621026,,4993,,,80852,5126,500.0,
,BAO_0000219,,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621027,,4994,,,80852,6844,500.0,
,BAO_0000219,,N,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL876397,,4995,,,80852,6844,500.0,
,BAO_0000219,,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883797,,4996,,,80852,4925,500.0,
,BAO_0000219,,N,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621028,,4997,,,80852,4925,500.0,
,BAO_0000219,,N,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621029,,4998,,,80852,13978,500.0,
,BAO_0000219,,N,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621030,,4999,,,80852,16786,500.0,
,BAO_0000219,,H,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,1,A-431,,F,,,8,Expert,CHEMBL621147,,5000,,,9,13412,500.0,
,BAO_0000218,,N,,In vivo antiproliferative activity against A431 cell line,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621148,,5001,,,80852,17824,500.0,
,BAO_0000219,,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621149,,5002,,,9,12751,500.0,
,BAO_0000219,,N,,Inhibition of A431 human epidermoid carcinoma cell proliferation,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621150,,5003,,,80852,12380,500.0,
,BAO_0000219,,D,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621151,,5004,,,9,4959,500.0,
,BAO_0000219,,N,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621152,,5005,,,80852,6333,500.0,
,BAO_0000219,,N,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621153,,5006,,,80852,6333,500.0,
,BAO_0000219,,N,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884000,,5007,,,80852,6333,500.0,
,BAO_0000019,,D,,Inhibition of EGFR overexpressing A431 cell proliferation,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621154,,5008,,,9,5296,,
,BAO_0000219,,N,,Inhibition of A431 cell proliferation,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621155,,5009,,,80852,12624,500.0,
,BAO_0000219,,D,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621156,,5010,,,9,14926,500.0,
,BAO_0000219,,D,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621157,,5011,,,9,14926,500.0,
,BAO_0000219,,H,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),1,A-431,,F,,,8,Expert,CHEMBL621158,,5012,,,9,14926,500.0,
,BAO_0000219,,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621159,,5013,,,80852,15144,500.0,
,BAO_0000219,,N,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621160,,5014,,,80852,15144,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621161,,5015,,,80852,5245,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621162,,5016,,,80852,5245,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621163,,5017,,,80852,5245,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621164,,5018,,,80852,5245,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621165,,5019,,,80852,5245,500.0,
,BAO_0000019,,U,,Half-life period in cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619159,,5020,,,22224,5922,,
Plasma,BAO_0000366,,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL619160,,5021,In vitro,,22224,1116,,
,BAO_0000218,,U,,Longer half-life in monkey (i.v.) at 0.5 mpk,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619161,,5022,In vivo,,22224,17853,,
Plasma,BAO_0000366,,U,,Plasma half life in monkey,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL619162,,5023,,,22224,993,,
Plasma,BAO_0000366,,U,,Plasma half-life in rhesus monkey,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL619163,,5024,,,22224,4514,,
Plasma,BAO_0000218,,U,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL619164,,5025,In vivo,,22224,5334,,
Plasma,BAO_0000218,,U,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL619320,,5026,In vivo,,22224,5334,,
,BAO_0000218,,U,,Tested for half life upon iv administration to african green monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619321,,5027,In vivo,,22224,4578,,
,BAO_0000218,,U,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL873336,,5028,In vivo,,22224,2661,,
,BAO_0000218,,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619322,,5029,In vivo,,22224,5355,,
,BAO_0000218,,U,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619323,,5030,In vivo,,22224,5355,,
,BAO_0000218,,U,,The time for peak concentration value after oral administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619324,,5031,In vivo,,22224,5355,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619325,,5032,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876411,,5033,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619326,,5034,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619327,,5035,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619328,,5036,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619329,,5037,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619330,,5038,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619331,,5039,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619332,,5040,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619333,,5041,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619334,,5042,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619335,,5043,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619336,,5044,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619337,,5045,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619338,,5046,,,22224,11271,,
,BAO_0000019,,U,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL619339,,5047,,,22224,11271,,
,BAO_0000218,,N,,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619340,,5048,In vivo,,50597,5809,,
Plasma,BAO_0000218,,N,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873496,,5049,In vivo,,50597,17720,,
Plasma,BAO_0000218,,N,,AUC value in rat after IV administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL619341,,5050,,,50597,3546,,
Plasma,BAO_0000218,,N,,AUC value in rat after oral administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL619342,,5051,,,50597,3546,,
,BAO_0000218,,N,,Cmax value in rat after oral administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619343,,5052,In vivo,,50597,3546,,
,BAO_0000218,,N,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619344,,5053,In vivo,,50597,3546,,
,BAO_0000218,,N,,Tmax value in rat after oral administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619345,,5054,In vivo,,50597,3546,,
,BAO_0000218,,N,,Vc value in rat after IV administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619346,,5055,,,50597,3546,,
,BAO_0000218,,N,,Half life period in rat after IV administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619347,,5056,In vivo,,50597,3546,,
,BAO_0000019,,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL619348,,5057,,,22224,10625,,
,BAO_0000019,,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL619349,,5058,,,22224,10625,,
,BAO_0000019,,U,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL619350,,5059,,,22224,10625,,
,BAO_0000019,,U,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL619351,,5060,,,22224,10625,,
,BAO_0000019,,U,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL875953,,5061,,,22224,10625,,
,BAO_0000019,,U,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL621716,,5062,,,22224,10625,,
,BAO_0000019,,U,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL621717,,5063,,,22224,10625,,
,BAO_0000019,,U,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,1,,9557.0,A,Papio hamadryas,,0,Autocuration,CHEMBL621718,,5064,,,22224,10625,,
,BAO_0000019,,U,,Area under curve after 1 mpk peroral administration to beagles,1,,9615.0,A,beagle,,0,Autocuration,CHEMBL621719,,5065,,,22224,3510,,
,BAO_0000019,,U,,Area under curve after 2 mpk peroral administration to beagles,1,,9615.0,A,beagle,,0,Autocuration,CHEMBL621720,,5066,,,22224,3510,,
,BAO_0000218,,U,,Cmax value after 1 mpk peroral administration to beagles,1,,9615.0,A,beagle,,0,Autocuration,CHEMBL621721,,5067,In vivo,,22224,3510,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL621722,,5068,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL621723,,5069,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL621724,,5070,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL623443,,5071,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL623444,,5072,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL623445,,5073,,,22224,7766,,
Urine,BAO_0000019,,U,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,1,,9606.0,A,Homo sapiens,1088.0,0,Autocuration,CHEMBL623446,,5074,,,22224,7766,,
Liver,BAO_0000251,,U,Microsomes,Metabolic stability observed at 30 min after administration in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL623447,,5075,,,22224,16643,,
,BAO_0000019,,U,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL623448,,5076,,,22224,6852,,
,BAO_0000019,,U,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL623449,,5077,,,22224,6852,,
,BAO_0000019,,U,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL623450,,5078,,,22224,6852,,
Liver,BAO_0000251,,U,Microsomes,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL623451,,5079,,,22224,6567,,
,BAO_0000019,,U,,Metabolic stability (% remaining at 30 mins) in human S9.,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL623452,,5080,,,22224,6570,,
,BAO_0000019,,U,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL623453,,5081,,,22224,6570,,
Liver,BAO_0000251,,U,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL623454,,5082,,,22224,5237,,
Liver,BAO_0000251,,U,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL623455,,5083,,,22224,5237,,
Liver,BAO_0000251,,U,Microsomes,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL624371,,5084,,,22224,5237,,
,BAO_0000218,,U,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624372,,5085,,,22224,5202,,
,BAO_0000019,,U,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624373,,5086,,,22224,5481,,
,BAO_0000019,,U,,Percent remaining in human plasma after incubation for 60 min at 37 C.,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624374,,5087,,,22224,5481,,
,BAO_0000019,,U,,The percent remaining in human plasma after 30 min was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624556,,5088,,,22224,3956,,
Plasma,BAO_0000366,,U,,Conversion rate of the prodrug in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL624557,,5089,,,22224,5074,,
Plasma,BAO_0000366,,U,,Conversion rate of the prodrug in human plasma; ND means no data,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL624558,,5090,,,22224,5074,,
Blood,BAO_0000221,,U,,Half life of compound was determined in human blood,1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL624559,,5091,,,22224,4727,,
,BAO_0000019,,U,,Half life of compound was determined in man with once daily dosing,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624560,,5092,,,22224,5965,,
,BAO_0000251,,U,Microsomes,Half life in human microsomes,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624561,,5093,In vitro,,22224,5732,,
Plasma,BAO_0000366,,U,,Half life in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL624562,,5094,,,22224,5819,,
Plasma,BAO_0000366,,U,,Half life in human plasma; Not detected,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL624563,,5095,,,22224,5819,,
,BAO_0000218,,U,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624564,,5096,In vivo,,22224,1916,,
Liver,BAO_0000251,,U,Microsomes,Half-life for oxidative metabolic stability was determined using rat liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL624565,,5097,In vitro,,22224,6597,,
Plasma,BAO_0000366,,U,,Half-life in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL875152,,5098,,,22224,5229,,
Plasma,BAO_0000366,,U,,Half-life of the parent prodrug in plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL624566,,5099,,,22224,5229,,
Plasma,BAO_0000366,,U,,In vitro half life in human plasma was determined,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL873805,,5100,In vitro,,22224,2192,,
Liver,BAO_0000251,,U,Microsomes,The compound was tested In Vitro for half life in human liver microsomes.,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL624567,,5101,In vitro,,22224,3032,,
,BAO_0000218,,U,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624568,,5102,In vivo,,22224,1916,,
,BAO_0000218,,U,,Observed volume of distribution,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624569,,5103,In vivo,,22224,17716,,
,BAO_0000218,,U,,Oral bioavailability in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624570,,5104,In vivo,,22224,15778,,
,BAO_0000019,,U,,Tested for human plasma protein binding of the compound,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624571,,5105,,,22224,17313,,
,BAO_0000019,,U,,"First order rate constant, k was determined in human plasma",1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624572,,5106,,,22224,4231,,
,BAO_0000019,,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624573,,5107,,,22224,4755,,
,BAO_0000019,,U,,Observed rate constant in 80% human plasma at 37 degree Centigrade,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL875153,,5108,,,22224,4755,,
Liver,BAO_0000251,,U,Microsomes,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL624574,,5109,,,22224,16907,,
,BAO_0000019,,U,,The compound was tested for the plasma binding in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624575,,5110,,,22224,10839,,
,BAO_0000019,,U,,Plasma protein binding (human),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL624576,,5111,,,22224,10839,,
Liver,BAO_0000251,,U,Microsomes,Compound was evaluated for half-life in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL624577,,5112,In vitro,,22224,3199,,
Blood,BAO_0000221,,U,,Half life measured in vitro for its stability in human blood,1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL624578,,5113,In vitro,,22224,1345,,
Serum,BAO_0000019,,U,,Half life in human serum,1,,9606.0,A,Homo sapiens,1977.0,0,Autocuration,CHEMBL622796,,5114,,,22224,4297,,
Serum,BAO_0000019,,U,,Half life in human serum; ND=not determined,1,,9606.0,A,Homo sapiens,1977.0,0,Autocuration,CHEMBL622797,,5115,,,22224,4297,,
,BAO_0000019,,U,,Half life were determined in CEM-SS cell extract in decomposition step 1,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL622798,,5116,,,22224,4297,,
,BAO_0000019,,U,,Half life were determined in CEM-SS cell extract in decomposition step 2,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL622799,,5117,,,22224,4297,,
Plasma,BAO_0000366,,U,,Half life of the in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL622800,,5118,,,22224,4231,,
,BAO_0000220,,U,S9,Half life period in human hepatic S9 fraction was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL622801,,5119,In vitro,,22224,5633,,
Liver,BAO_0000251,,U,Microsomes,Half life period in human liver microsome was determined,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL622802,,5120,In vitro,,22224,5633,,
,BAO_0000019,,U,,Half life period was determined; 6-7,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL622803,,5121,,,22224,17791,,
,BAO_0000019,,U,,Half life period was evaluated in human,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL875154,,5122,,,22224,17791,,
Plasma,BAO_0000366,,U,,Half life time in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL622804,,5123,,,22224,3160,,
Brain,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622805,,5124,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622611,,5125,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622612,,5126,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL875160,,5127,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL622613,,5128,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL622614,,5129,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622615,,5130,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622616,,5131,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622617,,5132,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL622618,,5133,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL622619,,5134,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL622620,,5135,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622621,,5136,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in blood tissue,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622622,,5137,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622623,,5138,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622624,,5139,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622625,,5140,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622626,,5141,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622627,,5142,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in brain tissue of mice,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622628,,5143,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622629,,5144,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622630,,5145,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622631,,5146,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622632,,5147,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622633,,5148,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in heart tissue of mice,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622634,,5149,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622635,,5150,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL875161,,5151,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622636,,5152,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL623335,,5153,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL623336,,5154,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623337,,5155,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623338,,5156,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623339,,5157,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623524,,5158,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623525,,5159,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in liver tissue,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623526,,5160,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623527,,5161,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623528,,5162,In vivo,,50594,16438,,
,BAO_0000219,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624615,,5163,,,80852,5245,500.0,
,BAO_0000219,,N,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621672,,5164,,,80852,5245,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",1,A-431,,F,,,1,Expert,CHEMBL621673,,5165,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",1,A-431,,F,,,1,Expert,CHEMBL621674,,5166,,,80852,16289,500.0,
,BAO_0000219,,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL884002,,5167,,,9,16093,500.0,
,BAO_0000219,,N,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621850,,5168,,,80852,16825,500.0,
,BAO_0000219,,N,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621851,,5169,,,80852,4848,500.0,
,BAO_0000219,,D,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621852,,5170,,,9,14827,500.0,
,BAO_0000219,,D,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621853,,5171,,,9,14827,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",1,A-431,,F,,,1,Expert,CHEMBL621854,,5172,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,A-431,,F,,,1,Expert,CHEMBL621855,,5173,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",1,A-431,,F,,,1,Expert,CHEMBL623724,,5174,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",1,A-431,,F,,,1,Expert,CHEMBL623725,,5175,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",1,A-431,,F,,,1,Expert,CHEMBL623726,,5176,,,80852,16289,500.0,
,BAO_0000219,,D,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL623727,,5177,,,9,16289,500.0,
,BAO_0000219,,H,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,1,A-431,,F,,,8,Expert,CHEMBL623728,,5178,,,9,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",1,A-431,,F,,,1,Expert,CHEMBL623729,,5179,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,A-431,,F,,,1,Expert,CHEMBL623730,,5180,,,80852,16289,500.0,
,BAO_0000218,,N,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",1,A-431,,F,,,1,Expert,CHEMBL623731,,5181,,,80852,16289,500.0,
,BAO_0000218,,N,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",1,A-431,10090.0,F,Mus musculus,,1,Expert,CHEMBL623732,,5182,,,80852,14555,500.0,
,BAO_0000218,,N,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",1,A-431,10090.0,F,Mus musculus,,1,Expert,CHEMBL623733,,5183,,,80852,14555,500.0,
,BAO_0000218,,N,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,A-431,10090.0,F,Mus musculus,,1,Expert,CHEMBL623734,,5184,,,80852,14555,500.0,
,BAO_0000218,,N,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",1,A-431,10090.0,F,Mus musculus,,1,Expert,CHEMBL623735,,5185,,,80852,14555,500.0,
,BAO_0000219,,N,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623736,,5186,,,80852,1937,500.0,
,BAO_0000219,,N,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623737,,5187,,,80852,13739,500.0,
,BAO_0000219,,N,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623738,,5188,,,80852,3558,500.0,
,BAO_0000219,,N,,Dose giving a 50% decrease in the living cell number (A437 cells),1,A-431,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875168,,5189,,,80852,3558,500.0,
,BAO_0000219,,N,,In vitro inhibitory concentration against proliferation of A459 cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623739,,5190,,,80682,17686,646.0,
,BAO_0000219,,N,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623740,,5191,,,80682,5305,646.0,
,BAO_0000219,,N,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624424,,5192,,,80682,3614,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against renal A498 tumor cell lines,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624425,,5193,,,80021,17229,624.0,
,BAO_0000219,,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624426,,5194,,,80021,15935,624.0,
,BAO_0000219,,N,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624427,,5195,,,80021,15935,624.0,
,BAO_0000219,,N,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624428,,5196,,,80021,15560,624.0,
,BAO_0000219,,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624429,,5197,,,80021,13891,624.0,
,BAO_0000219,,N,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624620,,5198,,,80021,13891,624.0,
,BAO_0000219,,N,,Cytotoxicity on kidney carcinoma (A-498) cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624621,,5199,,,80021,13788,624.0,
,BAO_0000219,,N,,Compound was evaluated against Human cell line renal A498,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624622,,5200,,,80021,15403,624.0,
,BAO_0000219,,N,,Compound was tested for inhibition of A498 human renal cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624623,,5201,,,80021,1009,624.0,
,BAO_0000219,,N,,Growth inhibitory activity against A498 human cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL874365,,5202,,,80021,1043,624.0,
,BAO_0000219,,N,,In vitro antitumor activity against human renal A498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624624,,5203,,,80021,5858,624.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against renal (A498) cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624625,,5204,,,80021,5958,624.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human renal cancer (A498) cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624626,,5205,,,80021,5506,624.0,
,BAO_0000219,,N,,Tested for cytostatic activity against renal A498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624627,,5206,,,80021,12781,624.0,
,BAO_0000219,,N,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883157,,5207,,,80021,14399,624.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,1,A498,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624628,,5208,,,80021,5958,624.0,
,BAO_0000218,,U,,Cmax value after 2 mpk peroral administration to beagles,1,,9615.0,A,beagle,,0,Autocuration,CHEMBL624629,,5209,In vivo,,22224,3510,,
,BAO_0000218,beagle,U,,Bioavailability,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL623551,,5210,In vivo,,22224,3510,,
,BAO_0000218,beagle,U,,Bioavailability after 1 mpk peroral administration to beagles,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL623552,,5211,In vivo,,22224,3510,,
,BAO_0000218,beagle,U,,Bioavailability after 2 mpk peroral administration to beagles,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL623553,,5212,In vivo,,22224,3510,,
,BAO_0000019,,U,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623554,,5213,,,22224,3085,,
,BAO_0000019,,U,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623555,,5214,,,22224,3085,,
,BAO_0000019,,U,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623556,,5215,,,22224,3085,,
,BAO_0000019,,U,,Solubility against bovine alpha-chymotrypsin,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623557,,5216,,,22224,9372,,
,BAO_0000019,,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623558,,5217,,,22224,3085,,
,BAO_0000019,,U,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623559,,5218,,,22224,3085,,
Spleen,BAO_0000221,,U,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,1,,9913.0,A,Bos taurus,2106.0,0,Autocuration,CHEMBL623560,,5219,,,22224,1469,,
,BAO_0000019,,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623561,,5220,,,22224,4297,,
,BAO_0000019,,U,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623562,,5221,,,22224,4297,,
,BAO_0000019,,U,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623563,,5222,,,22224,17585,,
Spleen,BAO_0000221,,U,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,1,,9913.0,A,Bos taurus,2106.0,0,Autocuration,CHEMBL623564,,5223,,,22224,1336,,
,BAO_0000019,,U,,Half life in presence of 2 mg/mL BSA at pH 8.8,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL873806,,5224,,,22224,3085,,
,BAO_0000019,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623565,,5225,,,22224,2857,,
,BAO_0000019,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623566,,5226,,,22224,2857,,
,BAO_0000019,,U,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623567,,5227,,,22224,2857,,
,BAO_0000019,,U,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),1,,9913.0,A,Bos taurus,,0,Autocuration,CHEMBL623568,,5228,,,22224,1540,,
Plasma,BAO_0000218,,N,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623569,,5229,,,50588,6316,,
Plasma,BAO_0000218,,N,,AUC after administration at 100 mg/kg/day in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623570,,5230,,,50588,17594,,
Plasma,BAO_0000218,,N,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624254,,5231,,,50588,4953,,
Plasma,BAO_0000218,,N,,AUC value after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624255,,5232,,,50588,16907,,
Plasma,BAO_0000218,,N,,AUC value after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624256,,5233,,,50588,16907,,
Plasma,BAO_0000218,,N,,AUC value after administration of 4 mg/Kg oral dose in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624257,,5234,,,50588,2959,,
Plasma,BAO_0000218,,N,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624258,,5235,,,50588,17594,,
,BAO_0000218,,N,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875277,,5236,,,50588,5356,,
,BAO_0000218,,N,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622667,,5237,,,50588,16807,,
,BAO_0000218,,N,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622668,,5238,,,50588,4527,,
,BAO_0000218,,N,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622669,,5239,,,50588,4527,,
,BAO_0000218,,N,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622670,,5240,,,50588,15660,,
,BAO_0000218,,N,,Area under curve determined in dogs after oral administration of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622671,,5241,,,50588,15660,,
,BAO_0000218,,N,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622672,,5242,,,50588,5802,,
,BAO_0000218,,N,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Expert,CHEMBL622673,,5243,,,50588,3598,,
,BAO_0000218,,N,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Expert,CHEMBL622674,,5244,,,50588,3598,,
,BAO_0000218,,N,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622675,,5245,,,50588,5944,,
,BAO_0000218,,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622676,,5246,,,50588,5944,,
,BAO_0000218,,N,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622677,,5247,,,50588,5944,,
,BAO_0000218,,N,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622678,,5248,,,50588,5944,,
,BAO_0000218,,N,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622679,,5249,,,50588,4186,,
,BAO_0000218,,N,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622680,,5250,,,50588,5007,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622681,,5251,,,50588,5668,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 5 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875278,,5252,,,50588,5668,,
,BAO_0000218,,N,,Area under curve was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622682,,5253,,,50588,5006,,
,BAO_0000218,,N,,Area under curve in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622683,,5254,,,50588,5006,,
,BAO_0000218,,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622684,,5255,,,50588,3771,,
,BAO_0000218,,N,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622685,,5256,,,50588,3771,,
,BAO_0000218,,N,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622686,,5257,,,50588,3771,,
,BAO_0000218,,N,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618344,,5258,,,50588,1916,,
,BAO_0000218,,N,,Area under curve value in dog at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875582,,5259,,,50588,5302,,
,BAO_0000218,,N,,Area under curve was determined after 0.1 mg/kg iv administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618345,,5260,,,50588,5600,,
,BAO_0000218,,N,,Area under curve was determined after 0.3 mg/kg po administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618346,,5261,,,50588,5600,,
,BAO_0000218,,N,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618347,,5262,,,50588,17764,,
,BAO_0000218,,N,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618348,,5263,,,50588,4368,,
,BAO_0000019,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618349,,5264,,,22224,5318,,
,BAO_0000019,,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618350,,5265,,,22224,5318,,
,BAO_0000019,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618351,,5266,,,22224,5318,,
,BAO_0000019,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618352,,5267,,,22224,5318,,
Blood,BAO_0000221,,U,,Time taken to reduce 50% of the concentration of compound in blood plasma,1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL873494,,5268,,,22224,14518,,
Plasma,BAO_0000366,,U,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618353,,5269,,,22224,2209,,
Plasma,BAO_0000366,,U,,Half life in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618354,,5270,,,22224,6787,,
Plasma,BAO_0000366,,U,,Half life in human plasma was reported,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL875583,,5271,,,22224,4898,,
Serum,BAO_0000019,,U,,Half life in human serum,1,,9606.0,A,Homo sapiens,1977.0,0,Autocuration,CHEMBL618355,,5272,,,22224,6072,,
Plasma,BAO_0000366,,U,,Half life upon exposure to human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618356,,5273,,,22224,16907,,
,BAO_0000251,,U,Microsomes,t1/2 in human microsomes,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618357,,5274,In vitro,,22224,5656,,
Plasma,BAO_0000366,,U,,Half life period in 80% human plasma at 37 degree Centigrade,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618358,,5275,,,22224,4755,,
Zone of skin,BAO_0000221,,U,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),1,,9606.0,A,Homo sapiens,14.0,0,Autocuration,CHEMBL618359,,5276,,,22224,17503,,
Plasma,BAO_0000366,,U,,Half-life measured in in vitro Cathepsin B assay in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618360,,5277,In vitro,,22224,12357,,
,BAO_0000019,,U,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618361,,5278,,,22224,3076,,
Liver,BAO_0000251,,U,Microsomes,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618362,,5279,In vitro,,22224,6410,,
Plasma,BAO_0000366,,U,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618363,,5280,,,22224,3741,,
Plasma,BAO_0000366,,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618364,,5281,,,22224,3741,,
Plasma,BAO_0000366,,U,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL875584,,5282,,,22224,3741,,
,BAO_0000019,,U,,Half-life in the CEM cell extracts,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618365,,5283,,,22224,1540,,
Plasma,BAO_0000366,,U,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL873495,,5284,,,22224,2905,,
Plasma,BAO_0000366,,U,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618366,,5285,,,22224,2905,,
,BAO_0000019,,U,,Half-life was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618367,,5286,,,22224,5523,,
Blood,BAO_0000221,,U,,Half-life (human blood stability),1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL618368,,5287,,,22224,1499,,
Blood,BAO_0000221,,U,,Half-life (human blood stability); no data,1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL618369,,5288,,,22224,1499,,
Plasma,BAO_0000366,,U,,Half-life in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618370,,5289,,,22224,17065,,
,BAO_0000019,,U,,CYP3A4 metabolism half-life (t1/2),1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618371,,5290,,,22224,6861,,
Blood,BAO_0000221,,U,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),1,,9606.0,A,Homo sapiens,178.0,0,Autocuration,CHEMBL618372,,5291,,,22224,1499,,
Plasma,BAO_0000366,,U,,In vitro half life in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618373,,5292,In vitro,,22224,530,,
Plasma,BAO_0000366,,U,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618374,,5293,In vitro,,22224,1116,,
Plasma,BAO_0000366,,U,,In vitro hydrolysis in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618375,,5294,In vitro,,22224,6695,,
Plasma,BAO_0000366,,U,,In vitro hydrolysis in human plasma; no data,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618376,,5295,In vitro,,22224,6695,,
Liver,BAO_0000251,,U,Microsomes,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL618377,,5296,In vitro,,22224,10,,
Plasma,BAO_0000366,,U,,Plasma half life in human,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618378,,5297,,,22224,993,,
Plasma,BAO_0000366,,U,,Stability after incubation with human plasma (at 37 degree C),1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618379,,5298,,,22224,15429,,
Plasma,BAO_0000366,,U,,T1/2 was evaluated in human plasma,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618380,,5299,,,22224,1675,,
Plasma,BAO_0000366,,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618381,,5300,,,22224,2209,,
Plasma,BAO_0000366,,U,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL618382,,5301,,,22224,2209,,
,BAO_0000019,,U,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618383,,5302,,,22224,5318,,
,BAO_0000019,,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618384,,5303,In vitro,,22224,2412,,
,BAO_0000019,,U,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL618385,,5304,In vitro,,22224,2412,,
Plasma,BAO_0000366,,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL619099,,5305,,,22224,2906,,
Plasma,BAO_0000366,,U,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL619100,,5306,,,22224,2906,,
,BAO_0000019,,U,,Time taken for 50% to be consumed by serum PON1 was determined,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619101,,5307,,,22224,5495,,
,BAO_0000019,,U,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,1,,9606.0,A,Homo sapiens,,0,Autocuration,CHEMBL619102,,5308,,,22224,5495,,
Liver,BAO_0000251,,U,Microsomes,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,0,Autocuration,CHEMBL619103,,5309,,,22224,4397,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL619268,,5310,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL619269,,5311,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL619270,,5312,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL619271,,5313,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL875585,,5314,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL619272,,5315,,,22224,2413,,
,BAO_0000219,,N,,Compound tested for growth inhibition of renal cancer cell line 786-0,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619273,,5316,,,80640,6058,391.0,
,BAO_0000219,,N,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619274,,5317,,,80640,17708,391.0,
,BAO_0000219,,N,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,1,786-0,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619275,,5318,,,80640,14017,391.0,
,BAO_0000219,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619276,,5319,,,80640,16818,391.0,
,BAO_0000219,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619277,,5320,,,80640,16818,391.0,
,BAO_0000219,,N,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619278,,5321,,,80640,16818,391.0,
,BAO_0000219,,N,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619279,,5322,,,80640,11970,391.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL858458,,5323,,,80640,12400,391.0,
,BAO_0000219,,N,,Cytotoxic effect on renal cancer line 786-0,1,786-0,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619280,,5324,,,80640,12888,391.0,
,BAO_0000219,,N,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619281,,5325,,,80640,15300,391.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619282,,5326,,,80640,14769,391.0,
,BAO_0000219,,N,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619283,,5327,,,80640,15895,391.0,
,BAO_0000219,,N,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619284,,5328,,,80640,17376,391.0,
,BAO_0000219,,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619285,,5329,,,80640,14882,391.0,
,BAO_0000219,,N,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619286,,5330,,,80640,14882,391.0,
,BAO_0000219,,N,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619287,,5331,,,80640,15176,391.0,
,BAO_0000219,,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL857455,,5332,,,80640,12696,391.0,
,BAO_0000219,,N,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883801,,5333,,,80640,2496,391.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619288,,5334,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619289,,5335,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619290,,5336,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619291,,5337,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619292,,5338,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619293,,5339,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619294,,5340,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619295,,5341,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619296,,5342,,,80641,11831,972.0,
,BAO_0000219,,N,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,1,791T cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619297,,5343,,,80641,11831,972.0,
,BAO_0000219,,N,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,1,786-0,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619298,,5344,,,80640,12782,391.0,
,BAO_0000019,,U,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL619299,,5345,,,22226,1229,,
,BAO_0000219,,N,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619300,,5346,,,80433,15313,741.0,
,BAO_0000219,,N,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619301,,5347,,,80433,15313,741.0,
,BAO_0000219,,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619302,,5348,,,80433,11544,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619303,,5349,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619304,,5350,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL857706,,5351,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619305,,5352,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619306,,5353,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619307,,5354,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619308,,5355,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619309,,5356,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619310,,5357,,,80433,9424,741.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619311,,5358,,,80021,14769,624.0,
,BAO_0000219,,N,,Compound was tested for the growth inhibition of A498 renal tumor cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619312,,5359,,,80021,15354,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619313,,5360,,,80021,17445,624.0,
,BAO_0000219,,N,,In vitro inhibitory concentration against renal cancer cell line A498,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619314,,5361,,,80021,4337,624.0,
,BAO_0000219,,N,,Cytotoxicity against A 498 tumor cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619959,,5362,,,80021,15277,624.0,
,BAO_0000219,,N,,In vitro antitumor activity against A498 human cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619960,,5363,,,80021,4812,624.0,
,BAO_0000219,,N,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619961,,5364,,,80021,4812,624.0,
,BAO_0000219,,N,,Inhibitory dose required against A498 human tumor cell lines,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619962,,5365,,,80021,4995,624.0,
,BAO_0000219,,N,,Anticancer activity against one renal cancer (A498 cell line),1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875586,,5366,,,80021,5847,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity against melanoma A498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619963,,5367,,,80021,6557,624.0,
,BAO_0000219,,N,,Compound was tested for growth inhibitory activity against A498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619964,,5368,,,80021,2597,624.0,
,BAO_0000219,,N,,Compound tested for growth inhibition of renal cancer cell line A498,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620108,,5369,,,80021,6058,624.0,
,BAO_0000219,,N,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620109,,5370,,,80021,17708,624.0,
,BAO_0000219,,N,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620110,,5371,,,80021,15176,624.0,
,BAO_0000219,,N,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620111,,5372,,,80021,15300,624.0,
,BAO_0000219,,N,,Tested for cytotoxicity against A498 cell lines in renal cancer,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620112,,5373,,,80021,11970,624.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620113,,5374,,,80021,12400,624.0,
,BAO_0000219,,N,,Cytotoxic effect on renal cancer lines A498,1,A498,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620114,,5375,,,80021,12888,624.0,
,BAO_0000219,,N,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620115,,5376,,,80021,3030,624.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620116,,5377,,,80021,14769,624.0,
,BAO_0000219,,N,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620117,,5378,,,80021,17376,624.0,
,BAO_0000219,,N,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620118,,5379,,,80021,16558,624.0,
,BAO_0000219,,N,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620119,,5380,,,80021,5194,624.0,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620120,,5381,,,80021,10708,624.0,
,BAO_0000219,,N,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620121,,5382,,,80682,16880,646.0,
,BAO_0000219,,N,,Antitumor activity against A549 human lung carcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620122,,5383,,,80682,10196,646.0,
,BAO_0000219,,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620123,,5384,,,80682,10196,646.0,
,BAO_0000219,,N,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620124,,5385,,,80682,10196,646.0,
,BAO_0000219,,N,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620125,,5386,,,80682,12083,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620126,,5387,,,80682,16464,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883027,,5388,,,80682,16464,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human lung A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620127,,5389,,,80682,16470,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620128,,5390,,,80682,16470,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human lung A549 cell line),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620129,,5391,,,80682,16470,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620130,,5392,,,80682,16470,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620131,,5393,,,80682,16582,646.0,
,BAO_0000219,,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620132,,5394,,,80682,15935,646.0,
,BAO_0000219,,N,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620133,,5395,,,80682,15935,646.0,
,BAO_0000219,,N,,Inhibition of A549 human lung carcinoma cell proliferation,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620134,,5396,,,80682,16597,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620135,,5397,,,80682,17376,646.0,
,BAO_0000219,,N,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620136,,5398,,,80682,16496,646.0,
,BAO_0000219,,N,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620137,,5399,,,80682,16152,646.0,
,BAO_0000219,,N,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620268,,5400,,,80682,16152,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620269,,5401,,,80682,16464,646.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620270,,5402,,,80682,2288,646.0,
,BAO_0000219,,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620271,,5403,,,80682,17350,646.0,
,BAO_0000219,,N,,Inhibition of A549 cancer cell proliferation,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620272,,5404,,,80682,4090,646.0,
,BAO_0000219,,N,,Inhibition of A549 cancer cell proliferation (Not tested),1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620273,,5405,,,80682,4090,646.0,
,BAO_0000219,,N,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620274,,5406,,,80682,17350,646.0,
,BAO_0000219,,N,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620275,,5407,,,80682,4197,646.0,
,BAO_0000219,,N,,Antiproliferative potency determined as inhibitory concentration against A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620276,,5408,,,80682,17072,646.0,
,BAO_0000219,,N,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620277,,5409,,,80682,17072,646.0,
,BAO_0000219,,N,,Cytotoxicity against Renal cell lines A549 was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620278,,5410,,,80682,5194,646.0,
,BAO_0000218,,N,,Area under curve was determined in dog after a 3 mg/kg of oral dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620279,,5411,,,50588,4257,,
,BAO_0000218,,N,,Area under curve was determined in dog after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620280,,5412,,,50588,6123,,
,BAO_0000218,,N,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620281,,5413,,,50588,1337,,
,BAO_0000218,,N,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620282,,5414,,,50588,1337,,
,BAO_0000218,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621134,,5415,,,50588,8833,,
,BAO_0000218,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621135,,5416,,,50588,8833,,
,BAO_0000218,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621136,,5417,,,50588,8833,,
,BAO_0000218,,N,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621137,,5418,,,50588,8833,,
Plasma,BAO_0000218,,N,,Area under plasma concentration time curve in dog upon oral administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621138,,5419,,,50588,17657,,
Plasma,BAO_0000218,,N,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL875587,,5420,,,50588,17650,,
,BAO_0000218,,N,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621139,,5421,,,50588,1977,,
,BAO_0000218,,N,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621140,,5422,,,50588,1977,,
,BAO_0000218,,N,,Area under the curve for the compound was obtained when tested in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621141,,5423,,,50588,3132,,
,BAO_0000218,,N,,Area under the curve at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621142,,5424,,,50588,5473,,
,BAO_0000218,,N,,Area under the curve at a dose of 1 mg/kg (oral),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621143,,5425,,,50588,5474,,
,BAO_0000218,,N,,Area under the curve at i.v. dose of 0.2 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621144,,5426,,,50588,5474,,
,BAO_0000218,,N,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621145,,5427,,,50588,6062,,
,BAO_0000218,,N,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621146,,5428,,,50588,4709,,
,BAO_0000218,,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622567,,5429,,,50588,2652,,
,BAO_0000218,,N,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622568,,5430,,,50588,2652,,
,BAO_0000218,,N,,Compound was evaluated for area under the curve in dog blood.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622569,,5431,,,50588,2877,,
,BAO_0000218,,N,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622570,,5432,,,50588,5444,,
Plasma,BAO_0000218,,N,,AUC in dog after oral dose (1 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622571,,5433,,,50588,5130,,
,BAO_0000218,,N,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622572,,5434,,,50588,6265,,
,BAO_0000218,,N,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622573,,5435,,,50588,4657,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC after intravenous administration to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622574,,5436,,,50588,16367,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC after oral administration to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622575,,5437,,,50588,16367,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622576,,5438,,,50588,9579,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622577,,5439,,,50588,9579,,
,BAO_0000218,,N,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622578,,5440,,,50588,5983,,
,BAO_0000218,,N,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622579,,5441,,,50588,6241,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622580,,5442,,,50588,5313,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622581,,5443,,,50588,5313,,
,BAO_0000218,,N,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622582,,5444,,,50588,6642,,
,BAO_0000218,,N,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622583,,5445,,,50588,6642,,
,BAO_0000218,,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622584,,5446,,,50588,6641,,
,BAO_0000218,,N,,Oral AUCN in dog (dosed at 0.5 mpk iv ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622585,,5447,,,50588,6642,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in dog; 90-100,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622586,,5448,,,50588,17791,,
,BAO_0000218,,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623281,,5449,,,50588,17655,,
,BAO_0000218,,N,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623282,,5450,,,50588,17655,,
,BAO_0000218,,N,,PAPP (membrane permeability) in dog kidney cell monolayer assay,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623283,,5451,,,50588,6596,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623284,,5452,,,50588,3880,,
,BAO_0000218,,N,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623285,,5453,,,50588,16367,,
Plasma,BAO_0000218,,N,,Plasma protein binding towards dog plasma at 10 uM,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623463,,5454,,,50588,17409,,
Plasma,BAO_0000218,,N,,Plasma protein binding towards dog plasma at 100 uM,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL875952,,5455,,,50588,17409,,
,BAO_0000218,,N,,Bioavailability in dog (dose 4 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621705,,5456,In vivo,,50588,2959,,
,BAO_0000218,,N,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621706,,5457,In vivo,,50588,13501,,
,BAO_0000218,,N,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621707,,5458,In vivo,,50588,4527,,
,BAO_0000218,,N,,Bioavailability in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621708,,5459,In vivo,,50588,15145,,
,BAO_0000218,,N,,Bioavailability,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621709,,5460,In vivo,,50588,4219,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621710,,5461,In vivo,,50588,17538,,
,BAO_0000218,,N,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621711,,5462,In vivo,,50588,17538,,
,BAO_0000218,,N,,Bioavailability in dog (dose 10.0 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621712,,5463,In vivo,,50588,1466,,
,BAO_0000218,,N,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621713,,5464,In vivo,,50588,17650,,
,BAO_0000218,,N,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621714,,5465,In vivo,,50588,3132,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL621715,,5466,,,22224,2413,,
Liver,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,2107.0,0,Autocuration,CHEMBL623717,,5467,,,22224,2413,,
Liver,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,10095.0,A,Mus sp.,2107.0,0,Autocuration,CHEMBL623718,,5468,,,22224,2413,,
Liver,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,2107.0,0,Autocuration,CHEMBL623719,,5469,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL623720,,5470,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL623721,,5471,,,22224,2413,,
Muscle tissue,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,2385.0,0,Autocuration,CHEMBL623722,,5472,,,22224,2413,,
Muscle tissue,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,10095.0,A,Mus sp.,2385.0,0,Autocuration,CHEMBL623723,,5473,,,22224,2413,,
Muscle tissue,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,2385.0,0,Autocuration,CHEMBL618543,,5474,,,22224,2413,,
Spleen,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,2106.0,0,Autocuration,CHEMBL618544,,5475,,,22224,2413,,
Spleen,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,2106.0,0,Autocuration,CHEMBL875155,,5476,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL618545,,5477,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL618546,,5478,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL623529,,5479,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL623530,,5480,,,22224,2413,,
,BAO_0000218,,U,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,1,,10095.0,A,Mus sp.,,0,Autocuration,CHEMBL621764,,5481,,,22224,2413,,
,BAO_0000019,,U,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621765,,5482,,,22224,17827,,
Cerebellum,BAO_0000019,,U,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,2037.0,0,Autocuration,CHEMBL621766,,5483,,,22224,17827,,
Frontal cortex,BAO_0000019,,U,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,1870.0,0,Autocuration,CHEMBL621767,,5484,,,22224,17827,,
,BAO_0000019,,U,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621768,,5485,,,22224,17827,,
Striatum,BAO_0000019,,U,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,2435.0,0,Autocuration,CHEMBL621769,,5486,,,22224,17827,,
,BAO_0000019,,U,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621770,,5487,,,22224,17827,,
Cerebellum,BAO_0000019,,U,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,2037.0,0,Autocuration,CHEMBL621771,,5488,,,22224,17827,,
Frontal cortex,BAO_0000019,,U,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,1870.0,0,Autocuration,CHEMBL621772,,5489,,,22224,17827,,
,BAO_0000019,,U,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621773,,5490,,,22224,17827,,
Striatum,BAO_0000019,,U,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),1,,9527.0,A,Cercopithecidae,2435.0,0,Autocuration,CHEMBL621774,,5491,,,22224,17827,,
,BAO_0000218,,U,,Compound was evaluated for oral bioavailability in rats,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621775,,5492,,,22224,17791,,
Plasma,BAO_0000218,,U,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL621776,,5493,In vivo,,22224,17667,,
,BAO_0000019,,U,,Half life period was evaluated in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621777,,5494,,,22224,17791,,
,BAO_0000218,,U,,Half-life in rhesus monkeys by intravenous administration of dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL875162,,5495,In vivo,,22224,110,,
Plasma,BAO_0000218,,N,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL621778,,5496,,,50594,5781,,
Plasma,BAO_0000218,,N,,AUC after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL621779,,5497,,,50594,17734,,
Plasma,BAO_0000218,,N,,AUC value was determined after oral administration,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622479,,5498,,,50594,17718,,
,BAO_0000218,,N,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622480,,5499,,,50594,4573,,
,BAO_0000218,,N,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622481,,5500,,,50594,3277,,
,BAO_0000218,,N,,Area under curve by ioral administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622482,,5501,,,50594,2862,,
,BAO_0000218,,N,,Area under curve by iv administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622483,,5502,,,50594,2862,,
,BAO_0000218,,N,,Area under curve at 0-8 hr in IRC mice after peroral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622484,,5503,,,50594,5951,,
,BAO_0000218,,N,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622641,,5504,,,50594,17729,,
,BAO_0000218,,N,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622642,,5505,,,50594,17728,,
,BAO_0000218,,N,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622643,,5506,,,50594,17728,,
,BAO_0000218,,N,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622644,,5507,,,50594,17729,,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622645,,5508,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622646,,5509,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621238,,5510,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621239,,5511,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621240,,5512,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621241,,5513,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621242,,5514,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620350,,5515,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620351,,5516,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620352,,5517,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620353,,5518,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620354,,5519,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620355,,5520,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620356,,5521,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620357,,5522,,,80433,9424,741.0,
,BAO_0000219,,N,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620358,,5523,,,80433,9424,741.0,
,BAO_0000219,,N,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620359,,5524,,,80433,9424,741.0,
,BAO_0000219,,N,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620360,,5525,,,80433,11544,741.0,
,BAO_0000219,,N,,Cytotoxicity of compound against 8226/DOX1V cells,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620361,,5526,,,80433,17378,741.0,
,BAO_0000219,,N,,Cytotoxicity of compound against 8226/S cells,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620362,,5527,,,80433,17378,741.0,
,BAO_0000219,,N,,Inhibitory concentration against 8226 myeloma cancer cell line,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620363,,5528,,,80433,17079,741.0,
,BAO_0000219,,N,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,1,RPMI-8226,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620364,,5529,,,80433,17079,741.0,
,BAO_0000219,,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,1,833K,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620365,,5530,,,80647,13466,854.0,
,BAO_0000219,,N,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',1,833K,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620366,,5531,,,80647,13466,854.0,
,BAO_0000219,,N,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,1,833K,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620367,,5532,,,80647,2392,854.0,
,BAO_0000219,,N,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,1,833K,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620368,,5533,,,80647,2392,854.0,
,BAO_0000019,,U,,Inhibitory activity against caspase-1,1,,,B,,,0,Autocuration,CHEMBL620369,,5534,,,22226,6608,,
,BAO_0000357,,H,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,1,,1351.0,B,Enterococcus faecalis,,8,Autocuration,CHEMBL620370,,5535,,,45,10199,,
,BAO_0000219,,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,1,8701-BC,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620371,,5536,,,80648,17749,705.0,
,BAO_0000219,,N,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,1,8701-BC,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620372,,5537,,,80648,17749,705.0,
,BAO_0000019,,U,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL876492,,5538,,,22226,1229,,
,BAO_0000019,,U,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL620373,,5539,,,22226,1229,,
,BAO_0000019,,U,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,1,,,F,,,0,Intermediate,CHEMBL620374,,5540,,,22226,1229,,
,BAO_0000019,,U,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,1,,,B,,,0,Autocuration,CHEMBL620375,,5541,,,22226,6390,,
,BAO_0000019,,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,,1314.0,F,Streptococcus pyogenes,,0,Autocuration,CHEMBL857902,,5542,,,22226,16219,,
,BAO_0000019,,U,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,1,,1314.0,F,Streptococcus pyogenes,,0,Autocuration,CHEMBL620376,,5543,,,22226,16219,,
,BAO_0000357,,H,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,1,,,B,,,8,Autocuration,CHEMBL620377,,5544,,,11922,17043,,
,BAO_0000219,,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,KB ,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620378,,5545,,,81115,6929,324.0,
,BAO_0000219,,N,,Tested for in vitro cytotoxic potency of compound in 9KB assay,1,KB ,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL620379,,5546,,,81115,6929,324.0,
,BAO_0000219,,U,,In vitro cytotoxicity of compound was tested against 9KB cells.,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL620380,,5547,,,22226,7083,,
,BAO_0000219,,N,,Cytotoxic concentration against 9L cells was determined on day 3,1,9L,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL884006,,5548,,,80653,12446,392.0,
,BAO_0000219,,N,,Tested in vitro for anticancer activity against 9L cells,1,9L,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL620381,,5549,,,80653,15345,392.0,
,BAO_0000219,,N,,Tested in vitro for anticancer activity against 9L cells; Not determined,1,9L,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL620382,,5550,,,80653,15345,392.0,
,BAO_0000219,,N,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620383,,5551,,,80682,6301,646.0,
,BAO_0000219,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876493,,5552,,,80682,4833,646.0,
,BAO_0000219,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620384,,5553,,,80682,4833,646.0,
,BAO_0000219,,N,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620385,,5554,,,80682,4833,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620386,,5555,,,80682,13330,646.0,
,BAO_0000219,,D,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,1,A549,9606.0,F,Homo sapiens,,9,Expert,CHEMBL620387,,5556,,,25,17517,646.0,
,BAO_0000219,,D,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",1,A549,9606.0,F,Homo sapiens,,9,Expert,CHEMBL621404,,5557,,,25,17517,646.0,
,BAO_0000219,,N,,"In vitro growth inhibition of A549, lung carcinoma",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621405,,5558,,,80682,14425,646.0,
,BAO_0000219,,N,,"In vitro growth inhibition of A549, lung carcinoma.",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621406,,5559,,,80682,14425,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621407,,5560,,,80682,5228,646.0,
,BAO_0000219,,N,,Cytotoxic activity against human lung cancer A549 cell line was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621408,,5561,,,80682,5351,646.0,
,BAO_0000219,,N,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL885345,,5562,,,80682,12198,646.0,
,BAO_0000219,,N,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621409,,5563,,,80682,13891,646.0,
,BAO_0000219,,N,,Cytotoxicity in A549 (human carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL876034,,5564,,,80682,5677,646.0,
,BAO_0000219,,N,,Cytotoxicity on lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621410,,5565,,,80682,13788,646.0,
,BAO_0000219,,N,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621411,,5566,,,80682,13384,646.0,
,BAO_0000219,,N,,Effective dose of compound against replication of A549 cell line was evaluated,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621412,,5567,,,80682,6726,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621413,,5568,,,80682,3455,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621414,,5569,,,80682,5726,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621415,,5570,,,80682,5726,646.0,
,BAO_0000219,,N,,The compound was evaluated for antiproliferative activity against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621416,,5571,,,80682,3936,646.0,
,BAO_0000219,,N,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621417,,5572,,,80682,14991,646.0,
,BAO_0000219,,N,,Concentration required for growth inhibition of human lung carcinoma cell line A549,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621418,,5573,,,80682,5243,646.0,
,BAO_0000219,,N,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621419,,5574,,,80682,12858,646.0,
,BAO_0000219,,N,,Growth inhibition against A549 cell line was evaluated,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621420,,5575,,,80682,6776,646.0,
,BAO_0000219,,N,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875823,,5576,,,80682,16558,646.0,
,BAO_0000219,,N,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621421,,5577,,,80682,4583,646.0,
,BAO_0000219,,N,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621422,,5578,,,80682,13514,646.0,
,BAO_0000219,,N,,Chemosensitivity against DT-diaphorase rich A549 cell lines,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL884014,,5579,,,80682,15166,646.0,
,BAO_0000219,,N,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621423,,5580,,,80682,13873,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621424,,5581,,,80682,6447,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621425,,5582,,,80682,2068,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621426,,5583,,,80682,1863,646.0,
,BAO_0000219,,N,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621427,,5584,,,80682,13873,646.0,
,BAO_0000219,,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621428,,5585,,,80682,13873,646.0,
,BAO_0000219,,N,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621429,,5586,,,80682,13873,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621430,,5587,,,80682,579,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621431,,5588,,,80682,579,646.0,
,BAO_0000219,,N,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621432,,5589,,,80682,4584,646.0,
,BAO_0000219,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621433,,5590,,,80682,5421,646.0,
,BAO_0000219,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875824,,5591,,,80682,5421,646.0,
,BAO_0000219,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621434,,5592,,,80682,5421,646.0,
,BAO_0000219,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621435,,5593,,,80682,5421,646.0,
,BAO_0000219,,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621436,,5594,,,80682,14188,646.0,
,BAO_0000219,,N,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621437,,5595,,,80682,14188,646.0,
,BAO_0000219,,N,,Compound was tested for the growth inhibition of A549 lung tumor cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621438,,5596,,,80682,15354,646.0,
,BAO_0000219,,N,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621439,,5597,,,80682,14253,646.0,
,BAO_0000219,,N,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621440,,5598,,,80682,13873,646.0,
,BAO_0000218,,N,,Oral bioavailability in dog (conscious),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621441,,5599,In vivo,,50588,3043,,
,BAO_0000218,,N,,Compound was evaluated for the oral bioavailability after oral administration in dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621442,,5600,In vivo,,50588,3045,,
,BAO_0000218,,N,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621443,,5601,In vivo,,50588,3022,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621444,,5602,In vivo,,50588,4453,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625133,,5603,In vivo,,50588,1696,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625134,,5604,In vivo,,50588,5045,,
,BAO_0000218,,N,,Oral bioavailability in dog (fasted),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625135,,5605,In vivo,,50588,5356,,
,BAO_0000218,,N,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625136,,5606,In vivo,,50588,17764,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625137,,5607,In vivo,,50588,6448,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625138,,5608,In vivo,,50588,1475,,
,BAO_0000218,,N,,Percent bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625139,,5609,In vivo,,50588,3788,,
,BAO_0000218,,N,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL872264,,5610,In vivo,,50588,3639,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625140,,5611,In vivo,,50588,13397,,
,BAO_0000218,,N,,The compound was evaluated for bioavailability in dogs; 34-44,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624436,,5612,In vivo,,50588,2137,,
,BAO_0000218,,N,,Bioavailability in dog (dose 4 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624437,,5613,In vivo,,50588,2959,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL872261,,5614,In vivo,,50588,6448,,
,BAO_0000218,,N,,8 hour trough Blood level in dog was measured after administration of compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624438,,5615,,,50588,6084,,
Plasma,BAO_0000218,,N,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624439,,5616,In vivo,,50588,3639,,
,BAO_0000218,,N,,C24 after oral administration at 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624440,,5617,,,50588,6316,,
,BAO_0000218,,N,,Clearance after oral and iv dosing in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624441,,5618,,,50588,5238,,
Plasma,BAO_0000218,,N,,Clearance of the drug was measured in the plasma of dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624442,,5619,,,50588,17796,,
,BAO_0000218,,N,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624443,,5620,,,50588,2652,,
,BAO_0000218,,N,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624444,,5621,In vivo,,50588,5654,,
,BAO_0000218,,N,,Clearance of compound was determined in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624445,,5622,In vivo,,50588,6621,,
,BAO_0000218,,N,,Clearance on i.v. administration of 2 mg/kg was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624446,,5623,In vivo,,50588,6505,,
,BAO_0000218,,N,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624447,,5624,In vivo,,50588,5802,,
,BAO_0000218,,N,,Plasma clearance in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624448,,5625,In vivo,,50588,17267,,
,BAO_0000218,,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624449,,5626,In vivo,,50588,4521,,
,BAO_0000218,,N,,Plasma clearance in dog after administration of 0.25 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624450,,5627,In vivo,,50588,6535,,
,BAO_0000218,,N,,Plasma clearance in dog after administration of 1 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875942,,5628,In vivo,,50588,6535,,
,BAO_0000218,,N,,Plasma clearance in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624451,,5629,In vivo,,50588,6535,,
,BAO_0000218,,N,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624452,,5630,In vivo,,50588,5542,,
,BAO_0000218,,N,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624453,,5631,In vivo,,50588,5199,,
,BAO_0000218,,N,,Plasma clearance after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624454,,5632,In vivo,,50588,16907,,
,BAO_0000218,,N,,Plasma clearance after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624455,,5633,In vivo,,50588,16907,,
,BAO_0000218,,N,,Plasma administration to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624456,,5634,In vivo,,50588,16367,,
,BAO_0000218,,N,,Plasma clearance was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624457,,5635,In vivo,,50588,5505,,
,BAO_0000218,,N,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624458,,5636,In vivo,,50588,6215,,
,BAO_0000218,,N,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624459,,5637,In vivo,,50588,1466,,
Liver,BAO_0000251,,S,Microsomes,Intrinsic clearance in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,2,Intermediate,CHEMBL624460,,5638,In vitro,,102164,5007,,
Liver,BAO_0000251,,S,Microsomes,Intrinsic clearance in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,2,Intermediate,CHEMBL624461,,5639,In vitro,,102164,5007,,
,BAO_0000218,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875943,,5640,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624462,,5641,In vivo,,50588,16452,,
,BAO_0000218,,N,,Clearance in dog (dose 1 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624463,,5642,In vivo,,50588,16452,,
,BAO_0000218,,N,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624464,,5643,In vivo,,50588,6221,,
,BAO_0000218,,N,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624465,,5644,In vivo,,50588,5007,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624466,,5645,In vivo,,50588,5668,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 5 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624467,,5646,In vivo,,50588,5668,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 5 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624468,,5647,In vivo,,50588,5668,,
,BAO_0000218,,N,,Plasma clearance was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624469,,5648,In vivo,,50588,15660,,
,BAO_0000218,,N,,Plasma clearance was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624470,,5649,In vivo,,50588,15660,,
,BAO_0000218,,N,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624471,,5650,In vivo,,50588,5983,,
,BAO_0000218,,N,,Total clearance was determined after 0.1 mg/kg iv administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624472,,5651,In vivo,,50588,5600,,
,BAO_0000218,,N,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622775,,5652,In vivo,,50588,17764,,
,BAO_0000218,,N,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622776,,5653,In vivo,,50588,6039,,
,BAO_0000218,,N,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622777,,5654,In vivo,,50588,6039,,
,BAO_0000218,,N,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622778,,5655,In vivo,,50588,6039,,
,BAO_0000218,,N,,Clearance by intravenous administration of 1.2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622779,,5656,In vivo,,50588,4368,,
,BAO_0000218,,N,,Clearance by iv administration in dogs at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622780,,5657,In vivo,,50588,4305,,
Plasma,BAO_0000218,,N,,Clearance value was evaluated in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622781,,5658,In vivo,,50588,1918,,
,BAO_0000218,,N,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622782,,5659,In vivo,,50588,6005,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622783,,5660,In vivo,,50588,4839,,
,BAO_0000218,,N,,Pharmacokinetic property (Plasma clearance) was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622784,,5661,In vivo,,50588,4239,,
,BAO_0000218,,N,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622785,,5662,,,50594,17729,,
,BAO_0000218,,N,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622786,,5663,,,50594,17728,,
,BAO_0000218,,N,,Area under curve value in mouse at a dose of 10 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622787,,5664,,,50594,5302,,
,BAO_0000218,,N,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875949,,5665,,,50594,5506,,
,BAO_0000218,,N,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622788,,5666,,,50594,5506,,
,BAO_0000218,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622789,,5667,,,50594,17764,,
,BAO_0000218,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622790,,5668,,,50594,17764,,
,BAO_0000218,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622791,,5669,,,50594,17764,,
,BAO_0000218,,N,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622792,,5670,,,50594,17764,,
,BAO_0000218,,N,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622793,,5671,,,50594,17764,,
,BAO_0000218,,N,,Area under curve was determined for the compound at 24 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622794,,5672,,,50594,17753,,
,BAO_0000218,,N,,Area under curve was determined for the compound at 40 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622795,,5673,,,50594,17753,,
,BAO_0000218,,N,,Area under curve was determined for the compound at 5 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621803,,5674,,,50594,17753,,
,BAO_0000218,,N,,Area under the curve for the compound is obtained at dose 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621804,,5675,,,50594,3132,,
,BAO_0000218,,N,,Area under the curve for the compound was obtained when tested in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621805,,5676,,,50594,3132,,
,BAO_0000218,,N,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621806,,5677,,,50594,17837,,
,BAO_0000218,,N,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621807,,5678,,,50594,17837,,
,BAO_0000218,,N,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621808,,5679,,,50594,6062,,
,BAO_0000218,,N,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621809,,5680,,,50594,4066,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621810,,5681,,,50594,16597,,
,BAO_0000218,,N,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875164,,5682,,,50594,14239,,
,BAO_0000218,,N,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621811,,5683,,,50594,14239,,
,BAO_0000218,,N,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621812,,5684,,,50594,4890,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621813,,5685,,,50594,429,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621814,,5686,,,50594,429,,
,BAO_0000218,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621815,,5687,,,50594,5969,,
,BAO_0000218,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621816,,5688,,,50594,5969,,
,BAO_0000218,,N,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621817,,5689,,,50594,5969,,
,BAO_0000218,,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621818,,5690,,,50594,6091,,
,BAO_0000218,,N,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621819,,5691,,,50594,6091,,
,BAO_0000218,,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621820,,5692,,,50594,6091,,
,BAO_0000218,,N,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621821,,5693,,,50594,6091,,
,BAO_0000218,,N,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621822,,5694,,,50594,6178,,
,BAO_0000218,,N,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619474,,5695,,,50594,6178,,
,BAO_0000218,,N,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619475,,5696,,,50594,6619,,
,BAO_0000218,,N,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619476,,5697,,,50594,6619,,
,BAO_0000218,,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619477,,5698,,,50594,3760,,
,BAO_0000218,,N,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619478,,5699,,,50594,3760,,
,BAO_0000218,,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619479,,5700,,,50594,3760,,
,BAO_0000218,,N,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619480,,5701,,,50594,3760,,
,BAO_0000218,,N,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619481,,5702,,,50594,3192,,
,BAO_0000218,,N,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619482,,5703,,,50594,3192,,
,BAO_0000218,,N,,Area under the curve was evaluated in mice after intravenous administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619483,,5704,,,50594,2675,,
,BAO_0000218,,N,,Area under the curve was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619484,,5705,,,50594,2675,,
Plasma,BAO_0000218,,N,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL619485,,5706,,,50594,16597,,
Plasma,BAO_0000218,,N,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL619486,,5707,,,50594,16597,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619487,,5708,,,50594,16597,,
,BAO_0000218,,N,,AUMC after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619488,,5709,,,50594,17734,,
Blood,BAO_0000218,,N,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL620106,,5710,In vivo,,50594,7767,,
,BAO_0000219,,N,,The compound was tested in vitro for anticancer activity against 9L cells,1,9L,,F,,,1,Intermediate,CHEMBL620107,,5711,,,80653,15345,392.0,
,BAO_0000019,,U,,Anti proliferation activity determined; Weak effect,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL620283,,5712,,,22226,2181,,
,BAO_0000219,,U,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL875176,,5713,,,22226,2181,,
,BAO_0000219,,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL620284,,5714,,,22226,2181,,
,BAO_0000219,,U,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL623515,,5715,,,22226,2181,,
,BAO_0000019,,U,,The cytotoxic activity was in vitro tested by 9PS assay method,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL623516,,5716,,,22226,10486,,
,BAO_0000019,,U,,The cytotoxic activity was in vitro tested by 9PS assay method.,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL623517,,5717,,,22226,10486,,
,BAO_0000019,,U,,Partition coefficient (logD6.5),1,,,A,,,0,Autocuration,CHEMBL857878,,5718,,,22224,15508,,
,BAO_0000219,,N,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623518,,5719,,,81034,5242,478.0,
,BAO_0000219,,N,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624195,,5720,,,80018,16167,455.0,
,BAO_0000219,,N,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624196,,5721,,,80852,4782,500.0,
,BAO_0000219,,D,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,1,A-431,9606.0,F,Homo sapiens,,9,Expert,CHEMBL624197,,5722,,,9,16093,500.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624198,,5723,,,80021,2596,624.0,
,BAO_0000219,,N,,in vitro cytotoxicity against A 498 cancer cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621287,,5724,,,80021,2596,624.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621288,,5725,,,80021,3239,624.0,
,BAO_0000219,,N,,Cytotoxic activity against A 498 renal cancer cell lines.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876496,,5726,,,80021,1847,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621289,,5727,,,80021,10553,624.0,
,BAO_0000019,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,,1280.0,F,Staphylococcus aureus,,0,Autocuration,CHEMBL621290,,5728,,,22226,16219,,
,BAO_0000019,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,1,,1280.0,F,Staphylococcus aureus,,0,Autocuration,CHEMBL621291,,5729,,,22226,16219,,
,BAO_0000019,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,,1280.0,F,Staphylococcus aureus,,0,Autocuration,CHEMBL621292,,5730,,,22226,16219,,
,BAO_0000019,,U,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,1,,1280.0,F,Staphylococcus aureus,,0,Autocuration,CHEMBL621293,,5731,,,22226,16219,,
,BAO_0000219,,N,,Inhibitory concentration required against A 549 lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621294,,5732,,,80682,4782,646.0,
,BAO_0000219,,N,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621295,,5733,,,80682,11805,646.0,
,BAO_0000219,,N,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884007,,5734,,,80682,11805,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against lung cancer A 549 cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621296,,5735,,,80682,2007,646.0,
,BAO_0000219,,N,,Compound was tested for its cytotoxicity against A 549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621297,,5736,,,80682,4594,646.0,
,BAO_0000219,,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL839828,,5737,,,80682,6018,646.0,
,BAO_0000219,,N,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620397,,5738,,,80682,6018,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620398,,5739,,,80682,3599,646.0,
,BAO_0000219,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620399,,5740,,,80682,2551,646.0,
,BAO_0000219,,N,,In vitro inhibition of A549 (human lung cancer) cell growth.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620400,,5741,,,80682,16132,646.0,
,BAO_0000219,,N,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620401,,5742,,,80682,16132,646.0,
,BAO_0000219,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620402,,5743,,,80682,2551,646.0,
,BAO_0000219,,N,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620403,,5744,,,80682,2551,646.0,
,BAO_0000218,,U,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,1,,,F,,,0,Autocuration,CHEMBL620404,,5745,,,22226,11913,,
,BAO_0000218,,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,1,,,F,,,4,Autocuration,CHEMBL620405,,5746,In vivo,,104694,12621,,
,BAO_0000218,,H,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,1,,,F,,,4,Autocuration,CHEMBL620406,,5747,In vivo,,104694,12621,,
,BAO_0000218,,H,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,1,,,F,,,4,Autocuration,CHEMBL620407,,5748,In vivo,,104694,12621,,
,BAO_0000218,,H,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,1,,,F,,,4,Autocuration,CHEMBL620408,,5749,In vivo,,104694,12621,,
,BAO_0000218,,H,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,1,,,F,,,4,Autocuration,CHEMBL620409,,5750,In vivo,,104694,12621,,
,BAO_0000219,,N,,Inhibition of A-498 human Renal cell proliferation,1,A498,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620410,,5751,,,80021,3600,624.0,
,BAO_0000019,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL620411,,5752,,,22226,1796,,
,BAO_0000019,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL620412,,5753,,,22226,1796,,
,BAO_0000019,,U,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL876596,,5754,,,22226,1796,,
,BAO_0000219,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,1,A 172,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620413,,5755,,,80012,16464,622.0,
,BAO_0000219,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620414,,5756,,,80012,16464,622.0,
,BAO_0000219,,N,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620415,,5757,,,80012,16464,622.0,
,BAO_0000219,,N,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620416,,5758,,,80682,13617,646.0,
,BAO_0000219,,N,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620417,,5759,,,80682,4584,646.0,
,BAO_0000219,,N,,Cytotoxic activity evaluated against A549 tumor cells,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620418,,5760,,,80682,13799,646.0,
,BAO_0000219,,N,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620419,,5761,,,80682,16726,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620420,,5762,,,80682,16109,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620421,,5763,,,80682,16109,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620422,,5764,,,80682,15474,646.0,
,BAO_0000219,,N,,Cytotoxicity of compound against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620423,,5765,,,80682,6851,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung cell carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620424,,5766,,,80682,17534,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620425,,5767,,,80682,2621,646.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620426,,5768,,,80682,830,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620427,,5769,,,80682,14255,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620428,,5770,,,80682,14255,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620429,,5771,,,80682,1590,646.0,
,BAO_0000219,,N,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620430,,5772,,,80682,6146,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL839887,,5773,,,80682,17427,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620431,,5774,,,80682,5280,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884010,,5775,,,80682,16786,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549 (human lung cancer),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620538,,5776,,,80682,5895,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620539,,5777,,,80682,14297,646.0,
,BAO_0000218,,N,,In vivo antiproliferative activity against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623373,,5778,,,80682,17824,646.0,
,BAO_0000219,,N,,Inhibition of non-small-cell lung adenocarcinoma (A549),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623374,,5779,,,80682,14368,646.0,
,BAO_0000219,,N,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623375,,5780,,,80682,14368,646.0,
,BAO_0000219,,N,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623376,,5781,,,80682,14254,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623377,,5782,,,80682,15897,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623378,,5783,,,80682,13866,646.0,
,BAO_0000219,,N,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623379,,5784,,,80682,13370,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623380,,5785,,,80682,4862,646.0,
,BAO_0000219,,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623381,,5786,,,80682,4862,646.0,
,BAO_0000219,,N,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623382,,5787,,,80682,4862,646.0,
,BAO_0000219,,N,,Inhibitory concentration against A549 (lung cancer) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623383,,5788,,,80682,15970,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623384,,5789,,,80682,17713,646.0,
,BAO_0000219,,N,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623385,,5790,,,80682,4833,646.0,
,BAO_0000219,,N,,Activity against A549 cancer cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623386,,5791,,,80682,13736,646.0,
,BAO_0000219,,N,,The compound was evaluated for cytotoxicity against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884105,,5792,,,80682,4312,646.0,
,BAO_0000219,,N,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623387,,5793,,,80682,5421,646.0,
,BAO_0000219,,N,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621568,,5794,,,80682,5421,646.0,
,BAO_0000219,,N,,Growth inhibitory activity was measured for human A549 tumor cell line.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621569,,5795,,,80682,14717,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621570,,5796,,,80682,4634,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 cell line; inactive,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621571,,5797,,,80682,1149,646.0,
,BAO_0000219,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621572,,5798,,,80682,5421,646.0,
,BAO_0000219,,N,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621573,,5799,,,80682,5421,646.0,
,BAO_0000219,,N,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621574,,5800,,,80682,5421,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621575,,5801,,,80682,3320,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621576,,5802,,,80682,3320,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621577,,5803,,,80682,3320,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621578,,5804,,,80682,3320,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621579,,5805,,,80682,3320,646.0,
,BAO_0000219,,N,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621580,,5806,,,80682,5726,646.0,
,BAO_0000218,,N,,Plasma clearance (in vivo) in mongrel dogs was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621581,,5807,In vivo,,50588,17800,,
,BAO_0000218,,N,,Plasma clearance was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621582,,5808,In vivo,,50588,5985,,
,BAO_0000218,,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621583,,5809,In vivo,,50588,5530,,
,BAO_0000218,,N,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621584,,5810,In vivo,,50588,5530,,
Plasma,BAO_0000218,,N,,Tested for plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621585,,5811,In vivo,,50588,4839,,
,BAO_0000218,,N,,The compound was tested for clearance in dog plasma.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621586,,5812,In vivo,,50588,3639,,
,BAO_0000218,,N,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875835,,5813,In vivo,,50588,4838,,
,BAO_0000218,,N,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621587,,5814,In vivo,,50588,4137,,
Plasma,BAO_0000218,,N,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621588,,5815,In vivo,,50588,5017,,
Liver,BAO_0000218,,N,Microsomes,In vitro clearance in dog liver microsomes,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL621589,,5816,In vitro,,50588,17538,,
,BAO_0000218,,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621590,,5817,In vivo,,50588,6161,,
,BAO_0000218,,N,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621591,,5818,In vivo,,50588,6161,,
,BAO_0000218,,N,,Plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621592,,5819,In vivo,,50588,1696,,
,BAO_0000218,,N,,Clearance rate in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621593,,5820,In vivo,,50588,6762,,
Plasma,BAO_0000218,,N,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621594,,5821,In vivo,,50588,5932,,
,BAO_0000218,,N,,Clearance in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621595,,5822,In vivo,,50588,6305,,
,BAO_0000218,,N,,Plasma clearance in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621596,,5823,In vivo,,50588,4942,,
,BAO_0000218,,N,,Plasma clearance was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621597,,5824,In vivo,,50588,4219,,
,BAO_0000218,,N,,Lower clearance in dog (i.v.) at 0.5 mpk,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621598,,5825,In vivo,,50588,17853,,
,BAO_0000218,,N,,Plasma clearance in Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621599,,5826,In vivo,,50588,4514,,
,BAO_0000218,,N,,Plasma clearance (Clp) in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875836,,5827,In vivo,,50588,6448,,
,BAO_0000218,,N,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621600,,5828,In vivo,,50588,6227,,
,BAO_0000218,,N,,Plasma clearance (pharmacokinetic parameter) in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621601,,5829,In vivo,,50588,6227,,
,BAO_0000218,,N,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618474,,5830,In vivo,,50588,6062,,
,BAO_0000218,,N,,Plasma clearance of compound was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618475,,5831,In vivo,,50588,6821,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624524,,5832,In vivo,,50588,4709,,
,BAO_0000218,,N,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624525,,5833,In vivo,,50588,4521,,
,BAO_0000218,,N,,Plasma clearance in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624526,,5834,In vivo,,50588,5374,,
,BAO_0000218,,N,,Plasma clearance was calculated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624527,,5835,In vivo,,50588,6057,,
,BAO_0000218,,N,,Plasma clearance at the dose of 2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624528,,5836,In vivo,,50588,4727,,
,BAO_0000218,,N,,Plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624529,,5837,In vivo,,50588,5145,,
,BAO_0000218,,N,,Plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624530,,5838,In vivo,,50588,17657,,
,BAO_0000218,,N,,Plasma clearance in dog; Unable to calculate,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624531,,5839,In vivo,,50588,17657,,
,BAO_0000218,,N,,Plasma clearance in rhesus monkey,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624532,,5840,In vivo,,50588,5145,,
,BAO_0000218,,N,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624533,,5841,In vivo,,50588,6642,,
,BAO_0000218,,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624534,,5842,In vivo,,50588,6641,,
,BAO_0000218,,N,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624535,,5843,In vivo,,50588,6642,,
,BAO_0000218,,N,,Plasma clearance was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624536,,5844,In vivo,,50588,5472,,
,BAO_0000218,,N,,Plasma clearance was evaluated in dog; Not tested,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624537,,5845,In vivo,,50588,5472,,
,BAO_0000218,,N,,Plasma clearance was evaluated in rhesus,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624538,,5846,In vivo,,50588,5472,,
,BAO_0000218,,N,,Plasma clearance was evaluated in rhesus; Not tested,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624539,,5847,In vivo,,50588,5472,,
,BAO_0000218,,N,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624540,,5848,In vivo,,50588,4257,,
,BAO_0000218,,N,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624541,,5849,In vivo,,50588,6679,,
,BAO_0000218,,N,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624542,,5850,In vivo,,50588,5546,,
,BAO_0000218,,N,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624543,,5851,In vivo,,50588,6348,,
,BAO_0000218,,N,,Clearance value at a dose of 0.2 mg/kg i.v.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624544,,5852,In vivo,,50588,5474,,
Plasma,BAO_0000218,,N,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624545,,5853,In vivo,,50588,6316,,
,BAO_0000218,,N,,Cmax after oral dose of compound at 3 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624546,,5854,In vivo,,50588,17594,,
,BAO_0000218,,N,,Cmax after single intravenous bolus of 1 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875957,,5855,In vivo,,50588,17594,,
,BAO_0000218,,N,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624547,,5856,In vivo,,50588,5802,,
,BAO_0000218,,N,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624548,,5857,In vivo,,50588,6535,,
,BAO_0000218,,N,,Cmax in dog after administration of 1 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624549,,5858,In vivo,,50588,6535,,
Plasma,BAO_0000218,,N,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624550,,5859,In vivo,,50588,1466,,
,BAO_0000218,,N,,Cmax on p.o. administration of 10 mg/kg was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621613,,5860,In vivo,,50588,6505,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621614,,5861,In vivo,,50588,5668,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 5 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623431,,5862,In vivo,,50588,5668,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 5 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623432,,5863,In vivo,,50588,5668,,
,BAO_0000218,,N,,Cmax after 0.3 mg/kg po administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623433,,5864,In vivo,,50588,5600,,
,BAO_0000218,,N,,Cmax after peroral administration in dogs at 2.4 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623434,,5865,In vivo,,50588,17764,,
,BAO_0000218,,N,,Cmax in dog after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623435,,5866,In vivo,,50588,6123,,
,BAO_0000218,,N,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623436,,5867,In vivo,,50588,6123,,
,BAO_0000218,,N,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875958,,5868,In vivo,,50588,6757,,
,BAO_0000218,,N,,Cmax value after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623437,,5869,In vivo,,50588,16907,,
Blood,BAO_0000218,,N,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL623438,,5870,In vivo,,50594,7767,,
Blood,BAO_0000218,,N,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL623439,,5871,In vivo,,50594,7767,,
Bone,BAO_0000218,,N,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL623440,,5872,In vivo,,50594,7767,,
Bone,BAO_0000218,,N,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL623441,,5873,In vivo,,50594,7767,,
Bone,BAO_0000218,,N,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL623442,,5874,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623469,,5875,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623470,,5876,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623471,,5877,In vivo,,50594,7767,,
Heart,BAO_0000218,,N,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL623472,,5878,In vivo,,50594,7767,,
Heart,BAO_0000218,,N,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL623473,,5879,In vivo,,50594,7767,,
Heart,BAO_0000218,,N,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL623474,,5880,In vivo,,50594,7767,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623475,,5881,In vivo,,50594,7767,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623476,,5882,In vivo,,50594,7767,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623477,,5883,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL621896,,5884,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL621897,,5885,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL621898,,5886,In vivo,,50594,7767,,
Liver,BAO_0000218,,N,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621899,,5887,In vivo,,50594,7767,,
Liver,BAO_0000218,,N,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621900,,5888,In vivo,,50594,7767,,
Liver,BAO_0000218,,N,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621901,,5889,In vivo,,50594,7767,,
Lung,BAO_0000218,,N,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621902,,5890,In vivo,,50594,7767,,
Lung,BAO_0000218,,N,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621903,,5891,In vivo,,50594,7767,,
Lung,BAO_0000218,,N,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL622587,,5892,In vivo,,50594,7767,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL620285,,5893,In vivo,,50594,7767,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL875285,,5894,In vivo,,50594,7767,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL620286,,5895,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620287,,5896,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620288,,5897,In vivo,,50594,7767,,
,BAO_0000218,,N,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620289,,5898,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL620290,,5899,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL620291,,5900,In vivo,,50594,7767,,
Intestine,BAO_0000218,,N,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL620292,,5901,In vivo,,50594,7767,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL620293,,5902,In vivo,,50594,7767,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL620294,,5903,In vivo,,50594,7767,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618614,,5904,In vivo,,50594,7767,,
Stomach,BAO_0000218,,N,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL618615,,5905,In vivo,,50594,7767,,
Stomach,BAO_0000218,,N,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL618616,,5906,In vivo,,50594,7767,,
,BAO_0000219,,N,,Cytotoxicity against A-172 human tumor cell lines,1,A 172,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618617,,5907,,,80012,2036,622.0,
,BAO_0000219,,N,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618618,,5908,,,80012,2357,622.0,
,BAO_0000219,,N,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,1,A204,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618619,,5909,,,80014,1457,623.0,
,BAO_0000219,,N,,Tested for antiproliferative activity against A-2780 tumoral cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618620,,5910,,,81034,4379,478.0,
,BAO_0000219,,N,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618621,,5911,,,80018,1093,455.0,
,BAO_0000219,,N,,Tested in vitro against A-375 cell line human melanoma,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618622,,5912,,,80018,12152,455.0,
,BAO_0000219,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,1,A-427,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618623,,5913,,,80019,16464,797.0,
,BAO_0000219,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618624,,5914,,,80019,16464,797.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,1,A-427,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618625,,5915,,,80019,16582,797.0,
,BAO_0000219,,N,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618626,,5916,,,80019,16464,797.0,
,BAO_0000219,,N,,Antitumor activity on A-427 lung carcinoma cell lines,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618627,,5917,,,80019,10413,797.0,
,BAO_0000219,,N,,Cytotoxic activity against human A-427 lung tumor cell line,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618628,,5918,,,80019,6418,797.0,
,BAO_0000219,,N,,In vitro antitumor effects against human A-427 cell lines.,1,A-427,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618629,,5919,,,80019,17134,797.0,
,BAO_0000219,,N,,In vitro inhibition of A-427 (human lung cancer) cell growth.,1,A-427,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618630,,5920,,,80019,16132,797.0,
,BAO_0000219,,N,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618631,,5921,,,80019,16132,797.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-427 lung human tumor cell line,1,A-427,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618632,,5922,,,80019,16780,797.0,
,BAO_0000219,,N,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,1,A-431,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618633,,5923,,,80852,4085,500.0,
,BAO_0000219,,N,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619315,,5924,,,80021,1276,624.0,
,BAO_0000219,,N,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,1,A498,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619316,,5925,,,80021,3498,624.0,
,BAO_0000219,,N,,Cytotoxicity against human kidney carcinoma A-498cell lines,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619317,,5926,,,80021,1169,624.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619318,,5927,,,80021,4450,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619319,,5928,,,80021,3311,624.0,
,BAO_0000219,,N,,Antitumor cytotoxic activity against A-498 cell line was determined,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619739,,5929,,,80021,4461,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619740,,5930,,,80021,3311,624.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883158,,5931,,,80021,3311,624.0,
,BAO_0000219,,N,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884012,,5932,,,80021,1457,624.0,
,BAO_0000219,,N,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619741,,5933,,,80021,3664,624.0,
,BAO_0000219,,N,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",1,A498,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619742,,5934,,,80021,15895,624.0,
,BAO_0000219,,N,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876610,,5935,,,80682,11843,646.0,
,BAO_0000219,,N,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619743,,5936,,,80682,11843,646.0,
,BAO_0000219,,N,,In vitro antiproliferative activity against human A-549 NSCL cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619744,,5937,,,80682,17705,646.0,
,BAO_0000219,,N,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619745,,5938,,,80682,17705,646.0,
,BAO_0000219,,N,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619746,,5939,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619747,,5940,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619748,,5941,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619749,,5942,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619750,,5943,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624014,,5944,,,80682,4369,646.0,
,BAO_0000219,,N,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624015,,5945,,,80682,4369,646.0,
,BAO_0000219,,N,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL885344,,5946,,,80682,4787,646.0,
,BAO_0000219,,N,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623224,,5947,,,80682,4787,646.0,
,BAO_0000219,,N,,Cytotoxic activity against A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623225,,5948,,,80682,6513,646.0,
,BAO_0000219,,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622698,,5949,,,80682,6690,646.0,
,BAO_0000219,,N,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622699,,5950,,,80682,6690,646.0,
,BAO_0000219,,N,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622700,,5951,,,80682,12263,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622701,,5952,,,80682,1054,646.0,
,BAO_0000219,,N,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622702,,5953,,,80682,1359,646.0,
,BAO_0000219,,N,,Cytotoxic activity against human lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622703,,5954,,,80682,3547,646.0,
,BAO_0000219,,N,,Cytotoxic activity towards A-549 cells,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622704,,5955,,,80682,5771,646.0,
,BAO_0000219,,N,,"In vitro percent inhibition of A549, lung carcinoma.",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622705,,5956,,,80682,14425,646.0,
,BAO_0000219,,N,,"In vitro percent inhibition of A549, lung carcinoma",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622706,,5957,,,80682,14425,646.0,
,BAO_0000219,,N,,"In vitro percent inhibition of A549, lung carcinoma.",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622707,,5958,,,80682,14425,646.0,
,BAO_0000219,,N,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622708,,5959,,,80682,14425,646.0,
,BAO_0000219,,N,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622709,,5960,,,80682,5280,646.0,
,BAO_0000219,,N,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622710,,5961,,,80682,15176,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622711,,5962,,,80682,15300,646.0,
,BAO_0000218,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622712,,5963,,,80682,17824,646.0,
,BAO_0000218,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622713,,5964,,,80682,17824,646.0,
,BAO_0000218,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622714,,5965,,,80682,17824,646.0,
,BAO_0000218,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622715,,5966,,,80682,17824,646.0,
,BAO_0000218,,N,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622716,,5967,,,80682,17824,646.0,
,BAO_0000219,,N,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622717,,5968,,,80682,17824,646.0,
,BAO_0000218,,N,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622718,,5969,,,80682,17528,646.0,
,BAO_0000219,,N,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622719,,5970,,,80682,6870,646.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622720,,5971,,,80682,6870,646.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622721,,5972,,,80682,6870,646.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622722,,5973,,,80682,6870,646.0,
,BAO_0000219,,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876030,,5974,,,80682,16726,646.0,
,BAO_0000219,,N,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620206,,5975,,,80682,6170,646.0,
,BAO_0000219,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620207,,5976,,,80682,6583,646.0,
,BAO_0000219,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620208,,5977,,,80682,6583,646.0,
,BAO_0000219,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620209,,5978,,,80682,6583,646.0,
,BAO_0000219,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620210,,5979,,,80682,6583,646.0,
,BAO_0000219,,N,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621639,,5980,,,80682,6583,646.0,
,BAO_0000219,,N,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621640,,5981,,,80682,17321,646.0,
,BAO_0000219,,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621641,,5982,,,80682,17528,646.0,
,BAO_0000219,,N,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621642,,5983,,,80682,12888,646.0,
,BAO_0000219,,N,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621643,,5984,,,80682,4312,646.0,
,BAO_0000219,,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621644,,5985,,,80682,4312,646.0,
,BAO_0000219,,N,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621645,,5986,,,80682,4312,646.0,
,BAO_0000219,,N,,In vitro antiproliferative activity against A549 cell line,1,A549,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL621646,,5987,,,80682,17737,646.0,
,BAO_0000219,,N,,Synergism with indomethacin in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621647,,5988,,,80682,6630,646.0,
,BAO_0000219,,N,,Synergism with tolmetin in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621648,,5989,,,80682,6630,646.0,
,BAO_0000219,,N,,Synergism with sulindac in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621649,,5990,,,80682,6630,646.0,
,BAO_0000219,,N,,Antagonism of indomethacin in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621650,,5991,,,80682,6630,646.0,
,BAO_0000219,,N,,Antagonism of sulindac in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621651,,5992,,,80682,6630,646.0,
,BAO_0000219,,N,,Antagonism of tolmetin in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621652,,5993,,,80682,6630,646.0,
,BAO_0000219,,N,,Synergism with indomethacin in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621653,,5994,,,80682,6630,646.0,
,BAO_0000219,,N,,Synergism with sulindac in A549 cells,1,A549,,F,,,1,Intermediate,CHEMBL621654,,5995,,,80682,6630,646.0,
,BAO_0000219,,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,1,A549,,F,,,1,Intermediate,CHEMBL621655,,5996,,,80682,6630,646.0,
,BAO_0000218,,N,,Cmax value after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621656,,5997,In vivo,,50588,16907,,
,BAO_0000218,,N,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621657,,5998,In vivo,,50588,5944,,
,BAO_0000218,,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621658,,5999,In vivo,,50588,5944,,
,BAO_0000218,,N,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621659,,6000,In vivo,,50588,5944,,
,BAO_0000218,,N,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621660,,6001,In vivo,,50588,5944,,
,BAO_0000218,,N,,Cmax value after administration of 4 mg/Kg oral dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621661,,6002,In vivo,,50588,2959,,
,BAO_0000218,,N,,Cmax value in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621662,,6003,In vivo,,50588,6241,,
,BAO_0000218,,N,,Cmax value in dogs after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621663,,6004,In vivo,,50588,6241,,
,BAO_0000218,,N,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621664,,6005,In vivo,,50588,2652,,
Plasma,BAO_0000218,,N,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621665,,6006,In vivo,,50588,1806,,
Plasma,BAO_0000218,,N,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621666,,6007,In vivo,,50588,1806,,
,BAO_0000218,,N,,Concentration maxima after oral dosing in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621667,,6008,In vivo,,50588,1021,,
,BAO_0000218,,N,,Concentration maxima after oral dosing in dogs; not available,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876738,,6009,In vivo,,50588,1021,,
,BAO_0000218,,N,,Concentration maxima after oral dosing in dogs; not available,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621668,,6010,In vivo,,50588,1021,,
,BAO_0000218,,N,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621669,,6011,In vivo,,50588,5444,,
,BAO_0000218,,N,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621670,,6012,In vivo,,50588,5444,,
,BAO_0000218,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621671,,6013,In vivo,,50588,5444,,
,BAO_0000218,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622360,,6014,In vivo,,50588,5444,,
,BAO_0000218,,N,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622361,,6015,In vivo,,50588,5444,,
Plasma,BAO_0000218,,N,,Cmax in dog plasma after oral dose (1 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622362,,6016,In vivo,,50588,5130,,
Plasma,BAO_0000218,,N,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622363,,6017,In vivo,,50588,3249,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622364,,6018,In vivo,,50588,5473,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration at a dose of 1 mg/kg (oral),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622365,,6019,In vivo,,50588,5474,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622533,,6020,In vivo,,50588,4657,,
,BAO_0000218,,N,,Maximum concentration of compound in dog was evaluated.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622534,,6021,In vivo,,50588,3031,,
,BAO_0000218,,N,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622535,,6022,In vivo,,50588,4527,,
,BAO_0000218,,N,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876739,,6023,In vivo,,50588,4186,,
,BAO_0000218,,N,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622536,,6024,In vivo,,50588,5007,,
Plasma,BAO_0000218,,N,,Maximum concentration obtained in dog plasma was determined,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622537,,6025,In vivo,,50588,3132,,
,BAO_0000218,,N,,Maximum concentration was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622538,,6026,In vivo,,50588,5006,,
,BAO_0000218,,N,,Maximum concentration at the dose of 2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627867,,6027,In vivo,,50588,4727,,
,BAO_0000218,,N,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627868,,6028,In vivo,,50588,1916,,
Plasma,BAO_0000218,,N,,Maximum concentration was evaluated in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627869,,6029,In vivo,,50588,1918,,
,BAO_0000218,,N,,Maximum concentration was evaluated after 75 min after administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627870,,6030,In vivo,,50588,3045,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration determined in dog after oral administration of 17b,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627871,,6031,In vivo,,50588,9579,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration determined in dog after oral administration of 2b,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627872,,6032,In vivo,,50588,9579,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627873,,6033,In vivo,,50588,933,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627874,,6034,In vivo,,50588,17839,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627875,,6035,In vivo,,50588,17839,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627876,,6036,In vivo,,50588,17839,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627877,,6037,In vivo,,50588,17839,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627878,,6038,In vivo,,50588,6348,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627879,,6039,In vivo,,50588,16367,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL875355,,6040,In vivo,,50588,1337,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627880,,6041,In vivo,,50588,1337,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627881,,6042,In vivo,,50588,5199,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627882,,6043,In vivo,,50588,17650,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627883,,6044,In vivo,,50588,6679,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628526,,6045,In vivo,,50588,5356,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628527,,6046,In vivo,,50588,5356,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628528,,6047,In vivo,,50588,6227,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628529,,6048,In vivo,,50588,6227,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628530,,6049,In vivo,,50588,6227,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625243,,6050,In vivo,,50588,6227,,
Plasma,BAO_0000218,,N,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Expert,CHEMBL625244,,6051,In vivo,,50588,3598,,
,BAO_0000218,,N,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625245,,6052,In vivo,,50588,4368,,
,BAO_0000218,,N,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625246,,6053,In vivo,,50588,6265,,
Stomach,BAO_0000218,,N,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL625247,,6054,In vivo,,50594,7767,,
Urine,BAO_0000218,,N,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL625248,,6055,In vivo,,50594,7767,,
Urine,BAO_0000218,,N,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL625249,,6056,In vivo,,50594,7767,,
Urine,BAO_0000218,,N,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL625250,,6057,In vivo,,50594,7767,,
,BAO_0000218,,N,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625251,,6058,,,50594,17811,,
,BAO_0000218,,N,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875356,,6059,,,50594,17811,,
,BAO_0000218,,N,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625252,,6060,,,50594,17827,,
Blood,BAO_0000218,,N,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL625253,,6061,,,50594,17827,,
,BAO_0000218,,N,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625254,,6062,,,50594,17827,,
,BAO_0000218,,N,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625255,,6063,,,50594,17827,,
,BAO_0000218,,N,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625256,,6064,,,50594,17827,,
Blood,BAO_0000218,,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL625257,,6065,,,50594,17827,,
Blood,BAO_0000218,,N,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL625258,,6066,,,50594,17827,,
,BAO_0000218,,N,,Compound was evaluated for washout rate in mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625259,,6067,,,50594,17827,,
,BAO_0000218,,N,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625260,,6068,,,50594,17827,,
,BAO_0000218,,N,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625261,,6069,,,50594,17827,,
,BAO_0000218,,N,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625262,,6070,,,50594,17827,,
,BAO_0000218,,N,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622639,,6071,,,50594,17827,,
,BAO_0000218,,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622640,,6072,,,50594,17257,,
,BAO_0000218,,N,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622812,,6073,,,50594,17257,,
,BAO_0000218,,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622813,,6074,,,50594,17257,,
,BAO_0000218,,N,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622814,,6075,,,50594,17257,,
,BAO_0000218,,N,,Time at maximum activity in mice (Radiolabeled compound),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622815,,6076,,,50594,17827,,
,BAO_0000218,,N,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625342,,6077,,,50594,3760,,
,BAO_0000218,,N,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625343,,6078,,,50594,3760,,
,BAO_0000218,,N,,Binding towards mouse plasma protein at 10 uM,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL877591,,6079,,,50594,17409,,
,BAO_0000218,,N,,Binding towards mouse plasma protein at 100 uM,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625344,,6080,,,50594,17409,,
,BAO_0000218,,N,,Bioavailability was evaluated in mice after intravenous administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625345,,6081,In vivo,,50594,2675,,
,BAO_0000218,,N,,Bioavailability was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625346,,6082,In vivo,,50594,2675,,
,BAO_0000218,,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625347,,6083,In vivo,,50594,3132,,
,BAO_0000218,,N,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625348,,6084,In vivo,,50594,3132,,
,BAO_0000218,,N,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625349,,6085,In vivo,,50594,16597,,
,BAO_0000218,,N,,Oral bioavailability in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625350,,6086,In vivo,,50594,2862,,
,BAO_0000218,,N,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL882952,,6087,In vivo,,50594,17764,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625351,,6088,In vivo,,50594,846,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625352,,6089,In vivo,,50594,846,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL877592,,6090,In vivo,,50594,846,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625353,,6091,In vivo,,50594,846,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625354,,6092,In vivo,,50594,846,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL626019,,6093,In vivo,,50594,846,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL626020,,6094,In vivo,,50594,846,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL626021,,6095,In vivo,,50594,846,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL626022,,6096,In vivo,,50594,846,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL626192,,6097,In vivo,,50594,846,,
,BAO_0000219,,N,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626193,,6098,,,80682,1276,646.0,
,BAO_0000219,,N,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL626194,,6099,,,80682,3498,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma A-549 cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626195,,6100,,,80682,1169,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626196,,6101,,,80682,4450,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626197,,6102,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626198,,6103,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626199,,6104,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626200,,6105,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626201,,6106,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626202,,6107,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626203,,6108,,,80682,358,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A-549 human lung cancer cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL626204,,6109,,,80682,15167,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624701,,6110,,,80682,4139,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624702,,6111,,,80682,833,646.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624703,,6112,,,80682,15718,646.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624704,,6113,,,80682,12373,646.0,
,BAO_0000219,,N,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624705,,6114,,,80682,637,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624706,,6115,,,80682,14867,646.0,
,BAO_0000219,,N,,Antitumor cytotoxic activity against A-549 cell line was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624707,,6116,,,80682,4461,646.0,
,BAO_0000219,,N,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624708,,6117,,,80682,5406,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624709,,6118,,,80682,4457,646.0,
,BAO_0000219,,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL884107,,6119,,,80682,1386,646.0,
,BAO_0000219,,N,,Antitumoral activity was assayed against A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624710,,6120,,,80682,3265,646.0,
,BAO_0000219,,N,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624711,,6121,,,80682,2359,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624712,,6122,,,80682,4457,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624713,,6123,,,80682,12454,646.0,
,BAO_0000219,,N,,Compound was tested for inhibition of cell growth of A-549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624714,,6124,,,80682,1481,646.0,
,BAO_0000219,,N,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624715,,6125,,,80682,1750,646.0,
,BAO_0000219,,N,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624716,,6126,,,80682,5065,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549-human lung carcinoma cells.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619505,,6127,,,80682,808,646.0,
,BAO_0000219,,N,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619506,,6128,,,80682,16364,646.0,
,BAO_0000219,,N,,Cytotoxic activity against A-549 cell lines.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619507,,6129,,,80682,1847,646.0,
,BAO_0000219,,N,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619508,,6130,,,80682,1747,646.0,
,BAO_0000219,,N,,Cytotoxicity against human A549 non small cell lung cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619509,,6131,,,80682,1003,646.0,
,BAO_0000219,,N,,Inhibition of cell growth in (A-549) lung cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619510,,6132,,,80682,15313,646.0,
,BAO_0000219,,N,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619511,,6133,,,80682,3122,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against A-549 tumor cells.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619512,,6134,,,80682,16049,646.0,
,BAO_0000219,,N,,In vitro antitumor effects against human A-549 cell lines.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619513,,6135,,,80682,17134,646.0,
,BAO_0000219,,N,,In vitro cytotoxic activity of compound against A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619514,,6136,,,80682,6406,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619515,,6137,,,80682,627,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619516,,6138,,,80682,12307,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884005,,6139,,,80682,17861,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619517,,6140,,,80682,6682,646.0,
,BAO_0000219,,N,,Inhibitory concentration of compound against A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619518,,6141,,,80682,6663,646.0,
,BAO_0000219,,N,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619519,,6142,,,80682,2454,646.0,
,BAO_0000219,,N,,cytotoxic activity against leukemia (A-549) cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876489,,6143,,,80682,14709,646.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619520,,6144,,,80682,15718,646.0,
,BAO_0000219,,N,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619521,,6145,,,80682,15718,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619522,,6146,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619523,,6147,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619524,,6148,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619525,,6149,,,80682,17130,646.0,
,BAO_0000219,,N,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,1,A549,,F,,,1,Intermediate,CHEMBL619526,,6150,,,80682,6630,646.0,
,BAO_0000219,,N,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619527,,6151,,,80682,16726,646.0,
,BAO_0000219,,N,,Cytotoxicity against A549 cells; No cytotoxicity,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619528,,6152,,,80682,17846,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma (A549) cell lines,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619529,,6153,,,80682,3415,646.0,
,BAO_0000219,,N,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619530,,6154,,,80682,3415,646.0,
,BAO_0000219,,N,,In vitro anticancer activity against human lung (A549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876490,,6155,,,80682,5609,646.0,
,BAO_0000219,,N,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619531,,6156,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619532,,6157,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619533,,6158,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619534,,6159,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620164,,6160,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620165,,6161,,,80682,17206,646.0,
,BAO_0000219,,N,,Inhibition of A549 human lung tumor cell proliferation,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620166,,6162,,,80682,16295,646.0,
,BAO_0000219,,N,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620167,,6163,,,80682,16825,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human tumor cell line A549,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620168,,6164,,,80682,3439,646.0,
,BAO_0000219,,N,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620338,,6165,,,80682,10870,646.0,
,BAO_0000219,,N,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620339,,6166,,,80682,4845,646.0,
,BAO_0000219,,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620340,,6167,,,80682,5822,646.0,
,BAO_0000219,,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620341,,6168,,,80682,5822,646.0,
,BAO_0000219,,N,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876491,,6169,,,80682,5822,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620342,,6170,,,80682,16381,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620343,,6171,,,80682,16381,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620344,,6172,,,80682,16381,646.0,
,BAO_0000219,,N,,In vitro anticancer activity against human lung (A549) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620345,,6173,,,80682,5609,646.0,
,BAO_0000219,,N,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620346,,6174,,,80682,4644,646.0,
,BAO_0000219,,N,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620347,,6175,,,80682,4644,646.0,
,BAO_0000219,,N,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620348,,6176,,,80682,4644,646.0,
,BAO_0000219,,N,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620349,,6177,,,80682,4644,646.0,
,BAO_0000219,,N,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618667,,6178,,,80682,5822,646.0,
,BAO_0000219,,N,,Percentage inhibition of human lung carcinoma (A549) cell lines,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618668,,6179,,,80682,3415,646.0,
,BAO_0000219,,N,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876031,,6180,,,80682,16726,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618759,,6181,,,80682,17206,646.0,
,BAO_0000219,,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618760,,6182,,,80682,17206,646.0,
,BAO_0000219,,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619000,,6183,,,80682,17206,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619001,,6184,,,80682,17206,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619002,,6185,,,80682,17206,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619003,,6186,,,80682,17206,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619597,,6187,,,80682,17206,646.0,
,BAO_0000219,,N,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619598,,6188,,,80682,17206,646.0,
,BAO_0000219,,N,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619599,,6189,,,80682,17206,646.0,
,BAO_0000219,,N,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619600,,6190,,,80682,17206,646.0,
,BAO_0000219,,N,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619601,,6191,,,80682,16726,646.0,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619602,,6192,,,80682,17206,646.0,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619603,,6193,,,80682,17206,646.0,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619604,,6194,,,80682,17206,646.0,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619605,,6195,,,80682,17206,646.0,
,BAO_0000218,,N,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619606,,6196,In vivo,,50588,6084,,
,BAO_0000218,,N,,Pharmacokinetic activity (Cmax) in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876032,,6197,In vivo,,50588,6084,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619607,,6198,In vivo,,50588,4809,,
,BAO_0000218,,N,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619608,,6199,In vivo,,50588,5983,,
,BAO_0000218,,N,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619609,,6200,In vivo,,50588,6251,,
Plasma,BAO_0000218,,N,,Cmax in dog plasma after 30mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL619610,,6201,In vivo,,50588,5932,,
Blood,BAO_0000218,,N,,Tested for the peak blood level in dog,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL619611,,6202,In vivo,,50588,4273,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619612,,6203,In vivo,,50588,5313,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619613,,6204,In vivo,,50588,5313,,
Blood,BAO_0000218,,N,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL619614,,6205,In vivo,,50588,6221,,
,BAO_0000218,,N,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619615,,6206,,,50588,4709,,
,BAO_0000218,,N,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619616,,6207,,,50588,167,,
Plasma,BAO_0000218,,N,,Final plasma concentration in dogs after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL619617,,6208,,,50588,6241,,
,BAO_0000218,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619618,,6209,,,50588,344,,
,BAO_0000218,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876033,,6210,,,50588,344,,
,BAO_0000218,,N,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619619,,6211,,,50588,344,,
,BAO_0000218,,N,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619620,,6212,,,50588,2189,,
Urine,BAO_0000218,,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL619621,,6213,,,50588,2189,,
Urine,BAO_0000218,,N,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL619622,,6214,,,50588,2189,,
Urine,BAO_0000218,,N,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL618874,,6215,,,50588,2189,,
,BAO_0000218,,N,,Absolute bioavailability was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618875,,6216,In vivo,,50588,4257,,
,BAO_0000218,,N,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618876,,6217,In vivo,,50588,6221,,
,BAO_0000218,,N,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618877,,6218,In vivo,,50588,6215,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618878,,6219,In vivo,,50588,17267,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618879,,6220,In vivo,,50588,6621,,
,BAO_0000218,,N,,Bioavailability after intravenous administration in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618880,,6221,In vivo,,50588,3854,,
,BAO_0000218,,N,,Bioavailability after peroral administration in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618881,,6222,In vivo,,50588,3854,,
,BAO_0000218,,N,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618882,,6223,In vivo,,50588,5007,,
,BAO_0000218,,N,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624226,,6224,In vivo,,50588,4333,,
Plasma,BAO_0000218,,N,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624227,,6225,In vivo,,50588,4333,,
,BAO_0000218,,N,,Bioavailability,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624228,,6226,In vivo,,50588,5006,,
,BAO_0000218,,N,,Bioavailability,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624229,,6227,In vivo,,50588,5199,,
,BAO_0000218,,N,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624230,,6228,In vivo,,50588,4368,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624231,,6229,In vivo,,50588,3771,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624232,,6230,In vivo,,50588,4953,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625127,,6231,In vivo,,50588,5064,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625128,,6232,In vivo,,50588,17657,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621675,,6233,In vivo,,50588,17796,,
,BAO_0000218,,N,,Bioavailability in dog (p.o.) at 2.0 mpk,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621676,,6234,In vivo,,50588,17853,,
,BAO_0000218,,N,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621677,,6235,In vivo,,50588,4521,,
,BAO_0000218,,N,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621678,,6236,In vivo,,50588,4521,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621679,,6237,In vivo,,50588,5006,,
,BAO_0000218,,N,,Bioavailability was evaluated after oral administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621680,,6238,In vivo,,50588,16365,,
,BAO_0000218,,N,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621681,,6239,In vivo,,50588,1916,,
,BAO_0000218,,N,,Bioavailability was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876740,,6240,In vivo,,50588,1918,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621682,,6241,In vivo,,50588,4239,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621683,,6242,In vivo,,50588,6505,,
,BAO_0000218,,N,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621684,,6243,In vivo,,50588,5334,,
,BAO_0000218,,N,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621685,,6244,In vivo,,50588,5334,,
,BAO_0000218,,N,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621686,,6245,In vivo,,50588,4809,,
,BAO_0000218,,N,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621687,,6246,In vivo,,50588,6348,,
,BAO_0000218,,N,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621688,,6247,In vivo,,50588,6005,,
,BAO_0000218,,N,,Bioavailability of compound in dog was determined after peroral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621689,,6248,In vivo,,50588,17804,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621690,,6249,In vivo,,50588,3184,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621691,,6250,In vivo,,50588,1806,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875941,,6251,In vivo,,50588,1806,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621692,,6252,In vivo,,50588,1806,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621693,,6253,In vivo,,50588,4839,,
,BAO_0000218,,N,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621694,,6254,In vivo,,50588,5017,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621695,,6255,In vivo,,50594,846,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621696,,6256,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621697,,6257,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621698,,6258,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623420,,6259,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623421,,6260,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623422,,6261,In vivo,,50594,846,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623423,,6262,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623424,,6263,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623425,,6264,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623426,,6265,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623427,,6266,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623428,,6267,In vivo,,50594,846,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL875947,,6268,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623429,,6269,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623430,,6270,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL622588,,6271,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL622589,,6272,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL622751,,6273,In vivo,,50594,846,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL622752,,6274,In vivo,,50594,846,,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622753,,6275,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622647,,6276,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875163,,6277,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622648,,6278,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622649,,6279,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622650,,6280,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622651,,6281,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622652,,6282,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622653,,6283,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622654,,6284,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622655,,6285,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622656,,6286,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622657,,6287,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622658,,6288,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622659,,6289,,,50594,6599,42.0,
Kidney,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL624630,,6290,,,50594,6599,42.0,
Kidney,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL624631,,6291,,,50594,6599,42.0,
Kidney,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL624632,,6292,,,50594,6599,42.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624633,,6293,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624634,,6294,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624635,,6295,,,80682,17130,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624636,,6296,,,80682,17130,646.0,
,BAO_0000219,,N,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL857055,,6297,,,80682,3263,646.0,
,BAO_0000219,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624637,,6298,,,80682,6663,646.0,
,BAO_0000219,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624638,,6299,,,80682,6663,646.0,
,BAO_0000219,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL874366,,6300,,,80682,6663,646.0,
,BAO_0000219,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624639,,6301,,,80682,6663,646.0,
,BAO_0000219,,N,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624640,,6302,,,80682,6663,646.0,
,BAO_0000219,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624641,,6303,,,80682,6663,646.0,
,BAO_0000219,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624642,,6304,,,80682,6663,646.0,
,BAO_0000219,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624643,,6305,,,80682,6663,646.0,
,BAO_0000219,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624644,,6306,,,80682,6663,646.0,
,BAO_0000219,,N,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624645,,6307,,,80682,6663,646.0,
,BAO_0000219,,N,,The compound was evaluated for its cytotoxic potency against A-549 cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619445,,6308,,,80682,3983,646.0,
,BAO_0000219,,N,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL839886,,6309,,,80682,11141,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 tumor cell line.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619446,,6310,,,80682,5076,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619447,,6311,,,80682,3311,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619448,,6312,,,80682,3311,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619449,,6313,,,80682,3311,646.0,
,BAO_0000219,,N,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619450,,6314,,,80682,5076,646.0,
,BAO_0000219,,N,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619451,,6315,,,80682,4150,646.0,
,BAO_0000219,,N,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619452,,6316,,,80682,2150,646.0,
,BAO_0000219,,N,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619453,,6317,,,80682,4644,646.0,
,BAO_0000219,,N,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL874367,,6318,,,80682,263,646.0,
,BAO_0000219,,N,,Cytotoxic concentration against A-549 tumor cells.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619454,,6319,,,80682,11333,646.0,
,BAO_0000219,,N,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619455,,6320,,,80682,11333,646.0,
,BAO_0000219,,N,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619456,,6321,,,80682,15895,646.0,
,BAO_0000218,,N,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,1,,470.0,F,Acinetobacter baumannii,,1,Expert,CHEMBL619457,,6322,,,50191,16677,,
,BAO_0000218,,N,,Activity against Acinetobacter calcoaceticus (AC54),1,,471.0,F,Acinetobacter calcoaceticus,,1,Intermediate,CHEMBL619458,,6323,,,50192,10624,,
,BAO_0000218,,N,,In vitro antifungal activity against Aspergillus flavus CM74,1,,5059.0,F,Aspergillus flavus,,1,Expert,CHEMBL619459,,6324,,,50274,16717,,
,BAO_0000218,,N,,In vitro antifungal activity against Aspergillus flavus CM74,1,,5059.0,F,Aspergillus flavus,,1,Expert,CHEMBL619460,,6325,,,50274,16717,,
,BAO_0000218,,N,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,1,,746128.0,F,Aspergillus fumigatus,,1,Intermediate,CHEMBL619461,,6326,,,50416,5513,,
,BAO_0000218,,N,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),1,,746128.0,F,Aspergillus fumigatus,,1,Intermediate,CHEMBL619462,,6327,,,50416,15962,,
,BAO_0000218,,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,746128.0,F,Aspergillus fumigatus,,1,Intermediate,CHEMBL620388,,6328,,,50416,15962,,
,BAO_0000218,,N,,Antimicrobial activity against Aspergillus fumigatus (MIC),1,,746128.0,F,Aspergillus fumigatus,,1,Intermediate,CHEMBL620389,,6329,,,50416,15962,,
,BAO_0000218,,N,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),1,,746128.0,F,Aspergillus fumigatus,,1,Intermediate,CHEMBL620390,,6330,,,50416,15962,,
,BAO_0000218,,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,746128.0,F,Aspergillus fumigatus,,1,Expert,CHEMBL620391,,6331,,,50416,16717,,
,BAO_0000218,,N,,In vitro antifungal activity against Aspergillus fumigatus 48238E,1,,746128.0,F,Aspergillus fumigatus,,1,Expert,CHEMBL621073,,6332,,,50416,16717,,
,BAO_0000218,,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL621074,,6333,,,50296,8117,,
,BAO_0000218,,N,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL621075,,6334,,,50366,8117,,
,BAO_0000218,,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL619554,,6335,,,50535,15472,,
,BAO_0000218,,N,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL619555,,6336,,,50535,15472,,
,BAO_0000218,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,1,,714.0,F,Aggregatibacter actinomycetemcomitans,,1,Intermediate,CHEMBL619556,,6337,,,50169,16443,,
,BAO_0000218,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,1,,714.0,F,Aggregatibacter actinomycetemcomitans,,1,Intermediate,CHEMBL619557,,6338,,,50169,16443,,
,BAO_0000218,,N,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,1,,714.0,F,Aggregatibacter actinomycetemcomitans,,1,Intermediate,CHEMBL619558,,6339,,,50169,16443,,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619559,,6340,,,80682,17206,646.0,
,BAO_0000219,,N,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619560,,6341,,,80682,17206,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619561,,6342,,,80682,16381,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619562,,6343,,,80682,16381,646.0,
,BAO_0000219,,N,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619563,,6344,,,80682,16381,646.0,
,BAO_0000219,,N,,GI values against A549 cells (lung cancer),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL857457,,6345,,,80682,16381,646.0,
,BAO_0000219,,N,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619564,,6346,,,80682,17206,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 human adenocarcinoma,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619565,,6347,,,80682,16325,646.0,
,BAO_0000218,,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619566,,6348,,,80682,10708,646.0,
,BAO_0000218,,N,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619567,,6349,,,80682,10708,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619568,,6350,,,80682,17376,646.0,
,BAO_0000219,,N,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619569,,6351,,,80682,17376,646.0,
,BAO_0000219,,N,,Cytotoxicity against human A549 lung cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619570,,6352,,,80682,17488,646.0,
,BAO_0000218,,N,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619571,,6353,,,80682,17404,646.0,
,BAO_0000219,,N,,Growth inhibition of A549 (human lung carcinoma) cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619572,,6354,,,80682,10958,646.0,
,BAO_0000219,,N,,Effective dose required for inhibitory activity against A549 human tumor cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619573,,6355,,,80682,17099,646.0,
,BAO_0000219,,N,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619574,,6356,,,80682,17099,646.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619575,,6357,,,80682,4096,646.0,
,BAO_0000219,,N,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619576,,6358,,,80682,4096,646.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619577,,6359,,,80682,4096,646.0,
,BAO_0000219,,N,,In vitro inhibitory activity against A549 tumor cell culture,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619578,,6360,,,80682,2525,646.0,
,BAO_0000219,,N,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884009,,6361,,,80682,2525,646.0,
,BAO_0000219,,N,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619579,,6362,,,80682,5302,646.0,
,BAO_0000219,,N,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619580,,6363,,,80682,16325,646.0,
,BAO_0000219,,N,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619581,,6364,,,80682,16939,646.0,
,BAO_0000219,,N,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619582,,6365,,,80682,17229,646.0,
,BAO_0000219,,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619583,,6366,,,80682,17380,646.0,
,BAO_0000219,,N,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876502,,6367,,,80682,17380,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619584,,6368,,,80682,1903,646.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619585,,6369,,,80682,3838,646.0,
,BAO_0000219,,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619586,,6370,,,80682,14696,646.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619587,,6371,,,80682,3838,646.0,
,BAO_0000219,,N,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619588,,6372,,,80682,1522,646.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619589,,6373,,,80682,12400,646.0,
,BAO_0000219,,N,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619590,,6374,,,80682,14696,646.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619591,,6375,,,80682,14769,646.0,
,BAO_0000219,,N,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619592,,6376,,,80682,14696,646.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619593,,6377,,,80682,1888,646.0,
,BAO_0000219,,N,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620217,,6378,,,80682,12016,646.0,
,BAO_0000219,,N,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620218,,6379,,,80682,6058,646.0,
,BAO_0000219,,N,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620219,,6380,,,80682,17708,646.0,
,BAO_0000219,,N,,Antitumor activity against A549/ATCC cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620220,,6381,,,80682,12301,646.0,
,BAO_0000219,,N,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625141,,6382,,,80682,11970,646.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A549/ATCC cell line.,1,A549,9606.0,F,Homo sapiens,,1,Expert,CHEMBL625142,,6383,,,80682,11818,646.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625143,,6384,,,80682,12400,646.0,
,BAO_0000219,,N,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625144,,6385,,,80682,3381,646.0,
,BAO_0000219,,N,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622474,,6386,,,80682,17376,646.0,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,1,A549,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884104,,6387,,,80682,10708,646.0,
,BAO_0000219,,U,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL622475,,6388,,,22226,2964,,
,BAO_0000218,,U,,Compound was tested for oral bioavailability in dogs,1,,9615.0,A,Canis lupus familiaris,,0,Intermediate,CHEMBL622476,,6389,In vivo,,22224,5005,,
,BAO_0000218,,N,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875831,,6390,In vivo,,50588,6229,,
,BAO_0000218,,N,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622477,,6391,In vivo,,50588,6229,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622478,,6392,In vivo,,50588,5374,,
,BAO_0000218,,N,,Compound was tested for the oral bioavailability in dog; No availability,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623172,,6393,In vivo,,50588,5374,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623173,,6394,In vivo,,50588,6265,,
,BAO_0000218,,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623174,,6395,In vivo,,50588,5654,,
,BAO_0000218,,N,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623175,,6396,In vivo,,50588,5654,,
,BAO_0000218,,N,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623340,,6397,In vivo,,50588,16456,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623341,,6398,In vivo,,50588,5302,,
,BAO_0000218,,N,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623342,,6399,In vivo,,50588,3624,,
,BAO_0000218,,N,,Oral bioavailability of active FTIs in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623343,,6400,In vivo,,50588,16452,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623344,,6401,In vivo,,50588,5802,,
,BAO_0000218,,N,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Expert,CHEMBL623345,,6402,In vivo,,50588,3598,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875832,,6403,In vivo,,50588,17839,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623346,,6404,In vivo,,50588,6762,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623347,,6405,In vivo,,50588,6821,,
,BAO_0000218,,N,,Oral bioavailability of compound was determined in dog; Not tested,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623348,,6406,In vivo,,50588,6821,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623349,,6407,In vivo,,50588,5210,,
,BAO_0000218,,N,,Oral bioavailability (10 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623350,,6408,In vivo,,50588,6227,,
,BAO_0000218,,N,,Oral bioavailability,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623351,,6409,In vivo,,50588,761,,
,BAO_0000218,,N,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623352,,6410,In vivo,,50588,761,,
,BAO_0000218,,N,,Oral bioavailability administered in solution in rats,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623353,,6411,In vivo,,50588,761,,
,BAO_0000218,,N,,Oral bioavailability after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875833,,6412,In vivo,,50588,16907,,
,BAO_0000218,,N,,Oral bioavailability at a dose of 1 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623354,,6413,In vivo,,50588,5474,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 1 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623355,,6414,In vivo,,50588,6535,,
,BAO_0000218,,N,,Oral bioavailability in Dog; ND = not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623356,,6415,In vivo,,50588,6535,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623357,,6416,In vivo,,50588,3352,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623358,,6417,In vivo,,50588,6168,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623359,,6418,In vivo,,50588,5988,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623360,,6419,In vivo,,50588,4942,,
,BAO_0000218,,N,,Oral bioavailability in dogs; No data,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623361,,6420,In vivo,,50588,4942,,
,BAO_0000218,,N,,Oral bioavailability measured in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623362,,6421,In vivo,,50588,14541,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623363,,6422,In vivo,,50588,4449,,
,BAO_0000218,,N,,Oral bioavailability was calculated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623364,,6423,In vivo,,50588,6057,,
,BAO_0000218,,N,,Oral bioavailability after 0.3 mg/kg po administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875834,,6424,In vivo,,50588,5600,,
,BAO_0000218,,N,,Oral bioavailability in dog (i.v. dosing),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623365,,6425,In vivo,,50588,5542,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623366,,6426,In vivo,,50588,5542,,
,BAO_0000218,,N,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623367,,6427,In vivo,,50588,5546,,
,BAO_0000218,,N,,Oral bioavailability in Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623368,,6428,In vivo,,50588,4514,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623369,,6429,In vivo,,50588,3624,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623370,,6430,In vivo,,50588,3854,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623371,,6431,In vivo,,50588,5836,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623372,,6432,In vivo,,50588,5940,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621351,,6433,In vivo,,50588,6168,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621352,,6434,In vivo,,50588,6227,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621353,,6435,In vivo,,50588,6251,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621354,,6436,In vivo,,50588,6448,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621355,,6437,In vivo,,50588,6647,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621356,,6438,In vivo,,50588,5940,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621357,,6439,In vivo,,50588,933,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621358,,6440,In vivo,,50588,5210,,
,BAO_0000218,,N,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621359,,6441,In vivo,,50588,6642,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621360,,6442,In vivo,,50588,6641,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621361,,6443,In vivo,,50588,6642,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621362,,6444,In vivo,,50588,5472,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621363,,6445,In vivo,,50588,5985,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621364,,6446,In vivo,,50588,15660,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621166,,6447,In vivo,,50588,5530,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 1 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621167,,6448,In vivo,,50588,5530,,
,BAO_0000218,,N,,Oral bioavailability (F) in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621168,,6449,In vivo,,50588,6305,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621169,,6450,In vivo,,50588,5210,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875950,,6451,In vivo,,50588,5238,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621170,,6452,In vivo,,50588,5668,,
,BAO_0000218,,N,,Oral bioavailability after peroral administration at 5 mpk in Dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621171,,6453,In vivo,,50588,5668,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621172,,6454,In vivo,,50588,5668,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621173,,6455,In vivo,,50588,6084,,
Kidney,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621174,,6456,,,50594,6599,42.0,
Kidney,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621175,,6457,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621176,,6458,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621177,,6459,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621178,,6460,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621179,,6461,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621180,,6462,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL875951,,6463,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621181,,6464,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621182,,6465,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621183,,6466,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL621184,,6467,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621185,,6468,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621186,,6469,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621187,,6470,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621188,,6471,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621189,,6472,,,50594,6599,42.0,
Spleen,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621190,,6473,,,50594,6599,42.0,
Spleen,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618520,,6474,,,50594,6599,42.0,
Spleen,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621739,,6475,,,50594,6599,42.0,
Spleen,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621740,,6476,,,50594,6599,42.0,
Spleen,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621741,,6477,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621742,,6478,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621743,,6479,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621744,,6480,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621745,,6481,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621746,,6482,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621747,,6483,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621748,,6484,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621749,,6485,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621750,,6486,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621751,,6487,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621752,,6488,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621753,,6489,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL875955,,6490,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621754,,6491,,,50594,6599,42.0,
Heart,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621755,,6492,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621756,,6493,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624199,,6494,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624200,,6495,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624375,,6496,,,50594,6599,42.0,
Liver,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624376,,6497,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624377,,6498,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624378,,6499,,,50594,6599,42.0,
,BAO_0000218,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,107673.0,F,aeinetobacter anitrotap,,1,Intermediate,CHEMBL857901,,6500,,,50067,12269,,
,BAO_0000218,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,107673.0,F,Acinetobacter calcoaceticus subsp. anitratus,,1,Intermediate,CHEMBL875274,,6501,,,50067,12269,,
,BAO_0000218,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,107673.0,F,Acinetobacter calcoaceticus subsp. anitratus,,1,Intermediate,CHEMBL624379,,6502,,,50067,12269,,
,BAO_0000218,,N,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,1,,107673.0,F,aeinetobacter anitrotap,,1,Intermediate,CHEMBL624380,,6503,,,50067,12269,,
,BAO_0000218,,N,,Activity against Acinetobacter calcoaceticus (AC54),1,,471.0,F,Acinetobacter calcoaceticus,,1,Intermediate,CHEMBL624381,,6504,,,50192,10624,,
,BAO_0000218,,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,1,,28377.0,F,Anolis carolinensis,,1,Intermediate,CHEMBL624382,,6505,,,50714,17216,,
,BAO_0000218,,N,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,1,,28377.0,F,Anolis carolinensis,,1,Intermediate,CHEMBL624383,,6506,,,50714,17216,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces naeslundii 631,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624384,,6507,,,50296,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces naeslundii B74,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624385,,6508,,,50296,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624386,,6509,,,50296,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624387,,6510,,,50296,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces naeslundii 631,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624388,,6511,,,50296,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces naeslundii N/9,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624389,,6512,,,50296,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces naeslundii B74,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL624390,,6513,,,50296,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces naeslundii N/3,1,,1655.0,F,Actinomyces naeslundii,,1,Intermediate,CHEMBL875275,,6514,,,50296,9560,,
,BAO_0000218,,N,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,1,,85549.0,F,Artemia salina,,1,Intermediate,CHEMBL624391,,6515,,,50056,114,,
,BAO_0000218,,N,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",1,,85549.0,F,Artemia salina,,1,Intermediate,CHEMBL623636,,6516,,,50056,114,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623637,,6517,,,50532,10841,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623638,,6518,,,50532,10841,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623639,,6519,,,50532,10841,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623640,,6520,,,50532,10841,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623641,,6521,,,50532,10841,,
,BAO_0000218,,N,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623642,,6522,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623643,,6523,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623644,,6524,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623645,,6525,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623646,,6526,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623647,,6527,,,50532,10841,,
,BAO_0000218,,N,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,1,,6253.0,F,Ascaris suum,,1,Intermediate,CHEMBL623648,,6528,,,50532,10841,,
,BAO_0000218,,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623649,,6529,,,50366,8117,,
,BAO_0000218,,N,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623650,,6530,,,50366,8117,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623651,,6531,,,50366,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces viscosus M-100,1,,1656.0,F,Actinomyces viscosus,,1,Expert,CHEMBL623652,,6532,,,50366,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces viscosus M-626,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623653,,6533,,,50366,9560,,
,BAO_0000218,,N,,Chlorohexidine coefficient for Actinomyces viscosus T14V,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623654,,6534,,,50366,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces viscosus 8A06,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623655,,6535,,,50366,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces viscosus M-100,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623656,,6536,,,50366,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,1,,1656.0,F,Actinomyces viscosus,,1,Expert,CHEMBL623657,,6537,,,50366,9560,,
,BAO_0000218,,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623658,,6538,,,50366,9560,,
,BAO_0000218,,N,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623659,,6539,,,50366,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces viscosus 626,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623660,,6540,,,50366,9560,,
,BAO_0000218,,N,,Plaque bactericidal index against Actinomyces viscosus T14V,1,,1656.0,F,Actinomyces viscosus,,1,Intermediate,CHEMBL623661,,6541,,,50366,9560,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL875281,,6542,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL623662,,6543,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL623663,,6544,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL623664,,6545,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL623665,,6546,,,50535,10986,,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,1,A673,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621856,,6547,,,80023,10708,165.0,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,1,A704,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620432,,6548,,,80661,10708,645.0,
,BAO_0000219,,U,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,1,,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL620433,,6549,,,22226,416,,
,BAO_0000219,,N,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620434,,6550,,,80024,14354,625.0,
,BAO_0000219,,N,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620435,,6551,,,80024,14354,625.0,
,BAO_0000219,,N,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,1,A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL620436,,6552,,,80024,5116,625.0,
,BAO_0000219,,N,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,1,A9,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876597,,6553,,,80024,5116,625.0,
,BAO_0000219,,N,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,1,Human ovarian carcinoma cell line,9606.0,F,Homo sapiens,,1,Expert,CHEMBL620437,,6554,,,81037,15694,874.0,
,BAO_0000219,,N,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",1,A9,10090.0,F,Mus musculus,,1,Expert,CHEMBL620438,,6555,,,80024,13038,625.0,
,BAO_0000219,,N,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,1,A9,10090.0,F,Mus musculus,,1,Expert,CHEMBL620439,,6556,,,80024,13038,625.0,
,BAO_0000219,,N,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,1,A9,10090.0,F,Mus musculus,,1,Expert,CHEMBL619657,,6557,,,80024,10923,625.0,
,BAO_0000219,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619658,,6558,,,80024,10923,625.0,
,BAO_0000219,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619659,,6559,,,80024,10923,625.0,
,BAO_0000019,,H,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",1,,,F,,,8,Expert,CHEMBL619660,,6560,,,10649,10923,,
,BAO_0000219,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619661,,6561,,,80024,10923,625.0,
,BAO_0000219,,N,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,1,A9,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL619662,,6562,,,80024,10923,625.0,
,BAO_0000219,,N,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,1,AA6,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619663,,6563,,,80663,8158,975.0,
,BAO_0000219,,U,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL619664,,6564,,,22226,15494,,
,BAO_0000219,,U,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",1,,9606.0,F,Homo sapiens,,0,Autocuration,CHEMBL619665,,6565,,,22226,15494,,
,BAO_0000219,,N,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),1,AA5,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883244,,6566,,,80662,12348,974.0,
,BAO_0000219,,N,,Cytotoxicity was measured against AA5/HIV-1(IIIB),1,AA5,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884011,,6567,,,80662,12348,974.0,
,BAO_0000219,,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,1,AA5,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619666,,6568,,,80662,2726,974.0,
,BAO_0000219,,N,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,1,U-937,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619667,,6569,,,80566,2726,379.0,
,BAO_0000219,,N,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,1,UV4,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619668,,6570,,,80578,10747,274.0,
,BAO_0000219,,N,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL619669,,6571,,,80089,11005,185.0,
,BAO_0000219,,N,,Average intracellular compound concentration when the hypoxic SER=1.6,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL876608,,6572,,,80089,12687,185.0,
,BAO_0000219,,N,,Average intracellular compound concentration when the hypoxic SER=1.6.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619670,,6573,,,80089,12687,185.0,
,BAO_0000219,,N,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619671,,6574,,,80089,12687,185.0,
,BAO_0000219,,N,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619672,,6575,,,80089,12687,185.0,
,BAO_0000219,,N,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619673,,6576,,,80089,12687,185.0,
,BAO_0000219,,N,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619674,,6577,,,80089,13436,185.0,
,BAO_0000219,,N,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619675,,6578,,,80089,13435,185.0,
,BAO_0000219,,N,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619676,,6579,,,80089,13302,185.0,
,BAO_0000219,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL619677,,6580,,,80089,12687,185.0,
,BAO_0000219,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL619678,,6581,,,80089,12687,185.0,
,BAO_0000219,,N,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL619679,,6582,,,80089,12687,185.0,
,BAO_0000219,,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Expert,CHEMBL619680,,6583,,,80089,12878,185.0,
,BAO_0000219,,N,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL621457,,6584,,,80089,12878,185.0,
,BAO_0000219,,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL876609,,6585,,,80089,14367,185.0,
,BAO_0000219,,N,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL621458,,6586,,,80089,14367,185.0,
,BAO_0000219,,N,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,1,CHO-AA8,36483.0,F,hampster,,1,Expert,CHEMBL621459,,6587,,,80089,12398,185.0,
,BAO_0000219,,N,,Aerobic growth inhibition in Chinese hamster cell line AA8,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL621460,,6588,,,80089,12878,185.0,
,BAO_0000219,,N,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL621461,,6589,,,80089,13820,185.0,
,BAO_0000219,,N,,Inhibition of growth under aerobic conditions in AA8 cells,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL621462,,6590,,,80089,13436,185.0,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621463,,6591,In vivo,,50588,6084,,
,BAO_0000218,,N,,Oral bioavailability in dog at 10 mg/kg of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621464,,6592,In vivo,,50588,5711,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621465,,6593,In vivo,,50588,4353,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621466,,6594,In vivo,,50588,4353,,
,BAO_0000218,,N,,Oral bioavailability in dog (mongrel),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621467,,6595,In vivo,,50588,17800,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621468,,6596,In vivo,,50588,3994,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 10 mg/kg),1,,9615.0,F,Canis lupus familiaris,,1,Intermediate,CHEMBL876734,,6597,In vivo,,50588,3994,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618476,,6598,In vivo,,50588,5145,,
,BAO_0000218,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618477,,6599,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618478,,6600,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618479,,6601,In vivo,,50588,5983,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618480,,6602,In vivo,,50588,4273,,
,BAO_0000218,,N,,Bioavailability in dog (dose 3-10 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618481,,6603,In vivo,,50588,12500,,
Plasma,BAO_0000218,,N,,The compound was tested for bioavailability of compound in plasma of dog; Complete,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618482,,6604,In vivo,,50588,12500,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618483,,6605,In vivo,,50588,3639,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618484,,6606,In vivo,,50588,3880,,
,BAO_0000218,,N,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618485,,6607,In vivo,,50588,4838,,
,BAO_0000218,,N,,oral bioavailability was measured in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618486,,6608,In vivo,,50588,15600,,
,BAO_0000218,,N,,Compound was tested for plasma protein binding in dog; Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618487,,6609,,,50588,17248,,
,BAO_0000218,,N,,Compound was tested for plasma protein binding of dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618488,,6610,,,50588,17248,,
,BAO_0000218,,N,,Compound was tested for plasma protein binding of dog; Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876735,,6611,,,50588,17248,,
,BAO_0000218,,N,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618489,,6612,,,50588,17443,,
,BAO_0000218,,N,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618490,,6613,In vivo,,50588,4186,,
,BAO_0000218,,N,,Half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618491,,6614,,,50588,3749,,
,BAO_0000218,,N,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618492,,6615,In vivo,,50588,3249,,
,BAO_0000218,,N,,Half life was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873354,,6616,,,50588,3022,,
,BAO_0000218,,N,,Half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618493,,6617,,,50588,3749,,
,BAO_0000218,,N,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618494,,6618,In vivo,,50588,2517,,
Heart,BAO_0000218,,N,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,948.0,1,Intermediate,CHEMBL618495,,6619,In vivo,,50588,2517,,
Kidney,BAO_0000218,,N,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,2113.0,1,Intermediate,CHEMBL618496,,6620,In vivo,,50588,2517,,
Liver,BAO_0000218,,N,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL618497,,6621,In vivo,,50588,2517,,
Lung,BAO_0000218,,N,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,2048.0,1,Intermediate,CHEMBL618498,,6622,In vivo,,50588,2517,,
Spleen,BAO_0000218,,N,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),1,,9615.0,A,Canis lupus familiaris,2106.0,1,Intermediate,CHEMBL618499,,6623,In vivo,,50588,2517,,
,BAO_0000218,,N,,LogP in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876736,,6624,,,50588,3639,,
,BAO_0000218,,N,,Partition coefficient (logP),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618500,,6625,,,50588,6227,,
,BAO_0000218,,N,,Partition coefficient in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL857831,,6626,,,50588,6227,,
,BAO_0000218,,N,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618501,,6627,In vivo,,50588,17764,,
,BAO_0000218,,N,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618502,,6628,In vivo,,50588,4809,,
,BAO_0000218,,N,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618503,,6629,,,50588,5600,,
,BAO_0000218,,N,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618504,,6630,,,50588,14294,,
,BAO_0000218,,N,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618505,,6631,,,50588,14294,,
,BAO_0000218,,N,,Metabolism of compound in dog S9 microsomes; Trace,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618506,,6632,,,50588,14294,,
Liver,BAO_0000218,,N,,In vitro metabolic potential in dog liver microsomes,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL618507,,6633,,,50588,6251,,
,BAO_0000218,,N,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876737,,6634,In vivo,,50588,3748,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618508,,6635,In vivo,,50588,2713,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618509,,6636,In vivo,,50588,6512,,
,BAO_0000218,,N,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618510,,6637,In vivo,,50588,6679,,
,BAO_0000218,,N,,The compound was tested for bioavailability in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618511,,6638,In vivo,,50588,3749,,
,BAO_0000218,,N,,The compound was tested for oral bioavailability in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618512,,6639,In vivo,,50588,3749,,
,BAO_0000218,,N,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618513,,6640,In vivo,,50588,6742,,
,BAO_0000218,,N,,Compound was tested for percent protein binding (PB) in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618514,,6641,,,50588,6227,,
,BAO_0000218,,N,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620052,,6642,,,50588,6874,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma clearance.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620053,,6643,In vivo,,50588,2877,,
Plasma,BAO_0000218,,N,,The compound was tested for plasma clearance in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620054,,6644,In vivo,,50588,12500,,
Plasma,BAO_0000218,,N,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620055,,6645,In vivo,,50588,12500,,
,BAO_0000218,,N,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620056,,6646,,,50588,4709,,
Liver,BAO_0000218,,N,,In vitro relative rate of metabolism was determined in dog liver microsomes,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL620057,,6647,,,50588,5542,,
,BAO_0000218,,N,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618939,,6648,In vivo,,50588,17594,,
,BAO_0000218,,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618940,,6649,In vivo,,50588,2652,,
,BAO_0000218,,N,,Half life after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618941,,6650,In vivo,,50588,17764,,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624473,,6651,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624474,,6652,,,50594,6599,42.0,
Lung,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624475,,6653,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624476,,6654,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623478,,6655,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623479,,6656,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623480,,6657,,,50594,6599,42.0,
,BAO_0000218,,N,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,1,CCRF S-180,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623481,,6658,,,50594,6599,42.0,
Brain,BAO_0000218,,N,,C2 in brain of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL623482,,6659,,,50594,17641,,
Kidney,BAO_0000218,,N,,C2 in kidney of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623483,,6660,,,50594,17641,,
Liver,BAO_0000218,,N,,C2 in liver of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623484,,6661,,,50594,17641,,
Lung,BAO_0000218,,N,,C2 in lungs of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623485,,6662,,,50594,17641,,
Spleen,BAO_0000218,,N,,C2 in spleen of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL623486,,6663,,,50594,17641,,
,BAO_0000218,,N,,Plasma clearance in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623487,,6664,In vivo,,50594,17852,,
,BAO_0000218,,N,,Clearance of compound after intravenous administration in mice at 24 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623488,,6665,In vivo,,50594,17764,,
,BAO_0000218,,N,,Clearance from mouse blood following i.v. administration of 10 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623489,,6666,In vivo,,50594,17837,,
,BAO_0000218,,N,,Clearance was evaluated in mice after intravenous administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875157,,6667,In vivo,,50594,2675,,
,BAO_0000218,,N,,Clearance was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623490,,6668,In vivo,,50594,2675,,
,BAO_0000218,,N,,Pharmacokinetic property (Plasma clearance) was measured in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623491,,6669,In vivo,,50594,4239,,
,BAO_0000218,,N,,Plasma clearance of compound was determined at 40 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623492,,6670,In vivo,,50594,17753,,
,BAO_0000218,,N,,Plasma clearance of at 24 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623493,,6671,In vivo,,50594,17753,,
,BAO_0000218,,N,,Plasma clearance at 24 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623494,,6672,In vivo,,50594,17753,,
,BAO_0000218,,N,,Plasma clearance at 5 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623495,,6673,In vivo,,50594,17753,,
,BAO_0000218,,N,,Plasma clearance in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623496,,6674,In vivo,,50594,5727,,
,BAO_0000218,,N,,Plasma clearance value upon iv administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623497,,6675,In vivo,,50594,2862,,
Plasma,BAO_0000218,,N,,Total plasma clearance in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623498,,6676,In vivo,,50594,5980,,
,BAO_0000218,,N,,Clearance in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623499,,6677,In vivo,,50594,17592,,
,BAO_0000218,,N,,Clearance value was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623500,,6678,In vivo,,50594,17718,,
,BAO_0000218,,N,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623501,,6679,In vivo,,50594,16597,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Intermediate,CHEMBL875158,,6680,,,22229,17384,,
,BAO_0000218,,N,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623502,,6681,In vivo,,50594,6062,,
,BAO_0000218,,N,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623503,,6682,In vivo,,50594,17734,,
,BAO_0000218,,N,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623504,,6683,In vivo,,50594,6348,,
,BAO_0000218,,N,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623505,,6684,In vivo,,50594,5969,,
,BAO_0000218,,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623506,,6685,In vivo,,50594,5969,,
,BAO_0000218,,N,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623507,,6686,In vivo,,50594,5969,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623508,,6687,In vivo,,50594,16597,,
,BAO_0000218,,N,,Cmax after oral administration at 30 mg/kg in ICR mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623509,,6688,In vivo,,50594,5781,,
,BAO_0000218,,N,,Cmax after peroral administration in mice at 2.4 uM/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875159,,6689,In vivo,,50594,17764,,
Brain,BAO_0000218,,N,,Cmax in brain of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL623510,,6690,In vivo,,50594,17641,,
Kidney,BAO_0000218,,N,,Cmax in kidney of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL623511,,6691,In vivo,,50594,17641,,
Liver,BAO_0000218,,N,,Cmax in liver of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623512,,6692,In vivo,,50594,17641,,
Lung,BAO_0000218,,N,,Cmax in lungs of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623513,,6693,In vivo,,50594,17641,,
,BAO_0000218,,N,,Cmax in mice at 18 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL623514,,6694,In vivo,,50594,17764,,
,BAO_0000218,,N,,Cmax in mice at 23 uM/kg i.v. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622609,,6695,In vivo,,50594,17764,,
,BAO_0000218,,N,,Cmax in mice at 24 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622610,,6696,In vivo,,50594,17764,,
,BAO_0000218,,N,,Cmax in mice at 25 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL621823,,6697,In vivo,,50594,17764,,
,BAO_0000218,,N,,Cmax in mice at 26 uM/kg i.p. administration,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL621824,,6698,In vivo,,50594,17764,,
Spleen,BAO_0000218,,N,,Cmax in spleen of mice at the oral dose of 50 mg/kg,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621825,,6699,In vivo,,50594,17641,,
,BAO_0000218,,N,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621826,,6700,In vivo,,50594,16597,,
,BAO_0000218,,N,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621827,,6701,In vivo,,50594,16597,,
,BAO_0000218,,N,,Cmax value was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621828,,6702,In vivo,,50594,5727,,
,BAO_0000218,,N,,Cmax value in IRC mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621829,,6703,In vivo,,50594,5951,,
,BAO_0000218,,N,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621830,,6704,In vivo,,50594,5506,,
,BAO_0000218,,N,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621831,,6705,In vivo,,50594,5506,,
Plasma,BAO_0000218,,N,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL621832,,6706,In vivo,,50594,14239,,
Plasma,BAO_0000218,,N,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL624579,,6707,In vivo,,50594,4890,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624580,,6708,In vivo,,50594,429,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL624581,,6709,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL624582,,6710,,,50535,10986,,
,BAO_0000218,,N,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,1,,6277.0,F,Acanthocheilonema viteae,,1,Intermediate,CHEMBL624583,,6711,,,50535,10986,,
,BAO_0000219,,N,,Inhibitory activity against human tumor cell line A0375 melanoma.,1,A-375,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624584,,6712,,,80018,13227,455.0,
,BAO_0000249,,D,Brain membranes,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,1,,10116.0,B,Rattus norvegicus,,9,Expert,CHEMBL624585,,6713,,,12512,4481,,
,BAO_0000019,,D,,Forskolin-induced cAMP production at human A1 adenosine receptor,1,,9606.0,F,Homo sapiens,,9,Expert,CHEMBL875165,,6714,,,114,16931,,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL619490,,6715,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,CHO,,F,,,8,Autocuration,CHEMBL619491,,6716,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,1,CHO,,F,,,8,Expert,CHEMBL619492,,6717,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,1,CHO,,F,,,8,Expert,CHEMBL619493,,6718,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,1,CHO,,F,,,8,Autocuration,CHEMBL619494,,6719,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,1,CHO,,F,,,8,Autocuration,CHEMBL619495,,6720,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL619496,,6721,,,114,3850,449.0,
,BAO_0000219,,D,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,1,CHO,9606.0,F,Homo sapiens,,9,Expert,CHEMBL619497,,6722,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,1,CHO,,F,,,8,Autocuration,CHEMBL619498,,6723,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL619499,,6724,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,1,CHO,,F,,,8,Expert,CHEMBL619500,,6725,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL619501,,6726,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,1,CHO,,F,,,8,Expert,CHEMBL619502,,6727,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,1,CHO,,F,,,8,Autocuration,CHEMBL619503,,6728,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,CHO,,F,,,8,Autocuration,CHEMBL619504,,6729,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL621298,,6730,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,1,CHO,,F,,,8,Expert,CHEMBL621299,,6731,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,1,CHO,,F,,,8,Autocuration,CHEMBL621300,,6732,,,114,3850,449.0,
,BAO_0000219,,H,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,1,CHO,,F,,,8,Autocuration,CHEMBL621301,,6733,,,114,3850,449.0,
,BAO_0000219,,H,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,1,CHO,,F,,,8,Expert,CHEMBL621302,,6734,,,114,3850,449.0,
,BAO_0000219,,N,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,1,A10,9986.0,F,Oryctolagus cuniculus,,1,Intermediate,CHEMBL621303,,6735,,,80013,12680,164.0,
,BAO_0000219,,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,1,A10,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL621304,,6736,,,22226,1313,164.0,
,BAO_0000219,,U,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,1,A10,10116.0,F,Rattus norvegicus,,0,Autocuration,CHEMBL621305,,6737,,,22226,1313,164.0,
,BAO_0000219,,N,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,1,A10,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL621306,,6738,,,80013,17567,164.0,
,BAO_0000219,,N,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,1,A10,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618444,,6739,,,80013,17567,164.0,
,BAO_0000219,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,1,A10,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618445,,6740,,,80013,11819,164.0,
,BAO_0000219,,N,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618446,,6741,,,80089,13436,185.0,
,BAO_0000219,,N,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618447,,6742,,,80089,12687,185.0,
,BAO_0000219,,N,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618448,,6743,,,80089,12651,185.0,
,BAO_0000219,,N,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618449,,6744,,,80089,13300,185.0,
,BAO_0000219,,N,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618637,,6745,,,80089,15296,185.0,
,BAO_0000219,,N,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618638,,6746,,,80089,15328,185.0,
,BAO_0000219,,N,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618639,,6747,,,80089,13302,185.0,
,BAO_0000219,,N,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL618640,,6748,,,80089,14367,185.0,
,BAO_0000219,,N,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL618641,,6749,,,80089,17002,185.0,
,BAO_0000219,,N,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618642,,6750,,,80089,13436,185.0,
,BAO_0000219,,N,,Inhibitory activity against aerobic growth of AA8 cells.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL618643,,6751,,,80089,13435,185.0,
,BAO_0000219,,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL884013,,6752,,,80089,10503,185.0,
,BAO_0000219,,N,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL622723,,6753,,,80089,10503,185.0,
,BAO_0000219,,N,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622724,,6754,,,80089,10503,185.0,
,BAO_0000219,,N,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL622725,,6755,,,80089,15090,185.0,
,BAO_0000219,,N,,Cytotoxicity against AA8 cell line,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL622726,,6756,,,80089,10368,185.0,
,BAO_0000219,,N,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622727,,6757,,,80089,12651,185.0,
,BAO_0000219,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL622728,,6758,,,80089,12687,185.0,
,BAO_0000219,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622729,,6759,,,80089,12687,185.0,
,BAO_0000219,,N,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),1,CHO-AA8,10029.0,A,Cricetulus griseus,,1,Intermediate,CHEMBL622730,,6760,,,80089,12687,185.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622731,,6761,,,80089,1890,185.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622732,,6762,,,80089,10747,185.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Intermediate,CHEMBL622733,,6763,,,80089,10747,185.0,
,BAO_0000218,,U,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL622734,,6764,,,22224,11616,,
,BAO_0000219,,N,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL622735,,6765,,,80089,11616,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618746,,6766,,,22224,3471,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618747,,6767,,,22224,3471,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL620540,,6768,,,22224,3471,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL620541,,6769,,,22224,3471,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL620542,,6770,,,22224,3471,185.0,
,BAO_0000219,,U,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL620543,,6771,,,22224,3471,185.0,
,BAO_0000219,,U,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618832,,6772,,,22224,3471,185.0,
,BAO_0000219,,N,,Concentration required to reduce AA8 cell survival by 10%,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL618833,,6773,,,80089,11616,185.0,
,BAO_0000219,,U,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618834,,6774,,,22224,2656,185.0,
,BAO_0000219,,U,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618835,,6775,,,22224,10518,185.0,
,BAO_0000219,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618836,,6776,,,22224,10518,185.0,
,BAO_0000219,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618837,,6777,,,22224,10518,185.0,
,BAO_0000219,,U,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618838,,6778,,,22224,10518,185.0,
,BAO_0000219,,U,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618839,,6779,,,22224,16156,185.0,
,BAO_0000219,,U,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618840,,6780,,,22224,2656,185.0,
,BAO_0000019,,U,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618841,,6781,,,22224,11005,,
,BAO_0000219,,U,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618842,,6782,,,22224,11942,185.0,
,BAO_0000219,,U,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL618843,,6783,,,22224,2128,185.0,
,BAO_0000218,,N,,Half life period after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618844,,6784,In vivo,,50588,16907,,
,BAO_0000218,,N,,Half life period after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618845,,6785,In vivo,,50588,16907,,
,BAO_0000218,,N,,Half life was measured after oral 2b administration (tested in 6 dogs),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618846,,6786,In vivo,,50588,9579,,
,BAO_0000218,,N,,Half life was measured in dog after oral 17b administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618847,,6787,In vivo,,50588,9579,,
,BAO_0000218,,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618848,,6788,In vivo,,50588,9579,,
,BAO_0000218,,N,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618849,,6789,In vivo,,50588,9579,,
,BAO_0000218,,N,,Tmax value after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618850,,6790,In vivo,,50588,16907,,
,BAO_0000218,,N,,Tmax value after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618851,,6791,In vivo,,50588,16907,,
,BAO_0000218,,N,,Compound was evaluated for its half life when administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873815,,6792,In vivo,,50588,3184,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618852,,6793,In vivo,,50588,5017,,
,BAO_0000218,,N,,Elimination Half-life of compound was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618853,,6794,,,50588,6821,,
,BAO_0000218,,N,,Half life of compound in dog following oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618854,,6795,In vivo,,50588,17839,,
,BAO_0000218,,N,,Half life of compound was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618855,,6796,,,50588,17267,,
Blood,BAO_0000218,,N,,Half life of compound was determined in dog blood,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL618856,,6797,,,50588,4727,,
,BAO_0000218,,N,,Half life after oral and iv dosing in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875827,,6798,In vivo,,50588,5238,,
,BAO_0000218,,N,,Half life in dogs in hours,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618857,,6799,,,50588,4942,,
,BAO_0000218,,N,,Half life on i.v. administration of 2 mg/kg was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618858,,6800,In vivo,,50588,6505,,
,BAO_0000218,,N,,t1/2 in dog after oral dose (1 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618859,,6801,In vivo,,50588,5130,,
,BAO_0000218,,N,,Half life was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618860,,6802,,,50588,1475,,
,BAO_0000218,,N,,Half life period of compound was determined after intravenous administration at 2 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618861,,6803,In vivo,,50588,17804,,
,BAO_0000218,,N,,Half life period of compound was determined after peroral administration at 2 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622539,,6804,In vivo,,50588,17804,,
,BAO_0000218,,N,,Half life period (10 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622540,,6805,In vivo,,50588,6084,,
,BAO_0000218,,N,,Half life period (10 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873803,,6806,In vivo,,50588,6084,,
,BAO_0000218,,N,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873804,,6807,In vivo,,50588,5542,,
,BAO_0000218,,N,,Half life period by po administration in dog at a dose of 0.3 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624311,,6808,In vivo,,50588,5542,,
,BAO_0000218,,N,,Half life period in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624312,,6809,,,50588,6084,,
,BAO_0000218,,N,,Half life period in dogs after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624313,,6810,In vivo,,50588,6241,,
,BAO_0000218,,N,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624314,,6811,In vivo,,50588,1916,,
,BAO_0000218,,N,,Half-life of compound was determined in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624315,,6812,,,50588,6621,,
Plasma,BAO_0000218,,N,,Half-life in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624316,,6813,,,50588,1696,,
,BAO_0000218,,N,,Half-life in mongrel dogs was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624317,,6814,,,50588,17800,,
,BAO_0000218,,N,,Half-life in dog upon oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624318,,6815,In vivo,,50588,17657,,
,BAO_0000218,,N,,Half-life in dog upon oral administration; Unable to calculate,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624319,,6816,In vivo,,50588,17657,,
,BAO_0000218,,N,,Half-life was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624496,,6817,,,50588,4239,,
,BAO_0000218,,N,,Half-life was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624497,,6818,,,50588,5985,,
,BAO_0000218,,N,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624498,,6819,,,50588,9932,,
,BAO_0000218,,N,,Oral half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624499,,6820,In vivo,,50588,5199,,
Plasma,BAO_0000218,,N,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624500,,6821,In vivo,,50588,5199,,
Plasma,BAO_0000218,,N,,Plasma half life was evaluated,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL624501,,6822,,,50588,1475,,
Plasma,BAO_0000218,,N,,Plasma half life was evaluated in Dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623666,,6823,,,50588,1475,,
Plasma,BAO_0000218,,N,,Plasma half life was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623667,,6824,,,50588,1475,,
,BAO_0000218,,N,,T1/2 (Half-life) was after oral administration at 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623668,,6825,In vivo,,50588,6316,,
,BAO_0000218,,N,,Tested for the half life value in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623669,,6826,,,50588,4883,,
,BAO_0000218,,N,,Maximum time at the dose of 2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623670,,6827,In vivo,,50588,4727,,
,BAO_0000218,,N,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623671,,6828,In vivo,,50588,1916,,
Blood,BAO_0000218,,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL875945,,6829,In vivo,,50588,1337,,
Blood,BAO_0000218,,N,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL623672,,6830,In vivo,,50588,1337,,
,BAO_0000218,,N,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623673,,6831,In vivo,,50588,6265,,
,BAO_0000218,,N,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623674,,6832,In vivo,,50588,4809,,
,BAO_0000218,,N,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623675,,6833,In vivo,,50588,5983,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL872526,,6834,,,50588,5313,,
,BAO_0000218,,N,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623676,,6835,In vivo,,50588,5313,,
Plasma,BAO_0000218,,N,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623677,,6836,In vivo,,50588,17650,,
Plasma,BAO_0000218,,N,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623678,,6837,In vivo,,50588,5199,,
Plasma,BAO_0000218,,N,,Time taken for maximum plasma concentration in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623679,,6838,,,50588,933,,
,BAO_0000218,,N,,Time to reach Cmax after oral administration to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623680,,6839,In vivo,,50588,16367,,
Plasma,BAO_0000218,,N,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623681,,6840,In vivo,,50588,6348,,
,BAO_0000218,,N,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623682,,6841,In vivo,,50588,6316,,
,BAO_0000218,,N,,Tmax after peroral administration (1 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623683,,6842,In vivo,,50588,6215,,
,BAO_0000218,,N,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Expert,CHEMBL623684,,6843,In vivo,,50588,3598,,
,BAO_0000218,,N,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622745,,6844,In vivo,,50588,4527,,
,BAO_0000218,,N,,Tmax after peroral administration in dogs at 2.4 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622746,,6845,In vivo,,50588,17764,,
,BAO_0000218,,N,,In vivo Cmax in mice at dose of 100 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622747,,6846,In vivo,,50594,5969,,
,BAO_0000218,,N,,In vivo Cmax in mice at dose of 50 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622748,,6847,In vivo,,50594,5969,,
,BAO_0000218,,N,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622749,,6848,In vivo,,50594,4573,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622750,,6849,In vivo,,50594,3277,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623411,,6850,In vivo,,50594,17734,,
Plasma,BAO_0000218,,N,,Maximum concentration obtained in mouse plasma was determined,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL875946,,6851,In vivo,,50594,3132,,
Plasma,BAO_0000218,,N,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623412,,6852,In vivo,,50594,3132,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623413,,6853,In vivo,,50594,6348,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623414,,6854,In vivo,,50594,17729,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623415,,6855,In vivo,,50594,17729,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623416,,6856,In vivo,,50594,17729,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623417,,6857,In vivo,,50594,17728,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623418,,6858,In vivo,,50594,17728,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623419,,6859,In vivo,,50594,17728,,
,BAO_0000218,,N,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622816,,6860,In vivo,,50594,4066,,
,BAO_0000218,,N,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623313,,6861,In vivo,,50594,6178,,
,BAO_0000218,,N,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623314,,6862,In vivo,,50594,6178,,
,BAO_0000218,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876788,,6863,In vivo,,50594,3760,,
,BAO_0000218,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623315,,6864,In vivo,,50594,3760,,
,BAO_0000218,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623316,,6865,In vivo,,50594,3760,,
,BAO_0000218,,N,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623317,,6866,In vivo,,50594,3760,,
,BAO_0000218,,N,,Cmax in male mice after 2 mg/kg oral dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623319,,6868,In vivo,,50594,5961,,
,BAO_0000218,,N,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623320,,6869,In vivo,,50594,6137,,
,BAO_0000218,,N,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623321,,6870,In vivo,,50594,3802,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623322,,6871,,,50594,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623323,,6872,,,50594,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623324,,6873,,,50594,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623325,,6874,,,50594,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623326,,6875,,,50594,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623327,,6876,,,50594,3535,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma upon oral administration in mouse,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623328,,6877,,,50594,2862,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623329,,6878,,,50594,2675,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623330,,6879,In vivo,,50594,2675,,
,BAO_0000218,,N,,Dose at which the compound induced fecal excretion in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876789,,6880,,,50594,5399,,
,BAO_0000219,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,1,A10,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL623333,,6893,,,80013,11819,164.0,
,BAO_0000219,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,1,A10,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL623334,,6894,,,80013,11819,164.0,
,BAO_0000219,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,1,A10,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL627536,,6895,,,80013,11819,164.0,
,BAO_0000219,,N,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,1,A10,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL627537,,6896,,,80013,11819,164.0,
,BAO_0000219,,N,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),1,A10,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL627538,,6897,,,80013,16361,164.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884106,,6898,,,80655,2288,393.0,
,BAO_0000219,,N,,Anticancer activity against human ovarian carcinoma A121 cells,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625294,,6899,,,80655,10404,393.0,
,BAO_0000219,,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625295,,6900,,,80655,14790,393.0,
,BAO_0000219,,N,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625296,,6901,,,80655,14790,393.0,
,BAO_0000219,,N,,Growth inhibition of human ovarian carcinoma (A121) cell line,1,A121,9606.0,F,Homo sapiens,,1,Expert,CHEMBL625297,,6902,,,80655,14253,393.0,
,BAO_0000219,,N,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,1,A121,9606.0,F,Homo sapiens,,1,Expert,CHEMBL625298,,6903,,,80655,13617,393.0,
,BAO_0000219,,N,,Cytotoxicity against human A121 ovarian cells,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625960,,6904,,,80655,1003,393.0,
,BAO_0000219,,N,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625961,,6905,,,80655,830,393.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human ovarian carcinoma A21,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL625962,,6906,,,80655,12307,393.0,
,BAO_0000219,,N,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624717,,6907,,,80655,14254,393.0,
,BAO_0000219,,N,,Inhibitory activity of compound against human A121 ovarian cell line.,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624718,,6908,,,80655,13370,393.0,
,BAO_0000219,,N,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624719,,6909,,,80655,14790,393.0,
,BAO_0000219,,N,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,1,A121,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624720,,6910,,,80655,3614,393.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624721,,6911,,,80012,2664,622.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A172 human tumor cell lines.,1,A 172,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624722,,6912,,,80012,2037,622.0,
,BAO_0000219,,N,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL877597,,6913,,,80012,14539,622.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624723,,6914,,,80012,2836,622.0,
,BAO_0000219,,N,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,1,A 172,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624724,,6915,,,80012,10708,622.0,
,BAO_0000224,,H,,Association constant against A2 adenosine receptor,1,,9615.0,B,Canis lupus familiaris,,4,Autocuration,CHEMBL624725,,6916,,,104729,8975,,
,BAO_0000219,,N,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,1,A2,,F,fish,,1,Intermediate,CHEMBL624726,,6917,,,80656,7645,1085.0,
,BAO_0000224,,D,,Ratio of Ki for adenosine A2 and A1 receptor binding,1,,10116.0,B,Rattus norvegicus,,5,Autocuration,CHEMBL857535,,6918,,,104713,11377,,
,BAO_0000219,,N,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,1,A204,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624727,,6919,,,80014,13528,623.0,
,BAO_0000219,,N,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,1,A204,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624728,,6920,,,80014,10160,623.0,
,BAO_0000219,,N,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,1,A2058,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624729,,6921,,,80015,15144,404.0,
,BAO_0000219,,N,,Growth inhibition against Human squamous cell line(A 253),1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624730,,6922,,,80657,13160,973.0,
,BAO_0000219,,N,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624731,,6923,,,80657,12898,973.0,
,BAO_0000219,,N,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624732,,6924,,,80657,13069,973.0,
,BAO_0000219,,N,,Growth inhibition of A253 cell lines.,1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL883245,,6925,,,80657,15984,973.0,
,BAO_0000219,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624733,,6926,,,80657,15564,973.0,
,BAO_0000219,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624734,,6927,,,80657,15564,973.0,
,BAO_0000219,,N,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,1,A253 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624735,,6928,,,80657,15564,973.0,
,BAO_0000219,,N,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621780,,6929,,,81034,4720,478.0,
,BAO_0000219,,N,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL877598,,6930,,,81034,16112,478.0,
,BAO_0000219,,N,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621781,,6931,,,81034,16597,478.0,
,BAO_0000219,,N,,Cytotoxicity against human cancer cell lines A2780 (ovarian),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621782,,6932,,,81034,16378,478.0,
,BAO_0000219,,N,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621783,,6933,,,81034,16085,478.0,
,BAO_0000219,,N,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621784,,6934,,,81034,16317,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621785,,6935,,,81034,15748,478.0,
,BAO_0000219,,N,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621968,,6936,,,81034,16597,478.0,
,BAO_0000219,,N,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621969,,6937,,,81034,16597,478.0,
,BAO_0000219,,N,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621970,,6938,,,81034,16597,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621971,,6939,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621972,,6940,,,81034,15608,478.0,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884108,,6941,,,81034,15608,478.0,
,BAO_0000019,,U,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623826,,6942,,,22224,15296,,
,BAO_0000219,,U,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,1,CHO-AA8,10029.0,A,Cricetulus griseus,,0,Autocuration,CHEMBL623827,,6943,,,22224,10251,185.0,
,BAO_0000219,,U,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623828,,6944,,,22224,10251,185.0,
,BAO_0000219,,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623829,,6945,,,22224,10251,185.0,
,BAO_0000219,,U,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623830,,6946,,,22224,10251,185.0,
,BAO_0000019,,U,,Growth inhibition against CHO-derived cell line AA8,1,,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623831,,6947,,,22224,11858,,
,BAO_0000219,,U,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623832,,6948,,,22224,11858,185.0,
,BAO_0000219,,N,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,1,CHO-AA8,36483.0,F,hampster,,1,Expert,CHEMBL623833,,6949,,,80089,11616,185.0,
,BAO_0000219,,N,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL623834,,6950,,,80089,11616,185.0,
,BAO_0000219,,U,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623835,,6951,,,22224,10518,185.0,
,BAO_0000219,,U,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623836,,6952,,,22224,11396,185.0,
,BAO_0000219,,U,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,1,CHO-AA8,10029.0,F,Cricetulus griseus,,0,Autocuration,CHEMBL623837,,6953,,,22224,10518,185.0,
,BAO_0000219,,N,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,1,CHO-AA8,10029.0,F,Cricetulus griseus,,1,Expert,CHEMBL623838,,6954,,,80089,11616,185.0,
,BAO_0000019,,H,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,1,,,F,,,8,Autocuration,CHEMBL623839,,6955,,,12675,14837,,
,BAO_0000019,,H,,Number of binding sites (n) of isolated serum protein AAG,1,,,F,,,8,Autocuration,CHEMBL623840,,6956,,,12675,14837,,
,BAO_0000225,,M,,Association constant for binding to AATT duplex,1,,,B,,,3,Intermediate,CHEMBL623841,,6957,,,22222,16037,,
,BAO_0000219,,N,,Inhibition of ABAE human fibroblast cell proliferation,1,ABAE,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623842,,6958,,,100090,16597,416.0,
,BAO_0000218,,N,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",1,AC755,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL623843,,6959,,,80668,8831,1064.0,
,BAO_0000218,,D,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,1,,9986.0,F,Oryctolagus cuniculus,,9,Expert,CHEMBL618669,,6960,,,102444,13419,,
,BAO_0000218,,D,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,1,,9986.0,F,Oryctolagus cuniculus,,9,Expert,CHEMBL618670,,6961,In vivo,,102444,13419,,
,BAO_0000357,,H,,Inhibitory activity against angiotensin-converting enzyme (ACE).,1,,,B,,,8,Autocuration,CHEMBL618671,,6962,,,69,15778,,
,BAO_0000357,,H,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,1,,,B,,,8,Autocuration,CHEMBL618672,,6963,,,69,15778,,
,BAO_0000219,,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,1,ACH-2 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618673,,6964,,,80669,12988,978.0,
,BAO_0000219,,N,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),1,ACH-2 cell line,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618674,,6965,,,80669,12988,978.0,
,BAO_0000219,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,1,T cell line,11676.0,F,Human immunodeficiency virus 1,,0,Autocuration,CHEMBL618675,,6966,,,22224,12988,998.0,
,BAO_0000219,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),1,T cell line,11676.0,F,Human immunodeficiency virus 1,,0,Autocuration,CHEMBL618676,,6967,,,22224,12988,998.0,
,BAO_0000219,,U,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),1,T cell line,11676.0,F,Human immunodeficiency virus 1,,0,Autocuration,CHEMBL618677,,6968,,,22224,12988,998.0,
,BAO_0000219,,N,,Inhibition of growth of renal cancer ACHN cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618678,,6969,,,80025,11843,626.0,
,BAO_0000219,,N,,Inhibition of growth of ACHN renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618679,,6970,,,80025,16939,626.0,
,BAO_0000219,,N,,Inhibitory concentration required against ACHN renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618680,,6971,,,80025,4782,626.0,
,BAO_0000219,,N,,Concentration required to inhibit growth of human renal (ACHN) cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618681,,6972,,,80025,6310,626.0,
,BAO_0000219,,N,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618682,,6973,,,80025,6310,626.0,
,BAO_0000219,,N,,Cytotoxic activity against ACHN Renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618683,,6974,,,80025,12858,626.0,
,BAO_0000219,,N,,Cytotoxicity evaluation against ACHN renal cancer cells,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618684,,6975,,,80025,17380,626.0,
,BAO_0000219,,N,,In vitro antitumor activity against human renal ACHN cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618685,,6976,,,80025,5858,626.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL876499,,6977,,,80025,3838,626.0,
,BAO_0000219,,N,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618686,,6978,,,80025,3838,626.0,
,BAO_0000219,,N,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618687,,6979,,,80025,5406,626.0,
,BAO_0000219,,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618688,,6980,,,80025,4071,626.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,1,ACHN,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618689,,6981,,,80025,4071,626.0,
,BAO_0000219,,N,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618690,,6982,,,80025,4071,626.0,
,BAO_0000219,,N,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618691,,6983,,,80025,15002,626.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619373,,6984,,,80025,14769,626.0,
,BAO_0000219,,N,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884008,,6985,,,80025,13958,626.0,
,BAO_0000219,,N,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619374,,6986,,,80025,1665,626.0,
,BAO_0000219,,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619375,,6987,,,80025,15354,626.0,
,BAO_0000219,,N,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619376,,6988,,,80025,15354,626.0,
,BAO_0000219,,N,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619377,,6989,,,80025,13978,626.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619378,,6990,,,80025,6798,626.0,
,BAO_0000218,,N,,Tmax value after administration of 4 mg/Kg oral dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL872527,,6991,In vivo,,50588,2959,,
,BAO_0000218,,N,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876500,,6992,,,50588,9932,,
,BAO_0000218,,N,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619379,,6993,,,50588,5546,,
,BAO_0000218,,N,,Volume distribution after 15 mg/kg iv dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619538,,6994,In vivo,,50588,16907,,
,BAO_0000218,,N,,Volume distribution after 30 mg/kg po dose in Dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619539,,6995,In vivo,,50588,16907,,
,BAO_0000218,,N,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619540,,6996,In vivo,,50588,4257,,
,BAO_0000218,,N,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619541,,6997,In vivo,,50588,4305,,
,BAO_0000218,,N,,Volume of distribution was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619542,,6998,In vivo,,50588,5472,,
,BAO_0000218,,N,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619543,,6999,In vivo,,50588,6062,,
,BAO_0000218,,N,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Expert,CHEMBL619544,,7000,,,50588,3598,,
,BAO_0000218,,N,,The compound was tested for volume of distribution in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619545,,7001,In vivo,,50588,12500,,
,BAO_0000218,,N,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619546,,7002,In vivo,,50588,12500,,
,BAO_0000218,,N,,Vd (1 mg/kg) was determined in dog (in vivo),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619547,,7003,In vivo,,50588,6227,,
,BAO_0000218,,N,,Vd in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619548,,7004,In vivo,,50588,6227,,
,BAO_0000218,,N,,Volume distribution was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619549,,7005,In vivo,,50588,4219,,
,BAO_0000218,,N,,Volume of distribution in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619550,,7006,In vivo,,50588,1696,,
,BAO_0000218,,N,,Volume of distribution by as 4 fold increase by iv administration in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876501,,7007,In vivo,,50588,5542,,
,BAO_0000218,,N,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619551,,7008,In vivo,,50588,5199,,
,BAO_0000218,,N,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619552,,7009,In vivo,,50588,6348,,
,BAO_0000218,,N,,Volume distribution at the dose of 2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619553,,7010,In vivo,,50588,4727,,
,BAO_0000218,,N,,Steady state volume of distribution was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618722,,7011,In vivo,,50588,16367,,
,BAO_0000218,,N,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618723,,7012,In vivo,,50588,2652,,
,BAO_0000218,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618724,,7013,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618725,,7014,In vivo,,50588,16452,,
,BAO_0000218,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618726,,7015,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618727,,7016,In vivo,,50588,5334,,
,BAO_0000218,,N,,Pharmacokinetic property (vdss) was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624233,,7017,In vivo,,50588,4239,,
,BAO_0000218,,N,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624234,,7018,In vivo,,50588,4709,,
,BAO_0000218,,N,,Vdss was determined after iv 0.1 mg/kg administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624235,,7019,In vivo,,50588,5600,,
,BAO_0000218,,N,,Volume displacement was calculated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624236,,7020,In vivo,,50588,6057,,
,BAO_0000218,,N,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624237,,7021,In vivo,,50588,5654,,
,BAO_0000218,,N,,Volume distribution constant was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624238,,7022,In vivo,,50588,5505,,
,BAO_0000218,,N,,Volume distribution at a dose of 1 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624239,,7023,In vivo,,50588,4527,,
,BAO_0000218,,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875829,,7024,In vivo,,50588,4521,,
,BAO_0000218,,N,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624240,,7025,In vivo,,50588,4521,,
,BAO_0000218,,N,,Volume distribution (Vdss) was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624241,,7026,In vivo,,50588,15660,,
,BAO_0000218,,N,,Volume distribution (Vdss) was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624242,,7027,In vivo,,50588,15660,,
,BAO_0000218,,N,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624243,,7028,In vivo,,50588,6679,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624244,,7029,In vivo,,50588,5145,,
,BAO_0000218,,N,,Volume of distribution of compound was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624245,,7030,In vivo,,50588,6821,,
,BAO_0000218,,N,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624246,,7031,In vivo,,50588,4137,,
,BAO_0000218,,N,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624247,,7032,In vivo,,50588,5334,,
,BAO_0000218,,N,,Volume of distribution (Vdss) was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624248,,7033,In vivo,,50588,15660,,
,BAO_0000218,,N,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624249,,7034,In vivo,,50588,6642,,
,BAO_0000218,,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624250,,7035,In vivo,,50588,6641,,
,BAO_0000218,,N,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624251,,7036,In vivo,,50588,6642,,
,BAO_0000218,,N,,Maximum rate of depolarization of the upstroke of the action potential,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624252,,7037,,,50588,11659,,
,BAO_0000218,,N,,Steady state volume distribution in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624253,,7038,In vivo,,50588,6448,,
,BAO_0000218,,N,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624950,,7039,In vivo,,50588,5474,,
,BAO_0000218,,N,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624951,,7040,In vivo,,50588,1466,,
,BAO_0000218,,N,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875830,,7041,In vivo,,50588,6535,,
,BAO_0000218,,N,,Volume distribution in dog after administration of 1 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624952,,7042,In vivo,,50588,6535,,
,BAO_0000218,,N,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624953,,7043,In vivo,,50588,17764,,
,BAO_0000218,,N,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624954,,7044,In vivo,,50588,6215,,
,BAO_0000218,,N,,Vss on i.v. administration of 2 mg/kg was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624955,,7045,In vivo,,50588,6505,,
,BAO_0000218,,N,,Vss was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624956,,7046,,,50588,3639,,
,BAO_0000218,,N,,Vss in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625129,,7047,,,50588,3639,,
,BAO_0000218,,N,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625130,,7048,In vivo,,50588,6062,,
,BAO_0000218,,N,,Volume distribution in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625131,,7049,In vivo,,50588,4942,,
,BAO_0000218,,N,,Volume of distribution in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625132,,7050,In vivo,,50588,17796,,
,BAO_0000218,,N,,Tested for the oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL872263,,7051,In vivo,,50588,4883,,
,BAO_0000218,,N,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624336,,7060,In vivo,,50594,17837,,
,BAO_0000218,,N,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624337,,7061,In vivo,,50594,17729,,
,BAO_0000218,,N,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624338,,7062,In vivo,,50594,17729,,
,BAO_0000218,,N,,Bioavailability was measured in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624339,,7063,In vivo,,50594,4239,,
,BAO_0000218,,N,,Bioavailability in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624340,,7064,In vivo,,50594,17592,,
,BAO_0000218,,N,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624341,,7065,In vivo,,50594,6348,,
,BAO_0000218,,N,,Bioavailability in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624342,,7066,In vivo,,50594,2801,,
,BAO_0000218,,N,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624343,,7067,In vivo,,50594,2801,,
,BAO_0000218,,N,,Oral bioavailability in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624344,,7068,In vivo,,50594,17718,,
,BAO_0000218,,N,,Oral availability at 50 mg/kg po in male mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624345,,7069,In vivo,,50594,5727,,
,BAO_0000218,,N,,Oral bioavailability in mouse (dose 10 mg/kg),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624346,,7070,In vivo,,50594,5302,,
,BAO_0000218,,N,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,1,,10090.0,A,Mus musculus,,1,Expert,CHEMBL624347,,7071,In vivo,,50594,3598,,
,BAO_0000218,,N,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624348,,7072,In vivo,,50594,5961,,
,BAO_0000218,,N,,Oral bioavailability in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622754,,7074,In vivo,,50594,6091,,
,BAO_0000218,,N,,Oral bioavailability in vivo in mice;ND=Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622755,,7075,In vivo,,50594,6091,,
,BAO_0000218,,N,,Oral bioavailability in mouse at 10 mg/kg of the compound,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622756,,7076,In vivo,,50594,5711,,
,BAO_0000218,,N,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622757,,7077,In vivo,,50594,17728,,
,BAO_0000218,,N,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622758,,7078,In vivo,,50594,17728,,
,BAO_0000218,,N,,Tested for bioavailability of the compound,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622759,,7079,In vivo,,50594,3802,,
,BAO_0000218,,N,,Tested for half life at the dose of 10 mg/kg when administered intravenously,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622760,,7080,In vivo,,50594,3802,,
Plasma,BAO_0000218,,N,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622761,,7081,,,50594,14029,,
Plasma,BAO_0000218,,N,,The plasma half life of compound was determined on heparin prepared by human plasma. ,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622762,,7082,,,50594,14029,,
Plasma,BAO_0000218,,N,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622763,,7083,,,50594,14029,,
Plasma,BAO_0000218,,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622764,,7084,,,50594,14029,,
Plasma,BAO_0000218,,N,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622765,,7085,,,50594,14029,,
,BAO_0000218,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,1,,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL622766,,7086,,,50594,17753,,
,BAO_0000218,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622767,,7087,,,50594,17753,,
,BAO_0000218,,N,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622768,,7088,,,50594,17753,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL875948,,7089,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622769,,7090,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622770,,7091,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622771,,7092,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622772,,7093,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622773,,7094,In vivo,,50594,10107,,
Blood,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622774,,7095,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL621725,,7096,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL621726,,7097,In vivo,,50594,10107,,
,BAO_0000219,,N,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621727,,7098,,,81034,15608,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622413,,7099,,,81034,3290,478.0,
,BAO_0000219,,N,,Compound was evaluated for cytotoxicity against A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622414,,7100,,,81034,2859,478.0,
,BAO_0000219,,N,,Inhibition of A2780 cell clonogenic assay,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622415,,7101,,,81034,15688,478.0,
,BAO_0000219,,N,,Cytotoxic effect on ovarian cancer cell line (A2780),1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL884001,,7102,,,81034,5642,478.0,
,BAO_0000219,,N,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622416,,7103,,,81034,6633,478.0,
,BAO_0000219,,N,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622417,,7104,,,81034,3906,478.0,
,BAO_0000219,,N,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622590,,7105,,,81034,6788,478.0,
,BAO_0000219,,N,,Antiproliferative activity against human A2780 cells,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622591,,7106,,,81034,17582,478.0,
,BAO_0000219,,N,,Inhibition of human A2780 cell proliferation,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622592,,7107,,,81034,17764,478.0,
,BAO_0000219,,N,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622593,,7108,,,81034,17764,478.0,
,BAO_0000219,,N,,Inhibition of human A2780 cell proliferation (No data),1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622594,,7109,,,81034,17764,478.0,
,BAO_0000219,,N,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622595,,7110,,,81034,2815,478.0,
,BAO_0000219,,N,,Compound was evaluated against human Ovarian carcinoma cell line A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622596,,7111,,,81034,16930,478.0,
,BAO_0000219,,N,,Growth inhibition against A2780 wild-type ovarian cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622597,,7112,,,81034,17777,478.0,
,BAO_0000219,,N,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622598,,7113,,,81034,17777,478.0,
,BAO_0000019,,D,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,1,,9606.0,F,Homo sapiens,,5,Autocuration,CHEMBL622599,,7114,,,104766,16936,,
,BAO_0000219,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622600,,7115,,,81034,13759,478.0,
,BAO_0000219,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622601,,7116,,,81034,13759,478.0,
,BAO_0000219,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622602,,7117,,,81034,13759,478.0,
,BAO_0000219,,N,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622603,,7118,,,81034,13759,478.0,
,BAO_0000219,,N,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622604,,7119,,,81034,15292,478.0,
,BAO_0000219,,N,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622605,,7120,,,81034,15292,478.0,
,BAO_0000219,,N,,In vitro inhibition of human ovarian cell line A2780,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL622606,,7121,,,81034,15069,478.0,
,BAO_0000219,,N,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619463,,7122,,,81034,15069,478.0,
,BAO_0000219,,N,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619464,,7123,,,81034,14073,478.0,
,BAO_0000219,,N,,Concentration required to inhibit A2780-cell growth by 50%,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619465,,7124,,,81034,14553,478.0,
,BAO_0000219,,N,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619466,,7125,,,81034,13040,478.0,
,BAO_0000219,,N,,Cytotoxic effect on human ovarian (A2780) cancer cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619467,,7126,,,81034,6891,478.0,
,BAO_0000219,,N,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619468,,7127,,,81034,15569,478.0,
,BAO_0000219,,N,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619469,,7128,,,81034,14190,478.0,
,BAO_0000219,,N,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL619470,,7129,,,81034,15014,478.0,
,BAO_0000219,,N,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619471,,7130,,,81034,15014,478.0,
,BAO_0000219,,N,,Cytotoxicity against human ovarian carcinoma A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619472,,7131,,,81034,17496,478.0,
,BAO_0000219,,N,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL619473,,7132,,,81034,13617,478.0,
,BAO_0000219,,N,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL874368,,7133,,,81034,13617,478.0,
,BAO_0000219,,N,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884003,,7134,,,81034,13617,478.0,
,BAO_0000219,,N,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622690,,7135,,,81034,13617,478.0,
,BAO_0000219,,N,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622691,,7136,,,81034,17672,478.0,
,BAO_0000219,,N,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL622692,,7137,,,81034,4544,478.0,
,BAO_0000219,,N,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623406,,7138,,,81034,4544,478.0,
,BAO_0000219,,N,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL884004,,7139,,,81034,16317,478.0,
,BAO_0000219,,N,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623407,,7140,,,81034,15099,478.0,
,BAO_0000219,,N,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623408,,7141,,,81034,13978,478.0,
,BAO_0000219,,N,,In vitro antitumor activity against A2780 cell line.,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623409,,7142,,,81034,12989,478.0,
,BAO_0000219,,N,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623410,,7143,,,81034,5574,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623576,,7144,,,81034,13528,478.0,
,BAO_0000219,,N,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623577,,7145,,,80025,12782,626.0,
,BAO_0000219,,N,,The IC50 value was measured on ACHN cell line in renal tumor type.,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623578,,7146,,,80025,14255,626.0,
,BAO_0000219,,N,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623579,,7147,,,80025,16364,626.0,
,BAO_0000219,,N,,In vitro lethal concentration against most sensitive ACHN cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623580,,7148,,,80025,17376,626.0,
,BAO_0000219,,N,,Tested for cytotoxic activity against renal cancer ACHN cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623581,,7149,,,80025,12016,626.0,
,BAO_0000219,,N,,Compound tested for growth inhibition of renal cancer cell line ACHN,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL857456,,7150,,,80025,6058,626.0,
,BAO_0000219,,N,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623582,,7151,,,80025,17708,626.0,
,BAO_0000219,,N,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623583,,7152,,,80025,15176,626.0,
,BAO_0000219,,N,,In vitro anticancer activity against ACHN renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623584,,7153,,,80025,2806,626.0,
,BAO_0000219,,N,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623585,,7154,,,80025,15300,626.0,
,BAO_0000219,,N,,Percent selectivity was evaluated in renal ACHN cell lines,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623586,,7155,,,80025,16364,626.0,
,BAO_0000219,,N,,In vitro inhibitory activity against renal ACHN cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623587,,7156,,,80025,13859,626.0,
,BAO_0000219,,N,,Tested for cytotoxicity against ACHN cell lines in renal cancer,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875279,,7157,,,80025,11970,626.0,
,BAO_0000219,,N,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623588,,7158,,,80025,2450,626.0,
,BAO_0000219,,N,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623589,,7159,,,80025,12696,626.0,
,BAO_0000219,,N,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623590,,7160,,,80025,12400,626.0,
,BAO_0000219,,N,,Cytotoxic effect on renal cancer line ACHN,1,ACHN,9606.0,F,Homo sapiens,,1,Expert,CHEMBL623591,,7161,,,80025,12888,626.0,
,BAO_0000219,,N,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623592,,7162,,,80025,3156,626.0,
,BAO_0000219,,N,,In vitro inhibition of Renal Cancer ACHN cell lines,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623593,,7163,,,80025,3381,626.0,
,BAO_0000219,,N,,Antitumor activity against human renal adenocarcinoma ACHN cells,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL623594,,7164,,,80025,16747,626.0,
,BAO_0000219,,N,,Antitumor activity against human renal adenocarcinoma ACHN cells.,1,ACHN,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621833,,7165,,,80025,16748,626.0,
,BAO_0000219,,N,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621834,,7166,,,80025,12062,626.0,
,BAO_0000219,,N,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621835,,7167,,,80025,14769,626.0,
,BAO_0000219,,N,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621836,,7168,,,80025,15895,626.0,
,BAO_0000219,,N,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621837,,7169,,,80025,17376,626.0,
,BAO_0000219,,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875280,,7170,,,80025,14882,626.0,
,BAO_0000219,,N,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621838,,7171,,,80025,14882,626.0,
,BAO_0000219,,N,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,1,ACHN,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621839,,7172,,,80025,15661,626.0,
,BAO_0000019,,U,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL621840,,7173,,,22224,9680,,
,BAO_0000019,,H,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,1,,,F,,,8,Autocuration,CHEMBL621841,,7174,,,10647,14579,,
,BAO_0000218,,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,1,HEL,10358.0,F,Cytomegalovirus,,1,Expert,CHEMBL622979,,7175,,,50529,17290,468.0,
,BAO_0000218,,N,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,1,,10358.0,F,Cytomegalovirus,,1,Intermediate,CHEMBL876595,,7176,,,50529,17290,,
,BAO_0000357,,H,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),1,,,B,,,8,Autocuration,CHEMBL620221,,7177,,,12159,15891,,
,BAO_0000357,,H,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),1,,,B,,,8,Autocuration,CHEMBL620222,,7178,,,12159,15890,,
,BAO_0000219,,N,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,1,ADDP cell line,9913.0,F,Bos taurus,,1,Intermediate,CHEMBL620506,,7179,,,80670,3801,979.0,
,BAO_0000219,,N,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,1,ADJ/PC6,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620507,,7180,,,80671,9222,980.0,
,BAO_0000219,,N,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,1,ADJ/PC6,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620508,,7181,,,80671,9222,980.0,
,BAO_0000219,,N,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",1,ADJ/PC6,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620509,,7182,,,80671,7257,980.0,
,BAO_0000219,,N,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,1,ADJ/PC6,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620510,,7183,,,80671,7257,980.0,
,BAO_0000219,,N,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,1,ADJ/PC6,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620511,,7184,,,80671,7257,980.0,
,BAO_0000219,,N,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,1,ADJ/PC6,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL620512,,7185,,,80671,8084,980.0,
,BAO_0000019,,U,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620513,,7186,,,22224,14943,,
,BAO_0000019,,U,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620514,,7187,,,22224,14943,,
,BAO_0000019,,U,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,1,,10090.0,F,Mus musculus,,0,Autocuration,CHEMBL620515,,7188,,,22224,14943,,
,BAO_0000218,,U,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,1423.0,A,Bacillus subtilis,,0,Autocuration,CHEMBL620516,,7189,In vivo,,22224,10524,,
Plasma,BAO_0000218,,N,,AUC value in dog after IV administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620517,,7190,,,50588,3546,,
Plasma,BAO_0000218,,N,,AUC value in dog after oral administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620518,,7191,,,50588,3546,,
,BAO_0000218,,N,,Cmax value in dog after oral administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620519,,7192,In vivo,,50588,3546,,
,BAO_0000218,,N,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621386,,7193,In vivo,,50588,3546,,
,BAO_0000218,,N,,Tmax value in dog after oral administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621387,,7194,In vivo,,50588,3546,,
,BAO_0000218,,N,,Compound was evaluated for its clearance when administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621388,,7195,In vivo,,50588,3184,,
,BAO_0000218,,N,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621389,,7196,In vivo,,50588,16456,,
,BAO_0000218,,N,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621390,,7197,In vivo,,50588,4809,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Intermediate,CHEMBL621391,,7198,,,22229,4219,,
,BAO_0000218,,N,,Half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621392,,7199,,,50588,3748,,
,BAO_0000218,,N,,Time taken for EC90 was determined when tested in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621393,,7200,,,50588,3132,,
,BAO_0000218,,N,,Half life (iv) was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621394,,7201,,,50588,4219,,
Liver,BAO_0000218,,N,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL621395,,7202,,,50588,16907,,
,BAO_0000218,,N,,Area under the curve was calculated in dog after iv administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621396,,7203,,,50588,6057,,
,BAO_0000218,,N,,Area under the curve was calculated in dog after peroral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621397,,7204,,,50588,6057,,
,BAO_0000218,,N,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621398,,7205,,,50588,17853,,
,BAO_0000218,,N,,pKa was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618818,,7206,,,50588,3639,,
,BAO_0000218,,N,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618819,,7207,,,50588,14541,,
,BAO_0000218,,N,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618820,,7208,In vivo,,50588,16456,,
,BAO_0000218,,N,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873810,,7209,In vivo,,50588,16456,,
,BAO_0000218,,N,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876606,,7210,In vivo,,50588,2652,,
,BAO_0000218,,N,,Compound was evaluated for the half-life (t 1/2) in hours,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618821,,7211,,,50588,3624,,
Blood,BAO_0000218,,N,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL618822,,7212,In vivo,,50588,1337,,
Blood,BAO_0000218,,N,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL618823,,7213,In vivo,,50588,1337,,
,BAO_0000218,,N,,Half life after intravenous administration of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618824,,7214,In vivo,,50588,4709,,
,BAO_0000218,,N,,Half life was measured in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618825,,7215,,,50588,15660,,
,BAO_0000218,,N,,Half life period in dog after 5 mg/kg dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618826,,7216,In vivo,,50588,5302,,
,BAO_0000218,,N,,Half life period was evaluated in dog; 4-4.8,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618827,,7217,,,50588,17791,,
,BAO_0000218,,N,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618828,,7218,In vivo,,50588,6348,,
,BAO_0000218,,N,,Half-life was determined in dog after a3 mg/kg of iv dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618829,,7219,In vivo,,50588,4257,,
,BAO_0000218,,N,,Half-life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618830,,7220,,,50588,3771,,
,BAO_0000218,,N,,Half life in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618831,,7221,,,50588,6305,,
Plasma,BAO_0000218,,N,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL619489,,7222,In vivo,,50588,13501,,
,BAO_0000218,,N,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619649,,7223,In vivo,,50588,17594,,
,BAO_0000218,,N,,Compound was evaluated for the half life period after iv administration in Beagle dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876607,,7224,In vivo,,50588,3045,,
,BAO_0000218,,N,,Compound was evaluated for the half life period after oral administration in conscious dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619650,,7225,In vivo,,50588,3043,,
,BAO_0000218,,N,,Compound was tested for half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619651,,7226,,,50588,4839,,
,BAO_0000218,,N,,Compound was tested for its half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619652,,7227,,,50588,4839,,
,BAO_0000218,,N,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619653,,7228,In vivo,,50588,5802,,
,BAO_0000218,,N,,Half life of compound in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619654,,7229,,,50588,17839,,
,BAO_0000218,,N,,Half life (iv) was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619655,,7230,In vivo,,50588,4219,,
Blood,BAO_0000218,,N,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL619656,,7231,,,50588,13966,,
Plasma,BAO_0000218,,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL873812,,7232,In vivo,,50588,3994,,
Plasma,BAO_0000218,,N,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,1,,9615.0,F,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621365,,7233,In vivo,,50588,3994,,
,BAO_0000218,,N,,Half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621366,,7234,,,50588,4453,,
Plasma,BAO_0000218,,N,,Half life in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621367,,7235,,,50588,6535,,
Plasma,BAO_0000218,,N,,Half life in dog plasma after administration of 0.25 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621368,,7236,In vivo,,50588,6535,,
Plasma,BAO_0000218,,N,,Half life in dog plasma after administration of 1 mg/kg iv,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621369,,7237,In vivo,,50588,6535,,
Plasma,BAO_0000218,,N,,Half life in dog plasma was determined at dose 10 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621370,,7238,In vivo,,50588,3132,,
,BAO_0000218,,N,,Half life in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621371,,7239,,,50588,5374,,
,BAO_0000218,,N,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621372,,7240,In vivo,,50588,5007,,
Plasma,BAO_0000218,,N,,Half life upon exposure to human plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621373,,7241,,,50588,16907,,
,BAO_0000218,,N,,Half life was calculated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621374,,7242,,,50588,6057,,
,BAO_0000218,,N,,Half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621375,,7243,,,50588,5006,,
,BAO_0000218,,N,,Half life was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621376,,7244,,,50588,5473,,
,BAO_0000218,,N,,Half life by intravenous administration of 1.2 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619624,,7245,In vivo,,50588,4368,,
,BAO_0000218,,N,,Half life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875840,,7246,,,50588,6448,,
,BAO_0000218,,N,,Half life in dog after intra venous administration of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619625,,7247,,,50588,4353,,
,BAO_0000218,,N,,Half life in dog after intra venous administration of the compound; ND means Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619626,,7248,,,50588,4353,,
,BAO_0000218,,N,,Half life in dog after po administration of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619627,,7249,In vivo,,50588,4353,,
,BAO_0000218,,N,,Half life in dog after po administration of the compound; ND means Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873817,,7250,In vivo,,50588,4353,,
,BAO_0000218,,N,,Half life in dog at the single oral dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619628,,7251,In vivo,,50588,6265,,
,BAO_0000218,,N,,Half life in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619629,,7252,,,50588,5006,,
,BAO_0000218,,N,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619630,,7253,In vivo,,50588,5356,,
,BAO_0000218,,N,,Half life in rat,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619631,,7254,,,50588,405,,
,BAO_0000218,,N,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL619632,,7255,In vivo,,50588,6642,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL619633,,7256,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL875841,,7257,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL619634,,7258,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL619635,,7259,In vivo,,50594,10107,,
Bone,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL619636,,7260,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619637,,7261,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619638,,7262,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619639,,7263,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619640,,7264,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619641,,7265,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619642,,7266,In vivo,,50594,10107,,
Gut,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,10000004.0,1,Intermediate,CHEMBL619643,,7267,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL619644,,7268,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621112,,7269,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621113,,7270,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621114,,7271,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621115,,7272,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621116,,7273,In vivo,,50594,10107,,
Heart,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL621117,,7274,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621118,,7275,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621119,,7276,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621120,,7277,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621757,,7278,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621758,,7279,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621759,,7280,In vivo,,50594,10107,,
Kidney,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621760,,7281,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621761,,7282,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621762,,7283,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621763,,7284,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624502,,7285,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624503,,7286,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624504,,7287,In vivo,,50594,10107,,
Liver,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624505,,7288,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624506,,7289,In vivo,,50594,10107,,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780 (human ovarian cancer),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624507,,7290,,,81034,5895,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624508,,7291,,,81034,6338,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624509,,7292,,,81034,15163,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624510,,7293,,,81034,15163,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL875956,,7294,,,81034,15000,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL839885,,7295,,,81034,15000,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL624511,,7296,,,81034,14729,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity against A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624512,,7297,,,81034,17270,478.0,
,BAO_0000219,,N,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624513,,7298,,,81034,5685,478.0,
,BAO_0000219,,N,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL624514,,7299,,,81034,3563,478.0,
,BAO_0000218,,N,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618547,,7300,,,81034,17753,478.0,
,BAO_0000219,,N,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618548,,7301,,,81034,16317,478.0,
,BAO_0000219,,N,,Inhibition of tubulin polymerization in analogy of ca.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618549,,7302,,,81034,16936,478.0,
,BAO_0000219,,N,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618550,,7303,,,81034,3801,478.0,
,BAO_0000219,,N,,Cytotoxic effect in ovarian cancer cell line (A2780),1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618551,,7304,,,81034,6181,478.0,
,BAO_0000219,,N,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618552,,7305,,,81034,5318,478.0,
,BAO_0000219,,N,,Tested for the cytotoxicity in A2780 ovarian cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618553,,7306,,,81034,4840,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618554,,7307,,,81034,15748,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618555,,7308,,,81034,15748,478.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,1,A2780cisR,,F,,,1,Intermediate,CHEMBL618556,,7309,,,80017,15748,481.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),1,A2780cisR,,F,,,1,Intermediate,CHEMBL618557,,7310,,,80017,15748,481.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,1,A2780cisR,,F,,,1,Intermediate,CHEMBL618558,,7311,,,80017,15748,481.0,
,BAO_0000219,,N,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),1,A2780cisR,,F,,,1,Intermediate,CHEMBL618559,,7312,,,80017,15748,481.0,
,BAO_0000218,,N,,In vivo log of cells killed after administration of compound in A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618560,,7313,,,81034,17753,478.0,
,BAO_0000218,,N,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618561,,7314,In vivo,,81034,17753,478.0,
,BAO_0000219,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618562,,7315,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618563,,7316,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618564,,7317,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618565,,7318,,,81034,16936,478.0,
,BAO_0000218,,N,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618566,,7319,,,81034,17528,478.0,
,BAO_0000219,,N,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL618567,,7320,,,81034,6633,478.0,
,BAO_0000219,,N,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618568,,7321,,,81034,15000,478.0,
,BAO_0000219,,N,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL618569,,7322,,,81034,17528,478.0,
,BAO_0000219,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621857,,7323,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621858,,7324,,,81034,16936,478.0,
,BAO_0000219,,N,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621859,,7325,,,81034,16936,478.0,
,BAO_0000219,,N,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621860,,7326,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621861,,7327,,,81034,16936,478.0,
,BAO_0000219,,N,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",1,A2780,9606.0,F,Homo sapiens,,1,Expert,CHEMBL621862,,7328,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621863,,7329,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621864,,7330,,,81034,16936,478.0,
,BAO_0000219,,N,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621865,,7331,,,81034,16936,478.0,
,BAO_0000219,,N,,In vitro antiproliferative activity against A2780 cell line,1,A2780,10090.0,F,Mus musculus,,1,Intermediate,CHEMBL621866,,7332,,,81034,17737,478.0,
,BAO_0000219,,N,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,1,A2780,10090.0,F,Mus musculus,,1,Expert,CHEMBL621867,,7333,,,81034,17764,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL621868,,7334,,,81034,3830,478.0,
,BAO_0000219,,N,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,1,A2780,9606.0,F,Homo sapiens,,1,Intermediate,CHEMBL875282,,7335,,,81034,3829,478.0,
,BAO_0000218,,N,,Vc value in dog after IV administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621869,,7336,,,50588,3546,,
,BAO_0000218,,N,,Half life period in dog after IV administration at a dose of 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621870,,7337,In vivo,,50588,3546,,
,BAO_0000019,,U,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621871,,7338,,,22224,5668,,
Plasma,BAO_0000218,,U,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL621243,,7339,,,22224,3443,,
Plasma,BAO_0000218,,U,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,1969.0,0,Autocuration,CHEMBL621244,,7340,,,22224,3443,,
,BAO_0000218,,U,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL621245,,7341,In vivo,,22224,4256,,
,BAO_0000218,,U,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL621246,,7342,In vivo,,22224,4256,,
,BAO_0000218,,U,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL621247,,7343,In vivo,,22224,4256,,
,BAO_0000218,,U,,Oral Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL618386,,7344,In vivo,,22224,4256,,
,BAO_0000218,,U,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618387,,7345,,,22224,1916,,
,BAO_0000218,,U,,Area under curve value in monkey at a dose of 5 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618388,,7346,,,22224,5302,,
,BAO_0000218,,U,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618389,,7347,,,22224,4257,,
,BAO_0000019,,U,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618574,,7348,,,22224,5355,,
,BAO_0000019,,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618575,,7349,,,22224,5355,,
,BAO_0000019,,U,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618576,,7350,,,22224,5355,,
,BAO_0000218,,U,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618577,,7351,,,22224,6078,,
,BAO_0000218,,U,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876487,,7352,,,22224,6078,,
,BAO_0000218,,U,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618578,,7353,,,22224,6062,,
,BAO_0000218,,U,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618579,,7354,,,22224,2661,,
,BAO_0000019,,U,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618580,,7355,,,22224,2661,,
,BAO_0000218,,U,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618581,,7356,,,22224,5394,,
,BAO_0000218,,U,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618582,,7357,,,22224,4397,,
,BAO_0000218,,U,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618583,,7358,,,22224,17509,,
,BAO_0000218,,U,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618584,,7359,,,22224,17509,,
,BAO_0000218,,U,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618585,,7360,In vivo,,22224,6641,,
,BAO_0000218,,U,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618586,,7361,,,22224,5355,,
,BAO_0000218,,U,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618587,,7362,In vivo,,22224,3443,,
,BAO_0000218,,U,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618588,,7363,In vivo,,22224,3443,,
,BAO_0000019,,U,,Binding towards monkey plasma protein at 10 uM,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618589,,7364,,,22224,17409,,
,BAO_0000019,,U,,Binding towards monkey plasma protein at 100 uM,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618590,,7365,,,22224,17409,,
,BAO_0000218,,U,,Apparent bioavailability in squirrel monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL872262,,7366,In vivo,,22224,1052,,
,BAO_0000218,,U,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618591,,7367,In vivo,,22224,13501,,
,BAO_0000218,,U,,Bioavailability in monkey (dose 2 mg/kg),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL618592,,7368,In vivo,,22224,17509,,
,BAO_0000218,,U,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL876488,,7369,In vivo,,22224,5394,,
,BAO_0000218,,U,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618593,,7370,In vivo,,22224,2661,,
,BAO_0000218,,U,,Bioavailability in monkey (i.d. dosing),1,,9443.0,A,monkey,,0,Autocuration,CHEMBL618594,,7371,In vivo,,22224,11219,,
,BAO_0000218,,U,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL618595,,7372,In vivo,,22224,3045,,
,BAO_0000019,,U,,Clearance of the drug was measured in cynomolgus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621469,,7373,,,22224,17796,,
,BAO_0000218,,U,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621470,,7374,In vivo,,22224,1399,,
,BAO_0000218,,U,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621471,,7375,In vivo,,22224,2661,,
Plasma,BAO_0000218,,U,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,9544.0,A,Macaca mulatta,1969.0,0,Autocuration,CHEMBL621472,,7376,In vivo,,22224,5005,,
,BAO_0000218,,U,,Plasma clearance in rhesus monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621473,,7377,In vivo,,22224,17267,,
,BAO_0000218,,U,,Plasma clearance in monkey after administration of 1 mg/kg iv,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621474,,7378,In vivo,,22224,6535,,
,BAO_0000218,,U,,Plasma clearance in cynomolgus monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621475,,7379,In vivo,,22224,5922,,
,BAO_0000218,,U,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL621476,,7380,In vivo,,22224,6221,,
,BAO_0000218,,U,,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624290,,7381,In vivo,,22224,5668,,
,BAO_0000218,,U,,The total clearance was determined after intravenous administration in cynomolgus monkeys,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624291,,7382,In vivo,,22224,5355,,
,BAO_0000218,,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624292,,7383,In vivo,,22224,5355,,
,BAO_0000218,,U,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624293,,7384,In vivo,,22224,5355,,
,BAO_0000218,,U,,Tested for Clearance upon iv administration to african green monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624294,,7385,In vivo,,22224,4578,,
,BAO_0000218,,U,,Clearance in monkey,1,,9527.0,A,Cercopithecidae,,0,Autocuration,CHEMBL624295,,7386,In vivo,,22224,17592,,
,BAO_0000218,,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624296,,7387,In vivo,,50588,6641,,
,BAO_0000218,,N,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624297,,7388,In vivo,,50588,6642,,
,BAO_0000218,,N,,Half life was evaluated after intravenous administration to dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624298,,7389,In vivo,,50588,16367,,
,BAO_0000218,,N,,Half life was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624299,,7390,,,50588,5472,,
,BAO_0000218,,N,,Half life was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624300,,7391,,,50588,5474,,
,BAO_0000218,,N,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624301,,7392,In vivo,,50588,5654,,
,BAO_0000218,,N,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624302,,7393,In vivo,,50588,6227,,
,BAO_0000218,,N,,Half life period after intravenous administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876026,,7394,In vivo,,50588,6227,,
,BAO_0000218,,N,,Half life period after oral administration (2.5 mg/kg) in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624303,,7395,In vivo,,50588,6221,,
,BAO_0000218,,N,,Half life period at a dose of 1 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624304,,7396,,,50588,4527,,
,BAO_0000218,,N,,Half life period was determine after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624305,,7397,In vivo,,50588,5668,,
,BAO_0000218,,N,,Half life period was determine after peroral administration at 5 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624306,,7398,In vivo,,50588,5668,,
,BAO_0000218,,N,,Half life period was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624307,,7399,,,50588,3854,,
,BAO_0000218,,N,,Half life period was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624308,,7400,,,50588,5505,,
,BAO_0000218,,N,,Half life period by iv administration in dog at a dose of 6 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624309,,7401,In vivo,,50588,6251,,
,BAO_0000218,,N,,Half life period was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624310,,7402,,,50588,1918,,
,BAO_0000218,,N,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625003,,7403,In vivo,,50588,5546,,
,BAO_0000218,,N,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625004,,7404,In vivo,,50588,4809,,
,BAO_0000218,,N,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625005,,7405,In vivo,,50588,6215,,
,BAO_0000218,,N,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873813,,7406,In vivo,,50588,4527,,
,BAO_0000218,,N,,Half-life after oral dose of compound at 3 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625006,,7407,In vivo,,50588,17594,,
,BAO_0000218,,N,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625007,,7408,In vivo,,50588,17839,,
,BAO_0000218,,N,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876027,,7409,In vivo,,50588,17839,,
,BAO_0000218,,N,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625008,,7410,In vivo,,50588,17839,,
,BAO_0000218,,N,,Half-life of compound in dog following p.o. administration of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625009,,7411,In vivo,,50588,17839,,
Plasma,BAO_0000218,,N,,Half-life of compound in plasma of dog was determined,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625010,,7412,,,50588,5210,,
,BAO_0000218,,N,,Half-life of compound was determined in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625011,,7413,,,50588,5210,,
,BAO_0000218,,N,,Half-life after administration of 4 mg/Kg oral dose in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621553,,7414,In vivo,,50588,2959,,
,BAO_0000218,,N,,Half-life after intravenous administration of 1 mg/kg/h in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621554,,7415,In vivo,,50588,4137,,
,BAO_0000218,,N,,Half-life in Dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621555,,7416,,,50588,5064,,
,BAO_0000218,,N,,Half-life in Dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621556,,7417,,,50588,5147,,
,BAO_0000218,,N,,Half-life in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621557,,7418,,,50588,5145,,
,BAO_0000218,,N,,Half-life in dog after oral administration at 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621558,,7419,In vivo,,50588,6123,,
,BAO_0000218,,N,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621559,,7420,In vivo,,50588,6123,,
,BAO_0000218,,N,,Half-life in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621560,,7421,,,50588,4333,,
,BAO_0000218,,N,,Half-life in dogs; ND indicates not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL876028,,7422,,,50588,4333,,
Plasma,BAO_0000218,,N,,Half-life in plasma of dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621561,,7423,,,50588,12500,,
Plasma,BAO_0000218,,N,,Half-life in plasma of dog at dose of 3-10 mgkg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621562,,7424,,,50588,12500,,
,BAO_0000218,,N,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621563,,7425,In vivo,,50588,6005,,
,BAO_0000218,,N,,Half-life was measured in dog after an iv dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621564,,7426,In vivo,,50588,6062,,
,BAO_0000218,,N,,Half-life was measured in dogs after an oral dose of 10 uM/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621565,,7427,In vivo,,50588,17650,,
,BAO_0000218,,N,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621566,,7428,In vivo,,50588,5530,,
,BAO_0000218,,N,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621567,,7429,In vivo,,50588,5530,,
,BAO_0000218,,N,,Half-life of the compound after 0.3 mg/kg po administration in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622978,,7430,In vivo,,50588,5600,,
,BAO_0000218,,N,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL873814,,7431,In vivo,,50588,6039,,
,BAO_0000218,,N,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623219,,7432,In vivo,,50588,6039,,
,BAO_0000218,,N,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624477,,7433,In vivo,,50588,6039,,
,BAO_0000218,,N,,t1/2 in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624478,,7434,,,50588,6227,,
,BAO_0000218,,N,,Half-life period measured in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624479,,7435,,,50588,14541,,
,BAO_0000218,,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624480,,7436,In vivo,,50588,4521,,
,BAO_0000218,,N,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623595,,7437,In vivo,,50588,4521,,
,BAO_0000218,,N,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623596,,7438,In vivo,,50588,6679,,
Plasma,BAO_0000218,,N,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623597,,7439,In vitro,,50588,1116,,
,BAO_0000218,,N,,In vivo half life period was calculated at 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623598,,7440,In vivo,,50588,5444,,
,BAO_0000218,,N,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623599,,7441,In vivo,,50588,5444,,
,BAO_0000218,,N,,Longer half-life in dog (i.v.) at 0.5 mpk,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623600,,7442,In vivo,,50588,17853,,
,BAO_0000218,,N,,Oral bioavailability in dog (dose 5 uM/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623601,,7443,In vivo,,50588,4353,,
,BAO_0000218,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623602,,7444,In vivo,,50588,16452,,
,BAO_0000218,,N,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623603,,7445,In vivo,,50588,16452,,
,BAO_0000218,,N,,Bioavailability in dog (dose 1 mg/kg i.v.),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623604,,7446,In vivo,,50588,16452,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623605,,7447,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623606,,7448,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623607,,7449,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623608,,7450,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623609,,7451,In vivo,,50594,10107,,
Lung,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL623610,,7452,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623611,,7453,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623612,,7454,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623613,,7455,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623614,,7456,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623615,,7457,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623616,,7458,In vivo,,50594,10107,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL623617,,7459,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL875944,,7460,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623618,,7461,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623619,,7462,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623620,,7463,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623621,,7464,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623622,,7465,In vivo,,50594,10107,,
Zone of skin,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL623623,,7466,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL623624,,7467,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618521,,7468,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618522,,7469,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618523,,7470,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618524,,7471,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL618525,,7472,In vivo,,50594,10107,,
Spleen,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL624586,,7473,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624587,,7474,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624588,,7475,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624589,,7476,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624590,,7477,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624591,,7478,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624592,,7479,In vivo,,50594,10107,,
Stomach,BAO_0000218,,N,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL624593,,7480,In vivo,,50594,10107,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624594,,7481,In vivo,,50597,4689,,
,BAO_0000218,,N,,Tested for the bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624595,,7482,In vivo,,50597,4950,,
,BAO_0000218,,N,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624596,,7483,In vivo,,50597,5328,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624597,,7484,In vivo,,50597,406,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624598,,7485,In vivo,,50597,12500,,
,BAO_0000218,,N,,Bioavailability in rat (dose 3-10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624599,,7486,In vivo,,50597,12500,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875166,,7487,In vivo,,50597,5247,,
Plasma,BAO_0000218,,N,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624600,,7488,In vivo,,50597,4186,,
Plasma,BAO_0000218,,N,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624601,,7489,In vivo,,50597,4186,,
,BAO_0000218,,N,,Half life after oral administration was determined in rats at 6 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624602,,7490,In vivo,,50597,6647,,
,BAO_0000218,,N,,Half life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624603,,7491,,,50597,6484,,
,BAO_0000218,,N,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624604,,7492,In vivo,,50597,3249,,
Plasma,BAO_0000218,,N,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624605,,7493,In vivo,,50597,6281,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624606,,7494,,,50597,3307,,
Blood,BAO_0000218,,N,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624607,,7495,In vivo,,50597,12058,,
,BAO_0000218,,N,,Hill coefficient of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624608,,7496,,,50597,8833,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624609,,7497,,,50597,3193,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624610,,7498,,,50597,3193,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624611,,7499,,,50597,3193,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624612,,7500,,,50597,3193,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL875167,,7501,,,50597,3193,,
Blood,BAO_0000218,,N,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624613,,7502,,,50597,3193,,
Blood,BAO_0000218,,N,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624614,,7503,,,50597,3193,,
,BAO_0000218,,N,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624392,,7504,,,50597,5960,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624393,,7505,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624394,,7506,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624395,,7507,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624396,,7508,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624397,,7509,In vivo,,50597,13950,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624398,,7510,In vivo,,50597,13950,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624399,,7511,In vivo,,50597,13950,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624400,,7512,In vivo,,50597,13950,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624401,,7513,In vivo,,50597,13950,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624402,,7514,In vivo,,50597,13950,,
Blood,BAO_0000218,,N,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624403,,7515,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624404,,7516,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624405,,7517,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL624406,,7518,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL624407,,7519,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL624408,,7520,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL618644,,7521,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL618645,,7522,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL618646,,7523,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL618647,,7524,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL618648,,7525,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL618649,,7526,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL618650,,7527,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL618651,,7528,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL876497,,7529,In vivo,,50597,9866,,
Lung,BAO_0000218,,N,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL618652,,7530,In vivo,,50597,9866,,
Lung,BAO_0000218,,N,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL618653,,7531,In vivo,,50597,9866,,
Lung,BAO_0000218,,N,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL618654,,7532,In vivo,,50597,9866,,
,BAO_0000218,,N,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618655,,7533,,,50597,6351,,
,BAO_0000218,,N,,Compound was tested for solubility in water,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618656,,7534,,,50597,1465,,
,BAO_0000100,,U,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),1,,,P,,,0,Intermediate,CHEMBL618657,,7535,,,22229,5182,,
,BAO_0000218,,N,,Solubility was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618658,,7536,,,50597,17847,,
,BAO_0000218,,N,,solubility in water (ug/mL) at 37 degree C.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618659,,7537,,,50597,15339,,
,BAO_0000218,,N,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618660,,7538,,,50597,5202,,
,BAO_0000218,,N,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618661,,7539,,,50597,1088,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873807,,7540,,,50597,3169,,
,BAO_0000218,,N,,Half life in Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618662,,7541,,,50597,5353,,
,BAO_0000218,,N,,Half life period after 3 mg/kg iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618663,,7542,In vivo,,50597,2864,,
,BAO_0000218,,N,,Half life period after 3 mg/kg iv administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618664,,7543,In vivo,,50597,2864,,
,BAO_0000218,,N,,Half life period after 3 mg/kg iv administration in the rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618665,,7544,In vivo,,50597,2864,,
,BAO_0000218,,N,,Half life period in female Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876498,,7545,,,50597,6362,,
,BAO_0000218,,N,,Half life period in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618666,,7546,,,50597,6249,,
,BAO_0000218,,N,,Half-life in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620440,,7547,,,50597,3169,,
,BAO_0000218,,N,,Half-life in rats with metabolic oxidation,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620441,,7548,,,50597,3169,,
,BAO_0000218,,N,,Half-life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620442,,7549,,,50597,3169,,
,BAO_0000218,,N,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620443,,7550,In vivo,,50597,17260,,
,BAO_0000218,,N,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620444,,7551,In vivo,,50597,17260,,
,BAO_0000218,,N,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620445,,7552,In vivo,,50597,17260,,
,BAO_0000218,,N,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620446,,7553,In vivo,,50597,17260,,
Plasma,BAO_0000218,,N,,Biological half-life measured in plasma of rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620447,,7554,,,50597,2879,,
Plasma,BAO_0000218,,N,,Biological half-life measured in plasma of rat; 22-25,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621129,,7555,,,50597,2879,,
Plasma,BAO_0000218,,N,,Biological half-life measured in plasma of rat; 9-16,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621130,,7556,,,50597,2879,,
,BAO_0000218,,N,,Compound was evaluated for its half life when administered intravenously in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873808,,7557,In vivo,,50597,3184,,
,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876598,,7558,In vivo,,50597,4891,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621131,,7559,In vivo,,50597,429,,
,BAO_0000218,,N,,Half life (T1/2) after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621132,,7560,In vivo,,50597,5656,,
,BAO_0000218,,N,,Half life of compound after iv administration of 20 mg/kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621133,,7561,In vivo,,50597,4413,,
,BAO_0000218,,N,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL621312,,7562,In vivo,,50597,3598,,
,BAO_0000218,,N,,Half life of compound was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621313,,7563,,,50597,17267,,
Blood,BAO_0000218,,N,,Half life of compound was determined in rat blood,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621314,,7564,,,50597,4727,,
,BAO_0000218,,N,,Half life at 1 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621315,,7565,In vivo,,50597,17651,,
,BAO_0000218,,N,,Half life at 10 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621316,,7566,In vivo,,50597,17651,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621317,,7567,,,50597,401,,
,BAO_0000218,,N,,Half life in rats in hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621318,,7568,,,50597,4942,,
,BAO_0000218,,N,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621319,,7569,In vivo,,50597,17735,,
,BAO_0000218,,N,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621377,,7570,In vivo,,50597,6056,,
,BAO_0000218,,N,,Half life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621378,,7571,,,50597,5213,,
,BAO_0000218,,N,,Half life after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876599,,7572,In vivo,,50597,6616,,
,BAO_0000218,,N,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621379,,7573,In vivo,,50597,5937,,
Plasma,BAO_0000218,,N,,Half life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621380,,7574,,,50597,5819,,
Plasma,BAO_0000218,,N,,Half life in rat plasma; Not detected,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621381,,7575,,,50597,5819,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618515,,7576,,,50597,6803,,
,BAO_0000218,,N,,Half life period of compound was determined after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618516,,7577,In vivo,,50597,17804,,
,BAO_0000218,,N,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618517,,7578,In vivo,,50597,17804,,
,BAO_0000218,,N,,Half life period in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618518,,7579,,,50597,5948,,
,BAO_0000218,,N,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618519,,7580,In vivo,,50597,1916,,
,BAO_0000218,,N,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618698,,7581,In vivo,,50597,1916,,
,BAO_0000218,,N,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618862,,7582,In vivo,,50597,1916,,
,BAO_0000218,,N,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618863,,7583,In vivo,,50597,4890,,
,BAO_0000218,,N,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618864,,7584,In vivo,,50597,17764,,
,BAO_0000218,,N,,Half life time in rat the dose of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618865,,7585,In vivo,,50597,4727,,
,BAO_0000218,,N,,Half-life 24 hr after 10 mg/kg iv administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618866,,7586,In vivo,,50597,17509,,
,BAO_0000218,,N,,Half-life 24 hr after 2 mg/kg iv administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618867,,7587,In vivo,,50597,17509,,
,BAO_0000218,,N,,Half-life consistent with the observed metabolic steady state in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875828,,7588,,,50597,6597,,
,BAO_0000218,,N,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618868,,7589,In vivo,,50597,17735,,
,BAO_0000218,,N,,Half-life for oxidative metabolic stability was determined using male human,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618869,,7590,,,50597,6597,,
,BAO_0000218,,N,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618870,,7591,In vivo,,50597,17670,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618871,,7592,,,50597,1696,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618872,,7593,,,50597,1742,,
,BAO_0000218,,N,,Half-life in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873816,,7594,,,50597,17800,,
,BAO_0000218,,U,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,1,,,A,,,0,Autocuration,CHEMBL618873,,7595,,,22224,12923,,
,BAO_0000019,,U,,Area under curve after oral dose of 0.1 mg//kg,1,,,A,,,0,Autocuration,CHEMBL621602,,7596,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 0.3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621603,,7597,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 1 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621604,,7598,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 10 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621605,,7599,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 23.4 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621606,,7600,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621607,,7601,,,22224,11954,,
,BAO_0000218,,U,,Area under curve after oral dose of 3.87 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621608,,7602,,,22224,11954,,
,BAO_0000019,,U,,Area under curve was determined,1,,,A,,,0,Autocuration,CHEMBL621609,,7603,,,22224,5237,,
,BAO_0000218,,U,,Area under curve at a dose of 10 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621610,,7604,,,22224,4026,,
,BAO_0000218,,N,,Area under curve was determined; ND=No data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621611,,7605,,,50597,5237,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621612,,7606,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622308,,7607,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622309,,7608,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622310,,7609,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622311,,7610,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622312,,7611,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622931,,7612,,,50597,14793,,
,BAO_0000218,,N,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622932,,7613,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622736,,7614,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622737,,7615,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622738,,7616,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622739,,7617,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622740,,7618,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622741,,7619,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622742,,7620,,,50597,14793,,
Plasma,BAO_0000218,,N,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622743,,7621,,,50597,14793,,
Plasma,BAO_0000218,,N,,AUC in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL622744,,7622,,,50594,11637,,
,BAO_0000019,,U,,Area under curve was measured from the graph obtained from concentration Vs time,1,,,A,,,0,Autocuration,CHEMBL624134,,7623,,,22224,11149,,
,BAO_0000019,,U,,Area under curve value of compound per hour after oral administration,1,,,A,,,0,Autocuration,CHEMBL624135,,7624,,,22224,10016,,
,BAO_0000218,,N,,Area under curve was determined after oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624136,,7625,,,50597,17796,,
,BAO_0000218,,N,,Area under curve was determined after oral administration in rats; No data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624137,,7626,,,50597,17796,,
,BAO_0000218,,N,,Area under curve was determined after oral administration in rats;No data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624320,,7627,,,50597,17796,,
,BAO_0000218,,N,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624321,,7628,,,50588,12923,,
,BAO_0000218,,N,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624322,,7629,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after iv dose of 5.06 in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624323,,7630,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624324,,7631,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624325,,7632,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624326,,7633,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624327,,7634,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624328,,7635,,,50597,15372,,
,BAO_0000218,,N,,Area under curve was determined in Dogs after peroral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627848,,7636,,,50588,14169,,
,BAO_0000218,,N,,Area under curve was determined in Rats after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627849,,7637,,,50597,14169,,
,BAO_0000218,,N,,Area under curve was determined in carotid blood of rat when administered intradermally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627850,,7638,,,50597,14258,,
,BAO_0000218,,N,,Area under curve was determined in portal blood of rat when administered intradermally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627851,,7639,,,50597,14258,,
,BAO_0000218,,N,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627852,,7640,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627853,,7641,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627854,,7642,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627855,,7643,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627856,,7644,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875339,,7645,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627857,,7646,,,50594,15011,,
Spleen,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627858,,7647,In vivo,,50597,11195,,
Blood,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627859,,7648,,,50597,10130,,
Brain,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627860,,7649,,,50597,10130,,
Heart,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627019,,7650,,,50597,10130,,
Liver,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627020,,7651,,,50597,10130,,
Lung,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627021,,7652,,,50597,10130,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627022,,7653,,,50597,10130,,
,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627023,,7654,,,50597,10130,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627024,,7655,,,50597,10130,,
Thyroid gland,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627025,,7656,,,50597,10130,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627026,,7657,,,50597,10130,,
Blood,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627027,,7658,,,50597,10130,,
Brain,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627028,,7659,,,50597,10130,,
Heart,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627029,,7660,,,50597,10130,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627030,,7661,,,50597,10130,,
Liver,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627031,,7662,,,50597,10130,,
Lung,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627032,,7663,,,50597,10130,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627033,,7664,,,50597,10130,,
,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627034,,7665,,,50597,10130,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627035,,7666,,,50597,10130,,
Thyroid gland,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627036,,7667,,,50597,10130,,
Blood,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL875340,,7668,,,50597,10130,,
Heart,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627037,,7669,,,50597,10130,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627038,,7670,,,50597,10130,,
Liver,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627039,,7671,,,50597,10130,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627040,,7672,,,50597,10130,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL624663,,7673,,,50597,10130,,
Thyroid gland,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL625963,,7674,,,50597,10130,,
Brain,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL876799,,7675,,,50597,10130,,
Lung,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626133,,7676,,,50597,10130,,
,BAO_0000218,,N,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626134,,7677,,,50597,10130,,
,BAO_0000218,,N,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626135,,7678,,,50597,6295,,
,BAO_0000218,,N,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626136,,7679,,,50597,6296,,
,BAO_0000218,,N,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626137,,7680,,,50597,6296,,
,BAO_0000218,,N,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626138,,7681,,,50597,6295,,
,BAO_0000218,,N,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626139,,7682,,,50597,6296,,
,BAO_0000218,,N,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626140,,7683,In vivo,,50597,17260,,
,BAO_0000218,,N,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626141,,7684,In vivo,,50597,17260,,
,BAO_0000218,,N,,C24h in rat p.o. at 20 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626142,,7685,,,50597,17686,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627930,,7686,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627931,,7687,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627932,,7688,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627933,,7689,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627934,,7690,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627935,,7691,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627936,,7692,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627937,,7693,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627938,,7694,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627939,,7695,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627940,,7696,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627941,,7697,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL876800,,7698,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627942,,7699,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627943,,7700,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627944,,7701,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627945,,7702,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628584,,7703,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628585,,7704,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628586,,7705,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628587,,7706,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628588,,7707,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628589,,7708,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625304,,7709,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625305,,7710,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625306,,7711,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625307,,7712,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625308,,7713,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627740,,7714,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627741,,7715,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627742,,7716,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627743,,7717,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627744,,7718,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627745,,7719,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627746,,7720,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627747,,7721,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL876810,,7722,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627748,,7723,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627749,,7724,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627750,,7725,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618728,,7726,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618729,,7727,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618730,,7728,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618731,,7729,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618732,,7730,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618733,,7731,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618734,,7732,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618735,,7733,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL876602,,7734,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618736,,7735,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618737,,7736,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618738,,7737,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618739,,7738,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618740,,7739,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618741,,7740,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618742,,7741,In vivo,,50597,9866,,
Bone,BAO_0000218,,N,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL618743,,7742,In vivo,,50597,9866,,
Plasma,BAO_0000218,,N,,Half-life from rat plasma at a single oral dose of 25 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618744,,7743,In vivo,,50597,17752,,
,BAO_0000218,,N,,Half-life in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618745,,7744,,,50597,5610,,
,BAO_0000218,,N,,Half-life in rat after peroral administration at 10 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620479,,7745,In vivo,,50597,5939,,
,BAO_0000218,,N,,Half-life in rat after peroral administration at 5 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620480,,7746,In vivo,,50597,5939,,
,BAO_0000218,,N,,Half-life in rat at a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620481,,7747,In vivo,,50597,17771,,
,BAO_0000218,,N,,Half-life was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620482,,7748,,,50597,1974,,
,BAO_0000218,,N,,Half-life was measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876603,,7749,,,50597,4239,,
,BAO_0000218,,N,,Half-life period for the compound was determined in rats at 50 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620483,,7750,In vivo,,50597,6681,,
,BAO_0000218,,N,,Half-life period in rats after intravenous administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620484,,7751,In vivo,,50597,17752,,
,BAO_0000218,,N,,Half-life period in rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620485,,7752,In vivo,,50597,6046,,
,BAO_0000218,,N,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620486,,7753,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620487,,7754,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620488,,7755,In vivo,,50597,6685,,
,BAO_0000218,,N,,Half-life time in rat the dose of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620489,,7756,In vivo,,50597,4727,,
,BAO_0000218,,N,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620490,,7757,In vivo,,50597,1088,,
,BAO_0000218,,N,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620491,,7758,In vivo,,50597,5610,,
Plasma,BAO_0000218,,N,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876604,,7759,In vivo,,50597,3032,,
,BAO_0000218,,N,,Oral half life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620492,,7760,In vivo,,50597,5199,,
,BAO_0000218,,N,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620493,,7761,In vivo,,50597,14941,,
,BAO_0000218,,N,,Pharmacokinetic property (t1/2) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620494,,7762,In vivo,,50597,4408,,
Plasma,BAO_0000218,,N,,Plasma elimination half-life was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620495,,7763,,,50597,2552,,
Plasma,BAO_0000218,,N,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620496,,7764,In vivo,,50597,5199,,
Plasma,BAO_0000218,,N,,Plasma half life was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620497,,7765,In vivo,,50597,15662,,
Plasma,BAO_0000218,,N,,Plasma half-life was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620498,,7766,,,50597,1465,,
Plasma,BAO_0000218,,N,,Plasma half-life following oral administration in Fisher rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620499,,7767,In vivo,,50597,1446,,
Plasma,BAO_0000218,,N,,Plasma half-life in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620500,,7768,,,50597,6824,,
Plasma,BAO_0000218,,N,,Plasmatic Half-life after intravenous administration to rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873809,,7769,In vivo,,50597,17533,,
,BAO_0000218,,N,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620501,,7770,In vivo,,50597,5979,,
,BAO_0000218,,N,,Terminal half life after intravenous administration (1 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620502,,7771,In vivo,,50597,4689,,
,BAO_0000218,,N,,Terminal half life in Rat at a oral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620503,,7772,In vivo,,50597,4689,,
,BAO_0000218,,N,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620504,,7773,In vivo,,50597,2463,,
,BAO_0000218,,N,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876605,,7774,In vivo,,50597,4883,,
,BAO_0000218,,N,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620505,,7775,In vivo,,50597,4883,,
Plasma,BAO_0000218,,N,,plasma half life was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873811,,7776,In vivo,,50597,15662,,
,BAO_0000218,,N,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL624016,,7777,In vivo,,50597,3598,,
,BAO_0000218,,N,,Half life of compound determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624017,,7778,,,50597,4576,,
,BAO_0000218,,N,,Mean residence time determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624018,,7779,,,50597,4576,,
,BAO_0000218,,N,,Plasma half life determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624019,,7780,,,50597,4576,,
Brain,BAO_0000218,,N,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624020,,7781,In vivo,,50597,4910,,
,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic parameter maximum time period,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624201,,7782,In vivo,,50597,4891,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL872528,,7783,In vivo,,50597,429,,
,BAO_0000218,,N,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624202,,7784,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624203,,7785,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624350,,7786,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621320,,7787,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621321,,7788,In vivo,,50597,17582,,
,BAO_0000218,,N,,Maximum time (Tmax) required to reach Cmax in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621322,,7789,,,50597,4026,,
,BAO_0000218,,N,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621323,,7790,In vivo,,50597,4890,,
,BAO_0000218,,N,,Maximum time of clearance of compound in rats after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621324,,7791,In vivo,,50597,6571,,
,BAO_0000218,,N,,Maximum time at the dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621325,,7792,,,50597,4727,,
Plasma,BAO_0000218,,N,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL875837,,7793,In vivo,,50597,17651,,
Plasma,BAO_0000218,,N,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621326,,7794,In vivo,,50597,17651,,
,BAO_0000218,,N,,Tmax in Guinea pig (PO dose),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621327,,7795,In vivo,,50597,14465,,
,BAO_0000218,,N,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621328,,7796,In vivo,,50597,14941,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Tmax) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621329,,7797,In vivo,,50597,5960,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Tmax) was estimated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621330,,7798,In vivo,,50597,5022,,
,BAO_0000218,,N,,Pharmacokinetic property (Tmax) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621331,,7799,In vivo,,50597,4408,,
,BAO_0000218,,N,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621332,,7800,In vivo,,50597,5983,,
,BAO_0000218,,N,,T max in Rat at a oral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621333,,7801,In vivo,,50597,4689,,
,BAO_0000218,,N,,T max was determined at 10 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621334,,7802,In vivo,,50597,2792,,
,BAO_0000218,,N,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621335,,7803,,,50594,15011,,
,BAO_0000218,,N,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621336,,7804,,,50588,14180,,
,BAO_0000218,,N,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621337,,7805,,,50597,14180,,
,BAO_0000218,,N,,Area under curve was measured after i.v. administration into Beagle dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621338,,7806,,,50588,14599,,
,BAO_0000218,,N,,Area under curve was measured after iv administration into Beagle dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875838,,7807,,,50588,14599,,
,BAO_0000218,,N,,Area under curve was measured after po administration into Beagle dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621339,,7808,,,50588,14599,,
,BAO_0000218,,N,,Area under curve was measured after po administration into Beagle dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621340,,7809,,,50588,14599,,
,BAO_0000218,,U,,Area under curve was measured at peroral dose of 3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL621341,,7810,,,22224,15675,,
,BAO_0000019,,U,,Area under curve was measured by using concentration Vs time,1,,,A,,,0,Autocuration,CHEMBL621342,,7811,,,22224,12706,,
,BAO_0000019,,U,,Area under curve was measured by using concentration Vs time; not tested,1,,,A,,,0,Autocuration,CHEMBL621343,,7812,,,22224,12706,,
,BAO_0000218,,N,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621344,,7813,,,50594,9750,,
,BAO_0000218,,N,,Area under curve(AUC) was measured in mice after oral administration.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621345,,7814,,,50594,9750,,
,BAO_0000019,,U,,Area under curve(AUC) value of the compound,1,,,A,,,0,Autocuration,CHEMBL621346,,7815,,,22224,14691,,
,BAO_0000218,,U,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,1,,,A,,,0,Autocuration,CHEMBL621347,,7816,,,22224,14691,,
,BAO_0000218,,N,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621348,,7817,,,50588,14691,,
Blood,BAO_0000019,,U,,Area under curve(carotid artery) was determined by the availability in blood,1,,,A,,178.0,0,Autocuration,CHEMBL621349,,7818,,,22224,2939,,
Blood,BAO_0000019,,U,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,1,,,A,,178.0,0,Autocuration,CHEMBL621350,,7819,,,22224,2939,,
Blood,BAO_0000019,,U,,Area under curve(carotid artery) was determined by the availability in blood; No data,1,,,A,,178.0,0,Autocuration,CHEMBL875839,,7820,,,22224,2939,,
Blood,BAO_0000019,,U,,Area under curve(portal vein) was determined by the availability in blood,1,,,A,,178.0,0,Autocuration,CHEMBL620211,,7821,,,22224,2939,,
Blood,BAO_0000019,,U,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,1,,,A,,178.0,0,Autocuration,CHEMBL620212,,7822,,,22224,2939,,
Blood,BAO_0000019,,U,,Area under curve(portal vein) was determined by the availability in blood; No data,1,,,A,,178.0,0,Autocuration,CHEMBL620213,,7823,,,22224,2939,,
Plasma,BAO_0000218,,N,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL620214,,7824,,,50797,9552,,
Plasma,BAO_0000218,,N,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL620215,,7825,,,50797,9552,,
Plasma,BAO_0000218,,N,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL620216,,7826,,,50797,9552,,
Plasma,BAO_0000218,,N,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620888,,7827,,,50588,9552,,
Plasma,BAO_0000218,,N,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL620889,,7828,,,50588,9552,,
Plasma,BAO_0000019,,U,,Area under plasma concentration vs time curve observed in rats for 0-3 h,1,,,A,,1969.0,0,Autocuration,CHEMBL620890,,7829,,,22224,9552,,
Plasma,BAO_0000218,,N,,Area under plasma time curve determined in male rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL620891,,7830,,,50597,11911,,
,BAO_0000019,,U,,Area under the MAP curve measured over 5 min.,1,,,A,,,0,Autocuration,CHEMBL620892,,7831,,,22224,16618,,
,BAO_0000218,,N,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621079,,7832,,,50594,14387,,
,BAO_0000218,,N,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL621080,,7833,,,50594,14387,,
,BAO_0000218,,N,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621081,,7834,,,50588,12836,,
,BAO_0000218,,N,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL621082,,7835,,,100712,12836,,
,BAO_0000218,,N,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621083,,7836,,,50597,12836,,
,BAO_0000218,,N,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621084,,7837,,,50588,14339,,
,BAO_0000218,,N,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621085,,7838,,,50588,14339,,
,BAO_0000218,,N,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621086,,7839,,,50588,14339,,
,BAO_0000218,,N,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621087,,7840,,,50588,10524,,
,BAO_0000218,,N,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622607,,7841,,,50588,9994,,
,BAO_0000218,,N,,Serum AUC in marmosets (IV dose),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622608,,7842,,,50588,11325,,
,BAO_0000019,,U,,Area under the curve after intravenous administration at a dose of 10 umol/kg,1,,,A,,,0,Autocuration,CHEMBL624481,,7843,,,22224,12536,,
,BAO_0000019,,U,,Area under the curve after intravenous administration at a dose of 2 umol/kg,1,,,A,,,0,Autocuration,CHEMBL624482,,7844,,,22224,12536,,
,BAO_0000019,,U,,Area under the curve after intravenous administration at a dose of 4 umol/kg,1,,,A,,,0,Autocuration,CHEMBL624483,,7845,,,22224,12536,,
,BAO_0000019,,U,,Area under the curve after intravenous administration at a dose of 40 umol/kg,1,,,A,,,0,Autocuration,CHEMBL624484,,7846,,,22224,12536,,
,BAO_0000019,,U,,Area under the curve after intravenous administration at a dose of 5 umol/kg,1,,,A,,,0,Autocuration,CHEMBL624485,,7847,,,22224,12536,,
,BAO_0000218,,N,,Area under the curve for fumarate salt was evaluated in F344 Rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624486,,7848,,,50597,15556,,
,BAO_0000019,,U,,Area under the curve for the compound was calculated.,1,,,A,,,0,Autocuration,CHEMBL624487,,7849,,,22224,2809,,
,BAO_0000019,,U,,Area under the curve in concentration/ time,1,,,A,,,0,Autocuration,CHEMBL624488,,7850,,,22224,9511,,
,BAO_0000218,,N,,Area under the curve administered intraintestinal in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624489,,7851,,,50597,12818,,
,BAO_0000218,,N,,Area under the curve administered intravenously in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625184,,7852,,,50597,12818,,
,BAO_0000019,,U,,Area under the curve during intravenous administration,1,,,A,,,0,Autocuration,CHEMBL625185,,7853,,,22224,15118,,
,BAO_0000019,,U,,Area under the curve during intravenous administration; Not determined,1,,,A,,,0,Autocuration,CHEMBL875954,,7854,,,22224,15118,,
,BAO_0000019,,U,,Area under the curve during systemic administration,1,,,A,,,0,Autocuration,CHEMBL625186,,7855,,,22224,15118,,
,BAO_0000019,,U,,Area under the curve during systemic administration; Not determined,1,,,A,,,0,Autocuration,CHEMBL625187,,7856,,,22224,15118,,
,BAO_0000019,,U,,Area under the curve was calculated for the compound.,1,,,A,,,0,Autocuration,CHEMBL625188,,7857,,,22224,2632,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625189,,7858,,,50588,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625190,,7859,,,50588,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621733,,7860,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621734,,7861,,,50597,14346,,
,BAO_0000218,,N,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621735,,7862,,,50597,11149,,
Plasma,BAO_0000218,,N,,Clearance of the drug was measured in the plasma of rat; No data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621736,,7863,,,50597,17796,,
Plasma,BAO_0000218,,N,,The pharmacokinetic parameter plasma clearance in vivo in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621737,,7864,,,50597,5247,,
,BAO_0000218,,N,,Plasma clearance at the dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621738,,7865,,,50597,4727,,
,BAO_0000218,,N,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622806,,7866,In vivo,,50597,5654,,
,BAO_0000218,,N,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623519,,7867,In vivo,,50597,5654,,
,BAO_0000218,,N,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623520,,7868,In vivo,,50597,17260,,
,BAO_0000218,,N,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623521,,7869,In vivo,,50597,17065,,
,BAO_0000218,,N,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623522,,7870,In vivo,,50597,17671,,
,BAO_0000218,,N,,Clearance rate in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623523,,7871,In vivo,,50597,6672,,
,BAO_0000218,,N,,Clearance rate in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623690,,7872,In vivo,,50597,6673,,
,BAO_0000218,,N,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623691,,7873,In vivo,,50597,5978,,
,BAO_0000218,,N,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623692,,7874,In vivo,,50597,5978,,
,BAO_0000218,,N,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623693,,7875,In vivo,,50597,5978,,
,BAO_0000218,,N,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623694,,7876,In vivo,,50597,5978,,
,BAO_0000218,,N,,Clearance of compound after iv administration of 20 mg/kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623695,,7877,In vivo,,50597,4413,,
,BAO_0000218,,N,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623696,,7878,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623697,,7879,In vivo,,50597,2661,,
Plasma,BAO_0000218,,U,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,9544.0,A,Macaca mulatta,1969.0,0,Intermediate,CHEMBL623698,,7880,In vivo,,22224,5005,,
Plasma,BAO_0000218,,U,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,0,Intermediate,CHEMBL623699,,7881,In vivo,,22224,5005,,
,BAO_0000218,,N,,Mean (%CV) PK parameters for CL(mL/min/kg).,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623700,,7882,In vivo,,50597,15765,,
,BAO_0000218,,N,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623701,,7883,In vivo,,50597,3747,,
Plasma,BAO_0000218,,N,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623702,,7884,In vivo,,50597,16366,,
,BAO_0000218,,N,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623703,,7885,In vivo,,50597,4199,,
,BAO_0000218,,N,,Plasma clearance in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623704,,7886,In vivo,,50597,17267,,
,BAO_0000218,,N,,Plasma clearance in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623705,,7887,In vivo,,50597,6535,,
,BAO_0000218,,N,,Plasma clearance in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623706,,7888,In vivo,,50597,6535,,
,BAO_0000218,,N,,Plasma clearance was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623707,,7889,In vivo,,50597,5041,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623708,,7890,In vivo,,50597,5960,,
,BAO_0000218,,N,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623709,,7891,In vivo,,50597,5937,,
,BAO_0000218,,N,,Plasma clearance in rat by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623710,,7892,In vivo,,50597,5871,,
,BAO_0000218,,N,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623711,,7893,In vivo,,50597,5874,,
,BAO_0000218,,N,,Plasma clearance in rat p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623712,,7894,In vivo,,50597,6504,,
,BAO_0000218,,N,,Plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623713,,7895,In vivo,,50597,6803,,
,BAO_0000218,,N,,Plasma clearance was determined; ND denotes no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623714,,7896,In vivo,,50597,5041,,
,BAO_0000218,,N,,Plasma clearance was determined; ND denotes not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623715,,7897,In vivo,,50597,5041,,
,BAO_0000218,,N,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623716,,7898,In vivo,,50597,1916,,
,BAO_0000218,,N,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622980,,7899,In vivo,,50597,5199,,
,BAO_0000218,,N,,Plasma administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622981,,7900,In vivo,,50597,16367,,
,BAO_0000218,,N,,Plasma clearance of the compound in female Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622982,,7901,In vivo,,50597,6362,,
,BAO_0000218,,N,,Plasma clearance was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622983,,7902,In vivo,,50597,15662,,
,BAO_0000218,,N,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622984,,7903,In vivo,,50597,6215,,
,BAO_0000218,,N,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622985,,7904,In vivo,,50597,1466,,
Plasma,BAO_0000218,,N,,plasma clearance was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623631,,7905,In vivo,,50597,15662,,
,BAO_0000218,,N,,In vivo CL/F determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623632,,7906,In vivo,,50597,4723,,
Plasma,BAO_0000218,,N,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623633,,7907,In vivo,,50597,2792,,
Plasma,BAO_0000218,,N,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623634,,7908,In vivo,,50597,2792,,
,BAO_0000218,,N,,Compound was tested for the lower blood clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623635,,7909,In vivo,,50597,5213,,
,BAO_0000218,,N,,Evaluated for the low clearance in rat (in vivo),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621195,,7910,In vivo,,50597,4687,,
,BAO_0000218,,N,,Pharmacokinetic property (CLb)of the compound was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621196,,7911,In vivo,,50597,3371,,
,BAO_0000218,,N,,Rapid clearance after intravenous administration in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875287,,7912,In vivo,,50597,4690,,
,BAO_0000218,,N,,Clearance measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621197,,7913,In vivo,,50597,5702,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621198,,7914,In vivo,,50597,740,,
Plasma,BAO_0000218,,N,,Low plasma clearance was calculated in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621199,,7915,In vivo,,50597,4853,,
,BAO_0000218,,N,,Pharmacokinetic property (Clp) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621200,,7916,In vivo,,50597,5789,,
,BAO_0000218,,N,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621201,,7917,In vivo,,50597,4527,,
,BAO_0000218,,N,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621202,,7918,In vivo,,50597,4527,,
,BAO_0000218,,N,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621203,,7919,In vivo,,50597,6518,,
,BAO_0000218,,N,,Plasma clearance after IV dosing at 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621204,,7920,In vivo,,50597,6518,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621205,,7921,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621206,,7922,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621207,,7923,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621208,,7924,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621209,,7925,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL876484,,7926,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621210,,7927,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621211,,7928,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621212,,7929,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621213,,7930,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621214,,7931,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621215,,7932,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621216,,7933,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621217,,7934,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621218,,7935,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621219,,7936,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621220,,7937,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621221,,7938,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621222,,7939,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621223,,7940,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL876485,,7941,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621224,,7942,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621225,,7943,In vivo,,50597,9866,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621226,,7944,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621227,,7945,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621228,,7946,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621229,,7947,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621230,,7948,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621231,,7949,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621232,,7950,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621233,,7951,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621234,,7952,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621235,,7953,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621236,,7954,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621237,,7955,In vivo,,50597,9866,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL876486,,7956,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622436,,7957,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622437,,7958,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622438,,7959,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622439,,7960,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622440,,7961,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622441,,7962,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622442,,7963,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622443,,7964,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622444,,7965,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622445,,7966,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622446,,7967,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622447,,7968,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622448,,7969,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622449,,7970,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622450,,7971,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622451,,7972,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622452,,7973,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622453,,7974,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622454,,7975,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622455,,7976,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL876024,,7977,In vivo,,50597,9866,,
,BAO_0000218,,N,,T max was determined at 3 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622456,,7978,In vivo,,50597,2792,,
,BAO_0000218,,N,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622457,,7979,In vivo,,50597,15078,,
,BAO_0000218,,N,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622458,,7980,In vivo,,50597,15078,,
,BAO_0000218,,N,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622459,,7981,,,50597,15022,,
,BAO_0000218,,N,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873343,,7982,,,50597,15022,,
,BAO_0000218,,N,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622460,,7983,,,50597,15022,,
Plasma,BAO_0000218,,N,,Time for maximum plasma concentration determined in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622461,,7984,,,50597,4576,,
Plasma,BAO_0000218,,N,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622462,,7985,In vivo,,50597,6681,,
,BAO_0000218,,N,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622463,,7986,In vivo,,50597,16365,,
,BAO_0000218,,N,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622464,,7987,In vivo,,50597,16365,,
,BAO_0000218,,N,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622465,,7988,In vivo,,50597,16365,,
,BAO_0000218,,N,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622466,,7989,In vivo,,50597,16365,,
,BAO_0000218,,N,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622467,,7990,In vivo,,50597,16365,,
Plasma,BAO_0000218,,N,,Time of maximum plasma concentration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622468,,7991,,,50597,6824,,
Plasma,BAO_0000218,,N,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876025,,7992,,,50597,6685,,
Plasma,BAO_0000218,,N,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622469,,7993,,,50597,6685,,
Plasma,BAO_0000218,,N,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622470,,7994,,,50597,6685,,
,BAO_0000218,,N,,Time required to reach maximum concentration (Cmax) after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622471,,7995,In vivo,,50597,15662,,
Plasma,BAO_0000218,,N,,Time required to reach maximum concentration in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622472,,7996,,,50597,1742,,
Plasma,BAO_0000218,,N,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622473,,7997,In vivo,,50597,2774,,
Plasma,BAO_0000218,,N,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624282,,7998,In vivo,,50597,5199,,
Plasma,BAO_0000218,,N,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624283,,7999,In vivo,,50597,12873,,
Plasma,BAO_0000218,,N,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624284,,8000,In vivo,,50597,12873,,
Plasma,BAO_0000218,,N,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624285,,8001,In vivo,,50597,1916,,
,BAO_0000218,,N,,Time to reach Cmax after oral administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624286,,8002,In vivo,,50597,16367,,
,BAO_0000218,,N,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624287,,8003,In vivo,,50597,16366,,
,BAO_0000218,,N,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624288,,8004,,,50597,216,,
Plasma,BAO_0000218,,N,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624289,,8005,In vivo,,50597,6410,,
Plasma,BAO_0000218,,N,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873344,,8006,In vivo,,50597,6410,,
,BAO_0000218,,N,,Tmax after peroral administration (10 mg/kg) was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619623,,8007,In vivo,,50597,6215,,
,BAO_0000218,,N,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL621399,,8008,In vivo,,50597,3598,,
,BAO_0000218,,N,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621400,,8009,In vivo,,50597,4527,,
,BAO_0000218,,N,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621401,,8010,In vivo,,50597,17670,,
,BAO_0000218,,N,,Tmax was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621402,,8011,,,50597,1465,,
,BAO_0000218,,N,,Tmax was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621403,,8012,,,50597,2552,,
,BAO_0000218,,N,,Tmax after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621121,,8013,In vivo,,50597,5656,,
,BAO_0000218,,N,,Tmax after peroral administration in rats at 2.4 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL872525,,8014,In vivo,,50597,17764,,
,BAO_0000218,,N,,Tmax in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621122,,8015,,,50597,5610,,
,BAO_0000218,,N,,Tmax in rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621123,,8016,In vivo,,50597,6046,,
,BAO_0000218,,N,,Tmax in rat by po administration at a dose of 40 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621124,,8017,In vivo,,50597,5874,,
,BAO_0000218,,N,,Tmax in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621125,,8018,,,50597,17596,,
,BAO_0000218,,N,,Tmax was measured in rats after peroral administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621126,,8019,In vivo,,50597,17804,,
,BAO_0000218,,N,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621127,,8020,In vivo,,50597,1908,,
,BAO_0000218,,N,,Tmax value after administration of 20 mg/Kg oral dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621128,,8021,In vivo,,50597,2959,,
,BAO_0000218,,N,,Tmax value at a dose of 10 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618263,,8022,In vivo,,50597,6757,,
,BAO_0000218,,N,,Tmax value at a dose of 100 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618264,,8023,In vivo,,50597,6757,,
,BAO_0000218,,N,,Tmax value at a dose of 50 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618265,,8024,In vivo,,50597,6757,,
Plasma,BAO_0000218,,N,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618266,,8025,In vivo,,50597,4186,,
,BAO_0000218,,N,,time required to reach maximum concentration (Cmax) after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618267,,8026,In vivo,,50597,15662,,
Urine,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL618450,,8027,,,50597,429,,
Urine,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL618451,,8028,,,50597,429,,
,BAO_0000218,,N,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618452,,8029,,,50597,5546,,
Urine,BAO_0000218,,N,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL618453,,8030,,,50597,3173,,
Urine,BAO_0000218,,N,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL618454,,8031,,,50597,3173,,
Urine,BAO_0000218,,N,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL618455,,8032,,,50597,3173,,
,BAO_0000218,,N,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618456,,8033,In vivo,,50597,4257,,
,BAO_0000218,,N,,Compound distribution in rat tissues was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618457,,8034,In vivo,,50597,6011,,
,BAO_0000218,,N,,Volume of distribution was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618458,,8035,In vivo,,50597,5472,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618459,,8036,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876733,,8037,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL618460,,8038,,,50588,14346,,
,BAO_0000218,,N,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618461,,8039,,,50597,14346,,
,BAO_0000019,,U,,Area under the curve was determined after oral administration (300 uM/Kg),1,,,A,,,0,Autocuration,CHEMBL618462,,8040,,,22224,15469,,
,BAO_0000218,,N,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618463,,8041,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618464,,8042,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618465,,8043,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618466,,8044,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618467,,8045,,,50597,14346,,
,BAO_0000218,,N,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618468,,8046,,,50597,15372,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618469,,8047,,,50588,12935,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL618470,,8048,,,50588,12935,,
,BAO_0000218,,U,,Plasma drug AUC in rat (PO dose),1,,,A,,,0,Autocuration,CHEMBL618471,,8049,,,22224,14813,,
,BAO_0000218,,N,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618472,,8050,,,50594,15792,,
,BAO_0000218,,U,,Area under was determined at a dose of 30 mg/kg,1,,,A,,,0,Autocuration,CHEMBL618473,,8051,,,22224,3579,,
,BAO_0000218,,N,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL621699,,8052,,,50506,12487,,
,BAO_0000218,,N,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621700,,8053,,,50597,12487,,
,BAO_0000218,,N,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621701,,8054,,,50597,12487,,
,BAO_0000218,,N,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL621702,,8055,,,50506,12487,,
,BAO_0000218,,N,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621703,,8056,,,50588,12487,,
,BAO_0000218,,N,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL621704,,8057,,,50588,12487,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624259,,8058,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624260,,8059,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624430,,8060,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624431,,8061,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624432,,8062,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624433,,8063,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624434,,8064,,,50597,12902,,
,BAO_0000218,,N,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624435,,8065,,,50597,12902,,
,BAO_0000218,,N,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618570,,8066,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618571,,8067,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618572,,8068,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618573,,8069,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619267,,8070,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619431,,8071,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619432,,8072,,,50594,12745,,
,BAO_0000218,,N,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619433,,8073,,,50594,12745,,
Plasma,BAO_0000218,,U,,AUC in mice after oral dose (50 mg/kg),1,,,A,,1969.0,0,Autocuration,CHEMBL619434,,8074,,,22224,13298,,
Serum,BAO_0000218,,N,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,1,,10090.0,A,Mus musculus,1977.0,1,Intermediate,CHEMBL619435,,8075,,,50594,12226,,
Plasma,BAO_0000019,,U,,AUC (0-4 hr) ug/ml/h,1,,,A,,1969.0,0,Autocuration,CHEMBL619436,,8076,,,22224,12634,,
,BAO_0000218,,N,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619437,,8077,,,50597,14810,,
,BAO_0000218,,U,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,1,,,A,,,0,Autocuration,CHEMBL619438,,8078,,,22224,13889,,
,BAO_0000218,,N,,Compound was evaluated for Area under curve in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619439,,8079,,,50594,10018,,
,BAO_0000218,,N,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619440,,8080,,,50597,8758,,
,BAO_0000218,,U,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,,F,,,0,Autocuration,CHEMBL619441,,8081,,,22224,8758,,
,BAO_0000218,,N,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619442,,8082,,,50597,8758,,
,BAO_0000019,,U,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,1,,,A,,,0,Autocuration,CHEMBL875156,,8083,,,22224,2249,,
,BAO_0000019,,U,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,1,,,A,,,0,Autocuration,CHEMBL619443,,8084,,,22224,2249,,
,BAO_0000019,,U,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,1,,,A,,,0,Autocuration,CHEMBL619444,,8085,,,22224,2249,,
,BAO_0000019,,U,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,1,,,A,,,0,Autocuration,CHEMBL623464,,8086,,,22224,2249,,
,BAO_0000218,,N,,Compound was evaluated for area under curve when administered through oral route in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623465,,8087,,,50594,15115,,
,BAO_0000218,,N,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623466,,8088,In vivo,,50597,6518,,
,BAO_0000218,,N,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623467,,8089,In vivo,,50597,6518,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623468,,8090,In vivo,,50597,6249,,
,BAO_0000218,,N,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622660,,8091,In vivo,,50597,2463,,
,BAO_0000218,,N,,Plasma clearance rate in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622661,,8092,In vivo,,50597,4969,,
,BAO_0000218,,N,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL622662,,8093,In vivo,,50597,17720,,
,BAO_0000218,,N,,Pharmacokinetic property (total body clearance) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622663,,8094,In vivo,,50597,3457,,
,BAO_0000218,,N,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622664,,8095,In vivo,,50597,5983,,
,BAO_0000218,,N,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622665,,8096,,,50597,6295,,
,BAO_0000218,,N,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622666,,8097,,,50597,6296,,
,BAO_0000218,,N,,Cl in rat i.v. at 2 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621615,,8098,In vivo,,50597,17686,,
,BAO_0000218,,N,,Clearance of compound after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621616,,8099,In vivo,,50597,17764,,
,BAO_0000218,,N,,Clearance was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621617,,8100,In vivo,,50597,5503,,
,BAO_0000218,,N,,Clearance by intravenous administration of 3.4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621618,,8101,In vivo,,50597,4368,,
,BAO_0000218,,N,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621619,,8102,In vivo,,50597,6005,,
,BAO_0000218,,N,,Clearance rate after i.v. administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621620,,8103,In vivo,,50597,5031,,
,BAO_0000218,,N,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621786,,8104,In vivo,,50597,4890,,
,BAO_0000218,,N,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621787,,8105,In vivo,,50597,5182,,
,BAO_0000218,,N,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621788,,8106,In vivo,,50597,5979,,
,BAO_0000218,,N,,Clearance (Cl) after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621789,,8107,In vivo,,50597,5656,,
,BAO_0000218,,N,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621790,,8108,In vivo,,50597,17804,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621791,,8109,In vivo,,50597,4839,,
,BAO_0000218,,N,Microsomes,In vitro microsome metabolism clearance in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621792,,8110,In vitro,,50597,5041,,
,BAO_0000218,,N,Microsomes,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621793,,8111,In vitro,,50597,5041,,
,BAO_0000218,,N,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621794,,8112,In vivo,,50597,5974,,
Plasma,BAO_0000218,,N,,In vivo plasma clearance was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621795,,8113,In vivo,,50597,5496,,
,BAO_0000218,,N,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621796,,8114,In vivo,,50597,5739,,
Liver,BAO_0000218,,N,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,1,Hepatocyte,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621797,,8115,In vivo,,50597,5676,401.0,
,BAO_0000218,,N,,Pharmacokinetic property (Plasma clearance) was measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621798,,8116,In vivo,,50597,4239,,
,BAO_0000218,,N,,Pharmacokinetic property (clearance) in rat i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621799,,8117,In vivo,,50597,5676,,
,BAO_0000218,,N,,"Plasma Clearance was evaluated in rats, iv",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621800,,8118,In vivo,,50597,1918,,
,BAO_0000218,,N,,Plasma clearance (in vivo) in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621801,,8119,In vivo,,50597,17800,,
,BAO_0000218,,N,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621802,,8120,In vivo,,50597,6056,,
,BAO_0000218,,N,,Plasma clearance was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618596,,8121,In vivo,,50597,5496,,
,BAO_0000218,,N,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618597,,8122,In vivo,,50597,5939,,
,BAO_0000218,,N,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618598,,8123,In vivo,,50597,5939,,
,BAO_0000218,,N,,Plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618599,,8124,In vivo,,50597,17752,,
,BAO_0000218,,N,,Plasma clearance rate determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618600,,8125,In vivo,,50597,4576,,
,BAO_0000218,,N,,Plasma clearance was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618601,,8126,In vivo,,50597,6011,,
,BAO_0000218,,N,,Plasma clearance was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618602,,8127,In vivo,,50597,5510,,
,BAO_0000218,,N,,Plasma clearance value in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618603,,8128,In vivo,,50597,5948,,
Liver,BAO_0000218,,N,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL618604,,8129,Ex vivo,,50597,6125,,
,BAO_0000218,,N,,Clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618605,,8130,In vivo,,50597,4839,,
,BAO_0000218,,N,,Total body clearance in rat i.v. at 2 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618606,,8131,In vivo,,50597,17686,,
,BAO_0000218,,N,,Clearance of compound in rats after intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618607,,8132,In vivo,,50597,6571,,
,BAO_0000218,,N,,Clearance after iv administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618608,,8133,In vivo,,50597,3364,,
,BAO_0000218,,N,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618609,,8134,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618610,,8135,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618611,,8136,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618612,,8137,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618613,,8138,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621076,,8139,In vivo,,50597,13569,,
,BAO_0000218,,N,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621077,,8140,In vivo,,50597,13569,,
,BAO_0000218,,N,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621078,,8141,In vivo,,50597,17670,,
,BAO_0000218,,N,,Clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621251,,8142,In vivo,,50597,5970,,
,BAO_0000218,,N,,Clearance in rat after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621252,,8143,In vivo,,50597,6495,,
,BAO_0000218,,N,,Clearance in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621253,,8144,In vivo,,50597,4590,,
,BAO_0000218,,N,,Clearance rate following an oral dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621254,,8145,In vivo,,50597,6193,,
,BAO_0000218,,N,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621255,,8146,In vivo,,50597,2832,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621256,,8147,In vivo,,50597,1052,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621257,,8148,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621258,,8149,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621259,,8150,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621260,,8151,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL876494,,8152,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621261,,8153,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621262,,8154,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621263,,8155,In vivo,,50597,9866,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621264,,8156,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621265,,8157,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621266,,8158,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621267,,8159,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621268,,8160,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621269,,8161,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621270,,8162,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621271,,8163,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621272,,8164,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621273,,8165,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621274,,8166,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL876495,,8167,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621275,,8168,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621276,,8169,In vivo,,50597,9866,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621277,,8170,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621278,,8171,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621279,,8172,In vivo,,50597,9866,,
Intestine,BAO_0000218,,N,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621280,,8173,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621281,,8174,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621282,,8175,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621283,,8176,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621284,,8177,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621285,,8178,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621286,,8179,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL623220,,8180,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL623221,,8181,In vivo,,50597,9866,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL876029,,8182,In vivo,,50597,9866,,
Stomach,BAO_0000218,,N,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL623222,,8183,In vivo,,50597,9866,,
Stomach,BAO_0000218,,N,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL623223,,8184,In vivo,,50597,9866,,
Stomach,BAO_0000218,,N,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL621445,,8185,In vivo,,50597,9866,,
Blood,BAO_0000218,,N,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621446,,8186,In vivo,,50597,13950,,
Blood,BAO_0000218,,N,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621447,,8187,In vivo,,50597,13950,,
Blood,BAO_0000218,,N,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL619681,,8188,In vivo,,50597,13950,,
Blood,BAO_0000218,,N,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL619682,,8189,In vivo,,50597,13950,,
Blood,BAO_0000218,,N,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL619683,,8190,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619684,,8191,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619685,,8192,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619686,,8193,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619687,,8194,In vivo,,50597,13950,,
Brain,BAO_0000218,,N,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619688,,8195,In vivo,,50597,13950,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL619689,,8196,In vivo,,50597,13950,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL619690,,8197,In vivo,,50597,13950,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL619691,,8198,In vivo,,50597,13950,,
,BAO_0000218,,N,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619692,,8199,In vivo,,50597,6062,,
,BAO_0000218,,N,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL619693,,8200,,,50597,3598,,
,BAO_0000218,,N,,Vc value after IV dose at a dose of 5 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619694,,8201,In vivo,,50597,1908,,
,BAO_0000218,,N,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619695,,8202,In vivo,,50597,17596,,
,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic parameter volume of distribution,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619696,,8203,In vivo,,50597,4891,,
,BAO_0000218,,N,,Compound was evaluated for volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619697,,8204,In vivo,,50597,740,,
,BAO_0000218,,N,,Steady state volume distribution was determined; steady state(ss),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619698,,8205,In vivo,,50597,16366,,
,BAO_0000218,,N,,Steady state volume of distribution after iv administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619699,,8206,In vivo,,50597,3364,,
,BAO_0000218,,N,,Steady state volume of distribution dosing at 3 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619700,,8207,In vivo,,50597,2552,,
,BAO_0000218,,N,,The compound was evaluated for volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619701,,8208,In vivo,,50597,406,,
,BAO_0000218,,N,,The compound was tested for volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL619702,,8209,In vivo,,50597,12500,,
,BAO_0000218,,N,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620335,,8210,In vivo,,50597,12500,,
,BAO_0000218,,N,,Volume distribution (VD) after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620336,,8211,In vivo,,50597,5656,,
,BAO_0000218,,N,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620337,,8212,In vivo,,50597,17671,,
,BAO_0000218,,N,,Volume distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620520,,8213,In vivo,,50597,1094,,
,BAO_0000218,,N,,Volume distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620521,,8214,In vivo,,50597,5833,,
,BAO_0000218,,N,,Volume distribution in rat after peroral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875825,,8215,In vivo,,50597,5939,,
,BAO_0000218,,N,,Volume distribution in rat after peroral administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620522,,8216,In vivo,,50597,5939,,
,BAO_0000218,,N,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620523,,8217,In vivo,,50597,6005,,
,BAO_0000218,,N,,Volume of distribution in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620524,,8218,In vivo,,50597,1696,,
,BAO_0000218,,N,,Volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620525,,8219,In vivo,,50597,6672,,
,BAO_0000218,,N,,Volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620526,,8220,In vivo,,50597,6673,,
,BAO_0000218,,N,,Volume of distribution in rat by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620527,,8221,In vivo,,50597,5871,,
,BAO_0000218,,N,,Volume of distribution in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620528,,8222,In vivo,,50597,6803,,
,BAO_0000218,,N,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620529,,8223,In vivo,,50597,5199,,
,BAO_0000218,,N,,Volume distribution at the dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620530,,8224,,,50597,4727,,
,BAO_0000218,,N,,Steady state volume of distribution was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620531,,8225,In vivo,,50597,16367,,
,BAO_0000218,,U,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,1,,9544.0,A,Macaca mulatta,,0,Intermediate,CHEMBL620532,,8226,In vivo,,22224,5005,,
,BAO_0000218,,U,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL620533,,8227,In vivo,,22224,5005,,
,BAO_0000218,,U,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL620534,,8228,In vivo,,22224,5005,,
,BAO_0000218,,N,,Mean (%CV) PK parameters for Vdss(mL/kg).,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620535,,8229,In vivo,,50597,15765,,
,BAO_0000218,,N,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875826,,8230,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620536,,8231,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620537,,8232,In vivo,,50597,5334,,
,BAO_0000218,,N,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618526,,8233,In vivo,,50597,5334,,
,BAO_0000218,,N,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618527,,8234,In vivo,,50597,5739,,
,BAO_0000218,,N,,Pharmacokinetic property (Vdss) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618528,,8235,In vivo,,50597,5789,,
,BAO_0000218,,N,,Pharmacokinetic property (vdss) was measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618529,,8236,In vivo,,50597,4239,,
,BAO_0000218,,N,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618530,,8237,In vivo,,50597,4709,,
,BAO_0000218,,N,,Volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618531,,8238,In vivo,,50597,6642,,
,BAO_0000218,,N,,The pharmacokinetic parameter volume of distribution in vivo in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618532,,8239,In vivo,,50597,5247,,
,BAO_0000218,,N,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL618533,,8240,In vivo,,50597,17720,,
,BAO_0000218,,N,,Vdss in rat i.v. at 2 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618534,,8241,In vivo,,50597,17686,,
,BAO_0000218,,N,,Volume distribution after intravenous administration (1 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618535,,8242,In vivo,,50597,4689,,
,BAO_0000218,,N,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618536,,8243,In vivo,,50597,5654,,
,BAO_0000218,,N,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618537,,8244,In vivo,,50597,5654,,
,BAO_0000218,,N,,Volume distribution at a dose of 10 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618538,,8245,In vivo,,50597,4527,,
,BAO_0000218,,N,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618539,,8246,In vivo,,50597,4521,,
,BAO_0000218,,N,,Volume distribution was calculated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618540,,8247,In vivo,,50597,6057,,
,BAO_0000218,,N,,Volume distribution was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618541,,8248,In vivo,,50597,5510,,
,BAO_0000218,,N,,Volume of distribution after intravenous administration was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618542,,8249,In vivo,,50597,2938,,
,BAO_0000218,,N,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622544,,8250,In vivo,,50597,6679,,
,BAO_0000218,,N,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622545,,8251,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622546,,8252,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622547,,8253,In vivo,,50597,6685,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622548,,8254,In vivo,,50597,5145,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622549,,8255,In vivo,,50597,6467,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622550,,8256,In vivo,,50597,6467,,
,BAO_0000218,,N,,Compound was evaluated for area under curve when administered through oral route to mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622551,,8257,,,50594,15115,,
,BAO_0000218,,N,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622552,,8258,,,50597,8758,,
,BAO_0000218,,N,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622553,,8259,,,50597,8758,,
,BAO_0000218,,U,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,1,,,F,,,0,Autocuration,CHEMBL622554,,8260,In vivo,,22224,8267,,
,BAO_0000218,,N,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622555,,8261,,,50588,8267,,
,BAO_0000218,,N,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622556,,8262,,,50594,14239,,
,BAO_0000218,,N,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622557,,8263,,,50594,14239,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622558,,8264,,,50594,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622559,,8265,,,50594,10754,,
,BAO_0000218,,N,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622560,,8266,,,50588,10754,,
,BAO_0000218,,N,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622561,,8267,,,50597,14681,,
,BAO_0000218,,N,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622562,,8268,,,50597,14681,,
,BAO_0000218,,N,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622563,,8269,,,50597,14681,,
,BAO_0000019,,U,,Concentration of compound in Central nervous system,1,,,A,,,0,Autocuration,CHEMBL622564,,8270,,,22224,13118,,
,BAO_0000019,,U,,Concentration of compound in Central nervous system; Not detectable,1,,,A,,,0,Autocuration,CHEMBL622565,,8271,,,22224,13118,,
,BAO_0000218,,N,,"Concentration of diester in the blood, following oral administration in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622566,,8272,,,50594,13318,,
,BAO_0000218,,N,,"Concentration of monoester in the blood, following oral administration in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624515,,8273,,,50594,13318,,
,BAO_0000218,,N,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624516,,8274,,,50594,13318,,
,BAO_0000019,,U,,Evaluated for Pharmacokinetic property: Area under the curve,1,,,A,,,0,Autocuration,CHEMBL624517,,8275,,,22224,15692,,
,BAO_0000218,,N,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624518,,8276,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624519,,8277,,,100710,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624520,,8278,,,100710,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624521,,8279,,,100710,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624522,,8280,,,100710,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624523,,8281,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624409,,8282,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624410,,8283,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL624411,,8284,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623531,,8285,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623532,,8286,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623533,,8287,,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623534,,8288,,,100710,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623535,,8289,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623536,,8290,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623537,,8291,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623538,,8292,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623539,,8293,,,50594,14839,,
,BAO_0000218,,N,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623540,,8294,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623541,,8295,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623542,,8296,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623543,,8297,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623544,,8298,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623545,,8299,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623546,,8300,,,50594,14839,,
Plasma,BAO_0000218,,N,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623547,,8301,In vivo,,50597,5408,,
,BAO_0000218,,N,,High i.v. clearance in Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623548,,8302,In vivo,,50597,6827,,
Liver,BAO_0000218,,N,Microsomes,In vitro clearance in rat liver microsomes,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623549,,8303,In vitro,,50597,17538,,
Liver,BAO_0000218,,N,Microsomes,Intrinsic clearance in rat liver microsomes was determined,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623550,,8304,In vitro,,50597,6331,,
Liver,BAO_0000218,,N,,Intrinsic clearance in rat hepatocytes was determined,1,Hepatocyte,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL875276,,8305,In vitro,,50597,5948,401.0,
,BAO_0000218,,N,,Plasma Clearance was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621872,,8306,In vivo,,50597,4026,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621873,,8307,In vivo,,50597,6647,,
,BAO_0000218,,N,,Plasma clearance in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621874,,8308,In vivo,,50597,1696,,
,BAO_0000218,,N,,Plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621875,,8309,In vivo,,50597,6597,,
,BAO_0000218,,N,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621876,,8310,In vivo,,50597,347,,
,BAO_0000218,,N,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621877,,8311,In vivo,,50597,16423,,
,BAO_0000218,,N,,Plasma clearance was measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621878,,8312,In vivo,,50597,2879,,
,BAO_0000218,,N,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621879,,8313,In vivo,,50597,4883,,
Plasma,BAO_0000218,,N,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621880,,8314,In vivo,,50597,5328,,
,BAO_0000218,,N,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621881,,8315,In vivo,,50597,5160,,
,BAO_0000218,,N,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621882,,8316,In vivo,,50597,17582,,
,BAO_0000218,,N,,Total clearance at 1 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875283,,8317,In vivo,,50597,17651,,
,BAO_0000218,,N,,Total clearance at 10 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621883,,8318,In vivo,,50597,17651,,
,BAO_0000218,,N,,Clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621884,,8319,In vivo,,50597,6596,,
,BAO_0000218,,N,,Plasma clearance rate determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621885,,8320,In vivo,,50597,4796,,
,BAO_0000218,,N,,Clearance of compound in rat was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621886,,8321,In vivo,,50597,6850,,
Plasma,BAO_0000218,,N,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621887,,8322,In vivo,,50597,5932,,
,BAO_0000218,,N,,Pharmacokinetic property (blood clearance) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621888,,8323,In vivo,,50597,3371,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621889,,8324,In vivo,,50597,2083,,
,BAO_0000218,,N,,Plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621890,,8325,In vivo,,50597,4942,,
Liver,BAO_0000218,,N,Microsomes,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621891,,8326,In vitro,,50597,6838,,
,BAO_0000218,,N,,Clearance in Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621892,,8327,In vivo,,50597,5353,,
,BAO_0000218,,N,,Clearance rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621893,,8328,In vivo,,50597,6641,,
,BAO_0000218,,N,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621894,,8329,In vivo,,50597,6641,,
,BAO_0000218,,N,,Clearance rat; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621895,,8330,In vivo,,50597,6641,,
,BAO_0000218,,N,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875284,,8331,In vivo,,50597,6444,,
,BAO_0000218,,N,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618699,,8332,In vivo,,50597,6444,,
,BAO_0000218,,N,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618700,,8333,In vivo,,50597,6444,,
,BAO_0000218,,N,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618701,,8334,In vivo,,50597,6211,,
Plasma,BAO_0000218,,N,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876600,,8335,In vivo,,50597,12873,,
,BAO_0000218,,N,,Clearance of compound in rat after 1 mg/kg i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618702,,8336,In vivo,,50597,6570,,
,BAO_0000218,,N,,Compound was evaluated for Hepatic clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618703,,8337,In vivo,,50597,3341,,
,BAO_0000218,,N,,In vivo clearance after 5 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618704,,8338,In vivo,,50597,4891,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618705,,8339,In vivo,,50597,1094,,
,BAO_0000218,,N,,Hepatic clearance after intravenous administration was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618706,,8340,In vivo,,50597,2938,,
,BAO_0000218,,N,,Lower clearance in rat (i.v.) at 0.5 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618707,,8341,In vivo,,50597,17853,,
Plasma,BAO_0000218,,N,,Pharmacokinetic parameter expressed as plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618708,,8342,In vivo,,50597,6049,,
,BAO_0000218,,N,,Pharmacokinetic property (Clp) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618709,,8343,In vivo,,50597,5789,,
,BAO_0000218,,N,,Plasma clearance in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618710,,8344,In vivo,,50597,4514,,
,BAO_0000218,,N,,Plasma clearance (Clp) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618711,,8345,In vivo,,50597,6448,,
,BAO_0000218,,N,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618712,,8346,In vivo,,50597,6062,,
,BAO_0000218,,N,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618713,,8347,In vivo,,50597,5710,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618714,,8348,In vivo,,50597,4709,,
,BAO_0000218,,N,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618715,,8349,In vivo,,50597,4521,,
,BAO_0000218,,N,,Plasma clearance in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618716,,8350,In vivo,,50597,1742,,
,BAO_0000218,,N,,Plasma clearance measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876601,,8351,In vivo,,50597,6057,,
,BAO_0000218,,N,,Plasma clearance was calculated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618717,,8352,In vivo,,50597,6057,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618718,,8353,In vivo,,50597,5145,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618719,,8354,In vivo,,50597,5833,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618720,,8355,In vivo,,50597,6453,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618721,,8356,In vivo,,50597,6640,,
,BAO_0000218,,N,,Plasma clearance in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621477,,8357,In vivo,,50597,6305,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621478,,8358,In vivo,,50597,6642,,
,BAO_0000218,,N,,Plasma clearance was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621479,,8359,In vivo,,50597,5472,,
,BAO_0000218,,N,,Plasma clearance was evaluated in rat; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621480,,8360,In vivo,,50597,5472,,
,BAO_0000218,,N,,Plasma clearance rate was determined for the compound in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621481,,8361,In vivo,,50597,5144,,
,BAO_0000218,,N,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621482,,8362,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621483,,8363,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621484,,8364,In vivo,,50597,6685,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621485,,8365,In vivo,,50597,13950,,
Heart,BAO_0000218,,N,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL621486,,8366,In vivo,,50597,13950,,
Intestine,BAO_0000218,,N,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621487,,8367,In vivo,,50597,13950,,
Intestine,BAO_0000218,,N,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621488,,8368,In vivo,,50597,13950,,
Intestine,BAO_0000218,,N,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621489,,8369,In vivo,,50597,13950,,
Intestine,BAO_0000218,,N,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621490,,8370,In vivo,,50597,13950,,
Intestine,BAO_0000218,,N,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL621491,,8371,In vivo,,50597,13950,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621492,,8372,In vivo,,50597,13950,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621493,,8373,In vivo,,50597,13950,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621494,,8374,In vivo,,50597,13950,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621495,,8375,In vivo,,50597,13950,,
Kidney,BAO_0000218,,N,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621496,,8376,In vivo,,50597,13950,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621497,,8377,In vivo,,50597,13950,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621498,,8378,In vivo,,50597,13950,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621499,,8379,In vivo,,50597,13950,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL618634,,8380,In vivo,,50597,13950,,
Liver,BAO_0000218,,N,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL618635,,8381,In vivo,,50597,13950,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL618636,,8382,In vivo,,50597,13950,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL619737,,8383,In vivo,,50597,13950,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL619738,,8384,In vivo,,50597,13950,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624329,,8385,In vivo,,50597,13950,,
Lung,BAO_0000218,,N,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624330,,8386,In vivo,,50597,13950,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624331,,8387,In vivo,,50597,13950,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624332,,8388,In vivo,,50597,13950,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624333,,8389,In vivo,,50597,13950,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624334,,8390,In vivo,,50597,13950,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624335,,8391,In vivo,,50597,13950,,
Spleen,BAO_0000218,,N,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL620016,,8392,In vivo,,50597,13950,,
Spleen,BAO_0000218,,N,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL620169,,8393,In vivo,,50597,13950,,
Spleen,BAO_0000218,,N,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL620170,,8394,In vivo,,50597,13950,,
Spleen,BAO_0000218,,N,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL620171,,8395,In vivo,,50597,13950,,
Spleen,BAO_0000218,,N,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL620172,,8396,In vivo,,50597,13950,,
Stomach,BAO_0000218,,N,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL620173,,8397,In vivo,,50597,13950,,
Stomach,BAO_0000218,,N,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL620174,,8398,In vivo,,50597,13950,,
Stomach,BAO_0000218,,N,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL620175,,8399,In vivo,,50597,13950,,
Stomach,BAO_0000218,,N,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL620176,,8400,In vivo,,50597,13950,,
Stomach,BAO_0000218,,N,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL620177,,8401,In vivo,,50597,13950,,
Cerebellum,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL620178,,8402,,,50597,13950,,
Cerebellum,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL620179,,8403,,,50597,13950,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620180,,8404,,,50597,13950,,
,BAO_0000218,,N,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620181,,8405,In vivo,,50597,6570,,
,BAO_0000218,,N,,Volume of distribution of compound in rats after intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620182,,8406,In vivo,,50597,6571,,
,BAO_0000218,,N,,Volume of distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620183,,8407,In vivo,,50597,6453,,
,BAO_0000218,,N,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620184,,8408,In vivo,,50597,6444,,
,BAO_0000218,,N,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620185,,8409,In vivo,,50597,6444,,
,BAO_0000218,,N,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620186,,8410,In vivo,,50597,6444,,
,BAO_0000218,,N,,Volume of distribution was determined in Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620187,,8411,In vivo,,50597,5353,,
,BAO_0000218,,N,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620188,,8412,In vivo,,50597,5334,,
,BAO_0000218,,N,,Volume of distribution was reported in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620189,,8413,In vivo,,50597,5334,,
,BAO_0000218,,N,,Volumes of distribution in rat after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620190,,8414,In vivo,,50597,6641,,
,BAO_0000218,,N,,Volumes of distribution in rat after po administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620191,,8415,In vivo,,50597,6641,,
,BAO_0000218,,N,,Volumes of distribution in rat after po administration; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620192,,8416,In vivo,,50597,6641,,
,BAO_0000218,,N,,Pharmacokinetic property (Volume) in rat i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620193,,8417,In vivo,,50597,5676,,
,BAO_0000218,,N,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620194,,8418,In vivo,,50597,6410,,
,BAO_0000218,,N,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876730,,8419,In vivo,,50597,17670,,
,BAO_0000218,,N,,Volume distribution in rat after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620195,,8420,In vivo,,50597,6495,,
,BAO_0000218,,N,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620196,,8421,In vivo,,50597,5408,,
,BAO_0000218,,N,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620197,,8422,In vivo,,50597,4883,,
,BAO_0000218,,N,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620198,,8423,In vivo,,50597,6647,,
,BAO_0000218,,N,,Volume of distribution in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620199,,8424,In vivo,,50597,6495,,
,BAO_0000218,,N,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620200,,8425,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620201,,8426,In vivo,,50597,2661,,
,BAO_0000218,,N,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620202,,8427,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620203,,8428,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620204,,8429,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620205,,8430,In vivo,,50597,5974,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Vss) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624664,,8431,In vivo,,50597,5960,,
,BAO_0000218,,N,,Pharmacokinetic property (Volume) in rat i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624665,,8432,In vivo,,50597,5676,,
,BAO_0000218,,N,,Pharmacokinetic property (Vss) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624666,,8433,,,50597,5948,,
,BAO_0000218,,N,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624667,,8434,In vivo,,50597,5979,,
,BAO_0000218,,N,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624668,,8435,In vivo,,50597,5978,,
,BAO_0000218,,N,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624669,,8436,In vivo,,50597,5978,,
,BAO_0000218,,N,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624670,,8437,In vivo,,50597,5978,,
,BAO_0000218,,N,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624671,,8438,In vivo,,50597,5978,,
,BAO_0000218,,N,,Steady state volume distribution in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624672,,8439,In vivo,,50597,6448,,
Plasma,BAO_0000218,,N,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624673,,8440,In vivo,,50597,12873,,
,BAO_0000218,,N,,Steady state volume of distribution determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624674,,8441,In vivo,,50597,4576,,
,BAO_0000218,,N,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624675,,8442,In vivo,,50597,17582,,
,BAO_0000218,,N,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621728,,8443,In vivo,,50597,1466,,
,BAO_0000218,,N,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621729,,8444,,,50597,5182,,
,BAO_0000218,,N,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621730,,8445,,,50597,5182,,
,BAO_0000218,,N,,Volume distribution in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621731,,8446,In vivo,,50597,6535,,
,BAO_0000218,,N,,Volume distribution in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621732,,8447,In vivo,,50597,6535,,
,BAO_0000218,,N,,Volume in steady state distribution value was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621908,,8448,In vivo,,50597,5041,,
,BAO_0000218,,N,,Volume in steady state distribution value was determined; ND denotes no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875347,,8449,In vivo,,50597,5041,,
,BAO_0000218,,N,,Volume in steady state distribution value was determined; ND denotes not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621909,,8450,In vivo,,50597,5041,,
,BAO_0000218,,N,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621910,,8451,In vivo,,50597,17065,,
,BAO_0000218,,N,,Volume of distribution at steady state was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621911,,8452,In vivo,,50597,6597,,
,BAO_0000218,,N,,Volume of distribution at steady state was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621912,,8453,In vivo,,50597,15662,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621913,,8454,In vivo,,50597,6485,,
,BAO_0000218,,N,,Volume of distribution in steady state was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621914,,8455,In vivo,,50597,17655,,
,BAO_0000218,,N,,Volume of distribution after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621915,,8456,In vivo,,50597,6616,,
,BAO_0000218,,N,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621916,,8457,In vivo,,50597,1916,,
Liver,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621917,,8458,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL621918,,8459,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,Biodistribution of compound (oxidized form) in spleen tissue,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621919,,8460,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621920,,8461,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL621921,,8462,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL622401,,8463,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL875348,,8464,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL622402,,8465,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622403,,8466,In vivo,,50594,16438,,
Blood,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL622404,,8467,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622405,,8468,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622406,,8469,In vivo,,50594,16438,,
Brain,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622407,,8470,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622408,,8471,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622409,,8472,In vivo,,50594,16438,,
Heart,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL622410,,8473,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL622411,,8474,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL627864,,8475,In vivo,,50594,16438,,
Kidney,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL627865,,8476,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627866,,8477,In vivo,,50594,16438,,
Liver,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627751,,8478,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL627752,,8479,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL627753,,8480,In vivo,,50594,16438,,
Spleen,BAO_0000218,,N,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL627754,,8481,In vivo,,50594,16438,,
,BAO_0000218,,N,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627755,,8482,,,50594,12467,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627756,,8483,In vivo,,50594,17208,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627757,,8484,In vivo,,50594,17208,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627758,,8485,In vivo,,50594,17208,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627759,,8486,In vivo,,50594,17208,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627760,,8487,In vivo,,50594,17208,,
Brain,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627761,,8488,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL876811,,8489,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL627762,,8490,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL627763,,8491,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL627764,,8492,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL627765,,8493,In vivo,,50594,17208,,
Heart,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL627766,,8494,In vivo,,50594,17208,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL627767,,8495,In vivo,,50594,17208,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL627768,,8496,In vivo,,50594,17208,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL628422,,8497,In vivo,,50594,17208,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL628423,,8498,In vivo,,50594,17208,,
,BAO_0000218,,N,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628424,,8499,In vivo,,50597,5089,,
,BAO_0000218,,N,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628425,,8500,In vivo,,50597,5089,,
,BAO_0000218,,N,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628426,,8501,In vivo,,50597,4257,,
,BAO_0000218,,N,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628427,,8502,In vivo,,50597,6679,,
,BAO_0000218,,N,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626938,,8503,In vivo,,50597,5546,,
,BAO_0000218,,N,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626939,,8504,In vivo,,50597,6141,,
,BAO_0000218,,N,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626940,,8505,In vivo,,50597,5334,,
,BAO_0000218,,N,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626941,,8506,In vivo,,50597,5334,,
,BAO_0000218,,N,,Plasma clearance was reported in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626942,,8507,In vivo,,50597,5334,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration (1 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876812,,8508,In vivo,,50597,4689,,
,BAO_0000218,,N,,Plasma clearance of compound in rats was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626943,,8509,In vivo,,50597,6848,,
,BAO_0000218,,N,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626944,,8510,In vivo,,50597,6848,,
,BAO_0000218,,N,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626945,,8511,In vivo,,50597,6467,,
,BAO_0000218,,N,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626946,,8512,In vivo,,50597,6467,,
,BAO_0000218,,N,,Plasma clearance rate in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626856,,8513,In vivo,,50597,4956,,
,BAO_0000218,,N,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626857,,8514,In vivo,,50597,5529,,
Plasma,BAO_0000218,,N,,The compound was evaluated for plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626858,,8515,In vivo,,50597,406,,
Plasma,BAO_0000218,,N,,Total plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627018,,8516,In vivo,,50597,17655,,
Blood,BAO_0000218,,N,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625331,,8517,In vivo,,50597,3293,,
Blood,BAO_0000218,,N,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625332,,8518,In vivo,,50597,4075,,
,BAO_0000218,,N,,C max was determined at 10 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877590,,8519,In vivo,,50597,2792,,
,BAO_0000218,,N,,C max was determined at 3 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625333,,8520,In vivo,,50597,2792,,
,BAO_0000218,,N,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625334,,8521,In vivo,,50597,17594,,
,BAO_0000218,,N,,Cmax after single intravenous bolus of 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625335,,8522,In vivo,,50597,17594,,
,BAO_0000218,,N,,Cmax of compound at 5 mg/kg after po administration was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625336,,8523,In vivo,,50597,4762,,
,BAO_0000218,,N,,Cmax 24 hr after 10 mg/kg oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625337,,8524,In vivo,,50597,17509,,
,BAO_0000218,,N,,Cmax 24 hr after 2 mg/kg oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625338,,8525,In vivo,,50597,17509,,
Plasma,BAO_0000218,,N,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625339,,8526,In vivo,,50597,1466,,
,BAO_0000218,,N,,Cmax in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625340,,8527,In vivo,,50597,6535,,
,BAO_0000218,,N,,Cmax in rat after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625341,,8528,In vivo,,50597,6535,,
,BAO_0000218,,N,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622687,,8529,In vivo,,50597,3169,,
Plasma,BAO_0000218,,N,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622688,,8530,In vivo,,50597,6515,,
Blood,BAO_0000218,,N,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622689,,8531,In vivo,,50597,11149,,
Blood,BAO_0000218,,N,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL620295,,8532,In vivo,,50597,11149,,
,BAO_0000218,,N,,Cmax after 10 mg/kg oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620296,,8533,In vivo,,50597,17858,,
,BAO_0000218,,N,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620297,,8534,In vivo,,50597,6518,,
,BAO_0000218,,N,,Cmax after IV dosing at 1 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620298,,8535,In vivo,,50597,6518,,
,BAO_0000218,,N,,Cmax after oral administration at 20 mpk in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620299,,8536,In vivo,,50597,4426,,
,BAO_0000218,,N,,Cmax after oral administration at 20 mpk in rats; Not performed.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620300,,8537,In vivo,,50597,4426,,
,BAO_0000218,,N,,Cmax after oral administration at 20 mpk in rats d; Not performed.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620301,,8538,In vivo,,50597,4426,,
,BAO_0000218,,N,,Cmax after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620302,,8539,In vivo,,50597,5656,,
,BAO_0000218,,N,,Cmax after oral administration at a dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620303,,8540,In vivo,,50597,6518,,
,BAO_0000218,,N,,Cmax after oral administration at a dose of 4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620304,,8541,In vivo,,50597,6518,,
,BAO_0000218,,N,,Cmax in rats after 20 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620305,,8542,In vivo,,50597,6113,,
,BAO_0000218,,N,,Cmax after peroral administration in rats at 2.4 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620306,,8543,In vivo,,50597,17764,,
,BAO_0000218,,N,,Cmax at the dose of 2 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620307,,8544,In vivo,,50597,4756,,
,BAO_0000218,,N,,Cmax at the dose of 5 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620308,,8545,In vivo,,50597,4756,,
,BAO_0000218,,N,,Cmax by administering at 20 mg/kg p.o. in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620309,,8546,In vivo,,50597,6402,,
,BAO_0000218,,N,,Cmax in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620310,,8547,In vivo,,50597,5610,,
,BAO_0000218,,N,,Cmax in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620311,,8548,In vivo,,50597,5207,,
,BAO_0000218,,N,,Cmax in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620312,,8549,In vivo,,50597,6011,,
,BAO_0000218,,N,,Cmax in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620313,,8550,In vivo,,50597,6504,,
,BAO_0000218,,N,,Cmax in rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620314,,8551,In vivo,,50597,6046,,
,BAO_0000218,,N,,Cmax in rat at the dose of 1 mg/kg i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620315,,8552,In vivo,,50597,6504,,
,BAO_0000218,,N,,Cmax in rat by po administration at a dose of 40 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620316,,8553,In vivo,,50597,5874,,
,BAO_0000218,,N,,Cmax in rat p.o. at 20 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620317,,8554,In vivo,,50597,17686,,
,BAO_0000218,,N,,Cmax in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620318,,8555,In vivo,,50597,5836,,
,BAO_0000218,,N,,Cmax in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620319,,8556,In vivo,,50597,17596,,
,BAO_0000218,,N,,Cmax was evaluated after 20 uM/kg of peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620320,,8557,In vivo,,50597,16423,,
,BAO_0000218,,N,,Cmax was measured in rats after peroral administration at 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620321,,8558,In vivo,,50597,17804,,
,BAO_0000218,,N,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620322,,8559,In vivo,,50597,1908,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620323,,8560,,,50597,13950,,
Frontal cortex,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,1870.0,1,Intermediate,CHEMBL620324,,8561,,,50597,13950,,
Frontal cortex,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,1870.0,1,Intermediate,CHEMBL620325,,8562,,,50597,13950,,
Hippocampus,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL620326,,8563,,,50597,13950,,
Hippocampus,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL620327,,8564,,,50597,13950,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620328,,8565,,,50597,13950,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620329,,8566,,,50597,13950,,
Midbrain,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,1891.0,1,Intermediate,CHEMBL620330,,8567,,,50597,13950,,
Midbrain,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,1891.0,1,Intermediate,CHEMBL875286,,8568,,,50597,13950,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620331,,8569,,,50597,13950,,
,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620332,,8570,,,50597,13950,,
Striatum,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL620333,,8571,,,50597,13950,,
Striatum,BAO_0000218,,N,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL620334,,8572,,,50597,13950,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621015,,8573,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621016,,8574,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621191,,8575,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621192,,8576,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621193,,8577,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621194,,8578,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624204,,8579,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624205,,8580,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624206,,8581,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624207,,8582,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624208,,8583,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624209,,8584,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624210,,8585,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624211,,8586,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624212,,8587,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624213,,8588,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL876611,,8589,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624214,,8590,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624215,,8591,,,50597,16434,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624216,,8592,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624217,,8593,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624218,,8594,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624219,,8595,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624220,,8596,,,50597,16435,,
Blood,BAO_0000218,,N,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624221,,8597,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624222,,8598,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624223,,8599,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624224,,8600,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624225,,8601,,,50597,16434,,
,BAO_0000218,,N,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622420,,8602,In vivo,,50597,17764,,
,BAO_0000218,,N,,Volume of steady state distribution after i.v. administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622421,,8603,In vivo,,50597,5031,,
,BAO_0000218,,N,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622422,,8604,In vivo,,50597,6215,,
,BAO_0000218,,N,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622423,,8605,In vivo,,50597,17671,,
,BAO_0000218,,N,,Vss was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622424,,8606,In vivo,,50597,17752,,
,BAO_0000218,,N,,Vss in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622425,,8607,In vivo,,50597,6596,,
,BAO_0000218,,N,,Vss was evaluated after 10 uM/kg of intra arterial administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876612,,8608,In vivo,,50597,16423,,
,BAO_0000218,,N,,volume of distribution at steady state was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622426,,8609,In vivo,,50597,15662,,
,BAO_0000218,,N,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622427,,8610,In vivo,,50597,6062,,
,BAO_0000218,,N,,Pharmacokinetic (PK) parameter Vz in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622428,,8611,In vivo,,50597,5874,,
,BAO_0000218,,N,,Volume distribution in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622429,,8612,In vivo,,50597,4942,,
,BAO_0000218,,N,,Volume of distribution in rat; No data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622430,,8613,In vivo,,50597,17796,,
,BAO_0000218,,N,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622431,,8614,In vivo,,50597,4890,,
Ileum,BAO_0000218,,N,,% absorption predicted from in vitro rat ileum transport studies,1,,10116.0,A,Rattus norvegicus,2116.0,1,Intermediate,CHEMBL622432,,8615,,,50597,15765,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622433,,8616,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622434,,8617,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622435,,8618,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618748,,8619,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618749,,8620,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618750,,8621,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618751,,8622,In vivo,,50597,13569,,
,BAO_0000218,,N,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618752,,8623,In vivo,,50597,13569,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618753,,8624,In vivo,,50597,4576,,
Plasma,BAO_0000218,,N,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL618754,,8625,In vivo,,50597,750,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618755,,8626,In vivo,,50597,750,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618756,,8627,In vivo,,50597,4590,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618757,,8628,In vivo,,50597,1716,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618758,,8629,In vivo,,50597,1974,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 30 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621088,,8630,In vivo,,50597,4502,,
,BAO_0000218,,N,,Pharmacokinetic property (cLogP) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621089,,8631,,,50597,3371,,
Blood,BAO_0000218,,N,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,1,,10116.0,F,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621090,,8632,,,50597,9099,,
Blood,BAO_0000218,,N,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,1,,10116.0,F,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621091,,8633,,,50597,9099,,
,BAO_0000218,,N,,Clearance in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876731,,8634,In vivo,,50597,4590,,
,BAO_0000218,,N,,Compound was evaluated for its clearance when administered intravenously in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621092,,8635,In vivo,,50597,3184,,
,BAO_0000218,,N,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621093,,8636,In vivo,,50597,16456,,
,BAO_0000218,,N,,Blood: Brain distribution ratio is determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621094,,8637,,,50597,4199,,
,BAO_0000218,,N,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621095,,8638,,,50597,4199,,
,BAO_0000218,,N,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621096,,8639,,,50597,4199,,
Kidney,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621097,,8640,In vivo,,50597,8677,,
,BAO_0000218,,N,,Percent dose excreted in 0-48 hours administered ip to male rat,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL621098,,8641,,,50597,7449,,
Cerebellum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL621099,,8642,,,50597,11977,,
Cerebellum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL621100,,8643,,,50597,11977,,
Cerebellum,BAO_0000218,,N,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL621101,,8644,,,50597,11977,,
Cerebellum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL621102,,8645,,,50597,11977,,
Cerebellum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL876732,,8646,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621103,,8647,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621104,,8648,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621105,,8649,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621106,,8650,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621107,,8651,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621108,,8652,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621109,,8653,,,50597,11977,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621110,,8654,In vivo,,50594,17208,,
Kidney,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL621111,,8655,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622541,,8656,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622542,,8657,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL622543,,8658,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624412,,8659,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624413,,8660,In vivo,,50594,17208,,
Liver,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL624414,,8661,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624415,,8662,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624416,,8663,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624417,,8664,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624418,,8665,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624419,,8666,In vivo,,50594,17208,,
Lung,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL624420,,8667,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL624421,,8668,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL624422,,8669,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL624423,,8670,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL625123,,8671,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL625124,,8672,In vivo,,50594,17208,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL625125,,8673,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL625126,,8674,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL626947,,8675,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL626948,,8676,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL626949,,8677,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL626950,,8678,In vivo,,50594,17208,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL626951,,8679,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626952,,8680,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626953,,8681,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626954,,8682,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626955,,8683,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626956,,8684,In vivo,,50594,17208,,
Spleen,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL626957,,8685,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626958,,8686,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626959,,8687,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626960,,8688,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626961,,8689,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL627589,,8690,In vivo,,50594,17208,,
Blood,BAO_0000218,,N,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL627590,,8691,In vivo,,50594,17208,,
,BAO_0000218,,N,,Time taken for EC90 was determined when tested in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627591,,8692,,,50594,3132,,
,BAO_0000218,,N,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627592,,8693,,,50594,3132,,
,BAO_0000218,,N,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627593,,8694,In vivo,,50594,16597,,
,BAO_0000218,,N,,Half life in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627594,,8695,,,50594,5727,,
,BAO_0000218,,N,,Half life period in mouse after 10 mg/Kg dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876813,,8696,In vivo,,50594,5302,,
,BAO_0000218,,N,,Half life period in mouse after 10 mg/kg dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627595,,8697,In vivo,,50594,5302,,
,BAO_0000218,,N,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627596,,8698,In vivo,,50594,6348,,
,BAO_0000218,,N,,Cmax value at 5 mg/kg po was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627597,,8699,In vivo,,50597,5964,,
,BAO_0000218,,N,,Cmax value evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627598,,8700,In vivo,,50597,6078,,
Brain,BAO_0000218,,N,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627599,,8701,In vivo,,50597,5206,,
,BAO_0000218,,N,,Cmax value after administration of 20 mg/Kg oral dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627600,,8702,In vivo,,50597,2959,,
,BAO_0000218,,N,,Cmax value at 1 mg/kg po in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627601,,8703,In vivo,,50597,5964,,
,BAO_0000218,,N,,Cmax value at 5 mg/kg po in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627776,,8704,In vivo,,50597,5964,,
,BAO_0000218,,N,,Cmax value at a dose of 10 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627777,,8705,In vivo,,50597,6757,,
,BAO_0000218,,N,,Cmax value at a dose of 100 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627778,,8706,In vivo,,50597,6757,,
,BAO_0000218,,N,,Cmax value at a dose of 50 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627779,,8707,In vivo,,50597,6757,,
,BAO_0000218,,N,,Cmax value in rats at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876814,,8708,In vivo,,50597,17617,,
,BAO_0000218,,N,,Cmax value was evaluated in rats at a dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627780,,8709,In vivo,,50597,1445,,
,BAO_0000218,,N,,Cmax value was determined after peroral administration of 20 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627781,,8710,In vivo,,50597,6082,,
,BAO_0000218,,N,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627782,,8711,In vivo,,50597,1446,,
Plasma,BAO_0000218,,N,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627783,,8712,In vivo,,50597,5407,,
Plasma,BAO_0000218,,N,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627784,,8713,In vivo,,50597,2690,,
,BAO_0000218,,N,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627785,,8714,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627786,,8715,In vivo,,50597,2661,,
Plasma,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627787,,8716,In vivo,,50597,4891,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627788,,8717,In vivo,,50597,2807,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626579,,8718,In vivo,,50597,2807,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626580,,8719,In vivo,,50597,2807,,
,BAO_0000218,,N,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876815,,8720,In vivo,,50597,3634,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626581,,8721,In vivo,,50597,1881,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626582,,8722,In vivo,,50597,1881,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626583,,8723,In vivo,,50597,429,,
,BAO_0000218,,N,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626205,,8724,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626206,,8725,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626207,,8726,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623882,,8727,In vivo,,50597,5974,,
,BAO_0000218,,N,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623883,,8728,In vivo,,50597,17582,,
,BAO_0000218,,N,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623884,,8729,In vivo,,50597,17582,,
Plasma,BAO_0000218,,N,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623885,,8730,In vivo,,50597,3032,,
Plasma,BAO_0000218,,N,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623886,,8731,In vivo,,50597,6295,,
,BAO_0000218,,N,,Maximal concentration in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623887,,8732,In vivo,,50597,6619,,
,BAO_0000218,,N,,Maximal concentration after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623888,,8733,In vivo,,50597,6616,,
Plasma,BAO_0000218,,N,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623889,,8734,In vivo,,50597,3249,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623890,,8735,In vivo,,50597,17791,,
Plasma,BAO_0000218,,N,,Cmax in rat plasma after oral dose (50 mg/Kg),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623891,,8736,In vivo,,50597,17791,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration was determined.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623892,,8737,In vivo,,50597,1360,,
Plasma,BAO_0000218,,N,,Maximal plasma drug concentration was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623893,,8738,In vivo,,50597,2552,,
,BAO_0000218,,N,,Maximal concentration in rats after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877616,,8739,In vivo,,50597,6571,,
,BAO_0000218,,N,,Maximum concentration in rat after 2 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623894,,8740,In vivo,,50597,6570,,
Plasma,BAO_0000218,,N,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623895,,8741,In vivo,,50597,6567,,
,BAO_0000218,,N,,Maximum concentration of compound in rat was evaluated.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623896,,8742,In vivo,,50597,3031,,
,BAO_0000218,,N,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623897,,8743,In vivo,,50597,3436,,
,BAO_0000218,,N,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623898,,8744,In vivo,,50597,3436,,
,BAO_0000218,,N,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623899,,8745,In vivo,,50597,2083,,
,BAO_0000218,,N,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623900,,8746,In vivo,,50597,3436,,
,BAO_0000218,,N,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623901,,8747,In vivo,,50597,4527,,
,BAO_0000218,,N,,Maximum concentration was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623902,,8748,In vivo,,50597,1974,,
Cerebrospinal fluid,BAO_0000218,,N,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,1,,10116.0,A,Rattus norvegicus,1359.0,1,Intermediate,CHEMBL623903,,8749,In vivo,,50597,3307,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623904,,8750,In vivo,,50597,3307,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL877617,,8751,In vivo,,50597,1916,,
,BAO_0000218,,N,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623905,,8752,In vivo,,50597,1500,,
,BAO_0000218,,N,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623906,,8753,In vivo,,50597,1500,,
Plasma,BAO_0000218,,N,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623907,,8754,In vivo,,50597,4186,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623908,,8755,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623909,,8756,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623910,,8757,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623911,,8758,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623912,,8759,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624616,,8760,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624617,,8761,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624618,,8762,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624619,,8763,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624794,,8764,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624795,,8765,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623921,,8766,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623922,,8767,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623923,,8768,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623924,,8769,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623925,,8770,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623926,,8771,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623927,,8772,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623928,,8773,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623929,,8774,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623930,,8775,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623931,,8776,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622165,,8777,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621249,,8778,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621250,,8779,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621448,,8780,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621449,,8781,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621450,,8782,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621451,,8783,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621452,,8784,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621453,,8785,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621454,,8786,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621455,,8787,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621456,,8788,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625145,,8789,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL875847,,8790,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625146,,8791,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625147,,8792,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625148,,8793,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625149,,8794,,,50597,16434,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625150,,8795,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625151,,8796,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625152,,8797,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625153,,8798,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625154,,8799,,,50597,16435,,
Brain,BAO_0000218,,N,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625155,,8800,,,50597,16435,,
,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625156,,8801,,,50597,11977,,
,BAO_0000218,,N,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624354,,8802,,,50597,11977,,
Hippocampus,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL624355,,8803,,,50597,11977,,
Hippocampus,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL624356,,8804,,,50597,11977,,
Hippocampus,BAO_0000218,,N,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL624357,,8805,,,50597,11977,,
Hippocampus,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL624358,,8806,,,50597,11977,,
Striatum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL624359,,8807,,,50597,11977,,
Striatum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL624360,,8808,,,50597,11977,,
Striatum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL624361,,8809,,,50597,11977,,
Striatum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL624362,,8810,,,50597,11977,,
Striatum,BAO_0000218,,N,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL624363,,8811,,,50597,11977,,
Blood,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624364,,8812,In vivo,,50597,11977,,
Blood,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624365,,8813,In vivo,,50597,11977,,
Blood,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624366,,8814,In vivo,,50597,11977,,
Blood,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624367,,8815,In vivo,,50597,11977,,
Brain,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624368,,8816,In vivo,,50597,11977,,
Brain,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624369,,8817,In vivo,,50597,11977,,
Brain,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624370,,8818,In vivo,,50597,11977,,
Brain,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625069,,8819,In vivo,,50597,11977,,
Brain,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625070,,8820,In vivo,,50597,11977,,
Heart,BAO_0000218,,N,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626051,,8821,In vivo,,50597,11977,,
Heart,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626052,,8822,In vivo,,50597,11977,,
Heart,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626053,,8823,In vivo,,50597,11977,,
Heart,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626054,,8824,In vivo,,50597,11977,,
Heart,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626055,,8825,In vivo,,50597,11977,,
Kidney,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626056,,8826,In vivo,,50597,11977,,
Kidney,BAO_0000218,,N,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626057,,8827,In vivo,,50597,11977,,
Kidney,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625193,,8828,In vivo,,50597,11977,,
Kidney,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625194,,8829,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625195,,8830,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625196,,8831,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625197,,8832,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625198,,8833,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627929,,8834,In vivo,,50597,11977,,
Lung,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627074,,8835,In vivo,,50597,11977,,
Lung,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627075,,8836,In vivo,,50597,11977,,
Lung,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627076,,8837,In vivo,,50597,11977,,
Lung,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627077,,8838,In vivo,,50597,11977,,
Lung,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627078,,8839,In vivo,,50597,11977,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627079,,8840,In vivo,,50597,11977,,
,BAO_0000218,,N,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL873824,,8841,In vivo,,50594,4573,,
Plasma,BAO_0000218,,N,,Half life in mouse plasma was determined at dose 25 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627080,,8842,In vivo,,50594,3132,,
,BAO_0000218,,N,,Half life was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627081,,8843,,,50594,17718,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627082,,8844,In vivo,,50594,17728,,
,BAO_0000218,,N,,Half-life in male mice after 1 mg/kg intravenous dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627083,,8845,In vivo,,50594,5961,,
Plasma,BAO_0000218,,N,,Half life in mice plasma,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627085,,8847,,,50594,17731,,
,BAO_0000218,,N,,Half life in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627086,,8848,,,50594,17592,,
Plasma,BAO_0000218,,N,,Half life in mouse plasma at dose 25 mg/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627087,,8849,In vivo,,50594,3132,,
,BAO_0000218,,N,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627088,,8850,In vivo,,50594,17729,,
,BAO_0000218,,N,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627089,,8851,In vivo,,50594,17729,,
,BAO_0000218,,N,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627090,,8852,In vivo,,50594,17729,,
,BAO_0000218,,N,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627091,,8853,In vivo,,50594,3277,,
,BAO_0000218,,N,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627092,,8854,In vivo,,50594,3760,,
,BAO_0000218,,N,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876785,,8855,In vivo,,50594,3760,,
,BAO_0000218,,N,,Half-life by iv administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627093,,8856,In vivo,,50594,2862,,
,BAO_0000218,,N,,Half-life by oral administration in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627094,,8857,In vivo,,50594,2862,,
,BAO_0000218,,N,,Half-life in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627095,,8858,,,50594,5980,,
Brain,BAO_0000218,,N,,Half-life using mouse brain homogenate,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627096,,8859,,,50594,6159,,
,BAO_0000218,,N,,Half-life was measured in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627097,,8860,,,50594,6254,,
,BAO_0000218,,N,,Half-life was measured in mouse after an iv dose of 1 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627098,,8861,In vivo,,50594,6062,,
Blood,BAO_0000218,,N,,Half-life period was determined in mouse blood,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL627099,,8862,,,50594,1574,,
Brain,BAO_0000218,,N,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL627100,,8863,,,50594,56,,
Plasma,BAO_0000218,,N,,Plasma half life in mouse,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627101,,8864,,,50594,993,,
,BAO_0000218,,N,,Stability of the peptide in the presence of mouse serum,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627102,,8865,,,50594,6652,,
,BAO_0000218,,N,,Terminal half life of compound was determined in mouse,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627103,,8866,,,50594,17852,,
,BAO_0000218,,N,,Terminal half life was evaluated in mice after intravenous administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627104,,8867,In vivo,,50594,2675,,
,BAO_0000218,,N,,Terminal half life was evaluated in mice after oral administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627105,,8868,In vivo,,50594,2675,,
,BAO_0000218,,N,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876786,,8869,,,50594,499,,
,BAO_0000218,,N,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL873825,,8870,,,50594,499,,
,BAO_0000218,,N,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627106,,8871,,,50594,499,,
,BAO_0000218,,N,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626336,,8872,In vivo,,50594,14239,,
,BAO_0000218,,N,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL877462,,8873,In vivo,,50594,5506,,
,BAO_0000218,,N,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626337,,8874,In vivo,,50594,5506,,
,BAO_0000218,,N,,Half life after intraperitoneal administration of 100 mg/kg in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626338,,8875,,,50594,17734,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626339,,8876,In vivo,,50594,17728,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626340,,8877,In vivo,,50594,17728,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625377,,8878,In vivo,,50594,17728,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625378,,8879,In vivo,,50594,17728,,
,BAO_0000218,,N,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625379,,8880,In vivo,,50594,17728,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625380,,8881,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625381,,8882,,,22224,14294,,
,BAO_0000019,,U,,Stability to porcine renal DHP-I,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625382,,8883,,,22224,6056,,
,BAO_0000218,,U,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL873828,,8884,In vivo,,22224,1317,,
,BAO_0000218,,U,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625383,,8885,In vivo,,22224,1317,,
,BAO_0000019,,U,,Half-life of the parent prodrug in porcine esterase solution,1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625384,,8886,,,22224,5229,,
,BAO_0000019,,U,,"First order rate constant, k was determined in in pig liver Esterase",1,,9823.0,A,Sus scrofa,,0,Autocuration,CHEMBL625385,,8887,,,22224,4231,,
Liver,BAO_0000221,,U,,Half life of the in pig liver Esterase,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL625386,,8888,,,22224,4231,,
Liver,BAO_0000221,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623571,,8889,,,22224,5318,,
Liver,BAO_0000221,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623572,,8890,,,22224,5318,,
Liver,BAO_0000221,,U,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623573,,8891,,,22224,5318,,
Liver,BAO_0000221,,U,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623574,,8892,,,22224,3305,,
Liver,BAO_0000221,,U,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623575,,8893,,,22224,3305,,
Liver,BAO_0000221,,U,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623749,,8894,,,22224,2842,,
Liver,BAO_0000221,,U,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623750,,8895,,,22224,2842,,
Liver,BAO_0000221,,U,,Half-life in vitro in pig liver,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623751,,8896,In vitro,,22224,889,,
Liver,BAO_0000221,,U,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,1,,9823.0,A,Sus scrofa,2107.0,0,Autocuration,CHEMBL623752,,8897,,,22224,1904,,
Plasma,BAO_0000218,,N,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623753,,8898,In vivo,,50597,4186,,
Plasma,BAO_0000218,,N,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623754,,8899,In vivo,,50597,2774,,
Plasma,BAO_0000218,,N,,Maximum concentration in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623755,,8900,In vivo,,50597,1742,,
,BAO_0000218,,N,,Maximum concentration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623756,,8901,In vivo,,50597,3169,,
,BAO_0000218,,N,,Maximum concentration in rats at 1-2 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623757,,8902,In vivo,,50597,3169,,
,BAO_0000218,,N,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623758,,8903,In vivo,,50597,2081,,
Brain,BAO_0000218,,N,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623759,,8904,In vivo,,50597,3307,,
,BAO_0000218,,N,,Maximum concentration at the dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623760,,8905,In vivo,,50597,4727,,
,BAO_0000218,,N,,Maximum concentration was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623761,,8906,In vivo,,50597,6597,,
Plasma,BAO_0000218,,N,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623762,,8907,In vivo,,50597,16365,,
Plasma,BAO_0000218,,N,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL877594,,8908,In vivo,,50597,16365,,
Plasma,BAO_0000218,,N,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623763,,8909,In vivo,,50597,16365,,
Plasma,BAO_0000218,,N,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623764,,8910,In vivo,,50597,16365,,
Plasma,BAO_0000218,,N,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623765,,8911,In vivo,,50597,16365,,
Blood,BAO_0000218,,N,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623766,,8912,In vivo,,50597,2591,,
Blood,BAO_0000218,,N,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623767,,8913,In vivo,,50597,2591,,
Blood,BAO_0000218,,N,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623768,,8914,In vivo,,50597,2591,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623769,,8915,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623770,,8916,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623771,,8917,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623772,,8918,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623773,,8919,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623774,,8920,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623775,,8921,In vivo,,50597,5978,,
,BAO_0000218,,N,,Cmax in rat (PO dose),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623776,,8922,In vivo,,50597,14465,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622191,,8923,In vivo,,50597,4723,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622192,,8924,In vivo,,50597,4723,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration determined in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622193,,8925,In vivo,,50597,4576,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622194,,8926,In vivo,,50597,12873,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622195,,8927,In vivo,,50597,12873,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622196,,8928,In vivo,,50597,6824,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622197,,8929,In vivo,,50597,17065,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622198,,8930,In vivo,,50597,2932,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622199,,8931,In vivo,,50597,2932,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was measured in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622200,,8932,In vivo,,50597,2879,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration after 20 mg/kg oral administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622201,,8933,In vivo,,50597,2864,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration after oral administration to rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623990,,8934,In vivo,,50597,16367,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623991,,8935,In vivo,,50597,17717,,
Plasma,BAO_0000218,,N,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623992,,8936,In vivo,,50597,17717,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623993,,8937,In vivo,,50597,17717,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623994,,8938,In vivo,,50597,17717,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,1,,10116.0,F,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623995,,8939,In vivo,,50597,17720,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,F,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623996,,8940,In vivo,,50597,17720,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,1,,10116.0,F,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623997,,8941,In vivo,,50597,17720,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration dosed orally in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623998,,8942,In vivo,,50597,4516,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration dosed orally in rats after 6 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623999,,8943,In vivo,,50597,4516,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624000,,8944,In vivo,,50597,4516,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624001,,8945,In vivo,,50597,5199,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in rat after po administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624002,,8946,In vivo,,50597,17538,,
Plasma,BAO_0000218,,N,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624003,,8947,In vivo,,50597,6685,,
Plasma,BAO_0000218,,N,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624004,,8948,In vivo,,50597,6685,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624005,,8949,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624006,,8950,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624007,,8951,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624008,,8952,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624009,,8953,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL874387,,8954,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624010,,8955,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624011,,8956,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624012,,8957,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624013,,8958,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624736,,8959,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624737,,8960,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624738,,8961,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624739,,8962,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624740,,8963,,,50597,16434,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624896,,8964,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624897,,8965,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624108,,8966,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624109,,8967,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624110,,8968,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624111,,8969,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624112,,8970,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624113,,8971,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL619709,,8972,,,50597,16435,,
Heart,BAO_0000218,,N,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL619710,,8973,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619711,,8974,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619712,,8975,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619713,,8976,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619714,,8977,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619715,,8978,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619716,,8979,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619717,,8980,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619718,,8981,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619719,,8982,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL875329,,8983,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619720,,8984,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619721,,8985,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619722,,8986,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619723,,8987,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619724,,8988,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619725,,8989,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619726,,8990,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619727,,8991,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619728,,8992,,,50597,16434,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL619729,,8993,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL619730,,8994,In vivo,,50597,11977,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL619731,,8995,In vivo,,50597,11977,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL619732,,8996,In vivo,,50597,11977,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL619733,,8997,In vivo,,50597,11977,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL619734,,8998,In vivo,,50597,11977,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL619735,,8999,In vivo,,50597,11977,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL875330,,9000,In vivo,,50597,11977,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL628465,,9001,In vivo,,50597,11977,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL628466,,9002,In vivo,,50597,11977,,
Zone of skin,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL628467,,9003,In vivo,,50597,11977,,
Spleen,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628468,,9004,In vivo,,50597,11977,,
Spleen,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628469,,9005,In vivo,,50597,11977,,
Spleen,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628470,,9006,In vivo,,50597,11977,,
Spleen,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628471,,9007,In vivo,,50597,11977,,
Spleen,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628472,,9008,In vivo,,50597,11977,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL625191,,9009,In vivo,,50597,11977,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL625192,,9010,In vivo,,50597,11977,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL875337,,9011,In vivo,,50597,11977,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626341,,9012,In vivo,,50597,11977,,
Thyroid gland,BAO_0000218,,N,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626342,,9013,In vivo,,50597,11977,,
Liver,BAO_0000218,,N,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621943,,9014,In vivo,,50597,11977,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621944,,9015,,,50597,3748,,
,BAO_0000218,,N,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621945,,9016,,,50597,15765,,
,BAO_0000218,,N,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621946,,9017,,,50597,4871,,
,BAO_0000218,,N,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621947,,9018,,,50597,4871,,
,BAO_0000218,,N,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621948,,9019,,,50597,4872,,
,BAO_0000218,,N,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621949,,9020,,,50597,4872,,
,BAO_0000218,,N,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621950,,9021,,,50597,5413,,
,BAO_0000218,,N,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621951,,9022,,,50597,5413,,
Blood,BAO_0000218,,N,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621952,,9023,In vivo,,50597,15272,,
Liver,BAO_0000218,,N,,Stability (%) in rat liver microsomes,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621953,,9024,,,50597,4689,,
,BAO_0000218,,N,,Area under curve was calculated after intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621954,,9025,,,50597,6057,,
,BAO_0000218,,N,,Area under the curve was calculated after iv administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621955,,9026,,,50597,6057,,
,BAO_0000218,,N,,Area under the curve was calculated in rat after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621956,,9027,,,50597,6057,,
,BAO_0000218,,N,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621957,,9028,,,50597,6211,,
,BAO_0000218,,N,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621958,,9029,,,50597,5710,,
,BAO_0000218,,N,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621959,,9030,,,50597,5710,,
,BAO_0000218,,N,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621960,,9031,,,50597,17853,,
,BAO_0000218,,N,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621961,,9032,,,50597,17853,,
,BAO_0000218,,N,,p value of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621962,,9033,,,50597,15765,,
,BAO_0000218,,N,,p value of the compound,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL876787,,9034,,,50597,15765,,
,BAO_0000218,,N,,p value of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621963,,9035,,,50597,15765,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622637,,9036,,,50597,6175,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622638,,9037,,,50597,6175,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL626561,,9038,,,50597,6175,,
,BAO_0000019,,U,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),1,,9986.0,F,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626562,,9039,,,22224,7991,,
,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626563,,9040,,,22224,429,,
,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626564,,9041,,,22224,429,,
,BAO_0000218,,U,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626565,,9042,In vivo,,22224,6253,,
,BAO_0000218,,U,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626566,,9043,In vivo,,22224,6253,,
,BAO_0000218,,U,,Clearance rate in rabbits,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626567,,9044,In vivo,,22224,3615,,
,BAO_0000218,,U,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626568,,9045,In vivo,,22224,4059,,
,BAO_0000218,,U,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626569,,9046,In vivo,,22224,5124,,
,BAO_0000218,,U,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626570,,9047,In vivo,,22224,5124,,
,BAO_0000218,,U,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626571,,9048,In vivo,,22224,5124,,
,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626572,,9049,In vivo,,22224,429,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,1,,9986.0,A,Oryctolagus cuniculus,1969.0,0,Autocuration,CHEMBL626573,,9050,In vivo,,22224,4059,,
Liver,BAO_0000251,,U,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,1,,9986.0,A,Oryctolagus cuniculus,2107.0,0,Autocuration,CHEMBL626574,,9051,,,22224,9659,,
Liver,BAO_0000251,,U,Microsomes,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,1,,9986.0,A,Oryctolagus cuniculus,2107.0,0,Autocuration,CHEMBL626575,,9052,,,22224,9659,,
,BAO_0000218,,U,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626576,,9053,,,22224,3639,,
,BAO_0000218,,U,,Dose at which bioavailability of perorally administered compound was tested in rabbit,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626577,,9054,,,22224,3639,,
,BAO_0000218,,U,,The compound was tested for its bioavailability in rabbit (by oral dosage).,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL626578,,9055,In vivo,,22224,3639,,
,BAO_0000218,,U,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL625263,,9056,In vivo,,22224,5124,,
,BAO_0000218,,U,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL625264,,9057,In vivo,,22224,5124,,
,BAO_0000218,,U,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL625265,,9058,In vivo,,22224,5124,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL625266,,9059,,,22224,14294,,
,BAO_0000251,,U,Microsomes,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL876796,,9060,,,22224,14294,,
,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL625267,,9061,In vivo,,22224,429,,
Plasma,BAO_0000218,,U,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,1969.0,0,Autocuration,CHEMBL625268,,9062,In vivo,,22224,5124,,
Plasma,BAO_0000218,,U,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,1969.0,0,Autocuration,CHEMBL625269,,9063,In vivo,,22224,5124,,
Plasma,BAO_0000218,,U,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,1969.0,0,Autocuration,CHEMBL624689,,9064,In vivo,,22224,5124,,
,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624690,,9065,In vivo,,22224,429,,
Urine,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),1,,9986.0,A,Oryctolagus cuniculus,1088.0,0,Autocuration,CHEMBL624691,,9066,,,22224,429,,
Urine,BAO_0000218,,U,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),1,,9986.0,A,Oryctolagus cuniculus,1088.0,0,Autocuration,CHEMBL624692,,9067,,,22224,429,,
,BAO_0000218,,U,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624693,,9068,In vivo,,22224,4059,,
,BAO_0000218,,U,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624694,,9069,In vivo,,22224,4137,,
,BAO_0000221,,U,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL877596,,9070,In vitro,,22224,11672,,
,BAO_0000019,,U,,Time within which only 10% of the drug was degraded,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624695,,9071,,,22224,12886,,
Liver,BAO_0000221,,U,,Half life period in rabbit liver homogenate,1,,9986.0,A,Oryctolagus cuniculus,2107.0,0,Autocuration,CHEMBL624696,,9072,,,22224,3853,,
,BAO_0000019,,U,,Half life value in rabbits,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624697,,9073,,,22224,3615,,
Blood,BAO_0000218,,U,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,1,,9986.0,A,Oryctolagus cuniculus,178.0,0,Autocuration,CHEMBL624698,,9074,In vivo,,22224,6253,,
Blood,BAO_0000218,,U,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,1,,9986.0,A,Oryctolagus cuniculus,178.0,0,Autocuration,CHEMBL624699,,9075,In vivo,,22224,6253,,
,BAO_0000218,,U,,Half-life period in rabbits following intravenous administration at 2 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,,0,Autocuration,CHEMBL624700,,9076,In vivo,,22224,6077,,
Plasma,BAO_0000218,,N,,AUC 0-8 hr value in rats at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622903,,9077,,,50597,17617,,
Plasma,BAO_0000218,,N,,AUC after administration at 2000 mg/kg/day in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622904,,9078,,,50597,17594,,
Plasma,BAO_0000218,,N,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622905,,9079,,,50597,6149,,
Plasma,BAO_0000218,,N,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622906,,9080,,,50597,17260,,
Plasma,BAO_0000218,,N,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622907,,9081,,,50597,17260,,
Plasma,BAO_0000218,,N,,AUC in rat after oral administration at 10.5 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622908,,9082,,,50597,6644,,
Plasma,BAO_0000218,,N,,AUC in rat after oral administration at 11.2 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622909,,9083,,,50597,6644,,
Plasma,BAO_0000218,,N,,AUC in rat after oral administration at 9.7 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622910,,9084,,,50597,6644,,
Brain,BAO_0000218,,N,,AUC in rat brain after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622911,,9085,,,50597,6495,,
Plasma,BAO_0000218,,N,,AUC in rat p.o.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622912,,9086,,,50597,6504,,
Plasma,BAO_0000218,,N,,AUC in rat p.o. at 20 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622913,,9087,,,50597,17686,,
Plasma,BAO_0000218,,N,,AUC in rat plasma after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622914,,9088,,,50597,6495,,
Plasma,BAO_0000218,,N,,AUC in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622915,,9089,,,50597,216,,
Plasma,BAO_0000218,,N,,AUC value after IV dose at a dose of 5 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622916,,9090,,,50597,1908,,
Plasma,BAO_0000218,,N,,AUC value after oral dose at a dose of 10 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622917,,9091,,,50597,1908,,
Plasma,BAO_0000218,,N,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622918,,9092,In vivo,,50597,6685,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622919,,9093,In vivo,,50597,216,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622920,,9094,In vivo,,50597,6049,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622921,,9095,In vivo,,50597,2463,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622922,,9096,In vivo,,50597,6679,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622923,,9097,In vivo,,50597,6681,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL877604,,9098,In vivo,,50597,4890,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622924,,9099,In vivo,,50597,6410,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622925,,9100,In vivo,,50597,6410,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622926,,9101,In vivo,,50597,16366,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623625,,9102,In vivo,,50597,6227,,
Plasma,BAO_0000218,,N,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Expert,CHEMBL623626,,9103,In vivo,,50597,3598,,
Plasma,BAO_0000218,,N,,Maximum plasma drug concentration was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623627,,9104,In vivo,,50597,1465,,
,BAO_0000218,,N,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623628,,9105,In vivo,,50597,4368,,
Plasma,BAO_0000218,,N,,Mean peak plasma concentration was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623629,,9106,In vivo,,50597,15662,,
Plasma,BAO_0000218,,N,,Mean peak plasma concentration was observed after oral administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623630,,9107,In vivo,,50597,15662,,
,BAO_0000218,,N,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623804,,9108,In vivo,,50597,5355,,
,BAO_0000218,,N,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623805,,9109,In vivo,,50597,5355,,
Plasma,BAO_0000218,,N,,Peak oral plasma concentration was determined in rats by oral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623806,,9110,In vivo,,50597,1567,,
Plasma,BAO_0000218,,N,,Peak plasma concentration (Cmax) was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623807,,9111,In vivo,,50597,4026,,
Plasma,BAO_0000218,,N,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623808,,9112,In vivo,,50597,6193,,
Plasma,BAO_0000218,,N,,Peak plasma concentration (Cmax) in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623809,,9113,In vivo,,50597,4026,,
Plasma,BAO_0000218,,N,,Peak plasma concentration at 1 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623810,,9114,In vivo,,50597,6485,,
Plasma,BAO_0000218,,N,,Peak plasma concentration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623811,,9115,In vivo,,50597,17655,,
Plasma,BAO_0000218,,N,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623812,,9116,In vivo,,50597,14941,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877605,,9117,In vivo,,50597,5394,,
,BAO_0000218,,N,,Pharmacokinetic property (Cmax) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623813,,9118,In vivo,,50597,4408,,
,BAO_0000218,,N,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623814,,9119,In vivo,,50597,5983,,
,BAO_0000218,,N,,Cmax in rat after 3mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623815,,9120,In vivo,,50597,4878,,
,BAO_0000218,Sprague-Dawley,N,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623816,,9121,In vivo,,50597,5862,,
,BAO_0000218,,N,,Cmax in rats after 20 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623145,,9122,In vivo,,50597,4517,,
Plasma,BAO_0000218,,N,,Cmax in rat plasma after 30mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623146,,9123,In vivo,,50597,5932,,
Plasma,BAO_0000218,,N,,Plasma concentration after oral administration of 100 mg/kg to rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623147,,9124,In vivo,,50597,5436,,
Brain,BAO_0000218,,N,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623042,,9125,In vivo,,50597,4910,,
,BAO_0000218,,N,,Tested for the Cmax in rat at 10 mg/kg per orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623043,,9126,In vivo,,50597,4950,,
,BAO_0000218,,N,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623044,,9127,In vivo,,50597,15078,,
,BAO_0000218,,N,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623045,,9128,In vivo,,50597,15078,,
,BAO_0000218,,N,,Bioavailability as oral Cmax in rats at 30 mins,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623046,,9129,In vivo,,50597,3360,,
,BAO_0000218,,N,,Bioavailability as oral Cmax in rats at 6hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623226,,9130,In vivo,,50597,3360,,
,BAO_0000218,,N,,The maximum concentration of compound was measured at the dose of 100 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623227,,9131,In vivo,,50597,15022,,
,BAO_0000218,,N,,The maximum concentration of compound was measured at the dose of 300 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623228,,9132,In vivo,,50597,15022,,
,BAO_0000218,,N,,The maximum concentration of compound was measured at the dose of 30 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623229,,9133,In vivo,,50597,15022,,
Plasma,BAO_0000218,,N,,The maximum plasma levels for the compounds were determined by LC-MS.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623230,,9134,In vivo,,50597,5160,,
Plasma,BAO_0000218,,N,,mean peak plasma concentration was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623231,,9135,In vivo,,50597,15662,,
Plasma,BAO_0000218,,N,,mean peak plasma concentration was observed after oral administration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623232,,9136,In vivo,,50597,15662,,
,BAO_0000218,,N,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623233,,9137,,,50597,4709,,
,BAO_0000218,,N,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623234,,9138,,,50597,3535,,
,BAO_0000218,,N,,Concentration in plasma (portal) following oral dose in rats at 1 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623235,,9139,,,50597,3535,,
,BAO_0000218,,N,,Concentration in plasma (portal) following oral dose in rats at 2 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623236,,9140,,,50597,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623237,,9141,,,50597,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623238,,9142,,,50597,3535,,
,BAO_0000218,,N,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623239,,9143,,,50597,3535,,
Plasma,BAO_0000218,,U,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,1,,10116.0,A,Rattus norvegicus,1969.0,0,Intermediate,CHEMBL623240,,9144,In vivo,,22224,5005,,
Hypothalamus,BAO_0000218,,N,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL623241,,9145,,,50597,6326,,
Hypothalamus,BAO_0000218,,N,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL623242,,9146,,,50597,6326,,
,BAO_0000218,,N,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874394,,9147,,,50597,6326,,
,BAO_0000218,,N,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623243,,9148,,,50597,6326,,
,BAO_0000218,,N,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623244,,9149,,,50597,17411,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623245,,9150,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623246,,9151,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623247,,9152,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623248,,9153,,,50597,16435,,
Kidney,BAO_0000218,,N,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623249,,9154,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625072,,9155,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625073,,9156,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625074,,9157,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625075,,9158,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625076,,9159,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625077,,9160,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625078,,9161,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL874395,,9162,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625079,,9163,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625080,,9164,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625081,,9165,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625082,,9166,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625083,,9167,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625084,,9168,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625085,,9169,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625086,,9170,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625087,,9171,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625088,,9172,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622205,,9173,,,50597,16434,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622206,,9174,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622207,,9175,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622366,,9176,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622367,,9177,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL875331,,9178,,,50597,16435,,
Liver,BAO_0000218,,N,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622368,,9179,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622369,,9180,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622370,,9181,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622371,,9182,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622372,,9183,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622373,,9184,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622374,,9185,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622375,,9186,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622376,,9187,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622377,,9188,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622378,,9189,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622379,,9190,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622380,,9191,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622381,,9192,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622382,,9193,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622383,,9194,,,50597,16434,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL875332,,9195,,,50597,6175,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622384,,9196,,,50597,6175,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622385,,9197,,,50597,6175,,
Stomach,BAO_0000218,,N,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622386,,9198,,,50597,6175,,
,BAO_0000218,,N,,The compound was tested for the plasma binding in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622387,,9199,,,50597,10839,,
,BAO_0000218,,N,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622388,,9200,,,50597,16459,,
,BAO_0000218,,N,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622389,,9201,,,50597,16459,,
,BAO_0000218,,N,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622390,,9202,,,50597,16459,,
,BAO_0000218,,N,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622391,,9203,,,50597,16459,,
,BAO_0000218,,N,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622392,,9204,,,50597,16459,,
,BAO_0000218,,N,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622393,,9205,,,50597,16459,,
,BAO_0000218,,N,,Plasma level at 2 hr after administration of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622394,,9206,,,50597,3278,,
,BAO_0000218,,N,,plasma level at 2 hr after administration of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622395,,9207,,,50597,3278,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 1 min,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL622396,,9208,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 10 min,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624894,,9209,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 10 mins,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624895,,9210,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 2 hr,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624058,,9211,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 3 min,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624059,,9212,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 3 mins,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624060,,9213,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 5 min,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624061,,9214,,,50597,4684,,
Serum,BAO_0000218,,N,,Stability in rat serum measured as % recovery at 5 mins,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL624062,,9215,,,50597,4684,,
,BAO_0000218,,N,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624063,,9216,In vivo,,50597,16456,,
,BAO_0000218,,N,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624064,,9217,In vivo,,50597,16456,,
Plasma,BAO_0000218,,N,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624065,,9218,,,50597,723,,
Plasma,BAO_0000218,,N,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624066,,9219,,,50597,723,,
,BAO_0000218,,N,,Half life tested in mature male rat at a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877490,,9220,In vivo,,50597,5160,,
,BAO_0000218,,N,,Half life after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874442,,9221,In vivo,,50597,4709,,
,BAO_0000218,,N,,Half life period after administration (30 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626890,,9222,In vivo,,50597,5633,,
,BAO_0000218,,N,,Half life period in rat after 5 mg/Kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626891,,9223,In vivo,,50597,5302,,
,BAO_0000218,,N,,Half life period in rat after 5 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626892,,9224,In vivo,,50597,5302,,
,BAO_0000218,,N,,Half life period was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626893,,9225,,,50597,17791,,
,BAO_0000218,,N,,Half life period was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626894,,9226,,,50597,17791,,
,BAO_0000218,,N,,Half life period was evaluated in rat; 0.5-1.0,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626895,,9227,,,50597,17791,,
,BAO_0000218,,N,,Half life period was evaluated in rat; 5.9-7.5,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626896,,9228,,,50597,17791,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626897,,9229,,,50597,14512,,
,BAO_0000218,,N,,Half-life time in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626898,,9230,,,50597,6230,,
,BAO_0000218,,N,,Terminal half-life after iv administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626899,,9231,In vivo,,50597,3364,,
,BAO_0000218,,N,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626900,,9232,In vivo,,50597,6874,,
,BAO_0000218,,N,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626901,,9233,,,50597,857,,
,BAO_0000218,,N,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626902,,9234,In vivo,,50597,858,,
,BAO_0000218,,N,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626903,,9235,In vivo,,50597,858,,
,BAO_0000218,,N,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874443,,9236,In vivo,,50597,5355,,
,BAO_0000218,,N,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626904,,9237,In vivo,,50597,5355,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626905,,9238,,,50597,6305,,
Plasma,BAO_0000218,,N,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873830,,9239,In vivo,,50597,13501,,
,BAO_0000218,,N,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626906,,9240,In vivo,,50597,17594,,
Plasma,BAO_0000218,,N,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631076,,9241,In vivo,,50597,4186,,
Plasma,BAO_0000218,,N,,Biological half-life was measured in plasma of rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631077,,9242,,,50597,2932,,
,BAO_0000218,,N,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631078,,9243,In vivo,,50597,17065,,
,BAO_0000218,,N,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631079,,9244,In vivo,,50597,15765,,
,BAO_0000218,,N,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631080,,9245,In vivo,,50597,2713,,
,BAO_0000218,,N,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631081,,9246,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631239,,9247,In vivo,,50597,2661,,
Plasma,BAO_0000218,,N,,Compound was evaluated for plasma half life in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631240,,9248,,,50597,740,,
Plasma,BAO_0000218,,N,,AUC value at a dose of 5 mg/kg (p.o.) in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631241,,9249,,,50597,6597,,
Plasma,BAO_0000218,,N,,AUC value after administration of 20 mg/Kg oral dose in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631242,,9250,,,50597,2959,,
Plasma,BAO_0000218,,N,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631243,,9251,,,50597,17594,,
Plasma,BAO_0000218,,N,,AUC0-96 after administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL874444,,9252,,,50597,17596,,
Plasma,BAO_0000218,,N,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631244,,9253,,,50597,17594,,
,BAO_0000218,,N,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631245,,9254,,,50597,3293,,
,BAO_0000218,,N,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627162,,9255,,,50597,6757,,
,BAO_0000218,,N,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627163,,9256,,,50597,6757,,
,BAO_0000218,,N,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627164,,9257,,,50597,6757,,
Kidney,BAO_0000218,,N,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627165,,9258,,,50597,5979,,
,BAO_0000218,,N,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627166,,9259,,,50597,5979,,
,BAO_0000218,,N,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627167,,9260,,,50597,5979,,
,BAO_0000218,,N,,Area under curve (AUC) at a dose of 30 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627822,,9261,,,50597,4026,,
,BAO_0000218,,N,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627823,,9262,,,50597,5355,,
,BAO_0000218,,N,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627824,,9263,,,50597,5355,,
,BAO_0000218,,N,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627825,,9264,,,50597,5355,,
,BAO_0000218,,N,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627826,,9265,,,50597,5633,,
,BAO_0000218,,N,,Area under curve (Pharmacokinetic property) was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627827,,9266,,,50597,1716,,
,BAO_0000218,,N,,Area under curve (Pharmacokinetic property) of the compound; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627828,,9267,,,50597,1716,,
,BAO_0000218,,N,,Area under curve after intravenous administration (1 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627829,,9268,,,50597,4689,,
,BAO_0000218,,N,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627830,,9269,,,50597,4527,,
,BAO_0000218,,N,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627831,,9270,,,50597,4527,,
,BAO_0000218,,N,,Area under curve in male SD rats was observed after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627832,,9271,,,50597,15662,,
,BAO_0000218,,N,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627833,,9272,,,50597,4413,,
,BAO_0000218,,N,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL627834,,9273,,,50597,3598,,
,BAO_0000218,,N,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL628004,,9274,,,50597,3598,,
,BAO_0000218,,N,,Area under curve at 5 mg/kg po was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628005,,9275,,,50597,5964,,
,BAO_0000218,,N,,Area under curve in Rat at a oral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628006,,9276,,,50597,4689,,
,BAO_0000218,,N,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628007,,9277,,,50597,4186,,
,BAO_0000218,,N,,Area under curve was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625676,,9278,,,50597,5510,,
,BAO_0000218,,N,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631309,,9279,,,50597,17858,,
,BAO_0000218,,N,,Area under curve after intravenous administration at 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631310,,9280,,,50597,17804,,
,BAO_0000218,,N,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631311,,9281,,,50597,6106,,
,BAO_0000218,,N,,Area under curve at 4 hr in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631312,,9282,,,50597,5964,,
,BAO_0000218,,N,,Area under curve at a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631313,,9283,,,50597,4026,,
,BAO_0000218,,N,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631314,,9284,,,50597,4756,,
,BAO_0000218,,N,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631315,,9285,,,50597,4756,,
,BAO_0000218,,N,,Area under curve for a 2-mpk po dose in SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631316,,9286,,,50597,5862,,
,BAO_0000218,,N,,Area under curve in SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631317,,9287,,,50597,5862,,
,BAO_0000218,,N,,Area under curve in rat after oral administration at 13 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874471,,9288,,,50597,6644,,
,BAO_0000218,,N,,Area under curve in rat by po administration at 0-24 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631318,,9289,,,50597,5871,,
Plasma,BAO_0000218,,N,,Area under curve in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631319,,9290,,,50597,5919,,
,BAO_0000218,,N,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631320,,9291,,,50597,5939,,
,BAO_0000218,,N,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631321,,9292,,,50597,5939,,
,BAO_0000218,,N,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631322,,9293,,,50597,10,,
,BAO_0000218,,N,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631323,,9294,,,50597,11149,,
,BAO_0000218,,N,,Area under curve value in rat at a dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631324,,9295,,,50597,5302,,
,BAO_0000218,,N,,Area under curve was determined after oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631325,,9296,,,50597,17796,,
,BAO_0000218,,N,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631326,,9297,,,50597,4890,,
,BAO_0000218,,N,,Area under curve was determined after peroral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631327,,9298,,,50597,6011,,
,BAO_0000218,,N,,Area under curve was determined at a dose 30 mpk administered orally.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631328,,9299,,,50597,5375,,
,BAO_0000218,,N,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631329,,9300,,,50597,17764,,
,BAO_0000218,,N,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627217,,9301,,,50597,4368,,
,BAO_0000218,,N,,Area under curve was determined in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626352,,9302,,,50597,5610,,
,BAO_0000218,,N,,Area under curve was determined in rat after PO administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626353,,9303,,,50597,5833,,
,BAO_0000218,,N,,Area under curve was determined in rat after a 3 mg/kg of oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626354,,9304,,,50597,4257,,
,BAO_0000218,,N,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626355,,9305,,,50597,5937,,
,BAO_0000218,,N,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626356,,9306,,,50597,5932,,
,BAO_0000218,,N,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626357,,9307,,,50597,5932,,
,BAO_0000218,,N,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626358,,9308,,,50597,17411,,
,BAO_0000218,,N,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626359,,9309,,,50597,17411,,
Plasma,BAO_0000218,,N,,Peak plasma concentration in rat at a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626360,,9310,,,50597,17771,,
,BAO_0000218,,N,,Plasma concentration at 2 hr in rats was evaluated.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626361,,9311,,,50597,1628,,
,BAO_0000218,,N,,Plasma concentration at 2 hr in rats was evaluated; Not available,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626362,,9312,,,50597,1628,,
,BAO_0000218,,N,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626363,,9313,,,50597,17411,,
,BAO_0000218,,N,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626970,,9314,,,50597,4910,,
,BAO_0000218,,N,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626971,,9315,,,50597,4910,,
Plasma,BAO_0000218,,N,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626972,,9316,,,50597,4910,,
Plasma,BAO_0000218,,N,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626973,,9317,,,50597,4910,,
Plasma,BAO_0000218,,N,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626974,,9318,,,50597,4910,,
Plasma,BAO_0000218,,N,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL874592,,9319,,,50597,4910,,
,BAO_0000218,,N,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626975,,9320,,,50597,5510,,
,BAO_0000218,,N,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626976,,9321,,,50597,5510,,
,BAO_0000218,,N,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626977,,9322,,,50597,5510,,
,BAO_0000218,,N,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626978,,9323,,,50597,5510,,
,BAO_0000218,,N,,PK study was carried to determine the relative absorption ranking in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626979,,9324,,,50597,16427,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626980,,9325,In vivo,,50597,4689,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626981,,9326,,,50597,11450,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626982,,9327,,,50597,11450,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626983,,9328,,,50597,11450,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622522,,9329,,,50597,11450,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622523,,9330,,,50597,11450,,
Blood,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622524,,9331,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622525,,9332,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622526,,9333,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619849,,9334,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL619850,,9335,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623864,,9336,,,50597,11450,,
Brain,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623865,,9337,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623866,,9338,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623867,,9339,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL877615,,9340,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623868,,9341,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623869,,9342,,,50597,11450,,
Heart,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623870,,9343,,,50597,11450,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL623871,,9344,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL623872,,9345,,,50597,16434,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622129,,9346,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622130,,9347,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622131,,9348,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622132,,9349,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622133,,9350,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622134,,9351,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622135,,9352,,,50597,16435,,
Lung,BAO_0000218,,N,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622136,,9353,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622137,,9354,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622138,,9355,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623017,,9356,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623018,,9357,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623019,,9358,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623020,,9359,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623021,,9360,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623022,,9361,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623023,,9362,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623024,,9363,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623025,,9364,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620545,,9365,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620546,,9366,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620547,,9367,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620548,,9368,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620549,,9369,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620550,,9370,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620551,,9371,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620552,,9372,,,50597,16434,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620553,,9373,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620554,,9374,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL875845,,9375,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620555,,9376,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620556,,9377,,,50597,16435,,
Muscle tissue,BAO_0000218,,N,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620557,,9378,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620558,,9379,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620559,,9380,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622939,,9381,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622940,,9382,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622941,,9383,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622942,,9384,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622943,,9385,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622944,,9386,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622945,,9387,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622946,,9388,,,50597,16435,,
,BAO_0000218,,N,,Compound was evaluated for terminal half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622947,,9389,,,50597,3341,,
Plasma,BAO_0000218,,N,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622948,,9390,In vivo,,50597,3634,,
Plasma,BAO_0000218,,N,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622949,,9391,In vivo,,50597,3634,,
,BAO_0000218,,N,,Compound was tested for its half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622950,,9392,,,50597,4839,,
Plasma,BAO_0000218,,U,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,1,,9544.0,A,Macaca mulatta,1969.0,0,Intermediate,CHEMBL622951,,9393,In vivo,,22224,5005,,
Plasma,BAO_0000366,,U,,Compound was tested for its plasma half life in Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,0,Intermediate,CHEMBL622952,,9394,,,22224,5005,,
Plasma,BAO_0000366,,U,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,1,,10116.0,A,Rattus norvegicus,1969.0,0,Intermediate,CHEMBL622953,,9395,,,22224,5005,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma half-life period in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873818,,9396,,,50597,1094,,
,BAO_0000218,,N,,Elimination half life after i.v. administration of compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622954,,9397,In vivo,,50597,5031,,
,BAO_0000218,,N,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622955,,9398,In vivo,,50597,6518,,
,BAO_0000218,,N,,Elimination half-life after IV dosing at 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875229,,9399,In vivo,,50597,6518,,
,BAO_0000218,,N,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622956,,9400,In vivo,,50597,6518,,
,BAO_0000218,,N,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622957,,9401,In vivo,,50597,6518,,
Brain,BAO_0000218,,N,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622958,,9402,In vivo,,50597,5408,,
Plasma,BAO_0000218,,N,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622959,,9403,In vivo,,50597,5408,,
Brain,BAO_0000218,,N,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622960,,9404,In vivo,,50597,5408,,
Plasma,BAO_0000218,,N,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622961,,9405,In vivo,,50597,5408,,
,BAO_0000218,,N,,Evaluated for the half life in rat (in vivo),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622962,,9406,In vivo,,50597,4687,,
,BAO_0000218,,N,,Hafl life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622963,,9407,,,50597,6640,,
,BAO_0000218,,N,,Hafl life rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622964,,9408,,,50597,6640,,
,BAO_0000218,,N,,Hafl life rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622965,,9409,,,50597,6641,,
,BAO_0000218,,N,,Hafl life rat; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622966,,9410,,,50597,6640,,
,BAO_0000218,,N,,Hafl life rat; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622967,,9411,,,50597,6641,,
Kidney,BAO_0000218,,N,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622968,,9412,In vivo,,50597,17411,,
Liver,BAO_0000218,,N,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622969,,9413,In vivo,,50597,17411,,
Lung,BAO_0000218,,N,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL875327,,9414,In vivo,,50597,17411,,
,BAO_0000218,,N,,Half life in rat after 1 mg/kg i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628638,,9415,In vivo,,50597,6570,,
,BAO_0000218,,N,,Half life in rat after 2 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628639,,9416,In vivo,,50597,6570,,
,BAO_0000218,,N,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625840,,9417,In vivo,,50597,17411,,
,BAO_0000218,,N,,Half life of 10 mg/kg oral dose determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625841,,9418,In vivo,,50597,4722,,
,BAO_0000218,,N,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625842,,9419,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625843,,9420,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625844,,9421,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873822,,9422,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625845,,9423,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627059,,9424,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627060,,9425,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627061,,9426,In vivo,,50597,5978,,
,BAO_0000218,,N,,Half life of compound at 5 mg/kg after po administration was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627709,,9427,In vivo,,50597,4762,,
,BAO_0000218,,N,,Half life of compound determined after intravenous administration to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627710,,9428,In vivo,,50597,5327,,
,BAO_0000218,,N,,Half life of compound was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627711,,9429,,,50597,4847,,
Plasma,BAO_0000218,,N,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627712,,9430,In vivo,,50597,17720,,
,BAO_0000218,,N,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627713,,9431,In vivo,,50597,4723,,
,BAO_0000218,,N,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627714,,9432,In vivo,,50597,4723,,
,BAO_0000218,,U,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,1,,9541.0,A,Macaca fascicularis,,0,Intermediate,CHEMBL627889,,9433,In vivo,,22224,4256,,
,BAO_0000218,,U,,Half life determined in rat by intravenous administration,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL627890,,9434,In vivo,,22224,4256,,
,BAO_0000218,,N,,Half life determined in rats after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627891,,9435,In vivo,,50597,4722,,
Plasma,BAO_0000218,,N,,Half life in rat plasma after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627892,,9436,In vivo,,50597,6535,,
Plasma,BAO_0000218,,N,,Half life in rat plasma after administration of 2 mg/kg iv,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627893,,9437,In vivo,,50597,6535,,
Plasma,BAO_0000218,,N,,Half life in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627894,,9438,,,50597,1435,,
Plasma,BAO_0000218,,N,,Half life in rat plasma was determined; NA means not applicable,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627895,,9439,,,50597,1435,,
,BAO_0000218,,N,,Half life in rat was tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627896,,9440,,,50597,5206,,
Plasma,BAO_0000218,,N,,Half life measured in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627897,,9441,,,50597,6080,,
,BAO_0000218,,N,,Half life recorded in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627898,,9442,,,50597,4449,,
,BAO_0000218,,N,,Half life was calculated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627899,,9443,,,50597,6057,,
,BAO_0000218,,N,,Half life was calculated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873823,,9444,,,50597,6057,,
,BAO_0000218,,N,,Half life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627900,,9445,,,50597,3747,,
,BAO_0000218,,N,,Half life after 10 mg/kg oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627901,,9446,In vivo,,50597,17858,,
,BAO_0000218,,N,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627902,,9447,In vivo,,50597,16365,,
,BAO_0000218,,N,,Half life after administering orally a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627903,,9448,In vivo,,50597,16365,,
,BAO_0000218,,N,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627904,,9449,,,50597,5031,,
,BAO_0000218,,N,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627905,,9450,,,50597,4722,,
,BAO_0000218,,N,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627906,,9451,,,50597,6078,,
,BAO_0000218,,N,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627907,,9452,,,50597,6078,,
,BAO_0000218,,N,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876783,,9453,,,50597,6078,,
,BAO_0000218,,N,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627908,,9454,,,50597,6078,,
,BAO_0000218,,N,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627909,,9455,,,50597,17065,,
,BAO_0000218,,N,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627910,,9456,,,50597,1353,,
,BAO_0000218,,N,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627911,,9457,,,50597,1353,,
,BAO_0000218,,N,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627912,,9458,,,50597,1353,,
,BAO_0000218,,N,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627913,,9459,,,50597,1353,,
,BAO_0000218,,N,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627914,,9460,,,50597,1353,,
,BAO_0000218,,N,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627915,,9461,,,50597,16423,,
,BAO_0000218,,N,,Area under the curve was evaluated after 20 uM/kg of peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627916,,9462,,,50597,16423,,
,BAO_0000218,,N,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627917,,9463,,,50597,6062,,
,BAO_0000218,,N,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627918,,9464,,,50597,6056,,
,BAO_0000218,,N,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627919,,9465,,,50597,5182,,
,BAO_0000218,,N,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627920,,9466,,,50597,6410,,
,BAO_0000218,,N,,Area under the curve was evaluated at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627921,,9467,,,50597,6410,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627922,,9468,,,50597,4723,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876784,,9469,,,50597,4723,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627923,,9470,,,50597,4723,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626208,,9471,,,50597,4723,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626209,,9472,,,50597,4723,,
,BAO_0000218,,N,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626210,,9473,,,50597,4723,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627994,,9474,,,50597,2463,,
,BAO_0000218,,N,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627995,,9475,,,50597,4709,,
,BAO_0000218,,N,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627996,,9476,,,50597,4075,,
,BAO_0000218,,N,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627997,,9477,,,50597,5394,,
,BAO_0000218,,N,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627998,,9478,,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628640,,9479,,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628641,,9480,,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628642,,9481,,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for area under the curve expressed as (h*ug/ml),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628643,,9482,,,50597,17791,,
,BAO_0000218,,N,,Compound was tested for area under curve in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628644,,9483,,,50597,2591,,
,BAO_0000218,,N,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628645,,9484,,,50597,6567,,
,BAO_0000218,,N,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628646,,9485,,,50597,6211,,
,BAO_0000218,,N,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628647,,9486,,,50597,5529,,
,BAO_0000218,,N,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628648,,9487,,,50597,5408,,
,BAO_0000218,,N,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625358,,9488,,,50597,5408,,
,BAO_0000218,,N,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625359,,9489,,,50597,5408,,
,BAO_0000218,,N,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625360,,9490,,,50597,5408,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625361,,9491,,,50597,429,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625362,,9492,,,50597,429,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625363,,9493,,,50597,429,,
,BAO_0000218,,N,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625364,,9494,,,50597,4796,,
,BAO_0000218,,N,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625365,,9495,,,50597,5974,,
,BAO_0000218,,N,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625366,,9496,,,50597,5974,,
,BAO_0000218,,N,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625367,,9497,,,50597,5974,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625368,,9498,,,50597,11450,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625369,,9499,,,50597,11450,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625370,,9500,,,50597,11450,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625371,,9501,,,50597,11450,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625372,,9502,,,50597,11450,,
Kidney,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625373,,9503,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625374,,9504,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL877593,,9505,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625375,,9506,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625376,,9507,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621973,,9508,,,50597,11450,,
Liver,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621974,,9509,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL621975,,9510,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622166,,9511,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622167,,9512,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622168,,9513,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622169,,9514,,,50597,11450,,
Lung,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622170,,9515,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622171,,9516,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622172,,9517,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622173,,9518,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622174,,9519,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622175,,9520,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622176,,9521,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622177,,9522,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622178,,9523,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622179,,9524,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622180,,9525,,,50597,11450,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622181,,9526,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622182,,9527,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622183,,9528,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622184,,9529,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622185,,9530,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622186,,9531,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622187,,9532,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625002,,9533,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622090,,9534,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622091,,9535,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622092,,9536,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622093,,9537,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622094,,9538,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622095,,9539,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622264,,9540,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622265,,9541,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622266,,9542,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622267,,9543,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622268,,9544,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622269,,9545,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625071,,9546,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621621,,9547,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621622,,9548,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621623,,9549,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621624,,9550,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621625,,9551,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621626,,9552,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621627,,9553,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621628,,9554,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL875328,,9555,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621629,,9556,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621630,,9557,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621631,,9558,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621632,,9559,,,50597,16434,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621633,,9560,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621634,,9561,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621635,,9562,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621636,,9563,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621637,,9564,,,50597,16435,,
Spleen,BAO_0000218,,N,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL621638,,9565,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618883,,9566,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618884,,9567,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628627,,9568,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628628,,9569,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628629,,9570,,,50597,16434,,
,BAO_0000218,,N,,Half life after administering orally a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628630,,9571,In vivo,,50597,16365,,
,BAO_0000218,,N,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628631,,9572,In vivo,,50597,16365,,
,BAO_0000218,,N,,Half life after administering intravenously a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628632,,9573,In vivo,,50597,16365,,
,BAO_0000218,,N,,Half life after oral dosing in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628633,,9574,In vivo,,50597,526,,
,BAO_0000218,,N,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628634,,9575,In vivo,,50597,16365,,
,BAO_0000218,,N,,Half life by intravenous administration of 3.4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627789,,9576,In vivo,,50597,4368,,
,BAO_0000218,,N,,Half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627790,,9577,,,50597,3371,,
,BAO_0000218,,N,,Half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627791,,9578,,,50597,6448,,
,BAO_0000218,,N,,Half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627792,,9579,,,50597,6453,,
,BAO_0000218,,N,,Half life in rat after intravenous administration of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627793,,9580,In vivo,,50597,4353,,
Plasma,BAO_0000218,,N,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627794,,9581,In vivo,,50597,4353,,
,BAO_0000218,,N,,Half life in rat after po administration of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627795,,9582,In vivo,,50597,4353,,
,BAO_0000218,,N,,Half life in rat after po administration of the compound; ND means Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627796,,9583,In vivo,,50597,4353,,
Plasma,BAO_0000218,,N,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL875335,,9584,In vivo,,50597,4353,,
Plasma,BAO_0000218,,N,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627797,,9585,In vivo,,50597,4353,,
,BAO_0000218,,N,,Half life in rat i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627798,,9586,In vivo,,50597,5789,,
,BAO_0000218,,N,,Half life in rat i.v. at 2 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627799,,9587,In vivo,,50597,17686,,
,BAO_0000218,,N,,Half life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627800,,9588,,,50597,6495,,
,BAO_0000218,,N,,Half life in rats after intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627801,,9589,In vivo,,50597,484,,
,BAO_0000218,,N,,Half life in rats at the dose of 1.0 mpk by i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627802,,9590,In vivo,,50597,6467,,
,BAO_0000218,,N,,Half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL627803,,9591,,,50597,6642,,
,BAO_0000218,,N,,Half life was evaluated after intravenous administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873820,,9592,In vivo,,50597,16367,,
,BAO_0000218,,N,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627804,,9593,,,50597,1369,,
,BAO_0000218,,N,,Half life was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627805,,9594,,,50597,5472,,
,BAO_0000218,,N,,Half life was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627806,,9595,,,50597,6049,,
,BAO_0000218,,N,,Half life was evaluated in rat; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627107,,9596,,,50597,5472,,
,BAO_0000218,,N,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627108,,9597,In vivo,,50597,16366,,
,BAO_0000218,,N,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627109,,9598,In vivo,,50597,11149,,
Blood,BAO_0000218,,N,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627110,,9599,In vivo,,50597,11149,,
,BAO_0000218,,U,,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,,9443.0,A,Primates,,0,Intermediate,CHEMBL627111,,9600,In vivo,,22224,2891,,
,BAO_0000218,,U,,Half life was measured in monkey at dose of 10 mg/kg by po administration,1,,9443.0,A,Primates,,0,Intermediate,CHEMBL627112,,9601,In vivo,,22224,2891,,
,BAO_0000218,,U,,Half life was measured in rat at dose of 30 mg/kg by iv administration,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL627113,,9602,In vivo,,22224,2891,,
,BAO_0000218,,U,,Half life was measured in rat at dose of 30 mg/kg by po administration,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL627114,,9603,In vivo,,22224,2891,,
,BAO_0000218,,N,,Half life (t1/2) was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627115,,9604,,,50597,4026,,
,BAO_0000218,,N,,Half life period at a dose of 10 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627116,,9605,,,50597,4527,,
,BAO_0000218,,N,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627117,,9606,In vivo,,50597,4527,,
,BAO_0000218,,N,,Half life period was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627118,,9607,,,50597,5503,,
,BAO_0000218,,N,,Half life period after intravenous administration at 20 mpk in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627119,,9608,In vivo,,50597,4426,,
,BAO_0000218,,N,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627120,,9609,In vivo,,50597,4426,,
,BAO_0000218,,N,,Half life period after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626922,,9610,In vivo,,50597,6109,,
,BAO_0000218,,N,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626923,,9611,In vivo,,50597,5654,,
,BAO_0000218,,N,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626924,,9612,In vivo,,50597,5654,,
Plasma,BAO_0000218,,N,,Half life period in 80% rat plasma at 37 degree Centigrade,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626925,,9613,,,50597,4755,,
,BAO_0000218,,N,,Half life period in SD rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626926,,9614,,,50597,5862,,
Plasma,BAO_0000218,,N,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626927,,9615,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626928,,9616,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626929,,9617,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626930,,9618,,,50597,1515,,
,BAO_0000218,,N,,Half life period in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626931,,9619,,,50597,5960,,
,BAO_0000218,,N,,Half life period in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626932,,9620,,,50597,6103,,
,BAO_0000218,,N,,Half life period in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626933,,9621,,,50597,6317,,
,BAO_0000218,,N,,Half life period in rat after oral administration at 10.5 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873826,,9622,In vivo,,50597,6644,,
,BAO_0000218,,N,,Half life period in rat after oral administration at 11.2 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626934,,9623,In vivo,,50597,6644,,
,BAO_0000218,,N,,Half life period in rat after oral administration at 13 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626935,,9624,In vivo,,50597,6644,,
,BAO_0000218,,N,,Half life period in rat after oral administration at 9.7 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626936,,9625,In vivo,,50597,6644,,
,BAO_0000218,,N,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626937,,9626,,,50597,5974,,
,BAO_0000218,,N,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625906,,9627,,,50597,6295,,
,BAO_0000218,,N,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625907,,9628,,,50597,6296,,
,BAO_0000218,,N,,PK study was carried to determine AUC (area under curve) value in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625908,,9629,,,50597,16427,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC after intravenous administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625909,,9630,,,50597,16367,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC after oral administration to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625910,,9631,,,50597,16367,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625911,,9632,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625912,,9633,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626538,,9634,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876794,,9635,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626539,,9636,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626540,,9637,,,50597,16365,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626541,,9638,,,50597,5394,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626542,,9639,,,50597,5394,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626543,,9640,,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626544,,9641,,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626545,,9642,,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626546,,9643,,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under curve was reported,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626547,,9644,,,50597,5334,,
,BAO_0000218,,N,,Pharmacokinetic property (AUC) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626548,,9645,,,50597,4408,,
,BAO_0000218,,N,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626549,,9646,,,50597,5983,,
,BAO_0000218,,N,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626550,,9647,,,50597,4397,,
,BAO_0000218,,N,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626551,,9648,,,50597,4397,,
,BAO_0000218,,N,,Pharmacokinetic property was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623777,,9649,,,50597,5491,,
,BAO_0000218,,N,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623778,,9650,,,50597,5491,,
,BAO_0000218,,N,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623779,,9651,,,50597,5491,,
Plasma,BAO_0000218,,N,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623780,,9652,,,50597,4199,,
Plasma,BAO_0000218,,N,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622015,,9653,,,50597,4199,,
Plasma,BAO_0000218,,N,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622016,,9654,,,50597,4199,,
,BAO_0000218,,N,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622017,,9655,,,50597,5173,,
,BAO_0000218,,N,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622018,,9656,,,50597,5173,,
,BAO_0000218,,N,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622019,,9657,,,50597,5173,,
,BAO_0000218,,N,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622020,,9658,,,50597,5173,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622021,,9659,,,50597,16366,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622022,,9660,,,50597,16366,,
,BAO_0000218,,N,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622023,,9661,,,50597,5327,,
,BAO_0000218,,N,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622024,,9662,,,50597,6681,,
,BAO_0000218,,N,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622693,,9663,,,50597,12873,,
,BAO_0000218,,N,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622694,,9664,,,50597,12873,,
,BAO_0000218,,N,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622695,,9665,,,50597,6685,,
,BAO_0000218,,N,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622696,,9666,,,50597,6685,,
,BAO_0000218,,N,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622697,,9667,,,50597,6685,,
,BAO_0000218,,N,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622874,,9668,,,50597,6619,,
,BAO_0000218,,N,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622875,,9669,,,50597,6619,,
,BAO_0000218,,N,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622876,,9670,,,50597,10363,,
,BAO_0000218,,N,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622877,,9671,,,50597,4796,,
,BAO_0000218,,N,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622878,,9672,,,50597,4910,,
Plasma,BAO_0000218,,N,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622879,,9673,,,50597,4910,,
,BAO_0000218,,N,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877602,,9674,,,50597,4839,,
,BAO_0000218,,N,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622880,,9675,,,50597,15078,,
,BAO_0000218,,N,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622881,,9676,,,50597,15078,,
,BAO_0000218,,N,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622882,,9677,,,50597,15078,,
,BAO_0000218,,N,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622883,,9678,,,50597,15078,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622884,,9679,,,50597,11450,,
Thyroid gland,BAO_0000218,,N,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622885,,9680,,,50597,11450,,
,BAO_0000218,,N,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622886,,9681,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622887,,9682,,,50597,8151,,
Urine,BAO_0000218,,N,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622888,,9683,,,50597,8151,,
Blood,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622889,,9684,In vivo,,50597,8677,,
Blood,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622890,,9685,In vivo,,50597,8677,,
Blood,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622891,,9686,In vivo,,50597,8677,,
Blood,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL877603,,9687,In vivo,,50597,8677,,
Brain,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622892,,9688,In vivo,,50597,8677,,
Brain,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622893,,9689,In vivo,,50597,8677,,
Brain,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622894,,9690,In vivo,,50597,8677,,
Brain,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622895,,9691,In vivo,,50597,8677,,
Brain,BAO_0000218,,N,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622896,,9692,In vivo,,50597,8677,,
Heart,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622897,,9693,In vivo,,50597,8677,,
Heart,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622898,,9694,In vivo,,50597,8677,,
Heart,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622899,,9695,In vivo,,50597,8677,,
Kidney,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622900,,9696,In vivo,,50597,8677,,
Kidney,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624114,,9697,In vivo,,50597,8677,,
Kidney,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624115,,9698,In vivo,,50597,8677,,
Kidney,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624116,,9699,In vivo,,50597,8677,,
Liver,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624117,,9700,In vivo,,50597,8677,,
Liver,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624118,,9701,In vivo,,50597,8677,,
Liver,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624119,,9702,In vivo,,50597,8677,,
Liver,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624120,,9703,In vivo,,50597,8677,,
Lung,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624121,,9704,In vivo,,50597,8677,,
Lung,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624122,,9705,In vivo,,50597,8677,,
Lung,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624123,,9706,In vivo,,50597,8677,,
Lung,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624124,,9707,In vivo,,50597,8677,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624125,,9708,In vivo,,50597,8677,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624126,,9709,In vivo,,50597,8677,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624127,,9710,In vivo,,50597,8677,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624128,,9711,In vivo,,50597,8677,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL624129,,9712,In vivo,,50597,8677,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL624130,,9713,In vivo,,50597,8677,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL622340,,9714,In vivo,,50597,8677,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL622341,,9715,In vivo,,50597,8677,,
Intestine,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622342,,9716,In vivo,,50597,8677,,
Intestine,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622343,,9717,In vivo,,50597,8677,,
Intestine,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622344,,9718,In vivo,,50597,8677,,
Intestine,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622345,,9719,In vivo,,50597,8677,,
Spleen,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622346,,9720,In vivo,,50597,8677,,
Spleen,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622347,,9721,In vivo,,50597,8677,,
Spleen,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622348,,9722,In vivo,,50597,8677,,
Spleen,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622349,,9723,In vivo,,50597,8677,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622350,,9724,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622351,,9725,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622352,,9726,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622353,,9727,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622354,,9728,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622355,,9729,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622356,,9730,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622357,,9731,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622358,,9732,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622359,,9733,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874393,,9734,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622872,,9735,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622873,,9736,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623047,,9737,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623048,,9738,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623049,,9739,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623050,,9740,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623051,,9741,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623052,,9742,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626343,,9743,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626344,,9744,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626345,,9745,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626346,,9746,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626347,,9747,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626348,,9748,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626349,,9749,,,50597,16434,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626350,,9750,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626351,,9751,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627650,,9752,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL627651,,9753,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627652,,9754,,,50597,16435,,
,BAO_0000218,,N,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627653,,9755,,,50597,16435,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627654,,9756,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627835,,9757,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627836,,9758,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627837,,9759,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627838,,9760,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875338,,9761,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627839,,9762,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627840,,9763,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627841,,9764,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627842,,9765,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627843,,9766,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627844,,9767,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627845,,9768,,,50597,13091,,
,BAO_0000218,,N,,Half life period in rat by iv administration at a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627846,,9769,In vivo,,50597,5874,,
Plasma,BAO_0000218,,N,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627847,,9770,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873821,,9771,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626079,,9772,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626080,,9773,,,50597,1515,,
Plasma,BAO_0000218,,N,,Half life period was evaluated in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626081,,9774,,,50597,5491,,
Plasma,BAO_0000218,,N,,Half life period was evaluated in rat plasma; Not tested,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL875344,,9775,,,50597,5491,,
,BAO_0000218,,N,,Half life period was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626082,,9776,,,50597,1918,,
,BAO_0000218,,N,,"Half life period was evaluated in rats, iv",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626250,,9777,In vivo,,50597,1918,,
,BAO_0000218,,N,,Half life period after intravenous administration at 5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626251,,9778,In vivo,,50597,6113,,
,BAO_0000218,,N,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626252,,9779,In vivo,,50597,5546,,
,BAO_0000218,,N,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626253,,9780,In vivo,,50597,5553,,
Plasma,BAO_0000218,,N,,Half life stability of compound was evaluated in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626254,,9781,,,50597,4188,,
,BAO_0000218,,N,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626255,,9782,In vivo,,50597,6215,,
,BAO_0000218,,N,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626256,,9783,In vivo,,50597,6141,,
,BAO_0000218,,N,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626257,,9784,In vivo,,50597,5182,,
,BAO_0000218,,N,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626258,,9785,In vivo,,50597,5182,,
,BAO_0000218,,N,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626259,,9786,In vivo,,50597,5710,,
,BAO_0000218,,N,,Half in rat i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626260,,9787,In vivo,,50597,5789,,
,BAO_0000218,,N,,Half period in rat after intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875345,,9788,In vivo,,50597,6011,,
,BAO_0000218,,N,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626261,,9789,In vivo,,50597,17594,,
Liver,BAO_0000218,,N,,Half-life measured in in vitro Cathepsin B assay in rat liver,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626262,,9790,In vitro,,50597,12357,,
,BAO_0000218,,N,,Half-life of compound was determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626263,,9791,,,50597,5210,,
,BAO_0000218,,N,,Half-life at 10 mg/kg in rat upon intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625270,,9792,In vivo,,50597,17596,,
,BAO_0000218,,N,,Half-life determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625271,,9793,,,50597,6672,,
,BAO_0000218,,N,,Half-life determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625272,,9794,,,50597,6673,,
Brain,BAO_0000218,,N,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625273,,9795,In vivo,,50597,4910,,
Plasma,BAO_0000218,,N,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625274,,9796,,,50597,3741,,
,BAO_0000218,,N,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625275,,9797,In vivo,,50597,17671,,
Plasma,BAO_0000218,,N,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625276,,9798,In vivo,,50597,4910,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625277,,9799,,,50597,17537,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625278,,9800,,,50597,4965,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma; Not tested,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625279,,9801,,,50597,17537,,
Serum,BAO_0000218,,N,,Half-life in rat serum,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL625280,,9802,,,50597,6124,,
Serum,BAO_0000218,,N,,Half-life in rat serum; na is not available,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL876797,,9803,,,50597,6124,,
,BAO_0000218,,N,,Half-life was calculated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625281,,9804,,,50597,6078,,
Plasma,BAO_0000218,,N,,Half-life was calculated in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL873827,,9805,,,50597,17668,,
,BAO_0000218,,N,,Half-life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625282,,9806,,,50597,3185,,
,BAO_0000218,,N,,Half-life was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625283,,9807,,,50597,4883,,
,BAO_0000218,,N,,Half-life after administration of 20 mg/Kg oral dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625284,,9808,In vivo,,50597,2959,,
,BAO_0000218,,N,,Half-life after administration of 3.2 mg/kg intravenously in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625285,,9809,In vivo,,50597,4029,,
,BAO_0000218,,N,,Half-life after intravenous administration in female rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625286,,9810,In vivo,,50597,4029,,
,BAO_0000218,,N,,Half-life after intravenous administration in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625287,,9811,In vivo,,50597,4029,,
,BAO_0000218,,N,,Half-life after intravenous dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625288,,9812,In vivo,,50597,6180,,
Liver,BAO_0000218,,N,,Half-life in a rat liver homogenate preparation,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625289,,9813,,,50597,1557,,
Plasma,BAO_0000218,,N,,Half-life in plasma of rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625290,,9814,,,50597,12500,,
Plasma,BAO_0000218,,N,,Half-life in plasma of rat at dose of 3-10 mgkg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876798,,9815,,,50597,12500,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625291,,9816,,,50597,5064,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625292,,9817,,,50597,5145,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625293,,9818,,,50597,5147,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622832,,9819,,,50597,5833,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622833,,9820,,,50597,6596,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622834,,9821,,,50597,17655,,
,BAO_0000218,,N,,Half-life in rat after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622835,,9822,In vivo,,50597,6495,,
,BAO_0000218,,N,,Half-life in rat after po administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622836,,9823,In vivo,,50597,17538,,
,BAO_0000218,,N,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622837,,9824,In vivo,,50597,17538,,
,BAO_0000218,,N,,Half-life in rat at 3 mg/kg dose administered intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622838,,9825,In vivo,,50597,10,,
Brain,BAO_0000218,,N,,Half-life in rat brain homogenate,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622839,,9826,,,50597,17669,,
Plasma,BAO_0000218,,N,,Half-life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622840,,9827,,,50597,17065,,
,BAO_0000218,,N,,Half-life in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622841,,9828,,,50597,4333,,
,BAO_0000218,,N,,Half-life in Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622842,,9829,,,50597,6827,,
Plasma,BAO_0000218,,N,,Half-life in vitro in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622843,,9830,In vitro,,50597,889,,
Plasma,BAO_0000218,,N,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622844,,9831,In vitro,,50597,889,,
,BAO_0000218,,N,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622845,,9832,,,50597,3747,,
,BAO_0000218,,N,,The area under the curve of compound was measured at the dose of 100 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622846,,9833,,,50597,15022,,
,BAO_0000218,,N,,The area under the curve of compound was measured at the dose of 300 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622847,,9834,,,50597,15022,,
,BAO_0000218,,N,,The area under the curve of compound was measured at the dose of 30 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622848,,9835,,,50597,15022,,
,BAO_0000218,,N,,Bioavailability as oral AUC in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622849,,9836,In vivo,,50597,3360,,
Plasma,BAO_0000218,,N,,The plasma concentration versus time curve (AUC) was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622850,,9837,,,50597,5334,,
,BAO_0000218,,N,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876807,,9838,,,50597,17411,,
,BAO_0000218,,N,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622851,,9839,,,50597,17411,,
,BAO_0000218,,N,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622852,,9840,,,50597,17411,,
,BAO_0000218,,N,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622853,,9841,,,50597,6570,,
,BAO_0000218,,N,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622854,,9842,,,50597,6570,,
,BAO_0000218,,N,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622855,,9843,,,50597,17411,,
Plasma,BAO_0000218,,N,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622856,,9844,,,50597,14941,,
Plasma,BAO_0000218,,N,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622857,,9845,,,50597,14941,,
Plasma,BAO_0000218,,N,,AUC in rat after po administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622858,,9846,,,50597,17538,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622859,,9847,,,50597,17752,,
,BAO_0000218,,N,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622860,,9848,,,50597,17509,,
,BAO_0000218,,N,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622861,,9849,,,50597,17509,,
,BAO_0000218,,N,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622862,,9850,,,50597,17509,,
,BAO_0000218,,N,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622863,,9851,,,50597,17509,,
,BAO_0000218,,N,,Area under curve value 6 hr after po administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623817,,9852,,,50597,17509,,
,BAO_0000218,,N,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623818,,9853,,,50597,17717,,
,BAO_0000218,,N,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623819,,9854,,,50597,17717,,
,BAO_0000218,,N,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623820,,9855,,,50597,17717,,
,BAO_0000218,,N,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623821,,9856,,,50597,17717,,
Plasma,BAO_0000218,,N,,AUC normalized for dose (AUCN) in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623822,,9857,,,50597,6642,,
,BAO_0000218,,N,,Area under curve in rat after p.o. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623823,,9858,,,50597,6640,,
,BAO_0000218,,N,,Area under curve in rat after p.o. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623824,,9859,,,50597,6641,,
,BAO_0000218,,N,,Area under curve in rat after p.o. administration; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623825,,9860,,,50597,6641,,
,BAO_0000218,,N,,Area under curve in rat after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622070,,9861,,,50597,6641,,
,BAO_0000218,,N,,Area under curve (carotid artery) value of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622071,,9862,,,50597,3603,,
,BAO_0000218,,N,,Bioavailability expressed as the area under curve of rat carotid artery,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622072,,9863,,,50597,3550,,
,BAO_0000218,,N,,Area under curve in male SD rats was observed after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622073,,9864,,,50597,15662,,
,BAO_0000218,,N,,Area under curve of the compound was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622074,,9865,,,50597,17720,,
,BAO_0000218,,N,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622075,,9866,,,50597,5407,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622076,,9867,,,50597,17752,,
Plasma,BAO_0000218,,N,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622077,,9868,,,50597,17752,,
,BAO_0000218,,N,,Area under curve (portal vein) value of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622078,,9869,,,50597,3603,,
,BAO_0000218,,N,,Bioavailability expressed as the area under curve of rat portal vein,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622079,,9870,,,50597,3550,,
Plasma,BAO_0000218,,N,,Area Under plasma concentration time curve in rat upon peroral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622080,,9871,,,50597,17655,,
,BAO_0000218,,N,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877612,,9872,,,50597,17582,,
,BAO_0000218,,N,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622081,,9873,,,50597,17582,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622082,,9874,,,50597,17791,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622083,,9875,,,50597,17791,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats; 30-80,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622084,,9876,,,50597,17791,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats; 50-60,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622085,,9877,,,50597,17791,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622086,,9878,,,50597,17791,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats; peptide,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622087,,9879,,,50597,17791,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622088,,9880,,,50597,7768,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622089,,9881,,,50597,7768,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623685,,9882,,,50597,7768,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623686,,9883,,,50597,7768,,
Stomach,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL623687,,9884,In vivo,,50597,8677,,
Stomach,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL623688,,9885,In vivo,,50597,8677,,
Stomach,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL623689,,9886,In vivo,,50597,8677,,
Stomach,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,945.0,1,Intermediate,CHEMBL622485,,9887,In vivo,,50597,8677,,
Thyroid gland,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622486,,9888,In vivo,,50597,8677,,
Thyroid gland,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL877613,,9889,In vivo,,50597,8677,,
Thyroid gland,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622487,,9890,In vivo,,50597,8677,,
Thyroid gland,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622488,,9891,In vivo,,50597,8677,,
Heart,BAO_0000218,,N,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622489,,9892,In vivo,,50597,8677,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622490,,9893,,,50597,6899,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622491,,9894,,,50597,6899,,
Liver,BAO_0000218,,N,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622492,,9895,,,50597,6899,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622493,,9896,,,50597,6899,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622494,,9897,,,50597,6899,,
Muscle tissue,BAO_0000218,,N,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622495,,9898,,,50597,8677,,
,BAO_0000218,,N,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622496,,9899,,,50597,6899,,
Urine,BAO_0000218,,N,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622497,,9900,,,50597,6899,,
,BAO_0000218,,N,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622498,,9901,,,50597,2189,,
Urine,BAO_0000218,,N,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624918,,9902,,,50597,2189,,
Urine,BAO_0000218,,N,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624919,,9903,,,50597,2189,,
Blood,BAO_0000218,,N,,Biodistribution of compound in rat blood after 5 min of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624920,,9904,In vivo,,50597,10839,,
Blood,BAO_0000218,,N,,Biodistribution of compound in rat blood after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624921,,9905,In vivo,,50597,10839,,
Brain,BAO_0000218,,N,,Biodistribution of compound in rat brain after 5 min of administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624922,,9906,In vivo,,50597,10839,,
Heart,BAO_0000218,,N,,Biodistribution of compound in rat heart after 5 min of administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624923,,9907,In vivo,,50597,10839,,
Heart,BAO_0000218,,N,,Biodistribution of compound in rat heart after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624924,,9908,In vivo,,50597,10839,,
Kidney,BAO_0000218,,N,,Biodistribution of compound in rat kidney after 5 min of administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624925,,9909,In vivo,,50597,10839,,
Kidney,BAO_0000218,,N,,Biodistribution of compound in rat kidney after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624926,,9910,In vivo,,50597,10839,,
Liver,BAO_0000218,,N,,Biodistribution of compound in rat liver after 5 min of administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624927,,9911,In vivo,,50597,10839,,
Liver,BAO_0000218,,N,,Biodistribution of compound in rat liver after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL874402,,9912,In vivo,,50597,10839,,
Lung,BAO_0000218,,N,,Biodistribution of compound in rat lung after 5 min of administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624928,,9913,In vivo,,50597,10839,,
Lung,BAO_0000218,,N,,Biodistribution of compound in rat lung after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624929,,9914,In vivo,,50597,10839,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of compound in rat muscle after 5 min of administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624930,,9915,In vivo,,50597,10839,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of compound in rat muscle after 5 min of administration.,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624931,,9916,In vivo,,50597,10839,,
Heart,BAO_0000218,,N,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624932,,9917,,,50597,4043,,
Heart,BAO_0000218,,N,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624933,,9918,,,50597,4043,,
Liver,BAO_0000218,,N,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624934,,9919,,,50597,4043,,
Liver,BAO_0000218,,N,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624935,,9920,,,50597,4043,,
,BAO_0000218,,N,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624936,,9921,,,50597,4043,,
,BAO_0000218,,N,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624937,,9922,,,50597,4043,,
Spleen,BAO_0000218,,N,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL624938,,9923,,,50597,4043,,
Spleen,BAO_0000218,,N,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL624939,,9924,,,50597,4043,,
,BAO_0000218,,N,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624940,,9925,,,50597,4043,,
,BAO_0000218,,N,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874403,,9926,,,50597,4043,,
,BAO_0000218,,N,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624941,,9927,,,50597,1446,,
Urine,BAO_0000218,,N,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624942,,9928,,,50597,9971,,
Urine,BAO_0000218,,N,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624943,,9929,,,50597,9971,,
,BAO_0000218,,N,,% Bioavailability after 1 day of the drug administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624944,,9930,In vivo,,50597,5765,,
,BAO_0000218,,N,,% Bioavailability after 4 day of the drug administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624945,,9931,In vivo,,50597,5765,,
,BAO_0000218,,N,,Absolute bioavailability was evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624946,,9932,In vivo,,50597,4257,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624947,,9933,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624948,,9934,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624949,,9935,,,50597,13091,,
Kidney,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622025,,9936,,,50597,13091,,
Kidney,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622026,,9937,,,50597,13091,,
Kidney,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622027,,9938,,,50597,13091,,
Kidney,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622028,,9939,,,50597,13091,,
Liver,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622029,,9940,,,50597,13091,,
Liver,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622208,,9941,,,50597,13091,,
Liver,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622209,,9942,,,50597,13091,,
Liver,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622210,,9943,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622211,,9944,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622212,,9945,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622213,,9946,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874404,,9947,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620452,,9948,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620453,,9949,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL620454,,9950,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624067,,9951,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624068,,9952,,,50597,13091,,
Female gonad,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL624069,,9953,,,50597,13091,,
Female gonad,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL624070,,9954,,,50597,13091,,
Female gonad,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL624071,,9955,,,50597,13091,,
Uterus,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL624072,,9956,,,50597,13091,,
Uterus,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL624073,,9957,,,50597,13091,,
Uterus,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL624788,,9958,,,50597,13091,,
Uterus,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL624789,,9959,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624790,,9960,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624791,,9961,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624792,,9962,,,50597,13091,,
,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624793,,9963,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL877491,,9964,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624957,,9965,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624958,,9966,,,50597,13091,,
Muscle tissue,BAO_0000218,,N,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624959,,9967,,,50597,13091,,
,BAO_0000218,,N,,Dissociation constant was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624960,,9968,,,50597,11977,,
,BAO_0000218,,N,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624961,,9969,,,50597,14941,,
,BAO_0000218,,N,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624962,,9970,,,50597,15078,,
,BAO_0000218,,N,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624963,,9971,,,50597,15078,,
,BAO_0000218,,N,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624964,,9972,,,50597,4755,,
,BAO_0000218,,N,,LogP value was evaluated in the in situ rat gut perfusion assay,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624965,,9973,,,50597,589,,
,BAO_0000218,,N,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624966,,9974,In vivo,,50597,17582,,
,BAO_0000218,,N,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624967,,9975,In vivo,,50597,5031,,
,BAO_0000218,,N,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624968,,9976,In vivo,,50597,17764,,
,BAO_0000218,,N,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624969,,9977,,,50597,17720,,
,BAO_0000218,,N,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,1,,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL624970,,9978,,,50597,2862,,
,BAO_0000218,,N,,Half-life was evaluated after 10 uM/kg of intra arterial administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624971,,9979,,,50597,16423,,
,BAO_0000218,,N,,Half-life was evaluated after 20 uM/kg of peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624972,,9980,In vivo,,50597,16423,,
,BAO_0000218,,N,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624973,,9981,In vivo,,50597,6005,,
Plasma,BAO_0000218,,N,,Half-life was evaluated in plasma of rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL624974,,9982,,,50597,2938,,
,BAO_0000218,,N,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624975,,9983,In vivo,,50597,6410,,
,BAO_0000218,,N,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877492,,9984,In vivo,,50597,6410,,
,BAO_0000218,,N,,Half-life was measured in rat after an iv dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624976,,9985,In vivo,,50597,6062,,
,BAO_0000218,,N,,Half-life period of compound in rats after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624977,,9986,In vivo,,50597,6571,,
Plasma,BAO_0000218,,N,,Half-life period of compound was measured in rat plasma.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626848,,9987,,,50597,3136,,
Plasma,BAO_0000218,,N,,Half-life period of compound was measured in rat plasma; ND is not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626849,,9988,,,50597,3136,,
Plasma,BAO_0000218,,N,,Half-life period of compound was measured in rat plasma; not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626850,,9989,,,50597,3136,,
,BAO_0000218,,N,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626851,,9990,In vivo,,50597,4521,,
,BAO_0000218,,N,,Half-life period in rat by iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626852,,9991,In vivo,,50597,5871,,
,BAO_0000218,,N,,Half-life period in rats following intravenous administration at 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626853,,9992,In vivo,,50597,6077,,
,BAO_0000218,,N,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626854,,9993,In vivo,,50597,6679,,
,BAO_0000218,,N,,Half-life period was determined for the compound in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627486,,9994,,,50597,5144,,
,BAO_0000218,,N,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627487,,9995,In vivo,,50597,4498,,
,BAO_0000218,,N,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627488,,9996,In vivo,,50597,4498,,
,BAO_0000218,,N,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627489,,9997,In vivo,,50597,1908,,
,BAO_0000218,,N,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627490,,9998,In vivo,,50597,6211,,
,BAO_0000218,,N,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873829,,9999,In vivo,,50597,5529,,
,BAO_0000218,,N,,Half-life was determined in rat at a dose of 1 mpk i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627655,,10000,In vivo,,50597,6444,,
,BAO_0000218,,N,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625994,,10001,In vivo,,50597,6444,,
,BAO_0000218,,N,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625995,,10002,In vivo,,50597,6444,,
,BAO_0000218,,N,,Half-life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625996,,10003,,,50597,5207,,
Plasma,BAO_0000218,,N,,In vitro half life in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625850,,10004,In vitro,,50597,530,,
Plasma,BAO_0000218,,N,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625851,,10005,In vitro,,50597,1116,,
,BAO_0000218,,N,,In vitro half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625852,,10006,In vitro,,50597,3219,,
,BAO_0000218,,N,,In vivo half life period after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625853,,10007,In vivo,,50597,6109,,
,BAO_0000218,,N,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625854,,10008,In vivo,,50597,17582,,
,BAO_0000218,,N,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874450,,10009,In vivo,,50597,17582,,
,BAO_0000218,,N,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625855,,10010,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625856,,10011,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625857,,10012,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873831,,10013,In vivo,,50597,5974,,
,BAO_0000218,,N,,Longer half-life in rat (i.v.) at 0.5 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625858,,10014,In vivo,,50597,17853,,
,BAO_0000218,,N,,Longer half-life in rat (p.o.) at 2.0 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625859,,10015,In vivo,,50597,17853,,
,BAO_0000218,,N,,Pharmacokinetic property (half life) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625860,,10016,,,50597,3457,,
,BAO_0000218,,N,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625861,,10017,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625862,,10018,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625863,,10019,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625864,,10020,In vivo,,50597,2792,,
,BAO_0000218,,N,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625865,,10021,In vivo,,50597,5739,,
,BAO_0000218,,N,,Pharmacokinetic half time was determined intravenously in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625866,,10022,In vivo,,50597,15765,,
Plasma,BAO_0000218,,N,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625867,,10023,In vivo,,50597,6567,,
Plasma,BAO_0000218,,N,,Plasma half life of hydrolysis of the compound,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625868,,10024,,,50597,2448,,
Plasma,BAO_0000218,,N,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625869,,10025,In vivo,,50597,5423,,
Plasma,BAO_0000218,,N,,Plasma half life period was calculated in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL874451,,10026,,,50597,4853,,
Plasma,BAO_0000218,,N,,Plasma half-life in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625870,,10027,,,50597,4514,,
Plasma,BAO_0000218,,N,,Plasma half-life in Sprague-Dawley rats; Not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625871,,10028,,,50597,4514,,
Plasma,BAO_0000218,,N,,Plasma half-life in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625872,,10029,,,50597,1500,,
Plasma,BAO_0000218,,N,,Plasma half-life in rats; <MQL,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625873,,10030,,,50597,1500,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625874,,10031,,,50597,5334,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625875,,10032,,,50597,5334,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625876,,10033,In vivo,,50597,5334,,
Plasma,BAO_0000218,,N,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631258,,10034,In vivo,,50597,5334,,
Plasma,BAO_0000218,,N,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631259,,10035,,,50597,4956,,
Plasma,BAO_0000218,,N,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631260,,10036,,,50597,4956,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631261,,10037,,,50597,7768,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631262,,10038,,,50597,7768,,
Blood,BAO_0000218,,N,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631263,,10039,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631264,,10040,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631265,,10041,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631266,,10042,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631267,,10043,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631268,,10044,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631269,,10045,,,50597,7768,,
,BAO_0000218,,N,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631270,,10046,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631271,,10047,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631272,,10048,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631273,,10049,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631274,,10050,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631275,,10051,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626984,,10052,,,50597,7768,,
Heart,BAO_0000218,,N,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626985,,10053,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626986,,10054,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626987,,10055,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626988,,10056,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626989,,10057,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626990,,10058,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626991,,10059,,,50597,7768,,
Liver,BAO_0000218,,N,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626992,,10060,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626993,,10061,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL874593,,10062,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626994,,10063,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626995,,10064,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626190,,10065,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626191,,10066,,,50597,7768,,
Lung,BAO_0000218,,N,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626364,,10067,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626365,,10068,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626366,,10069,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626367,,10070,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626368,,10071,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626369,,10072,,,50597,7768,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626370,,10073,,,50597,7768,,
,BAO_0000218,,N,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626371,,10074,In vivo,,50597,4498,,
,BAO_0000218,,N,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626372,,10075,In vivo,,50597,4498,,
,BAO_0000218,,N,,Bioavailability after a dose of 10 mg/kg p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626373,,10076,In vivo,,50597,3603,,
,BAO_0000218,,N,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626374,,10077,In vivo,,50597,6215,,
,BAO_0000218,,N,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626375,,10078,In vivo,,50597,5710,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626376,,10079,In vivo,,50597,5710,,
,BAO_0000218,,N,,Bioavailability in rat po was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626377,,10080,In vivo,,50597,5676,,
,BAO_0000218,,N,,Bioavailability of compound at 10 mg/kg in rat after oral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626378,,10081,In vivo,,50597,17667,,
,BAO_0000218,,N,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626379,,10082,In vivo,,50597,17667,,
,BAO_0000218,,N,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626380,,10083,In vivo,,50597,6848,,
,BAO_0000218,,N,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626381,,10084,In vivo,,50597,6848,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626382,,10085,In vivo,,50597,17267,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley) (female),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626383,,10086,In vivo,,50597,6362,,
,BAO_0000218,,N,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874652,,10087,In vivo,,50597,17671,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626384,,10088,In vivo,,50597,17671,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626385,,10089,In vivo,,50597,4333,,
,BAO_0000218,,N,,Bioavailability in rat at an oral dose of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626386,,10090,In vivo,,50597,6077,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626387,,10091,In vivo,,50597,3278,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626388,,10092,In vivo,,50597,5964,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626389,,10093,In vivo,,50597,4884,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626390,,10094,In vivo,,50597,4905,,
,BAO_0000218,,N,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626391,,10095,In vivo,,50597,4884,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626392,,10096,In vivo,,50597,6850,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626393,,10097,In vivo,,50597,2864,,
,BAO_0000218,,N,,Bioavailability was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623026,,10098,In vivo,,50597,5780,,
,BAO_0000218,,N,,Bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623027,,10099,In vivo,,50597,1465,,
,BAO_0000218,,N,,Bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623028,,10100,In vivo,,50597,5199,,
,BAO_0000218,,N,,Bioavailability in rat after 1 day dosing,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623029,,10101,In vivo,,50597,5765,,
,BAO_0000218,,N,,Bioavailability in rat after 4 day dosing,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623030,,10102,In vivo,,50597,5765,,
,BAO_0000218,,N,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623031,,10103,In vivo,,50597,6518,,
,BAO_0000218,,N,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623032,,10104,In vivo,,50597,6518,,
,BAO_0000218,,N,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623033,,10105,In vivo,,50597,6518,,
,BAO_0000218,,N,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623034,,10106,In vivo,,50597,6518,,
,BAO_0000218,,N,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623035,,10107,In vivo,,50597,2083,,
,BAO_0000218,,N,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623036,,10108,In vivo,,50597,17260,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623037,,10109,In vivo,,50597,4956,,
,BAO_0000218,,N,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623038,,10110,In vivo,,50597,4368,,
Plasma,BAO_0000218,,N,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL874385,,10111,In vivo,,50597,17752,,
,BAO_0000218,,N,,Bioavailability in rat (Fisher) (fasted),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623039,,10112,In vivo,,50597,1446,,
,BAO_0000218,,U,,Bioavailability in monkey after po administration of 10 mg/kg dose,1,,9443.0,A,Primates,,0,Intermediate,CHEMBL623040,,10113,In vivo,,22224,2891,,
,BAO_0000218,,U,,Oral bioavailability in monkey (dose 10 mg/kg),1,,9443.0,A,Primates,,0,Intermediate,CHEMBL623041,,10114,In vivo,,22224,2891,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623741,,10115,In vivo,,50597,6672,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623742,,10116,In vivo,,50597,6673,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623743,,10117,In vivo,,50597,17655,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623744,,10118,In vivo,,50597,17796,,
,BAO_0000218,,N,,Bioavailability in rat (dose 2.0 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623745,,10119,In vivo,,50597,17853,,
,BAO_0000218,,N,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623746,,10120,In vivo,,50597,4521,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 5 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623747,,10121,In vivo,,50597,4940,,
,BAO_0000218,,U,,Bioavailability in rat after po administration of 30 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL623748,,10122,In vivo,,22224,2891,,
,BAO_0000218,,U,,Bioavailability in rat after po administration of 30 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL623916,,10123,In vivo,,22224,2891,,
,BAO_0000218,,N,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623917,,10124,In vivo,,50597,4521,,
,BAO_0000218,,N,,Bioavailability in rat (dose 2 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623918,,10125,In vivo,,50597,17686,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874386,,10126,In vivo,,50597,17796,,
Plasma,BAO_0000218,,N,,Bioavailability in rat; Only traces detected in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623919,,10127,In vivo,,50597,17796,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623920,,10128,In vivo,,50597,5064,,
,BAO_0000218,,N,,Bioavailability upon oral administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623148,,10129,In vivo,,50597,5147,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623149,,10130,In vivo,,50597,1916,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623150,,10131,In vivo,,50597,6049,,
,BAO_0000218,,N,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623151,,10132,In vivo,,50597,1445,,
,BAO_0000218,,N,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623152,,10133,In vivo,,50597,1445,,
,BAO_0000218,,N,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,1,,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL623153,,10134,,,50597,2862,,
,BAO_0000218,,N,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,1,,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL623154,,10135,,,50597,2862,,
,BAO_0000218,,N,,In vitro and metabolic stability was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623155,,10136,,,50597,4194,,
,BAO_0000218,,N,,In vitro metabolic stability in rat hepatocytes,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623156,,10137,,,50597,4194,,
,BAO_0000218,,N,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623157,,10138,,,50597,5486,,
Liver,BAO_0000218,,N,,Metabolic rate for compound was observed in rat hepatocytes,1,Hepatocyte,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623158,,10139,In vitro,,50597,17582,401.0,
,BAO_0000218,,N,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623159,,10140,,,50597,5600,,
,BAO_0000218,,N,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874390,,10141,,,50597,14294,,
,BAO_0000218,,N,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623160,,10142,,,50597,14294,,
,BAO_0000218,,N,,Metabolism of compound in rat S9 microsomes; Trace,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623161,,10143,,,50597,14294,,
,BAO_0000218,,N,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623162,,10144,,,50597,17847,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623163,,10145,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623164,,10146,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623165,,10147,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623166,,10148,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624983,,10149,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624984,,10150,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624985,,10151,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622970,,10152,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622971,,10153,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622972,,10154,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622973,,10155,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622974,,10156,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622975,,10157,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622976,,10158,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622977,,10159,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624351,,10160,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624352,,10161,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624353,,10162,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622397,,10163,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622398,,10164,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622399,,10165,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622400,,10166,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628428,,10167,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628590,,10168,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628591,,10169,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628592,,10170,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628593,,10171,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875333,,10172,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628594,,10173,,,50597,11020,,
Plasma,BAO_0000218,,N,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628595,,10174,,,50597,4969,,
Plasma,BAO_0000218,,N,,Stability in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628596,,10175,,,50597,6737,,
Plasma,BAO_0000218,,N,,Stability in rat plasma was determined; ND= no data,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628597,,10176,,,50597,6737,,
Plasma,BAO_0000218,,N,,Tested for plasma half life period in rat (0-8 hr),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628598,,10177,,,50597,5089,,
Plasma,BAO_0000218,,N,,Tested for plasma half life period in rat (0-8 hr); Not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628599,,10178,,,50597,5089,,
,BAO_0000218,,N,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628600,,10179,In vivo,,50597,1466,,
,BAO_0000218,,N,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628601,,10180,In vivo,,50597,1466,,
,BAO_0000218,,N,,Tested for the half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628602,,10181,,,50597,4950,,
,BAO_0000218,,N,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628603,,10182,In vitro,,50597,2412,,
,BAO_0000218,,N,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628604,,10183,In vitro,,50597,2412,,
,BAO_0000218,,N,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628605,,10184,In vitro,,50597,2412,,
,BAO_0000218,,N,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628606,,10185,In vitro,,50597,2412,,
,BAO_0000218,,N,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628607,,10186,In vitro,,50597,2412,,
,BAO_0000218,,N,,The biological half life the compound was measured at the dose of 100 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628608,,10187,,,50597,15022,,
,BAO_0000218,,N,,The biological half life the compound was measured at the dose of 30 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628609,,10188,,,50597,15022,,
Plasma,BAO_0000218,,N,,The compound was evaluated for plasma half life period in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628610,,10189,,,50597,406,,
,BAO_0000218,,N,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL873819,,10190,In vivo,,50597,15078,,
,BAO_0000218,,N,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628611,,10191,In vivo,,50597,15078,,
,BAO_0000218,,N,,The pharmacokinetic parameter half-life period in vivo in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628612,,10192,In vivo,,50597,5247,,
,BAO_0000218,,N,,"The pharmacokinetic property, Half-life was determined",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628613,,10193,In vivo,,50597,5041,,
,BAO_0000218,,N,,"The pharmacokinetic property, Half-life in rat in vivo",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628614,,10194,In vivo,,50597,5041,,
,BAO_0000218,,N,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628615,,10195,In vivo,,50597,5041,,
,BAO_0000218,,N,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628616,,10196,In vivo,,50597,5041,,
Plasma,BAO_0000218,,N,,The plasma half life period in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627924,,10197,,,50597,3918,,
Liver,BAO_0000218,,N,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627925,,10198,,,50597,2906,,
,BAO_0000218,,N,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627926,,10199,In vivo,,50597,6467,,
,BAO_0000218,,N,,t1/2 (apparent elimination)of the compound was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627927,,10200,,,50597,5510,,
,BAO_0000218,,N,,t1/2 value in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627928,,10201,,,50597,3788,,
,BAO_0000218,,N,,Half life in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627539,,10202,,,50597,17796,,
Plasma,BAO_0000218,,N,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876790,,10203,In vivo,,50597,12873,,
,BAO_0000218,,N,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL858186,,10204,In vivo,,50597,5983,,
,BAO_0000218,,N,,Half-life period in fasted rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627540,,10205,,,50597,15765,,
,BAO_0000218,,N,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627541,,10206,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627715,,10207,In vivo,,50597,2661,,
,BAO_0000218,,N,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627716,,10208,In vivo,,50597,429,,
,BAO_0000218,,N,,Maximum time required to achieve Cmax was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627717,,10209,,,50597,17655,,
,BAO_0000218,,N,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627718,,10210,In vivo,,50597,17717,,
,BAO_0000218,,N,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627719,,10211,In vivo,,50597,17717,,
,BAO_0000218,,N,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627720,,10212,In vivo,,50597,17717,,
,BAO_0000218,,N,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627721,,10213,In vivo,,50597,6570,,
,BAO_0000218,,N,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627722,,10214,In vivo,,50597,6570,,
,BAO_0000218,,N,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627723,,10215,In vivo,,50597,5978,,
,BAO_0000218,,N,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626058,,10216,In vivo,,50597,5978,,
,BAO_0000218,,N,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626059,,10217,In vivo,,50597,5978,,
,BAO_0000218,,N,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626060,,10218,In vivo,,50597,5978,,
Plasma,BAO_0000218,,N,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626061,,10219,In vivo,,50597,17720,,
,BAO_0000218,,N,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876791,,10220,In vivo,,50597,4723,,
,BAO_0000218,,N,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626062,,10221,In vivo,,50597,4723,,
,BAO_0000218,,N,,Tmax at the dose of 2 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626063,,10222,In vivo,,50597,4756,,
,BAO_0000218,,N,,Tmax at the dose of 5 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626064,,10223,In vivo,,50597,4756,,
Plasma,BAO_0000218,,N,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626065,,10224,In vivo,,50597,17720,,
Plasma,BAO_0000218,,N,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626066,,10225,In vivo,,50597,17720,,
,BAO_0000218,,N,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626067,,10226,In vivo,,50597,1466,,
,BAO_0000218,,N,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626068,,10227,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626069,,10228,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of 3-methoxyacetaminophen glucuronide,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626070,,10229,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of N-methoxyacetaminophen glucuronide,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626071,,10230,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of N-methoxyacetaminophen sulfate,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626072,,10231,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of acetaminophen,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626073,,10232,,,50597,7449,,
Thyroid gland,BAO_0000218,,N,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626741,,10233,,,50597,7768,,
,BAO_0000218,,N,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626742,,10234,,,50597,17655,,
,BAO_0000218,,N,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626743,,10235,,,50597,17735,,
,BAO_0000218,,N,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876792,,10236,,,50597,5960,,
,BAO_0000218,,N,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626744,,10237,,,50597,17735,,
,BAO_0000218,,N,,Compound was tested for antidiuretic activity in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626745,,10238,,,50597,7116,,
Plasma,BAO_0000218,,N,,AUC in rat after 3mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626746,,10239,In vivo,,50597,4878,,
,BAO_0000218,,N,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626747,,10240,,,50597,5939,,
,BAO_0000218,,N,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626748,,10241,,,50597,5939,,
,BAO_0000218,,N,,Bioavailability administered orally at a dose of 10 mg/kg to rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626749,,10242,,,50597,16367,,
,BAO_0000218,,N,,Oral Bioavailability was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626750,,10243,,,50597,16366,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626751,,10244,,,50597,4426,,
,BAO_0000218,,N,,Oral bioavailability in rat; Not performed.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626913,,10245,,,50597,4426,,
,BAO_0000218,,N,,Bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626914,,10246,,,50597,5041,,
,BAO_0000218,,N,,Bioavailability was determined; ND denotes no data,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626915,,10247,,,50597,5041,,
,BAO_0000218,,N,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626916,,10248,,,50597,1500,,
,BAO_0000218,,N,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626917,,10249,,,50597,1500,,
,BAO_0000218,,N,,Binding towards rat plasma protein at 10 uM,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626918,,10250,,,50597,17409,,
,BAO_0000218,,N,,Binding towards rat plasma protein at 100 uM,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626919,,10251,,,50597,17409,,
,BAO_0000218,,N,,Bioavailability in rat (dose 20 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626920,,10252,In vivo,,50597,2959,,
,BAO_0000218,,N,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621976,,10253,In vivo,,50597,13501,,
,BAO_0000218,,N,,Bioavailability in rat after 5 mg/kg oral gavage,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877599,,10254,In vivo,,50597,6567,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621977,,10255,In vivo,,50597,6571,,
,BAO_0000218,,N,,Bioavailability in rat (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621978,,10256,In vivo,,50597,6715,,
,BAO_0000218,,N,,Bioavailability in rat (dose 3 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621979,,10257,In vivo,,50597,6715,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621980,,10258,In vivo,,50597,2932,,
,BAO_0000218,,N,,Bioavailability of the compound in rats after administration of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621981,,10259,In vivo,,50597,4171,,
,BAO_0000218,,N,,Bioavailability after administration of 10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621982,,10260,In vivo,,50597,17509,,
,BAO_0000218,,N,,Bioavailability after administration of 2 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL882953,,10261,In vivo,,50597,17509,,
,BAO_0000218,,N,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621983,,10262,In vivo,,50597,4527,,
,BAO_0000218,,N,,Bioavailability in dogs was determined; high,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621984,,10263,In vivo,,50597,4026,,
,BAO_0000218,,N,,Bioavailability in monkey after intravenous administration at 1 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621985,,10264,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in monkey after peroral administration at 10 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621986,,10265,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in rat after intravenous administration at 1 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621987,,10266,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in rat after intravenous administration at 2 mpk,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL877600,,10267,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in rat after peroral administration at 30 mpk,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621988,,10268,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in rat after peroral administration at at 100 mpk,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL621989,,10269,In vivo,,50597,6659,,
,BAO_0000218,,N,,Bioavailability in rats was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621990,,10270,In vivo,,50597,6597,,
,BAO_0000218,,N,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621991,,10271,In vivo,,50597,1202,,
,BAO_0000218,,N,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621992,,10272,In vivo,,50597,1202,,
,BAO_0000218,,N,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621993,,10273,In vivo,,50597,1202,,
,BAO_0000218,,N,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621994,,10274,In vivo,,50597,1202,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621995,,10275,In vivo,,50597,5207,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621996,,10276,In vivo,,50597,5970,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621997,,10277,In vivo,,50597,17538,,
,BAO_0000218,,N,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621998,,10278,In vivo,,50597,17538,,
,BAO_0000218,,N,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621999,,10279,In vivo,,50597,1466,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622000,,10280,In vivo,,50597,2879,,
,BAO_0000218,,N,,Bioavailability was measured in rat after oral administration; 2-4,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622001,,10281,In vivo,,50597,2879,,
,BAO_0000218,,N,,Bioavailability was measured in rat after oral administration; 3-7,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622002,,10282,In vivo,,50597,2879,,
,BAO_0000218,,N,,Bioavailability in rat (intraduodenal administration),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622003,,10283,In vivo,,50597,3777,,
,BAO_0000218,,N,,Bioavailability in rat (intraduodenal administration),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877601,,10284,In vivo,,50597,3777,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624871,,10285,In vivo,,50597,3777,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622004,,10286,In vivo,,50597,3777,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL882954,,10287,In vivo,,50597,5423,,
,BAO_0000218,,N,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622005,,10288,In vivo,,50597,16365,,
,BAO_0000218,,N,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622006,,10289,In vivo,,50597,16365,,
,BAO_0000218,,N,,Bioavailability was measured in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622007,,10290,In vivo,,50597,4239,,
,BAO_0000218,,N,,Bioavailability was reported,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622008,,10291,In vivo,,50597,5438,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622009,,10292,In vivo,,50597,5334,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622010,,10293,In vivo,,50597,5334,,
,BAO_0000218,,N,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622011,,10294,In vivo,,50597,4199,,
,BAO_0000218,,N,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622012,,10295,In vivo,,50597,4199,,
,BAO_0000218,,N,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622013,,10296,In vivo,,50597,4199,,
,BAO_0000218,,N,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622014,,10297,In vivo,,50597,4890,,
,BAO_0000218,,N,,Bioavailability was determined at 3 mg/kg po dose in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624749,,10298,In vivo,,50597,2792,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624750,,10299,In vivo,,50597,5529,,
,BAO_0000218,,N,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624751,,10300,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624752,,10301,In vivo,,50597,6685,,
,BAO_0000218,,N,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624753,,10302,In vivo,,50597,6685,,
,BAO_0000218,,N,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624754,,10303,In vivo,,50597,6005,,
,BAO_0000218,,N,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624755,,10304,In vivo,,50597,6410,,
,BAO_0000218,,N,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624756,,10305,In vivo,,50597,6410,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624757,,10306,In vivo,,50597,6103,,
,BAO_0000218,,N,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624758,,10307,In vivo,,50597,6410,,
,BAO_0000218,,N,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622270,,10308,In vivo,,50597,6410,,
,BAO_0000218,,N,,Bioavailability in rat (Sprague-Dawley),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622271,,10309,In vivo,,50597,5353,,
,BAO_0000218,,N,,Bioavailability in rat at the dose of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622272,,10310,In vivo,,50597,4727,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622273,,10311,In vivo,,50597,17804,,
,BAO_0000218,,N,,Bioavailability in rat (cannulated) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622274,,10312,In vivo,,50597,5809,,
,BAO_0000218,,N,,Bioavailability value of compound in rats was determined after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622275,,10313,In vivo,,50597,17804,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 20 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622276,,10314,In vivo,,50597,3634,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622277,,10315,In vivo,,50597,3341,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 5 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622278,,10316,In vivo,,50597,2690,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622279,,10317,In vivo,,50597,3184,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622280,,10318,In vivo,,50597,740,,
,BAO_0000218,,N,,Compound was evaluated for oral bioavailability in rats; 15-27 %,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624083,,10319,In vivo,,50597,1806,,
,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624084,,10320,In vivo,,50597,4891,,
,BAO_0000218,,N,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624085,,10321,In vivo,,50597,3634,,
,BAO_0000218,,N,,Compound was tested for bioavailability in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624086,,10322,In vivo,,50597,64,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624087,,10323,In vivo,,50597,4839,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624088,,10324,In vivo,,50597,1094,,
,BAO_0000218,,U,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,1,,9544.0,A,Macaca mulatta,,0,Intermediate,CHEMBL624089,,10325,In vivo,,22224,5005,,
,BAO_0000218,,U,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,0,Intermediate,CHEMBL624090,,10326,In vivo,,22224,5005,,
,BAO_0000218,,N,,Evaluated for the bioavailability in rat (in vivo),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624091,,10327,In vivo,,50597,4687,,
,BAO_0000218,,N,,F value of compound in rats was determined after peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624092,,10328,In vivo,,50597,17804,,
,BAO_0000218,,N,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624093,,10329,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624094,,10330,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624095,,10331,In vivo,,50597,5974,,
,BAO_0000218,,N,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624096,,10332,In vivo,,50597,5974,,
,BAO_0000218,,N,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624097,,10333,In vivo,,50597,1088,,
,BAO_0000218,,N,,Maximum fall in carotid flow in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624098,,10334,In vivo,,50597,1742,,
,BAO_0000218,,N,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874392,,10335,In vivo,,50597,4689,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 5 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624099,,10336,In vivo,,50597,2463,,
,BAO_0000218,,N,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624100,,10337,In vivo,,50597,5654,,
,BAO_0000218,,N,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624101,,10338,In vivo,,50597,5654,,
,BAO_0000218,,N,,Oral bioavailability in rat (male Wistar),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624102,,10339,In vivo,,50597,6874,,
,BAO_0000218,,N,,Oral bioavailability after administration (30 mg/kg) in rat; good,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624103,,10340,In vivo,,50597,5633,,
,BAO_0000218,,N,,Oral bioavailability at the dose of 2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624104,,10341,In vivo,,50597,5496,,
,BAO_0000218,,N,,Oral bioavailability determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624105,,10342,In vivo,,50597,2358,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624106,,10343,In vivo,,50597,16456,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose single 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624107,,10344,In vivo,,50597,5302,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose single 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623943,,10345,In vivo,,50597,5302,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623944,,10346,In vivo,,50597,5302,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623945,,10347,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623946,,10348,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623947,,10349,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623948,,10350,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623949,,10351,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623950,,10352,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874398,,10353,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623951,,10354,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623952,,10355,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623953,,10356,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623954,,10357,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623955,,10358,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623956,,10359,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627807,,10360,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627808,,10361,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627809,,10362,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627810,,10363,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627811,,10364,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627812,,10365,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627813,,10366,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627814,,10367,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875336,,10368,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627815,,10369,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627816,,10370,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627817,,10371,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627818,,10372,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627819,,10373,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627820,,10374,,,50597,11020,,
,BAO_0000218,,N,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627821,,10375,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628464,,10376,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626239,,10377,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626240,,10378,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626241,,10379,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626242,,10380,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626243,,10381,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626244,,10382,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626907,,10383,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626908,,10384,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626909,,10385,,,50597,11020,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626910,,10386,,,50597,11020,,
,BAO_0000218,,N,,Percent total excretion of acetaminophen cysteine conjugate,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL875342,,10387,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of acetaminophen glucuronide,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626911,,10388,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of acetaminophen sulfate,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL626912,,10389,,,50597,7449,,
,BAO_0000218,,N,,Percent total excretion of acetaminophen-mercapturic acid,1,,10116.0,F,Rattus norvegicus,,1,Intermediate,CHEMBL627065,,10390,,,50597,7449,,
Urine,BAO_0000218,,N,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627066,,10391,,,50597,3172,,
,BAO_0000218,,N,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627067,,10392,In vivo,,50597,16456,,
Muscle tissue,BAO_0000218,,U,,Biodistribution of compound in rat muscle after 5 min of administration,1,,8656.0,A,ratrat,2385.0,0,Autocuration,CHEMBL627068,,10393,In vivo,,22224,10839,,
Muscle tissue,BAO_0000218,,U,,Biodistribution of compound in rat muscle after 5 min of administration.,1,,8656.0,A,ratrat,2385.0,0,Autocuration,CHEMBL627069,,10394,In vivo,,22224,10839,,
,BAO_0000218,,U,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL627070,,10395,In vivo,,22224,5334,,
,BAO_0000218,,U,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL627071,,10396,In vivo,,22224,5334,,
,BAO_0000218,,U,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL627072,,10397,In vivo,,22224,5334,,
,BAO_0000218,,U,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL627073,,10398,In vivo,,22224,5334,,
,BAO_0000218,,U,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL625387,,10399,In vivo,,22224,5334,,
,BAO_0000218,,U,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,,0,Autocuration,CHEMBL625388,,10400,In vivo,,22224,5334,,
Plasma,BAO_0000218,,U,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,1969.0,0,Autocuration,CHEMBL625389,,10401,In vivo,,22224,5334,,
Plasma,BAO_0000218,,U,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),1,,9940.0,A,Ovis aries,1969.0,0,Autocuration,CHEMBL875343,,10402,In vivo,,22224,5334,,
,BAO_0000218,,N,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),1,,8570.0,A,Serpentes,,1,Intermediate,CHEMBL876795,,10403,,,50497,1735,,
,BAO_0000218,,N,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,1,,8570.0,A,Serpentes,,1,Intermediate,CHEMBL626552,,10404,,,50497,1469,,
,BAO_0000218,,N,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,1,,8570.0,A,Serpentes,,1,Intermediate,CHEMBL626553,,10405,,,50497,1336,,
Plasma,BAO_0000366,,U,,The human biological plasma half life of the compound,1,,9606.0,A,Homo sapiens,1969.0,0,Autocuration,CHEMBL626554,,10406,,,22224,12403,,
Urine,BAO_0000218,,N,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626555,,10407,,,50597,8151,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626556,,10408,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626557,,10409,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626558,,10410,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626559,,10411,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626560,,10412,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876803,,10413,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627964,,10414,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627965,,10415,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627966,,10416,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627967,,10417,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627968,,10418,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627969,,10419,,,50597,8004,,
,BAO_0000218,,N,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627970,,10420,,,50597,8004,,
Blood,BAO_0000218,,N,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627971,,10421,,,50597,8004,,
Blood,BAO_0000218,,N,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627972,,10422,,,50597,8004,,
,BAO_0000357,,D,,Dissociation constant against binding to human cyclophilin A,1,,9606.0,B,Homo sapiens,,9,Expert,CHEMBL856029,,10423,,,180,15917,,
,BAO_0000019,,H,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,1,,9913.0,B,Bos taurus,,8,Expert,CHEMBL627973,,10424,,,11591,12396,,
,BAO_0000019,,U,,-Log C was determined by performing the electroshock minimum test,1,,,A,,,0,Autocuration,CHEMBL627974,,10425,,,22224,7065,,
,BAO_0000019,,U,,-Log C was determined by performing the foot shock test,1,,,A,,,0,Autocuration,CHEMBL627975,,10426,,,22224,7065,,
,BAO_0000019,,U,,-Log C was determined by performing the incl screen test,1,,,A,,,0,Autocuration,CHEMBL627976,,10427,,,22224,7065,,
,BAO_0000019,,U,,-Log C was determined by performing the maximum electroshock test,1,,,A,,,0,Autocuration,CHEMBL627977,,10428,,,22224,7065,,
,BAO_0000019,,U,,-Log C was determined by performing the pentylenetetrazole test,1,,,A,,,0,Autocuration,CHEMBL627978,,10429,,,22224,7065,,
,BAO_0000019,,U,,Tested for experimental arotinoid inhibitory dose,1,,,A,,,0,Autocuration,CHEMBL627979,,10430,,,22224,12415,,
,BAO_0000019,,U,,Negative log transformed activity,1,,,A,,,0,Autocuration,CHEMBL876804,,10431,,,22224,10256,,
,BAO_0000019,,U,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",1,,,A,,,0,Autocuration,CHEMBL627980,,10432,,,22224,7991,,
,BAO_0000218,,N,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL627981,,10433,,,50512,14342,,
,BAO_0000218,,N,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL627982,,10434,,,50512,14342,,
,BAO_0000218,,N,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL627983,,10435,,,50512,14342,,
Ileum,BAO_0000218,,N,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,1,,10141.0,A,Cavia porcellus,2116.0,1,Intermediate,CHEMBL627984,,10436,,,50512,14342,,
,BAO_0000100,,U,,Solubility in water was determined; values expressed as -log,1,,,P,,,0,Autocuration,CHEMBL627985,,10437,,,22229,6047,,
,BAO_0000019,,U,,Ratio of Kcat to that of Km was determined,1,,,A,,,0,Autocuration,CHEMBL627986,,10438,,,22224,17269,,
,BAO_0000019,,U,,Observed first order rate constant,1,,,A,,,0,Autocuration,CHEMBL627987,,10439,,,22224,10026,,
,BAO_0000019,,U,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,1,,,A,,,0,Autocuration,CHEMBL627988,,10440,,,22224,14583,,
,BAO_0000218,,N,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627989,,10441,In vivo,,50597,2661,,
,BAO_0000218,,N,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627990,,10442,In vivo,,50597,2661,,
,BAO_0000218,,N,,Oral Bioavailability after administration of 10 mg/kg in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876805,,10443,In vivo,,50597,4029,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627991,,10444,In vivo,,50597,17735,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627992,,10445,In vivo,,50597,4576,,
,BAO_0000218,,N,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627993,,10446,In vivo,,50597,17582,,
,BAO_0000218,,N,,Oral bioavailability at 1 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622817,,10447,In vivo,,50597,17651,,
,BAO_0000218,,N,,Oral bioavailability at 10 mg/kg was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622818,,10448,In vivo,,50597,17651,,
,BAO_0000218,,N,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622819,,10449,In vivo,,50597,17670,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL872267,,10450,In vivo,,50597,5045,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622820,,10451,In vivo,,50597,1696,,
,BAO_0000218,,N,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622821,,10452,In vivo,,50597,17764,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622822,,10453,In vivo,,50597,6448,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622823,,10454,In vivo,,50597,6596,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622824,,10455,In vivo,,50597,17547,,
,BAO_0000218,,N,,Oral bioavailability in rat at a dose of 3 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622825,,10456,In vivo,,50597,17771,,
,BAO_0000218,,N,,Oral bioavailability in rat after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622901,,10457,In vivo,,50597,6495,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622902,,10458,In vivo,,50597,4558,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621844,,10459,In vivo,,50597,17596,,
,BAO_0000218,,N,,Oral bioavailability in Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621845,,10460,In vivo,,50597,6827,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621846,,10461,In vivo,,50597,4026,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 30 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621847,,10462,In vivo,,50597,10,,
,BAO_0000218,,N,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877609,,10463,In vivo,,50597,17717,,
,BAO_0000218,,N,,Bioavailability in rat (dose 3 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621848,,10464,In vivo,,50597,17717,,
,BAO_0000218,,N,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621849,,10465,In vivo,,50597,17717,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622030,,10466,In vivo,,50597,17717,,
,BAO_0000218,,N,,Percent oral bioavailability determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622031,,10467,In vivo,,50597,4796,,
,BAO_0000218,,N,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622032,,10468,In vivo,,50597,4883,,
,BAO_0000218,,N,,The compound was evaluated for bioavailability in rats; 32-51,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622033,,10469,In vivo,,50597,2137,,
,BAO_0000218,,N,,Bioavailability in rat (dose 20 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622034,,10470,In vivo,,50597,2959,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622035,,10471,In vivo,,50597,1361,,
,BAO_0000218,,N,,Bioavailability percent in rat at the dose of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL882966,,10472,In vivo,,50597,4727,,
,BAO_0000218,,N,,Bioavailability was evaluated after 20 uM/kg of peroral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622036,,10473,In vivo,,50597,16423,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622037,,10474,In vivo,,50597,5206,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622038,,10475,In vivo,,50597,6448,,
,BAO_0000218,,N,,Bioavailability in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622039,,10476,In vivo,,50597,17723,,
Blood,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622040,,10477,In vivo,,50597,17738,,
Blood,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622041,,10478,In vivo,,50597,17738,,
Blood,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622042,,10479,In vivo,,50597,17738,,
Blood,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622043,,10480,In vivo,,50597,17738,,
Blood,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622044,,10481,In vivo,,50597,17738,,
Bone,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL622045,,10482,In vivo,,50597,17738,,
Bone,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL622046,,10483,In vivo,,50597,17738,,
Bone,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL622047,,10484,In vivo,,50597,17738,,
Bone,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL877610,,10485,In vivo,,50597,17738,,
Brain,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622048,,10486,In vivo,,50597,17738,,
Brain,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622049,,10487,In vivo,,50597,17738,,
Brain,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622050,,10488,In vivo,,50597,17738,,
Brain,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622051,,10489,In vivo,,50597,17738,,
,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622052,,10490,In vivo,,50597,17738,,
,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622053,,10491,In vivo,,50597,17738,,
,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622054,,10492,In vivo,,50597,17738,,
,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622055,,10493,In vivo,,50597,17738,,
,BAO_0000218,,N,,Oral bioavailability in rats was determined; High,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622056,,10494,In vivo,,50597,5237,,
,BAO_0000218,,N,,Oral bioavailability in the rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622057,,10495,In vivo,,50597,5503,,
,BAO_0000218,,N,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628008,,10496,In vivo,,50597,15765,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622058,,10497,In vivo,,50597,15660,,
,BAO_0000218,,N,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622059,,10498,In vivo,,50597,5978,,
,BAO_0000218,,N,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622060,,10499,In vivo,,50597,5978,,
,BAO_0000218,,N,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622061,,10500,In vivo,,50597,5978,,
,BAO_0000218,,N,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622062,,10501,In vivo,,50597,5978,,
,BAO_0000218,,N,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622063,,10502,In vivo,,50597,5656,,
,BAO_0000218,,N,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL877611,,10503,In vivo,,50597,3598,,
,BAO_0000218,,N,,Oral bioavailability of compound in Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622064,,10504,In vivo,,50597,4216,,
,BAO_0000218,,N,,Oral bioavailability of compound in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622065,,10505,In vivo,,50597,17839,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622066,,10506,In vivo,,50597,6570,,
,BAO_0000218,,N,,Oral bioavailability of compound in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622067,,10507,In vivo,,50597,5334,,
,BAO_0000218,,N,,Oral bioavailability of compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622068,,10508,In vivo,,50597,6886,,
,BAO_0000218,,N,,Oral bioavailability of compound was determined in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622069,,10509,In vivo,,50597,5210,,
,BAO_0000218,,N,,Oral bioavailability at a dose of 30 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624796,,10510,In vivo,,50597,4170,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624797,,10511,In vivo,,50597,6028,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623053,,10512,In vivo,,50597,6028,,
,BAO_0000218,,N,,Oral bioavailability evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623054,,10513,In vivo,,50597,6078,,
,BAO_0000218,,N,,Oral bioavailability in fasted rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623055,,10514,In vivo,,50597,6168,,
,BAO_0000218,,N,,Oral bioavailability in fed rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623056,,10515,In vivo,,50597,6168,,
,BAO_0000218,,N,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623057,,10516,In vivo,,50597,5160,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623058,,10517,In vivo,,50597,6057,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623059,,10518,In vivo,,50597,6535,,
,BAO_0000218,,N,,Oral bioavailability in rat after administration of 10 mg/kg po,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623060,,10519,In vivo,,50597,6535,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623061,,10520,In vivo,,50597,4194,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623062,,10521,In vivo,,50597,6230,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623063,,10522,In vivo,,50597,6619,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623064,,10523,In vivo,,50597,17607,,
,BAO_0000218,,N,,Oral bioavailability in ratrs,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623065,,10524,In vivo,,50597,4942,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623066,,10525,In vivo,,50597,4942,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623067,,10526,In vivo,,50597,6646,,
,BAO_0000218,,N,,Oral bioavailability in rats was determined; High,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623068,,10527,In vivo,,50597,5237,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623069,,10528,In vivo,,50597,6646,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623070,,10529,In vivo,,50597,4449,,
,BAO_0000218,,N,,Oral bioavailability was calculated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623071,,10530,In vivo,,50597,6057,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623072,,10531,In vivo,,50597,2552,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623073,,10532,In vivo,,50597,5496,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623074,,10533,In vivo,,50597,6484,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623075,,10534,In vivo,,50597,6485,,
,BAO_0000218,,N,,Oral bioavailability after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623076,,10535,In vivo,,50597,6616,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623077,,10536,In vivo,,50597,4969,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623078,,10537,In vivo,,50597,5862,,
,BAO_0000218,,N,,Oral bioavailability in Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623079,,10538,In vivo,,50597,4514,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623080,,10539,In vivo,,50597,4514,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623081,,10540,In vivo,,50597,4514,,
,BAO_0000218,,N,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623082,,10541,In vivo,,50597,5546,,
,BAO_0000218,,N,,Oral bioavailability in fasted rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874400,,10542,In vivo,,50597,6168,,
,BAO_0000218,,N,,Oral bioavailability in fed rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623083,,10543,In vivo,,50597,6168,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623084,,10544,In vivo,,50597,3624,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623085,,10545,In vivo,,50597,5213,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623086,,10546,In vivo,,50597,5496,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623087,,10547,In vivo,,50597,5553,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623088,,10548,In vivo,,50597,5833,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623089,,10549,In vivo,,50597,5836,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623090,,10550,In vivo,,50597,5865,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623091,,10551,In vivo,,50597,5960,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623092,,10552,In vivo,,50597,6249,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623093,,10553,In vivo,,50597,6448,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874401,,10554,In vivo,,50597,6453,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623094,,10555,In vivo,,50597,6640,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623095,,10556,In vivo,,50597,17607,,
,BAO_0000218,,N,,Oral bioavailability in rat after peroral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623096,,10557,In vivo,,50597,5939,,
,BAO_0000218,,N,,Oral bioavailability in rat after peroral administration at 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624913,,10558,In vivo,,50597,5939,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624914,,10559,In vivo,,50597,6281,,
,BAO_0000218,,N,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624915,,10560,In vivo,,50597,5874,,
,BAO_0000218,,N,,Oral bioavailability in rat; Not measured,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624916,,10561,In vivo,,50597,5213,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624917,,10562,In vivo,,50597,4964,,
,BAO_0000218,,N,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625157,,10563,,,50597,11020,,
Liver,BAO_0000218,,N,,In vitro metabolic potential in rat liver microsomes,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625158,,10564,,,50597,6251,,
,BAO_0000218,,N,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625159,,10565,In vivo,,50597,1568,,
,BAO_0000218,,N,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625160,,10566,In vivo,,50597,3032,,
,BAO_0000218,,N,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625161,,10567,In vivo,,50597,3748,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625162,,10568,In vivo,,50597,401,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625163,,10569,In vivo,,50597,6512,,
,BAO_0000218,,N,,Oral bioavailability in rats at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625164,,10570,In vivo,,50597,17617,,
,BAO_0000218,,N,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625165,,10571,In vivo,,50597,6679,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625166,,10572,In vivo,,50597,6742,,
,BAO_0000218,,N,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625167,,10573,,,50597,589,,
,BAO_0000218,,N,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625168,,10574,,,50597,589,,
,BAO_0000218,,N,,Plasma clearance of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625169,,10575,In vivo,,50597,3185,,
,BAO_0000218,,N,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626264,,10576,In vivo,,50597,17596,,
,BAO_0000218,,N,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626265,,10577,In vivo,,50597,2713,,
Plasma,BAO_0000218,,N,,The compound was tested for plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626266,,10578,In vivo,,50597,12500,,
Plasma,BAO_0000218,,N,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626267,,10579,In vivo,,50597,12500,,
,BAO_0000218,,N,,Plasma concentration upon oral administration of 1 mg/Kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626268,,10580,,,50597,2713,,
,BAO_0000218,,N,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626269,,10581,,,50597,1446,,
,BAO_0000218,,N,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626270,,10582,,,50597,6227,,
,BAO_0000218,,N,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626271,,10583,,,50597,4709,,
,BAO_0000218,,N,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626272,,10584,,,50597,5510,,
,BAO_0000218,,N,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626273,,10585,,,50597,5510,,
,BAO_0000218,,N,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875346,,10586,,,50597,5510,,
,BAO_0000218,,N,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626274,,10587,,,50597,5510,,
,BAO_0000218,,N,,Compound was tested for protein binding in rat plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626275,,10588,,,50597,4514,,
,BAO_0000218,,N,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624646,,10589,,,50597,2713,,
,BAO_0000218,,N,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624647,,10590,,,50597,2713,,
Liver,BAO_0000218,,N,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624648,,10591,,,50597,5340,,
,BAO_0000218,,N,,Area under curve ratio was determined (po/iv) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624649,,10592,,,50597,12058,,
,BAO_0000218,,N,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624650,,10593,,,50597,11195,,
,BAO_0000218,,N,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624651,,10594,,,50597,11195,,
,BAO_0000218,,N,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624652,,10595,,,50597,11195,,
,BAO_0000218,,N,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624653,,10596,,,50597,6495,,
,BAO_0000218,,N,,Ratio of AUCbrain to AUCplasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624654,,10597,,,50597,6078,,
,BAO_0000218,,N,,Ratio of brain to plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624655,,10598,,,50597,5656,,
,BAO_0000218,,N,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624656,,10599,,,50597,4910,,
,BAO_0000218,,N,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624657,,10600,,,50597,4910,,
,BAO_0000218,,N,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624658,,10601,,,50597,4910,,
,BAO_0000218,,N,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624659,,10602,,,50597,10130,,
,BAO_0000218,,N,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624660,,10603,,,50597,10130,,
,BAO_0000218,,N,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624661,,10604,,,50597,10130,,
,BAO_0000218,,N,,Steady state brain :blood ratio was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624662,,10605,,,50597,5213,,
,BAO_0000218,,N,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625199,,10606,,,50597,4910,,
,BAO_0000218,,N,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625200,,10607,,,50597,4910,,
,BAO_0000218,,N,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625201,,10608,,,50597,4910,,
,BAO_0000218,,N,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625202,,10609,,,50597,4910,,
,BAO_0000218,,N,,Percentage recovery after 3h incubation with rat hapatocytes was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625203,,10610,,,50597,2083,,
,BAO_0000218,,N,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625204,,10611,,,50597,2082,,
,BAO_0000218,,N,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625205,,10612,,,50597,2082,,
,BAO_0000218,,N,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625206,,10613,,,50597,6351,,
,BAO_0000019,,U,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",1,,,A,,,0,Autocuration,CHEMBL625207,,10614,,,22224,14583,,
,BAO_0000019,,U,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,1,,,A,,,0,Autocuration,CHEMBL625208,,10615,,,22224,14583,,
,BAO_0000218,,N,,In vivo absorption in Caco-2 cell line monolayers was determined,1,Caco-2,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL625209,,10616,,,50587,4608,495.0,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625210,,10617,,,22229,13668,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 10 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625211,,10618,,,50597,5669,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL625212,,10619,,,50797,5669,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 160 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625213,,10620,,,50597,5669,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 20 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625214,,10621,,,50597,5669,,
,BAO_0000218,,N,,Area under curve was determine after peroral administration at 50 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874542,,10622,,,50597,5669,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (AlogP),1,,,P,,,0,Autocuration,CHEMBL625215,,10623,,,22229,6472,,
,BAO_0000019,,U,,Activated partial thromboplastin time measured,1,,,A,,,0,Autocuration,CHEMBL625216,,10624,,,22224,15106,,
,BAO_0000100,,U,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),1,,,P,,,0,Autocuration,CHEMBL625217,,10625,,,22224,15207,,
,BAO_0000100,,U,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),1,,,P,,,0,Autocuration,CHEMBL625218,,10626,,,22224,15207,,
Plasma,BAO_0000218,,N,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622864,,10627,,,50588,13941,,
Plasma,BAO_0000218,,N,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622865,,10628,,,50597,13941,,
Plasma,BAO_0000218,,N,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622866,,10629,,,50597,13941,,
Plasma,BAO_0000218,,N,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622867,,10630,,,50588,13941,,
Plasma,BAO_0000218,,N,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,1,,10141.0,A,Cavia porcellus,1969.0,1,Intermediate,CHEMBL876808,,10631,,,50512,15240,,
Brain,BAO_0000019,,U,,AUC in brain,1,,,A,,955.0,0,Autocuration,CHEMBL627725,,10632,,,22224,10655,,
Serum,BAO_0000019,,U,,AUC in serum,1,,,A,,1977.0,0,Autocuration,CHEMBL627726,,10633,,,22224,10655,,
Plasma,BAO_0000019,,U,,AUC was determined,1,,,A,,1969.0,0,Autocuration,CHEMBL627727,,10634,,,22224,6504,,
Plasma,BAO_0000019,,U,,AUC of the compound.,1,,,A,,1969.0,0,Autocuration,CHEMBL627728,,10635,,,22224,10615,,
Plasma,BAO_0000019,,U,,AUC value (0-4 hr),1,,,A,,1969.0,0,Autocuration,CHEMBL627729,,10636,,,22224,10353,,
Plasma,BAO_0000019,,U,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",1,,,A,,1969.0,0,Autocuration,CHEMBL627730,,10637,,,22224,14907,,
Plasma,BAO_0000019,,U,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,1,,,A,,1969.0,0,Autocuration,CHEMBL627731,,10638,,,22224,14907,,
Plasma,BAO_0000019,,U,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",1,,,A,,1969.0,0,Autocuration,CHEMBL627732,,10639,,,22224,14907,,
Plasma,BAO_0000019,,U,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",1,,,A,,1969.0,0,Autocuration,CHEMBL627733,,10640,,,22224,14907,,
Plasma,BAO_0000218,,N,,AUC(area under curve) was determined after intravenous administration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627734,,10641,,,50597,16359,,
Plasma,BAO_0000218,,N,,AUC(area under curve) was determined after oral administration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627735,,10642,,,50597,16359,,
Plasma,BAO_0000218,,N,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,1,,10141.0,A,Cavia porcellus,1969.0,1,Intermediate,CHEMBL627736,,10643,,,50512,15240,,
Plasma,BAO_0000218,,N,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876809,,10644,,,50597,15240,,
,BAO_0000019,,U,,Area Under Curve after oral dosing of 100 uM/Kg,1,,,A,,,0,Autocuration,CHEMBL627737,,10645,,,22224,15469,,
,BAO_0000019,,U,,Area Under Curve after oral dosing of 30 uM/Kg,1,,,A,,,0,Autocuration,CHEMBL627738,,10646,,,22224,15469,,
,BAO_0000019,,U,,Area Under Curve was measured by ploting the graph between concentration verses time,1,,,A,,,0,Autocuration,CHEMBL627739,,10647,,,22224,13520,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626143,,10648,,,50588,17025,,
,BAO_0000218,,U,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626144,,10649,,,22224,17025,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL626145,,10650,,,50592,17025,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626146,,10651,,,50597,17025,,
Blood,BAO_0000218,,N,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626147,,10652,,,50597,12032,,
,BAO_0000019,,U,,Area under curve (AUC) was determined,1,,,A,,,0,Autocuration,CHEMBL626148,,10653,,,22224,10291,,
,BAO_0000218,,U,,Area under curve (AUC) following ip administration at 1 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626149,,10654,,,22224,5767,,
,BAO_0000019,,U,,Area under curve (AUC) was determined; ND is Not determined,1,,,A,,,0,Autocuration,CHEMBL626150,,10655,,,22224,1434,,
,BAO_0000218,,N,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626151,,10656,,,50588,14925,,
,BAO_0000218,,N,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626152,,10657,,,50588,14925,,
,BAO_0000218,,N,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626153,,10658,,,50588,14925,,
,BAO_0000019,,U,,Area under curve (AUR) was determined,1,,,A,,,0,Autocuration,CHEMBL626154,,10659,,,22224,1434,,
,BAO_0000019,,U,,Area under curve at 1 uM/dg administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626155,,10660,,,22224,11883,,
,BAO_0000019,,U,,Area under curve at 10 uM/dg administered perorally,1,,,A,,,0,Autocuration,CHEMBL626156,,10661,,,22224,11883,,
,BAO_0000019,,U,,Area under curve at 2 uM/dg administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626157,,10662,,,22224,11883,,
,BAO_0000019,,U,,Area under curve at 20 uM/dg administered perorally,1,,,A,,,0,Autocuration,CHEMBL626158,,10663,,,22224,11883,,
,BAO_0000218,,N,,Area under curve at a peroral dose of 3 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626159,,10664,,,50588,15233,,
,BAO_0000218,,N,,Area under curve at a peroral dose of 3 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626160,,10665,,,50597,15233,,
,BAO_0000218,,N,,Area under curve at an iv dose of 1 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626161,,10666,,,50588,15233,,
,BAO_0000218,,N,,Area under curve at an iv dose of 1 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626162,,10667,,,50597,15233,,
,BAO_0000019,,U,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,1,,,A,,,0,Autocuration,CHEMBL626163,,10668,,,22224,12978,,
,BAO_0000019,,U,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,1,,,A,,,0,Autocuration,CHEMBL626164,,10669,,,22224,12978,,
,BAO_0000218,,N,,Area under curve measured as conc vs time after intravenous administration to mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626165,,10670,,,50594,11355,,
,BAO_0000218,,N,,Area under curve measured as conc vs time after peroral administration to mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626166,,10671,,,50594,11355,,
,BAO_0000218,,N,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626167,,10672,,,50588,12923,,
,BAO_0000218,,N,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626168,,10673,,,50588,12923,,
,BAO_0000218,,N,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL877463,,10674,,,50588,12923,,
,BAO_0000218,,N,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626169,,10675,,,50588,12923,,
Heart,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626170,,10676,In vivo,,50597,17738,,
Heart,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626171,,10677,In vivo,,50597,17738,,
Heart,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626172,,10678,In vivo,,50597,17738,,
Heart,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626173,,10679,In vivo,,50597,17738,,
Kidney,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626174,,10680,In vivo,,50597,17738,,
Kidney,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626175,,10681,In vivo,,50597,17738,,
Kidney,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626176,,10682,In vivo,,50597,17738,,
Kidney,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626177,,10683,In vivo,,50597,17738,,
Kidney,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622499,,10684,In vivo,,50597,17738,,
Liver,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622500,,10685,In vivo,,50597,17738,,
Liver,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622501,,10686,In vivo,,50597,17738,,
Liver,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622502,,10687,In vivo,,50597,17738,,
Liver,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622503,,10688,In vivo,,50597,17738,,
Liver,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL877614,,10689,In vivo,,50597,17738,,
Lung,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624839,,10690,In vivo,,50597,17738,,
Lung,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624840,,10691,In vivo,,50597,17738,,
Lung,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624841,,10692,In vivo,,50597,17738,,
Lung,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624842,,10693,In vivo,,50597,17738,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624843,,10694,In vivo,,50597,17738,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624844,,10695,In vivo,,50597,17738,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624845,,10696,In vivo,,50597,17738,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL621904,,10697,In vivo,,50597,17738,,
Blood,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621905,,10698,In vivo,,50597,11195,,
Blood,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL874382,,10699,In vivo,,50597,11195,,
Blood,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL621906,,10700,In vivo,,50597,11195,,
Brain,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL621907,,10701,In vivo,,50597,11195,,
Brain,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622096,,10702,In vivo,,50597,11195,,
Brain,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622097,,10703,In vivo,,50597,11195,,
Heart,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622098,,10704,In vivo,,50597,11195,,
Heart,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622099,,10705,In vivo,,50597,11195,,
Heart,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622100,,10706,In vivo,,50597,11195,,
Kidney,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622101,,10707,In vivo,,50597,11195,,
Kidney,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622102,,10708,In vivo,,50597,11195,,
Kidney,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622103,,10709,In vivo,,50597,11195,,
Liver,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622104,,10710,In vivo,,50597,11195,,
Liver,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622105,,10711,In vivo,,50597,11195,,
Liver,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622106,,10712,In vivo,,50597,11195,,
Lung,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622107,,10713,In vivo,,50597,11195,,
Lung,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622108,,10714,In vivo,,50597,11195,,
Lung,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622109,,10715,In vivo,,50597,11195,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622110,,10716,In vivo,,50597,11195,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622111,,10717,In vivo,,50597,11195,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL874383,,10718,In vivo,,50597,11195,,
Zone of skin,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL622112,,10719,In vivo,,50597,11195,,
Zone of skin,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL622113,,10720,In vivo,,50597,11195,,
Zone of skin,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL622114,,10721,In vivo,,50597,11195,,
Spleen,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622115,,10722,In vivo,,50597,11195,,
Spleen,BAO_0000218,,N,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622116,,10723,In vivo,,50597,11195,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622117,,10724,In vivo,,50597,6193,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622118,,10725,In vivo,,50597,6803,,
,BAO_0000218,,N,,Oral bioavailability in rats at 6 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622119,,10726,In vivo,,50597,6647,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 6 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622120,,10727,In vivo,,50597,6647,,
,BAO_0000218,,N,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622121,,10728,In vivo,,50597,6647,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622122,,10729,In vivo,,50597,6640,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622123,,10730,In vivo,,50597,6641,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622124,,10731,In vivo,,50597,6641,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622125,,10732,In vivo,,50597,6642,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622126,,10733,In vivo,,50597,5472,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620455,,10734,In vivo,,50597,6141,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620456,,10735,In vivo,,50597,4390,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620457,,10736,In vivo,,50597,5472,,
,BAO_0000218,,N,,Oral bioavailability was evaluated; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620458,,10737,In vivo,,50597,5472,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620459,,10738,In vivo,,50597,5438,,
,BAO_0000218,,N,,Oral bioavailability in rat by oral dosing,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620460,,10739,In vivo,,50597,4883,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 10 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620461,,10740,In vivo,,50597,1908,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620462,,10741,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620463,,10742,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620464,,10743,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620465,,10744,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620466,,10745,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620467,,10746,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620468,,10747,In vivo,,50597,4853,,
,BAO_0000218,,N,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620469,,10748,In vivo,,50597,12873,,
,BAO_0000218,,N,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620470,,10749,In vivo,,50597,12873,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620471,,10750,In vivo,,50597,3169,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620472,,10751,In vivo,,50597,6305,,
,BAO_0000218,,N,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620473,,10752,In vivo,,50597,4762,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620474,,10753,In vivo,,50597,17847,,
,BAO_0000218,,N,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620475,,10754,In vivo,,50597,6211,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620476,,10755,In vivo,,50597,6011,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620477,,10756,In vivo,,50597,6317,,
,BAO_0000218,,N,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620478,,10757,In vivo,,50597,6644,,
,BAO_0000218,,N,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618768,,10758,In vivo,,50597,6644,,
,BAO_0000218,,N,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618769,,10759,In vivo,,50597,6644,,
,BAO_0000218,,N,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618770,,10760,In vivo,,50597,6644,,
,BAO_0000218,,N,,Oral bioavailability (dose 20 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618771,,10761,In vivo,,50597,6113,,
,BAO_0000218,,N,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618772,,10762,In vivo,,50597,5937,,
,BAO_0000218,,N,,Oral bioavailability in rat at 10 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618773,,10763,In vivo,,50597,5711,,
,BAO_0000218,,N,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875842,,10764,In vivo,,50597,17717,,
,BAO_0000218,,N,,Bioavailability in rat (dose 3 mg/kg i.v.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618774,,10765,In vivo,,50597,17717,,
,BAO_0000218,,N,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618775,,10766,In vivo,,50597,17717,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 60 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618776,,10767,In vivo,,50597,17717,,
,BAO_0000218,,N,,Percent bioavailability (F) in rats after iv administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618777,,10768,In vivo,,50597,4722,,
,BAO_0000218,,N,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618778,,10769,In vivo,,50597,4722,,
,BAO_0000218,,N,,Bioavailability in rat (dose 5 uM/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618779,,10770,In vivo,,50597,4353,,
,BAO_0000218,,N,,Oral bioavailability,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618780,,10771,In vivo,,50597,15662,,
,BAO_0000218,,N,,Bioavailability in rat (dose 2 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618781,,10772,In vivo,,50597,4756,,
,BAO_0000218,,N,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618782,,10773,In vivo,,50597,4756,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 20 mg/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618783,,10774,In vivo,,50597,3436,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618784,,10775,In vivo,,50597,17800,,
,BAO_0000218,,N,,Percent oral bioavailability evaluated in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618785,,10776,In vivo,,50597,15762,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618786,,10777,In vivo,,50597,5089,,
,BAO_0000218,,N,,Percent oral bioavailability in rat; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618787,,10778,In vivo,,50597,5089,,
,BAO_0000218,,N,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618788,,10779,In vivo,,50597,3185,,
,BAO_0000218,,N,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618789,,10780,In vivo,,50597,5145,,
,BAO_0000218,,N,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618790,,10781,In vivo,,50597,3457,,
,BAO_0000218,,N,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618791,,10782,In vivo,,50597,3457,,
,BAO_0000218,,N,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875843,,10783,In vivo,,50597,5983,,
,BAO_0000218,,N,,Oral bioavailability in rat (dose 20 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL618792,,10784,In vivo,,50597,5739,,
,BAO_0000218,,N,,Cmax at a dose of 30 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623395,,10785,In vivo,,50597,3579,,
,BAO_0000218,,U,,Cmax in monkeys at a dose of 1 mg/kg,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL623396,,10786,In vivo,,22224,17788,,
,BAO_0000218,,N,,Cmax in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623397,,10787,In vivo,,50597,14956,,
,BAO_0000218,,N,,Cmax in rats at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623398,,10788,In vivo,,50597,17788,,
,BAO_0000218,,N,,Cmax was measured in mice after an oral dose of 50 mg/kg.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623399,,10789,In vivo,,50594,9750,,
,BAO_0000218,,U,,"Cmax value at a dose of 12.7 uM/kg, po",1,,,A,,,0,Autocuration,CHEMBL623400,,10790,In vivo,,22224,12767,,
,BAO_0000218,,U,,"Cmax value at a dose of 6.3 uM/kg, iv",1,,,A,,,0,Autocuration,CHEMBL623401,,10791,In vivo,,22224,12767,,
,BAO_0000218,,U,,"Cmax value at a dose of 7.1 uM/kg, iv",1,,,A,,,0,Autocuration,CHEMBL623402,,10792,In vivo,,22224,12767,,
,BAO_0000218,,U,,Cmax value of compound was determined after 1 hr,1,,,A,,,0,Autocuration,CHEMBL623403,,10793,In vivo,,22224,12703,,
,BAO_0000218,,U,,Cmax value of the compound,1,,,A,,,0,Autocuration,CHEMBL623404,,10794,In vivo,,22224,15778,,
,BAO_0000218,,N,,Cmax value administered intraintestinal in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625997,,10795,In vivo,,50597,12818,,
,BAO_0000218,,N,,Cmax value administered perorally was determined in rat; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625998,,10796,In vivo,,50597,14964,,
,BAO_0000218,,U,,Cmax value at the dose of 2.3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL625999,,10797,In vivo,,22224,15808,,
,BAO_0000218,,U,,Cmax value at the dose of 5 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626000,,10798,In vivo,,22224,15808,,
,BAO_0000218,,U,,Cmax value in the period of 8 hr after dosing. ,1,,,A,,,0,Autocuration,CHEMBL626001,,10799,In vivo,,22224,15778,,
,BAO_0000218,,U,,Cmax value at a oral dose of 20 mg/kg; Not tested,1,,,A,,,0,Autocuration,CHEMBL626002,,10800,In vivo,,22224,3715,,
,BAO_0000218,,U,,Cmax value at a oral dose of 20 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626003,,10801,In vivo,,22224,3715,,
,BAO_0000218,,N,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626004,,10802,In vivo,,50597,1446,,
,BAO_0000218,,N,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL626005,,10803,In vivo,,50512,15240,,
,BAO_0000218,,N,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626006,,10804,In vivo,,50597,15240,,
Plasma,BAO_0000218,,N,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626007,,10805,In vivo,,50597,14810,,
Plasma,BAO_0000218,,N,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL626008,,10806,In vivo,,50594,14239,,
Liver,BAO_0000218,,N,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL626009,,10807,In vivo,,50588,12555,,
,BAO_0000218,,N,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626010,,10808,In vivo,,50588,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626011,,10809,In vivo,,50594,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626012,,10810,In vivo,,50594,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626013,,10811,In vivo,,50594,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL626014,,10812,In vivo,,50594,10754,,
Blood,BAO_0000218,,N,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL877496,,10813,In vivo,,50594,10754,,
,BAO_0000218,,N,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,1,,9615.0,F,Canis lupus familiaris,,1,Intermediate,CHEMBL626015,,10814,In vivo,,50588,14600,,
,BAO_0000218,,N,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,1,,9615.0,F,Canis lupus familiaris,,1,Intermediate,CHEMBL626016,,10815,In vivo,,50588,14600,,
,BAO_0000218,,N,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,1,,9615.0,F,Canis lupus familiaris,,1,Intermediate,CHEMBL626017,,10816,In vivo,,50588,14600,,
Plasma,BAO_0000218,,N,,Bioavailability as maximal plasma concentration in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626018,,10817,In vivo,,50588,13543,,
Plasma,BAO_0000218,,N,,Bioavailability as maximal plasma concentration in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626692,,10818,In vivo,,50588,13543,,
Plasma,BAO_0000218,,N,,Bioavailability as maximal plasma concentration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626693,,10819,In vivo,,50597,13543,,
Plasma,BAO_0000218,,U,,Bioavailability as maximal plasma concentration in rats,1,,10116.0,A,Rattus norvegicus,1969.0,0,Autocuration,CHEMBL626694,,10820,In vivo,,22224,13543,,
Blood,BAO_0000218,,N,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626695,,10821,In vivo,,50588,14600,,
Blood,BAO_0000218,,N,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626696,,10822,In vivo,,50588,14600,,
Blood,BAO_0000218,,N,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626697,,10823,In vivo,,50588,14600,,
Blood,BAO_0000218,,N,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626859,,10824,In vivo,,50588,14600,,
Blood,BAO_0000218,,N,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626860,,10825,In vivo,,50588,14600,,
Blood,BAO_0000218,,N,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL626861,,10826,In vivo,,50588,14600,,
,BAO_0000218,,N,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626296,,10827,In vivo,,50597,14681,,
,BAO_0000218,,U,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626297,,10828,In vivo,,22224,15905,,
Plasma,BAO_0000218,,U,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,1,,,A,,1969.0,0,Autocuration,CHEMBL626298,,10829,In vivo,,22224,15905,,
Plasma,BAO_0000218,,N,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626299,,10830,In vivo,,50597,13304,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626300,,10831,In vivo,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626301,,10832,In vivo,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626962,,10833,In vivo,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626963,,10834,In vivo,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626964,,10835,In vivo,,50597,15137,,
Plasma,BAO_0000218,,N,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL626965,,10836,In vivo,,100710,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL626966,,10837,In vivo,,50594,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL626967,,10838,In vivo,,50594,14839,,
Plasma,BAO_0000218,,N,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL626968,,10839,In vivo,,100710,14839,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626969,,10840,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627126,,10841,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631276,,10842,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631277,,10843,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631278,,10844,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL874457,,10845,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631279,,10846,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631280,,10847,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631281,,10848,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631968,,10849,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631969,,10850,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631970,,10851,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631971,,10852,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL631972,,10853,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630435,,10854,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630436,,10855,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630437,,10856,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630438,,10857,,,50597,8418,,
Heart,BAO_0000218,,N,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630439,,10858,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630440,,10859,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630441,,10860,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630442,,10861,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625234,,10862,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625235,,10863,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625236,,10864,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625237,,10865,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626125,,10866,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626126,,10867,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626127,,10868,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626128,,10869,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626129,,10870,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626130,,10871,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626131,,10872,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626132,,10873,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626752,,10874,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626753,,10875,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626754,,10876,,,50597,8418,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626755,,10877,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626756,,10878,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626757,,10879,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626758,,10880,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626759,,10881,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626760,,10882,,,50597,8418,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626394,,10883,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626395,,10884,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626396,,10885,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626397,,10886,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626398,,10887,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626399,,10888,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874653,,10889,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626400,,10890,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626401,,10891,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626402,,10892,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626403,,10893,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626404,,10894,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626405,,10895,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625529,,10896,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625530,,10897,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625531,,10898,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625532,,10899,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625533,,10900,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875474,,10901,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625534,,10902,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625535,,10903,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625536,,10904,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625537,,10905,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625538,,10906,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625539,,10907,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625540,,10908,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625541,,10909,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625542,,10910,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625543,,10911,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625544,,10912,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625545,,10913,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625546,,10914,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625547,,10915,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625548,,10916,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625549,,10917,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625550,,10918,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625551,,10919,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875475,,10920,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625552,,10921,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625553,,10922,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625554,,10923,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625555,,10924,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625556,,10925,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624986,,10926,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624987,,10927,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624988,,10928,,,50588,6996,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624989,,10929,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624990,,10930,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL874391,,10931,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624991,,10932,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624992,,10933,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624993,,10934,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624994,,10935,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624995,,10936,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624996,,10937,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624997,,10938,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624998,,10939,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624999,,10940,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL882955,,10941,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625000,,10942,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625001,,10943,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625089,,10944,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625090,,10945,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625091,,10946,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625092,,10947,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625093,,10948,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625094,,10949,In vivo,,50588,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL625095,,10950,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for its bioavailability in the dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625096,,10951,In vivo,,50588,2249,,
,BAO_0000218,,N,,Compound was evaluated for its bioavailability in the rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625097,,10952,In vivo,,50597,2249,,
,BAO_0000218,,U,,Compound was evaluated for oral bioavailability,1,,,A,,,0,Autocuration,CHEMBL882956,,10953,In vivo,,22224,17515,,
,BAO_0000218,,N,,Compound was evaluated for percentage of Oral bioavailability in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625098,,10954,In vivo,,50597,14541,,
,BAO_0000218,,U,,Bioavailability in guinea pig,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL625099,,10955,In vivo,,22224,12797,,
,BAO_0000218,,N,,Compound was evaluated for the oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625100,,10956,In vivo,,50597,12797,,
,BAO_0000218,,N,,Compound was evaluated for the oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625101,,10957,In vivo,,50588,12797,,
,BAO_0000218,,N,,Compound was evaluated for the oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874396,,10958,In vivo,,50597,12797,,
,BAO_0000218,,U,,Bioavailability in dog (dosed i.v.),1,,9615.0,F,Canis lupus familiaris,,0,Autocuration,CHEMBL625102,,10959,In vivo,,22224,11727,,
,BAO_0000218,,N,,Compound was tested for in vivo bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625103,,10960,In vivo,,50588,13249,,
,BAO_0000218,,N,,Compound was tested for in vivo bioavailability in hamsters,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL625104,,10961,In vivo,,100712,13249,,
,BAO_0000218,,U,,Compound was tested for in vivo bioavailability in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625105,,10962,In vivo,,22224,13249,,
,BAO_0000218,,N,,Compound was tested for in vivo bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625106,,10963,In vivo,,50597,13249,,
,BAO_0000218,,U,,Oral bioavailability in mouse,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL625107,,10964,In vivo,,22224,9552,,
,BAO_0000218,,N,,Compound was tested for percent of oral bioavailability in mice; 56-74,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625108,,10965,In vivo,,50594,9552,,
,BAO_0000218,,U,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL625109,,10966,In vivo,,22224,14839,,
,BAO_0000218,,U,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL625110,,10967,In vivo,,22224,14839,,
,BAO_0000218,,U,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL625111,,10968,In vivo,,22224,14839,,
,BAO_0000218,,N,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625112,,10969,In vivo,,50594,14839,,
,BAO_0000218,,N,,Oral bioavailability in nude mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875334,,10970,In vivo,,50594,14839,,
,BAO_0000218,,U,,Bioavailability in monkey (i.d. dosing),1,,9443.0,A,Primates,,0,Autocuration,CHEMBL628617,,10971,In vivo,,22224,11219,,
,BAO_0000218,,U,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL628618,,10972,In vivo,,22224,9552,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,1,,,A,,,0,Autocuration,CHEMBL628619,,10973,In vivo,,22224,11732,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,1,,,A,,,0,Autocuration,CHEMBL628620,,10974,In vivo,,22224,11732,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL628621,,10975,In vivo,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL628622,,10976,In vivo,,100710,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL628623,,10977,In vivo,,100710,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL628624,,10978,In vivo,,100710,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL628625,,10979,In vivo,,50594,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL628626,,10980,In vivo,,100710,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627041,,10981,In vivo,,50594,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627042,,10982,In vivo,,50594,14839,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627043,,10983,In vivo,,50594,14839,,
Plasma,BAO_0000218,,U,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,1,,,A,,1969.0,0,Autocuration,CHEMBL627044,,10984,In vivo,,22224,13932,,
Plasma,BAO_0000218,,N,,Cmax in mouse plasma,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL627045,,10985,In vivo,,50594,11637,,
Plasma,BAO_0000218,,U,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,1,,,A,,1969.0,0,Autocuration,CHEMBL627046,,10986,In vivo,,22224,11637,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627047,,10987,In vivo,,50597,13960,,
Plasma,BAO_0000218,,N,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627048,,10988,In vivo,,50597,15905,,
,BAO_0000218,,N,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627049,,10989,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627050,,10990,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627051,,10991,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627052,,10992,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627053,,10993,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627054,,10994,In vivo,,50597,14062,,
,BAO_0000218,,N,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627055,,10995,In vivo,,50594,15011,,
,BAO_0000218,,N,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627056,,10996,In vivo,,50594,15011,,
,BAO_0000218,,N,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627057,,10997,In vivo,,50594,15011,,
,BAO_0000218,,N,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627058,,10998,In vivo,,50594,15011,,
,BAO_0000218,,N,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626211,,10999,In vivo,,50594,15011,,
,BAO_0000218,,U,,Maximum Concentration of the compound.,1,,,A,,,0,Autocuration,CHEMBL626212,,11000,In vivo,,22224,10291,,
,BAO_0000218,,N,,Maximum Concentration was measured after iv administration into Beagle dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626213,,11001,In vivo,,50588,14599,,
,BAO_0000218,,N,,Maximum Concentration was measured after iv administration into Beagle dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626214,,11002,In vivo,,50588,14599,,
,BAO_0000218,,N,,Maximum Concentration was measured after po administration into Beagle dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626215,,11003,In vivo,,50588,14599,,
,BAO_0000218,,N,,Maximum Concentration was measured after po administration into Beagle dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626216,,11004,In vivo,,50588,14599,,
Blood,BAO_0000218,,U,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,1,,,A,,178.0,0,Autocuration,CHEMBL626217,,11005,In vivo,,22224,12767,,
Blood,BAO_0000218,,U,,Maximum blood level reached after an iv dose of 12.2 uM/kg,1,,,A,,178.0,0,Autocuration,CHEMBL626218,,11006,In vivo,,22224,12767,,
Blood,BAO_0000218,,U,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,1,,,A,,178.0,0,Autocuration,CHEMBL626219,,11007,In vivo,,22224,12767,,
Blood,BAO_0000218,,U,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,1,,,A,,178.0,0,Autocuration,CHEMBL626220,,11008,In vivo,,22224,12767,,
Blood,BAO_0000218,,U,,Maximum blood level reached after an oral dose of 5.0 mg/kg,1,,,A,,178.0,0,Autocuration,CHEMBL626221,,11009,In vivo,,22224,12767,,
Blood,BAO_0000218,,U,,Maximum blood level reached at dose of 10.6 uM/kg orally,1,,,A,,178.0,0,Autocuration,CHEMBL626222,,11010,In vivo,,22224,12767,,
,BAO_0000218,,N,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL626223,,11011,In vivo,,50512,14706,,
,BAO_0000218,,N,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL626224,,11012,In vivo,,50512,14706,,
Brain,BAO_0000218,,N,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL626225,,11013,In vivo,,50597,14793,,
Brain,BAO_0000218,,N,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL626226,,11014,In vivo,,50597,14793,,
Brain,BAO_0000218,,N,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL626227,,11015,In vivo,,50597,14793,,
Brain,BAO_0000218,,N,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL626228,,11016,In vivo,,50597,14793,,
,BAO_0000218,,N,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626229,,11017,In vivo,,50597,14793,,
,BAO_0000218,,N,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626921,,11018,In vivo,,50597,14793,,
,BAO_0000218,,N,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876793,,11019,In vivo,,50597,14793,,
,BAO_0000218,,N,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625309,,11020,In vivo,,50597,14793,,
,BAO_0000218,,N,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),1,,1423.0,A,Bacillus subtilis,,1,Intermediate,CHEMBL625310,,11021,In vivo,,50278,10524,,
,BAO_0000218,,U,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625311,,11022,In vivo,,22224,11871,,
,BAO_0000218,,N,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625312,,11023,In vivo,,50597,11871,,
,BAO_0000218,,U,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,1,,,A,,,0,Autocuration,CHEMBL625313,,11024,In vivo,,22224,3437,,
,BAO_0000218,,N,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625314,,11025,In vivo,,50594,12038,,
,BAO_0000218,,N,,Maximum concentration in male rats after iv administration of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625315,,11026,In vivo,,50597,12038,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625316,,11027,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625317,,11028,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625318,,11029,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625319,,11030,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625320,,11031,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625321,,11032,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625322,,11033,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL876801,,11034,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625323,,11035,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625324,,11036,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625325,,11037,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625326,,11038,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625327,,11039,,,50597,8418,,
Liver,BAO_0000218,,N,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625328,,11040,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625329,,11041,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625330,,11042,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627774,,11043,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627775,,11044,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627949,,11045,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627950,,11046,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627951,,11047,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627952,,11048,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627953,,11049,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627954,,11050,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627955,,11051,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627956,,11052,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL876802,,11053,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627957,,11054,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627958,,11055,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627959,,11056,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627960,,11057,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627961,,11058,,,50597,8418,,
Lung,BAO_0000218,,N,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627962,,11059,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627963,,11060,,,50597,9796,,
,BAO_0000218,,N,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624759,,11061,,,50597,9796,,
,BAO_0000218,,N,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624760,,11062,,,50597,9796,,
,BAO_0000218,,N,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624761,,11063,,,50597,9796,,
,BAO_0000218,,N,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877607,,11064,,,50597,9796,,
Liver,BAO_0000218,,N,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624762,,11065,,,50597,9796,,
Liver,BAO_0000218,,N,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624763,,11066,,,50597,9796,,
Liver,BAO_0000218,,N,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624764,,11067,,,50597,9796,,
Liver,BAO_0000218,,N,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624765,,11068,,,50597,9796,,
Liver,BAO_0000218,,N,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624766,,11069,,,50597,9796,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624767,,11070,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624768,,11071,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624769,,11072,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624770,,11073,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624771,,11074,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624772,,11075,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624773,,11076,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624774,,11077,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624775,,11078,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624776,,11079,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624777,,11080,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624778,,11081,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624779,,11082,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624780,,11083,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624781,,11084,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877608,,11085,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624782,,11086,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624783,,11087,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624784,,11088,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624785,,11089,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624786,,11090,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624787,,11091,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628676,,11092,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621842,,11093,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL621843,,11094,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623873,,11095,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623874,,11096,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623875,,11097,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623876,,11098,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623877,,11099,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623878,,11100,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623879,,11101,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623880,,11102,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623881,,11103,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623957,,11104,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623958,,11105,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623959,,11106,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623960,,11107,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623961,,11108,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623962,,11109,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624676,,11110,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624677,,11111,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624678,,11112,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624679,,11113,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624680,,11114,,,50588,6996,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,1,,,A,,,0,Autocuration,CHEMBL624849,,11115,In vivo,,22224,11732,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,1,,,A,,,0,Autocuration,CHEMBL624850,,11116,In vivo,,22224,11732,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,1,,,A,,,0,Autocuration,CHEMBL874399,,11117,In vivo,,22224,11732,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,1,,,A,,,0,Autocuration,CHEMBL624851,,11118,In vivo,,22224,11732,,
,BAO_0000218,,U,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,1,,,A,,,0,Autocuration,CHEMBL624852,,11119,In vivo,,22224,11732,,
,BAO_0000218,,U,,Oral bioavailability in rat (dose 10 mg/kg),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL624853,,11120,In vivo,,22224,13359,,
,BAO_0000218,,U,,Oral bioavailability in rat (Sprague-Dawley),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL624854,,11121,In vivo,,22224,16618,,
,BAO_0000218,,U,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL624855,,11122,In vivo,,22224,13960,,
,BAO_0000218,,U,,Oral bioavailability in rats was determined in vivo,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL624856,,11123,In vivo,,22224,13917,,
,BAO_0000218,,U,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL882957,,11124,In vivo,,22224,14266,,
,BAO_0000218,,U,,Oral bioavailability of compound in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL624857,,11125,In vivo,,22224,12359,,
,BAO_0000218,,N,,Oral bioavailability of compound in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622202,,11126,In vivo,,50597,12359,,
,BAO_0000218,,U,,Bioavailability in rat of PMEA prodrug,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL622203,,11127,In vivo,,22224,12359,,
,BAO_0000218,,N,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625522,,11128,In vivo,,50597,12359,,
,BAO_0000218,,U,,Serum conc at 3 hours following 25 mg/kg dose,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL622868,,11129,In vivo,,22224,10791,,
Urine,BAO_0000218,,U,,Urine conc 0-5 hours following 25 mg/kg dose,1,,9544.0,A,Macaca mulatta,1088.0,0,Autocuration,CHEMBL622869,,11130,In vivo,,22224,10791,,
Urine,BAO_0000218,,U,,Urine conc 0-24 hours following 25 mg/kg dose,1,,9544.0,A,Macaca mulatta,1088.0,0,Autocuration,CHEMBL622870,,11131,In vivo,,22224,10791,,
,BAO_0000218,,U,,Oral bioavailability in African green monkeys; 20-25,1,,9534.0,A,Chlorocebus aethiops,,0,Autocuration,CHEMBL622871,,11132,In vivo,,22224,138,,
,BAO_0000218,,N,,Oral bioavailability in cynomolgus monkey.,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL620560,,11133,In vivo,,100710,14521,,
,BAO_0000218,,U,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL620561,,11134,In vivo,,22224,13953,,
,BAO_0000218,,N,,Oral bioavailability in dog at 10 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620562,,11135,In vivo,,50588,12836,,
,BAO_0000218,,N,,Oral bioavailability in hamster at 10 mg/kg oral dose,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL620563,,11136,In vivo,,100712,12836,,
,BAO_0000218,,N,,Oral bioavailability in rat at 10 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL620564,,11137,In vivo,,50597,12836,,
,BAO_0000218,,U,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL872265,,11138,In vivo,,22224,14521,,
,BAO_0000218,,U,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL620565,,11139,In vivo,,22224,13953,,
,BAO_0000218,,U,,Oral bioavailability,1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL620566,,11140,In vivo,,22224,6799,,
,BAO_0000218,,U,,Oral bioavailability was determined; range 49-102%,1,,,A,,,0,Autocuration,CHEMBL620567,,11141,In vivo,,22224,11311,,
,BAO_0000218,,N,,Oral bioavailability was determined in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL620568,,11142,In vivo,,50588,4013,,
,BAO_0000218,,U,,Oral bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL620569,,11143,In vivo,,22224,4013,,
,BAO_0000218,,U,,Oral bioavailability,1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL620570,,11144,In vivo,,22224,17591,,
,BAO_0000218,,U,,Oral bioavailability was determined; Not orally available,1,,,A,,,0,Autocuration,CHEMBL620571,,11145,In vivo,,22224,17591,,
,BAO_0000218,,N,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620572,,11146,In vivo,,50594,15011,,
,BAO_0000218,,U,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL620573,,11147,In vivo,,22224,15011,,
,BAO_0000218,,U,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,1,,10090.0,A,Mus musculus,,0,Autocuration,CHEMBL620574,,11148,In vivo,,22224,15011,,
,BAO_0000218,,U,,Oral bioavailability in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,0,Autocuration,CHEMBL620575,,11149,In vivo,,22224,9552,,
,BAO_0000218,,U,,Oral bioavailability in dog (female mongrel),1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL620576,,11150,In vivo,,22224,9552,,
,BAO_0000218,,U,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,1,,,A,,,0,Autocuration,CHEMBL875846,,11151,In vivo,,22224,3639,,
,BAO_0000218,,U,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL620577,,11152,In vivo,,22224,13397,,
,BAO_0000218,,U,,Percentage Bioavailability was evaluated.,1,,,A,,,0,Autocuration,CHEMBL620578,,11153,In vivo,,22224,3031,,
,BAO_0000218,,U,,Bioavailability in rat administered i.d.,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL620579,,11154,In vivo,,22224,12818,,
,BAO_0000218,,U,,Bioavailability,1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL621248,,11155,In vivo,,22224,4847,,
,BAO_0000218,,U,,Bioavailability in dog (male Beagle) i.v. administration,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL625390,,11156,In vivo,,22224,12421,,
,BAO_0000218,,U,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625391,,11157,In vivo,,22224,11966,,
,BAO_0000218,,U,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),1,,9443.0,A,Primates,,0,Autocuration,CHEMBL872266,,11158,In vivo,,22224,11218,,
,BAO_0000218,,U,,Oral bioavailability in rat (Sprague-Dawley) (male),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625392,,11159,In vivo,,22224,13129,,
,BAO_0000218,,N,,The oral bioavailability was measured on rats after oral administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625393,,11160,In vivo,,50597,12350,,
,BAO_0000218,,N,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625394,,11161,In vivo,,50597,2231,,
,BAO_0000218,,N,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL625395,,11162,In vivo,,50797,2231,,
,BAO_0000218,,U,,Bioavailability in rat (dose 10 mg/kg i.d.),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625396,,11163,In vivo,,22224,12187,,
,BAO_0000218,,U,,Bioavailability in dog (male Beagle) i.v. administration,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL625397,,11164,In vivo,,22224,12421,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625398,,11165,In vivo,,50594,13256,,
Blood,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL625399,,11166,In vivo,,50594,13256,,
Cerebellum,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2037.0,1,Intermediate,CHEMBL626074,,11167,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626075,,11168,In vivo,,50594,13256,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626076,,11169,In vivo,,50597,2231,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL626077,,11170,In vivo,,50797,2231,,
Blood,BAO_0000218,,N,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626078,,11171,In vivo,,50597,12178,,
Blood,BAO_0000218,,U,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),1,,,A,,178.0,0,Autocuration,CHEMBL625846,,11172,In vivo,,22224,12178,,
Blood,BAO_0000218,,U,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),1,,,A,,178.0,0,Autocuration,CHEMBL625847,,11173,In vivo,,22224,12178,,
,BAO_0000218,,N,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL625848,,11174,In vivo,,50597,15633,,
Plasma,BAO_0000218,,N,,Maximum concentration of compound in plasma administered orally to rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625849,,11175,In vivo,,50597,14258,,
Plasma,BAO_0000218,,N,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626023,,11176,In vivo,,50588,14224,,
Plasma,BAO_0000218,,N,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626024,,11177,In vivo,,50588,14224,,
Plasma,BAO_0000218,,N,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626025,,11178,In vivo,,50588,14224,,
,BAO_0000218,,U,,Maximum concentration after 10 mg/kg by oral administration,1,,,A,,,0,Autocuration,CHEMBL626026,,11179,In vivo,,22224,5566,,
,BAO_0000218,,U,,Maximum concentration at a dose of 1.5 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626027,,11180,In vivo,,22224,16935,,
,BAO_0000218,,U,,Maximum concentration at a dose of 2.0 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626028,,11181,In vivo,,22224,16935,,
Plasma,BAO_0000218,,N,,Maximum concentration in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626029,,11182,In vivo,,50588,14224,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,1,,,A,,1969.0,0,Autocuration,CHEMBL626030,,11183,In vivo,,22224,12536,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,1,,,A,,1969.0,0,Autocuration,CHEMBL626031,,11184,In vivo,,22224,12536,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,1,,,A,,1969.0,0,Autocuration,CHEMBL626032,,11185,In vivo,,22224,12536,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,1,,,A,,1969.0,0,Autocuration,CHEMBL626033,,11186,In vivo,,22224,12536,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,1,,,A,,1969.0,0,Autocuration,CHEMBL626034,,11187,In vivo,,22224,12536,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626035,,11188,In vivo,,50588,9994,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma at Tmax,1,,,A,,1969.0,0,Autocuration,CHEMBL626036,,11189,In vivo,,22224,1434,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Expert,CHEMBL626037,,11190,In vivo,,50588,12836,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,1,,10026.0,A,Cricetinae,1969.0,1,Intermediate,CHEMBL626038,,11191,In vivo,,100712,12836,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626039,,11192,In vivo,,50597,12836,,
Plasma,BAO_0000218,,N,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626040,,11193,In vivo,,50597,12545,,
Plasma,BAO_0000218,,N,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,1,,9986.0,A,Oryctolagus cuniculus,1969.0,1,Intermediate,CHEMBL626041,,11194,In vivo,,50592,13856,,
,BAO_0000218,,U,,Maximum concentration was calculated,1,,,A,,,0,Autocuration,CHEMBL626042,,11195,In vivo,,22224,3550,,
,BAO_0000218,,U,,Maximum concentration was calculated.,1,,,A,,,0,Autocuration,CHEMBL626043,,11196,In vivo,,22224,2632,,
,BAO_0000218,,U,,Maximum concentration at a peroral dose of 10 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626044,,11197,In vivo,,22224,5566,,
,BAO_0000218,,U,,Maximum concentration of the drug at 10 uM/dg administered perorally,1,,,A,,,0,Autocuration,CHEMBL626045,,11198,In vivo,,22224,11883,,
,BAO_0000218,,U,,Maximum concentration of the drug at 2 uM/dg administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626046,,11199,In vivo,,22224,11883,,
Plasma,BAO_0000218,,N,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626047,,11200,In vivo,,50588,14122,,
Plasma,BAO_0000218,,N,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",1,,10026.0,A,Cricetinae,1969.0,1,Intermediate,CHEMBL626048,,11201,In vivo,,100712,14122,,
Plasma,BAO_0000218,,N,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626049,,11202,In vivo,,50597,14122,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626050,,11203,In vivo,,50597,12542,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL874541,,11204,In vivo,,50588,12542,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,1,,10026.0,A,Cricetinae,1969.0,1,Intermediate,CHEMBL622826,,11205,In vivo,,100712,12542,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,1,,10026.0,A,Cricetinae,1969.0,1,Intermediate,CHEMBL622827,,11206,In vivo,,100712,12542,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622828,,11207,In vivo,,50597,12542,,
Plasma,BAO_0000218,,N,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622829,,11208,In vivo,,50597,14080,,
,BAO_0000218,,N,,Maximum concentration reached following intravenous administration in male rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876806,,11209,In vivo,,50597,11911,,
,BAO_0000218,,N,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622830,,11210,In vivo,,50588,13204,,
,BAO_0000218,,N,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622831,,11211,In vivo,,50597,13204,,
,BAO_0000218,,N,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626794,,11212,In vivo,,50588,14346,,
,BAO_0000218,,N,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626795,,11213,In vivo,,50597,14346,,
,BAO_0000218,,N,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626796,,11214,In vivo,,50597,14346,,
,BAO_0000218,,N,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626797,,11215,In vivo,,50597,14346,,
,BAO_0000218,,N,,Maximum drug concentration is determined after oral dosing in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626798,,11216,In vivo,,50597,14127,,
,BAO_0000218,,N,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626799,,11217,In vivo,,50588,14339,,
,BAO_0000218,,N,,Maximum observed concentration in oral (5 mg/kg) fed dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626800,,11218,In vivo,,50588,14339,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration,1,,,A,,1969.0,0,Autocuration,CHEMBL626801,,11219,In vivo,,22224,13494,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876816,,11220,In vivo,,50597,14925,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626802,,11221,In vivo,,50597,14474,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626803,,11222,In vivo,,50588,14474,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration following oral administration of 30 umol/kg,1,,,A,,1969.0,0,Autocuration,CHEMBL626804,,11223,In vivo,,22224,13917,,
Plasma,BAO_0000218,,N,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626805,,11224,,,50597,9796,,
Plasma,BAO_0000218,,N,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626309,,11225,,,50597,9796,,
Plasma,BAO_0000218,,N,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626310,,11226,,,50597,9796,,
Plasma,BAO_0000218,,N,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626311,,11227,,,50597,9796,,
Plasma,BAO_0000218,,N,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626312,,11228,,,50597,9796,,
Uterus,BAO_0000218,,N,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626313,,11229,,,50597,9796,,
Uterus,BAO_0000218,,N,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626314,,11230,,,50597,9796,,
Uterus,BAO_0000218,,N,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626315,,11231,,,50597,9796,,
Uterus,BAO_0000218,,N,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626316,,11232,,,50597,9796,,
Uterus,BAO_0000218,,N,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626317,,11233,,,50597,9796,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626318,,11234,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626319,,11235,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626320,,11236,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875053,,11237,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626321,,11238,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626322,,11239,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626323,,11240,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626324,,11241,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626325,,11242,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626326,,11243,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626327,,11244,,,50597,8363,,
,BAO_0000218,,N,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626328,,11245,,,50597,8363,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626329,,11246,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626330,,11247,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626331,,11248,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626332,,11249,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626333,,11250,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626334,,11251,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626335,,11252,,,50597,8684,,
Blood,BAO_0000218,,N,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624798,,11253,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624799,,11254,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624800,,11255,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624801,,11256,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624802,,11257,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624803,,11258,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624804,,11259,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624805,,11260,,,50597,8684,,
Brain,BAO_0000218,,N,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL624806,,11261,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624807,,11262,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624808,,11263,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624809,,11264,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624810,,11265,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877618,,11266,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624811,,11267,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624812,,11268,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624813,,11269,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624814,,11270,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624815,,11271,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624816,,11272,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624817,,11273,,,50597,8684,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624818,,11274,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624819,,11275,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624820,,11276,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624821,,11277,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624822,,11278,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624823,,11279,,,50588,6996,,
,BAO_0000218,,N,,Observed diffusion coefficient in organic solvent for Escherichia coli,1,,562.0,A,Escherichia coli,,1,Intermediate,CHEMBL624824,,11280,,,50212,15599,,
Blood,BAO_0000218,,N,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624825,,11281,,,50597,9614,,
Blood,BAO_0000218,,N,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624826,,11282,,,50597,9614,,
Cardiac atrium,BAO_0000218,,N,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,2081.0,1,Intermediate,CHEMBL876817,,11283,,,50597,9614,,
Cardiac atrium,BAO_0000218,,N,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,2081.0,1,Intermediate,CHEMBL624827,,11284,,,50597,9614,,
,BAO_0000218,,N,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624828,,11285,,,50597,9614,,
,BAO_0000218,,N,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624829,,11286,,,50597,9614,,
Liver,BAO_0000218,,N,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624830,,11287,,,50597,9614,,
Liver,BAO_0000218,,N,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624831,,11288,,,50597,9614,,
Cardiac atrium,BAO_0000218,,N,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,2081.0,1,Intermediate,CHEMBL624832,,11289,,,50597,9614,,
Cardiac atrium,BAO_0000218,,N,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,2081.0,1,Intermediate,CHEMBL624833,,11290,,,50597,9614,,
,BAO_0000218,,N,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624834,,11291,,,50597,9614,,
,BAO_0000218,,N,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624835,,11292,,,50597,9614,,
Spleen,BAO_0000218,,N,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL624836,,11293,,,50597,9614,,
Spleen,BAO_0000218,,N,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL624837,,11294,,,50597,9614,,
Blood,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624838,,11295,,,50597,9071,,
Blood,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622188,,11296,,,50597,9071,,
Heart,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622189,,11297,,,50597,9071,,
Heart,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622190,,11298,,,50597,9071,,
Heart,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625170,,11299,,,50597,9071,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625171,,11300,,,50597,9071,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625172,,11301,,,50597,9071,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625173,,11302,,,50597,9071,,
Liver,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625174,,11303,,,50597,9071,,
Liver,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625175,,11304,,,50597,9071,,
Liver,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625176,,11305,,,50597,9071,,
Lung,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625177,,11306,,,50597,9071,,
Lung,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625178,,11307,,,50597,9071,,
Lung,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625179,,11308,,,50597,9071,,
Lung,BAO_0000218,,N,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625180,,11309,,,50597,9071,,
,BAO_0000218,,U,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",1,,,A,,,0,Autocuration,CHEMBL625181,,11310,,,22224,10677,,
Urine,BAO_0000218,,N,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL625182,,11311,,,50594,9750,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625183,,11312,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875848,,11313,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622260,,11314,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622261,,11315,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622262,,11316,,,50597,8319,,
Kidney,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622263,,11317,,,50597,8319,,
Kidney,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622418,,11318,,,50597,8319,,
Liver,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622419,,11319,,,50597,8319,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623388,,11320,In vivo,,50594,13256,,
Liver,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL623389,,11321,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623390,,11322,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623391,,11323,In vivo,,50594,13256,,
Blood,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL623392,,11324,In vivo,,50594,13256,,
Cerebellum,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2037.0,1,Intermediate,CHEMBL623393,,11325,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623394,,11326,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618885,,11327,In vivo,,50594,13256,,
Liver,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618886,,11328,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618887,,11329,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619535,,11330,In vivo,,50594,13256,,
Blood,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL619536,,11331,In vivo,,50594,13256,,
Cerebellum,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2037.0,1,Intermediate,CHEMBL619537,,11332,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619705,,11333,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619706,,11334,In vivo,,50594,13256,,
Liver,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL619707,,11335,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL619708,,11336,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625219,,11337,In vivo,,50594,13256,,
Blood,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL625220,,11338,In vivo,,50594,13256,,
Cerebellum,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2037.0,1,Intermediate,CHEMBL625221,,11339,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625222,,11340,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625223,,11341,In vivo,,50594,13256,,
Liver,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL625224,,11342,In vivo,,50594,13256,,
,BAO_0000218,,N,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625225,,11343,In vivo,,50594,13256,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 24 hours of iv administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625226,,11344,In vivo,,50597,8829,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625227,,11345,In vivo,,50597,8829,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 30 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625228,,11346,In vivo,,50597,8829,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL875354,,11347,In vivo,,50597,8829,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 5 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625229,,11348,In vivo,,50597,8829,,
Blood,BAO_0000218,,N,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625230,,11349,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 24 hours of iv administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625231,,11350,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625900,,11351,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 30 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625901,,11352,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625902,,11353,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 5 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625903,,11354,In vivo,,50597,8829,,
Heart,BAO_0000218,,N,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625904,,11355,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 24 hours of iv administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625905,,11356,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627861,,11357,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 30 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627862,,11358,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627863,,11359,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 30 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627769,,11360,In vivo,,50597,8829,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL627770,,11361,In vivo,,50588,13249,,
,BAO_0000218,,N,,Cmax in cynomolgus monkey (PO dose),1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL627771,,11362,In vivo,,100710,13622,,
,BAO_0000218,,N,,Cmax in rat (PO dose),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627772,,11363,In vivo,,50597,13622,,
,BAO_0000218,,N,,Cmax in rat (PO dose),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627773,,11364,In vivo,,50597,13622,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621922,,11365,In vivo,,50597,13494,,
Plasma,BAO_0000218,,N,,Cmax in rat plasma after oral dose (10 mg/kg),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621923,,11366,In vivo,,50597,12170,,
Plasma,BAO_0000218,,U,,Cmax in plasma after oral dose (10 mg/kg),1,,,A,,1969.0,0,Autocuration,CHEMBL621924,,11367,In vivo,,22224,12170,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621925,,11368,In vivo,,50588,17025,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL621926,,11369,In vivo,,22224,17025,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,1,,9986.0,A,Oryctolagus cuniculus,1969.0,1,Intermediate,CHEMBL621927,,11370,In vivo,,50592,17025,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621928,,11371,In vivo,,50597,17025,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621929,,11372,In vivo,,50597,14187,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL621930,,11373,In vivo,,50594,14816,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration after oral dosing in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621931,,11374,In vivo,,50597,17820,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621932,,11375,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621933,,11376,In vivo,,22224,14380,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621934,,11377,In vivo,,50588,14691,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL621935,,11378,In vivo,,50588,14691,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL621936,,11379,In vivo,,50597,13375,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was determined,1,,,A,,1969.0,0,Autocuration,CHEMBL621937,,11380,In vivo,,22224,6236,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621938,,11381,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621939,,11382,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621940,,11383,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621941,,11384,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL621942,,11385,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL626178,,11386,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL626179,,11387,In vivo,,22224,14380,,
Plasma,BAO_0000218,,U,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,1,,,A,,1969.0,0,Autocuration,CHEMBL626180,,11388,In vivo,,22224,14380,,
Plasma,BAO_0000218,,N,,Plasma Cmax in rat (PO dose),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626181,,11389,In vivo,,50597,13622,,
,BAO_0000218,,N,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626182,,11390,In vivo,,50597,15372,,
,BAO_0000218,,N,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626183,,11391,In vivo,,50597,15372,,
,BAO_0000218,,N,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626184,,11392,In vivo,,50597,15372,,
,BAO_0000218,,N,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626185,,11393,In vivo,,50597,15372,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626186,,11394,In vivo,,50588,14925,,
Plasma,BAO_0000218,,N,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL877589,,11395,In vivo,,50588,14925,,
,BAO_0000218,,U,,Maximum concentration of the drug at 1 uM/dg administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626187,,11396,In vivo,,22224,11883,,
,BAO_0000218,,U,,Maximum concentration of the drug at 20 uM/dg administered perorally,1,,,A,,,0,Autocuration,CHEMBL626188,,11397,In vivo,,22224,11883,,
,BAO_0000218,,U,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,1,,,A,,,0,Autocuration,CHEMBL626189,,11398,In vivo,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL626855,,11399,In vivo,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL623781,,11400,In vivo,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL623782,,11401,In vivo,,22224,13391,,
Plasma,BAO_0000218,,N,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623783,,11402,In vivo,,50597,16360,,
Plasma,BAO_0000218,,N,,Cmax in dog plasma after 1mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623784,,11403,In vivo,,50588,3673,,
Plasma,BAO_0000218,,N,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623785,,11404,In vivo,,50588,14431,,
Plasma,BAO_0000218,,N,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623786,,11405,In vivo,,50597,14431,,
,BAO_0000218,,N,,Oral maximum concentration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623787,,11406,In vivo,,50597,14964,,
,BAO_0000218,,N,,Oral maximum concentration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623788,,11407,In vivo,,50597,14964,,
Plasma,BAO_0000218,,N,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623789,,11408,In vivo,,50594,14209,,
Blood,BAO_0000218,,N,,Peak concentration in blood after intravenous administration to mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL623790,,11409,In vivo,,50594,11355,,
Blood,BAO_0000218,,N,,Peak concentration in blood after peroral administration to mice,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL623791,,11410,In vivo,,50594,11355,,
Plasma,BAO_0000218,,N,,Peak concentration in rat plasma was determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623792,,11411,In vivo,,50597,11966,,
Plasma,BAO_0000218,,U,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL623793,,11412,In vivo,,22224,8918,,
Plasma,BAO_0000218,,N,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623794,,11413,In vivo,,50594,8918,,
Plasma,BAO_0000218,,N,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623795,,11414,In vivo,,50597,8918,,
,BAO_0000218,,N,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623796,,11415,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623797,,11416,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623798,,11417,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623799,,11418,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624490,,11419,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624491,,11420,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624492,,11421,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624493,,11422,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL877595,,11423,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624494,,11424,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624495,,11425,,,50597,8684,,
Intestine,BAO_0000218,,N,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL624681,,11426,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624682,,11427,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624683,,11428,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624684,,11429,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624685,,11430,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624686,,11431,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624687,,11432,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624688,,11433,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627161,,11434,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622127,,11435,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622128,,11436,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874384,,11437,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624898,,11438,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624899,,11439,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624900,,11440,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624901,,11441,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624902,,11442,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624903,,11443,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624904,,11444,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624905,,11445,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624906,,11446,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624907,,11447,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624908,,11448,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624909,,11449,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624910,,11450,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624911,,11451,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL874388,,11452,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL624912,,11453,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622930,,11454,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623121,,11455,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623122,,11456,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623123,,11457,,,50597,8684,,
Muscle tissue,BAO_0000218,,N,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623124,,11458,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623125,,11459,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623126,,11460,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623127,,11461,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623128,,11462,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623129,,11463,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623130,,11464,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623131,,11465,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623132,,11466,,,50597,8684,,
Liver,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623133,,11467,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623134,,11468,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874389,,11469,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623135,,11470,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623136,,11471,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623137,,11472,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623138,,11473,,,50597,8319,,
Kidney,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623139,,11474,,,50597,8319,,
Kidney,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623140,,11475,,,50597,8319,,
Liver,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623141,,11476,,,50597,8319,,
Liver,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623142,,11477,,,50597,8319,,
,BAO_0000218,,N,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623143,,11478,,,50597,8319,,
Urine,BAO_0000218,,N,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL623144,,11479,,,50594,14571,,
Urine,BAO_0000218,,N,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623405,,11480,,,50597,14571,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624074,,11481,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624075,,11482,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624076,,11483,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624077,,11484,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624078,,11485,,,50597,8319,,
Kidney,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624079,,11486,,,50597,8319,,
Kidney,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624261,,11487,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624262,,11488,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624263,,11489,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624264,,11490,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624265,,11491,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624266,,11492,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624267,,11493,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624268,,11494,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875227,,11495,,,50597,8319,,
Kidney,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624269,,11496,,,50597,8319,,
Kidney,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624270,,11497,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624271,,11498,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624272,,11499,,,50597,8319,,
,BAO_0000218,,N,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624273,,11500,,,50597,8319,,
Urine,BAO_0000218,,N,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624274,,11501,,,50597,12064,,
Urine,BAO_0000218,,N,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624275,,11502,,,50597,12064,,
Urine,BAO_0000218,,N,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624276,,11503,,,50597,12064,,
Urine,BAO_0000218,,N,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624277,,11504,,,50597,12038,,
,BAO_0000019,,U,,% dose converted to 2-amino-5-chlorophenyl sulfate,1,,,A,,,0,Autocuration,CHEMBL624278,,11505,,,22224,14314,,
,BAO_0000019,,U,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),1,,,A,,,0,Autocuration,CHEMBL624279,,11506,,,22224,14314,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL624280,,11507,,,50597,11488,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL624281,,11508,,,50597,11488,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL622933,,11509,,,50597,11488,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL622934,,11510,,,50597,11488,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622935,,11511,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 5 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622936,,11512,In vivo,,50597,8829,,
Liver,BAO_0000218,,N,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL875228,,11513,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 24 hours of iv administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622937,,11514,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622938,,11515,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 30 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL619736,,11516,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625117,,11517,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 5 minutes of iv administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625118,,11518,In vivo,,50597,8829,,
Lung,BAO_0000218,,N,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625119,,11519,In vivo,,50597,8829,,
Cerebellum,BAO_0000218,,N,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL625120,,11520,In vivo,,50597,14972,,
,BAO_0000218,,N,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625121,,11521,In vivo,,50597,14972,,
Thalamus,BAO_0000218,,N,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",1,,10116.0,A,Rattus norvegicus,10000006.0,1,Intermediate,CHEMBL625122,,11522,In vivo,,50597,14972,,
Blood,BAO_0000218,,N,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL622204,,11523,In vivo,,50597,14608,,
Blood,BAO_0000218,,N,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL877503,,11524,In vivo,,50597,14608,,
Blood,BAO_0000218,,N,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627127,,11525,In vivo,,50597,14608,,
Hippocampus,BAO_0000218,,U,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,,A,,10000000.0,0,Autocuration,CHEMBL627128,,11526,In vivo,,22224,14608,,
Hippocampus,BAO_0000218,,U,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,,A,,10000000.0,0,Autocuration,CHEMBL627129,,11527,In vivo,,22224,14608,,
Hippocampus,BAO_0000218,,U,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,,A,,10000000.0,0,Autocuration,CHEMBL627130,,11528,In vivo,,22224,14608,,
Brain,BAO_0000218,,N,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627131,,11529,In vivo,,50597,14608,,
Brain,BAO_0000218,,N,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627132,,11530,In vivo,,50597,14608,,
Brain,BAO_0000218,,N,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL627133,,11531,In vivo,,50597,14608,,
Cerebellum,BAO_0000218,,N,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL627134,,11532,In vivo,,50597,14608,,
Cerebellum,BAO_0000218,,N,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL627135,,11533,In vivo,,50597,14608,,
Cerebellum,BAO_0000218,,N,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL627136,,11534,In vivo,,50597,14608,,
,BAO_0000218,,N,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628435,,11535,In vivo,,50597,14608,,
,BAO_0000218,,N,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628436,,11536,In vivo,,50597,14608,,
,BAO_0000218,,N,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628437,,11537,In vivo,,50597,14608,,
Heart,BAO_0000218,,N,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL628438,,11538,In vivo,,50597,14608,,
Heart,BAO_0000218,,N,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL628439,,11539,In vivo,,50597,14608,,
Heart,BAO_0000218,,N,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL628440,,11540,In vivo,,50597,14608,,
Hippocampus,BAO_0000218,,N,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628441,,11541,In vivo,,50597,14608,,
Hippocampus,BAO_0000218,,N,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628442,,11542,In vivo,,50597,14608,,
Hippocampus,BAO_0000218,,N,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628443,,11543,In vivo,,50597,14608,,
Kidney,BAO_0000218,,N,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628444,,11544,In vivo,,50597,14608,,
Kidney,BAO_0000218,,N,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628445,,11545,In vivo,,50597,14608,,
Kidney,BAO_0000218,,N,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL877504,,11546,In vivo,,50597,14608,,
Liver,BAO_0000218,,N,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628446,,11547,In vivo,,50597,14608,,
Liver,BAO_0000218,,N,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626874,,11548,In vivo,,50597,14608,,
Liver,BAO_0000218,,N,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626875,,11549,In vivo,,50597,14608,,
Lung,BAO_0000218,,N,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626876,,11550,In vivo,,50597,14608,,
Lung,BAO_0000218,,N,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626877,,11551,In vivo,,50597,14608,,
Lung,BAO_0000218,,N,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626878,,11552,In vivo,,50597,14608,,
Muscle tissue,BAO_0000218,,N,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL626879,,11553,In vivo,,50597,14608,,
Plasma,BAO_0000218,,U,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL626880,,11554,In vivo,,22224,8918,,
Plasma,BAO_0000218,,N,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL626881,,11555,In vivo,,50594,8918,,
Plasma,BAO_0000218,,N,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626882,,11556,In vivo,,50597,8918,,
Plasma,BAO_0000218,,N,,Peak plasma concentration was measured in dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626883,,11557,In vivo,,50588,14470,,
,BAO_0000218,,N,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626884,,11558,In vivo,,50597,14393,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626885,,11559,In vivo,,50597,14886,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626886,,11560,In vivo,,50597,14886,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626887,,11561,In vivo,,50597,14886,,
,BAO_0000218,,N,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626888,,11562,In vivo,,50597,14393,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626889,,11563,In vivo,,50588,13465,,
,BAO_0000218,,U,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626761,,11564,In vivo,,22224,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626762,,11565,In vivo,,50588,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626763,,11566,In vivo,,50588,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626764,,11567,In vivo,,50597,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626765,,11568,In vivo,,50597,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626766,,11569,In vivo,,50588,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626767,,11570,In vivo,,50597,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626768,,11571,In vivo,,50597,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626769,,11572,In vivo,,50588,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL874463,,11573,In vivo,,50588,13465,,
,BAO_0000218,,U,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626770,,11574,In vivo,,22224,13465,,
,BAO_0000218,,U,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626771,,11575,In vivo,,22224,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626772,,11576,In vivo,,50597,13465,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL626773,,11577,In vivo,,100710,14731,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626774,,11578,In vivo,,50594,14731,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626775,,11579,In vivo,,50588,13376,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626776,,11580,In vivo,,50588,13376,,
,BAO_0000218,,N,,Maximum concentration (Cmax) in rat when administered orally,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626777,,11581,In vivo,,50597,14443,,
Plasma,BAO_0000218,,U,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL626778,,11582,In vivo,,22224,13465,,
,BAO_0000218,,U,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL626779,,11583,In vivo,,22224,16359,,
,BAO_0000218,,U,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL626780,,11584,In vivo,,22224,16359,,
Plasma,BAO_0000218,,U,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,1,,,A,,1969.0,0,Autocuration,CHEMBL626781,,11585,In vivo,,22224,15618,,
,BAO_0000218,,N,,Pharmacokinetic profile Cmax was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632164,,11586,In vivo,,50597,14554,,
,BAO_0000218,,N,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL632165,,11587,In vivo,,50588,11537,,
,BAO_0000218,,N,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL632166,,11588,In vivo,,50594,11537,,
,BAO_0000218,,N,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL632167,,11589,In vivo,,50588,11537,,
,BAO_0000218,,N,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL632168,,11590,In vivo,,50594,11537,,
Plasma,BAO_0000218,,U,,Cmax in rat plasma,1,,10116.0,A,Rattus norvegicus,1969.0,0,Autocuration,CHEMBL632169,,11591,In vivo,,22224,2021,,
Plasma,BAO_0000218,,N,,Cmax in dog plasma after 30mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL632170,,11592,In vivo,,50588,5932,,
Plasma,BAO_0000218,,N,,Cmax in rat plasma after 30mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632171,,11593,In vivo,,50597,5932,,
Plasma,BAO_0000218,,N,,Plasma level in rats at 30 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632172,,11594,In vivo,,50597,17320,,
Plasma,BAO_0000218,,N,,Tested for maximum plasma concentration in mice,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL632173,,11595,In vivo,,50594,15831,,
,BAO_0000218,,N,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632174,,11596,In vivo,,50597,15078,,
,BAO_0000218,,N,,The Cmax values in female wistar rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632175,,11597,In vivo,,50597,14941,,
Plasma,BAO_0000218,,N,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL632176,,11598,In vivo,,50588,15343,,
Plasma,BAO_0000218,,N,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632177,,11599,In vivo,,50597,15343,,
Plasma,BAO_0000218,,N,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632178,,11600,In vivo,,50597,14856,,
,BAO_0000218,,N,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632179,,11601,In vivo,,50597,13129,,
Blood,BAO_0000218,,N,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632180,,11602,In vivo,,50597,13098,,
Blood,BAO_0000218,,N,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632181,,11603,In vivo,,50597,13098,,
Blood,BAO_0000218,,N,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632182,,11604,In vivo,,50597,13098,,
Blood,BAO_0000218,,U,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,1,,10090.0,A,Mus musculus,178.0,0,Autocuration,CHEMBL632183,,11605,In vivo,,22224,15478,,
,BAO_0000218,,N,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL632184,,11606,In vivo,,50588,15341,,
,BAO_0000218,,N,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874470,,11607,In vivo,,50597,15341,,
,BAO_0000218,,N,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631302,,11608,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631303,,11609,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631304,,11610,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631305,,11611,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631306,,11612,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631307,,11613,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631308,,11614,,,50597,8684,,
,BAO_0000218,,N,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625557,,11615,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625558,,11616,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625559,,11617,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625560,,11618,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625561,,11619,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625562,,11620,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL875320,,11621,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625563,,11622,,,50597,8684,,
Spleen,BAO_0000218,,N,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625564,,11623,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL625565,,11624,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL625566,,11625,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL625567,,11626,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL625568,,11627,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL628217,,11628,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL628218,,11629,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL628219,,11630,,,50597,8684,,
Uterus,BAO_0000218,,N,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL628220,,11631,,,50597,8684,,
,BAO_0000019,,U,,Distribution in the blood after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628221,,11632,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the blood after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628222,,11633,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the blood after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628223,,11634,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the blood after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628224,,11635,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the blood after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628225,,11636,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the blood after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628226,,11637,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628227,,11638,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL875481,,11639,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628228,,11640,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628229,,11641,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628230,,11642,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the bone after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628231,,11643,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628232,,11644,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628233,,11645,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628234,,11646,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628235,,11647,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628236,,11648,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the heart after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628237,,11649,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628238,,11650,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628239,,11651,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628240,,11652,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628241,,11653,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628242,,11654,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the kidneys after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL875482,,11655,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628243,,11656,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628244,,11657,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628245,,11658,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628246,,11659,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628247,,11660,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the liver after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628248,,11661,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the lung after 120 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628249,,11662,,,22224,8926,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625452,,11663,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625453,,11664,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625454,,11665,,,50594,14839,,
,BAO_0000218,,N,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623844,,11666,,,50594,14839,,
,BAO_0000218,,N,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623845,,11667,,,50597,12178,,
,BAO_0000218,,N,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623846,,11668,,,50597,12178,,
,BAO_0000218,,U,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,1,,,A,,,0,Autocuration,CHEMBL623847,,11669,,,22224,12178,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623848,,11670,,,100710,12186,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623849,,11671,,,100710,12186,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623850,,11672,,,100710,12186,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623851,,11673,,,100710,12186,,
,BAO_0000218,,U,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL623852,,11674,,,22224,12187,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL624551,,11675,,,50506,12187,,
,BAO_0000218,,N,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL624552,,11676,,,50506,12187,,
,BAO_0000218,,U,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL624553,,11677,,,22224,12187,,
,BAO_0000218,,U,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL624554,,11678,,,22224,12187,,
,BAO_0000218,,N,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624555,,11679,,,50597,12187,,
,BAO_0000218,,N,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624741,,11680,,,50597,12187,,
,BAO_0000218,,N,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624742,,11681,,,50588,14122,,
,BAO_0000218,,N,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL624743,,11682,,,100712,14122,,
,BAO_0000218,,N,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877606,,11683,,,50597,14122,,
,BAO_0000218,,U,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,1,,,A,,,0,Autocuration,CHEMBL624744,,11684,,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL624745,,11685,,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL624746,,11686,,,22224,13391,,
Blood,BAO_0000218,,U,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,1,,,A,,178.0,0,Autocuration,CHEMBL624747,,11687,,,22224,13391,,
,BAO_0000019,,U,,Oral absorption expressed as Area under curve was determined,1,,,A,,,0,Autocuration,CHEMBL624748,,11688,,,22224,16360,,
,BAO_0000218,,N,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622504,,11689,,,50588,3673,,
,BAO_0000218,,N,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622505,,11690,,,50588,14122,,
,BAO_0000218,,N,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL622506,,11691,,,100712,14122,,
,BAO_0000218,,N,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL622507,,11692,,,100712,14122,,
,BAO_0000218,,N,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622508,,11693,,,50597,14122,,
,BAO_0000019,,U,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,1,,,A,,,0,Autocuration,CHEMBL622509,,11694,,,22224,13889,,
,BAO_0000218,,N,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622510,,11695,,,50597,14393,,
,BAO_0000218,,N,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622511,,11696,,,50597,17279,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL622512,,11697,,,100710,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL622513,,11698,,,100710,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL622514,,11699,,,100710,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622515,,11700,,,50588,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622516,,11701,,,50588,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622517,,11702,,,50597,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622518,,11703,,,50597,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622519,,11704,,,50597,14548,,
Muscle tissue,BAO_0000218,,N,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622520,,11705,In vivo,,50597,14608,,
Muscle tissue,BAO_0000218,,N,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622521,,11706,In vivo,,50597,14608,,
Zone of skin,BAO_0000218,,N,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL625113,,11707,In vivo,,50594,14608,,
Zone of skin,BAO_0000218,,N,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL625114,,11708,In vivo,,50597,14608,,
Zone of skin,BAO_0000218,,N,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL874397,,11709,In vivo,,50597,14608,,
Spleen,BAO_0000218,,N,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625115,,11710,In vivo,,50597,14608,,
Spleen,BAO_0000218,,N,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625116,,11711,In vivo,,50597,14608,,
Spleen,BAO_0000218,,N,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL623932,,11712,In vivo,,50597,14608,,
Striatum,BAO_0000218,,N,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL623933,,11713,In vivo,,50597,14608,,
Striatum,BAO_0000218,,N,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL623934,,11714,In vivo,,50597,14608,,
Striatum,BAO_0000218,,N,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL623935,,11715,In vivo,,50597,14608,,
Thyroid gland,BAO_0000218,,N,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL623936,,11716,In vivo,,50597,14608,,
Thyroid gland,BAO_0000218,,N,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL623937,,11717,In vivo,,50597,14608,,
Thyroid gland,BAO_0000218,,N,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL623938,,11718,In vivo,,50597,14608,,
,BAO_0000218,,N,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623939,,11719,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623940,,11720,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623941,,11721,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627216,,11722,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623942,,11723,,,50594,15383,,
Brain,BAO_0000218,,N,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618793,,11724,,,50594,15383,,
Brain,BAO_0000218,,N,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618794,,11725,,,50594,15383,,
Brain,BAO_0000218,,N,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL618795,,11726,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618796,,11727,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618797,,11728,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618798,,11729,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618799,,11730,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618800,,11731,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618801,,11732,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618802,,11733,,,50594,15383,,
Kidney,BAO_0000218,,N,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL618803,,11734,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618804,,11735,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618805,,11736,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618806,,11737,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618807,,11738,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618808,,11739,,,50594,15383,,
Liver,BAO_0000218,,N,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL618809,,11740,,,50594,15383,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618810,,11741,,,50594,15383,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618811,,11742,,,50594,15383,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL875844,,11743,,,50594,15383,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618812,,11744,,,50594,15383,,
Muscle tissue,BAO_0000218,,N,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL618813,,11745,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618814,,11746,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618815,,11747,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618816,,11748,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL618817,,11749,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL620544,,11750,,,50594,15383,,
,BAO_0000218,,N,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626230,,11751,In vivo,,50597,15341,,
,BAO_0000218,,N,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626231,,11752,In vivo,,50597,15341,,
,BAO_0000218,,N,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626232,,11753,In vivo,,50597,15341,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626233,,11754,In vivo,,50588,14906,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626234,,11755,In vivo,,50597,14906,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL875341,,11756,In vivo,,50597,14906,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (100 mg/kg) administered orally in human,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL626235,,11757,In vivo,,50587,14215,,
Plasma,BAO_0000218,,U,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,1,,9481.0,A,Callithrix,1969.0,0,Autocuration,CHEMBL626236,,11758,In vivo,,22224,14215,,
Plasma,BAO_0000218,,U,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL626237,,11759,In vivo,,22224,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626238,,11760,In vivo,,50588,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (200 mg/kg) administered orally in human,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL622412,,11761,In vivo,,50587,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623114,,11762,In vivo,,50597,14215,,
Plasma,BAO_0000218,,U,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,1,,9481.0,A,Callithrix,1969.0,0,Autocuration,CHEMBL623115,,11763,In vivo,,22224,14215,,
Plasma,BAO_0000218,,U,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL623116,,11764,In vivo,,22224,14215,,
Plasma,BAO_0000218,,U,,The maximum plasma concentration (30 mg/kg) administered orally in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,0,Autocuration,CHEMBL623117,,11765,In vivo,,22224,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (400 mg/kg) administered orally in human,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL623118,,11766,In vivo,,50587,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623119,,11767,In vivo,,50597,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (50 mg/kg) administered orally in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623120,,11768,In vivo,,50597,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration (800 mg/kg) administered orally in human,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL623286,,11769,In vivo,,50587,14215,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration was measured on rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623287,,11770,In vivo,,50597,14067,,
Plasma,BAO_0000218,,N,,The maximum plasma concentration was measured on rats after oral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623288,,11771,In vivo,,50597,12350,,
Plasma,BAO_0000218,,N,,Plasma drug Cmax in rat (PO dose),1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623289,,11772,In vivo,,50597,14813,,
,BAO_0000218,,U,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,1,,,A,,,0,Autocuration,CHEMBL623290,,11773,In vivo,,22224,12536,,
Plasma,BAO_0000218,,N,,maximum Plasma concentration in Dog was determined after Peroral administration,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623291,,11774,In vivo,,50588,14169,,
Plasma,BAO_0000218,,N,,maximum Plasma concentration in Rats was determined after Peroral administration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623292,,11775,In vivo,,50597,14169,,
Plasma,BAO_0000218,,N,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL623293,,11776,In vivo,,50588,15604,,
Plasma,BAO_0000218,,U,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL623294,,11777,In vivo,,22224,15604,,
Plasma,BAO_0000218,,N,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623295,,11778,In vivo,,50597,15604,,
,BAO_0000218,,N,,maximum concentration was measured when administered through oral route in mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623296,,11779,In vivo,,50594,14387,,
,BAO_0000218,,N,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875349,,11780,,,50594,15115,,
,BAO_0000019,,U,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL623297,,11781,,,22224,15115,,
,BAO_0000019,,U,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL623298,,11782,,,22224,15115,,
,BAO_0000019,,U,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL623299,,11783,,,22224,15115,,
,BAO_0000218,,N,,Pharmacokinetic parameter was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623300,,11784,,,50597,16359,,
,BAO_0000218,,N,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623301,,11785,,,50594,12829,,
,BAO_0000218,,N,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623302,,11786,,,50594,12829,,
,BAO_0000218,,N,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623303,,11787,,,50594,12829,,
,BAO_0000218,,N,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623304,,11788,,,50594,12829,,
,BAO_0000218,,N,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623305,,11789,,,50594,12829,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623306,,11790,,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623307,,11791,,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL623308,,11792,,,50597,15137,,
Plasma,BAO_0000218,,N,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL623309,,11793,,,50594,15137,,
,BAO_0000218,,N,,Plasma Concentration after 120 min of oral administration to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623310,,11794,,,50594,13509,,
,BAO_0000218,,N,,Plasma Concentration after 30 min of oral administration to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623311,,11795,,,50594,13509,,
,BAO_0000218,,N,,Plasma Concentration after 60 min of oral administration to mice,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL623312,,11796,,,100710,13509,,
,BAO_0000218,,N,,Plasma Concentration after 60 min of oral administration to mice; Not determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL875350,,11797,,,50594,13509,,
,BAO_0000218,,N,,Plasma Concentration after 90 min of oral administration to mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628635,,11798,,,50594,13509,,
,BAO_0000218,,N,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628636,,11799,,,50597,12064,,
,BAO_0000218,,N,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628637,,11800,,,50597,12064,,
,BAO_0000218,,N,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628058,,11801,,,50597,12064,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628059,,11802,,,50597,10677,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628060,,11803,,,50597,10677,,
,BAO_0000019,,U,,Distribution in the lung after 15 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628061,,11804,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the lung after 30 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628062,,11805,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the lung after 5 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628063,,11806,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the lung after 60 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628064,,11807,,,22224,8926,,
,BAO_0000019,,U,,Distribution in the lung after 90 min of intravenous administration,1,,,A,,,0,Autocuration,CHEMBL628065,,11808,,,22224,8926,,
Muscle tissue,BAO_0000019,,U,,Distribution in the muscle after 120 min of intravenous administration,1,,,A,,2385.0,0,Autocuration,CHEMBL628066,,11809,,,22224,8926,,
Muscle tissue,BAO_0000019,,U,,Distribution in the muscle after 15 min of intravenous administration,1,,,A,,2385.0,0,Autocuration,CHEMBL628067,,11810,,,22224,8926,,
Muscle tissue,BAO_0000218,,N,,Distribution in the muscle after 30 min of intravenous administration,1,,10090.0,A,Mus musculus,2385.0,1,Intermediate,CHEMBL874646,,11811,,,50594,8926,,
Muscle tissue,BAO_0000019,,U,,Distribution in the muscle after 5 min of intravenous administration,1,,,A,,2385.0,0,Autocuration,CHEMBL628068,,11812,,,22224,8926,,
Muscle tissue,BAO_0000019,,U,,Distribution in the muscle after 60 min of intravenous administration,1,,,A,,2385.0,0,Autocuration,CHEMBL628069,,11813,,,22224,8926,,
Muscle tissue,BAO_0000019,,U,,Distribution in the muscle after 90 min of intravenous administration,1,,,A,,2385.0,0,Autocuration,CHEMBL628070,,11814,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 120 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628071,,11815,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 15 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628072,,11816,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 30 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628073,,11817,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 5 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628074,,11818,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 60 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628075,,11819,,,22224,8926,,
Spleen,BAO_0000019,,U,,Distribution in the spleen after 90 min of intravenous administration,1,,,A,,2106.0,0,Autocuration,CHEMBL628076,,11820,,,22224,8926,,
Adrenal cortex,BAO_0000218,,N,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,1235.0,1,Intermediate,CHEMBL628077,,11821,,,50597,7570,,
Blood,BAO_0000218,,N,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628078,,11822,,,50597,7570,,
Liver,BAO_0000218,,N,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628079,,11823,,,50597,7570,,
Female gonad,BAO_0000218,,N,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL628080,,11824,,,50597,7570,,
Thyroid gland,BAO_0000218,,N,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628081,,11825,,,50597,7570,,
Adrenal cortex,BAO_0000218,,N,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,1235.0,1,Intermediate,CHEMBL628082,,11826,,,50597,7570,,
Blood,BAO_0000218,,N,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL874647,,11827,,,50597,7570,,
Liver,BAO_0000218,,N,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626406,,11828,,,50597,7570,,
Female gonad,BAO_0000218,,N,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL626407,,11829,,,50597,7570,,
Thyroid gland,BAO_0000218,,N,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626408,,11830,,,50597,7570,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626409,,11831,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626410,,11832,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626411,,11833,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626412,,11834,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626413,,11835,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626414,,11836,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626415,,11837,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626416,,11838,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627062,,11839,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627063,,11840,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627064,,11841,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627227,,11842,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627228,,11843,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627229,,11844,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625792,,11845,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625793,,11846,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625794,,11847,,,50597,8608,,
Blood,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625795,,11848,,,50597,8608,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625796,,11849,,,50594,13792,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625797,,11850,,,50588,13376,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625798,,11851,,,50588,13376,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL875613,,11852,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625799,,11853,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625800,,11854,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625801,,11855,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625802,,11856,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625803,,11857,,,22224,14380,,
,BAO_0000019,,U,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,1,,,A,,,0,Autocuration,CHEMBL625804,,11858,,,22224,14380,,
,BAO_0000218,,U,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL622530,,11859,,,22224,14380,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622531,,11860,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622532,,11861,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623176,,11862,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623177,,11863,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623178,,11864,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623179,,11865,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623180,,11866,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623181,,11867,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624131,,11868,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624132,,11869,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624133,,11870,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624846,,11871,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624847,,11872,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL624848,,11873,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625012,,11874,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625013,,11875,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625014,,11876,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625015,,11877,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625016,,11878,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625017,,11879,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625018,,11880,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625019,,11881,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625020,,11882,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625021,,11883,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625022,,11884,,,50597,14393,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625023,,11885,,,50594,14731,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL625024,,11886,,,100710,14731,,
,BAO_0000218,,N,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL627626,,11887,,,100710,14731,,
Brain,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,1,,,A,,955.0,0,Autocuration,CHEMBL627627,,11888,,,22224,13758,,
Serum,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,1,,,A,,1977.0,0,Autocuration,CHEMBL627628,,11889,,,22224,13758,,
Brain,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,1,,,A,,955.0,0,Autocuration,CHEMBL627629,,11890,,,22224,13758,,
Serum,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,1,,,A,,1977.0,0,Autocuration,CHEMBL627630,,11891,,,22224,13758,,
,BAO_0000019,,U,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),1,,,A,,,0,Autocuration,CHEMBL627631,,11892,,,22224,16359,,
,BAO_0000218,,U,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),1,,,A,,,0,Autocuration,CHEMBL629515,,11893,,,22224,16359,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL629516,,11894,,,50594,15383,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL629517,,11895,,,50594,15383,,
Spleen,BAO_0000218,,N,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL629518,,11896,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL877499,,11897,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629519,,11898,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629520,,11899,,,50594,15383,,
,BAO_0000218,,N,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629521,,11900,,,50594,15383,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629522,,11901,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629523,,11902,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629524,,11903,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629525,,11904,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629526,,11905,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629527,,11906,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629528,,11907,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629529,,11908,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629530,,11909,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629531,,11910,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628656,,11911,,,50594,14439,,
,BAO_0000218,,N,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628657,,11912,,,50594,14439,,
,BAO_0000218,,N,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628658,,11913,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628659,,11914,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877500,,11915,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628660,,11916,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628661,,11917,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628662,,11918,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628663,,11919,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628664,,11920,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628665,,11921,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628666,,11922,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628667,,11923,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628668,,11924,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628669,,11925,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628670,,11926,In vivo,,50597,13751,,
Blood,BAO_0000218,,N,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628671,,11927,In vivo,,50597,13751,,
Bone,BAO_0000218,,N,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL628672,,11928,In vivo,,50597,13751,,
Bone,BAO_0000218,,N,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL630300,,11929,In vivo,,50597,13751,,
Bone,BAO_0000218,,N,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL629787,,11930,In vivo,,50597,13751,,
Bone,BAO_0000218,,N,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL629788,,11931,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629789,,11932,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629790,,11933,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629791,,11934,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629792,,11935,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629793,,11936,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629794,,11937,In vivo,,50597,13751,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874459,,11938,,,50597,10677,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629795,,11939,,,50597,10677,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629796,,11940,,,50597,10677,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629797,,11941,,,50597,10677,,
,BAO_0000218,,N,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629798,,11942,,,50597,10677,,
Adrenal gland,BAO_0000218,,N,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2369.0,1,Intermediate,CHEMBL629799,,11943,In vivo,,50597,10911,,
Adrenal gland,BAO_0000218,,N,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2369.0,1,Intermediate,CHEMBL629800,,11944,In vivo,,50597,10911,,
Adrenal gland,BAO_0000218,,N,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2369.0,1,Intermediate,CHEMBL629801,,11945,In vivo,,50597,10911,,
Adrenal gland,BAO_0000218,,N,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,1,,10116.0,A,Rattus norvegicus,2369.0,1,Intermediate,CHEMBL629802,,11946,In vivo,,50597,10911,,
Adrenal gland,BAO_0000218,,N,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2369.0,1,Intermediate,CHEMBL629803,,11947,In vivo,,50597,10911,,
Blood,BAO_0000218,,N,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629804,,11948,In vivo,,50597,10911,,
Blood,BAO_0000218,,N,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629805,,11949,In vivo,,50597,10911,,
Blood,BAO_0000218,,N,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629806,,11950,In vivo,,50597,10911,,
Blood,BAO_0000218,,N,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629807,,11951,In vivo,,50597,10911,,
Blood,BAO_0000218,,N,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629808,,11952,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629809,,11953,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629810,,11954,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629811,,11955,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629812,,11956,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629813,,11957,In vivo,,50597,10911,,
Brain,BAO_0000218,,N,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL874460,,11958,In vivo,,50597,10911,,
,BAO_0000218,,N,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629814,,11959,In vivo,,50597,10911,,
,BAO_0000218,,N,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629815,,11960,In vivo,,50597,10911,,
,BAO_0000218,,N,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629816,,11961,In vivo,,50597,10911,,
,BAO_0000218,,N,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629817,,11962,In vivo,,50597,10911,,
Kidney,BAO_0000218,,N,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626643,,11963,In vivo,,50597,10911,,
Kidney,BAO_0000218,,N,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626644,,11964,In vivo,,50597,10911,,
Kidney,BAO_0000218,,N,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626806,,11965,In vivo,,50597,10911,,
Kidney,BAO_0000218,,N,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626807,,11966,In vivo,,50597,10911,,
Liver,BAO_0000218,,N,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627261,,11967,In vivo,,50597,10911,,
Liver,BAO_0000218,,N,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627262,,11968,In vivo,,50597,10911,,
Liver,BAO_0000218,,N,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627263,,11969,In vivo,,50597,10911,,
Liver,BAO_0000218,,N,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627264,,11970,In vivo,,50597,10911,,
Lung,BAO_0000218,,N,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627265,,11971,In vivo,,50597,10911,,
Lung,BAO_0000218,,N,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627266,,11972,In vivo,,50597,10911,,
Lung,BAO_0000218,,N,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627267,,11973,In vivo,,50597,10911,,
Lung,BAO_0000218,,N,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627268,,11974,In vivo,,50597,10911,,
Muscle tissue,BAO_0000218,,N,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627269,,11975,In vivo,,50597,10911,,
Muscle tissue,BAO_0000218,,N,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627270,,11976,In vivo,,50597,10911,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627271,,11977,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627946,,11978,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875472,,11979,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627947,,11980,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627948,,11981,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628113,,11982,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628114,,11983,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628115,,11984,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628116,,11985,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628117,,11986,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628118,,11987,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628119,,11988,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628120,,11989,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628121,,11990,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628122,,11991,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627297,,11992,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627298,,11993,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627299,,11994,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627300,,11995,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627301,,11996,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627302,,11997,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627303,,11998,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627304,,11999,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627305,,12000,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627306,,12001,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623982,,12002,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623983,,12003,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623984,,12004,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623985,,12005,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623986,,12006,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623987,,12007,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623988,,12008,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623989,,12009,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622215,,12010,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622216,,12011,,,50597,8608,,
,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877481,,12012,,,50597,8608,,
,BAO_0000218,,U,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),1,,,A,,,0,Autocuration,CHEMBL622217,,12013,,,22224,16359,,
,BAO_0000218,,N,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622218,,12014,,,50594,13701,,
,BAO_0000218,,N,,Pharmacokinetic profile AUC was evaluated in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622219,,12015,,,50597,14554,,
,BAO_0000019,,U,,Pharmacokinetic property (Area under curve),1,,,A,,,0,Autocuration,CHEMBL622220,,12016,,,22224,6241,,
,BAO_0000218,,N,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622221,,12017,,,50588,11537,,
,BAO_0000218,,N,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622222,,12018,,,50594,11537,,
,BAO_0000218,,N,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL622223,,12019,,,50588,11537,,
,BAO_0000218,,N,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622224,,12020,,,50594,11537,,
,BAO_0000019,,U,,Plasma concentration (AUC) was determined,1,,,A,,,0,Autocuration,CHEMBL622225,,12021,,,22224,13118,,
,BAO_0000019,,U,,Plasma concentration (AUC) was determined; Not detectable,1,,,A,,,0,Autocuration,CHEMBL622226,,12022,,,22224,13118,,
,BAO_0000218,,N,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL624154,,12023,,,50512,9562,,
,BAO_0000218,,N,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624155,,12024,,,50597,10363,,
,BAO_0000218,,N,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624156,,12025,,,50597,10363,,
,BAO_0000218,,N,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624157,,12026,,,50597,10363,,
,BAO_0000218,,N,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624158,,12027,,,50597,10363,,
,BAO_0000218,,N,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624159,,12028,,,50597,12504,,
,BAO_0000218,,N,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624160,,12029,,,50597,12504,,
,BAO_0000218,,N,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624161,,12030,,,50597,12504,,
,BAO_0000218,,N,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624162,,12031,,,50597,12504,,
,BAO_0000218,,N,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624163,,12032,,,50588,13317,,
,BAO_0000218,,N,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624164,,12033,,,50597,15078,,
,BAO_0000218,,N,,The AUC(0-infinity) values in female wistar rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624165,,12034,,,50597,14941,,
,BAO_0000218,,N,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624166,,12035,,,50597,15078,,
,BAO_0000218,,N,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624167,,12036,,,50597,15078,,
,BAO_0000218,,N,,The AUC(0-t)values in female wistar rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624168,,12037,,,50597,14941,,
,BAO_0000218,,N,,The Area under the concentration time curve of compound was measured on rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624169,,12038,,,50597,14067,,
,BAO_0000218,,N,,The area under curve (100 mg/kg) administered orally in humans,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL624170,,12039,,,50587,14215,,
,BAO_0000218,,U,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,1,,9481.0,A,Callithrix,,0,Autocuration,CHEMBL624171,,12040,,,22224,14215,,
,BAO_0000218,,U,,The area under curve (12.5 mg/kg) administered intravenously in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL624172,,12041,,,22224,14215,,
,BAO_0000218,,N,,The area under curve (15 mg/kg) administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624173,,12042,,,50588,14215,,
,BAO_0000218,,N,,The area under curve (200 mg/kg) administered orally in humans,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL877488,,12043,,,50587,14215,,
,BAO_0000218,,N,,The area under curve (25 mg/kg) administered intravenously in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624174,,12044,,,50597,14215,,
,BAO_0000218,,U,,The area under curve (25 mg/kg) administered orally in marmoset,1,,9481.0,A,Callithrix,,0,Autocuration,CHEMBL624175,,12045,,,22224,14215,,
,BAO_0000218,,U,,The area under curve (25 mg/kg) administered orally in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL624176,,12046,,,22224,14215,,
,BAO_0000218,,N,,The area under curve (30 mg/kg) administered orally in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624177,,12047,,,50588,14215,,
,BAO_0000218,,N,,The area under curve (400 mg/kg) administered orally in humans,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL624178,,12048,,,50587,14215,,
,BAO_0000218,,N,,The area under curve (50 mg/kg) administered orally in fasted rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624179,,12049,,,50597,14215,,
,BAO_0000218,,N,,The area under curve (50 mg/kg) administered orally in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627689,,12050,,,50597,14215,,
,BAO_0000218,,N,,The area under curve (800 mg/kg) administered orally in humans,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL627690,,12051,,,50587,14215,,
,BAO_0000019,,U,,The compound was evaluated for area under the curve,1,,,A,,,0,Autocuration,CHEMBL627691,,12052,,,22224,11324,,
,BAO_0000019,,U,,The compound was evaluated for area under the curve in marmosets,1,,9481.0,A,Callithrix,,0,Autocuration,CHEMBL627692,,12053,,,22224,11324,,
,BAO_0000019,,U,,The compound was evaluated for area under the curve in marmosets,1,,9481.0,A,Callithrix,,0,Autocuration,CHEMBL627693,,12054,,,22224,11324,,
,BAO_0000218,,N,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627694,,12055,,,50597,13875,,
,BAO_0000218,,N,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627695,,12056,,,50597,13875,,
,BAO_0000218,,U,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),1,,,A,,,0,Autocuration,CHEMBL627696,,12057,,,22224,13875,,
,BAO_0000218,,N,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627697,,12058,,,50597,13875,,
,BAO_0000218,,N,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627698,,12059,,,50597,13875,,
,BAO_0000218,,N,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627699,,12060,,,50597,13875,,
,BAO_0000218,,N,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627700,,12061,,,50597,13807,,
,BAO_0000218,,N,,Total drug exposure is determined after oral dosing in rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627701,,12062,,,50597,14127,,
,BAO_0000218,,U,,Total drug exposure (5 mg/kg) when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL627702,,12063,,,22224,15116,,
,BAO_0000218,,U,,Total drug exposure (5 mg/kg) when administered orally,1,,,A,,,0,Autocuration,CHEMBL627703,,12064,,,22224,15116,,
,BAO_0000218,,U,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626873,,12065,,,22224,15604,,
,BAO_0000218,,N,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629583,,12066,,,50597,15604,,
,BAO_0000218,,N,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629584,,12067,,,50588,15604,,
,BAO_0000218,,N,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629585,,12068,,,50588,15604,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629586,,12069,In vivo,,50597,13751,,
Brain,BAO_0000218,,N,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL629587,,12070,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629588,,12071,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629589,,12072,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629590,,12073,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629591,,12074,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629592,,12075,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629593,,12076,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629594,,12077,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL629595,,12078,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630290,,12079,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627137,,12080,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627138,,12081,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627139,,12082,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627140,,12083,In vivo,,50597,13751,,
Heart,BAO_0000218,,N,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627141,,12084,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627142,,12085,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627143,,12086,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL874449,,12087,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627144,,12088,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627145,,12089,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627146,,12090,In vivo,,50597,13751,,
Kidney,BAO_0000218,,N,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627147,,12091,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627148,,12092,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627149,,12093,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL632160,,12094,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL632161,,12095,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL632162,,12096,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL632163,,12097,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL874469,,12098,In vivo,,50597,13751,,
Lung,BAO_0000218,,N,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627182,,12099,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627183,,12100,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627184,,12101,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627185,,12102,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627186,,12103,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627187,,12104,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627188,,12105,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627189,,12106,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627190,,12107,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627191,,12108,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627192,,12109,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627193,,12110,In vivo,,50597,13751,,
Muscle tissue,BAO_0000218,,N,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL874590,,12111,In vivo,,50597,10911,,
Muscle tissue,BAO_0000218,,N,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627194,,12112,In vivo,,50597,10911,,
Muscle tissue,BAO_0000218,,N,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627195,,12113,In vivo,,50597,10911,,
Female gonad,BAO_0000218,,N,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL627196,,12114,In vivo,,50597,10911,,
Female gonad,BAO_0000218,,N,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL627197,,12115,In vivo,,50597,10911,,
Female gonad,BAO_0000218,,N,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL627198,,12116,In vivo,,50597,10911,,
Female gonad,BAO_0000218,,N,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL627199,,12117,In vivo,,50597,10911,,
Female gonad,BAO_0000218,,N,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,992.0,1,Intermediate,CHEMBL627200,,12118,In vivo,,50597,10911,,
Plasma,BAO_0000218,,N,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627201,,12119,In vivo,,50597,10911,,
Plasma,BAO_0000218,,N,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627202,,12120,In vivo,,50597,10911,,
Plasma,BAO_0000218,,N,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627203,,12121,In vivo,,50597,10911,,
Plasma,BAO_0000218,,N,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627204,,12122,In vivo,,50597,10911,,
Spleen,BAO_0000218,,N,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627205,,12123,In vivo,,50597,10911,,
Spleen,BAO_0000218,,N,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627206,,12124,In vivo,,50597,10911,,
Spleen,BAO_0000218,,N,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627207,,12125,In vivo,,50597,10911,,
Spleen,BAO_0000218,,N,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627208,,12126,In vivo,,50597,10911,,
Thyroid gland,BAO_0000218,,N,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627209,,12127,In vivo,,50597,10911,,
Thyroid gland,BAO_0000218,,N,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627210,,12128,In vivo,,50597,10911,,
Thyroid gland,BAO_0000218,,N,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627211,,12129,In vivo,,50597,10911,,
Thyroid gland,BAO_0000218,,N,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627212,,12130,In vivo,,50597,10911,,
Uterus,BAO_0000218,,N,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL627213,,12131,In vivo,,50597,10911,,
Uterus,BAO_0000218,,N,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626599,,12132,In vivo,,50597,10911,,
Uterus,BAO_0000218,,N,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626600,,12133,In vivo,,50597,10911,,
Uterus,BAO_0000218,,N,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL626601,,12134,In vivo,,50597,10911,,
,BAO_0000019,,U,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,1,,,A,,,0,Autocuration,CHEMBL627484,,12135,,,22224,8081,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL627485,,12136,,,100710,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL628147,,12137,,,100710,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL628148,,12138,,,100710,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628149,,12139,,,50588,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628150,,12140,,,50588,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628318,,12141,,,50588,17248,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628319,,12142,,,50588,17248,,
,BAO_0000218,,N,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875609,,12143,,,50588,15592,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,1,,,A,,,0,Autocuration,CHEMBL628320,,12144,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,1,,,A,,,0,Autocuration,CHEMBL628321,,12145,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,1,,,A,,,0,Autocuration,CHEMBL628322,,12146,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,1,,,A,,,0,Autocuration,CHEMBL628323,,12147,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,1,,,A,,,0,Autocuration,CHEMBL628324,,12148,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,1,,,A,,,0,Autocuration,CHEMBL628325,,12149,,,22224,7040,,
,BAO_0000019,,U,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,1,,,A,,,0,Autocuration,CHEMBL628326,,12150,,,22224,7040,,
Adrenal medulla,BAO_0000218,,N,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL628327,,12151,,,50588,9614,,
Adrenal medulla,BAO_0000218,,N,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL628328,,12152,,,50588,9614,,
Blood,BAO_0000218,,N,,"Concentration of compound in blood of dog 1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL628329,,12153,,,50588,9614,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628330,,12154,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628331,,12155,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628332,,12156,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628333,,12157,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628334,,12158,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628335,,12159,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628336,,12160,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628337,,12161,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628338,,12162,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL875610,,12163,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628339,,12164,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628340,,12165,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628341,,12166,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622214,,12167,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623167,,12168,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623168,,12169,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623169,,12170,,,50597,8608,,
Liver,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623170,,12171,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627224,,12172,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL875634,,12173,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627225,,12174,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627226,,12175,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626083,,12176,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626084,,12177,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626085,,12178,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626086,,12179,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626087,,12180,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626088,,12181,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626089,,12182,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626090,,12183,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626091,,12184,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626092,,12185,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626093,,12186,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626094,,12187,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626095,,12188,,,50597,8608,,
Lung,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL626096,,12189,,,50597,8608,,
,BAO_0000218,,U,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626097,,12190,,,22224,15604,,
,BAO_0000218,,N,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626098,,12191,,,50597,15604,,
Plasma,BAO_0000218,,U,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,1,,,A,,1969.0,0,Autocuration,CHEMBL626099,,12192,,,22224,1806,,
Plasma,BAO_0000218,,U,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,1,,,A,,1969.0,0,Autocuration,CHEMBL626100,,12193,,,22224,1806,,
Plasma,BAO_0000218,,N,,AUC 0-inf in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626101,,12194,,,50588,17237,,
Plasma,BAO_0000218,,N,,AUC 0-inf in guinea pig,1,,10141.0,A,Cavia porcellus,1969.0,1,Intermediate,CHEMBL626102,,12195,,,50512,17237,,
Plasma,BAO_0000218,,N,,AUC 0-t in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626103,,12196,,,50588,17237,,
Plasma,BAO_0000218,,N,,AUC 0-t in guinea pig,1,,10141.0,A,Cavia porcellus,1969.0,1,Intermediate,CHEMBL628391,,12197,,,50512,17237,,
,BAO_0000218,,N,,The compound was tested for brain to plasma partition in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628392,,12198,,,50597,15194,,
,BAO_0000218,,N,,The compound was tested for brain to plasma partition in rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628393,,12199,,,50597,15194,,
Blood,BAO_0000019,,U,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,1,,,A,,178.0,0,Autocuration,CHEMBL628394,,12200,,,22224,8787,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628395,,12201,,,50588,17025,,
,BAO_0000218,,U,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628396,,12202,,,22224,17025,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL628397,,12203,,,50592,17025,,
,BAO_0000218,,N,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628398,,12204,,,50597,17025,,
,BAO_0000218,,N,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL628399,,12205,,,50797,4236,,
,BAO_0000218,,N,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628400,,12206,,,50588,15343,,
,BAO_0000218,,N,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874907,,12207,,,50597,15343,,
,BAO_0000019,,U,,Area under curve of the compound was determined,1,,,A,,,0,Autocuration,CHEMBL628401,,12208,,,22224,17720,,
Plasma,BAO_0000218,,U,,AUC in monkeys at a dose of 1 mg/kg,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL628402,,12209,,,22224,17788,,
Plasma,BAO_0000218,,N,,AUC in rats at a dose of 1 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628403,,12210,,,50597,17788,,
,BAO_0000019,,U,,Compound was evaluated for the overall absorbance loss at pH of 2,1,,,A,,,0,Autocuration,CHEMBL628404,,12211,,,22224,8778,,
,BAO_0000019,,U,,Compound was evaluated for the overall absorbance loss at pH of 4,1,,,A,,,0,Autocuration,CHEMBL628405,,12212,,,22224,8778,,
,BAO_0000019,,U,,Compound was evaluated for the overall absorbance loss at pH of 7,1,,,A,,,0,Autocuration,CHEMBL628406,,12213,,,22224,8778,,
,BAO_0000218,,N,,Compound was evaluated for its absorption in the rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628407,,12214,,,50597,2249,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628408,,12215,,,50597,8881,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629171,,12216,,,50597,8881,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629172,,12217,,,50597,8881,,
Urine,BAO_0000218,,N,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629173,,12218,,,50597,8881,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629174,,12219,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 10-17,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629175,,12220,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 10-18,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629176,,12221,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 10-19,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629177,,12222,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 12-15,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629178,,12223,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 13-19,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631869,,12224,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 14-17,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631870,,12225,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 15-18,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631871,,12226,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 2-5,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631872,,12227,,,50597,15286,,
Ileum,BAO_0000221,,U,,In vitro percent permeability into rat ileum; Range is 23-42,1,,,A,,2116.0,0,Autocuration,CHEMBL875775,,12228,,,22224,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 28-36,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631873,,12229,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 29-35,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631874,,12230,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 46-66,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631875,,12231,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 50-68,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631876,,12232,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; Range is 78-81,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631877,,12233,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631878,,12234,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; nd indicates not detected,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631879,,12235,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; nt indicates not detected,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631880,,12236,,,50597,15286,,
,BAO_0000218,,N,,In vitro percent permeability into rat ileum; nt indicates not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631881,,12237,,,50597,15286,,
,BAO_0000218,,N,,Compound was tested for oral absorption in bile-duct cannulated rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631882,,12238,,,50597,13770,,
,BAO_0000218,,N,,Compound was tested for oral absorption in bile-duct cannulated rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630749,,12239,,,50597,13770,,
,BAO_0000218,,N,,Oral absorption using Caco-2 cell monolayers.,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL630750,,12240,,,50587,5202,,
,BAO_0000218,,N,,Percent of the drug absorbed after administration to humans was determined,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL630253,,12241,,,50587,14920,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL630254,,12242,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL630255,,12243,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL630256,,12244,,,50597,14103,,
Liver,BAO_0000218,,N,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL875781,,12245,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL630257,,12246,In vivo,,50597,13751,,
Liver,BAO_0000218,,N,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL630258,,12247,In vivo,,50597,13751,,
,BAO_0000218,,N,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630259,,12248,,,50597,15807,,
Striatum,BAO_0000218,,N,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL630260,,12249,,,50597,15807,,
Striatum,BAO_0000218,,N,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL630261,,12250,,,50597,15807,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630262,,12251,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630263,,12252,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630264,,12253,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630265,,12254,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630266,,12255,,,50597,14950,,
Kidney,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630267,,12256,,,50597,14950,,
Kidney,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630268,,12257,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630269,,12258,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630270,,12259,,,50597,14950,,
Lung,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630141,,12260,,,50597,14950,,
Lung,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630142,,12261,,,50597,14950,,
Muscle tissue,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630143,,12262,,,50597,14950,,
Muscle tissue,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630144,,12263,,,50597,14950,,
Prostate gland,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,1,,10116.0,A,Rattus norvegicus,2367.0,1,Intermediate,CHEMBL630145,,12264,,,50597,14950,,
Prostate gland,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,1,,10116.0,A,Rattus norvegicus,2367.0,1,Intermediate,CHEMBL630146,,12265,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630147,,12266,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630148,,12267,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630149,,12268,,,50597,14950,,
Spleen,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630150,,12269,,,50597,14950,,
Spleen,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630151,,12270,,,50597,14950,,
Thyroid gland,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL632031,,12271,,,50597,14950,,
Thyroid gland,BAO_0000218,,N,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL632032,,12272,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632033,,12273,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632034,,12274,,,50597,14950,,
Muscle tissue,BAO_0000218,,N,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL632035,,12275,,,50597,14950,,
,BAO_0000218,,N,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632036,,12276,,,50597,14950,,
Thyroid gland,BAO_0000218,,N,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL632037,,12277,,,50597,14950,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632038,,12278,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632039,,12279,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632040,,12280,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL632041,,12281,,,50597,8631,,
Blood,BAO_0000218,,N,,"Concentration of compound in blood of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,178.0,1,Intermediate,CHEMBL632042,,12282,,,50588,9614,,
,BAO_0000218,,N,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL632043,,12283,,,50588,9614,,
,BAO_0000218,,N,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL632044,,12284,,,50588,9614,,
Liver,BAO_0000218,,N,,"Concentration of compound in liver of dog 1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL632045,,12285,,,50588,9614,,
Liver,BAO_0000218,,N,,"Concentration of compound in liver of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL632046,,12286,,,50588,9614,,
Lung,BAO_0000218,,N,,"Concentration of compound in lung of dog 1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2048.0,1,Intermediate,CHEMBL632047,,12287,,,50588,9614,,
Lung,BAO_0000218,,N,,"Concentration of compound in lung of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2048.0,1,Intermediate,CHEMBL632048,,12288,,,50588,9614,,
Muscle tissue,BAO_0000218,,N,,"Concentration of compound in muscle of dog 1, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2385.0,1,Intermediate,CHEMBL632049,,12289,,,50588,9614,,
Muscle tissue,BAO_0000218,,N,,"Concentration of compound in muscle of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2385.0,1,Intermediate,CHEMBL876418,,12290,,,50588,9614,,
Spleen,BAO_0000218,,N,,"Concentration of compound in spleen of dog 1,after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2106.0,1,Intermediate,CHEMBL632050,,12291,,,50588,9614,,
Spleen,BAO_0000218,,N,,"Concentration of compound in spleen of dog 2, after administering intravenously",1,,9615.0,A,Canis lupus familiaris,2106.0,1,Intermediate,CHEMBL632051,,12292,,,50588,9614,,
,BAO_0000218,,U,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,1,,,F,,,0,Autocuration,CHEMBL632052,,12293,,,22224,10353,,
,BAO_0000218,,U,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,1,,,F,,,0,Autocuration,CHEMBL632053,,12294,,,22224,10353,,
,BAO_0000218,,U,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,1,,,A,,,0,Autocuration,CHEMBL632054,,12295,,,22224,10353,,
,BAO_0000218,,U,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,1,,,F,,,0,Autocuration,CHEMBL632055,,12296,,,22224,10353,,
,BAO_0000218,,U,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,1,,,F,,,0,Autocuration,CHEMBL631181,,12297,,,22224,10353,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL631182,,12298,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL631183,,12299,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL631184,,12300,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL629774,,12301,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL629775,,12302,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL876549,,12303,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL628172,,12304,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL628173,,12305,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL628174,,12306,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL628175,,12307,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL628176,,12308,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL628177,,12309,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL628178,,12310,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL628179,,12311,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,1,,,A,,,0,Autocuration,CHEMBL628180,,12312,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL628181,,12313,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL628182,,12314,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL628183,,12315,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL628184,,12316,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL628185,,12317,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL875617,,12318,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL628186,,12319,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL628187,,12320,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL628188,,12321,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL628189,,12322,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL628190,,12323,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL628191,,12324,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL626513,,12325,,,22224,9196,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626514,,12326,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626515,,12327,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626516,,12328,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626517,,12329,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626518,,12330,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626519,,12331,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626520,,12332,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626521,,12333,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626522,,12334,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626523,,12335,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626524,,12336,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626688,,12337,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626689,,12338,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626690,,12339,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626691,,12340,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL627319,,12341,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624052,,12342,,,50597,8608,,
Thyroid gland,BAO_0000218,,N,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL624053,,12343,,,50597,8608,,
,BAO_0000218,,N,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624054,,12344,,,50597,8085,,
,BAO_0000218,,N,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624055,,12345,,,50597,8085,,
,BAO_0000218,,N,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624056,,12346,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL624057,,12347,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622281,,12348,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622282,,12349,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622283,,12350,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622284,,12351,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622285,,12352,,,50597,8085,,
Uterus,BAO_0000218,,N,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL622286,,12353,,,50597,8085,,
,BAO_0000100,,U,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,1,,,P,,,0,Autocuration,CHEMBL622287,,12354,,,22224,7657,,
,BAO_0000218,,N,,Partition coefficient (logD7.4),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622288,,12355,,,50594,8935,,
,BAO_0000218,,N,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622289,,12356,,,50594,13792,,
Brain,BAO_0000218,,N,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622290,,12357,,,50594,13792,,
,BAO_0000218,,N,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622291,,12358,,,50594,13792,,
Brain,BAO_0000218,,N,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622292,,12359,,,50594,13792,,
,BAO_0000218,,N,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622293,,12360,,,50594,13792,,
Brain,BAO_0000218,,N,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL622294,,12361,,,50594,13792,,
,BAO_0000218,,N,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL622295,,12362,,,50594,13792,,
Brain,BAO_0000218,,N,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL622296,,12363,,,50597,13792,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL874409,,12364,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622297,,12365,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622298,,12366,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622299,,12367,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622300,,12368,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622301,,12369,,,50597,14103,,
Plasma,BAO_0000218,,N,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622302,,12370,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622303,,12371,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622304,,12372,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622305,,12373,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622306,,12374,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626864,,12375,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626865,,12376,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626866,,12377,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626867,,12378,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626868,,12379,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626869,,12380,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626870,,12381,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626871,,12382,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626872,,12383,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632185,,12384,,,50597,14103,,
Plasma,BAO_0000218,,N,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL632186,,12385,,,50597,14103,,
,BAO_0000019,,U,,Amount of acetic acid produced by the compound,1,,,A,,,0,Autocuration,CHEMBL629310,,12386,,,22224,12904,,
,BAO_0000019,,U,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,1,,,A,,,0,Autocuration,CHEMBL629311,,12387,,,22224,12904,,
,BAO_0000218,,N,,Log of (Cbrain/Cblood) in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629312,,12388,,,50597,9663,,
,BAO_0000221,,U,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629313,,12389,,,22224,7652,,
,BAO_0000221,,U,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629314,,12390,,,22224,7652,,
,BAO_0000221,,U,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629315,,12391,,,22224,7652,,
,BAO_0000219,,U,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),1,,,B,,,0,Autocuration,CHEMBL629316,,12392,,,22224,7652,,
,BAO_0000221,,U,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629317,,12393,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629318,,12394,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL877497,,12395,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629319,,12396,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629320,,12397,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629496,,12398,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629497,,12399,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629498,,12400,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629499,,12401,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629500,,12402,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629501,,12403,,,22224,7652,,
,BAO_0000019,,U,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),1,,,A,,,0,Autocuration,CHEMBL629502,,12404,,,22224,7652,,
,BAO_0000218,,U,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,1,,,F,,,0,Autocuration,CHEMBL629503,,12405,In vivo,,22224,8267,,
,BAO_0000218,,N,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629504,,12406,,,50588,8267,,
,BAO_0000019,,U,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,1,,,A,,,0,Autocuration,CHEMBL629505,,12407,,,22224,14479,,
,BAO_0000019,,U,,Compound was evaluated for total body clearance,1,,,A,,,0,Autocuration,CHEMBL629506,,12408,,,22224,17515,,
,BAO_0000019,,U,,Compound was evaluated for volume of distribution at steady state,1,,,A,,,0,Autocuration,CHEMBL629507,,12409,,,22224,17515,,
,BAO_0000019,,U,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,1,,,A,,,0,Autocuration,CHEMBL877498,,12410,,,22224,8142,,
,BAO_0000019,,U,,Percentage of the diamine which is monoprotonated at pH 7.4,1,,,A,,,0,Autocuration,CHEMBL629508,,12411,,,22224,14849,,
,BAO_0000019,,U,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,1,,,A,,,0,Autocuration,CHEMBL629509,,12412,,,22224,7653,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629510,,12413,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629511,,12414,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629512,,12415,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629513,,12416,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629514,,12417,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628447,,12418,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628448,,12419,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628449,,12420,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631119,,12421,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631120,,12422,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631121,,12423,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL874458,,12424,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631122,,12425,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631123,,12426,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631124,,12427,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631125,,12428,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631290,,12429,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631291,,12430,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631292,,12431,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631293,,12432,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631294,,12433,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631295,,12434,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631296,,12435,,,50597,8631,,
Blood,BAO_0000218,,N,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631297,,12436,,,50597,8631,,
,BAO_0000218,,U,,Maximum biodistribution (Bmax) was determined.,1,,,A,,,0,Autocuration,CHEMBL631298,,12437,,,22224,10263,,
,BAO_0000218,,N,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631299,,12438,,,50594,12364,,
,BAO_0000218,,N,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631300,,12439,,,50594,12364,,
,BAO_0000218,,N,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631301,,12440,,,50594,12364,,
,BAO_0000218,,N,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630291,,12441,,,50594,12364,,
,BAO_0000218,,U,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,1,,,A,,,0,Autocuration,CHEMBL630292,,12442,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL630293,,12443,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL630294,,12444,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,1,,,A,,,0,Autocuration,CHEMBL630295,,12445,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL630296,,12446,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626782,,12447,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626783,,12448,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,1,,,A,,,0,Autocuration,CHEMBL626784,,12449,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626785,,12450,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626786,,12451,,,22224,14793,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL626787,,12452,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL626788,,12453,,,22224,9196,,
,BAO_0000218,,U,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL625927,,12454,,,22224,9196,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625928,,12455,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625929,,12456,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625930,,12457,,,50597,8374,,
Blood,BAO_0000218,,N,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625931,,12458,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627230,,12459,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627231,,12460,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627232,,12461,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627233,,12462,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL875470,,12463,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627234,,12464,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627235,,12465,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627236,,12466,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627237,,12467,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627238,,12468,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627239,,12469,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627240,,12470,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627241,,12471,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627242,,12472,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627243,,12473,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627244,,12474,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627245,,12475,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627246,,12476,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627247,,12477,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627248,,12478,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627249,,12479,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625569,,12480,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625570,,12481,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625571,,12482,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625572,,12483,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625573,,12484,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625574,,12485,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626245,,12486,,,50597,8374,,
Blood,BAO_0000218,,N,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626246,,12487,,,50597,8374,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL626247,,12488,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL626248,,12489,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL626249,,12490,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL626420,,12491,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL626421,,12492,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL626422,,12493,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL626423,,12494,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL626424,,12495,,,22224,9196,,
,BAO_0000218,,N,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626425,,12496,,,50588,12023,,
,BAO_0000218,,N,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875476,,12497,,,50597,12023,,
,BAO_0000218,,N,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL626426,,12498,,,100710,12023,,
,BAO_0000100,,U,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,1,,,P,,,0,Autocuration,CHEMBL626427,,12499,,,22224,10580,,
,BAO_0000100,,U,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,1,,,P,,,0,Autocuration,CHEMBL626428,,12500,,,22224,10580,,
,BAO_0000019,,U,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,1,,,A,,,0,Autocuration,CHEMBL626429,,12501,,,22224,16032,,
Urine,BAO_0000019,,U,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,1,,,A,,1088.0,0,Autocuration,CHEMBL625025,,12502,,,22224,16032,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625026,,12503,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625027,,12504,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL874410,,12505,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625028,,12506,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625029,,12507,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625030,,12508,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625031,,12509,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625032,,12510,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625033,,12511,,,50597,8594,,
Blood,BAO_0000218,,N,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625034,,12512,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624872,,12513,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624873,,12514,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624874,,12515,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624875,,12516,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624876,,12517,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624877,,12518,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624878,,12519,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624879,,12520,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624880,,12521,,,50597,8594,,
Heart,BAO_0000218,,N,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624881,,12522,,,50597,8594,,
Heart,BAO_0000218,,N,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL624882,,12523,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624883,,12524,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624884,,12525,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624885,,12526,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624886,,12527,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624887,,12528,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624888,,12529,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624889,,12530,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL624890,,12531,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621964,,12532,,,50597,8594,,
Kidney,BAO_0000218,,N,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL621965,,12533,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621966,,12534,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL621967,,12535,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL622164,,12536,,,50597,8594,,
,BAO_0000019,,U,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),1,,,A,,,0,Autocuration,CHEMBL623097,,12537,,,22224,7653,,
,BAO_0000019,,U,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),1,,,A,,,0,Autocuration,CHEMBL623098,,12538,,,22224,7653,,
,BAO_0000019,,U,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,1,,,A,,,0,Autocuration,CHEMBL623099,,12539,,,22224,7653,,
,BAO_0000019,,U,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,1,,,A,,,0,Autocuration,CHEMBL623100,,12540,,,22224,7653,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628673,,12541,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628674,,12542,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628675,,12543,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627644,,12544,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627645,,12545,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627646,,12546,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627647,,12547,,,50597,9104,,
,BAO_0000218,,N,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627648,,12548,,,50597,9104,,
,BAO_0000218,,N,,Free level in rat plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627649,,12549,,,50597,12902,,
,BAO_0000019,,U,,Level reaching in blood plasma of rat or human was determined,1,,,A,,,0,Autocuration,CHEMBL628313,,12550,,,22224,6614,,
,BAO_0000218,,N,,Log (Cbrain/Cblood) in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628314,,12551,,,50597,9663,,
,BAO_0000019,,U,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,1,,,A,,,0,Autocuration,CHEMBL628315,,12552,,,22224,17658,,
,BAO_0000019,,U,,Mean percentage of compound transport through membrane; expressed as membrane transport,1,,,A,,,0,Autocuration,CHEMBL628316,,12553,,,22224,17658,,
,BAO_0000218,,U,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,1,,,A,,,0,Autocuration,CHEMBL628317,,12554,,,22224,14314,,
,BAO_0000019,,U,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,1,,,A,,,0,Autocuration,CHEMBL628473,,12555,,,22224,7385,,
,BAO_0000019,,U,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",1,,,A,,,0,Autocuration,CHEMBL628474,,12556,,,22224,7385,,
,BAO_0000019,,U,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,1,,,A,,,0,Autocuration,CHEMBL628475,,12557,,,22224,7385,,
,BAO_0000019,,U,,Net water uptake by a carrier mediated transport (%cm) mechanism,1,,,A,,,0,Autocuration,CHEMBL628476,,12558,,,22224,1329,,
,BAO_0000218,,U,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628477,,12559,,,22224,12187,,
,BAO_0000218,,N,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL628478,,12560,,,50506,12187,,
,BAO_0000218,,N,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL628479,,12561,,,50506,12187,,
,BAO_0000218,,U,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628480,,12562,,,22224,12187,,
,BAO_0000218,,U,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628481,,12563,,,22224,12187,,
,BAO_0000218,,N,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628482,,12564,,,50597,12187,,
,BAO_0000218,,N,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628483,,12565,,,50597,12187,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628484,,12566,,,50597,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628485,,12567,,,50597,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL628486,,12568,,,100710,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL628487,,12569,,,50587,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628488,,12570,,,50597,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628489,,12571,,,50597,9278,,
Plasma,BAO_0000218,,N,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628490,,12572,,,50597,9278,,
,BAO_0000218,,N,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL628491,,12573,,,100710,12186,,
,BAO_0000218,,N,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL877507,,12574,,,100710,12186,,
,BAO_0000218,,U,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,1,,,A,,,0,Autocuration,CHEMBL628492,,12575,,,22224,12186,,
,BAO_0000019,,U,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628493,,12576,,,22224,12041,,
,BAO_0000019,,U,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628494,,12577,,,22224,12041,,
,BAO_0000019,,U,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL628495,,12578,,,22224,12041,,
,BAO_0000218,,N,,Permeability in Caco-2 assay at 10E-6,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL628496,,12579,,,50587,6737,,
Brain,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,1,,,A,,955.0,0,Autocuration,CHEMBL628497,,12580,,,22224,13758,,
Brain,BAO_0000218,,U,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,1,,,A,,955.0,0,Autocuration,CHEMBL628498,,12581,,,22224,13758,,
,BAO_0000019,,U,,Plasma protein binding was determined,1,,,A,,,0,Autocuration,CHEMBL628499,,12582,,,22224,5676,,
,BAO_0000218,,U,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL627656,,12583,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,1,,,A,,,0,Autocuration,CHEMBL627657,,12584,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL626808,,12585,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626809,,12586,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626810,,12587,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,1,,,A,,,0,Autocuration,CHEMBL626811,,12588,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,1,,,A,,,0,Autocuration,CHEMBL874465,,12589,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626812,,12590,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626813,,12591,,,22224,14793,,
,BAO_0000218,,U,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,1,,,A,,,0,Autocuration,CHEMBL626814,,12592,,,22224,14793,,
,BAO_0000019,,U,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,1,,,A,,,0,Autocuration,CHEMBL626815,,12593,,,22224,14000,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL628566,,12594,,,22224,5948,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,,,P,,,0,Autocuration,CHEMBL628567,,12595,,,22229,13824,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL628568,,12596,,,22229,10778,,
,BAO_0000218,,N,,C max in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628569,,12597,In vivo,,50588,17237,,
,BAO_0000218,,N,,C max in guinea pig,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL628570,,12598,In vivo,,50512,17237,,
,BAO_0000218,,U,,C max value was evaluated,1,,,A,,,0,Autocuration,CHEMBL628571,,12599,In vivo,,22224,2809,,
,BAO_0000218,,U,,Cmax value after oral dose of 0.1 mg//kg,1,,,A,,,0,Autocuration,CHEMBL628572,,12600,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 0.3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628573,,12601,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 1 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628574,,12602,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 10 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628575,,12603,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 23.4 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628576,,12604,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628577,,12605,In vivo,,22224,11954,,
,BAO_0000218,,U,,Cmax value after oral dose of 3.87 mg/kg,1,,,A,,,0,Autocuration,CHEMBL628578,,12606,In vivo,,22224,11954,,
,BAO_0000218,,N,,Cmax value in female Beagle dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL874466,,12607,In vivo,,50588,12768,,
,BAO_0000218,,N,,Cmax value in male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628579,,12608,In vivo,,50597,12768,,
Plasma,BAO_0000218,,N,,Cmax value in rat plasma when administered 20 mg/kg perorally,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628580,,12609,In vivo,,50597,12780,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628581,,12610,In vivo,,50588,15592,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL628582,,12611,In vivo,,50588,15592,,
,BAO_0000218,,N,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628583,,12612,,,50588,17025,,
,BAO_0000218,,U,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625782,,12613,,,22224,17025,,
,BAO_0000218,,N,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL625783,,12614,,,50592,17025,,
,BAO_0000218,,N,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625784,,12615,,,50597,17025,,
Plasma,BAO_0000218,,N,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL625785,,12616,,,50797,4236,,
,BAO_0000218,,N,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625786,,12617,,,50597,15791,,
,BAO_0000019,,U,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,1,,,A,,,0,Autocuration,CHEMBL874467,,12618,,,22224,11149,,
,BAO_0000218,,N,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625787,,12619,,,50588,15592,,
,BAO_0000218,,N,,cytotoxicity against HIV protease enzyme.,1,,12721.0,A,Human immunodeficiency virus,,1,Intermediate,CHEMBL625964,,12620,,,50677,15778,,
,BAO_0000218,,N,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625965,,12621,,,50594,12745,,
,BAO_0000218,,N,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625966,,12622,,,50594,12745,,
Plasma,BAO_0000218,,N,,The plasma clearance in dog.,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625967,,12623,In vivo,,50588,13941,,
Plasma,BAO_0000218,,N,,The plasma clearance in rat.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625968,,12624,In vivo,,50597,13941,,
Plasma,BAO_0000218,,N,,Clearance from plasma in male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625969,,12625,In vivo,,50597,16449,,
Plasma,BAO_0000218,,N,,Clearance from plasma in male cynomolgus monkeys,1,,9541.0,A,Macaca fascicularis,1969.0,1,Intermediate,CHEMBL625970,,12626,In vivo,,100710,16449,,
Plasma,BAO_0000218,,N,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625971,,12627,In vivo,,50588,14224,,
Plasma,BAO_0000218,,N,,Clearance of compound in dog plasma,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625972,,12628,In vivo,,50588,14224,,
Plasma,BAO_0000218,,N,,Clearance of compound in human plasma,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL625973,,12629,In vivo,,50587,14224,,
,BAO_0000218,,N,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625974,,12630,In vivo,,50588,14317,,
,BAO_0000218,,N,,Clearance of compound when administered intravenously as an individual dose to a single dog.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625975,,12631,In vivo,,50588,14317,,
Plasma,BAO_0000218,,N,,"Clearance (10 mg/kg, intravenously) in dog plasma",1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625976,,12632,In vivo,,50588,14224,,
,BAO_0000218,,N,,Clearance value in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625977,,12633,In vivo,,50588,17237,,
,BAO_0000218,,N,,Clearance value in guinea pig,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL625978,,12634,In vivo,,50512,17237,,
,BAO_0000218,,N,,Clearance values in rats after iv administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874468,,12635,In vivo,,50597,14187,,
Plasma,BAO_0000218,,U,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,1,,,A,,1969.0,0,Autocuration,CHEMBL625421,,12636,In vivo,,22224,4806,,
,BAO_0000218,,N,,In vivo clearance (5 mg/kg) was determined in rabbits,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL625422,,12637,In vivo,,50592,15025,,
,BAO_0000218,,N,,Plasma Clearance rate was determined for the compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625423,,12638,In vivo,,50597,13197,,
,BAO_0000218,,U,,Plasma Clearance rate was determined for the compound in squirrel monkeys,1,,9520.0,A,Saimiri,,0,Autocuration,CHEMBL625424,,12639,In vivo,,22224,13197,,
,BAO_0000218,,N,,Plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625425,,12640,In vivo,,50597,13960,,
,BAO_0000218,,U,,Plasma clearance of the compound,1,,,A,,,0,Autocuration,CHEMBL625426,,12641,In vivo,,22224,17820,,
,BAO_0000218,,N,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL625427,,12642,In vivo,,50512,14706,,
,BAO_0000218,,N,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL625428,,12643,In vivo,,50512,14706,,
,BAO_0000218,,U,,Plasma clearance was determined,1,,,A,,,0,Autocuration,CHEMBL625429,,12644,In vivo,,22224,6504,,
,BAO_0000218,,N,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625430,,12645,In vivo,,50588,14925,,
,BAO_0000218,,N,,Plasma clearance rate was determined for the compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625431,,12646,In vivo,,50597,13197,,
,BAO_0000218,,U,,Plasma clearance rate was determined for the compound in squirrel monkeys,1,,9520.0,A,Saimiri,,0,Autocuration,CHEMBL627307,,12647,In vivo,,22224,13197,,
,BAO_0000218,,U,,Slow clearance (CL) was determined,1,,,A,,,0,Autocuration,CHEMBL627308,,12648,In vivo,,22224,3437,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL627309,,12649,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,1,,,A,,,0,Autocuration,CHEMBL627310,,12650,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL627311,,12651,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL627312,,12652,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL627313,,12653,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL627314,,12654,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL627315,,12655,,,22224,9196,,
,BAO_0000218,,U,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL627316,,12656,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,1,,,A,,,0,Autocuration,CHEMBL627317,,12657,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL627318,,12658,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL627999,,12659,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,1,,,A,,,0,Autocuration,CHEMBL628000,,12660,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL628001,,12661,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL628002,,12662,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL625610,,12663,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL625611,,12664,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,1,,,A,,,0,Autocuration,CHEMBL625612,,12665,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,1,,,A,,,0,Autocuration,CHEMBL625613,,12666,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,1,,,A,,,0,Autocuration,CHEMBL875479,,12667,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,1,,,A,,,0,Autocuration,CHEMBL625614,,12668,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,1,,,A,,,0,Autocuration,CHEMBL625615,,12669,,,22224,9196,,
,BAO_0000218,,U,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,1,,,A,,,0,Autocuration,CHEMBL626302,,12670,,,22224,9196,,
Blood,BAO_0000218,,N,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626303,,12671,,,50597,8374,,
Blood,BAO_0000218,,N,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627420,,12672,,,50597,8374,,
,BAO_0000218,,N,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627421,,12673,,,50597,13477,,
,BAO_0000218,,N,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625695,,12674,,,50597,13477,,
,BAO_0000218,,N,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625696,,12675,,,50597,13477,,
Brain,BAO_0000218,,N,,Distribution of compound in mice brain was measured after 1 hr,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL875606,,12676,,,50594,10009,,
Brain,BAO_0000218,,N,,Distribution of compound in mice brain was measured after 24 hr r,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625697,,12677,,,50594,10009,,
Brain,BAO_0000218,,N,,Distribution of compound in mice brain was measured after 2 hr,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625698,,12678,,,50594,10009,,
Brain,BAO_0000218,,N,,Distribution of compound in mice brain was measured after 3 hr,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625699,,12679,,,50594,10009,,
Brain,BAO_0000218,,N,,Distribution of compound in mice brain was measured after 6 hr,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL625700,,12680,,,50594,10009,,
,BAO_0000218,,N,,Distribution of compound in mice liver was measured after 1 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625701,,12681,,,50594,10009,,
,BAO_0000218,,N,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625702,,12682,,,50594,10009,,
,BAO_0000218,,N,,Distribution of compound in mice liver was measured after 2 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625703,,12683,,,50594,10009,,
,BAO_0000218,,N,,Distribution of compound in mice liver was measured after 3 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625704,,12684,,,50594,10009,,
,BAO_0000218,,N,,Distribution of compound in mice liver was measured after 6 hr,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625705,,12685,,,50594,10009,,
Adrenal medulla,BAO_0000218,,N,,Distribution in dog adrenal medulla 30 min after administration.,1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL625706,,12686,,,50588,8170,,
Adrenal medulla,BAO_0000218,,N,,Distribution in dog adrenal medulla 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL625707,,12687,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog Ovary 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625708,,12688,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog Ovary 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625709,,12689,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog adipose 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624180,,12690,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog adipose 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624181,,12691,,,50588,8170,,
Adrenal cortex,BAO_0000218,,N,,Distribution in female dog adrenal cortex 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1235.0,1,Intermediate,CHEMBL624182,,12692,,,50588,8170,,
Adrenal cortex,BAO_0000218,,N,,Distribution in female dog adrenal cortex 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1235.0,1,Intermediate,CHEMBL624183,,12693,,,50588,8170,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624184,,12694,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL877489,,12695,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624185,,12696,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624186,,12697,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624187,,12698,,,50597,8594,,
Liver,BAO_0000218,,N,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL624188,,12699,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624189,,12700,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624190,,12701,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624191,,12702,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624192,,12703,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624193,,12704,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624194,,12705,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624891,,12706,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624892,,12707,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL624893,,12708,,,50597,8594,,
Lung,BAO_0000218,,N,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627632,,12709,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627633,,12710,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627634,,12711,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627635,,12712,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627636,,12713,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626816,,12714,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626817,,12715,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626818,,12716,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626819,,12717,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626820,,12718,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626821,,12719,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626822,,12720,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626823,,12721,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626824,,12722,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626825,,12723,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626826,,12724,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626827,,12725,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626828,,12726,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626829,,12727,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL626830,,12728,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627150,,12729,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627151,,12730,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627152,,12731,,,50597,8594,,
,BAO_0000218,,N,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627153,,12732,,,50597,8594,,
,BAO_0000019,,U,,Rate of acetate production by the compound was determined,1,,,A,,,0,Autocuration,CHEMBL627154,,12733,,,22224,12904,,
,BAO_0000019,,U,,Rate of acetate production by the compound was determined; Not determined,1,,,A,,,0,Autocuration,CHEMBL627155,,12734,,,22224,12904,,
,BAO_0000019,,U,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,1,,,A,,,0,Autocuration,CHEMBL627156,,12735,,,22224,3730,,
,BAO_0000019,,U,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,1,,,A,,,0,Autocuration,CHEMBL627157,,12736,,,22224,3627,,
,BAO_0000218,,N,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL627158,,12737,,,50592,13799,,
Plasma,BAO_0000218,,N,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,1,,9986.0,A,Oryctolagus cuniculus,1969.0,1,Intermediate,CHEMBL627159,,12738,,,50592,13799,,
,BAO_0000218,,N,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627160,,12739,,,50594,13799,,
,BAO_0000218,,N,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628540,,12740,,,50597,13799,,
Plasma,BAO_0000218,,N,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628541,,12741,,,50597,13799,,
Plasma,BAO_0000218,,N,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628542,,12742,,,50597,13799,,
,BAO_0000100,,U,,Solubility after at a pH 1.2,1,,,P,,,0,Autocuration,CHEMBL628543,,12743,,,22229,6629,,
,BAO_0000100,,U,,Solubility after at pH 1.2,1,,,P,,,0,Autocuration,CHEMBL628544,,12744,,,22229,6629,,
,BAO_0000100,,U,,Solubility after injection of water,1,,,P,,,0,Autocuration,CHEMBL628545,,12745,,,22229,6629,,
,BAO_0000019,,U,,Statistical significance of IC 50 values; Expressed as R value,1,,,A,,,0,Autocuration,CHEMBL628546,,12746,,,22224,14000,,
,BAO_0000019,,U,,Systemic availability with respect to methyldopa was determined,1,,,A,,,0,Autocuration,CHEMBL874455,,12747,,,22224,8267,,
,BAO_0000218,,N,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628547,,12748,,,50597,13799,,
Plasma,BAO_0000218,,N,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL628548,,12749,,,50597,13799,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628549,,12750,,,50592,7132,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628550,,12751,,,50592,7132,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628551,,12752,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628552,,12753,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628553,,12754,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628554,,12755,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628555,,12756,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628556,,12757,,,50592,7132,,
Kidney,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,2113.0,1,Intermediate,CHEMBL628557,,12758,,,50592,7132,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628558,,12759,,,50592,7132,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628559,,12760,,,50592,7132,,
Feces,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628560,,12761,,,50592,7132,,
Urine,BAO_0000218,,N,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL874456,,12762,,,50592,7132,,
Feces,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628561,,12763,,,50592,7132,,
Feces,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL628562,,12764,,,50592,7132,,
Urine,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628563,,12765,,,50592,7132,,
Urine,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628564,,12766,,,50592,7132,,
Urine,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL628565,,12767,,,50592,7132,,
Urine,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL631248,,12768,,,50592,7132,,
Urine,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL631249,,12769,,,50592,7132,,
Kidney,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,2113.0,1,Intermediate,CHEMBL627214,,12770,,,50592,7132,,
Feces,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL874591,,12771,,,50592,7132,,
Feces,BAO_0000218,,N,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL627215,,12772,,,50592,7132,,
Feces,BAO_0000218,,N,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL625471,,12773,,,50592,7132,,
,BAO_0000218,,N,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL625472,,12774,,,50592,7132,,
,BAO_0000218,,N,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL625473,,12775,,,50592,7132,,
,BAO_0000218,,N,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625474,,12776,In vivo,,50588,13317,,
,BAO_0000218,,N,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625475,,12777,In vivo,,50588,15341,,
,BAO_0000218,,N,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625476,,12778,In vivo,,50597,15341,,
,BAO_0000218,,N,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625477,,12779,In vivo,,50597,15341,,
,BAO_0000218,,N,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625478,,12780,In vivo,,50597,15341,,
esophageal tunica muscularis mucosae,BAO_0000218,,N,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625479,,12781,In vitro,,50597,12801,,
esophageal tunica muscularis mucosae,BAO_0000218,,N,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625480,,12782,In vitro,,50597,12801,,
Plasma,BAO_0000218,,N,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625481,,12783,In vivo,,50597,14856,,
,BAO_0000218,,N,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625482,,12784,In vivo,,50597,14062,,
,BAO_0000218,,N,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625483,,12785,In vivo,,50597,14062,,
,BAO_0000218,,N,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625484,,12786,In vivo,,50597,14062,,
,BAO_0000218,,N,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625485,,12787,In vivo,,50597,14062,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625486,,12788,In vivo,,50588,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625487,,12789,In vivo,,50597,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625488,,12790,In vivo,,50597,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625489,,12791,In vivo,,50597,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625490,,12792,In vivo,,50597,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL625491,,12793,In vivo,,50588,14346,,
Plasma,BAO_0000218,,N,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625492,,12794,In vivo,,50597,14346,,
Plasma,BAO_0000218,,N,,plasma clearance in human,1,,9606.0,A,Homo sapiens,1969.0,1,Intermediate,CHEMBL625493,,12795,In vivo,,50587,15711,,
,BAO_0000218,,N,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625494,,12796,In vivo,,50597,14886,,
,BAO_0000218,,N,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625495,,12797,In vivo,,50597,14886,,
,BAO_0000218,,N,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625496,,12798,In vivo,,50597,14886,,
,BAO_0000100,,U,,1-Octanol/water partition coefficient measured at 7.4,1,,,P,,,0,Autocuration,CHEMBL625497,,12799,,,22229,4115,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625498,,12800,,,22229,13733,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL625499,,12801,,,22224,12102,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625500,,12802,,,22229,12676,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625501,,12803,,,22229,13733,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625502,,12804,,,22229,13740,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (relative to BAY K 8644),1,,,P,,,0,Autocuration,CHEMBL625503,,12805,,,22229,12766,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625504,,12806,,,22229,2764,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625505,,12807,,,22229,12355,,
,BAO_0000100,,U,,Calculated partition coefficient of the compound,1,,,P,,,0,Autocuration,CHEMBL625506,,12808,,,22229,11314,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL625507,,12809,,,22224,12706,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625508,,12810,,,22229,12645,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625509,,12811,,,22229,13668,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625510,,12812,,,22229,12819,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL883125,,12813,,,22229,13668,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625511,,12814,,,22229,13017,,
,BAO_0000019,,U,,Partition coefficient of the compound,1,,,A,,,0,Autocuration,CHEMBL874650,,12815,,,22224,2448,,
,BAO_0000019,,U,,Partition coefficient of the compound,1,,,A,,,0,Autocuration,CHEMBL625512,,12816,,,22224,11526,,
,BAO_0000019,,U,,Partition coefficient of compound was determined,1,,,A,,,0,Autocuration,CHEMBL625513,,12817,,,22224,12426,,
,BAO_0000019,,U,,Partition coefficient was determined,1,,,A,,,0,Autocuration,CHEMBL625514,,12818,,,22224,2448,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625515,,12819,,,22229,12001,,
,BAO_0000100,,U,,partition coefficient of compound was determined,1,,,P,,,0,Autocuration,CHEMBL625516,,12820,,,22229,12426,,
,BAO_0000218,,N,,The total body administered intravenously in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625517,,12821,In vivo,,50588,13204,,
,BAO_0000218,,N,,The total body administered intravenously in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625518,,12822,In vivo,,50597,13204,,
,BAO_0000218,,N,,Time taken for the administration to female NIH mice weighing 25-30 g.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625519,,12823,,,50594,13889,,
,BAO_0000019,,U,,Time taken for the administration,1,,,A,,,0,Autocuration,CHEMBL625520,,12824,,,22224,13889,,
,BAO_0000218,,N,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL874651,,12825,In vivo,,50588,17025,,
,BAO_0000218,,U,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625521,,12826,In vivo,,22224,17025,,
,BAO_0000218,,N,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL623171,,12827,In vivo,,50592,17025,,
,BAO_0000218,,N,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623853,,12828,In vivo,,50597,17025,,
,BAO_0000019,,U,,Plasma clearance for the compound was determined.,1,,,A,,,0,Autocuration,CHEMBL623854,,12829,,,22224,15067,,
,BAO_0000100,,U,,CLog P value of the compound,1,,,P,,,0,Autocuration,CHEMBL874405,,12830,,,22224,3091,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL623855,,12831,,,22229,15592,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL623856,,12832,,,22229,14738,,
,BAO_0000100,,U,,ClogP value of the compound; nd ='no data',1,,,P,,,0,Autocuration,CHEMBL623857,,12833,,,22224,14738,,
,BAO_0000100,,U,,ClogP value of the compound; nd ='not determined',1,,,P,,,0,Autocuration,CHEMBL623858,,12834,,,22224,14738,,
,BAO_0000100,,U,,CLog P was determined,1,,,P,,,0,Autocuration,CHEMBL623859,,12835,,,22224,6076,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL839829,,12836,,,22229,17840,,
,BAO_0000019,,U,,CLogP was calculated,1,,,A,,,0,Autocuration,CHEMBL623860,,12837,,,22224,13589,,
,BAO_0000019,,U,,CLogP value was determined,1,,,A,,,0,Autocuration,CHEMBL623861,,12838,,,22224,17655,,
,BAO_0000019,,U,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,1,,,A,,,0,Autocuration,CHEMBL623862,,12839,,,22224,5867,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL874406,,12840,,,22229,5867,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL623863,,12841,,,22229,10783,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624021,,12842,,,22229,14849,,
Adrenal medulla,BAO_0000218,,N,,Distribution in female dog adrenal medulla 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL624022,,12843,,,50588,8170,,
Adrenal medulla,BAO_0000218,,N,,Distribution in female dog adrenal medulla 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1236.0,1,Intermediate,CHEMBL624023,,12844,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog bile 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624024,,12845,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog bile 72 hr after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624025,,12846,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog blood 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624026,,12847,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog blood 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624027,,12848,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog heart 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624028,,12849,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog heart 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624029,,12850,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog kidney 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624030,,12851,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog kidney 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624031,,12852,,,50588,8170,,
Intestine,BAO_0000218,,N,,Distribution in female dog large intestine 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,160.0,1,Intermediate,CHEMBL624032,,12853,,,50588,8170,,
Intestine,BAO_0000218,,N,,Distribution in female dog large intestine 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,160.0,1,Intermediate,CHEMBL874407,,12854,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog liver 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624033,,12855,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog liver 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624034,,12856,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog lung 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624035,,12857,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog lung 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624036,,12858,,,50588,8170,,
Muscle tissue,BAO_0000218,,N,,Distribution in female dog muscle 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2385.0,1,Intermediate,CHEMBL624037,,12859,,,50588,8170,,
Muscle tissue,BAO_0000218,,N,,Distribution in female dog muscle 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2385.0,1,Intermediate,CHEMBL624038,,12860,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog pancreas 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624039,,12861,,,50588,8170,,
,BAO_0000218,,N,,Distribution in female dog pancreas 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624040,,12862,,,50588,8170,,
Intestine,BAO_0000218,,N,,Distribution in female dog small intestine 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,160.0,1,Intermediate,CHEMBL624041,,12863,,,50588,8170,,
Intestine,BAO_0000218,,N,,Distribution in female dog small intestine 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,160.0,1,Intermediate,CHEMBL624042,,12864,,,50588,8170,,
Spleen,BAO_0000218,,N,,Distribution in female dog spleen 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2106.0,1,Intermediate,CHEMBL624043,,12865,,,50588,8170,,
Spleen,BAO_0000218,,N,,Distribution in female dog spleen 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2106.0,1,Intermediate,CHEMBL624044,,12866,,,50588,8170,,
Stomach,BAO_0000218,,N,,Distribution in female dog stomach 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,945.0,1,Intermediate,CHEMBL624045,,12867,,,50588,8170,,
Stomach,BAO_0000218,,N,,Distribution in female dog stomach 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,945.0,1,Intermediate,CHEMBL624046,,12868,,,50588,8170,,
Thyroid gland,BAO_0000218,,N,,Distribution in female dog thyroid 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2046.0,1,Intermediate,CHEMBL624047,,12869,,,50588,8170,,
Thyroid gland,BAO_0000218,,N,,Distribution in female dog thyroid 72 hours after administration.,1,,9615.0,A,Canis lupus familiaris,2046.0,1,Intermediate,CHEMBL624048,,12870,,,50588,8170,,
Urine,BAO_0000218,,N,,Distribution in female dog urine 24 hours after administration.,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL874408,,12871,,,50588,8170,,
Urine,BAO_0000218,,N,,Distribution in female dog urine 72 hr after administration.,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL624049,,12872,,,50588,8170,,
Plasma,BAO_0000218,,U,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,1,,,A,,1969.0,0,Autocuration,CHEMBL624050,,12873,,,22224,14283,,
,BAO_0000019,,U,,Plasma concentration at 7 hr after intravenous dosing,1,,,A,,,0,Autocuration,CHEMBL624051,,12874,,,22224,5623,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623278,,12875,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623279,,12876,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623280,,12877,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623963,,12878,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623964,,12879,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623965,,12880,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623966,,12881,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874415,,12882,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623967,,12883,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623968,,12884,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623969,,12885,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628409,,12886,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628410,,12887,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628411,,12888,,,50597,13477,,
,BAO_0000218,,N,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628412,,12889,,,50597,13477,,
,BAO_0000019,,U,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,1,,,A,,,0,Autocuration,CHEMBL628413,,12890,,,22224,12553,,
Plasma,BAO_0000019,,U,,The concentration in plasmat; Not determined,1,,,A,,1969.0,0,Autocuration,CHEMBL628414,,12891,,,22224,14548,,
,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in blood,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628415,,12892,,,50597,14393,,
,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628416,,12893,,,50597,14393,,
,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in heart,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628417,,12894,,,50597,14393,,
Liver,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in liver,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL874908,,12895,,,50597,14393,,
,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in plasma,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628418,,12896,,,50597,14393,,
Muscle tissue,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL628419,,12897,,,50597,14393,,
,BAO_0000218,,N,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628420,,12898,,,50597,14393,,
,BAO_0000019,,U,,Water solubility at 37 degree C.,1,,,A,,,0,Autocuration,CHEMBL628421,,12899,,,22224,1629,,
,BAO_0000100,,U,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,1,,,P,,,0,Autocuration,CHEMBL626726,,12900,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,,,P,,,0,Autocuration,CHEMBL626727,,12901,,,22229,8194,,
Blood,BAO_0000218,,N,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626728,,12902,,,50597,8594,,
Blood,BAO_0000218,,N,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626729,,12903,,,50597,8594,,
Blood,BAO_0000218,,N,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626730,,12904,,,50597,8594,,
Blood,BAO_0000218,,N,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626731,,12905,,,50597,8594,,
Blood,BAO_0000218,,N,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL626732,,12906,,,50597,8594,,
Heart,BAO_0000218,,N,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626733,,12907,,,50597,8594,,
Heart,BAO_0000218,,N,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626734,,12908,,,50597,8594,,
Heart,BAO_0000218,,N,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626735,,12909,,,50597,8594,,
Heart,BAO_0000218,,N,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL874909,,12910,,,50597,8594,,
Heart,BAO_0000218,,N,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL626736,,12911,,,50597,8594,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL626737,,12912,,,50597,8594,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630999,,12913,,,50597,8594,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631000,,12914,,,50597,8594,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631001,,12915,,,50597,8594,,
Kidney,BAO_0000218,,N,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631002,,12916,,,50597,8594,,
Liver,BAO_0000218,,N,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631003,,12917,,,50597,8594,,
Liver,BAO_0000218,,N,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631004,,12918,,,50597,8594,,
Liver,BAO_0000218,,N,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631005,,12919,,,50597,8594,,
Liver,BAO_0000218,,N,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631006,,12920,,,50597,8594,,
Liver,BAO_0000218,,N,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631007,,12921,,,50597,8594,,
Lung,BAO_0000218,,N,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL631008,,12922,,,50597,8594,,
Lung,BAO_0000218,,N,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL631009,,12923,,,50597,8594,,
Lung,BAO_0000218,,N,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL631010,,12924,,,50597,8594,,
Lung,BAO_0000218,,N,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL631011,,12925,,,50597,8594,,
Lung,BAO_0000218,,N,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL631012,,12926,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630271,,12927,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630272,,12928,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630273,,12929,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630274,,12930,,,50597,8594,,
Thyroid gland,BAO_0000218,,N,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630275,,12931,,,50597,8594,,
,BAO_0000218,,N,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875782,,12932,,,50597,8594,,
,BAO_0000218,,N,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630276,,12933,,,50597,8594,,
,BAO_0000218,,N,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630277,,12934,,,50597,8594,,
,BAO_0000218,,N,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630278,,12935,,,50597,8594,,
,BAO_0000218,,N,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630279,,12936,,,50597,8594,,
,BAO_0000019,,U,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL630280,,12937,,,22224,8151,,
,BAO_0000019,,U,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL630281,,12938,,,22224,8151,,
,BAO_0000218,,N,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630282,,12939,,,50592,7132,,
,BAO_0000218,,N,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630283,,12940,,,50592,7132,,
,BAO_0000019,,U,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),1,,,A,,,0,Autocuration,CHEMBL630284,,12941,,,22224,5797,,
,BAO_0000019,,U,,Alkylating activity was determined,1,,,A,,,0,Autocuration,CHEMBL630285,,12942,,,22224,7849,,
,BAO_0000251,,U,Microsomes,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),1,,,A,,,0,Autocuration,CHEMBL630286,,12943,,,22224,14220,,
,BAO_0000218,,N,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630069,,12944,,,50592,8650,,
,BAO_0000218,,N,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630070,,12945,,,50592,8650,,
,BAO_0000218,,N,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630071,,12946,,,50592,8650,,
,BAO_0000218,,N,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL630072,,12947,,,50592,8650,,
,BAO_0000218,,N,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL875110,,12948,,,50592,8650,,
,BAO_0000218,,N,,Compound was tested for antidiuretic activity in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630073,,12949,,,50597,7116,,
,BAO_0000019,,U,,Compound was tested for inactivation kinetic values,1,,,A,,,0,Autocuration,CHEMBL630074,,12950,,,22224,14131,,
,BAO_0000218,,U,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,1,,,A,,,0,Autocuration,CHEMBL630075,,12951,In vivo,,22224,7415,,
,BAO_0000019,,U,,Dissociation rate calculated from the first-order equation using the t1/2 value,1,,,A,,,0,Autocuration,CHEMBL630076,,12952,,,22224,13178,,
,BAO_0000100,,U,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,1,,,P,,,0,Autocuration,CHEMBL630077,,12953,,,22229,8815,,
,BAO_0000100,,U,,Aqueous solubility was measured,1,,,P,,,0,Autocuration,CHEMBL630078,,12954,,,22229,1450,,
,BAO_0000100,,U,,Aqueous solubility was measured at a pH 4,1,,,P,,,0,Autocuration,CHEMBL630079,,12955,,,22229,1450,,
,BAO_0000100,,U,,Aqueous solubility (pH 7),1,,,P,,,0,Autocuration,CHEMBL630080,,12956,,,22229,1450,,
,BAO_0000100,,U,,Aqueous solubility was measured at a pH 9,1,,,P,,,0,Autocuration,CHEMBL630081,,12957,,,22229,1450,,
,BAO_0000019,,U,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",1,,,A,,,0,Autocuration,CHEMBL630082,,12958,,,22224,12711,,
,BAO_0000019,,U,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",1,,,A,,,0,Autocuration,CHEMBL630083,,12959,,,22224,12711,,
,BAO_0000019,,U,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",1,,,A,,,0,Autocuration,CHEMBL630084,,12960,,,22224,12711,,
,BAO_0000100,,U,,Aqueous solubility of the compound,1,,,P,,,0,Autocuration,CHEMBL629198,,12961,,,22229,15032,,
,BAO_0000100,,U,,Aqueous solubility at 37 degree Celsius at pH 7.38,1,,,P,,,0,Autocuration,CHEMBL629199,,12962,,,22229,9964,,
,BAO_0000100,,U,,Aqueous solubility in pH 7.4 phosphate buffer,1,,,P,,,0,Autocuration,CHEMBL629200,,12963,,,22229,14962,,
,BAO_0000218,,N,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629201,,12964,,,50588,12487,,
,BAO_0000218,,N,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629202,,12965,,,50588,12487,,
,BAO_0000218,,N,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL875111,,12966,,,50587,10026,,
,BAO_0000218,,N,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL629203,,12967,,,50587,10026,,
,BAO_0000218,,N,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL629204,,12968,,,50587,10026,,
,BAO_0000218,,N,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL629205,,12969,,,50587,10026,,
,BAO_0000218,,N,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL629206,,12970,,,50587,10026,,
,BAO_0000019,,U,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,1,,,A,,,0,Autocuration,CHEMBL631185,,12971,,,22224,10026,,
,BAO_0000218,,N,,Compound was evaluated for the average bile flow rat in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631186,,12972,,,50597,7415,,
,BAO_0000218,,N,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL631187,,12973,,,50592,17025,,
,BAO_0000218,,N,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL631188,,12974,,,50592,17025,,
,BAO_0000019,,U,,Average half life period was determined,1,,,A,,,0,Autocuration,CHEMBL876419,,12975,,,22224,10184,,
,BAO_0000019,,U,,Average half life period was determined,1,,,A,,,0,Autocuration,CHEMBL631189,,12976,,,22224,10184,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL631190,,12977,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL631191,,12978,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL631192,,12979,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632400,,12980,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL630564,,12981,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL630565,,12982,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL630566,,12983,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL631229,,12984,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL631230,,12985,,,50602,8613,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL876428,,12986,,,22229,6030,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631231,,12987,,,22229,6147,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (MacLogP),1,,,P,,,0,Autocuration,CHEMBL631232,,12988,,,22229,14556,,
,BAO_0000019,,U,,Hydrophilicity was determined,1,,,A,,,0,Autocuration,CHEMBL631233,,12989,,,22224,768,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631234,,12990,,,22229,14452,,
,BAO_0000019,,U,,Increased absorption was determined,1,,,A,,,0,Autocuration,CHEMBL883126,,12991,,,22224,5237,,
,BAO_0000100,,U,,Lipophilicity value was evaluated,1,,,P,,,0,Autocuration,CHEMBL631235,,12992,,,22224,14378,,
,BAO_0000100,,U,,Log P value of the compound.,1,,,P,,,0,Autocuration,CHEMBL631236,,12993,,,22224,14418,,
,BAO_0000019,,U,,Partition coefficient of compound was determined,1,,,A,,,0,Autocuration,CHEMBL631237,,12994,,,22224,5249,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631238,,12995,,,22229,14621,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL876429,,12996,,,22229,12542,,
,BAO_0000019,,U,,Partition coefficient was measured by medchem software; Not calculated,1,,,A,,,0,Autocuration,CHEMBL631414,,12997,,,22224,12542,,
,BAO_0000100,,U,,Partition coefficient was measured by octanol-water using standard shake-flask method,1,,,P,,,0,Autocuration,CHEMBL631415,,12998,,,22224,12542,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631416,,12999,,,22229,15462,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL631417,,13000,,,22224,14884,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631418,,13001,,,22229,16526,,
,BAO_0000100,,U,,The Octanol/Water partition coefficient CLogP,1,,,P,,,0,Autocuration,CHEMBL631419,,13002,,,22229,13693,,
,BAO_0000019,,U,,The pharmacokinetic parameter C Log p was reported,1,,,A,,,0,Autocuration,CHEMBL631420,,13003,,,22224,13693,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631421,,13004,,,22229,13779,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631422,,13005,,,22229,14772,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL631423,,13006,,,22229,14393,,
Plasma,BAO_0000218,,N,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL876430,,13007,In vivo,,50597,14793,,
Plasma,BAO_0000218,,N,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL631424,,13008,In vivo,,50597,14793,,
Plasma,BAO_0000218,,N,,Compound was administered intravenously in dog to evaluate plasma clearance values,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL631425,,13009,In vivo,,50588,13744,,
Plasma,BAO_0000218,,U,,Compound was administered intravenously in monkey to evaluate plasma clearance values,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL631426,,13010,In vivo,,22224,13744,,
Plasma,BAO_0000218,,N,,Compound was administered intravenously in mouse to evaluate plasma clearance values,1,,10090.0,A,Mus musculus,1969.0,1,Intermediate,CHEMBL631427,,13011,In vivo,,50594,13744,,
Plasma,BAO_0000218,,N,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL631428,,13012,In vivo,,50588,13207,,
Liver,BAO_0000218,,N,Microsomes,Intrinsic clearance in Rhesus liver microsome,1,,9544.0,A,Macaca mulatta,2107.0,1,Intermediate,CHEMBL631429,,13013,In vitro,,50797,5669,,
Liver,BAO_0000218,,N,Microsomes,Intrinsic clearance in dog liver microsome,1,,9615.0,A,Canis lupus familiaris,2107.0,1,Intermediate,CHEMBL631430,,13014,In vitro,,50588,5669,,
Liver,BAO_0000218,,N,Microsomes,Intrinsic clearance in rat liver microsome,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631431,,13015,In vitro,,50597,5669,,
Plasma,BAO_0000218,,N,,Low plasma clearance was calculated in rhesus monkey,1,,9544.0,A,Macaca mulatta,1969.0,1,Intermediate,CHEMBL631432,,13016,In vivo,,50797,4853,,
,BAO_0000218,,N,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631433,,13017,In vivo,,50588,16452,,
,BAO_0000218,,U,,Plasma clearance after intravenous dose of 0.3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL631434,,13018,In vivo,,22224,11954,,
,BAO_0000218,,U,,Plasma clearance after intravenous dose of 1 mg/kg,1,,,A,,,0,Autocuration,CHEMBL631435,,13019,In vivo,,22224,11954,,
,BAO_0000218,,U,,Plasma clearance after intravenous dose of 3 mg/kg,1,,,A,,,0,Autocuration,CHEMBL631436,,13020,In vivo,,22224,11954,,
,BAO_0000218,,U,,Plasma clearance after intravenous dose of 3.87 mg/kg,1,,,A,,,0,Autocuration,CHEMBL631437,,13021,In vivo,,22224,11954,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 10 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631438,,13022,In vivo,,50597,5669,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 10 mpk in Rhesus,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL876431,,13023,In vivo,,50797,5669,,
,BAO_0000218,,N,,Plasma clearance after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631439,,13024,In vivo,,50588,5669,,
,BAO_0000218,,N,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631440,,13025,In vivo,,50597,13662,,
,BAO_0000019,,U,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),1,,,A,,,0,Autocuration,CHEMBL631441,,13026,,,22224,8272,,
,BAO_0000019,,U,,Critical Micellar concentration was determined,1,,,A,,,0,Autocuration,CHEMBL631442,,13027,,,22224,13410,,
,BAO_0000019,,U,,Critical Micellar concentration of the compound. was determined,1,,,A,,,0,Autocuration,CHEMBL626525,,13028,,,22224,13410,,
,BAO_0000019,,U,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,1,,,A,,,0,Autocuration,CHEMBL627168,,13029,,,22224,12628,,
,BAO_0000019,,U,,Critical micellar concentration was measured in water by the dye solubilization method,1,,,A,,,0,Autocuration,CHEMBL875618,,13030,,,22224,9675,,
,BAO_0000019,,U,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,1,,,B,,,0,Autocuration,CHEMBL626612,,13031,,,22224,12628,,
,BAO_0000019,,U,,CMR value (relative to BAY K 8644),1,,,A,,,0,Autocuration,CHEMBL626613,,13032,,,22224,12766,,
,BAO_0000019,,U,,Carbamoylating activity was determined,1,,,A,,,0,Autocuration,CHEMBL626614,,13033,,,22224,7849,,
,BAO_0000218,,U,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL626615,,13034,,,22224,12187,,
,BAO_0000019,,U,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,1,,,A,,,0,Autocuration,CHEMBL626616,,13035,,,22224,2040,,
,BAO_0000019,,U,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,1,,,A,,,0,Autocuration,CHEMBL626617,,13036,,,22224,2040,,
Plasma,BAO_0000218,,N,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626618,,13037,In vivo,,50588,14180,,
Plasma,BAO_0000218,,N,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626619,,13038,In vivo,,50597,14180,,
,BAO_0000218,,N,,"Clearance rate at 0.46 mg/kg, iv, in dogs",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626620,,13039,In vivo,,50588,14474,,
,BAO_0000218,,N,,"Clearance rate at 5.5 mg/kg, iv, in rat",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626621,,13040,In vivo,,50597,14474,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL626622,,13041,In vivo,,100710,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL626623,,13042,In vivo,,100710,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626624,,13043,In vivo,,50588,14548,,
,BAO_0000218,,N,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626625,,13044,In vivo,,50597,14548,,
Liver,BAO_0000218,,N,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL626626,,13045,Ex vivo,,50597,6125,,
,BAO_0000218,,U,,Tested for the total clearance of the compound,1,,,A,,,0,Autocuration,CHEMBL626627,,13046,In vivo,,22224,6874,,
,BAO_0000218,,N,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626628,,13047,In vivo,,50588,15343,,
,BAO_0000218,,U,,Total body clearance was determined,1,,,A,,,0,Autocuration,CHEMBL626629,,13048,In vivo,,22224,6236,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626630,,13049,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626631,,13050,,,50597,11510,,
,BAO_0000100,,U,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,1,,,P,,,0,Autocuration,CHEMBL626632,,13051,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,,,P,,,0,Autocuration,CHEMBL626633,,13052,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,1,,,P,,,0,Autocuration,CHEMBL626634,,13053,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,1,,,P,,,0,Autocuration,CHEMBL626635,,13054,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,1,,,P,,,0,Autocuration,CHEMBL626636,,13055,,,22229,8194,,
,BAO_0000100,,U,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,1,,,P,,,0,Autocuration,CHEMBL626637,,13056,,,22229,8194,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL626638,,13057,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL626639,,13058,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL626640,,13059,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL626641,,13060,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL627272,,13061,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL627273,,13062,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL627441,,13063,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL628355,,13064,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL628356,,13065,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL628357,,13066,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL628358,,13067,,,50339,13273,,
,BAO_0000218,,N,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),1,,4754.0,A,Pneumocystis carinii,,1,Intermediate,CHEMBL622307,,13068,,,50339,13273,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,1,,,A,,,0,Autocuration,CHEMBL622527,,13069,,,22224,13118,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,1,,,A,,,0,Autocuration,CHEMBL622528,,13070,,,22224,13118,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,1,,,A,,,0,Autocuration,CHEMBL622529,,13071,,,22224,13118,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,1,,,A,,,0,Autocuration,CHEMBL622992,,13072,,,22224,13118,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,1,,,A,,,0,Autocuration,CHEMBL622993,,13073,,,22224,13118,,
,BAO_0000019,,U,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,1,,,A,,,0,Autocuration,CHEMBL622994,,13074,,,22224,13118,,
,BAO_0000218,,N,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622995,,13075,,,50597,10633,,
,BAO_0000218,,N,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622996,,13076,,,50597,10633,,
,BAO_0000218,,N,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622997,,13077,,,50597,10633,,
,BAO_0000218,,N,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622998,,13078,,,50597,10633,,
,BAO_0000218,,U,,Cp max following ip administration at 1 mg/kg,1,,,A,,,0,Autocuration,CHEMBL622999,,13079,,,22224,5767,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma was reported at 0.5 hour,1,,,A,,1969.0,0,Autocuration,CHEMBL623000,,13080,In vivo,,22224,3302,,
Plasma,BAO_0000218,,U,,Maximum concentration in plasma was reported at 2 hour,1,,,A,,1969.0,0,Autocuration,CHEMBL623001,,13081,In vivo,,22224,3302,,
,BAO_0000218,,N,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL623002,,13082,,,50594,12467,,
,BAO_0000100,,U,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),1,,,P,,,0,Autocuration,CHEMBL623003,,13083,,,22229,11778,,
,BAO_0000019,,U,,Steady state concentration was evaluated,1,,,A,,,0,Autocuration,CHEMBL623004,,13084,,,22224,4321,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL623005,,13085,,,22224,14884,,
,BAO_0000019,,U,,Partition coefficient (logD7.4),1,,,A,,,0,Autocuration,CHEMBL623006,,13086,,,22224,15234,,
Liver,BAO_0000218,,N,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623007,,13087,In vivo,,50597,14198,,
Bone,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL623008,,13088,In vivo,,50597,14198,,
Cerebellum,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL876654,,13089,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623009,,13090,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623010,,13091,In vivo,,50597,14198,,
Heart,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623011,,13092,In vivo,,50597,14198,,
Intestine,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL623012,,13093,In vivo,,50597,14198,,
,BAO_0000019,,U,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL623013,,13094,,,22224,8151,,
,BAO_0000019,,U,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL623014,,13095,,,22224,8151,,
Urine,BAO_0000019,,U,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,1,,,A,,1088.0,0,Autocuration,CHEMBL623015,,13096,,,22224,8151,,
Urine,BAO_0000019,,U,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,1,,,A,,1088.0,0,Autocuration,CHEMBL623016,,13097,,,22224,8151,,
Urine,BAO_0000019,,U,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,1,,,A,,1088.0,0,Autocuration,CHEMBL624858,,13098,,,22224,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624859,,13099,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624860,,13100,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624861,,13101,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624862,,13102,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624863,,13103,,,50597,8151,,
,BAO_0000218,,N,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876655,,13104,,,50597,8151,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624864,,13105,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624865,,13106,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624866,,13107,,,50588,6996,,
,BAO_0000218,,N,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,1,,9615.0,F,Canis lupus familiaris,,1,Expert,CHEMBL624867,,13108,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL624868,,13109,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628450,,13110,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628451,,13111,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628452,,13112,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628453,,13113,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628454,,13114,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628455,,13115,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628456,,13116,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628457,,13117,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL877505,,13118,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628458,,13119,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628459,,13120,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628460,,13121,,,50588,6996,,
,BAO_0000218,,N,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628461,,13122,,,50588,6996,,
,BAO_0000218,,U,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",1,,,B,,,0,Autocuration,CHEMBL628462,,13123,,,22224,6996,,
,BAO_0000218,,N,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628463,,13124,,,50588,6996,,
,BAO_0000218,,N,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",1,,10116.0,F,Rattus norvegicus,,1,Expert,CHEMBL625666,,13125,,,50597,6996,,
,BAO_0000218,,U,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,,B,,,0,Autocuration,CHEMBL625667,,13126,,,22224,6996,,
,BAO_0000218,,N,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,10116.0,A,Rattus norvegicus,,1,Expert,CHEMBL625668,,13127,,,50597,6996,,
,BAO_0000218,,N,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625669,,13128,,,50597,6996,,
,BAO_0000019,,U,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,1,,,A,,,0,Autocuration,CHEMBL625670,,13129,,,22224,7114,,
,BAO_0000218,,N,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625671,,13130,,,50597,7114,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL625672,,13131,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL625673,,13132,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL625674,,13133,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL625675,,13134,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627637,,13135,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627638,,13136,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627639,,13137,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627640,,13138,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627641,,13139,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL627642,,13140,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL877506,,13141,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627275,,13142,,,50594,8613,,
,BAO_0000218,,N,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL627643,,13143,,,50506,11219,,
,BAO_0000218,,N,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL631246,,13144,,,50506,11219,,
,BAO_0000218,,N,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL631247,,13145,,,50506,11219,,
,BAO_0000218,,N,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL629532,,13146,,,50506,11219,,
,BAO_0000218,,N,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL629533,,13147,,,50506,11219,,
,BAO_0000218,,N,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL629534,,13148,,,50506,11219,,
,BAO_0000218,,N,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,1,,9669.0,A,Mustela putorius furo,,1,Intermediate,CHEMBL629535,,13149,,,50506,11219,,
,BAO_0000019,,U,,Pharmacokinetic parameter :drug bound to plasma was reported,1,,,A,,,0,Autocuration,CHEMBL625932,,13150,,,22224,14837,,
,BAO_0000019,,U,,compound was evaluated for drug bound in plasma,1,,,A,,,0,Autocuration,CHEMBL625933,,13151,,,22224,14837,,
,BAO_0000218,,N,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625934,,13152,,,50597,15343,,
,BAO_0000218,,U,,Bioavailability,1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL625935,,13153,,,22224,13761,,
,BAO_0000218,,N,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625936,,13154,,,50597,14810,,
,BAO_0000218,,N,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625937,,13155,,,50597,14810,,
,BAO_0000218,,N,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625938,,13156,,,50588,13249,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL625939,,13157,,,50597,9267,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL625940,,13158,,,50597,9267,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL874464,,13159,,,50597,9267,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL625941,,13160,,,50597,9267,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL625942,,13161,,,50597,9267,,
Bile,BAO_0000218,,N,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,1,,10116.0,A,Rattus norvegicus,1970.0,1,Intermediate,CHEMBL625943,,13162,,,50597,9267,,
Serum,BAO_0000218,,N,,In vitro protein binding in human serum at 5 ug/ml,1,,9606.0,A,Homo sapiens,1977.0,1,Intermediate,CHEMBL625944,,13163,,,50587,15549,,
,BAO_0000019,,U,,Serum protein binding ability was measured,1,,,A,,,0,Autocuration,CHEMBL625945,,13164,,,22224,10929,,
,BAO_0000019,,U,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),1,,,A,,,0,Autocuration,CHEMBL625946,,13165,,,22224,15444,,
,BAO_0000218,,U,,Oral bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL625947,,13166,In vivo,,22224,12860,,
,BAO_0000218,,N,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625948,,13167,In vivo,,50597,12170,,
,BAO_0000218,,U,,Absolute oral bioavailability at an iv dose of 14 mg/kg,1,,,A,,,0,Autocuration,CHEMBL625949,,13168,In vivo,,22224,15173,,
,BAO_0000218,,U,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,1,,,A,,,0,Autocuration,CHEMBL625950,,13169,In vivo,,22224,15173,,
,BAO_0000218,,U,,Oral bioavailability (dose 15 mg/kg i.v.),1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL625951,,13170,In vivo,,22224,15173,,
,BAO_0000218,,U,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,1,,,A,,,0,Autocuration,CHEMBL625952,,13171,In vivo,,22224,15173,,
,BAO_0000218,,U,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,1,,,A,,,0,Autocuration,CHEMBL625953,,13172,In vivo,,22224,15173,,
,BAO_0000218,,U,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,1,,,A,,,0,Autocuration,CHEMBL625954,,13173,In vivo,,22224,15173,,
,BAO_0000218,,U,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,1,,,A,,,0,Autocuration,CHEMBL882959,,13174,In vivo,,22224,15173,,
,BAO_0000218,,N,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625955,,13175,In vivo,,50588,11767,,
,BAO_0000218,,U,,Bioavailability in ferret,1,,9669.0,A,Mustela putorius furo,,0,Autocuration,CHEMBL625956,,13176,In vivo,,22224,11219,,
,BAO_0000218,,N,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL625957,,13177,In vivo,,100710,12186,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625958,,13178,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625959,,13179,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626642,,13180,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631330,,13181,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631331,,13182,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631332,,13183,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631333,,13184,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632018,,13185,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632019,,13186,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632020,,13187,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632021,,13188,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632022,,13189,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632023,,13190,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632024,,13191,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874472,,13192,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632025,,13193,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632026,,13194,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632027,,13195,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632028,,13196,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626430,,13197,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626431,,13198,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626432,,13199,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626433,,13200,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626434,,13201,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627280,,13202,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627281,,13203,,,50597,11510,,
,BAO_0000218,,N,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627282,,13204,,,50597,11510,,
,BAO_0000019,,U,,Total body clearance was measured at given dose,1,,,A,,,0,Autocuration,CHEMBL627283,,13205,,,22224,7199,,
,BAO_0000218,,U,,Total body clearance was measured at given dose.,1,,,A,,,0,Autocuration,CHEMBL627284,,13206,,,22224,7199,,
,BAO_0000218,,N,,Metabolic clearance from the body in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627285,,13207,,,50597,7095,,
,BAO_0000218,,U,,Renal clearance from the body,1,,,A,,,0,Autocuration,CHEMBL627286,,13208,In vivo,,22224,7095,,
,BAO_0000218,,N,,Renal clearance from the body in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875477,,13209,In vivo,,50597,7095,,
,BAO_0000218,,N,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627287,,13210,In vivo,,50597,12528,,
,BAO_0000218,,N,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627288,,13211,In vivo,,50588,12528,,
,BAO_0000218,,N,,Total clearance from the body in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627289,,13212,,,50597,7095,,
Plasma,BAO_0000218,,N,,Clearance into cortex from rat plasma or PBS,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627290,,13213,In vivo,,50597,14223,,
,BAO_0000218,,U,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL627291,,13214,In vivo,,22224,13569,,
,BAO_0000218,,U,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL627292,,13215,In vivo,,22224,13569,,
,BAO_0000218,,U,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL627293,,13216,In vivo,,22224,13569,,
,BAO_0000218,,U,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL627294,,13217,In vivo,,22224,13569,,
,BAO_0000218,,U,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,1,,,A,,,0,Autocuration,CHEMBL875478,,13218,In vivo,,22224,13569,,
,BAO_0000218,,U,,Clearance was determined,1,,,A,,,0,Autocuration,CHEMBL627295,,13219,In vivo,,22224,13979,,
,BAO_0000218,,N,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627296,,13220,In vivo,,50594,14315,,
,BAO_0000218,,N,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,1,,9986.0,A,Oryctolagus cuniculus,,1,Intermediate,CHEMBL626119,,13221,In vivo,,50592,14315,,
,BAO_0000218,,N,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626120,,13222,In vivo,,50597,14315,,
,BAO_0000218,,N,,Clearance in rat after iv dose (100 ug/kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626121,,13223,In vivo,,50597,12174,,
,BAO_0000218,,U,,Clearance in guinea pig,1,,10141.0,A,Cavia porcellus,,0,Autocuration,CHEMBL626122,,13224,In vivo,,22224,12797,,
,BAO_0000218,,N,,Compound was evaluated for clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626123,,13225,In vivo,,50597,12797,,
,BAO_0000218,,N,,Compound was evaluated for the clearance in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL623456,,13226,In vivo,,50588,12797,,
,BAO_0000218,,N,,Compound was evaluated for the clearance in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623457,,13227,In vivo,,50597,12797,,
,BAO_0000218,,N,,Compound was tested in vivo for clearance after iv administration in the rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623458,,13228,In vivo,,50597,11500,,
,BAO_0000218,,U,,IV clearance determined at an iv dose of 14 mg/kg,1,,,A,,,0,Autocuration,CHEMBL623459,,13229,In vivo,,22224,15173,,
,BAO_0000218,,U,,IV clearance determined at an iv dose of 15.2 mg/kg,1,,,A,,,0,Autocuration,CHEMBL875484,,13230,In vivo,,22224,15173,,
,BAO_0000218,,U,,IV clearance determined at an iv dose of 15 mg/kg,1,,,A,,,0,Autocuration,CHEMBL623460,,13231,In vivo,,22224,15173,,
,BAO_0000218,,U,,IV clearance determined at an peroral dose of 30 mg/kg.,1,,,A,,,0,Autocuration,CHEMBL623461,,13232,In vivo,,22224,15173,,
,BAO_0000218,,U,,IV clearance determined at an peroral dose of 30.2 mg/kg.,1,,,A,,,0,Autocuration,CHEMBL623462,,13233,In vivo,,22224,15173,,
,BAO_0000218,,U,,IV clearance determined at an peroral dose of 30.3 mg/kg.,1,,,A,,,0,Autocuration,CHEMBL627386,,13234,In vivo,,22224,15173,,
Kidney,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627387,,13235,In vivo,,50597,14198,,
Liver,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627388,,13236,In vivo,,50597,14198,,
Lung,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627389,,13237,In vivo,,50597,14198,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627390,,13238,In vivo,,50597,14198,,
Plasma,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627391,,13239,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627392,,13240,In vivo,,50597,14198,,
Spleen,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL627393,,13241,In vivo,,50597,14198,,
Trachea,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,1,,10116.0,A,Rattus norvegicus,3126.0,1,Intermediate,CHEMBL627394,,13242,In vivo,,50597,14198,,
Bone,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627395,,13243,In vivo,,50597,14198,,
Cerebellum,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL875485,,13244,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627396,,13245,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627397,,13246,In vivo,,50597,14198,,
Heart,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL627398,,13247,In vivo,,50597,14198,,
Bone,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL627399,,13248,In vivo,,50597,14198,,
Kidney,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627400,,13249,In vivo,,50597,14198,,
Liver,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627401,,13250,In vivo,,50597,14198,,
Lung,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627402,,13251,In vivo,,50597,14198,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL627403,,13252,In vivo,,50597,14198,,
Plasma,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL627404,,13253,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623101,,13254,In vivo,,50597,14198,,
Spleen,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL877480,,13255,In vivo,,50597,14198,,
Trachea,BAO_0000218,,N,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,1,,10116.0,A,Rattus norvegicus,3126.0,1,Intermediate,CHEMBL623102,,13256,In vivo,,50597,14198,,
Bone,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL623103,,13257,In vivo,,50597,14198,,
Cerebellum,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL623104,,13258,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623105,,13259,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623106,,13260,In vivo,,50597,14198,,
Heart,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL623107,,13261,In vivo,,50597,14198,,
Intestine,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL623108,,13262,In vivo,,50597,14198,,
Kidney,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL623109,,13263,In vivo,,50597,14198,,
Liver,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL623110,,13264,In vivo,,50597,14198,,
Lung,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL623111,,13265,In vivo,,50597,14198,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625060,,13266,In vivo,,50597,14198,,
Plasma,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625061,,13267,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625062,,13268,In vivo,,50597,14198,,
Spleen,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625063,,13269,In vivo,,50597,14198,,
Trachea,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,1,,10116.0,A,Rattus norvegicus,3126.0,1,Intermediate,CHEMBL625064,,13270,In vivo,,50597,14198,,
Bone,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,1,,10116.0,A,Rattus norvegicus,10000001.0,1,Intermediate,CHEMBL625065,,13271,In vivo,,50597,14198,,
Cerebellum,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL625066,,13272,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625067,,13273,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625068,,13274,In vivo,,50597,14198,,
Heart,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL622159,,13275,In vivo,,50597,14198,,
Intestine,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,1,,10116.0,A,Rattus norvegicus,160.0,1,Intermediate,CHEMBL622160,,13276,In vivo,,50597,14198,,
Kidney,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL622161,,13277,In vivo,,50597,14198,,
Lung,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL622162,,13278,In vivo,,50597,14198,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL622163,,13279,In vivo,,50597,14198,,
Plasma,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622313,,13280,In vivo,,50597,14198,,
,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622314,,13281,In vivo,,50597,14198,,
Spleen,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622315,,13282,In vivo,,50597,14198,,
Trachea,BAO_0000218,,N,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,1,,10116.0,A,Rattus norvegicus,3126.0,1,Intermediate,CHEMBL622316,,13283,In vivo,,50597,14198,,
,BAO_0000218,,N,,Normal diffusion coefficient in water for Escherichia coli,1,,562.0,A,Escherichia coli,,1,Intermediate,CHEMBL877486,,13284,,,50212,15599,,
,BAO_0000019,,U,,Average max percent decrease in RVR (renal vascular resistance) was determined,1,,,A,,,0,Autocuration,CHEMBL622317,,13285,,,22224,8204,,
,BAO_0000019,,U,,Average max percent decrease in RVR (renal vascular resistance) was determined.,1,,,A,,,0,Autocuration,CHEMBL622318,,13286,,,22224,8204,,
,BAO_0000019,,U,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL622319,,13287,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL622320,,13288,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,1,,,A,,,0,Autocuration,CHEMBL622321,,13289,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL622322,,13290,,,22224,6154,,
,BAO_0000019,,U,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,1,,,A,,,0,Autocuration,CHEMBL622323,,13291,,,22224,7114,,
,BAO_0000218,,N,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622324,,13292,,,50597,7114,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622325,,13293,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622326,,13294,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL877487,,13295,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622327,,13296,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622328,,13297,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622329,,13298,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622330,,13299,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622331,,13300,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622332,,13301,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622333,,13302,,,50588,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL627658,,13303,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL630428,,13304,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL630429,,13305,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL630430,,13306,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL630431,,13307,,,22224,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL630432,,13308,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL630433,,13309,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL630434,,13310,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629372,,13311,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629553,,13312,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629554,,13313,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL874447,,13314,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629555,,13315,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629556,,13316,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629557,,13317,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629558,,13318,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629559,,13319,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629560,,13320,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629561,,13321,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629562,,13322,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629563,,13323,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629564,,13324,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629565,,13325,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629566,,13326,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629567,,13327,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629568,,13328,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629569,,13329,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL629570,,13330,,,50588,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL629571,,13331,,,22224,8133,,
,BAO_0000218,,U,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL629572,,13332,In vivo,,22224,12170,,
,BAO_0000218,,U,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL629573,,13333,In vivo,,22224,12170,,
,BAO_0000218,,U,,Bioavailability (dose 20 mg/kg),1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL629574,,13334,In vivo,,22224,4985,,
,BAO_0000218,,U,,Bioavailability in dog,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL629575,,13335,In vivo,,22224,15145,,
,BAO_0000218,,U,,Bioavailability in rat (Sprague-Dawley) (male),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL874448,,13336,In vivo,,22224,14080,,
,BAO_0000218,,U,,Bioavailability in monkey (dose 10 mg/kg i.d.),1,,9443.0,A,Primates,,0,Autocuration,CHEMBL629576,,13337,In vivo,,22224,11219,,
,BAO_0000218,,U,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL629577,,13338,In vivo,,22224,15145,,
,BAO_0000218,,U,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL629578,,13339,In vivo,,22224,15145,,
,BAO_0000218,,U,,Bioavailability in dog (dose 3.0 mg/kg p.o.),1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL629579,,13340,In vivo,,22224,1202,,
,BAO_0000218,,U,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL882958,,13341,In vivo,,22224,1202,,
,BAO_0000218,,N,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,1,,9598.0,A,Pan troglodytes,,1,Intermediate,CHEMBL629580,,13342,In vivo,,50505,1202,,
,BAO_0000218,,U,,Bioavailability,1,,9347.0,A,Eutheria,,0,Autocuration,CHEMBL629581,,13343,In vivo,,22224,4026,,
,BAO_0000218,,U,,Bioavailability in squirrel monkey,1,,9520.0,A,Saimiri,,0,Autocuration,CHEMBL629582,,13344,In vivo,,22224,1492,,
,BAO_0000218,,N,,Bioavailability was evaluated in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628522,,13345,In vivo,,50588,12793,,
,BAO_0000218,,N,,Bioavailability was evaluated in hamster,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL625432,,13346,In vivo,,100712,12793,,
,BAO_0000218,,U,,Bioavailability in rat,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625433,,13347,In vivo,,22224,12793,,
Plasma,BAO_0000218,,N,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625434,,13348,In vivo,,50597,14793,,
Plasma,BAO_0000218,,N,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL625435,,13349,In vivo,,50597,14793,,
,BAO_0000218,,U,,Bioavailability in rat (dose 10 mg/kg p.o.),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625436,,13350,In vivo,,22224,14793,,
,BAO_0000218,,N,,Bioavailability was measured in cynomolgus monkeys.,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL874588,,13351,In vivo,,100710,14731,,
,BAO_0000218,,N,,Bioavailability was measured in nude mice.,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625437,,13352,In vivo,,50594,14731,,
,BAO_0000218,,U,,Bioavailability in ferret (dose 10 mg/kg i.d.),1,,9669.0,A,Mustela putorius furo,,0,Autocuration,CHEMBL625438,,13353,In vivo,,22224,12187,,
,BAO_0000218,,U,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625439,,13354,In vivo,,22224,12187,,
,BAO_0000218,,U,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625440,,13355,In vivo,,22224,12187,,
,BAO_0000218,,U,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),1,,314293.0,A,Simiiformes,,0,Autocuration,CHEMBL625441,,13356,In vivo,,22224,12187,,
,BAO_0000218,,U,,Bioavailability in rat (dose 10 mg/kg i.d.),1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625442,,13357,In vivo,,22224,12187,,
,BAO_0000218,,N,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625443,,13358,In vivo,,50597,12187,,
,BAO_0000218,,U,,Bioavailability was determined; extremely poor,1,,,A,,,0,Autocuration,CHEMBL625444,,13359,In vivo,,22224,17431,,
,BAO_0000218,,N,,% bioavailability in mice after oral administration of prodrug,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625445,,13360,In vivo,,50594,13318,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625446,,13361,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL882960,,13362,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625447,,13363,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625448,,13364,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625449,,13365,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL874589,,13366,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625450,,13367,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625451,,13368,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626584,,13369,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626585,,13370,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626586,,13371,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626587,,13372,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626588,,13373,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626589,,13374,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626590,,13375,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626591,,13376,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL627181,,13377,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628083,,13378,In vivo,,50588,9025,,
,BAO_0000218,,U,,IV clearance determined at an peroral dose of 15 mg/kg.,1,,,A,,,0,Autocuration,CHEMBL628084,,13379,In vivo,,22224,15173,,
,BAO_0000218,,N,,Mouse oral clearance was measured against Hymenolepiasis nana.,1,,102285.0,F,Hymenolepis nana,,1,Expert,CHEMBL628085,,13380,In vivo,,50064,7732,,
,BAO_0000218,,N,,Mouse oral clearance was measured against Nematospiroides dubius,1,,6339.0,F,Heligmosomoides polygyrus,,1,Expert,CHEMBL628086,,13381,In vivo,,50545,7732,,
,BAO_0000218,,U,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,1,,,F,,,0,Autocuration,CHEMBL628087,,13382,In vivo,,22224,7732,,
,BAO_0000218,,N,,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628088,,13383,In vivo,,50594,7732,,
,BAO_0000218,,U,,Mouse oral clearance was measured against N. nana; NT is Not Tested,1,,,B,,,0,Autocuration,CHEMBL628089,,13384,In vivo,,22224,7732,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL628090,,13385,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL628091,,13386,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL628092,,13387,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL628093,,13388,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL875607,,13389,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL625710,,13390,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL625711,,13391,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL625712,,13392,In vivo,,22224,8328,,
,BAO_0000218,,U,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,1,,,A,,,0,Autocuration,CHEMBL625713,,13393,In vivo,,22224,8328,,
,BAO_0000218,,N,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625714,,13394,In vivo,,50588,13376,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL625715,,13395,In vivo,,50797,13477,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625716,,13396,In vivo,,50597,13477,,
,BAO_0000218,,N,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625717,,13397,In vivo,,50597,13477,,
,BAO_0000218,,N,,Plasma clearance was determined for the compound in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625718,,13398,In vivo,,50597,13313,,
,BAO_0000218,,N,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625719,,13399,In vivo,,50597,12504,,
,BAO_0000218,,N,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625720,,13400,In vivo,,50597,12504,,
,BAO_0000218,,N,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625721,,13401,In vivo,,50597,12504,,
,BAO_0000218,,N,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625722,,13402,In vivo,,50597,12504,,
,BAO_0000218,,N,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625723,,13403,In vivo,,50597,13129,,
,BAO_0000218,,N,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,1,,6339.0,A,Heligmosomoides polygyrus,,1,Intermediate,CHEMBL625724,,13404,In vivo,,50545,7732,,
,BAO_0000218,,N,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,1,,6339.0,A,Heligmosomoides polygyrus,,1,Intermediate,CHEMBL625725,,13405,In vivo,,50545,7732,,
,BAO_0000218,,N,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,1,,6339.0,A,Heligmosomoides polygyrus,,1,Intermediate,CHEMBL625726,,13406,In vivo,,50545,7732,,
,BAO_0000218,,N,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,1,,6339.0,A,Heligmosomoides polygyrus,,1,Intermediate,CHEMBL875608,,13407,In vivo,,50545,7732,,
,BAO_0000218,,N,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,1,,6339.0,A,Heligmosomoides polygyrus,,1,Intermediate,CHEMBL625727,,13408,In vivo,,50545,7732,,
Urine,BAO_0000218,,U,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,1,,10116.0,A,Rattus norvegicus,1088.0,0,Autocuration,CHEMBL625728,,13409,In vivo,,22224,9278,,
,BAO_0000218,,U,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625729,,13410,In vivo,,22224,9278,,
,BAO_0000218,,U,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL625730,,13411,In vivo,,22224,9278,,
Urine,BAO_0000218,,U,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,1,,10116.0,A,Rattus norvegicus,1088.0,0,Autocuration,CHEMBL625731,,13412,In vivo,,22224,9278,,
Urine,BAO_0000218,,U,,Urinary clearance was determined in rat at 25 mg/kg os dosage,1,,10116.0,A,Rattus norvegicus,1088.0,0,Autocuration,CHEMBL626417,,13413,In vivo,,22224,9278,,
Urine,BAO_0000218,,N,,Urinary clearance was determined at 100 mg/kg oral dosage in human,1,,9606.0,A,Homo sapiens,1088.0,1,Intermediate,CHEMBL626418,,13414,In vivo,,50587,9278,,
Urine,BAO_0000218,,N,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL626419,,13415,In vivo,,50588,9278,,
Plasma,BAO_0000218,,N,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626592,,13416,In vivo,,50588,5932,,
Plasma,BAO_0000218,,N,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626593,,13417,In vivo,,50597,5932,,
,BAO_0000218,,N,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626594,,13418,In vivo,,50597,5182,,
,BAO_0000218,,N,,Clearance rate in dogs,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625035,,13419,In vivo,,50588,10499,,
,BAO_0000019,,U,,Compound was measured for intrinsic clearance,1,,,A,,,0,Autocuration,CHEMBL625036,,13420,In vitro,,22224,6051,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625037,,13421,,,22229,17508,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625038,,13422,,,22229,6228,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625039,,13423,,,22229,6231,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625040,,13424,,,22229,17740,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625041,,13425,,,22229,6495,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625042,,13426,,,22229,2171,,
,BAO_0000019,,U,,Partition coefficient of the compound,1,,,A,,,0,Autocuration,CHEMBL874411,,13427,,,22224,3255,,
,BAO_0000019,,U,,Permeability,1,,,A,,,0,Autocuration,CHEMBL625043,,13428,,,22224,6821,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625044,,13429,,,22229,2685,,
,BAO_0000019,,U,,Partition coefficient (logD),1,,,A,,,0,Autocuration,CHEMBL625045,,13430,,,22224,17584,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,,,P,,,0,Autocuration,CHEMBL625046,,13431,,,22229,13824,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),1,,,P,,,0,Autocuration,CHEMBL625047,,13432,,,22229,13824,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625048,,13433,,,22229,16479,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625049,,13434,,,22229,11997,,
,BAO_0000100,,U,,Calculated logarithm of partition coefficient (P) was determined,1,,,P,,,0,Autocuration,CHEMBL625050,,13435,,,22229,2988,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625051,,13436,,,22229,931,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL874412,,13437,,,22229,4381,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625052,,13438,,,22229,4397,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL625053,,13439,,,22229,5889,,
,BAO_0000019,,U,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL623250,,13440,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL623251,,13441,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL623252,,13442,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,1,,,A,,,0,Autocuration,CHEMBL623253,,13443,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL623254,,13444,,,22224,6154,,
,BAO_0000019,,U,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,1,,,A,,,0,Autocuration,CHEMBL623255,,13445,,,22224,6154,,
,BAO_0000019,,U,,Percent degradation of compound at a pH of 1 over a 18 hr period,1,,,A,,,0,Autocuration,CHEMBL626831,,13446,,,22224,6887,,
,BAO_0000019,,U,,Percent degradation of compound at pH of 1 over an 18 hr period,1,,,A,,,0,Autocuration,CHEMBL877494,,13447,,,22224,6887,,
,BAO_0000019,,U,,Delta Logarithm of Partition Coefficient value was determined.,1,,,A,,,0,Autocuration,CHEMBL626832,,13448,,,22224,14116,,
,BAO_0000019,,U,,Delta logPoct-cyc,1,,,A,,,0,Autocuration,CHEMBL626833,,13449,,,22224,11137,,
,BAO_0000100,,U,,Lipophilicity estimated on reversed phase TLC,1,,,P,,,0,Autocuration,CHEMBL626834,,13450,,,22224,7230,,
,BAO_0000019,,U,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,1,,,A,,,0,Autocuration,CHEMBL626835,,13451,,,22224,15741,,
,BAO_0000019,,U,,Delta logPoct-cyc,1,,,A,,,0,Autocuration,CHEMBL626836,,13452,,,22224,9663,,
,BAO_0000100,,U,,Change in logarithm of partition coefficient of the compound,1,,,P,,,0,Autocuration,CHEMBL626837,,13453,,,22229,9663,,
,BAO_0000019,,U,,Delta logD (pH 6.5),1,,,A,,,0,Autocuration,CHEMBL626838,,13454,,,22224,13807,,
,BAO_0000100,,U,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",1,,,P,,,0,Autocuration,CHEMBL626839,,13455,,,22224,13807,,
,BAO_0000019,,U,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,1,,,A,,,0,Autocuration,CHEMBL626840,,13456,,,22224,17425,,
,BAO_0000019,,U,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),1,,,A,,,0,Autocuration,CHEMBL626841,,13457,,,22224,12143,,
,BAO_0000219,,U,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,1,,,A,,,0,Autocuration,CHEMBL626842,,13458,,,22224,12608,,
,BAO_0000219,,U,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,1,,,A,,,0,Autocuration,CHEMBL626843,,13459,,,22224,12608,,
,BAO_0000218,,N,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626844,,13460,,,50597,8649,,
,BAO_0000218,,N,,Amount of deuterium retained was reported after normal workup in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL877495,,13461,,,50597,8649,,
,BAO_0000218,,N,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626845,,13462,,,50597,8649,,
,BAO_0000218,,N,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626846,,13463,,,50597,8649,,
,BAO_0000218,,N,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626847,,13464,,,50597,8649,,
,BAO_0000218,,N,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628677,,13465,,,50597,8649,,
,BAO_0000218,,N,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628678,,13466,,,50597,8649,,
,BAO_0000019,,U,,Compound was subjected to electrochemical oxidation,1,,,A,,,0,Autocuration,CHEMBL628679,,13467,,,22224,9659,,
,BAO_0000019,,U,,Compound was subjected to photochemical oxidation,1,,,A,,,0,Autocuration,CHEMBL628680,,13468,,,22224,9659,,
,BAO_0000019,,U,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,1,,,A,,,0,Autocuration,CHEMBL628681,,13469,,,22224,9659,,
,BAO_0000019,,U,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,1,,,A,,,0,Autocuration,CHEMBL628682,,13470,,,22224,9659,,
,BAO_0000019,,U,,Oxidation of compound by methemoglobin in presence of hydroperoxide,1,,,A,,,0,Autocuration,CHEMBL628683,,13471,,,22224,9659,,
,BAO_0000218,,N,,Percent diffusion through fuzzy rat skin after 48 h of incubation,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628684,,13472,,,50597,9607,,
,BAO_0000100,,U,,Dissociation constant (pKa),1,,,P,,,0,Autocuration,CHEMBL877501,,13473,,,22229,7057,,
,BAO_0000100,,U,,Dissociation constant value of the compound; ND means not determined.,1,,,P,,,0,Autocuration,CHEMBL628685,,13474,,,22224,7057,,
Blood,BAO_0000218,,N,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628686,,13475,,,50597,7911,,
Blood,BAO_0000218,,N,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL628687,,13476,,,50597,7911,,
,BAO_0000218,,N,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628688,,13477,,,50597,7911,,
,BAO_0000218,,N,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628689,,13478,,,50597,7911,,
Liver,BAO_0000218,,N,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628690,,13479,,,50597,7911,,
Liver,BAO_0000218,,N,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL629363,,13480,,,50597,7911,,
Spleen,BAO_0000218,,N,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL629364,,13481,,,50597,7911,,
Spleen,BAO_0000218,,N,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL629365,,13482,,,50597,7911,,
,BAO_0000218,,N,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629366,,13483,,,50597,7911,,
Urine,BAO_0000218,,N,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629367,,13484,,,50597,7911,,
Feces,BAO_0000218,,N,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL629368,,13485,,,50597,7911,,
Urine,BAO_0000218,,N,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL877502,,13486,,,50597,7911,,
Cerebellum,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,1,,10090.0,A,Mus musculus,2037.0,1,Intermediate,CHEMBL629369,,13487,,,50594,13792,,
Brain,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL629370,,13488,,,50594,13792,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL629371,,13489,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL626276,,13490,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL626277,,13491,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL631250,,13492,,,22224,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631251,,13493,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631252,,13494,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631253,,13495,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631254,,13496,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631255,,13497,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631256,,13498,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631257,,13499,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628009,,13500,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628010,,13501,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628011,,13502,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628012,,13503,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628013,,13504,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628014,,13505,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628015,,13506,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628016,,13507,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL874461,,13508,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628017,,13509,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628018,,13510,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628019,,13511,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628020,,13512,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628021,,13513,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628022,,13514,,,50588,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL628023,,13515,,,50588,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL628024,,13516,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL628025,,13517,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL628026,,13518,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL628027,,13519,,,22224,8133,,
Urine,BAO_0000218,,U,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",1,,314293.0,A,Simiiformes,1088.0,0,Autocuration,CHEMBL628028,,13520,,,22224,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628029,,13521,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628030,,13522,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628031,,13523,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628032,,13524,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628033,,13525,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628034,,13526,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628035,,13527,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628036,,13528,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL874462,,13529,,,50597,8133,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628037,,13530,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628123,,13531,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628124,,13532,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628125,,13533,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628126,,13534,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628127,,13535,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628128,,13536,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628129,,13537,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628130,,13538,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628131,,13539,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628132,,13540,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628133,,13541,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628134,,13542,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628135,,13543,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628136,,13544,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628137,,13545,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628138,,13546,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628139,,13547,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628140,,13548,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628141,,13549,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628142,,13550,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628143,,13551,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628144,,13552,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628145,,13553,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL628146,,13554,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625355,,13555,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625356,,13556,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625357,,13557,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625527,,13558,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL875473,,13559,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL625528,,13560,In vivo,,50588,9025,,
,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626304,,13561,In vivo,,50597,9025,,
Artery,BAO_0000218,,N,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,1,,9615.0,A,Canis lupus familiaris,1637.0,1,Intermediate,CHEMBL624138,,13562,In vivo,,50588,9025,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624139,,13563,,,22229,6448,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624140,,13564,,,22229,17221,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624141,,13565,,,22229,6545,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624142,,13566,,,22229,577,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624143,,13567,,,22229,6285,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624144,,13568,,,22229,6500,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624145,,13569,,,22229,6716,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624146,,13570,,,22229,13658,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624147,,13571,,,22229,6549,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (MacLogP),1,,,P,,,0,Autocuration,CHEMBL883123,,13572,,,22229,14685,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL624148,,13573,,,22224,6893,,
,BAO_0000019,,U,,Kinetic parameter was determined,1,,,A,,,0,Autocuration,CHEMBL874416,,13574,,,22224,3687,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624149,,13575,,,22229,4207,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL624150,,13576,,,22229,4626,,
,BAO_0000100,,U,,Lipophilicity was determined,1,,,P,,,0,Autocuration,CHEMBL624151,,13577,,,22224,1021,,
,BAO_0000100,,U,,Lipophilicity was determined,1,,,P,,,0,Autocuration,CHEMBL624152,,13578,,,22224,3777,,
,BAO_0000100,,U,,Lipophilicity was determined,1,,,P,,,0,Autocuration,CHEMBL622139,,13579,,,22224,17533,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL622140,,13580,,,22229,6524,,
,BAO_0000100,,U,,Lipophilicity was determined,1,,,P,,,0,Autocuration,CHEMBL622141,,13581,,,22224,17533,,
,BAO_0000100,,U,,Lipophilicity in octanol-water,1,,,P,,,0,Autocuration,CHEMBL622142,,13582,,,22224,6480,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL622143,,13583,,,22229,17606,,
,BAO_0000100,,U,,Octanol-water partition coefficient was determined,1,,,P,,,0,Autocuration,CHEMBL622144,,13584,,,22229,6863,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL877473,,13585,,,22224,1356,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL622145,,13586,,,22229,3326,,
,BAO_0000019,,U,,Partition coefficient was determined; ND means not determined,1,,,A,,,0,Autocuration,CHEMBL622146,,13587,,,22224,1356,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP),1,,,P,,,0,Autocuration,CHEMBL622147,,13588,,,22229,12984,,
,BAO_0000019,,U,,Partition coefficient of the compound,1,,,A,,,0,Autocuration,CHEMBL622148,,13589,,,22224,17363,,
,BAO_0000019,,U,,Permeability was determined,1,,,A,,,0,Autocuration,CHEMBL883124,,13590,,,22224,6827,,
,BAO_0000100,,U,,The compound was evaluated for the partition coefficient,1,,,P,,,0,Autocuration,CHEMBL622149,,13591,,,22229,261,,
,BAO_0000019,,U,,Partition coefficient (logP),1,,,A,,,0,Autocuration,CHEMBL622150,,13592,,,22224,2685,,
,BAO_0000100,,U,,The lipophilicity was reported,1,,,P,,,0,Autocuration,CHEMBL622151,,13593,,,22224,414,,
,BAO_0000100,,U,,logarithm of the octanol-water partition coefficient for the compound,1,,,P,,,0,Autocuration,CHEMBL622152,,13594,,,22229,15769,,
,BAO_0000019,,U,,Clogp value was determined,1,,,A,,,0,Autocuration,CHEMBL622153,,13595,,,22224,17248,,
,BAO_0000218,,U,,Clp at a dose of 1.5 mg/kg,1,,,A,,,0,Autocuration,CHEMBL877474,,13596,In vivo,,22224,16935,,
,BAO_0000218,,U,,Clp at a dose of 2.0 mg/kg,1,,,A,,,0,Autocuration,CHEMBL622154,,13597,In vivo,,22224,16935,,
Plasma,BAO_0000218,,U,,"Clp, plasma clearance at a dose of 10 mg/kg",1,,,A,,1969.0,0,Autocuration,CHEMBL622155,,13598,In vivo,,22224,14832,,
Plasma,BAO_0000218,,U,,"Clp, plasma clearance at a dose of 50 mg/kg",1,,,A,,1969.0,0,Autocuration,CHEMBL622156,,13599,In vivo,,22224,14832,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622157,,13600,In vivo,,50597,2399,,
Plasma,BAO_0000218,,N,,Compound was tested for plasma clearance in rat; Not determined,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622158,,13601,In vivo,,50597,2399,,
,BAO_0000218,,N,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622807,,13602,In vivo,,50597,6227,,
,BAO_0000218,,N,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL622808,,13603,In vivo,,50797,6227,,
,BAO_0000218,,U,,Plasma clearance by iv administration at a dose 0.003 ug/mL,1,,,A,,,0,Autocuration,CHEMBL622809,,13604,In vivo,,22224,5623,,
,BAO_0000218,,U,,Plasma clearance determined,1,,,A,,,0,Autocuration,CHEMBL622810,,13605,In vivo,,22224,4854,,
,BAO_0000218,,N,,Plasma clearance after iv administration at 3 mg/kg in hamster,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL876653,,13606,In vivo,,100712,4493,,
,BAO_0000218,,N,,Plasma clearance after iv administration at 4 mg/kg in hamster,1,,10026.0,A,Cricetinae,,1,Intermediate,CHEMBL622811,,13607,In vivo,,100712,4493,,
,BAO_0000218,,N,,Rate of clearance in rat was determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622986,,13608,In vivo,,50597,14956,,
Plasma,BAO_0000218,,N,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622987,,13609,In vivo,,50597,15372,,
Plasma,BAO_0000218,,N,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622988,,13610,In vivo,,50597,15372,,
Plasma,BAO_0000218,,N,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622989,,13611,In vivo,,50597,15372,,
Plasma,BAO_0000218,,N,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622990,,13612,In vivo,,50597,15372,,
Plasma,BAO_0000218,,U,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,1,,314293.0,A,Simiiformes,1969.0,0,Autocuration,CHEMBL622991,,13613,In vivo,,22224,15604,,
Plasma,BAO_0000218,,N,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL622227,,13614,In vivo,,50597,15604,,
Plasma,BAO_0000218,,N,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL622228,,13615,In vivo,,50588,15604,,
,BAO_0000218,,N,,Clpl value in rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622229,,13616,In vivo,,50597,14964,,
,BAO_0000218,,N,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,1,,10141.0,A,Cavia porcellus,,1,Intermediate,CHEMBL622230,,13617,In vivo,,50512,15240,,
,BAO_0000218,,N,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL622231,,13618,In vivo,,50597,16449,,
,BAO_0000218,,N,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,1,,9541.0,A,Macaca fascicularis,,1,Intermediate,CHEMBL622232,,13619,In vivo,,100710,16449,,
,BAO_0000218,,U,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622233,,13620,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622234,,13621,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622235,,13622,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622236,,13623,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622237,,13624,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL877482,,13625,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622238,,13626,In vivo,,22224,12902,,
,BAO_0000218,,U,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,1,,,A,,,0,Autocuration,CHEMBL622239,,13627,In vivo,,22224,12902,,
Blood,BAO_0000218,,U,,Cmax was calculated as maximum concentration reached in the blood,1,,,A,,178.0,0,Autocuration,CHEMBL622240,,13628,In vivo,,22224,11149,,
Blood,BAO_0000218,,U,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,1,,,A,,178.0,0,Autocuration,CHEMBL622241,,13629,In vivo,,22224,11149,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 10 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631013,,13630,In vivo,,50597,5669,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 10 mpk in Rhesus,1,,9544.0,A,Macaca mulatta,,1,Intermediate,CHEMBL631014,,13631,In vivo,,50797,5669,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 10 mpk in dog,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631015,,13632,In vivo,,50588,5669,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 160 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631016,,13633,In vivo,,50597,5669,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 20 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631017,,13634,In vivo,,50597,5669,,
,BAO_0000218,,N,,Cmax was determine after peroral administration at 50 mpk in Rat,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631018,,13635,In vivo,,50597,5669,,
,BAO_0000218,,U,,Cmax was determined,1,,,A,,,0,Autocuration,CHEMBL631019,,13636,In vivo,,22224,4236,,
Brain,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL875761,,13637,,,50594,13792,,
Brain,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL631020,,13638,,,50594,13792,,
Brain,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL631669,,13639,,,50594,13792,,
Brain,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL631670,,13640,,,50594,13792,,
Striatum,BAO_0000218,,N,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,1,,10090.0,A,Mus musculus,2435.0,1,Intermediate,CHEMBL631671,,13641,,,50594,13792,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631672,,13642,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631673,,13643,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631856,,13644,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631857,,13645,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631858,,13646,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631859,,13647,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631860,,13648,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631861,,13649,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631862,,13650,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631863,,13651,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631864,,13652,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631865,,13653,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631866,,13654,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629360,,13655,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629361,,13656,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL629362,,13657,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630740,,13658,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630741,,13659,,,50597,8418,,
Blood,BAO_0000218,,N,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630742,,13660,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630743,,13661,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630744,,13662,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630745,,13663,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630746,,13664,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630747,,13665,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630748,,13666,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632056,,13667,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632057,,13668,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632058,,13669,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632059,,13670,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632060,,13671,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632061,,13672,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629207,,13673,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629208,,13674,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629209,,13675,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629210,,13676,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629211,,13677,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629212,,13678,,,50597,8418,,
,BAO_0000218,,N,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629213,,13679,,,50597,8418,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629214,,13680,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629215,,13681,,,50597,8133,,
Urine,BAO_0000218,,N,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL635154,,13682,,,50597,8133,,
,BAO_0000218,,N,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629216,,13683,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629217,,13684,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629218,,13685,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629219,,13686,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629220,,13687,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629221,,13688,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631127,,13689,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631128,,13690,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631129,,13691,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631130,,13692,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631131,,13693,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631132,,13694,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631133,,13695,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631134,,13696,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875120,,13697,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631135,,13698,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631136,,13699,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631137,,13700,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631138,,13701,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631139,,13702,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631140,,13703,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631141,,13704,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631142,,13705,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631143,,13706,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631144,,13707,,,50597,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631145,,13708,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631146,,13709,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631147,,13710,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631148,,13711,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631149,,13712,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631150,,13713,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631151,,13714,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631152,,13715,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631443,,13716,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631444,,13717,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631445,,13718,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631446,,13719,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631447,,13720,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631448,,13721,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631449,,13722,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL631450,,13723,,,50588,6996,,
,BAO_0000218,,N,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629724,,13724,,,50588,6996,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL629725,,13725,In vivo,,50594,9716,,
Zone of skin,BAO_0000218,,N,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,14.0,1,Intermediate,CHEMBL629726,,13726,In vivo,,50594,9716,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL629727,,13727,In vivo,,50594,9716,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL630404,,13728,In vivo,,50594,9716,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL630405,,13729,In vivo,,50594,9716,,
Spleen,BAO_0000218,,N,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL630406,,13730,In vivo,,50594,9716,,
Stomach,BAO_0000218,,N,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL630407,,13731,In vivo,,50594,9716,,
Stomach,BAO_0000218,,N,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL630573,,13732,In vivo,,50594,9716,,
Stomach,BAO_0000218,,N,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL630574,,13733,In vivo,,50594,9716,,
Stomach,BAO_0000218,,N,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL630575,,13734,In vivo,,50594,9716,,
,BAO_0000218,,N,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630576,,13735,In vivo,,50594,9716,,
,BAO_0000218,,N,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630577,,13736,In vivo,,50594,9716,,
,BAO_0000218,,N,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630578,,13737,In vivo,,50594,9716,,
,BAO_0000218,,N,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630579,,13738,In vivo,,50594,9716,,
Kidney,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630580,,13739,,,50594,12192,,
Kidney,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630581,,13740,,,50594,12192,,
Kidney,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630582,,13741,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630583,,13742,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630584,,13743,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630585,,13744,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630586,,13745,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630587,,13746,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630588,,13747,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630589,,13748,,,50594,12192,,
,BAO_0000218,,N,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL630590,,13749,,,50594,12192,,
Feces,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in feces at 24 h,1,,,A,,1988.0,0,Autocuration,CHEMBL630591,,13750,,,22224,12192,,
Feces,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),1,,,A,,1988.0,0,Autocuration,CHEMBL630592,,13751,,,22224,12192,,
,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,1,,,A,,,0,Autocuration,CHEMBL630593,,13752,,,22224,12192,,
,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),1,,,A,,,0,Autocuration,CHEMBL630594,,13753,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630595,,13754,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630596,,13755,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 0-24 h,1,,,A,,1088.0,0,Autocuration,CHEMBL630597,,13756,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630598,,13757,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 0-4 h,1,,,A,,1088.0,0,Autocuration,CHEMBL630599,,13758,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630600,,13759,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 4-24 h,1,,,A,,1088.0,0,Autocuration,CHEMBL630601,,13760,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630602,,13761,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630603,,13762,,,22224,12192,,
Urine,BAO_0000019,,U,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),1,,,A,,1088.0,0,Autocuration,CHEMBL630604,,13763,,,22224,12192,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624869,,13764,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL624870,,13765,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623189,,13766,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623190,,13767,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623191,,13768,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623192,,13769,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623193,,13770,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623194,,13771,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623195,,13772,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623196,,13773,In vivo,,50597,12017,,
,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623197,,13774,,,50597,11836,,
,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623198,,13775,,,50597,11836,,
,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623199,,13776,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623200,,13777,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623201,,13778,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623202,,13779,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623203,,13780,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623204,,13781,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623205,,13782,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623206,,13783,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623207,,13784,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623208,,13785,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623209,,13786,,,50597,11836,,
Muscle tissue,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL623210,,13787,,,50597,11836,,
,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623211,,13788,,,50597,11836,,
Uterus,BAO_0000218,,N,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL623212,,13789,,,50597,11836,,
,BAO_0000019,,U,,Tested in vitro for intrinsic activity relative to quinpirole,1,,,A,,,0,Autocuration,CHEMBL623213,,13790,,,22224,12640,,
,BAO_0000019,,U,,"Relative ion enhancement, determined in pulsed ultrafiltration",1,,,A,,,0,Autocuration,CHEMBL623214,,13791,,,22224,14218,,
,BAO_0000019,,U,,% ionization at the pH 7.4 at 37 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL623215,,13792,,,22224,11296,,
,BAO_0000019,,U,,Percentage ionization was measured,1,,,A,,,0,Autocuration,CHEMBL623216,,13793,,,22224,10929,,
,BAO_0000218,,N,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,1,,9913.0,A,Bos taurus,,1,Intermediate,CHEMBL623217,,13794,,,50591,13841,,
,BAO_0000019,,U,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,1,,,A,,,0,Autocuration,CHEMBL623218,,13795,,,22224,10431,,
,BAO_0000019,,U,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,1,,,A,,,0,Autocuration,CHEMBL623913,,13796,,,22224,10431,,
,BAO_0000019,,U,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,1,,,A,,,0,Autocuration,CHEMBL623914,,13797,,,22224,10431,,
,BAO_0000100,,U,,Compound was evaluated for the partition coefficient in octanol/water,1,,,P,,,0,Autocuration,CHEMBL623915,,13798,,,22229,8826,,
,BAO_0000100,,U,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),1,,,P,,,0,Autocuration,CHEMBL624080,,13799,,,22229,8826,,
,BAO_0000019,,U,,Equilibrium constant measured by the pulse radiolysis at pH 7,1,,,A,,,0,Autocuration,CHEMBL624081,,13800,,,22224,9884,,
,BAO_0000218,,N,,In vitro hydrolytic rate constant determined in human blood,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL624082,,13801,,,50587,9827,,
,BAO_0000218,,N,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL625054,,13802,,,50587,10009,,
,BAO_0000019,,U,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,1,,,A,,,0,Autocuration,CHEMBL877485,,13803,,,22224,10009,,
,BAO_0000218,,N,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625055,,13804,,,50594,10009,,
,BAO_0000218,,N,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625056,,13805,,,50594,10009,,
,BAO_0000218,,N,,In vitro oxidation of compound in presence of human plasma,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL625057,,13806,,,50587,10009,,
,BAO_0000019,,U,,In vitro oxidation of compound in presence of hydrogen peroxide,1,,,A,,,0,Autocuration,CHEMBL625058,,13807,,,22224,10009,,
,BAO_0000218,,N,,In vitro oxidation of compound in presence of mouse brain homogenate,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625059,,13808,,,50594,10009,,
,BAO_0000218,,N,,In vitro oxidation of compound in presence of mouse liver homogenate,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629536,,13809,,,50594,10009,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629537,,13810,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629538,,13811,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629539,,13812,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL874445,,13813,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629540,,13814,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629541,,13815,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629542,,13816,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630243,,13817,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630244,,13818,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630245,,13819,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630246,,13820,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630247,,13821,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630248,,13822,,,50597,11510,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630249,,13823,In vivo,,50597,13100,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630250,,13824,In vivo,,50597,13100,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630251,,13825,In vivo,,50597,13100,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood at 3 hr after dose administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630252,,13826,In vivo,,50597,13100,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL630408,,13827,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630409,,13828,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL874446,,13829,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630410,,13830,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630411,,13831,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630412,,13832,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630413,,13833,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 3 hr after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630414,,13834,In vivo,,50597,13100,,
Cerebellum,BAO_0000218,,N,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL630415,,13835,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630416,,13836,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630417,,13837,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630418,,13838,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630419,,13839,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630420,,13840,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630421,,13841,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 3 hr after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630422,,13842,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat cortex at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630423,,13843,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630424,,13844,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630425,,13845,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL629462,,13846,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630426,,13847,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL630427,,13848,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 3 hr after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625877,,13849,In vivo,,50597,13100,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625878,,13850,In vivo,,50597,13100,,
Hippocampus,BAO_0000218,,N,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625879,,13851,In vivo,,50597,13100,,
Hippocampus,BAO_0000218,,N,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625880,,13852,In vivo,,50597,13100,,
Hippocampus,BAO_0000218,,N,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625881,,13853,In vivo,,50597,13100,,
Hippocampus,BAO_0000218,,N,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625882,,13854,In vivo,,50597,13100,,
Hippocampus,BAO_0000218,,N,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625883,,13855,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625884,,13856,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625885,,13857,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628649,,13858,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628650,,13859,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628651,,13860,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628652,,13861,In vivo,,50597,13100,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL628653,,13862,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628654,,13863,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL628655,,13864,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625238,,13865,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625239,,13866,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625240,,13867,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625241,,13868,In vivo,,50597,13100,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625242,,13869,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL874587,,13870,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625405,,13871,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625406,,13872,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625407,,13873,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625408,,13874,In vivo,,50597,13100,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625409,,13875,In vivo,,50597,13100,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625410,,13876,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625411,,13877,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625412,,13878,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625413,,13879,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625414,,13880,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625415,,13881,,,50597,12361,,
Thoracic aorta,BAO_0000218,,N,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,1,,10116.0,A,Rattus norvegicus,1515.0,1,Intermediate,CHEMBL625416,,13882,,,50597,12361,,
Urine,BAO_0000218,,N,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625417,,13883,,,50597,12712,,
Feces,BAO_0000218,,N,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL625418,,13884,,,50597,7415,,
Urine,BAO_0000218,,N,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625419,,13885,,,50597,7415,,
,BAO_0000218,,N,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625420,,13886,,,50597,7415,,
,BAO_0000218,,N,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626996,,13887,,,50597,7415,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL626997,,13888,,,50597,7415,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626998,,13889,,,50597,7415,,
,BAO_0000218,,N,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626999,,13890,,,50597,7415,,
,BAO_0000218,,N,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627000,,13891,,,50594,8050,,
,BAO_0000218,,N,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627001,,13892,,,50594,8050,,
,BAO_0000218,,N,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627002,,13893,,,50594,8050,,
,BAO_0000218,,N,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627003,,13894,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627004,,13895,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627005,,13896,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL874594,,13897,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627006,,13898,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627007,,13899,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627884,,13900,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627885,,13901,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627886,,13902,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627887,,13903,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627888,,13904,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL628057,,13905,,,50594,8050,,
Urine,BAO_0000218,,N,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627405,,13906,,,50594,8050,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627406,,13907,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627407,,13908,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627408,,13909,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627409,,13910,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL875486,,13911,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627410,,13912,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627411,,13913,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627412,,13914,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627413,,13915,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627414,,13916,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627415,,13917,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627416,,13918,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627417,,13919,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627418,,13920,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627419,,13921,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627320,,13922,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627321,,13923,,,50588,12582,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627322,,13924,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627323,,13925,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627491,,13926,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627492,,13927,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL627493,,13928,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627494,,13929,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627495,,13930,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627496,,13931,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627497,,13932,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL627498,,13933,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627499,,13934,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627500,,13935,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627501,,13936,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625616,,13937,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625617,,13938,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625618,,13939,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625619,,13940,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625620,,13941,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625621,,13942,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625622,,13943,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625788,,13944,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625789,,13945,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625790,,13946,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625791,,13947,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL622334,,13948,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622335,,13949,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622336,,13950,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622337,,13951,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622338,,13952,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL622339,,13953,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL624153,,13954,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628430,,13955,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628431,,13956,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628432,,13957,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628433,,13958,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL628434,,13959,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL626789,,13960,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL626790,,13961,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL626791,,13962,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL626792,,13963,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL626793,,13964,In vivo,,50597,12017,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627436,,13965,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627437,,13966,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627438,,13967,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627439,,13968,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627440,,13969,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627602,,13970,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627603,,13971,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627604,,13972,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627605,,13973,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627606,,13974,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627607,,13975,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627608,,13976,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627609,,13977,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627610,,13978,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627611,,13979,,,50597,11510,,
,BAO_0000218,,N,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627612,,13980,,,50597,11510,,
,BAO_0000100,,U,,Octanol:water partition coefficient is evaluated,1,,,P,,,0,Autocuration,CHEMBL627613,,13981,,,22229,8362,,
,BAO_0000100,,U,,Partition coefficient in 1-octanol/water system,1,,,P,,,0,Autocuration,CHEMBL627614,,13982,,,22224,8257,,
,BAO_0000100,,U,,Partition coefficient in 1-octanol/water system measured using radio active compounds,1,,,P,,,0,Autocuration,CHEMBL627615,,13983,,,22224,8257,,
,BAO_0000100,,U,,Partition coefficient in octanol/water system was determined,1,,,P,,,0,Autocuration,CHEMBL627616,,13984,,,22224,9468,,
,BAO_0000100,,U,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,1,,,P,,,0,Autocuration,CHEMBL627617,,13985,,,22224,9468,,
,BAO_0000019,,U,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,1,,,A,,,0,Autocuration,CHEMBL627618,,13986,,,22224,10568,,
,BAO_0000019,,U,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",1,,,A,,,0,Autocuration,CHEMBL627619,,13987,,,22224,10568,,
,BAO_0000019,,U,,Pseudo-first-order rate constant of the compound,1,,,A,,,0,Autocuration,CHEMBL627620,,13988,,,22224,15359,,
,BAO_0000019,,U,,Pseudo-first-order rate constant with 1-min time point,1,,,A,,,0,Autocuration,CHEMBL627621,,13989,,,22224,15359,,
,BAO_0000019,,U,,Pseudo-first-order rate constant without 1-min time point,1,,,A,,,0,Autocuration,CHEMBL627622,,13990,,,22224,15359,,
,BAO_0000019,,U,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,1,,,A,,,0,Autocuration,CHEMBL627623,,13991,,,22224,10431,,
,BAO_0000019,,U,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,1,,,A,,,0,Autocuration,CHEMBL627624,,13992,,,22224,10431,,
,BAO_0000019,,U,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,1,,,A,,,0,Autocuration,CHEMBL627625,,13993,,,22224,10431,,
,BAO_0000019,,U,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,1,,,A,,,0,Autocuration,CHEMBL628523,,13994,,,22224,15704,,
,BAO_0000019,,U,,The alkaline hydrolysis second order rate constant(K OH) of the compound,1,,,A,,,0,Autocuration,CHEMBL628524,,13995,,,22224,15287,,
,BAO_0000019,,U,,The efflux rate constant of the compound,1,,,A,,,0,Autocuration,CHEMBL628525,,13996,,,22224,7516,,
,BAO_0000019,,U,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,,,A,,,0,Autocuration,CHEMBL625732,,13997,,,22224,12973,,
,BAO_0000019,,U,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,,,A,,,0,Autocuration,CHEMBL625733,,13998,,,22224,12973,,
,BAO_0000019,,U,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,1,,,F,,,0,Autocuration,CHEMBL625734,,13999,,,22224,12973,,
,BAO_0000019,,U,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,1,,,A,,,0,Autocuration,CHEMBL625913,,14000,,,22224,12973,,
,BAO_0000019,,U,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,1,,,A,,,0,Autocuration,CHEMBL625914,,14001,,,22224,8696,,
,BAO_0000019,,U,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,1,,,A,,,0,Autocuration,CHEMBL625915,,14002,,,22224,15052,,
,BAO_0000019,,U,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,1,,,A,,,0,Autocuration,CHEMBL625916,,14003,,,22224,15052,,
,BAO_0000019,,U,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),1,,,A,,,0,Autocuration,CHEMBL625917,,14004,,,22224,10503,,
,BAO_0000019,,U,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625918,,14005,,,22224,8354,,
,BAO_0000019,,U,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625919,,14006,,,22224,8354,,
,BAO_0000019,,U,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625920,,14007,,,22224,8354,,
,BAO_0000019,,U,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL874453,,14008,,,22224,8354,,
,BAO_0000019,,U,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625921,,14009,,,22224,8354,,
,BAO_0000019,,U,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,1,,,A,,,0,Autocuration,CHEMBL625922,,14010,,,22224,10503,,
,BAO_0000019,,U,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625923,,14011,,,22224,8354,,
,BAO_0000019,,U,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625924,,14012,,,22224,8354,,
,BAO_0000019,,U,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625925,,14013,,,22224,8354,,
,BAO_0000019,,U,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL625926,,14014,,,22224,8354,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL627704,,14015,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627705,,14016,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627706,,14017,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627707,,14018,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627708,,14019,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628361,,14020,In vivo,,50597,13100,,
,BAO_0000218,,N,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628362,,14021,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628363,,14022,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628364,,14023,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628365,,14024,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL874454,,14025,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628531,,14026,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628532,,14027,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 3 hr after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628533,,14028,In vivo,,50597,13100,,
Striatum,BAO_0000218,,N,,Biodistribution in rat striatum at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2435.0,1,Intermediate,CHEMBL628534,,14029,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628535,,14030,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628536,,14031,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628537,,14032,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628538,,14033,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL628539,,14034,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630297,,14035,In vivo,,50597,13100,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in rat thyroid at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL630298,,14036,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL630299,,14037,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL628094,,14038,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL628095,,14039,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL874648,,14040,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL628096,,14041,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL628097,,14042,In vivo,,50597,13100,,
Brain,BAO_0000218,,N,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL628098,,14043,In vivo,,50597,13100,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",1,,,A,,,0,Autocuration,CHEMBL628099,,14044,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",1,,,A,,,0,Autocuration,CHEMBL628100,,14045,,,22224,13331,,
,BAO_0000019,,U,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),1,,,A,,,0,Autocuration,CHEMBL628101,,14046,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",1,,,A,,,0,Autocuration,CHEMBL628102,,14047,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",1,,,A,,,0,Autocuration,CHEMBL628103,,14048,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",1,,,A,,,0,Autocuration,CHEMBL628104,,14049,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",1,,,A,,,0,Autocuration,CHEMBL628105,,14050,,,22224,13331,,
,BAO_0000019,,U,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",1,,,A,,,0,Autocuration,CHEMBL628106,,14051,,,22224,13331,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628107,,14052,,,50597,10086,,
Urine,BAO_0000218,,U,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,1,,,F,,1088.0,0,Autocuration,CHEMBL628108,,14053,,,22224,10086,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628109,,14054,,,50597,10086,,
Urine,BAO_0000218,,U,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,1,,,F,,1088.0,0,Autocuration,CHEMBL625299,,14055,,,22224,10086,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625300,,14056,,,50597,10086,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625301,,14057,,,50597,10086,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625302,,14058,,,50597,10086,,
Urine,BAO_0000218,,N,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL874649,,14059,,,50597,10086,,
,BAO_0000218,,N,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625303,,14060,,,50597,13248,,
,BAO_0000218,,N,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625463,,14061,,,50597,13248,,
Liver,BAO_0000218,,N,,In vitro metabolism in human liver microsomes,1,,9606.0,A,Homo sapiens,2107.0,1,Intermediate,CHEMBL625464,,14062,,,50587,14527,,
,BAO_0000218,,N,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL625465,,14063,,,50587,3008,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625466,,14064,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625467,,14065,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625468,,14066,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625469,,14067,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625470,,14068,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL632418,,14069,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627250,,14070,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627251,,14071,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627252,,14072,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627253,,14073,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627254,,14074,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875471,,14075,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627255,,14076,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627256,,14077,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627257,,14078,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627258,,14079,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627259,,14080,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627260,,14081,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623256,,14082,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL874413,,14083,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623257,,14084,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623258,,14085,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623259,,14086,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623260,,14087,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623261,,14088,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623262,,14089,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623263,,14090,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623264,,14091,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623265,,14092,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623266,,14093,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623267,,14094,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623268,,14095,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623269,,14096,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623270,,14097,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623271,,14098,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623272,,14099,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623273,,14100,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623274,,14101,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL874414,,14102,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623275,,14103,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629150,,14104,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623276,,14105,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623277,,14106,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623112,,14107,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623113,,14108,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623800,,14109,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623801,,14110,,,50597,12582,,
Spleen,BAO_0000218,,N,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL623802,,14111,In vivo,,50597,12017,,
Uterus,BAO_0000218,,N,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL623803,,14112,In vivo,,50597,12017,,
Uterus,BAO_0000218,,N,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL623970,,14113,In vivo,,50597,12017,,
Uterus,BAO_0000218,,N,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,995.0,1,Intermediate,CHEMBL623971,,14114,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623972,,14115,In vivo,,50597,14045,,
Blood,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623973,,14116,In vivo,,50597,14045,,
Blood,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623974,,14117,In vivo,,50597,14045,,
Blood,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL623975,,14118,In vivo,,50597,14045,,
Brain,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623976,,14119,In vivo,,50597,14045,,
Brain,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623977,,14120,In vivo,,50597,14045,,
Brain,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623978,,14121,In vivo,,50597,14045,,
Brain,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL623979,,14122,In vivo,,50597,14045,,
,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623980,,14123,In vivo,,50597,14045,,
,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL623981,,14124,In vivo,,50597,14045,,
,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626278,,14125,In vivo,,50597,14045,,
,BAO_0000218,,N,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626279,,14126,In vivo,,50597,14045,,
,BAO_0000218,,N,,Biodistribution in mice bladder plus excreted urine was determined,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626280,,14127,In vivo,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse blood, 10 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626281,,14128,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse blood, 30 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626282,,14129,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse blood, 5 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626283,,14130,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse blood, 60 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626284,,14131,,,50594,14045,,
Brain,BAO_0000218,,N,,"Percentage biodistribution in mouse brain, 10 minutes post injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL626285,,14132,,,50594,14045,,
Brain,BAO_0000218,,N,,"Percentage biodistribution in mouse brain, 30 minutes post injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL626286,,14133,,,50594,14045,,
Brain,BAO_0000218,,N,,"Percentage biodistribution in mouse brain, 5 minutes post injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL626287,,14134,,,50594,14045,,
Brain,BAO_0000218,,N,,"Percentage biodistribution in mouse brain, 60 minutes post injection",1,,10090.0,A,Mus musculus,955.0,1,Intermediate,CHEMBL626288,,14135,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse heart, 10 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626289,,14136,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse heart, 30 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626290,,14137,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse heart, 5 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL626291,,14138,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse heart, 60 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL839888,,14139,,,50594,14045,,
Intestine,BAO_0000218,,N,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL626292,,14140,,,50594,14045,,
Intestine,BAO_0000218,,N,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL626293,,14141,,,50594,14045,,
Intestine,BAO_0000218,,N,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL626294,,14142,,,50594,14045,,
Intestine,BAO_0000218,,N,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",1,,10090.0,A,Mus musculus,160.0,1,Intermediate,CHEMBL626295,,14143,,,50594,14045,,
Liver,BAO_0000218,,N,,"Percentage biodistribution in mouse liver, 10 minutes post injection",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627659,,14144,,,50594,14045,,
Liver,BAO_0000218,,N,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627660,,14145,,,50594,14045,,
Liver,BAO_0000218,,N,,"Percentage biodistribution in mouse liver, 5 minutes post injection",1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627661,,14146,,,50594,14045,,
Liver,BAO_0000218,,N,,Biodistribution in mice liver at 60 minutes of post injection,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL627662,,14147,In vivo,,50594,14045,,
Lung,BAO_0000218,,N,,Biodistribution in mice lungs at 10 min of post injection,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL627663,,14148,In vivo,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mouse lung, 30 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627664,,14149,,,50594,14045,,
,BAO_0000218,,N,,"Percentage biodistribution in mousee lung, 5 minutes post injection",1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL627665,,14150,,,50594,14045,,
Lung,BAO_0000218,,N,,Biodistribution in mice lungs at 60 min of post injection,1,,10090.0,A,Mus musculus,2048.0,1,Intermediate,CHEMBL627666,,14151,In vivo,,50594,14045,,
Spleen,BAO_0000218,,N,,Percentage biodistribution in mouse spleen,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL627667,,14152,,,50594,14045,,
Stomach,BAO_0000218,,N,,Percentage biodistribution in mouse stomach,1,,10090.0,A,Mus musculus,945.0,1,Intermediate,CHEMBL627668,,14153,,,50594,14045,,
Urine,BAO_0000218,,N,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,1,,10090.0,A,Mus musculus,1088.0,1,Intermediate,CHEMBL627669,,14154,,,50594,11745,,
Urinary bladder,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,1,,,A,,1255.0,0,Autocuration,CHEMBL627670,,14155,In vivo,,22224,13257,,
Blood,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,1,,,A,,178.0,0,Autocuration,CHEMBL627671,,14156,In vivo,,22224,13257,,
Bone element,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,1,,,A,,1474.0,0,Autocuration,CHEMBL627672,,14157,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,1,,,A,,,0,Autocuration,CHEMBL627673,,14158,In vivo,,22224,13257,,
Kidney,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,1,,,A,,2113.0,0,Autocuration,CHEMBL627674,,14159,In vivo,,22224,13257,,
Liver,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,1,,,A,,2107.0,0,Autocuration,CHEMBL627675,,14160,In vivo,,22224,13257,,
Lung,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,1,,,A,,2048.0,0,Autocuration,CHEMBL627676,,14161,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627677,,14162,In vivo,,22224,13257,,
,BAO_0000019,,U,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL627678,,14163,,,22224,8354,,
Serum,BAO_0000218,,N,,Affinity for protein binding expressed as association constant in fresh rat serum,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL627679,,14164,,,50597,7095,,
,BAO_0000019,,U,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,1,,,A,,,0,Autocuration,CHEMBL627680,,14165,,,22224,12185,,
,BAO_0000019,,U,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,1,,,A,,,0,Autocuration,CHEMBL627681,,14166,,,22224,12185,,
,BAO_0000019,,U,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,1,,,A,,,0,Autocuration,CHEMBL627682,,14167,,,22224,12185,,
,BAO_0000019,,U,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,1,,,A,,,0,Autocuration,CHEMBL627683,,14168,,,22224,12185,,
,BAO_0000019,,U,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,1,,,A,,,0,Autocuration,CHEMBL627684,,14169,,,22224,12686,,
,BAO_0000019,,U,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",1,,,A,,,0,Autocuration,CHEMBL874441,,14170,,,22224,12686,,
,BAO_0000019,,U,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,1,,,A,,,0,Autocuration,CHEMBL627685,,14171,,,22224,12686,,
,BAO_0000019,,U,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",1,,,A,,,0,Autocuration,CHEMBL627686,,14172,,,22224,12686,,
,BAO_0000019,,U,,Apparent rate constant Koff for inactivation of dTMP synthase.,1,,,A,,,0,Autocuration,CHEMBL627687,,14173,,,22224,8057,,
,BAO_0000019,,U,,The irreversible inhibitor activity by second order rate equation.,1,,,A,,,0,Autocuration,CHEMBL627688,,14174,,,22224,15778,,
,BAO_0000218,,N,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628038,,14175,,,50597,12375,,
,BAO_0000218,,N,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628039,,14176,,,50597,12375,,
,BAO_0000218,,N,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628040,,14177,,,50597,12375,,
,BAO_0000019,,U,,Dissociation rate calculated from the first-order equation using t1/2 value,1,,,A,,,0,Autocuration,CHEMBL628041,,14178,,,22224,13588,,
,BAO_0000019,,U,,The compound was tested for Binding constant against DNA,1,,,A,,,0,Autocuration,CHEMBL630226,,14179,,,22224,15039,,
,BAO_0000019,,U,,First order rate constant for cyclization of the compound,1,,,A,,,0,Autocuration,CHEMBL628042,,14180,,,22224,9500,,
,BAO_0000019,,U,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,1,,,A,,,0,Autocuration,CHEMBL625232,,14181,,,22224,10014,,
,BAO_0000019,,U,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,1,,,A,,,0,Autocuration,CHEMBL625233,,14182,,,22224,10014,,
,BAO_0000019,,U,,Hydrolysis rate constant was determined,1,,,A,,,0,Autocuration,CHEMBL625979,,14183,,,22224,568,,
,BAO_0000019,,U,,Observed first order rate constant,1,,,A,,,0,Autocuration,CHEMBL625980,,14184,,,22224,10026,,
,BAO_0000019,,U,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,,,A,,,0,Autocuration,CHEMBL625981,,14185,,,22224,10281,,
,BAO_0000019,,U,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,,,A,,,0,Autocuration,CHEMBL625982,,14186,,,22224,10281,,
,BAO_0000019,,U,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL625983,,14187,,,22224,9680,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625984,,14188,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625985,,14189,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625986,,14190,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625987,,14191,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625988,,14192,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625989,,14193,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625990,,14194,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625991,,14195,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625992,,14196,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL625993,,14197,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL631973,,14198,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632143,,14199,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632144,,14200,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632145,,14201,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632146,,14202,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632147,,14203,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632148,,14204,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632149,,14205,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632150,,14206,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL632151,,14207,,,22224,13028,,
,BAO_0000218,,N,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL632152,,14208,,,50587,3008,,
,BAO_0000218,,N,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL632153,,14209,,,50587,4509,,
,BAO_0000218,,N,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL632154,,14210,,,50587,4509,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632155,,14211,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632156,,14212,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632157,,14213,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632158,,14214,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL632159,,14215,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626305,,14216,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626306,,14217,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626307,,14218,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626308,,14219,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626479,,14220,,,50602,8613,,
,BAO_0000218,,N,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,1,,10298.0,A,Human herpesvirus 1,,1,Intermediate,CHEMBL626480,,14221,,,50602,8613,,
,BAO_0000100,,U,,Calculated partition coefficient (clogP) (MlogP),1,,,P,,,0,Autocuration,CHEMBL626481,,14222,,,22229,6021,,
,BAO_0000019,,U,,Equipotent potent ratio relative to carbachol (nicotinic activity),1,,,A,,,0,Autocuration,CHEMBL626482,,14223,,,22224,9348,,
,BAO_0000218,,N,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626483,,14224,,,50588,15592,,
,BAO_0000218,,N,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL626484,,14225,,,50588,15592,,
,BAO_0000100,,U,,Solubility at pH 7.4 in micro g/mL;NA denotes available,1,,,P,,,0,Autocuration,CHEMBL626485,,14226,,,22229,15592,,
,BAO_0000100,,U,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,1,,,P,,,0,Autocuration,CHEMBL626486,,14227,,,22229,15592,,
,BAO_0000100,,U,,Solubility at pH 7.4 in ug/mL;NA denotes not available,1,,,P,,,0,Autocuration,CHEMBL626487,,14228,,,22229,15592,,
Plasma,BAO_0000218,,N,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,1,,9615.0,A,Canis lupus familiaris,1969.0,1,Intermediate,CHEMBL626488,,14229,In vivo,,50588,15592,,
Serum,BAO_0000218,,N,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,1,,10116.0,A,Rattus norvegicus,1977.0,1,Intermediate,CHEMBL626489,,14230,,,50597,7095,,
,BAO_0000019,,U,,Area under the MAP curve measured over 5 min; ND means Not determined,1,,,A,,,0,Autocuration,CHEMBL626490,,14231,,,22224,16618,,
,BAO_0000100,,U,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,1,,,P,,,0,Autocuration,CHEMBL626491,,14232,,,22224,16835,,
,BAO_0000100,,U,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,1,,,P,,,0,Autocuration,CHEMBL626492,,14233,,,22229,15284,,
,BAO_0000019,,U,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,1,,,A,,,0,Autocuration,CHEMBL626493,,14234,,,22224,15750,,
,BAO_0000218,,N,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626494,,14235,In vivo,,50597,16618,,
,BAO_0000218,,U,,Half life after oral tested,1,,,A,,,0,Autocuration,CHEMBL626495,,14236,In vivo,,22224,16618,,
Plasma,BAO_0000218,,N,,Half life was determined in plasma of rat; NT indicates not tested,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626496,,14237,,,50597,15812,,
,BAO_0000218,,N,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626497,,14238,In vivo,,50597,16618,,
,BAO_0000218,,U,,Oral bioavailability after oral tested,1,,,A,,,0,Autocuration,CHEMBL626498,,14239,In vivo,,22224,16618,,
,BAO_0000218,,N,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626499,,14240,,,50597,13098,,
,BAO_0000218,,N,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626500,,14241,,,50597,13098,,
Plasma,BAO_0000218,,N,,half life was determined in plasma of rat; NT indicates not tested,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626501,,14242,,,50597,15812,,
Plasma,BAO_0000218,,N,,half life was determined in plasma of rat; NT means not tested,1,,10116.0,A,Rattus norvegicus,1969.0,1,Intermediate,CHEMBL626502,,14243,,,50597,15812,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626503,,14244,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626504,,14245,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626505,,14246,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626506,,14247,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626507,,14248,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626508,,14249,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626509,,14250,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875480,,14251,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626510,,14252,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626511,,14253,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL626512,,14254,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628208,,14255,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628209,,14256,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628210,,14257,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628211,,14258,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628212,,14259,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628213,,14260,,,50597,11510,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628214,,14261,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628215,,14262,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628216,,14263,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626595,,14264,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626596,,14265,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626597,,14266,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626598,,14267,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622242,,14268,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622243,,14269,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622244,,14270,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622245,,14271,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622246,,14272,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622247,,14273,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622248,,14274,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL877483,,14275,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL622249,,14276,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622250,,14277,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622251,,14278,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622252,,14279,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622253,,14280,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622254,,14281,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622255,,14282,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622256,,14283,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622257,,14284,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622258,,14285,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622259,,14286,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622927,,14287,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622928,,14288,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL622929,,14289,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL623182,,14290,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL623183,,14291,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623184,,14292,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623185,,14293,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL877484,,14294,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL627274,,14295,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623186,,14296,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623187,,14297,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL623188,,14298,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628055,,14299,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628056,,14300,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628200,,14301,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628201,,14302,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628202,,14303,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628203,,14304,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628204,,14305,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628205,,14306,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628206,,14307,,,50597,12582,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),1,,,A,,2367.0,0,Autocuration,CHEMBL628207,,14308,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,1,,,A,,2367.0,0,Autocuration,CHEMBL627220,,14309,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627221,,14310,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),1,,,A,,2367.0,0,Autocuration,CHEMBL627222,,14311,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,1,,,A,,,0,Autocuration,CHEMBL627223,,14312,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL632062,,14313,In vivo,,22224,13257,,
Spleen,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,1,,,A,,2106.0,0,Autocuration,CHEMBL632063,,14314,In vivo,,22224,13257,,
Urinary bladder,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,1,,,A,,1255.0,0,Autocuration,CHEMBL632064,,14315,In vivo,,22224,13257,,
Blood,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,1,,,A,,178.0,0,Autocuration,CHEMBL632065,,14316,In vivo,,22224,13257,,
Bone element,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,1,,,A,,1474.0,0,Autocuration,CHEMBL632066,,14317,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,1,,,A,,,0,Autocuration,CHEMBL632067,,14318,In vivo,,22224,13257,,
Kidney,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,1,,,A,,2113.0,0,Autocuration,CHEMBL629188,,14319,In vivo,,22224,13257,,
Liver,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,1,,,A,,2107.0,0,Autocuration,CHEMBL629189,,14320,In vivo,,22224,13257,,
Lung,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,1,,,A,,2048.0,0,Autocuration,CHEMBL629190,,14321,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629191,,14322,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),1,,,A,,2367.0,0,Autocuration,CHEMBL629192,,14323,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629193,,14324,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),1,,,A,,2367.0,0,Autocuration,CHEMBL629194,,14325,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,1,,,A,,,0,Autocuration,CHEMBL629195,,14326,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629373,,14327,In vivo,,22224,13257,,
Spleen,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,1,,,A,,2106.0,0,Autocuration,CHEMBL629374,,14328,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,1,,,A,,2367.0,0,Autocuration,CHEMBL629375,,14329,In vivo,,22224,13257,,
Urinary bladder,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,1,,,A,,1255.0,0,Autocuration,CHEMBL629376,,14330,In vivo,,22224,13257,,
Blood,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,1,,,A,,178.0,0,Autocuration,CHEMBL629377,,14331,In vivo,,22224,13257,,
Bone element,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,1,,,A,,1474.0,0,Autocuration,CHEMBL629378,,14332,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,1,,,A,,,0,Autocuration,CHEMBL629379,,14333,In vivo,,22224,13257,,
Kidney,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,1,,,A,,2113.0,0,Autocuration,CHEMBL629151,,14334,In vivo,,22224,13257,,
Liver,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,1,,,A,,2107.0,0,Autocuration,CHEMBL629152,,14335,In vivo,,22224,13257,,
Lung,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,1,,,A,,2048.0,0,Autocuration,CHEMBL629153,,14336,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629154,,14337,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),1,,,A,,2367.0,0,Autocuration,CHEMBL629155,,14338,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,1,,,A,,2367.0,0,Autocuration,CHEMBL629156,,14339,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629157,,14340,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),1,,,A,,2367.0,0,Autocuration,CHEMBL629158,,14341,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,1,,,A,,,0,Autocuration,CHEMBL629159,,14342,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629160,,14343,In vivo,,22224,13257,,
Spleen,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,1,,,A,,2106.0,0,Autocuration,CHEMBL629161,,14344,In vivo,,22224,13257,,
Urinary bladder,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,1,,,A,,1255.0,0,Autocuration,CHEMBL629162,,14345,In vivo,,22224,13257,,
Blood,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,1,,,A,,178.0,0,Autocuration,CHEMBL629163,,14346,In vivo,,22224,13257,,
Bone element,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,1,,,A,,1474.0,0,Autocuration,CHEMBL629164,,14347,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,1,,,A,,,0,Autocuration,CHEMBL629165,,14348,In vivo,,22224,13257,,
Liver,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,1,,,A,,2107.0,0,Autocuration,CHEMBL629166,,14349,In vivo,,22224,13257,,
Lung,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,1,,,A,,2048.0,0,Autocuration,CHEMBL629167,,14350,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL629168,,14351,In vivo,,22224,13257,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,1,,,A,,,0,Autocuration,CHEMBL629169,,14352,,,22224,2193,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,1,,,A,,,0,Autocuration,CHEMBL629170,,14353,,,22224,2193,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,1,,,A,,,0,Autocuration,CHEMBL631153,,14354,,,22224,2193,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,1,,,A,,,0,Autocuration,CHEMBL875121,,14355,,,22224,2193,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,1,,,A,,,0,Autocuration,CHEMBL631154,,14356,,,22224,2193,,
,BAO_0000019,,U,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,1,,,A,,,0,Autocuration,CHEMBL631155,,14357,,,22224,2193,,
,BAO_0000019,,U,,Hydrolysis rate constant was determined,1,,,A,,,0,Autocuration,CHEMBL631156,,14358,,,22224,568,,
,BAO_0000019,,U,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL631157,,14359,,,22224,9680,,
,BAO_0000019,,U,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL631158,,14360,,,22224,9680,,
,BAO_0000019,,U,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL631159,,14361,,,22224,9680,,
,BAO_0000019,,U,,Observed second order rate constant,1,,,A,,,0,Autocuration,CHEMBL631160,,14362,,,22224,10026,,
,BAO_0000019,,U,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,1,,,A,,,0,Autocuration,CHEMBL631161,,14363,,,22224,10281,,
,BAO_0000019,,U,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,1,,,A,,,0,Autocuration,CHEMBL631162,,14364,,,22224,10014,,
,BAO_0000019,,U,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,1,,,A,,,0,Autocuration,CHEMBL630313,,14365,,,22224,10014,,
,BAO_0000019,,U,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL630314,,14366,,,22224,9680,,
,BAO_0000019,,U,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL630315,,14367,,,22224,9680,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630316,,14368,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630986,,14369,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630987,,14370,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630988,,14371,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630989,,14372,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630990,,14373,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630991,,14374,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630992,,14375,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630993,,14376,,,22224,13028,,
,BAO_0000019,,U,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,1,,,A,,,0,Autocuration,CHEMBL630994,,14377,,,22224,13028,,
,BAO_0000218,,N,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630995,,14378,,,50597,10014,,
,BAO_0000019,,U,,Association constant for compound at 31 degree C was determined,1,,,A,,,0,Autocuration,CHEMBL629252,,14379,,,22224,9962,,
,BAO_0000019,,U,,Calculated antagonist equilibrium dissociation constant of the compound,1,,,A,,,0,Autocuration,CHEMBL629253,,14380,,,22224,12029,,
,BAO_0000019,,U,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,1,,,A,,,0,Autocuration,CHEMBL629944,,14381,,,22224,12029,,
Trachea,BAO_0000218,,N,,Dissociation constants vs LTE4 on guinea pig trachea,1,,10141.0,A,Cavia porcellus,3126.0,1,Intermediate,CHEMBL629945,,14382,,,50512,10583,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",1,,,A,,,0,Autocuration,CHEMBL629946,,14383,,,22224,568,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",1,,,A,,,0,Autocuration,CHEMBL629947,,14384,,,22224,568,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",1,,,A,,,0,Autocuration,CHEMBL629948,,14385,,,22224,568,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",1,,,A,,,0,Autocuration,CHEMBL856024,,14386,,,22224,568,,
,BAO_0000019,,U,,Affinity constant KD value was derived from TMP,1,,,A,,,0,Autocuration,CHEMBL629949,,14387,,,22224,7493,,
,BAO_0000019,,U,,Apparent dissociation (binding) rate constant was evaluated,1,,,A,,,0,Autocuration,CHEMBL629950,,14388,,,22224,8371,,
,BAO_0000100,,U,,Dissociation constant (KD) of the compound,1,,,P,,,0,Autocuration,CHEMBL630127,,14389,,,22224,13114,,
,BAO_0000100,,U,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,1,,,P,,,0,Autocuration,CHEMBL630128,,14390,,,22224,15515,,
,BAO_0000100,,U,,Dissociation constant from ESR titration experiments,1,,,P,,,0,Autocuration,CHEMBL630129,,14391,,,22224,522,,
,BAO_0000019,,U,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),1,,,,,,0,Autocuration,CHEMBL630130,,14392,,,22224,13888,,
,BAO_0000100,,U,,Dissociation constant was evaluated.,1,,,P,,,0,Autocuration,CHEMBL875234,,14393,,,22224,2616,,
,BAO_0000100,,U,,Dissociation constant was reported,1,,,P,,,0,Autocuration,CHEMBL630131,,14394,,,22224,3798,,
,BAO_0000218,,N,,Dissociation constant was determined in rat pituitary cells.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630132,,14395,,,50597,8731,,
,BAO_0000019,,U,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,1,,,A,,,0,Autocuration,CHEMBL630133,,14396,,,22224,11892,,
,BAO_0000019,,U,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,1,,,A,,,0,Autocuration,CHEMBL630134,,14397,,,22224,11892,,
,BAO_0000019,,U,,Equilibrium dissociation constant of the compound,1,,,A,,,0,Autocuration,CHEMBL630135,,14398,,,22224,2582,,
,BAO_0000019,,U,,Equilibrium dissociation constant was determined,1,,,A,,,0,Autocuration,CHEMBL630136,,14399,,,22224,11892,,
,BAO_0000019,,U,,Kinetic constant KD was evaluated,1,,,A,,,0,Autocuration,CHEMBL630137,,14400,,,22224,13396,,
,BAO_0000019,,U,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,1,,,A,,,0,Autocuration,CHEMBL630138,,14401,,,22224,603,,
,BAO_0000019,,U,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,1,,,A,,,0,Autocuration,CHEMBL630139,,14402,,,22224,15673,,
,BAO_0000019,,U,,Rate constant for hydrolysis in aqueous acetone.,1,,,A,,,0,Autocuration,CHEMBL630140,,14403,,,22224,10368,,
,BAO_0000019,,U,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,1,,,A,,,0,Autocuration,CHEMBL875235,,14404,,,22224,14228,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876439,,14405,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630605,,14406,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630606,,14407,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630607,,14408,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630608,,14409,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630609,,14410,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630610,,14411,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630611,,14412,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629552,,14413,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629733,,14414,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629734,,14415,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629735,,14416,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629736,,14417,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629737,,14418,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629738,,14419,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629739,,14420,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629740,,14421,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629741,,14422,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629742,,14423,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629743,,14424,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629744,,14425,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629745,,14426,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629746,,14427,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629747,,14428,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629748,,14429,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629749,,14430,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629750,,14431,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629751,,14432,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629752,,14433,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629753,,14434,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629754,,14435,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629755,,14436,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629756,,14437,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629757,,14438,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629758,,14439,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629759,,14440,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL629760,,14441,,,50597,11510,,
,BAO_0000218,,N,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876443,,14442,,,50597,11510,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629761,,14443,,,50588,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629762,,14444,,,50588,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629763,,14445,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629764,,14446,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629765,,14447,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629766,,14448,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629767,,14449,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629768,,14450,,,50588,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629769,,14451,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629770,,14452,,,50588,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,1,,9615.0,A,Canis lupus familiaris,,1,Intermediate,CHEMBL629771,,14453,,,50588,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629772,,14454,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL629773,,14455,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625455,,14456,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625456,,14457,,,50594,8310,,
,BAO_0000218,,N,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL625457,,14458,,,50594,8310,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625458,,14459,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625459,,14460,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875483,,14461,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL634779,,14462,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625460,,14463,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626117,,14464,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626118,,14465,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628342,,14466,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628343,,14467,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628344,,14468,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628345,,14469,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628346,,14470,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628347,,14471,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628348,,14472,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628349,,14473,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875611,,14474,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628350,,14475,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628351,,14476,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628352,,14477,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628353,,14478,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628354,,14479,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626667,,14480,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626668,,14481,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626669,,14482,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626670,,14483,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626671,,14484,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626672,,14485,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626673,,14486,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626674,,14487,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626675,,14488,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626676,,14489,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626677,,14490,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626678,,14491,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626679,,14492,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875612,,14493,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626680,,14494,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626681,,14495,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626682,,14496,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626683,,14497,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626684,,14498,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626685,,14499,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626686,,14500,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626687,,14501,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624978,,14502,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624979,,14503,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624980,,14504,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL624981,,14505,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL624982,,14506,,,50588,12582,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),1,,,A,,2367.0,0,Autocuration,CHEMBL627564,,14507,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),1,,,A,,2367.0,0,Autocuration,CHEMBL627565,,14508,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,1,,,A,,,0,Autocuration,CHEMBL627566,,14509,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627567,,14510,In vivo,,22224,13257,,
Spleen,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,1,,,A,,2106.0,0,Autocuration,CHEMBL627568,,14511,In vivo,,22224,13257,,
Kidney,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,1,,,A,,2113.0,0,Autocuration,CHEMBL627569,,14512,In vivo,,22224,13257,,
Urinary bladder,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,1,,,A,,1255.0,0,Autocuration,CHEMBL627570,,14513,In vivo,,22224,13257,,
Blood,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,1,,,A,,178.0,0,Autocuration,CHEMBL627571,,14514,In vivo,,22224,13257,,
Bone element,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,1,,,A,,1474.0,0,Autocuration,CHEMBL627572,,14515,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,1,,,A,,,0,Autocuration,CHEMBL627573,,14516,In vivo,,22224,13257,,
Kidney,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,1,,,A,,2113.0,0,Autocuration,CHEMBL627574,,14517,In vivo,,22224,13257,,
Liver,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,1,,,A,,2107.0,0,Autocuration,CHEMBL627575,,14518,In vivo,,22224,13257,,
Lung,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,1,,,A,,2048.0,0,Autocuration,CHEMBL627576,,14519,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627577,,14520,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),1,,,A,,2367.0,0,Autocuration,CHEMBL627578,,14521,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,1,,,A,,2367.0,0,Autocuration,CHEMBL627579,,14522,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627580,,14523,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),1,,,A,,2367.0,0,Autocuration,CHEMBL627581,,14524,In vivo,,22224,13257,,
,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,1,,,A,,,0,Autocuration,CHEMBL627582,,14525,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627583,,14526,In vivo,,22224,13257,,
Spleen,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,1,,,A,,2106.0,0,Autocuration,CHEMBL627584,,14527,In vivo,,22224,13257,,
Prostate gland,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,1,,,A,,2367.0,0,Autocuration,CHEMBL627585,,14528,In vivo,,22224,13257,,
Muscle tissue,BAO_0000218,,U,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,1,,,A,,2385.0,0,Autocuration,CHEMBL627586,,14529,In vivo,,22224,13257,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627587,,14530,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL627588,,14531,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628250,,14532,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628251,,14533,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628252,,14534,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628253,,14535,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL628254,,14536,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL877493,,14537,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628255,,14538,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628256,,14539,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL628257,,14540,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL628258,,14541,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628259,,14542,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628429,,14543,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL626862,,14544,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL626863,,14545,In vivo,,50597,15413,,
Cerebellum,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL625886,,14546,In vivo,,50597,15413,,
Cerebellum,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL625887,,14547,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625888,,14548,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625889,,14549,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625890,,14550,In vivo,,50597,15413,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL625891,,14551,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL625892,,14552,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL625893,,14553,In vivo,,50597,15413,,
Cerebellum,BAO_0000218,,N,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,1,,10116.0,A,Rattus norvegicus,2037.0,1,Intermediate,CHEMBL625894,,14554,In vivo,,50597,15413,,
,BAO_0000218,,N,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625895,,14555,In vivo,,50597,15413,,
,BAO_0000019,,U,,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,,,A,,,0,Autocuration,CHEMBL625896,,14556,,,22224,12404,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",1,,,A,,,0,Autocuration,CHEMBL625897,,14557,,,22224,568,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",1,,,A,,,0,Autocuration,CHEMBL625898,,14558,,,22224,568,,
,BAO_0000019,,U,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",1,,,A,,,0,Autocuration,CHEMBL625899,,14559,,,22224,568,,
,BAO_0000019,,U,,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,,,A,,,0,Autocuration,CHEMBL626124,,14560,,,22224,12404,,
,BAO_0000218,,N,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,1,,562.0,A,Escherichia coli,,1,Intermediate,CHEMBL628500,,14561,,,50212,7624,,
,BAO_0000218,,N,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL857856,,14562,,,50597,7624,,
,BAO_0000218,,N,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628501,,14563,,,50597,7624,,
,BAO_0000019,,U,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",1,,,A,,,0,Autocuration,CHEMBL628502,,14564,,,22224,4643,,
,BAO_0000019,,U,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,1,,,A,,,0,Autocuration,CHEMBL628503,,14565,,,22224,11532,,
,BAO_0000019,,U,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL628504,,14566,,,22224,11018,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",1,,,A,,,0,Autocuration,CHEMBL628505,,14567,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",1,,,A,,,0,Autocuration,CHEMBL874452,,14568,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",1,,,A,,,0,Autocuration,CHEMBL628506,,14569,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",1,,,A,,,0,Autocuration,CHEMBL628507,,14570,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",1,,,A,,,0,Autocuration,CHEMBL628508,,14571,,,22224,2276,,
,BAO_0000019,,U,,Michaelis constant (KM) was evaluated,1,,,A,,,0,Autocuration,CHEMBL628509,,14572,,,22224,8949,,
,BAO_0000019,,U,,Reaction rate parameter value for phosphate with transfer with respect to ATP,1,,,A,,,0,Autocuration,CHEMBL628510,,14573,,,22224,12404,,
,BAO_0000019,,U,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,1,,,B,,,0,Autocuration,CHEMBL628511,,14574,,,22224,7625,,
,BAO_0000019,,U,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,1,,,B,,,0,Autocuration,CHEMBL628512,,14575,,,22224,7625,,
,BAO_0000019,,U,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,1,,,B,,,0,Autocuration,CHEMBL628513,,14576,,,22224,7625,,
,BAO_0000019,,U,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,1,,,B,,,0,Autocuration,CHEMBL628514,,14577,,,22224,7625,,
,BAO_0000019,,U,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,1,,,A,,,0,Autocuration,CHEMBL628515,,14578,,,22224,12908,,
,BAO_0000019,,U,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,1,,,A,,,0,Autocuration,CHEMBL628516,,14579,,,22224,10368,,
,BAO_0000019,,U,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),1,,,A,,,0,Autocuration,CHEMBL628517,,14580,,,22224,13108,,
,BAO_0000019,,U,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),1,,,A,,,0,Autocuration,CHEMBL628518,,14581,,,22224,13108,,
,BAO_0000019,,U,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,1,,,A,,,0,Autocuration,CHEMBL628519,,14582,,,22224,15217,,
,BAO_0000019,,U,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,1,,,A,,,0,Autocuration,CHEMBL628520,,14583,,,22224,15217,,
,BAO_0000019,,U,,Binding constant was determined,1,,,A,,,0,Autocuration,CHEMBL628521,,14584,,,22224,10933,,
,BAO_0000019,,U,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL630443,,14585,,,22224,2363,,
,BAO_0000019,,U,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,1,,,A,,,0,Autocuration,CHEMBL630444,,14586,,,22224,2363,,
,BAO_0000019,,U,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,1,,,A,,,0,Autocuration,CHEMBL857732,,14587,,,22224,2276,,
,BAO_0000100,,U,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,1,,,P,,,0,Autocuration,CHEMBL630445,,14588,,,22224,14915,,
,BAO_0000019,,U,,Catalytic rate constant of the compound,1,,,A,,,0,Autocuration,CHEMBL630446,,14589,,,22224,8847,,
,BAO_0000019,,U,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,1,,,B,,,0,Autocuration,CHEMBL630447,,14590,,,22224,15357,,
,BAO_0000019,,U,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),1,,,A,,,0,Autocuration,CHEMBL630448,,14591,,,22224,2869,,
,BAO_0000019,,U,,Catalytic rate constant against phospholipase A2 was determined,1,,,A,,,0,Autocuration,CHEMBL630449,,14592,,,22224,3484,,
,BAO_0000019,,U,,"Compound was evaluated for catalytic constant, Kcat",1,,,A,,,0,Autocuration,CHEMBL630450,,14593,,,22224,1373,,
,BAO_0000019,,U,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,1,,,A,,,0,Autocuration,CHEMBL630451,,14594,,,22224,8142,,
,BAO_0000019,,U,,Kcat calculated from 0.693/T1/2,1,,,A,,,0,Autocuration,CHEMBL630452,,14595,,,22224,14131,,
,BAO_0000019,,U,,Kcat was determined,1,,,A,,,0,Autocuration,CHEMBL630453,,14596,,,22224,17269,,
,BAO_0000019,,U,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,1,,,A,,,0,Autocuration,CHEMBL630454,,14597,,,22224,3485,,
,BAO_0000019,,U,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,1,,,A,,,0,Autocuration,CHEMBL630455,,14598,,,22224,3485,,
,BAO_0000019,,U,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,1,,,A,,,0,Autocuration,CHEMBL631487,,14599,,,22224,3485,,
,BAO_0000019,,U,,Kcat value was determined,1,,,A,,,0,Autocuration,CHEMBL631488,,14600,,,22224,5962,,
,BAO_0000019,,U,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,1,,,A,,,0,Autocuration,CHEMBL876440,,14601,,,22224,3133,,
,BAO_0000019,,U,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,1,,,A,,,0,Autocuration,CHEMBL631489,,14602,,,22224,3133,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",1,,,A,,,0,Autocuration,CHEMBL857742,,14603,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",1,,,A,,,0,Autocuration,CHEMBL631490,,14604,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",1,,,A,,,0,Autocuration,CHEMBL631491,,14605,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",1,,,A,,,0,Autocuration,CHEMBL631492,,14606,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",1,,,A,,,0,Autocuration,CHEMBL631493,,14607,,,22224,2276,,
,BAO_0000019,,U,,Kinetic parameter for rate of conversion to PABA was determined,1,,,A,,,0,Autocuration,CHEMBL631494,,14608,,,22224,4892,,
,BAO_0000019,,U,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,1,,,A,,,0,Autocuration,CHEMBL631495,,14609,,,22224,3133,,
Feces,BAO_0000218,,N,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,,10116.0,A,Rattus norvegicus,1988.0,1,Intermediate,CHEMBL631496,,14610,,,50597,11488,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631497,,14611,,,50597,11488,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631498,,14612,,,50597,11488,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629776,,14613,,,50597,11488,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629777,,14614,,,50597,11488,,
Urine,BAO_0000218,,N,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL629778,,14615,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630456,,14616,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630457,,14617,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630458,,14618,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630459,,14619,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630460,,14620,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL876550,,14621,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630461,,14622,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630462,,14623,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630463,,14624,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630464,,14625,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630465,,14626,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630466,,14627,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630467,,14628,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630633,,14629,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630634,,14630,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630635,,14631,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630636,,14632,,,50597,11488,,
,BAO_0000218,,N,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630637,,14633,,,50597,11488,,
Feces,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL630638,,14634,,,50592,7132,,
Feces,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL630639,,14635,,,50592,7132,,
Feces,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL630640,,14636,,,50592,7132,,
Feces,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL876551,,14637,,,50592,7132,,
Urine,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL630641,,14638,,,50592,7132,,
Urine,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL630642,,14639,,,50592,7132,,
Urine,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL630643,,14640,,,50592,7132,,
Urine,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL630644,,14641,,,50592,7132,,
Urine,BAO_0000218,,N,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL630645,,14642,,,50592,7132,,
Feces,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL625599,,14643,,,50592,7132,,
Feces,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL625600,,14644,,,50592,7132,,
Feces,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL625601,,14645,,,50592,7132,,
Feces,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1988.0,1,Intermediate,CHEMBL625602,,14646,,,50592,7132,,
Urine,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL627470,,14647,,,50592,7132,,
Urine,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL627471,,14648,,,50592,7132,,
Urine,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL627472,,14649,,,50592,7132,,
Urine,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL627473,,14650,,,50592,7132,,
Urine,BAO_0000218,,N,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",1,,9986.0,A,Oryctolagus cuniculus,1088.0,1,Intermediate,CHEMBL627474,,14651,,,50592,7132,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627475,,14652,In vivo,,50597,13925,,
Blood,BAO_0000218,,N,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL627476,,14653,In vivo,,50597,13925,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627477,,14654,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627478,,14655,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627479,,14656,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627480,,14657,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627481,,14658,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627482,,14659,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL627483,,14660,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL875636,,14661,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625764,,14662,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625765,,14663,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625766,,14664,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625767,,14665,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625768,,14666,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625769,,14667,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625770,,14668,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625771,,14669,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625772,,14670,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,1,,9615.0,A,Canis lupus familiaris,1088.0,1,Intermediate,CHEMBL625773,,14671,,,50588,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625774,,14672,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625775,,14673,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625776,,14674,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625777,,14675,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625778,,14676,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625779,,14677,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625780,,14678,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL625781,,14679,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875637,,14680,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626473,,14681,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626474,,14682,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626475,,14683,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626476,,14684,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL634397,,14685,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL626477,,14686,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631069,,14687,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631070,,14688,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631071,,14689,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631072,,14690,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631073,,14691,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631074,,14692,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631075,,14693,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631725,,14694,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631726,,14695,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631727,,14696,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631728,,14697,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631729,,14698,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631730,,14699,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631731,,14700,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631910,,14701,,,50597,12582,,
Hippocampus,BAO_0000218,,N,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,1,,10116.0,A,Rattus norvegicus,10000000.0,1,Intermediate,CHEMBL631911,,14702,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL631912,,14703,In vivo,,50597,15413,,
Hypothalamus,BAO_0000218,,N,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,1,,10116.0,A,Rattus norvegicus,1898.0,1,Intermediate,CHEMBL631913,,14704,In vivo,,50597,15413,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631914,,14705,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631915,,14706,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL875778,,14707,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631916,,14708,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631917,,14709,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631918,,14710,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631919,,14711,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631920,,14712,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631921,,14713,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631922,,14714,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL631923,,14715,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631924,,14716,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630234,,14717,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630235,,14718,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630236,,14719,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630237,,14720,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630238,,14721,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630239,,14722,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630303,,14723,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630304,,14724,In vivo,,50597,12017,,
,BAO_0000218,,N,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630305,,14725,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630306,,14726,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630307,,14727,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630308,,14728,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL630309,,14729,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL629309,,14730,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL629993,,14731,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL629994,,14732,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL629995,,14733,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631993,,14734,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631994,,14735,In vivo,,50597,12017,,
Kidney,BAO_0000218,,N,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL631995,,14736,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631996,,14737,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631997,,14738,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631998,,14739,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631999,,14740,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL632000,,14741,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL632001,,14742,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL874424,,14743,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL632002,,14744,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL632003,,14745,In vivo,,50597,12017,,
,BAO_0000019,,U,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,1,,,A,,,0,Autocuration,CHEMBL632004,,14746,,,22224,3133,,
,BAO_0000019,,U,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,1,,,A,,,0,Autocuration,CHEMBL632005,,14747,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for amidase rate in the presence of N62C screen enzyme,1,,,A,,,0,Autocuration,CHEMBL632006,,14748,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,1,,,A,,,0,Autocuration,CHEMBL632007,,14749,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for amidase rate in the presence of S166C screen enzyme,1,,,A,,,0,Autocuration,CHEMBL632008,,14750,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,1,,,A,,,0,Autocuration,CHEMBL632009,,14751,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for esterase rate in the presence of N62C screen enzyme,1,,,A,,,0,Autocuration,CHEMBL632010,,14752,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,1,,,A,,,0,Autocuration,CHEMBL857750,,14753,,,22224,2742,,
,BAO_0000019,,U,,Compound was tested for esterase rate in the presence of S166C screen enzyme,1,,,A,,,0,Autocuration,CHEMBL632011,,14754,,,22224,2742,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL632012,,14755,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL632013,,14756,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL632014,,14757,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL629622,,14758,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL629623,,14759,,,22224,2276,,
,BAO_0000019,,U,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",1,,,A,,,0,Autocuration,CHEMBL629624,,14760,,,22224,2276,,
,BAO_0000019,,U,,Ratio of Kcat to that of Km was determined,1,,,A,,,0,Autocuration,CHEMBL629625,,14761,,,22224,17269,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",1,,,A,,,0,Autocuration,CHEMBL629626,,14762,,,22224,2276,,
,BAO_0000019,,U,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",1,,,A,,,0,Autocuration,CHEMBL629627,,14763,,,22224,2276,,
,BAO_0000019,,U,,"Compound was evaluated for constant, Kd",1,,,A,,,0,Autocuration,CHEMBL629628,,14764,,,22224,15917,,
,BAO_0000019,,U,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,1,,,A,,,0,Autocuration,CHEMBL629629,,14765,,,22224,10933,,
,BAO_0000019,,U,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,1,,,A,,,0,Autocuration,CHEMBL629630,,14766,,,22224,10933,,
,BAO_0000019,,U,,Dissociation Constant of compound determined,1,,,A,,,0,Autocuration,CHEMBL856030,,14767,,,22224,14293,,
,BAO_0000019,,U,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,1,,,B,,,0,Autocuration,CHEMBL629631,,14768,,,22224,6698,,
,BAO_0000019,,U,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,1,,,B,,,0,Autocuration,CHEMBL629632,,14769,,,22224,6698,,
,BAO_0000100,,U,,Dissociation constant of compound with Fructose was determined,1,,,P,,,0,Autocuration,CHEMBL629633,,14770,,,22224,4318,,
,BAO_0000100,,U,,Dissociation constant of compound with Fructose was determined; Not determined,1,,,P,,,0,Autocuration,CHEMBL629634,,14771,,,22224,4318,,
,BAO_0000100,,U,,Dissociation constant of compound with Lactulose was determined,1,,,P,,,0,Autocuration,CHEMBL629635,,14772,,,22224,4318,,
,BAO_0000100,,U,,Dissociation constant of compound with Lactulose was determined; Not determined,1,,,P,,,0,Autocuration,CHEMBL629636,,14773,,,22224,4318,,
,BAO_0000100,,U,,Dissociation constant of the Compound,1,,,P,,,0,Autocuration,CHEMBL629637,,14774,,,22224,14959,,
,BAO_0000100,,U,,Dissociation constant by non-linear regression analysis,1,,,P,,,0,Autocuration,CHEMBL629638,,14775,,,22224,5913,,
,BAO_0000100,,U,,Dissociation constant was determined,1,,,P,,,0,Autocuration,CHEMBL629639,,14776,,,22224,14218,,
,BAO_0000100,,U,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,1,,,P,,,0,Autocuration,CHEMBL629640,,14777,,,22224,10689,,
,BAO_0000100,,U,,Dissociation constant was determined,1,,,P,,,0,Autocuration,CHEMBL629641,,14778,,,22224,13925,,
,BAO_0000100,,U,,Dissociation constant was determined,1,,,P,,,0,Autocuration,CHEMBL631344,,14779,,,22224,16359,,
Muscle tissue,BAO_0000218,,N,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631345,,14780,,,50597,10944,,
,BAO_0000019,,U,,The dissociation constant determined by fluorescence displacement assay,1,,,A,,,0,Autocuration,CHEMBL631346,,14781,,,22224,11080,,
,BAO_0000019,,U,,kd value surface plasmon resonance (SPR) method,1,,,A,,,0,Autocuration,CHEMBL631524,,14782,,,22224,17805,,
Muscle tissue,BAO_0000218,,N,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631525,,14783,,,50597,10944,,
,BAO_0000019,,U,,First dissociation constant of the binding of compound to V30M TTR,1,,,F,,,0,Autocuration,CHEMBL631526,,14784,,,22224,16645,,
,BAO_0000019,,U,,Second dissociation constant of the binding of compound to V30M TTR,1,,,F,,,0,Autocuration,CHEMBL631527,,14785,,,22224,16645,,
,BAO_0000019,,U,,"Compound was evaluated for equilibrium constant, Ke",1,,,A,,,0,Autocuration,CHEMBL631528,,14786,,,22224,7793,,
Hypothalamus,BAO_0000019,,U,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,1,,,A,,1898.0,0,Autocuration,CHEMBL631529,,14787,,,22224,12199,,
Hypothalamus,BAO_0000019,,U,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,1,,,A,,1898.0,0,Autocuration,CHEMBL631530,,14788,,,22224,12199,,
,BAO_0000019,,U,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL631531,,14789,,,22224,9680,,
,BAO_0000019,,U,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL631532,,14790,,,22224,9680,,
,BAO_0000019,,U,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL631533,,14791,,,22224,9680,,
,BAO_0000218,,N,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL876552,,14792,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631534,,14793,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631535,,14794,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631536,,14795,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631537,,14796,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631538,,14797,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631539,,14798,,,50594,13758,,
,BAO_0000218,,N,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631540,,14799,,,50594,13758,,
,BAO_0000218,,N,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625637,,14800,,,50597,14393,,
,BAO_0000218,,N,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625638,,14801,,,50597,14393,,
,BAO_0000218,,N,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL625639,,14802,,,50597,15078,,
Brain,BAO_0000218,,N,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625640,,14803,In vivo,,50597,13925,,
Brain,BAO_0000218,,N,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625641,,14804,In vivo,,50597,13925,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625642,,14805,In vivo,,50597,13925,,
Heart,BAO_0000218,,N,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625643,,14806,In vivo,,50597,13925,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625644,,14807,In vivo,,50597,13925,,
Kidney,BAO_0000218,,N,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2113.0,1,Intermediate,CHEMBL625645,,14808,In vivo,,50597,13925,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625646,,14809,In vivo,,50597,13925,,
Liver,BAO_0000218,,N,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625647,,14810,In vivo,,50597,13925,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625648,,14811,In vivo,,50597,13925,,
Lung,BAO_0000218,,N,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL625649,,14812,In vivo,,50597,13925,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625650,,14813,In vivo,,50597,13925,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL625651,,14814,In vivo,,50597,13925,,
Zone of skin,BAO_0000218,,N,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL625652,,14815,In vivo,,50597,13925,,
Zone of skin,BAO_0000218,,N,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,14.0,1,Intermediate,CHEMBL625653,,14816,In vivo,,50597,13925,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625654,,14817,In vivo,,50597,13925,,
Spleen,BAO_0000218,,N,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL625655,,14818,In vivo,,50597,13925,,
Blood,BAO_0000218,,N,,Biodistribution of Compound in rat blood after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625656,,14819,In vivo,,50597,9712,,
Blood,BAO_0000218,,N,,Biodistribution of Compound in rat blood after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,178.0,1,Intermediate,CHEMBL625657,,14820,In vivo,,50597,9712,,
Brain,BAO_0000218,,N,,Biodistribution of Compound in rat brain after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625658,,14821,In vivo,,50597,9712,,
Brain,BAO_0000218,,N,,Biodistribution of Compound in rat brain after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,955.0,1,Intermediate,CHEMBL625659,,14822,In vivo,,50597,9712,,
Heart,BAO_0000218,,N,,Biodistribution of Compound in rat heart after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625660,,14823,In vivo,,50597,9712,,
Heart,BAO_0000218,,N,,Biodistribution of Compound in rat heart after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,948.0,1,Intermediate,CHEMBL625661,,14824,In vivo,,50597,9712,,
Liver,BAO_0000218,,N,,Biodistribution of Compound in rat liver after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625662,,14825,In vivo,,50597,9712,,
Liver,BAO_0000218,,N,,Biodistribution of Compound in rat liver after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL625663,,14826,In vivo,,50597,9712,,
Lung,BAO_0000218,,N,,Biodistribution of Compound in rat lung after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL875621,,14827,In vivo,,50597,9712,,
Lung,BAO_0000218,,N,,Biodistribution of Compound in rat lung after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL628382,,14828,In vivo,,50597,9712,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of Compound in rat muscle after 15 minutes of administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL628383,,14829,In vivo,,50597,9712,,
Muscle tissue,BAO_0000218,,N,,Biodistribution of Compound in rat muscle after 2 minutes of administration,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL628384,,14830,In vivo,,50597,9712,,
,BAO_0000218,,N,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628385,,14831,,,50597,13925,,
,BAO_0000218,,N,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875753,,14832,,,50597,13925,,
,BAO_0000218,,N,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628386,,14833,,,50597,13925,,
,BAO_0000218,,N,,Organ distribution in rat blood 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628387,,14834,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat blood 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628388,,14835,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat blood 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628389,,14836,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat blood 30 min after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL632756,,14837,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat brain 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628390,,14838,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat brain 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631811,,14839,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat brain 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631812,,14840,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat heart 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631813,,14841,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat heart 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631814,,14842,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat heart 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631815,,14843,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat kidney 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631816,,14844,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat kidney 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL875758,,14845,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat kidney 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631817,,14846,,,50597,6941,,
Liver,BAO_0000218,,N,,Organ distribution in rat liver 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631818,,14847,,,50597,6941,,
Liver,BAO_0000218,,N,,Organ distribution in rat liver 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631819,,14848,,,50597,6941,,
Liver,BAO_0000218,,N,,Organ distribution in rat liver 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL631820,,14849,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat lung 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631821,,14850,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat lung 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631822,,14851,,,50597,6941,,
,BAO_0000218,,N,,Organ distribution in rat lung 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL631823,,14852,,,50597,6941,,
Muscle tissue,BAO_0000218,,N,,Organ distribution in rat muscle 2 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631824,,14853,,,50597,6941,,
Muscle tissue,BAO_0000218,,N,,Organ distribution in rat muscle 2 hr after intravenous injection,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631825,,14854,,,50597,6941,,
Muscle tissue,BAO_0000218,,N,,Organ distribution in rat muscle 30 minutes after intravenous injection,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631826,,14855,,,50597,6941,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631827,,14856,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631828,,14857,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL631829,,14858,In vivo,,50594,14439,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875759,,14859,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631830,,14860,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631831,,14861,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631832,,14862,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631833,,14863,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631834,,14864,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631835,,14865,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631836,,14866,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631837,,14867,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631838,,14868,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631839,,14869,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631840,,14870,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631841,,14871,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631842,,14872,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631843,,14873,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631844,,14874,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631845,,14875,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631846,,14876,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL875760,,14877,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL632199,,14878,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631847,,14879,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL631848,,14880,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628707,,14881,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628708,,14882,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628709,,14883,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628710,,14884,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628711,,14885,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628712,,14886,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628713,,14887,,,50597,12582,,
Urine,BAO_0000218,,N,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,1,,10116.0,A,Rattus norvegicus,1088.0,1,Intermediate,CHEMBL628714,,14888,,,50597,12582,,
,BAO_0000218,,N,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL628715,,14889,,,50597,7415,,
,BAO_0000019,,U,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,1,,,A,,,0,Autocuration,CHEMBL629179,,14890,,,22224,7313,,
,BAO_0000019,,U,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,1,,,A,,,0,Autocuration,CHEMBL629180,,14891,,,22224,7313,,
,BAO_0000019,,U,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,1,,,A,,,0,Autocuration,CHEMBL875108,,14892,,,22224,7313,,
Adrenal cortex,BAO_0000019,,U,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629181,,14893,,,22224,7570,,
Adrenal cortex,BAO_0000019,,U,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629182,,14894,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629183,,14895,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629184,,14896,,,22224,7570,,
Adrenal cortex,BAO_0000019,,U,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629185,,14897,,,22224,7570,,
Adrenal cortex,BAO_0000019,,U,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629186,,14898,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629187,,14899,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629887,,14900,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629888,,14901,,,22224,7570,,
,BAO_0000019,,U,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629889,,14902,,,22224,7570,,
Adrenal cortex,BAO_0000019,,U,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629890,,14903,,,22224,7570,,
,BAO_0000019,,U,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629891,,14904,,,22224,7570,,
,BAO_0000019,,U,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629892,,14905,,,22224,7570,,
Adrenal cortex,BAO_0000019,,U,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,1,,,A,,1235.0,0,Autocuration,CHEMBL629893,,14906,,,22224,7570,,
,BAO_0000019,,U,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629894,,14907,,,22224,7570,,
,BAO_0000019,,U,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,1,,,A,,,0,Autocuration,CHEMBL629895,,14908,,,22224,7570,,
,BAO_0000218,,U,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",1,,9615.0,A,Canis lupus familiaris,,0,Autocuration,CHEMBL875109,,14909,In vivo,,22224,14122,,
,BAO_0000218,,U,,Absolute bioavailability in male cynomolgus monkeys,1,,9541.0,A,Macaca fascicularis,,0,Autocuration,CHEMBL629896,,14910,In vivo,,22224,16449,,
,BAO_0000218,,U,,Absolute bioavailability in maleSprague-Dawley rats,1,,10116.0,A,Rattus norvegicus,,0,Autocuration,CHEMBL629897,,14911,In vivo,,22224,16449,,
Liver,BAO_0000218,,N,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL629898,,14912,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL630057,,14913,In vivo,,50597,12017,,
Liver,BAO_0000218,,N,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2107.0,1,Intermediate,CHEMBL630058,,14914,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630059,,14915,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630060,,14916,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630061,,14917,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630062,,14918,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630063,,14919,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630064,,14920,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630065,,14921,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630066,,14922,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630067,,14923,In vivo,,50597,12017,,
Lung,BAO_0000218,,N,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2048.0,1,Intermediate,CHEMBL630068,,14924,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631113,,14925,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631114,,14926,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631115,,14927,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL631116,,14928,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630528,,14929,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630529,,14930,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630530,,14931,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630531,,14932,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630532,,14933,In vivo,,50597,12017,,
Muscle tissue,BAO_0000218,,N,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2385.0,1,Intermediate,CHEMBL630533,,14934,In vivo,,50597,12017,,
Blood,BAO_0000218,,N,,Biodistribution in normal mice blood after 120 hr,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL630534,,14935,In vivo,,50594,15045,,
Blood,BAO_0000218,,N,,Biodistribution in normal mice blood after 24 hr,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL630535,,14936,In vivo,,50594,15045,,
Blood,BAO_0000218,,N,,Biodistribution in normal mice blood after 4 hr,1,,10090.0,A,Mus musculus,178.0,1,Intermediate,CHEMBL630536,,14937,In vivo,,50594,15045,,
Bone,BAO_0000218,,N,,Biodistribution in normal mice bone after 120 hr,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL630537,,14938,In vivo,,50594,15045,,
Bone,BAO_0000218,,N,,Biodistribution in normal mice bone after 24 hr,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL630538,,14939,In vivo,,50594,15045,,
Bone,BAO_0000218,,N,,Biodistribution in normal mice bone after 4 hr,1,,10090.0,A,Mus musculus,10000001.0,1,Intermediate,CHEMBL630539,,14940,In vivo,,50594,15045,,
Heart,BAO_0000218,,N,,Biodistribution in normal mice heart after 120 hr,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL630540,,14941,In vivo,,50594,15045,,
Heart,BAO_0000218,,N,,Biodistribution in normal mice heart after 24 hr,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL630541,,14942,In vivo,,50594,15045,,
Heart,BAO_0000218,,N,,Biodistribution in normal mice heart after 4 hr,1,,10090.0,A,Mus musculus,948.0,1,Intermediate,CHEMBL630542,,14943,In vivo,,50594,15045,,
Kidney,BAO_0000218,,N,,Biodistribution in normal mice kidney after 120 hr,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630543,,14944,In vivo,,50594,15045,,
Kidney,BAO_0000218,,N,,Biodistribution in normal mice kidney after 24 hr,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630544,,14945,In vivo,,50594,15045,,
Kidney,BAO_0000218,,N,,Biodistribution in normal mice kidney after 4 hr,1,,10090.0,A,Mus musculus,2113.0,1,Intermediate,CHEMBL630545,,14946,In vivo,,50594,15045,,
Liver,BAO_0000218,,N,,Biodistribution in normal mice liver after 120 hr,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL630546,,14947,In vivo,,50594,15045,,
Liver,BAO_0000218,,N,,Biodistribution in normal mice liver after 24 hr,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL630547,,14948,In vivo,,50594,15045,,
Liver,BAO_0000218,,N,,Biodistribution in normal mice liver after 4 hr,1,,10090.0,A,Mus musculus,2107.0,1,Intermediate,CHEMBL630548,,14949,In vivo,,50594,15045,,
Spleen,BAO_0000218,,N,,Biodistribution in normal mice spleen after 120 hr,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL630549,,14950,In vivo,,50594,15045,,
Spleen,BAO_0000218,,N,,Biodistribution in normal mice spleen after 24 hr,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL630550,,14951,In vivo,,50594,15045,,
Spleen,BAO_0000218,,N,,Biodistribution in normal mice spleen after 4 hr,1,,10090.0,A,Mus musculus,2106.0,1,Intermediate,CHEMBL876426,,14952,In vivo,,50594,15045,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630551,,14953,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630552,,14954,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630553,,14955,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630554,,14956,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630555,,14957,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630556,,14958,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630557,,14959,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630558,,14960,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630559,,14961,In vivo,,50597,12017,,
Spleen,BAO_0000218,,N,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2106.0,1,Intermediate,CHEMBL630560,,14962,In vivo,,50597,12017,,
Thyroid gland,BAO_0000218,,N,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,1,,10116.0,A,Rattus norvegicus,2046.0,1,Intermediate,CHEMBL876427,,14963,In vivo,,50597,12017,,
,BAO_0000218,,N,,The Kel values in female wistar rats.,1,,10116.0,A,Rattus norvegicus,,1,Intermediate,CHEMBL630561,,14964,,,50597,14941,,
,BAO_0000019,,U,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL630562,,14965,,,22224,4646,,
,BAO_0000019,,U,,Hydrolysis rate constant of the compound,1,,,A,,,0,Autocuration,CHEMBL630563,,14966,,,22224,8847,,
,BAO_0000100,,U,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,1,,,P,,,0,Autocuration,CHEMBL629673,,14967,,,22229,11778,,
,BAO_0000019,,U,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL629674,,14968,,,22224,2363,,
,BAO_0000019,,U,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",1,,,A,,,0,Autocuration,CHEMBL629675,,14969,,,22224,2363,,
,BAO_0000019,,U,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",1,,,A,,,0,Autocuration,CHEMBL629676,,14970,,,22224,2363,,
,BAO_0000019,,U,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",1,,,A,,,0,Autocuration,CHEMBL629677,,14971,,,22224,2363,,
,BAO_0000019,,U,,Apparent inactivation rate constant was evaluated,1,,,A,,,0,Autocuration,CHEMBL629678,,14972,,,22224,8371,,
,BAO_0000019,,U,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,1,,,A,,,0,Autocuration,CHEMBL629679,,14973,,,22224,14883,,
,BAO_0000019,,U,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,1,,,A,,,0,Autocuration,CHEMBL629680,,14974,,,22224,14883,,
,BAO_0000019,,U,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,1,,,A,,,0,Autocuration,CHEMBL629681,,14975,,,22224,4643,,
,BAO_0000019,,U,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,1,,,A,,,0,Autocuration,CHEMBL629682,,14976,,,22224,3519,,
,BAO_0000019,,U,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,1,,,A,,,0,Autocuration,CHEMBL629683,,14977,,,22224,10600,,
,BAO_0000019,,U,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,1,,,F,,,0,Autocuration,CHEMBL629684,,14978,,,22224,8501,,
,BAO_0000100,,U,,Dissociation constant was determined,1,,,P,,,0,Autocuration,CHEMBL629685,,14979,,,22224,8505,,
,BAO_0000100,,U,,Dissociation constant was determined,1,,,P,,,0,Autocuration,CHEMBL629686,,14980,,,22224,9778,,
,BAO_0000100,,U,,Dissociation constant at pH 7.4,1,,,P,,,0,Autocuration,CHEMBL872932,,14981,,,22224,9778,,
,BAO_0000100,,U,,Dissociation constant in presence of 1 mM dithiothreitol,1,,,P,,,0,Autocuration,CHEMBL629687,,14982,,,22224,9778,,
,BAO_0000019,,U,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,1,,,A,,,0,Autocuration,CHEMBL872931,,14983,,,22224,13007,,
,BAO_0000019,,U,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,1,,,A,,,0,Autocuration,CHEMBL628151,,14984,,,22224,13007,,
,BAO_0000019,,U,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,1,,,A,,,0,Autocuration,CHEMBL628152,,14985,,,22224,13007,,
,BAO_0000019,,U,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,1,,,A,,,0,Autocuration,CHEMBL628153,,14986,,,22224,13007,,
,BAO_0000019,,U,,Kinetic constant for aromatization of androstenedione,1,,,A,,,0,Autocuration,CHEMBL628154,,14987,,,22224,11482,,
,BAO_0000019,,U,,Kinetic constant for aromatization of testosterone,1,,,A,,,0,Autocuration,CHEMBL628155,,14988,,,22224,11482,,
,BAO_0000019,,U,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,1,,,A,,,0,Autocuration,CHEMBL628156,,14989,,,22224,2303,,
,BAO_0000019,,U,,Local inhibition constant was determined,1,,,A,,,0,Autocuration,CHEMBL628157,,14990,,,22224,11964,,
,BAO_0000218,,N,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,1,,4932.0,A,Saccharomyces cerevisiae,,1,Intermediate,CHEMBL857533,,14991,,,50347,3140,,
,BAO_0000100,,U,,Dissociation constant value of the compound,1,,,P,,,0,Autocuration,CHEMBL628158,,14992,,,22224,10650,,
Cornea,BAO_0000019,,U,,In vitro permeability through cornea without epithelium,1,,,A,,964.0,0,Autocuration,CHEMBL628159,,14993,,,22224,4667,,
Cornea,BAO_0000019,,U,,In vitro permeability through intact cornea,1,,,A,,964.0,0,Autocuration,CHEMBL875616,,14994,,,22224,4667,,
Cornea,BAO_0000218,,N,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,1,,9986.0,A,Oryctolagus cuniculus,964.0,1,Intermediate,CHEMBL628160,,14995,,,50592,9199,,
,BAO_0000019,,U,,Rate of enzyme inactivation for the compound was determined,1,,,A,,,0,Autocuration,CHEMBL628161,,14996,,,22224,11966,,
Cornea,BAO_0000019,,U,,In vitro permeability through cornea without epithelium,1,,,A,,964.0,0,Autocuration,CHEMBL628162,,14997,,,22224,4667,,
Cornea,BAO_0000019,,U,,In vitro permeability through intact cornea,1,,,A,,964.0,0,Autocuration,CHEMBL628163,,14998,,,22224,4667,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628164,,14999,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628165,,15000,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628166,,15001,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628167,,15002,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628168,,15003,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628169,,15004,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628170,,15005,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628171,,15006,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL627434,,15007,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL627435,,15008,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628110,,15009,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628111,,15010,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628112,,15011,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628260,,15012,,,22224,8354,,
,BAO_0000019,,U,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",1,,,A,,,0,Autocuration,CHEMBL628261,,15013,,,22224,8354,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628262,,15014,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,1,,9606.0,A,Homo sapiens,,1,Intermediate,CHEMBL628263,,15015,In vivo,,50587,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628264,,15016,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628265,,15017,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628266,,15018,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628267,,15019,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628268,,15020,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628269,,15021,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628270,,15022,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628271,,15023,In vivo,,50594,14439,,
,BAO_0000218,,N,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),1,,10090.0,A,Mus musculus,,1,Intermediate,CHEMBL628272,,15024,In vivo,,50594,14439,,
